Empty,Metabolite,Name,Reference,ID,Group,DOI,tCr_u,tCr_std,IU_u,IU_std,mM_u,mM_std,Notes
,Ala,Ala,2021_akiyama_61,1,Control,10.2176/nmc.oa.2020-0274,,,0.44,0.03,,,
,Ala,Ala,2021_akiyama_61,2,NPH,10.2176/nmc.oa.2020-0274,,,0.48,0.89,,,
,Ala,Ala,2016_koob_11,1,Premature Neonates,10.1371/journal.pone.0160990,,,0.004,0.007,,,
,Ala,Ala,2016_koob_11,3,Infants - Control,10.1371/journal.pone.0160990,,,0.008,0.013,,,
,Ala,Ala,2019_wagoner_317,1,Non-OI,10.1152/ajpheart.00680.2018,,,1.9,0.212,,,
,Ala,Ala,2019_wagoner_317,2,OI,10.1152/ajpheart.00680.2018,,,2.6,1.327,,,
,Ala,Ala,2020_dehghani_83,3,Protocol 3,10.1002/mrm.28066,,,0.08,0.1,,,
,Ala,Ala,2016_lopezkolkovsky_75,1,Healthy_Rodent,10.1002/mrm.25602,,,,,1,0.2,
,Asc,Asc,2018_bednarik_38,1,Healthy,10.1177/0271678X17695291,,,,,0.98,0.14,
,Asc,Asc,2020_boillat_40,1,Baseline,10.1177/0271678X19831022,,,1.34,0.07,,,
,Asc,Asc,2020_boillat_40,2,positive BOLD,10.1177/0271678X19831022,,,0.06,0.15,,,
,Asc,Asc,2020_boillat_40,3,Baseline,10.1177/0271678X19831022,,,1.3,0.06,,,
,Asc,Asc,2020_boillat_40,4,negative BOLD,10.1177/0271678X19831022,,,0.09,0.26,,,
,Asc,Asc,2019_betinaip_39,1,Behavior - ON - 3% Visual Contrast,10.1523/JNEUROSCI.3021-18.2019,,,2.139,0.358,,,
,Asc,Asc,2019_betinaip_39,2,Behavior - ON - 12.5% Visual Contrast,10.1523/JNEUROSCI.3021-18.2019,,,2.133,0.379,,,
,Asc,Asc,2019_betinaip_39,3,Behavior - ON - 50% Visual Contrast,10.1523/JNEUROSCI.3021-18.2019,,,2.245,0.35,,,
,Asc,Asc,2019_betinaip_39,4,Behavior - ON - 100% Visual Contrast,10.1523/JNEUROSCI.3021-18.2019,,,2.132,0.379,,,
,Asc,Asc,2019_betinaip_39,5,Resting,10.1523/JNEUROSCI.3021-18.2019,,,2.158,0.406,,,
,Asc,Asc,2019_betinaip_39,6,Behavior - OFF - 3% Visual Contrast,10.1523/JNEUROSCI.3021-18.2019,,,2.154,0.358,,,
,Asc,Asc,2019_betinaip_39,7,Behavior - OFF - 12.5% Visual Contrast,10.1523/JNEUROSCI.3021-18.2019,,,2.191,0.472,,,
,Asc,Asc,2019_betinaip_39,8,Behavior - OFF - 50% Visual Contrast,10.1523/JNEUROSCI.3021-18.2019,,,2.156,0.435,,,
,Asc,Asc,2019_betinaip_39,9,Behavior - OFF - 100% Visual Contrast,10.1523/JNEUROSCI.3021-18.2019,,,2.223,0.355,,,
,Asc,Asc,2019_betinaip_39,10,Resting,10.1523/JNEUROSCI.3021-18.2019,,,2.154,0.432,,,
,Asc,Asc,2019_marjanska_68,1,Alzheimer's disease,10.3233/JAD-180861,,,,,1.52,0.24,
,Asc,Asc,2019_marjanska_68,2,Alzheimer's disease,10.3233/JAD-180861,,,,,1.66,0.24,
,Asc,Asc,2019_marjanska_68,3,Control,10.3233/JAD-180861,,,,,1.26,0.23,
,Asc,Asc,2019_marjanska_68,4,Control,10.3233/JAD-180861,,,,,1.42,0.23,
,Asc,Asc,2017_cheong_42,2,Control,10.1007/s11064-017-2248-2,,,,,2.5,0.5,
,Asc,Asc,2017_cheong_42,4,ALS,10.1007/s11064-017-2248-2,,,,,2.25,1,
,Asc,Asc,2020_dehghani_83,2,Protocol 2,10.1002/mrm.28066,,,0.85,0.25,,,
,Asc,Asc,2016_lopezkolkovsky_75,1,Healthy_Rodent,10.1002/mrm.25602,,,,,2.2,0.4,
,Asc,Asc,2018_deelchand_79,1,Healthy,10.1002/mrm.26788,,,,,2.053,1.633,
,Asc,Asc,2018_deelchand_79,2,Healthy,10.1002/mrm.26788,,,,,1.286,0.421,
,Asp,Asp,2018_adanyeguh_31,2,Healthy,10.1002/nbm.3880,,,,,3.1,0.5,Estimated Bar Graph
,Asp,Asp,2018_adanyeguh_31,4,HD,10.1002/nbm.3880,,,,,2.9,0.2,Estimated Bar Graph
,Asp,Asp,2018_bednarik_38,1,Healthy,10.1177/0271678X17695291,,,,,3.35,0.42,
,Asp,Asp,2021_akiyama_61,1,Control,10.2176/nmc.oa.2020-0274,,,0.59,0.2,,,
,Asp,Asp,2021_akiyama_61,2,NPH,10.2176/nmc.oa.2020-0274,,,0.49,0.71,,,
,Asp,Asp,2021_bednarik_15,1,Healthy,10.3389/fnins.2021.609485,,,,,3.7,0.3,
,Asp,Asp,2021_bednarik_15,2,Healthy,10.3389/fnins.2021.609485,,,,,3.68,0.3,
,Asp,Asp,2019_giapitzakis_81,1,Healthy,10.1002/mrm.27467,,,,,2.3,0.5,
,Asp,Asp,2019_giapitzakis_81,2,Healthy,10.1002/mrm.27467,,,,,1.5,0.8,
,Asp,Asp,2016_koob_11,1,Premature Neonates,10.1371/journal.pone.0160990,,,0.015,0.014,,,
,Asp,Asp,2016_koob_11,3,Infants - Control,10.1371/journal.pone.0160990,,,0.032,0.027,,,
,Asp,Asp,2019_marjanska_68,1,Alzheimer's disease,10.3233/JAD-180861,,,,,2.12,0.4,
,Asp,Asp,2019_marjanska_68,2,Alzheimer's disease,10.3233/JAD-180861,,,,,2.01,0.4,
,Asp,Asp,2019_marjanska_68,3,Control,10.3233/JAD-180861,,,,,1.98,0.345,
,Asp,Asp,2019_marjanska_68,4,Control,10.3233/JAD-180861,,,,,1.75,0.345,
,Asp,Asp,2019_starmose_20,1,Control,10.1186/s10194-019-1059-z,0.729,0.045,2.675,0.339,,,
,Asp,Asp,2019_starmose_20,2,Control,10.1186/s10194-019-1059-z,0.321,0.032,1.903,0.225,,,
,Asp,Asp,2019_starmose_20,3,Migraine with aura,10.1186/s10194-019-1059-z,0.452,0.032,2.718,0.29,,,
,Asp,Asp,2019_starmose_20,4,Migraine with aura,10.1186/s10194-019-1059-z,0.335,0.028,1.923,0.175,,,
,Asp,Asp,2018_povazan_79,1,Healthy,10.1002/mrm.26778,,,3.44,0.61,,,
,Asp,Asp,2018_povazan_79,2,Healthy,10.1002/mrm.26778,,,4.71,1.17,,,
,Asp,Asp,2018_povazan_79,3,Healthy,10.1002/mrm.26778,,,3.77,0.99,,,
,Asp,Asp,2018_povazan_79,4,Healthy,10.1002/mrm.26778,,,3.32,1.22,,,
,Asp,Asp,2018_povazan_79,5,Healthy,10.1002/mrm.26778,,,3.88,1.22,,,
,Asp,Asp,2018_povazan_79,6,Healthy,10.1002/mrm.26778,,,4.33,1.22,,,
,Asp,Asp,2018_povazan_79,7,Healthy,10.1002/mrm.26778,,,5.16,1.5,,,
,Asp,Asp,2020_menshchikov_84,2,Mild Traumatic Brain Injury ,10.1002/mrm.28332,0.029,0.004,,,0.83,0.13,
,Asp,Asp,2020_menshchikov_84,1,Control,10.1002/mrm.28332,0.035,0.004,,,0.95,0.12,
,Asp,Asp,2019_wiegers_62,1,Control,10.1007/s00125-019-4862-9,,,,,2.07,0.34,
,Asp,Asp,2019_wiegers_62,2,Type 1 diabetes - Normal awareness of hypoglycaemia,10.1007/s00125-019-4862-9,,,,,2.26,0.51,
,Asp,Asp,2019_wiegers_62,3,Type 1 diabetes,10.1007/s00125-019-4862-9,,,,,2.7,0.61,
,Asp,Asp,2019_reid_45,1,Control,10.1093/schbul/sbx190,,,1.49,0.21,,,
,Asp,Asp,2019_reid_45,2,Schizophrenia,10.1093/schbul/sbx190,,,1.45,0.23,,,
,Asp,Asp,2020_dehghani_83,1,Protocol 1,10.1002/mrm.28066,,,0.84,0.21,,,
,Asp,Asp,2020_dehghani_83,3,Protocol 3,10.1002/mrm.28066,,,1.08,0.17,,,
,Asp,Asp,2020_dehghani_83,3,Protocol 3,10.1002/mrm.28066,,,0.51,0.19,,,
,Asp,Asp,2018_giapitzakis_79,1,Healthy,10.1002/mrm.26873,,,,,3.38,0.638,Med/Quartile --> Mean/Std Greco 2015
,Asp,Asp,2018_giapitzakis_79,2,Healthy,10.1002/mrm.26873,,,,,1.91,2.774,Med/Quartile --> Mean/Std Wan 2014
,Asp,Asp,2016_lopezkolkovsky_75,1,Healthy_Rodent,10.1002/mrm.25602,,,,,2.9,0.3,
,Asp,Asp,2018_deelchand_79,1,Healthy,10.1002/mrm.26788,,,,,2.3,0.866,
,Asp,Asp,2018_deelchand_79,2,Healthy,10.1002/mrm.26788,,,,,3.314,0.965,
,Asp,Asp,2018_menshchikov_67,1,Healthy,10.1007/s11172-018-2119-2,0.18,0.015,,,,,
,Asp,Asp,2018_menshchikov_67,2,Healthy,10.1007/s11172-018-2119-2,0.207,0.011,,,,,
,BHB,BHB,2019_koush_184,1,Healthy (No Behavior),10.1016/j.neuroimage.2018.09.008,,,,,0.25,0.02,
,BHB,BHB,2019_koush_184,2,Healthy (Behavior),10.1016/j.neuroimage.2018.09.008,,,,,0.28,0.02,
,2HG,2HG,2019_branzoli_82,1,Cancer-1p/19q codeleted,10.1002/mrm.27810,,,,,2.52,2.14,
,2HG,2HG,2021_askari_86,1,IDH ,10.1002/mrm.28829,,,,,3.2,2,
,2HG,2HG,2021_askari_86,2,IDH,10.1002/mrm.28829,,,,,3.2,2,
,2HG,2HG,2021_askari_86,3,IDH WT,10.1002/mrm.28829,,,,,0.5,0.6,
,2HG,2HG,2018_an_79,1,Glioma - IDH1-mutated grade-II oligodendroglioma,10.1002/mrm.26884,,,0.052,0.053,,,
,2HG,2HG,2018_an_79,2,Glioma - IDH1-mutated grade-II oligodendroglioma,10.1002/mrm.26884,,,2.784,0.457,,,
,2HG,2HG,2018_an_79,3,Glioma - Radiographically suggested glioma,10.1002/mrm.26884,,,0,0.105,,,
,2HG,2HG,2018_an_79,4,Glioma - Radiographically suggested glioma,10.1002/mrm.26884,,,2.096,0.367,,,
,2HG,2HG,2018_an_79,5,Glioma - IDH wild-type glioblastoma,10.1002/mrm.26884,,,0,0.212,,,
,2HG,2HG,2018_an_79,6,Glioma - IDH wild-type glioblastoma,10.1002/mrm.26884,,,0,0.477,,,
,2HG,2HG,2018_berrington_31,1,Cancer - Glioma (IDH mutation),10.1002/nbm.3886,,,,,8.013,3.24,
,2HG,2HG,2018_berrington_31,2,Cancer - Glioma (IDH mutation),10.1002/nbm.3886,,,,,9.338,4.614,
,2HG,2HG,2018_berrington_31,3,Cancer - Glioma (IDH wild-type),10.1002/nbm.3886,,,,,2.9,,
,2HG,2HG,2018_berrington_31,4,Cancer - Glioma (IDH wild-type),10.1002/nbm.3886,,,,,0.3,,
,Chol,tCho,2017_hanquinet_27,1,control,10.1007/s00330-017-4808-x,0.8,0.1,,,,,Assumed Total (tCho) based on Analysis
,Chol,tCho,2017_hanquinet_27,2,isointense,10.1007/s00330-017-4808-x,0.8,0.2,,,,,Assumed Total (tCho) based on Analysis
,Chol,tCho,2017_hanquinet_27,3,hyperintense,10.1007/s00330-017-4808-x,0.7,0.1,,,,,Assumed Total (tCho) based on Analysis
,Chol,tCho,2017_hanquinet_27,4,much more hyperintense,10.1007/s00330-017-4808-x,0.8,0.3,,,,,Assumed Total (tCho) based on Analysis
,Cho,GPC,2017_sijens_42,1,control (normal development),10.1016/j.mri.2017.06.001,0.48,0.04,,,,,
,Cho,GPC,2017_sijens_42,5,mild disability,10.1016/j.mri.2017.06.001,0.49,0.01,,,,,
,Cho,GPC,2017_sijens_42,9,deceased,10.1016/j.mri.2017.06.001,0.5,0.06,,,,,
,Cho,GPC,2017_sijens_42,13,control (normal development),10.1016/j.mri.2017.06.001,0.44,0.05,,,,,
,Cho,GPC,2017_sijens_42,17,mild disability,10.1016/j.mri.2017.06.001,0.46,0.05,,,,,
,Cho,GPC,2017_sijens_42,21,deceased,10.1016/j.mri.2017.06.001,0.46,0.03,,,,,
,Cho,GPC,2019_andrade_13,1,Control,10.3389/fnhum.2019.00186,0.28,0.04,,,,,
,Cho,GPC,2019_andrade_13,2,OCD,10.3389/fnhum.2019.00186,0.29,0.05,,,,,
,Cho,GPC,2019_barbagallo_62,1,Control,10.1016/j.parkreldis.2018.12.008,0.3,0.01,1.49,0.1,,,
,Cho,GPC,2019_barbagallo_62,2,Progressive Supranuclear Palsy,10.1016/j.parkreldis.2018.12.008,0.299,0.013,1.125,0.125,,,
,Cho,GPC,2019_bell_39,1,Behavior,10.1523/JNEUROSCI.2110-18.2019,,,,,0.15,0.2,
,Cho,GPC,2019_bell_39,2,Behavior,10.1523/JNEUROSCI.2110-18.2019,,,,,0.24,0.17,
,Cho,GPC,2019_bell_39,3,Behavior,10.1523/JNEUROSCI.2110-18.2019,,,,,,,
,Cho,GPC,2019_bell_39,4,No-Behavior,10.1523/JNEUROSCI.2110-18.2019,,,,,0.11,0.16,
,Cho,GPC,2019_bell_39,5,No-Behavior,10.1523/JNEUROSCI.2110-18.2019,,,,,0.23,0.17,
,Cho,GPC,2019_bell_39,6,No-Behavior,10.1523/JNEUROSCI.2110-18.2019,,,,,,,
,PC/GPC,tCho,2019_bell_39,1,Behavior,10.1523/JNEUROSCI.2110-18.2019,,,,,0.27,0.1,
,PC/GPC,tCho,2019_bell_39,2,Behavior,10.1523/JNEUROSCI.2110-18.2019,,,,,0.27,0.12,
,PC/GPC,tCho,2019_bell_39,3,Behavior,10.1523/JNEUROSCI.2110-18.2019,,,,,,,
,PC/GPC,tCho,2019_bell_39,4,No-Behavior,10.1523/JNEUROSCI.2110-18.2019,,,,,0.36,0.14,
,PC/GPC,tCho,2019_bell_39,5,No-Behavior,10.1523/JNEUROSCI.2110-18.2019,,,,,0.25,0.14,
,PC/GPC,tCho,2019_bell_39,6,No-Behavior,10.1523/JNEUROSCI.2110-18.2019,,,,,,,
,tCho,tCho,2019_bell_39,1,Behavior,10.1523/JNEUROSCI.2110-18.2019,,,,,0.42,0.12,
,tCho,tCho,2019_bell_39,2,Behavior,10.1523/JNEUROSCI.2110-18.2019,,,,,0.5,0.17,
,tCho,tCho,2019_bell_39,3,Behavior,10.1523/JNEUROSCI.2110-18.2019,,,,,,,
,tCho,tCho,2019_bell_39,4,No-Behavior,10.1523/JNEUROSCI.2110-18.2019,,,,,0.46,0.1,
,tCho,tCho,2019_bell_39,5,No-Behavior,10.1523/JNEUROSCI.2110-18.2019,,,,,0.48,0.16,
,Cho,GPC,2019_bell_39,6,No-Behavior,10.1523/JNEUROSCI.2110-18.2019,,,,,,,
,Cho,tCho,2019_boban_27,1,Control,10.3174/ajnr.A5160,0.971,0.17,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2019_boban_27,2,Control,10.3174/ajnr.A5160,1.152,0.135,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2019_boban_27,3,Control,10.3174/ajnr.A5160,1.126,0.107,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2019_boban_27,4,Control,10.3174/ajnr.A5160,0.984,0.215,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2019_boban_27,5,Control,10.3174/ajnr.A5160,0.802,0.186,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2019_boban_27,6,Control,10.3174/ajnr.A5160,1.106,0.113,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2019_boban_27,7,Control,10.3174/ajnr.A5160,0.862,0.104,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2019_boban_27,8,Control,10.3174/ajnr.A5160,0.965,0.198,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2019_boban_27,9,Control,10.3174/ajnr.A5160,1.025,0.193,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2019_boban_27,10,Control,10.3174/ajnr.A5160,0.886,0.099,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2019_boban_27,11,Control,10.3174/ajnr.A5160,1.143,0.117,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2019_boban_27,12,Control,10.3174/ajnr.A5160,0.978,0.185,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2019_boban_27,13,HIV,10.3174/ajnr.A5160,1.055,0.212,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2019_boban_27,14,HIV,10.3174/ajnr.A5160,1.061,0.134,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2019_boban_27,15,HIV,10.3174/ajnr.A5160,1.191,0.198,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2019_boban_27,16,HIV,10.3174/ajnr.A5160,1.039,0.181,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2019_boban_27,17,HIV,10.3174/ajnr.A5160,0.824,0.156,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2019_boban_27,18,HIV,10.3174/ajnr.A5160,1.202,0.195,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2019_boban_27,19,HIV,10.3174/ajnr.A5160,0.828,0.11,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2019_boban_27,20,HIV,10.3174/ajnr.A5160,1.075,0.229,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2019_boban_27,21,HIV,10.3174/ajnr.A5160,1.053,0.201,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2019_boban_27,22,HIV,10.3174/ajnr.A5160,0.795,0.113,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2019_boban_27,23,HIV,10.3174/ajnr.A5160,1.085,0.14,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2019_boban_27,24,HIV,10.3174/ajnr.A5160,0.889,0.212,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2019_boban_27,25,cART,10.3174/ajnr.A5160,1.078,0.249,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2019_boban_27,26,cART,10.3174/ajnr.A5160,1.032,0.115,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2019_boban_27,27,cART,10.3174/ajnr.A5160,1.103,0.152,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2019_boban_27,28,cART,10.3174/ajnr.A5160,1.031,0.142,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2019_boban_27,29,cART,10.3174/ajnr.A5160,0.876,0.173,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2019_boban_27,30,cART,10.3174/ajnr.A5160,1.138,0.183,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2019_boban_27,31,cART,10.3174/ajnr.A5160,0.789,0.143,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2019_boban_27,32,cART,10.3174/ajnr.A5160,1.039,0.137,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2019_boban_27,33,cART,10.3174/ajnr.A5160,1.059,0.132,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2019_boban_27,34,cART,10.3174/ajnr.A5160,0.808,0.147,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2019_boban_27,35,cART,10.3174/ajnr.A5160,1.015,0.121,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2019_boban_27,36,cART,10.3174/ajnr.A5160,0.843,0.243,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2019_boban_27,37,HIV - cART_Long,10.1038/s41598-019-56330-0,0.991,0.127,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2019_boban_27,38,HIV - cART_Long,10.1038/s41598-019-56330-0,1.063,0.131,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2019_boban_27,39,HIV - cART_Long,10.1038/s41598-019-56330-0,1.05,0.128,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2019_boban_27,40,HIV - cART_Long,10.1038/s41598-019-56330-0,1.167,0.237,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2019_boban_27,41,HIV - cART_Long,10.1038/s41598-019-56330-0,1.049,0.197,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2019_boban_27,42,HIV - cART_Long,10.1038/s41598-019-56330-0,1.088,0.131,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2019_boban_27,43,HIV - cART_Long,10.1038/s41598-019-56330-0,1.074,0.117,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2019_boban_27,44,HIV - cART_Long,10.1038/s41598-019-56330-0,1.092,0.075,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2019_boban_27,45,HIV - cART_Long,10.1038/s41598-019-56330-0,1.052,0.125,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2019_boban_27,46,HIV - cART_Long,10.1038/s41598-019-56330-0,1.003,0.258,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2019_boban_27,47,HIV - cART_Long,10.1038/s41598-019-56330-0,1.014,0.226,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2019_boban_27,48,HIV - cART_Long,10.1038/s41598-019-56330-0,0.911,0.143,,,,,Assumed Total (tCho) based on Analysis
,Cho,GPC,2019_borgelt_21,1,Bipolar - First,10.1111/bdi.12782,,,,,2,0.45,
,Cho,GPC,2019_borgelt_21,2,Bipolar - First,10.1111/bdi.12782,,,,,2.05,0.39,
,Cho,GPC,2019_borgelt_21,3,Bipolar - First,10.1111/bdi.12782,,,,,1.67,0.38,
,Cho,GPC,2019_borgelt_21,4,Bipolar - Multiple,10.1111/bdi.12782,,,,,1.99,0.43,
,Cho,GPC,2019_borgelt_21,5,Bipolar - Multiple,10.1111/bdi.12782,,,,,2.8,0.36,
,Cho,GPC,2019_borgelt_21,6,Bipolar - Multiple,10.1111/bdi.12782,,,,,1.8,0.38,
,Cho,GPC,2019_bossong_76,1,Control,10.1001/jamapsychiatry.2018.3252,,,,,2.3,0.4,
,Cho,GPC,2019_bossong_76,2,Psychosis - HighRisk,10.1001/jamapsychiatry.2018.3252,,,,,2.4,0.43,
,Cho,GPC,2019_bossong_76,3,Psychosis,10.1001/jamapsychiatry.2018.3252,,,,,2.59,0.21,
,Cho,GPC,2019_brown_29,1,Corticosteroid,10.1016/j.euroneuro.2018.12.012,0.2,0.02,,,,,
,Cho,GPC,2019_brown_29,2,Corticosteroid,10.1016/j.euroneuro.2018.12.012,0.2,0.02,,,,,
,Cho,GPC,2019_brown_29,3,Corticosteroid,10.1016/j.euroneuro.2018.12.012,0.18,0.02,,,,,
,Cho,GPC,2019_brown_29,4,Corticosteroid,10.1016/j.euroneuro.2018.12.012,0.2,0.02,,,,,
,Cho,GPC,2019_brown_29,5,Corticosteroid,10.1016/j.euroneuro.2018.12.012,0.19,0.03,,,,,
,Cho,GPC,2019_brown_29,6,Corticosteroid,10.1016/j.euroneuro.2018.12.012,0.19,0.02,,,,,
,Cho,GPC,2019_brown_29,7,Corticosteroid,10.1016/j.euroneuro.2018.12.012,0.22,0.08,,,,,
,Cho,GPC,2019_brown_29,8,Corticosteroid,10.1016/j.euroneuro.2018.12.012,0.2,0.02,,,,,
,Cho,GPC,2019_bustillo_246,1,Control <40 GM,10.1016/j.jad.2018.12.064,,,,,3.2,0.6,
,Cho,GPC,2019_bustillo_246,2,Control <40 WM,10.1016/j.jad.2018.12.064,,,,,3.1,0.4,
,Cho,GPC,2019_bustillo_246,3,Control >40 GM,10.1016/j.jad.2018.12.064,,,,,3.5,0.6,
,Cho,GPC,2019_bustillo_246,4,Control >40 WM,10.1016/j.jad.2018.12.064,,,,,3.4,0.4,
,Cho,GPC,2019_bustillo_246,5,Bipolar <40 GM,10.1016/j.jad.2018.12.064,,,,,3.2,0.6,
,Cho,GPC,2019_bustillo_246,6,Bipolar <40 WM,10.1016/j.jad.2018.12.064,,,,,3.1,0.4,
,Cho,GPC,2019_bustillo_246,7,Bipolar >40 GM,10.1016/j.jad.2018.12.064,,,,,3.4,0.6,
,Cho,GPC,2019_bustillo_246,8,Bipolar >40 WM,10.1016/j.jad.2018.12.064,,,,,3.3,0.4,
,Cho,GPC,2019_bustillo_246,9,Schizophrenia <40 GM,10.1016/j.jad.2018.12.064,,,,,3.1,0.6,
,Cho,GPC,2019_bustillo_246,10,Schizophrenia <40 WM,10.1016/j.jad.2018.12.064,,,,,3.1,0.4,
,Cho,GPC,2019_bustillo_246,11,Schizophrenia >40 GM,10.1016/j.jad.2018.12.064,,,,,3.5,0.7,
,Cho,GPC,2019_bustillo_246,12,Schizophrenia >40 WM,10.1016/j.jad.2018.12.064,,,,,3.3,0.5,
,GPC+Pcho,tCho,2019_basu_9,1,Premature Infant,10.1038/s41598-018-37203-4,0.781,0.186,3.636,0.965,,,
,GPC+Pcho,tCho,2019_basu_9,5,Premature Infant,10.1038/s41598-018-37203-4,0.824,0.16,2.369,0.684,,,
,Cho,tCho,2019_chawla_32,1,Control,10.1177/1971400919846509,0.87,0.11,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2019_chawla_32,2,Cancer,10.1177/1971400919846509,1.31,0.05,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2019_cheng_43,1,Control,10.1097/RCT.0000000000000854,0.96,0.2,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2019_cheng_43,2,MMA-HC,10.1097/RCT.0000000000000854,0.93,0.26,,,,,Assumed Total (tCho) based on Analysis
,Cho,GPC,2019_cheong_90,1,Control - Visit 1,10.1136/jnnp-2018-318795,,,,,1.336,0.167,
,Cho,GPC,2019_cheong_90,2,Control - Visit 2,10.1136/jnnp-2018-318795,,,,,1.392,0.139,
,Cho,GPC,2019_cheong_90,3,Control - Visit 3,10.1136/jnnp-2018-318795,,,,,1.336,0.167,
,Cho,GPC,2019_cheong_90,4,Control - Visit 1,10.1136/jnnp-2018-318795,,,,,3.032,0.549,
,Cho,GPC,2019_cheong_90,5,Control - Visit 2,10.1136/jnnp-2018-318795,,,,,3.129,0.323,
,Cho,GPC,2019_cheong_90,6,Control - Visit 3,10.1136/jnnp-2018-318795,,,,,3.097,0.322,
,Cho,GPC,2019_cheong_90,7,ALS - Visit 1,10.1136/jnnp-2018-318795,,,,,1.373,0.165,
,Cho,GPC,2019_cheong_90,8,ALS - Visit 2,10.1136/jnnp-2018-318795,,,,,1.373,0.165,
,Cho,GPC,2019_cheong_90,9,ALS - Visit 3,10.1136/jnnp-2018-318795,,,,,1.373,0.055,
,Cho,GPC,2019_cheong_90,10,ALS - Visit 1,10.1136/jnnp-2018-318795,,,,,2.981,0.422,
,Cho,GPC,2019_cheong_90,11,ALS - Visit 2,10.1136/jnnp-2018-318795,,,,,2.949,0.519,
,Cho,GPC,2019_cheong_90,12,ALS - Visit 3,10.1136/jnnp-2018-318795,,,,,3.144,0.486,
,tCho,tCho,2019_davies_29,1,High-Risk Psychosis,10.1016/j.euroneuro.2019.03.008,0.33,0.02,2.37,0.41,,,
,tCho,tCho,2019_davies_29,2,High-Risk Psychosis,10.1016/j.euroneuro.2019.03.008,0.24,0.02,2.77,0.41,,,
,tCho,tCho,2019_davies_29,3,High-Risk Psychosis,10.1016/j.euroneuro.2019.03.008,0.29,0.02,2.13,0.2,,,
,tCho,tCho,2019_davies_29,4,High-Risk Psychosis,10.1016/j.euroneuro.2019.03.008,0.32,0.03,2.38,0.29,,,
,tCho,tCho,2019_davies_29,5,High-Risk Psychosis,10.1016/j.euroneuro.2019.03.008,0.25,0.02,2.93,0.36,,,
,tCho,tCho,2019_davies_29,6,High-Risk Psychosis,10.1016/j.euroneuro.2019.03.008,0.3,0.03,2.19,0.22,,,
,tCho,tCho,2018_adanyeguh_31,2,Healthy,10.1002/nbm.3880,,,,,1,0.1,Estimated Bar Graph 
,tCho,tCho,2018_adanyeguh_31,4,HD,10.1002/nbm.3880,,,,,1.1,0.2,Estimated Bar Graph 
,tCho,tCho,2018_adanyeguh_31,1,Healthy,10.1002/nbm.3880,,,,,1.8,0.2,Estimated Bar Graph 
,tCho,tCho,2018_adanyeguh_31,3,HD,10.1002/nbm.3880,,,,,2,0.3,Estimated Bar Graph 
,tCho,tCho,2018_al-iedani_108,1,Healthy,10.1016/j.ejrad.2018.09.020,0.23,0.01,,,,,
,tCho,tCho,2018_al-iedani_108,2,Healthy,10.1016/j.ejrad.2018.09.020,0.2,0,,,,,
,tCho,tCho,2018_an_80,1,Healthy,10.1002/mrm.27172,0.3,0.02,,,,,
,tCho,tCho,2018_atagun_235,1,BD-I,10.1016/j.jad.2018.04.010,,,0.29,0.05,,,
,tCho,tCho,2018_atagun_235,2,BD-I,10.1016/j.jad.2018.04.010,,,0.17,0.03,,,
,tCho,tCho,2018_atagun_235,3,BD-II,10.1016/j.jad.2018.04.010,,,0.3,0.05,,,
,tCho,tCho,2018_atagun_235,4,BD-II,10.1016/j.jad.2018.04.010,,,0.2,0.04,,,
,tCho,tCho,2018_atagun_235,5,Control,10.1016/j.jad.2018.04.010,,,0.28,0.06,,,
,tCho,tCho,2018_atagun_235,6,Control,10.1016/j.jad.2018.04.010,,,0.19,0.03,,,
,tCho,tCho,2018_barbagallo_47,4,Control,10.1016/j.parkreldis.2017.11.345,0.33,0.07,2.55,0.85,,,
,tCho,tCho,2018_barbagallo_47,5,Control,10.1016/j.parkreldis.2017.11.345,0.36,0.12,2.43,0.87,,,
,tCho,tCho,2018_barbagallo_47,6,Control,10.1016/j.parkreldis.2017.11.345,0.3,0.06,2.28,0.63,,,
,tCho,tCho,2018_barbagallo_47,1,Essential Tremor,10.1016/j.parkreldis.2017.11.345,0.31,0.04,2.36,0.73,,,
,tCho,tCho,2018_barbagallo_47,2,Essential Tremor,10.1016/j.parkreldis.2017.11.345,0.31,0.04,2.11,0.42,,,
,tCho,tCho,2018_barbagallo_47,3,Essential Tremor,10.1016/j.parkreldis.2017.11.345,0.31,0.07,2.24,0.59,,,
,tCho,tCho,2018_bauer_19,1,Healthy,10.1080/15622975.2016.1262060,,,2.24,0.33,,,
,tCho,tCho,2018_bauer_19,2,Healthy,10.1080/15622975.2016.1262060,,,1.73,0.38,,,
,tCho,tCho,2018_bauer_19,3,ADHD,10.1080/15622975.2016.1262060,,,2.39,0.47,,,
,tCho,tCho,2018_bauer_19,4,ADHD,10.1080/15622975.2016.1262060,,,1.89,0.33,,,
,Cho,tCho,2020_mohamadi_10,1,TTH,10.31661/jbpe.v0i0.1039,0.77,0.09,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2020_mohamadi_10,2,TTH,10.31661/jbpe.v0i0.1039,0.82,0.25,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2020_mohamadi_10,3,TTH,10.31661/jbpe.v0i0.1039,0.5,0.1,,,,,Assumed Total (tCho) based on Analysis
,Cho,GPC,2018_caravaggio_28,1,Healthy,10.1016/j.euroneuro.2017.12.002,,,2.14,0.25,,,
,Cho,GPC,2018_caravaggio_28,2,Healthy,10.1016/j.euroneuro.2017.12.002,,,2.09,0.28,,,
,Cho,GPC,2018_caravaggio_28,3,Healthy,10.1016/j.euroneuro.2017.12.002,,,2.11,0.3,,,
,Cho,GPC,2018_caravaggio_28,4,Healthy,10.1016/j.euroneuro.2017.12.002,,,1.97,0.19,,,
,Cho,GPC,2018_chiu_193,3,First-episode Schizophrenia,10.1016/j.schres.2017.07.021,,,,,2.52,0.51,
,Cho,GPC,2018_chiu_193,4,Healthy,10.1016/j.schres.2017.07.021,,,,,1.83,0.24,
,Cho,tCho,2018_cichocka_83,1,Healthy,10.5114/pjr.2018.74536,1.02,0.152,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2018_cichocka_83,2,Healthy,10.5114/pjr.2018.74536,1.06,0.177,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2018_cichocka_83,3,Healthy,10.5114/pjr.2018.74536,0.86,0.167,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2018_cichocka_83,4,Healthy,10.5114/pjr.2018.74536,0.81,0.273,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2018_cichocka_83,5,Healthy,10.5114/pjr.2018.74536,1.06,0.219,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2018_cichocka_83,6,Healthy,10.5114/pjr.2018.74536,1.12,0.39,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2018_cichocka_83,7,Healthy,10.5114/pjr.2018.74536,0.86,0.138,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2018_cichocka_83,8,Healthy,10.5114/pjr.2018.74536,1.03,0.217,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2018_cichocka_83,9,Healthy,10.5114/pjr.2018.74536,1.04,0.198,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2018_cichocka_83,10,Healthy,10.5114/pjr.2018.74536,1.05,1.241,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2018_cichocka_83,11,Healthy,10.5114/pjr.2018.74536,0.85,0.093,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2018_cichocka_83,12,Healthy,10.5114/pjr.2018.74536,1.09,0.201,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2018_cichocka_83,13,Healthy,10.5114/pjr.2018.74536,1.03,0.262,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2018_cichocka_83,14,Healthy,10.5114/pjr.2018.74536,0.92,0.15,,,,,Assumed Total (tCho) based on Analysis
,Cho,GPC,2018_de_239,1,Postpartum Depression,10.1016/j.jad.2018.07.028,0.3,0.03,,,,,
,Cho,GPC,2018_de_239,2,Postpartum Euthymic ,10.1016/j.jad.2018.07.028,0.3,0.05,,,,,
,tCho,tCho,2018_ding_38,1,Healthy - Pre-fasting,10.1177/0271678X17697721,,,1.96,0.18,,,
,tCho,tCho,2018_ding_38,2,Healthy - Pre-fasting,10.1177/0271678X17697721,,,2.08,0.27,,,
,tCho,tCho,2018_ding_38,3,Healthy - Pre-fasting,10.1177/0271678X17697721,,,1.68,0.19,,,
,tCho,tCho,2018_ding_38,4,Healthy - Pre-fasting,10.1177/0271678X17697721,,,1.8,0.17,,,
,tCho,tCho,2018_ding_38,5,Healthy - Pre-fasting,10.1177/0271678X17697721,,,1.74,0.16,,,
,tCho,tCho,2018_ding_38,6,Healthy - Pre-fasting,10.1177/0271678X17697721,,,1.76,0.17,,,
,tCho,tCho,2018_ding_38,7,Healthy - Pre-fasting,10.1177/0271678X17697721,,,1.35,0.16,,,
,tCho,tCho,2018_ding_38,8,Healthy - Pre-fasting,10.1177/0271678X17697721,,,1.44,0.2,,,
,tCho,tCho,2018_ding_38,9,Healthy - Pre-fasting,10.1177/0271678X17697721,,,2.28,0.2,,,
,tCho,tCho,2018_ding_38,10,Healthy - Post-fasting,10.1177/0271678X17697721,,,1.74,0.11,,,
,tCho,tCho,2018_ding_38,11,Healthy - Post-fasting,10.1177/0271678X17697721,,,1.83,0.19,,,
,tCho,tCho,2018_ding_38,12,Healthy - Post-fasting,10.1177/0271678X17697721,,,1.53,0.13,,,
,tCho,tCho,2018_ding_38,13,Healthy - Post-fasting,10.1177/0271678X17697721,,,1.58,0.15,,,
,tCho,tCho,2018_ding_38,14,Healthy - Post-fasting,10.1177/0271678X17697721,,,1.56,0.18,,,
,tCho,tCho,2018_ding_38,15,Healthy - Post-fasting,10.1177/0271678X17697721,,,1.59,0.14,,,
,tCho,tCho,2018_ding_38,16,Healthy - Post-fasting,10.1177/0271678X17697721,,,1.25,0.15,,,
,tCho,tCho,2018_ding_38,17,Healthy - Post-fasting,10.1177/0271678X17697721,,,1.26,0.14,,,
,tCho,tCho,2018_ding_38,18,Healthy - Post-fasting,10.1177/0271678X17697721,,,2.03,0.19,,,
,tCho,tCho,2018_ding_38,19,Healthy - Non-fasting,10.1177/0271678X17697721,,,2.03,0.23,,,
,tCho,tCho,2018_ding_38,20,Healthy - Non-fasting,10.1177/0271678X17697721,,,2.08,0.25,,,
,tCho,tCho,2018_ding_38,21,Healthy - Non-fasting,10.1177/0271678X17697721,,,1.74,0.17,,,
,tCho,tCho,2018_ding_38,22,Healthy - Non-fasting,10.1177/0271678X17697721,,,1.85,0.16,,,
,tCho,tCho,2018_ding_38,23,Healthy - Non-fasting,10.1177/0271678X17697721,,,1.71,0.19,,,
,tCho,tCho,2018_ding_38,24,Healthy - Non-fasting,10.1177/0271678X17697721,,,1.76,0.22,,,
,tCho,tCho,2018_ding_38,25,Healthy - Non-fasting,10.1177/0271678X17697721,,,1.32,0.13,,,
,tCho,tCho,2018_ding_38,26,Healthy - Non-fasting,10.1177/0271678X17697721,,,1.44,0.17,,,
,tCho,tCho,2018_ding_38,27,Healthy - Non-fasting,10.1177/0271678X17697721,,,2.33,0.22,,,
,tCho,tCho,2017_aleks_282,1,Control - Baseline,10.1148/radiol.2016152083,0.31,0.01,,,,,
,tCho,tCho,2017_aleks_282,2,Control - Follow-Up,10.1148/radiol.2016152083,0.32,0.01,,,,,
,tCho,tCho,2017_aleks_282,3,Cervical Spondylotic Myelopathy - Preoperative,10.1148/radiol.2016152083,0.29,0.01,,,,,
,tCho,tCho,2017_aleks_282,4,Cervical Spondylotic Myelopathy - Postoperative,10.1148/radiol.2016152083,0.28,0.01,,,,,
,tCho,tCho,2018_egerton_23,1,Healthy - Baseline,10.1038/s41380-018-0082-9,0.26,0.04,,,,,
,tCho,tCho,2018_egerton_23,2,Healthy - Baseline,10.1038/s41380-018-0082-9,0.24,0.03,,,,,
,tCho,tCho,2018_egerton_23,3,Healthy - Baseline,10.1038/s41380-018-0082-9,0.24,0.02,,,,,
,tCho,tCho,2018_egerton_23,4,Healthy - Baseline,10.1038/s41380-018-0082-9,0.28,0.03,,,,,
,tCho,tCho,2018_egerton_23,5,Healthy - Baseline,10.1038/s41380-018-0082-9,0.3,0.04,,,,,
,tCho,tCho,2018_egerton_23,6,Healthy - Baseline,10.1038/s41380-018-0082-9,0.32,0.04,,,,,
,tCho,tCho,2018_egerton_23,7,Healthy - After Amisulpride,10.1038/s41380-018-0082-9,0.25,0.03,,,,,
,tCho,tCho,2018_egerton_23,8,Healthy - After Amisulpride,10.1038/s41380-018-0082-9,0.24,0.03,,,,,
,tCho,tCho,2018_egerton_23,9,Healthy - After Amisulpride,10.1038/s41380-018-0082-9,0.23,0.03,,,,,
,tCho,tCho,2018_egerton_23,10,Healthy - After Amisulpride,10.1038/s41380-018-0082-9,0.3,0.03,,,,,
,tCho,tCho,2018_egerton_23,11,Healthy - After Amisulpride,10.1038/s41380-018-0082-9,0.3,0.03,,,,,
,tCho,tCho,2018_egerton_23,12,Healthy - After Amisulpride,10.1038/s41380-018-0082-9,0.31,0.02,,,,,
,tCho,tCho,2018_egerton_23,13,First Episode Psychosis - Baseline,10.1038/s41380-018-0082-9,0.27,0.03,,,,,
,tCho,tCho,2018_egerton_23,14,First Episode Psychosis - Baseline,10.1038/s41380-018-0082-9,0.23,0.02,,,,,
,tCho,tCho,2018_egerton_23,15,First Episode Psychosis - Baseline,10.1038/s41380-018-0082-9,0.24,0.04,,,,,
,tCho,tCho,2018_egerton_23,16,First Episode Psychosis - Baseline,10.1038/s41380-018-0082-9,0.28,0.02,,,,,
,tCho,tCho,2018_egerton_23,17,First Episode Psychosis - Baseline,10.1038/s41380-018-0082-9,0.29,0.03,,,,,
,tCho,tCho,2018_egerton_23,18,First Episode Psychosis - Baseline,10.1038/s41380-018-0082-9,0.31,0.04,,,,,
,tCho,tCho,2018_egerton_23,19,First Episode Psychosis - After Amisulpride,10.1038/s41380-018-0082-9,0.27,0.04,,,,,
,tCho,tCho,2018_egerton_23,20,First Episode Psychosis - After Amisulpride,10.1038/s41380-018-0082-9,0.24,0.02,,,,,
,tCho,tCho,2018_egerton_23,21,First Episode Psychosis - After Amisulpride,10.1038/s41380-018-0082-9,0.26,0.02,,,,,
,tCho,tCho,2018_egerton_23,22,First Episode Psychosis - After Amisulpride,10.1038/s41380-018-0082-9,0.28,0.03,,,,,
,tCho,tCho,2018_egerton_23,23,First Episode Psychosis - After Amisulpride,10.1038/s41380-018-0082-9,0.29,0.03,,,,,
,tCho,tCho,2018_egerton_23,24,First Episode Psychosis - After Amisulpride,10.1038/s41380-018-0082-9,0.32,0.03,,,,,
,tCho,tCho,2018_egerton_23,25,First Episode Psychosis - Remission (Baseline),10.1038/s41380-018-0082-9,0.27,0.03,,,,,
,tCho,tCho,2018_egerton_23,26,First Episode Psychosis - Remission (Baseline),10.1038/s41380-018-0082-9,0.23,0.02,,,,,
,tCho,tCho,2018_egerton_23,27,First Episode Psychosis - Remission (Baseline),10.1038/s41380-018-0082-9,0.26,0.04,,,,,
,tCho,tCho,2018_egerton_23,28,First Episode Psychosis - Remission (Baseline),10.1038/s41380-018-0082-9,0.27,0.03,,,,,
,tCho,tCho,2018_egerton_23,29,First Episode Psychosis - Remission (Baseline),10.1038/s41380-018-0082-9,0.29,0.03,,,,,
,tCho,tCho,2018_egerton_23,30,First Episode Psychosis - Remission (Baseline),10.1038/s41380-018-0082-9,0.31,0.04,,,,,
,tCho,tCho,2018_egerton_23,31,First Episode Psychosis - Remission (After Amisulpride),10.1038/s41380-018-0082-9,0.27,0.05,,,,,
,tCho,tCho,2018_egerton_23,32,First Episode Psychosis - Remission (After Amisulpride),10.1038/s41380-018-0082-9,0.23,0.02,,,,,
,tCho,tCho,2018_egerton_23,33,First Episode Psychosis - Remission (After Amisulpride),10.1038/s41380-018-0082-9,0.26,0.02,,,,,
,tCho,tCho,2018_egerton_23,34,First Episode Psychosis - Remission (After Amisulpride),10.1038/s41380-018-0082-9,0.28,0.03,,,,,
,tCho,tCho,2018_egerton_23,35,First Episode Psychosis - Remission (After Amisulpride),10.1038/s41380-018-0082-9,0.29,0.03,,,,,
,tCho,tCho,2018_egerton_23,36,First Episode Psychosis - Remission (After Amisulpride),10.1038/s41380-018-0082-9,0.32,0.03,,,,,
,tCho,tCho,2018_egerton_23,37,First Episode Psychosis - No Remission (Baseline),10.1038/s41380-018-0082-9,0.28,0.04,,,,,
,tCho,tCho,2018_egerton_23,38,First Episode Psychosis - No Remission (Baseline),10.1038/s41380-018-0082-9,0.24,0.02,,,,,
,tCho,tCho,2018_egerton_23,39,First Episode Psychosis - No Remission (Baseline),10.1038/s41380-018-0082-9,0.22,0.03,,,,,
,tCho,tCho,2018_egerton_23,40,First Episode Psychosis - No Remission (Baseline),10.1038/s41380-018-0082-9,0.28,0.03,,,,,
,tCho,tCho,2018_egerton_23,41,First Episode Psychosis - No Remission (Baseline),10.1038/s41380-018-0082-9,0.28,0.03,,,,,
,tCho,tCho,2018_egerton_23,42,First Episode Psychosis - No Remission (Baseline),10.1038/s41380-018-0082-9,0.3,0.03,,,,,
,tCho,tCho,2018_egerton_23,43,First Episode Psychosis - No Remission (After Amisulpride),10.1038/s41380-018-0082-9,0.27,0.03,,,,,
,tCho,tCho,2018_egerton_23,44,First Episode Psychosis - No Remission (After Amisulpride),10.1038/s41380-018-0082-9,0.25,0.02,,,,,
,tCho,tCho,2018_egerton_23,45,First Episode Psychosis - No Remission (After Amisulpride),10.1038/s41380-018-0082-9,0.25,0.01,,,,,
,tCho,tCho,2018_egerton_23,46,First Episode Psychosis - No Remission (After Amisulpride),10.1038/s41380-018-0082-9,0.28,0.03,,,,,
,tCho,tCho,2018_egerton_23,47,First Episode Psychosis - No Remission (After Amisulpride),10.1038/s41380-018-0082-9,0.29,0.02,,,,,
,tCho,tCho,2018_egerton_23,48,First Episode Psychosis - No Remission (After Amisulpride),10.1038/s41380-018-0082-9,0.3,0.05,,,,,
,Cho,GPC,2018_elmaki_36,1,Parkinson's Disease,10.1007/s11604-017-0714-z,,,2.31,0.25,,,
,Cho,GPC,2018_elmaki_36,2,Healthy,10.1007/s11604-017-0714-z,,,2.19,0.23,,,
,Cho,GPC,2018_evans_43,1,Control - Baseline,10.1038/s41386-018-0057-1,0.29,0.02,,,,,
,Cho,GPC,2018_evans_43,2,Control - Ketamine,10.1038/s41386-018-0057-1,0.3,0.03,,,,,
,Cho,GPC,2018_evans_43,3,Control - Placebo,10.1038/s41386-018-0057-1,0.28,0.03,,,,,
,Cho,GPC,2018_evans_43,4,Major Depressive Disorder - Baseline,10.1038/s41386-018-0057-1,0.31,0.02,,,,,
,Cho,GPC,2018_evans_43,5,Major Depressive Disorder - Ketamine,10.1038/s41386-018-0057-1,0.3,0.02,,,,,
,Cho,GPC,2018_evans_43,6,Major Depressive Disorder - Placebo,10.1038/s41386-018-0057-1,0.3,0.02,,,,,
,tCho,tCho,2018_ford_10,1,Healthy - Vitamin B (Baseline),10.3390/nu10121860,,,1.44,0.05,,,
,tCho,tCho,2018_ford_10,2,Healthy - Placebo (Baseline),10.3390/nu10121860,,,1.38,0.04,,,
,tCho,tCho,2018_ford_10,3,Healthy - Vitamin B (6 Months),10.3390/nu10121860,,,1.52,0.03,,,
,tCho,tCho,2018_ford_10,4,Healthy - Placebo (6 Months),10.3390/nu10121860,,,1.42,0.04,,,
,tCho,tCho,2018_galinska-skok_2018,1,Schizophrenia,10.1155/2018/3654894,0.99,0.17,0.26,0.04,,,
,tCho,tCho,2018_galinska-skok_2018,2,Schizophrenia,10.1155/2018/3654894,0.98,0.17,0.25,0.06,,,
,tCho,tCho,2018_galinska-skok_2018,3,Bipolar Disorder,10.1155/2018/3654894,0.99,0.12,0.27,0.05,,,
,tCho,tCho,2018_galinska-skok_2018,4,Bipolar Disorder,10.1155/2018/3654894,0.97,0.2,0.23,0.07,,,
,tCho,tCho,2018_galinska-skok_2018,5,Control,10.1155/2018/3654894,0.9,0.17,0.23,0.04,,,
,tCho,tCho,2018_galinska-skok_2018,6,Control,10.1155/2018/3654894,1,0.2,0.23,0.06,,,
,tCho,tCho,2018_gasparovic_48,1,Preterm Birth - Placebo (Scan 1),10.1007/s00247-017-4052-1,,,2.67,0.32,,,
,tCho,tCho,2018_gasparovic_48,2,Preterm Birth - Placebo (Scan 1),10.1007/s00247-017-4052-1,,,3.31,0.37,,,
,tCho,tCho,2018_gasparovic_48,3,Preterm Birth - Placebo (Scan 2),10.1007/s00247-017-4052-1,,,2.77,0.32,,,
,tCho,tCho,2018_gasparovic_48,4,Preterm Birth - Placebo (Scan 2),10.1007/s00247-017-4052-1,,,3.31,0.35,,,
,tCho,tCho,2018_gasparovic_48,5,Preterm Birth - Erythropoiesis Stimulating Agent (Scan 1),10.1007/s00247-017-4052-1,,,2.77,0.34,,,
,tCho,tCho,2018_gasparovic_48,6,Preterm Birth - Erythropoiesis Stimulating Agent (Scan 1),10.1007/s00247-017-4052-1,,,3.16,0.55,,,
,tCho,tCho,2018_gasparovic_48,7,Preterm Birth - Erythropoiesis Stimulating Agent (Scan 2),10.1007/s00247-017-4052-1,,,2.82,0.28,,,
,tCho,tCho,2018_gasparovic_48,8,Preterm Birth - Erythropoiesis Stimulating Agent (Scan 2),10.1007/s00247-017-4052-1,,,3.15,0.39,,,
,tCho,tCho,2018_gasparovic_48,9,Control - Scan 1,10.1007/s00247-017-4052-1,,,2.81,0.31,,,
,tCho,tCho,2018_gasparovic_48,10,Control - Scan 1,10.1007/s00247-017-4052-1,,,3.32,0.57,,,
,tCho,tCho,2018_gasparovic_48,11,Control - Scan 2,10.1007/s00247-017-4052-1,,,2.94,0.3,,,
,tCho,tCho,2018_gasparovic_48,12,Control - Scan 3,10.1007/s00247-017-4052-1,,,3.33,0.42,,,
,Cho,GPC,2018_gramegna_39,1,Mitochondrial Neurogastrointestinal Encephalopathy,10.3174/ajnr.A5507,0.39,0.06,,,1.53,0.23,
,Cho,GPC,2018_gramegna_39,2,Control,10.3174/ajnr.A5507,0.33,0.04,,,1.89,0.24,
,Cho,GPC,2018_harper_17,1,Urologic Chronic Pelvic Pain Syndrome,10.1016/j.nicl.2017.11.014,0.25,0.02,1.38,0.14,,,
,Cho,GPC,2018_harper_17,2,Urologic Chronic Pelvic Pain Syndrome,10.1016/j.nicl.2017.11.014,0.23,0.03,1.38,0.24,,,
,Cho,GPC,2018_harper_17,3,Urologic Chronic Pelvic Pain Syndrome,10.1016/j.nicl.2017.11.014,0.2,0.04,1.19,0.24,,,
,Cho,GPC,2018_harper_17,4,Urologic Chronic Pelvic Pain Syndrome,10.1016/j.nicl.2017.11.014,0.09,0.04,0.59,0.25,,,
,Cho,GPC,2018_harper_17,5,Control,10.1016/j.nicl.2017.11.014,0.22,0.03,1.25,0.17,,,
,Cho,GPC,2018_harper_17,6,Control,10.1016/j.nicl.2017.11.014,0.22,0.02,1.33,0.2,,,
,Cho,GPC,2018_harper_17,7,Control,10.1016/j.nicl.2017.11.014,0.2,0.02,1.18,0.14,,,
,Cho,GPC,2018_harper_17,8,Control,10.1016/j.nicl.2017.11.014,0.09,0.03,0.54,0.21,,,
,Cho,GPC,2018_hegarty_48,1,Autism Spectrum Disorder,10.1007/s10803-018-3613-y,,,4.35,0.42,,,
,Cho,GPC,2018_hegarty_48,2,Autism Spectrum Disorder,10.1007/s10803-018-3613-y,,,2.29,0.67,,,
,Cho,GPC,2018_hegarty_48,3,Control,10.1007/s10803-018-3613-y,,,4.37,0.5,,,
,Cho,GPC,2018_hegarty_48,4,Control,10.1007/s10803-018-3613-y,,,2.56,0.42,,,
,Cho,GPC,2018_hegarty_81,1,Autism Spectrum Disorder,10.1016/j.pnpbp.2017.09.016,0.29,0.06,,,,,
,Cho,GPC,2018_hegarty_81,2,Autism Spectrum Disorder,10.1016/j.pnpbp.2017.09.016,0.34,0.09,,,,,
,Cho,GPC,2018_hegarty_81,3,Control,10.1016/j.pnpbp.2017.09.016,0.3,0.04,,,,,
,Cho,GPC,2018_hegarty_81,4,Control,10.1016/j.pnpbp.2017.09.016,0.34,0.05,,,,,
,Cho,GPC,2018_hegarty_81,5,Autism Spectrum Disorder,10.1016/j.pnpbp.2017.09.016,0.28,0.05,,,,,
,Cho,GPC,2018_hegarty_81,6,Autism Spectrum Disorder,10.1016/j.pnpbp.2017.09.016,0.32,0.05,,,,,
,Cho,GPC,2018_hegarty_81,7,Control,10.1016/j.pnpbp.2017.09.016,0.31,0.04,,,,,
,Cho,GPC,2018_hegarty_81,8,Control,10.1016/j.pnpbp.2017.09.016,0.33,0.04,,,,,
,Cho,GPC,2018_hjelmervik_172,1,Healthy - Menstrual Phase,10.1016/j.neuroimage.2018.01.043,,,1.57,0.28,,,
,Cho,GPC,2018_hjelmervik_172,2,Healthy - Menstrual Phase,10.1016/j.neuroimage.2018.01.043,,,1.39,0.27,,,
,Cho,GPC,2018_hjelmervik_172,3,Healthy - Follicular Phase,10.1016/j.neuroimage.2018.01.043,,,1.63,0.33,,,
,Cho,GPC,2018_hjelmervik_172,4,Healthy - Follicular Phase,10.1016/j.neuroimage.2018.01.043,,,1.31,0.25,,,
,Cho,GPC,2018_hjelmervik_172,5,Healthy - Luteal Phase,10.1016/j.neuroimage.2018.01.043,,,1.49,0.31,,,
,Cho,GPC,2018_hjelmervik_172,6,Healthy - Luteal Phase,10.1016/j.neuroimage.2018.01.043,,,1.44,0.25,,,
,Cho,GPC,2018_hjelmervik_172,7,Healthy - Total,10.1016/j.neuroimage.2018.01.043,,,1.47,0.17,,,
,Cho,GPC,2018_hjelmervik_172,8,Healthy - Session 1,10.1016/j.neuroimage.2018.01.043,,,1.58,0.21,,,
,Cho,GPC,2018_hjelmervik_172,9,Healthy - Session 1,10.1016/j.neuroimage.2018.01.043,,,1.4,0.23,,,
,Cho,GPC,2018_hjelmervik_172,10,Healthy - Session 2,10.1016/j.neuroimage.2018.01.043,,,1.5,0.23,,,
,Cho,GPC,2018_hjelmervik_172,11,Healthy - Session 2,10.1016/j.neuroimage.2018.01.043,,,1.39,0.22,,,
,Cho,GPC,2018_hjelmervik_172,12,Healthy - Session 3,10.1016/j.neuroimage.2018.01.043,,,1.55,0.23,,,
,Cho,GPC,2018_hjelmervik_172,13,Healthy - Session 3,10.1016/j.neuroimage.2018.01.043,,,1.39,0.29,,,
,Cho,GPC,2018_hjelmervik_172,14,Healthy - Total,10.1016/j.neuroimage.2018.01.043,,,1.47,0.17,,,
,Cho,GPC,2018_horder_8,1,Control,10.1038/s41398-018-0155-1,,,1.97,0.24,,,
,Cho,GPC,2018_horder_8,2,Control,10.1038/s41398-018-0155-1,,,1.91,0.24,,,
,Cho,GPC,2018_horder_8,3,Autism Spectrum Disorder,10.1038/s41398-018-0155-1,,,2.12,0.3,,,
,Cho,GPC,2018_horder_8,4,Autism Spectrum Disorder,10.1038/s41398-018-0155-1,,,2.04,0.2,,,
,Cho,tCho,2018_ikeguchi_26,1,Glioma,10.1016/j.msard.2018.08.025,2.23,0.37,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2018_ikeguchi_26,2,High-grade Glioma,10.1016/j.msard.2018.08.025,2.63,0,,,,,2 patients' data excluded (n_exclusions=1); Assumed Total (tCho) based on Analysis
,Cho,tCho,2018_ikeguchi_26,3,Low-grade Glioma,10.1016/j.msard.2018.08.025,2.03,0.21,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2018_ikeguchi_26,4,Tumefactive Demyelinating Lesion,10.1016/j.msard.2018.08.025,5.25,8.47,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2018_ikeguchi_26,5,Multiple Sclerosis,10.1016/j.msard.2018.08.025,1.05,0.24,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2018_ikeguchi_26,6,Glioma,10.1016/j.msard.2018.08.025,2,0.63,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2018_ikeguchi_26,7,High-grade Glioma,10.1016/j.msard.2018.08.025,2.19,0.68,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2018_ikeguchi_26,8,Low-grade Glioma,10.1016/j.msard.2018.08.025,1.84,0.57,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2018_ikeguchi_26,9,Tumefactive Demyelinating Lesion,10.1016/j.msard.2018.08.025,1.75,0.33,,,,,Assumed Total (tCho) based on Analysis
,Cho,GPC,2018_kim_23,1,Methamphetamine Dependence ,10.1111/adb.12473,,,1.31,0.24,,,
,Cho,GPC,2018_kim_23,2,Control,10.1111/adb.12473,,,1.35,0.28,,,
,tCho,tCho,2020_bhogal_10,1,Healthy,10.1002/brb3.1852,0.23,0.04,,,,,
,tCho,tCho,2020_bhogal_10,2,Healthy,10.1002/brb3.1852,0.23,0.03,,,,,
,tCho,tCho,2020_bhogal_10,3,Healthy,10.1002/brb3.1852,0.24,0.03,,,,,
,tCho,tCho,2020_bhogal_10,4,Healthy,10.1002/brb3.1852,0.22,0.03,,,,,
,tCho,tCho,2020_bhogal_10,5,Healthy,10.1002/brb3.1852,0.18,0.01,,,,,
,tCho,tCho,2020_bhogal_10,6,Healthy,10.1002/brb3.1852,0.19,0.02,,,,,
,tCho,tCho,2020_bhogal_10,7,Healthy,10.1002/brb3.1852,0.22,0.03,,,,,
,tCho,tCho,2020_bhogal_10,8,Healthy,10.1002/brb3.1852,0.13,0.02,,,,,
,tCho,tCho,2020_bhogal_10,9,Healthy,10.1002/brb3.1852,0.21,0.04,,,,,
,tCho,tCho,2020_bhogal_10,10,Healthy,10.1002/brb3.1852,0.17,0.05,,,,,
,Cho,GPC,2020_blest-hopley_25,1,Current CU,10.1111/adb.12827,,,2.348,0.34,,,
,Cho,GPC,2020_blest-hopley_25,2,Healthy,10.1111/adb.12827,,,2.444,0.302,,,
,Cho,GPC,2018_kirov_139,1,Epilepsy,10.1016/j.eplepsyres.2017.11.017,,,,,1.3,0.2,
,Cho,GPC,2018_kirov_139,2,Control,10.1016/j.eplepsyres.2017.11.017,,,,,1.4,0.1,
,Cho,tCho,2018_lai_225,1,Acute Depressive Episode Bipolar Disorder,10.1016/j.jad.2017.07.036,0.97,0.71,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2018_lai_225,2,Acute Depressive Episode Bipolar Disorder,10.1016/j.jad.2017.07.036,0.89,0.55,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2018_lai_225,3,Euthymic Bipolar Disorder,10.1016/j.jad.2017.07.036,0.71,0.08,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2018_lai_225,4,Euthymic Bipolar Disorder,10.1016/j.jad.2017.07.036,0.91,0.84,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2018_lai_225,5,Control,10.1016/j.jad.2017.07.036,0.93,0.63,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2018_lai_225,6,Control,10.1016/j.jad.2017.07.036,0.93,0.72,,,,,Assumed Total (tCho) based on Analysis
,Cho,GPC,2017_barbagallo_43,1,Control,10.1016/j.parkreldis.2017.07.028,0.33,0.07,,,,,Right
,Cho,GPC,2017_barbagallo_43,2,Control,10.1016/j.parkreldis.2017.07.028,0.37,0.13,,,,,Left
,Cho,GPC,2017_barbagallo_43,3,Control,10.1016/j.parkreldis.2017.07.028,0.35,0.07,,,,,Both
,Cho,GPC,2017_barbagallo_43,4,Parkinson's Disease,10.1016/j.parkreldis.2017.07.028,0.27,0.04,,,,,Contralateral
,Cho,GPC,2017_barbagallo_43,5,Parkinson's Disease,10.1016/j.parkreldis.2017.07.028,0.27,0.04,,,,,Ipsilateral
,Cho,GPC,2017_barbagallo_43,6,Parkinson's Disease,10.1016/j.parkreldis.2017.07.028,0.27,0.03,,,,,Both
,Cho,GPC,2017_barbagallo_43,7,Essential Tremor,10.1016/j.parkreldis.2017.07.028,0.32,0.05,,,,,Contralateral
,Cho,GPC,2017_barbagallo_43,8,Essential Tremor,10.1016/j.parkreldis.2017.07.028,0.31,0.04,,,,,Ipsilateral
,Cho,GPC,2017_barbagallo_43,9,Essential Tremor,10.1016/j.parkreldis.2017.07.028,0.32,0.03,,,,,Both
,Cho,tCho,2018_lu_29,1,Liver Cirrhosis,10.1097/WNR.0000000000001063,0.6,0.2,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2018_lu_29,2,Liver Cirrhosis with Hepatic Encephalopathy,10.1097/WNR.0000000000001063,0.6,0.2,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2018_lu_29,3,Liver Cirrhosis without Hepatic Encephalopathy,10.1097/WNR.0000000000001063,0.7,0.1,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2018_lu_29,4,Control,10.1097/WNR.0000000000001063,0.9,0.1,,,,,Assumed Total (tCho) based on Analysis
,Cho,GPC,2018_marshall_265,1,Secondary Progressive Multiple Sclerosis,10.1007/s00415-018-8903-y,0.25,0.01,,,,,
,Cho,GPC,2018_marshall_265,2,Secondary Progressive Multiple Sclerosis,10.1007/s00415-018-8903-y,0.29,0.01,,,,,
,Cho,GPC,2018_marshall_265,3,Secondary Progressive Multiple Sclerosis,10.1007/s00415-018-8903-y,0.17,0.01,,,,,
,tCho,tCho,2018_mcqueen_235,1,Schizophrenia - Placebo,10.1007/s00213-018-4997-2,0.26,0.03,2.94,0.52,,,
,tCho,tCho,2018_mcqueen_235,2,Schizophrenia - Placebo,10.1007/s00213-018-4997-2,0.26,0.03,2.48,0.39,,,
,tCho,tCho,2018_mcqueen_235,3,Schizophrenia - N-Acetylcysteine ,10.1007/s00213-018-4997-2,0.25,0.02,3.12,0.49,,,
,tCho,tCho,2018_mcqueen_235,4,Schizophrenia - N-Acetylcysteine ,10.1007/s00213-018-4997-2,0.26,0.02,2.76,1.31,,,
,Cho,GPC,2018_modinos_48,1,Healthy - Low Schizotypy,10.1017/S0033291717003403,,,2.94,0.36,,,
,Cho,GPC,2018_modinos_48,2,Healthy - High Schizotypy,10.1017/S0033291717003403,,,2.99,0.46,,,
,Cho,tCho,2018_moon_227,1,Obsessive-compulsive Disorder,10.1016/j.jad.2017.11.059,0.68,0.14,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2018_moon_227,2,Control,10.1016/j.jad.2017.11.059,0.78,0.09,,,,,Assumed Total (tCho) based on Analysis
,Cho,GPC,2018_mora-peris_32,1,HIV - Baseline,10.1097/QAD.0000000000001786,0.21,0.04,,,,,
,Cho,GPC,2018_mora-peris_32,2,HIV - Baseline,10.1097/QAD.0000000000001786,0.31,0.06,,,,,
,Cho,GPC,2018_mora-peris_32,3,HIV - Baseline,10.1097/QAD.0000000000001786,0.26,0.05,,,,,
,Cho,GPC,2018_mora-peris_32,4,HIV - ART Week 48,10.1097/QAD.0000000000001786,0.22,0.04,,,,,
,Cho,GPC,2018_mora-peris_32,5,HIV - ART Week 49,10.1097/QAD.0000000000001786,0.32,0.07,,,,,
,Cho,GPC,2018_mora-peris_32,6,HIV - ART Week 50,10.1097/QAD.0000000000001786,0.26,0.05,,,,,
,tCho,tCho,2018_plitman_273,1,Schizophrenia,10.1016/j.pscychresns.2018.01.004,,,2.68,0.35,,,
,tCho,tCho,2018_plitman_273,2,Control,10.1016/j.pscychresns.2018.01.004,,,2.4,0.33,,,
,tCho,tCho,2018_plitman_273,3,Schizophrenia - Point 1,10.1016/j.pscychresns.2018.01.004,,,2.68,0.25,,,
,tCho,tCho,2018_plitman_273,4,Schizophrenia - Point 2,10.1016/j.pscychresns.2018.01.004,,,2.72,0.22,,,
,tCho,tCho,2018_plitman_273,5,Control - Point 1,10.1016/j.pscychresns.2018.01.004,,,2.51,0.37,,,
,tCho,tCho,2018_plitman_273,6,Control - Point 2,10.1016/j.pscychresns.2018.01.004,,,2.47,0.38,,,
,tCho,tCho,2018_rudler_48,1,"Cirrhosis - Before TIPSS, no MHE",10.1111/apt.14938,,,,,2.4,0.3,
,tCho,tCho,2018_rudler_48,2,"Cirrhosis - Before TIPSS, no MHE",10.1111/apt.14938,,,,,1.38,0.2,
,tCho,tCho,2018_rudler_48,3,"Cirrhosis - Before TIPSS, MHE",10.1111/apt.14938,,,,,2.1,0.5,
,tCho,tCho,2018_rudler_48,4,"Cirrhosis - Before TIPSS, MHE",10.1111/apt.14938,,,,,1.35,0.3,
,tCho,tCho,2018_rudler_48,5,"Cirrhosis - Before TIPSS, no development of HE after TIPSS",10.1111/apt.14938,,,,,2.3,0.4,
,tCho,tCho,2018_rudler_48,6,"Cirrhosis - Before TIPSS, no development of HE after TIPSS",10.1111/apt.14938,,,,,1.4,0.2,
,tCho,tCho,2018_rudler_48,7,"Cirrhosis - Before TIPSS, development of HE after TIPSS",10.1111/apt.14938,,,,,2.4,0.5,
,tCho,tCho,2018_rudler_48,8,"Cirrhosis - Before TIPSS, development of HE after TIPSS",10.1111/apt.14938,,,,,1.3,0.3,
,tCho,tCho,2018_rudler_48,9,"Cirrhosis - After TIPSS, no development of HE",10.1111/apt.14938,,,,,2.1,0.2,
,tCho,tCho,2018_rudler_48,10,"Cirrhosis - After TIPSS, no development of HE",10.1111/apt.14938,,,,,1.2,0.1,
,tCho,tCho,2018_rudler_48,11,"Cirrhosis - After TIPSS, development of HE",10.1111/apt.14938,,,,,1.9,0.1,
,tCho,tCho,2018_rudler_48,12,"Cirrhosis - After TIPSS, development of HE",10.1111/apt.14938,,,,,1.4,0.4,
,Cho,tCho,2018_ryan_13,1,Healthy - Sham,10.1371/journal.pone.0198053,0.68,0.02,,,2.4,0.1,Assumed Total (tCho) based on Analysis
,Cho,tCho,2018_ryan_13,2,Healthy - Transcranial direct current stimulation,10.1371/journal.pone.0198053,0.67,0.02,,,2.3,0.11,Assumed Total (tCho) based on Analysis
,tCho,tCho,2021_askari_86,1,IDH ,10.1002/mrm.28829,,,,,2.4,1.4,
,tCho,tCho,2021_askari_86,2,IDH,10.1002/mrm.28829,,,,,2.4,1.4,
,tCho,tCho,2021_askari_86,3,IDH WT,10.1002/mrm.28829,,,,,7.5,1.5,
,tCho,tCho,2021_bednarik_15,1,Healthy,10.3389/fnins.2021.609485,,,,,1.8,0.1,
,tCho,tCho,2021_bednarik_15,2,Healthy,10.3389/fnins.2021.609485,,,,,1.8,0.1,
,tCho,tCho,2018_schmitz_28,1,Healthy - <30 yrs,10.1111/jon.12514,,,2.34,0.14,,,
,tCho,tCho,2018_schmitz_28,2,Healthy - 30-39 yrs,10.1111/jon.12514,,,2.28,0.12,,,
,tCho,tCho,2018_schmitz_28,3,Healthy - 40-49 yrs,10.1111/jon.12514,,,2.44,0.17,,,
,tCho,tCho,2018_schmitz_28,4,Healthy - 50-59 yrs,10.1111/jon.12514,,,2.38,0.19,,,
,tCho,tCho,2018_schmitz_28,5,Healthy - >60 yrs,10.1111/jon.12514,,,2.42,0.2,,,
,tCho,tCho,2018_schmitz_28,6,Healthy,10.1111/jon.12514,,,2.37,0.17,,,
,tCho,tCho,2021_chaudhary_42,7,PD-CN,10.1007/s10072-020-04626-9,,,3.07,0.95,,,
,tCho,tCho,2021_chaudhary_42,22,PD-CI,10.1007/s10072-020-04626-9,,,2.25,0.88,,,
,tCho,tCho,2021_chaudhary_42,37,HC,10.1007/s10072-020-04626-9,,,2.79,0.8,,,
,tCho,tCho,2021_chaudhary_42,12,PD-CN,10.1007/s10072-020-04626-9,,,2.64,0.51,,,
,tCho,tCho,2021_chaudhary_42,27,PD-CI,10.1007/s10072-020-04626-9,,,2.21,0.39,,,
,tCho,tCho,2021_chaudhary_42,42,HC,10.1007/s10072-020-04626-9,,,2.6,0.45,,,
,tCho,tCho,2021_chaudhary_42,15,PD-CN,10.1007/s10072-020-04626-9,,,2.34,0.39,,,
,tCho,tCho,2021_chaudhary_42,30,PD-CI,10.1007/s10072-020-04626-9,,,1.95,0.29,,,
,tCho,tCho,2021_chaudhary_42,45,HC,10.1007/s10072-020-04626-9,,,2.18,0.47,,,
,Cho,GPC,2021_chen_299,3,BD with anxiety,10.1016/j.psychres.2021.113859,,,,,0.95,0.2,
,Cho,GPC,2021_chen_299,4,BD with anxiety,10.1016/j.psychres.2021.113859,,,,,0.89,0.16,
,Cho,GPC,2021_chen_299,9,BD without anxiety,10.1016/j.psychres.2021.113859,,,,,0.87,0.15,
,Cho,GPC,2021_chen_299,10,BD without anxiety,10.1016/j.psychres.2021.113859,,,,,0.97,0.51,
,Cho,GPC,2021_chenji_282,1,Control,10.1016/j.jad.2020.12.176,,,2.22,0.28,,,
,Cho,GPC,2021_chenji_282,3,MDD-Normal BMI,10.1016/j.jad.2020.12.176,,,2.24,0.29,,,
,Cho,GPC,2021_chenji_282,5,MDD-High BMI,10.1016/j.jad.2020.12.176,,,2.2,0.31,,,
,Cho,GPC,2021_chenji_282,2,Control,10.1016/j.jad.2020.12.176,,,2.34,0.33,,,
,Cho,GPC,2021_chenji_282,4,MDD-Normal BMI,10.1016/j.jad.2020.12.176,,,2.16,0.34,,,
,Cho,GPC,2021_chenji_282,6,MDD-High BMI,10.1016/j.jad.2020.12.176,,,2.28,0.31,,,
,Cho,GPC,2020_chen_131,1,Healthy Controls,10.1016/j.ejrad.2020.109252,0.71,0.35,,,,,
,Cho,GPC,2020_chen_131,2,NHE,10.1016/j.ejrad.2020.109252,0.71,0.39,,,,,
,Cho,GPC,2020_chen_131,3,Minimal Hepatic Encephalopathy,10.1016/j.ejrad.2020.109252,0.41,0.18,,,,,
,tCho,tCho,2018_shakory_43,1,Control,10.1038/s41386-018-0163-0,,,2.39,0.25,,,
,tCho,tCho,2018_shakory_43,2,Clinical high risk of psychosis,10.1038/s41386-018-0163-0,,,2.38,0.34,,,
,tCho,tCho,2018_shakory_43,3,First Episode Psychosis,10.1038/s41386-018-0163-0,,,2.53,0.25,,,
,Cho,tCho,2020_dehghan_33,1,Control,10.1177/1971400920932793,0.671,,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2020_dehghan_33,1,Control,10.1177/1971400920932793,0.671,,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2020_dehghan_33,2,Migraine without aura,10.1177/1971400920932793,1.159,,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2020_dehghan_33,2,Migraine without aura,10.1177/1971400920932793,1.159,,,,,,Assumed Total (tCho) based on Analysis
,tCho,tCho,2018_shattuck_47,1,Healthy - Rest,10.1002/jmri.25816,0.31,0.038,,,,,
,tCho,tCho,2018_shattuck_47,2,Healthy - Memorize,10.1002/jmri.25816,0.31,0.039,,,,,
,tCho,tCho,2018_shattuck_47,3,Healthy - Remember,10.1002/jmri.25816,0.32,0.041,,,,,
,tCho,tCho,2018_shattuck_47,4,Healthy - Test,10.1002/jmri.25816,0.31,0.037,,,,,
,tCho,tCho,2018_singh_60,1,Control,10.1007/s00234-017-1954-4,0.3,0.03,,,,,
,tCho,tCho,2018_singh_60,2,Schizophrenia,10.1007/s00234-017-1954-4,0.31,0.05,,,,,
,Cho,GPC,2018_sivaraman_281,1,Control,10.1016/j.pscychresns.2018.06.003,,,0.2,0.03,,,
,Cho,GPC,2018_sivaraman_281,2,First episode psychosis,10.1016/j.pscychresns.2018.06.003,,,0.24,0.04,,,
,Cho,GPC,2018_tan_28,1,Control,10.1007/s00330-018-5443-x,,,,,1.4,0.2,
,Cho,GPC,2018_tan_28,2,Control,10.1007/s00330-018-5443-x,,,,,1.4,0.1,
,Cho,GPC,2018_tan_28,3,Control,10.1007/s00330-018-5443-x,,,,,1.4,0.1,
,Cho,GPC,2018_tan_28,4,Temporal lobe epilespsy,10.1007/s00330-018-5443-x,,,,,1.5,0.2,
,Cho,GPC,2018_tan_28,5,Temporal lobe epilespsy,10.1007/s00330-018-5443-x,,,,,1.4,0.2,
,Cho,GPC,2018_tan_28,6,Temporal lobe epilespsy - Left seizure foci,10.1007/s00330-018-5443-x,,,,,1.5,0.2,
,Cho,GPC,2018_tan_28,7,Temporal lobe epilespsy - Left seizure foci,10.1007/s00330-018-5443-x,,,,,1.4,0.2,
,Cho,GPC,2018_tan_28,8,Temporal lobe epilespsy - Right seizure foci,10.1007/s00330-018-5443-x,,,,,1.4,0.2,
,Cho,GPC,2018_tan_28,9,Temporal lobe epilespsy - Right seizure foci,10.1007/s00330-018-5443-x,,,,,1.4,0.7,
,Cho,GPC,2018_van_89,1,Control,10.1136/jnnp-2017-316364,,,,,1.49,0.21,
,Cho,GPC,2018_van_89,2,Metachromatic leukodystrophy - Good outcome,10.1136/jnnp-2017-316364,,,,,2.11,0.23,
,Cho,GPC,2018_van_89,3,Metachromatic leukodystrophy - Moderate outcome,10.1136/jnnp-2017-316364,,,,,1.84,0.24,
,Cho,GPC,2018_van_89,4,Metachromatic leukodystrophy - Poor outcome,10.1136/jnnp-2017-316364,,,,,1.67,0.41,
,PCho,PCh,2019_betinaip_39,1,Behavior - ON - 3% Visual Contrast,10.1523/JNEUROSCI.3021-18.2019,,,0.876,0.134,,,
,PCho,PCh,2019_betinaip_39,2,Behavior - ON - 12.5% Visual Contrast,10.1523/JNEUROSCI.3021-18.2019,,,0.874,0.121,,,
,PCho,PCh,2019_betinaip_39,3,Behavior - ON - 50% Visual Contrast,10.1523/JNEUROSCI.3021-18.2019,,,0.891,0.123,,,
,PCho,PCh,2019_betinaip_39,4,Behavior - ON - 100% Visual Contrast,10.1523/JNEUROSCI.3021-18.2019,,,0.872,0.147,,,
,PCho,PCh,2019_betinaip_39,5,Resting,10.1523/JNEUROSCI.3021-18.2019,,,0.869,0.14,,,
,PCho,PCh,2019_betinaip_39,6,Behavior - OFF - 3% Visual Contrast,10.1523/JNEUROSCI.3021-18.2019,,,0.878,0.14,,,
,PCho,PCh,2019_betinaip_39,7,Behavior - OFF - 12.5% Visual Contrast,10.1523/JNEUROSCI.3021-18.2019,,,0.874,0.118,,,
,PCho,PCh,2019_betinaip_39,8,Behavior - OFF - 50% Visual Contrast,10.1523/JNEUROSCI.3021-18.2019,,,0.886,0.103,,,
,PCho,PCh,2019_betinaip_39,9,Behavior - OFF - 100% Visual Contrast,10.1523/JNEUROSCI.3021-18.2019,,,0.865,0.162,,,
,PCho,PCh,2019_betinaip_39,10,Resting,10.1523/JNEUROSCI.3021-18.2019,,,0.879,0.145,,,
,Cho,GPC,2019_davitz_50,1,TBI (Post-Concussive),10.1002/jmri.26718,,,,,1.6,0.4,
,Cho,GPC,2019_davitz_50,2,TBI (Post-Concussive),10.1002/jmri.26718,,,,,1.3,0.2,
,Cho,GPC,2019_davitz_50,3,TBI (Post-Concussive),10.1002/jmri.26718,,,,,1.8,0.2,
,Cho,GPC,2019_davitz_50,4,TBI (Post-Concussive),10.1002/jmri.26718,,,,,1.8,0.4,
,Cho,GPC,2019_davitz_50,5,TBI (Post-Concussive),10.1002/jmri.26718,,,,,1.6,0.3,
,Cho,GPC,2019_davitz_50,6,Control,10.1002/jmri.26718,,,,,1.5,0.5,
,Cho,GPC,2019_davitz_50,7,Control,10.1002/jmri.26718,,,,,1.3,0.3,
,Cho,GPC,2019_davitz_50,8,Control,10.1002/jmri.26718,,,,,1.9,0.4,
,Cho,GPC,2019_davitz_50,9,Control,10.1002/jmri.26718,,,,,1.8,0.3,
,Cho,GPC,2019_davitz_50,10,Control,10.1002/jmri.26718,,,,,1.5,0.3,
,Cho,GPC,2019_fayed_32,1,Fibromyalgia - Baseline,10.1177/1971400919857544,0.18,0.02,,,,,
,Cho,GPC,2019_fayed_32,3,Fibromyalgia - Baseline,10.1177/1971400919857544,0.24,0.03,1.31,0.14,,,
,Cho,GPC,2019_fayed_32,4,Fibromyalgia - Baseline,10.1177/1971400919857544,,,1.43,0.18,,,
,Cho,GPC,2019_fayed_32,5,Fibromyalgia - Baseline,10.1177/1971400919857544,0.34,0.04,,,,,
,Cho,GPC,2019_fayed_32,6,Fibromyalgia - Treatment,10.1177/1971400919857544,0.19,0.04,,,,,
,Cho,GPC,2019_fayed_32,8,Fibromyalgia - Treatment,10.1177/1971400919857544,0.23,0.02,1.29,0.11,,,
,Cho,GPC,2019_fayed_32,9,Fibromyalgia - Treatment,10.1177/1971400919857544,,,1.42,0.25,,,
,Cho,GPC,2019_fayed_32,10,Fibromyalgia - Treatment,10.1177/1971400919857544,0.33,0.02,,,,,
,tCho,tCho,2019_flamez_130,1,Parkinson's Dyskinesia - Sham Baseline,10.1016/j.clinph.2019.04.720,0.21,0.04,,,,,
,tCho,tCho,2019_flamez_130,2,Parkinson's Dyskinesia - Real Baseline,10.1016/j.clinph.2019.04.720,0.22,0.03,,,,,
,tCho,tCho,2019_flamez_130,3,Parkinson's Dyskinesia - Sham TMS,10.1016/j.clinph.2019.04.720,0.21,0.05,,,,,
,tCho,tCho,2019_flamez_130,4,Parkinson's Dyskinesia - Real TMS,10.1016/j.clinph.2019.04.720,0.22,0.04,,,,,
,tCho,tCho,2019_flamez_130,5,Parkinson's No Dyskinesia - Sham Baseline,10.1016/j.clinph.2019.04.720,0.23,0.04,,,,,
,tCho,tCho,2019_flamez_130,6,Parkinson's No Dyskinesia - Real Baseline,10.1016/j.clinph.2019.04.720,0.22,0.03,,,,,
,tCho,tCho,2019_flamez_130,7,Parkinson's No Dyskinesia - Sham TMS,10.1016/j.clinph.2019.04.720,0.21,0.03,,,,,
,tCho,tCho,2019_flamez_130,8,Parkinson's No Dyskinesia - Real TMS,10.1016/j.clinph.2019.04.720,0.23,0.04,,,,,
,Cho,GPC,2019_garkowski_266,1,Control,10.1007/s00415-019-09359-0,0.375,0.077,,,,,
,Cho,GPC,2019_garkowski_266,2,Control,10.1007/s00415-019-09359-0,0.393,0.048,,,,,
,Cho,GPC,2019_garkowski_266,3,Control,10.1007/s00415-019-09359-0,0.377,0.05,,,,,
,Cho,GPC,2019_garkowski_266,4,Control,10.1007/s00415-019-09359-0,0.362,0.038,,,,,
,Cho,GPC,2019_garkowski_266,5,Lyme Neuroborreliosis,10.1007/s00415-019-09359-0,0.371,0.061,,,,,
,Cho,GPC,2019_garkowski_266,6,Lyme Neuroborreliosis,10.1007/s00415-019-09359-0,0.386,0.044,,,,,
,Cho,GPC,2019_garkowski_266,7,Lyme Neuroborreliosis,10.1007/s00415-019-09359-0,0.379,0.048,,,,,
,Cho,GPC,2019_garkowski_266,8,Lyme Neuroborreliosis,10.1007/s00415-019-09359-0,0.376,0.058,,,,,
,tCho,tCho,2019_giapitzakis_81,1,Healthy,10.1002/mrm.27467,,,,,1.1,0.2,
,tCho,tCho,2019_giapitzakis_81,2,Healthy,10.1002/mrm.27467,,,,,1.3,0.2,
,tCho,tCho,2019_graf_32,1,Healthy,10.1002/nbm.4083,,,1.6,0.805,,,Med/Quartile --> Mean/Std Wan 2014
,Cho,tCho,2019_grech-sollars_11,1,Cancer - Grade 2,10.3390/cancers11121969,1.095,0.262,,,,,
,Cho,tCho,2019_grech-sollars_11,2,Cancer - Grade 3,10.3390/cancers11121969,1.56,0.391,,,,,
,Cho,tCho,2019_grech-sollars_11,3,Cancer - Grade 4,10.3390/cancers11121969,1.95,0.93,,,,,
,tCho,tCho,2019_hnilicova_407,1,Control,10.1016/j.jns.2019.116458,0.358,0.082,,,,,
,tCho,tCho,2019_hnilicova_407,2,Multiple Sclerosis,10.1016/j.jns.2019.116458,0.351,0.075,,,,,
,Cho,tCho,2019_holshouser_36,1,Control,10.1089/neu.2018.5919,1.08,0.11,,,,,
,Cho,tCho,2019_holshouser_36,2,Control,10.1089/neu.2018.5919,1.07,0.08,,,,,
,Cho,tCho,2019_holshouser_36,3,TBI Mild Acute,10.1089/neu.2018.5919,1.07,0.12,,,,,
,Cho,tCho,2019_holshouser_36,4,TBI Mild 12Month,10.1089/neu.2018.5919,1.09,0.1,,,,,
,Cho,tCho,2019_holshouser_36,5,TBI Severe Acute,10.1089/neu.2018.5919,1.14,0.14,,,,,
,Cho,tCho,2019_holshouser_36,6,TBI Severe 12Month,10.1089/neu.2018.5919,1.14,0.19,,,,,
,Cho,tCho,2019_holshouser_36,7,Control,10.1089/neu.2018.5919,1.24,0.14,,,,,
,Cho,tCho,2019_holshouser_36,8,Control,10.1089/neu.2018.5919,1.23,0.14,,,,,
,Cho,tCho,2019_holshouser_36,9,TBI Mild Acute,10.1089/neu.2018.5919,1.24,0.14,,,,,
,Cho,tCho,2019_holshouser_36,10,TBI Mild 12Month,10.1089/neu.2018.5919,1.24,0.11,,,,,
,Cho,tCho,2019_holshouser_36,11,TBI Severe Acute,10.1089/neu.2018.5919,1.27,0.12,,,,,
,Cho,tCho,2019_holshouser_36,12,TBI Severe 12Month,10.1089/neu.2018.5919,1.35,0.77,,,,,
,Cho,tCho,2019_holshouser_36,13,Control,10.1089/neu.2018.5919,0.85,0.09,,,,,
,Cho,tCho,2019_holshouser_36,14,Control,10.1089/neu.2018.5919,0.84,0.12,,,,,
,Cho,tCho,2019_holshouser_36,15,TBI Mild Acute,10.1089/neu.2018.5919,0.83,0.06,,,,,
,Cho,tCho,2019_holshouser_36,16,TBI Mild 12Month,10.1089/neu.2018.5919,0.84,0.1,,,,,
,Cho,tCho,2019_holshouser_36,17,TBI Severe Acute,10.1089/neu.2018.5919,0.87,0.1,,,,,
,Cho,tCho,2019_holshouser_36,18,TBI Severe 12Month,10.1089/neu.2018.5919,0.9,0.16,,,,,
,Cho,tCho,2019_holshouser_36,19,Control,10.1089/neu.2018.5919,1.22,0.13,,,,,
,Cho,tCho,2019_holshouser_36,20,Control,10.1089/neu.2018.5919,1.19,0.12,,,,,
,Cho,tCho,2019_holshouser_36,21,TBI Mild Acute,10.1089/neu.2018.5919,1.25,0.16,,,,,
,Cho,tCho,2019_holshouser_36,22,TBI Mild 12Month,10.1089/neu.2018.5919,1.22,0.15,,,,,
,Cho,tCho,2019_holshouser_36,23,TBI Severe Acute,10.1089/neu.2018.5919,1.28,0.18,,,,,
,Cho,tCho,2019_holshouser_36,24,TBI Severe 12Month,10.1089/neu.2018.5919,1.3,0.2,,,,,
,Cho,tCho,2019_holshouser_36,25,Control,10.1089/neu.2018.5919,1.13,0.14,,,,,
,Cho,tCho,2019_holshouser_36,26,Control,10.1089/neu.2018.5919,1.09,0.11,,,,,
,Cho,tCho,2019_holshouser_36,27,TBI Mild Acute,10.1089/neu.2018.5919,1.16,0.14,,,,,
,Cho,tCho,2019_holshouser_36,28,TBI Mild 12Month,10.1089/neu.2018.5919,1.11,0.13,,,,,
,Cho,tCho,2019_holshouser_36,29,TBI Severe Acute,10.1089/neu.2018.5919,1.19,0.14,,,,,
,Cho,tCho,2019_holshouser_36,30,TBI Severe 12Month,10.1089/neu.2018.5919,1.16,0.18,,,,,
,Cho,tCho,2019_holshouser_36,31,Control,10.1089/neu.2018.5919,1.15,0.13,,,,,
,Cho,tCho,2019_holshouser_36,32,Control,10.1089/neu.2018.5919,1.11,0.11,,,,,
,Cho,tCho,2019_holshouser_36,33,TBI Mild Acute,10.1089/neu.2018.5919,1.16,0.15,,,,,
,Cho,tCho,2019_holshouser_36,34,TBI Mild 12Month,10.1089/neu.2018.5919,1.12,0.12,,,,,
,Cho,tCho,2019_holshouser_36,35,TBI Severe Acute,10.1089/neu.2018.5919,1.21,0.17,,,,,
,Cho,tCho,2019_holshouser_36,36,TBI Severe 12Month,10.1089/neu.2018.5919,1.21,0.22,,,,,
,Cho,tCho,2019_holshouser_36,37,Control,10.1089/neu.2018.5919,0.93,0.12,,,,,
,Cho,tCho,2019_holshouser_36,38,Control,10.1089/neu.2018.5919,0.89,0.12,,,,,
,Cho,tCho,2019_holshouser_36,39,TBI Mild Acute,10.1089/neu.2018.5919,0.97,0.16,,,,,
,Cho,tCho,2019_holshouser_36,40,TBI Mild 12Month,10.1089/neu.2018.5919,0.93,0.12,,,,,
,Cho,tCho,2019_holshouser_36,41,TBI Severe Acute,10.1089/neu.2018.5919,0.98,0.12,,,,,
,Cho,tCho,2019_holshouser_36,42,TBI Severe 12Month,10.1089/neu.2018.5919,0.94,0.21,,,,,
,Cho,tCho,2019_holshouser_36,43,Control,10.1089/neu.2018.5919,0.97,0.11,,,,,
,Cho,tCho,2019_holshouser_36,44,Control,10.1089/neu.2018.5919,0.95,0.08,,,,,
,Cho,tCho,2019_holshouser_36,45,TBI Mild Acute,10.1089/neu.2018.5919,0.97,0.11,,,,,
,Cho,tCho,2019_holshouser_36,46,TBI Mild 12Month,10.1089/neu.2018.5919,0.94,0.1,,,,,
,Cho,tCho,2019_holshouser_36,47,TBI Severe Acute,10.1089/neu.2018.5919,1,0.11,,,,,
,Cho,tCho,2019_holshouser_36,48,TBI Severe 12Month,10.1089/neu.2018.5919,0.99,0.14,,,,,
,Cho,tCho,2019_holshouser_36,49,Control,10.1089/neu.2018.5919,1.08,0.13,,,,,
,Cho,tCho,2019_holshouser_36,50,Control,10.1089/neu.2018.5919,1.04,0.12,,,,,
,Cho,tCho,2019_holshouser_36,51,TBI Mild Acute,10.1089/neu.2018.5919,1.12,0.15,,,,,
,Cho,tCho,2019_holshouser_36,52,TBI Mild 12Month,10.1089/neu.2018.5919,1.02,0.13,,,,,
,Cho,tCho,2019_holshouser_36,53,TBI Severe Acute,10.1089/neu.2018.5919,1.13,0.17,,,,,
,Cho,tCho,2019_holshouser_36,54,TBI Severe 12Month,10.1089/neu.2018.5919,1.15,0.22,,,,,
,Cho,tCho,2019_holshouser_36,55,Control,10.1089/neu.2018.5919,1.04,0.1,,,,,
,Cho,tCho,2019_holshouser_36,56,Control,10.1089/neu.2018.5919,1.03,0.08,,,,,
,Cho,tCho,2019_holshouser_36,57,TBI Mild Acute,10.1089/neu.2018.5919,1.07,0.13,,,,,
,Cho,tCho,2019_holshouser_36,58,TBI Mild 12Month,10.1089/neu.2018.5919,1.02,0.11,,,,,
,Cho,tCho,2019_holshouser_36,59,TBI Severe Acute,10.1089/neu.2018.5919,1.11,0.12,,,,,
,Cho,tCho,2019_holshouser_36,60,TBI Severe 12Month,10.1089/neu.2018.5919,1.15,0.38,,,,,
,Cho,tCho,2019_holshouser_36,61,Control,10.1089/neu.2018.5919,1.14,0.11,,,,,
,Cho,tCho,2019_holshouser_36,62,Control,10.1089/neu.2018.5919,1.12,0.1,,,,,
,Cho,tCho,2019_holshouser_36,63,TBI Mild Acute,10.1089/neu.2018.5919,1.18,0.19,,,,,
,Cho,tCho,2019_holshouser_36,64,TBI Mild 12Month,10.1089/neu.2018.5919,1.12,0.15,,,,,
,Cho,tCho,2019_holshouser_36,65,TBI Severe Acute,10.1089/neu.2018.5919,1.24,0.17,,,,,
,Cho,tCho,2019_holshouser_36,66,TBI Severe 12Month,10.1089/neu.2018.5919,1.19,0.22,,,,,
,Cho,tCho,2019_holshouser_36,67,Control,10.1089/neu.2018.5919,1.18,0.12,,,,,
,Cho,tCho,2019_holshouser_36,68,Control,10.1089/neu.2018.5919,1.15,0.1,,,,,
,Cho,tCho,2019_holshouser_36,69,TBI Mild Acute,10.1089/neu.2018.5919,1.21,0.15,,,,,
,Cho,tCho,2019_holshouser_36,70,TBI Mild 12Month,10.1089/neu.2018.5919,1.18,0.09,,,,,
,Cho,tCho,2019_holshouser_36,71,TBI Severe Acute,10.1089/neu.2018.5919,1.23,0.13,,,,,
,Cho,tCho,2019_holshouser_36,72,TBI Severe 12Month,10.1089/neu.2018.5919,1.2,0.18,,,,,
,Cho,GPC,2019_iwata_85,1,Control,10.1016/j.biopsych.2018.09.009,,,2.46,0.34,,,
,Cho,GPC,2019_iwata_85,2,Control,10.1016/j.biopsych.2018.09.009,,,3.21,0.47,,,
,Cho,GPC,2019_iwata_85,3,Control,10.1016/j.biopsych.2018.09.009,,,2.27,0.29,,,
,Cho,GPC,2019_iwata_85,4,Schizophrenia Ultra-Resistant,10.1016/j.biopsych.2018.09.009,,,2.54,0.51,,,
,Cho,GPC,2019_iwata_85,5,Schizophrenia Ultra-Resistant,10.1016/j.biopsych.2018.09.009,,,3.55,0.58,,,
,Cho,GPC,2019_iwata_85,6,Schizophrenia Ultra-Resistant,10.1016/j.biopsych.2018.09.009,,,2.55,0.38,,,
,Cho,GPC,2019_iwata_85,7,Schizophrenia Non-Ultra Resistant,10.1016/j.biopsych.2018.09.009,,,2.63,0.31,,,
,Cho,GPC,2019_iwata_85,8,Schizophrenia Non-Ultra Resistant,10.1016/j.biopsych.2018.09.009,,,3.64,0.42,,,
,Cho,GPC,2019_iwata_85,9,Schizophrenia Non-Ultra Resistant,10.1016/j.biopsych.2018.09.009,,,2.64,0.29,,,
,Cho,GPC,2019_iwata_85,10,Schizophrenia Non-Treatment Resistant,10.1016/j.biopsych.2018.09.009,,,2.56,0.39,,,
,Cho,GPC,2019_iwata_85,11,Schizophrenia Non-Treatment Resistant,10.1016/j.biopsych.2018.09.009,,,3.44,0.47,,,
,Cho,GPC,2019_iwata_85,12,Schizophrenia Non-Treatment Resistant,10.1016/j.biopsych.2018.09.009,,,2.44,0.34,,,
,Cho,GPC,2019_joe_13,1,Predisposed Alzheimer's Mutation Carriers,10.1007/s11682-018-9913-1,0.33,0.05,1.66,0.21,,,
,Cho,GPC,2019_joe_13,2,Predisposed Alzheimer's Mutation Carriers,10.1007/s11682-018-9913-1,0.3,0.04,1.66,0.34,,,
,Cho,GPC,2019_joe_13,3,Predisposed Alzheimer's Mutation Carriers,10.1007/s11682-018-9913-1,0.25,0.06,1.63,0.24,,,
,Cho,GPC,2019_joe_13,4,Predisposed Alzheimer's Mutation Carriers,10.1007/s11682-018-9913-1,0.2,0.02,1.24,0.15,,,
,Cho,GPC,2019_joe_13,5,Predisposed Alzheimer's Non-Carriers,10.1007/s11682-018-9913-1,0.36,0.1,1.84,0.34,,,
,Cho,GPC,2019_joe_13,6,Predisposed Alzheimer's Non-Carriers,10.1007/s11682-018-9913-1,0.33,0.08,1.75,0.2,,,
,Cho,GPC,2019_joe_13,7,Predisposed Alzheimer's Non-Carriers,10.1007/s11682-018-9913-1,0.25,0.03,1.65,0.07,,,
,Cho,GPC,2019_joe_13,8,Predisposed Alzheimer's Non-Carriers,10.1007/s11682-018-9913-1,0.19,0.03,1.2,0.13,,,
,Cho,tCho,2019_khomenko_49,1,Aged,10.1007/s11055-019-00858-1,1.05,0.11,,,,,
,Cho,tCho,2019_khomenko_49,2,Aged,10.1007/s11055-019-00858-1,0.94,0.1,,,,,
,Cho,tCho,2019_khomenko_49,3,Aged,10.1007/s11055-019-00858-1,0.89,0.07,,,,,
,Cho,tCho,2019_khomenko_49,4,Aged,10.1007/s11055-019-00858-1,1.04,0.09,,,,,
,Cho,tCho,2019_khomenko_49,5,Aged,10.1007/s11055-019-00858-1,0.96,0.09,,,,,
,Cho,tCho,2019_khomenko_49,6,Aged,10.1007/s11055-019-00858-1,0.9,0.07,,,,,
,Cho,tCho,2019_khomenko_49,7,Aged,10.1007/s11055-019-00858-1,0.98,0.1,,,,,
,Cho,tCho,2019_khomenko_49,8,Aged,10.1007/s11055-019-00858-1,0.89,0.07,,,,,
,Cho,tCho,2019_khomenko_49,9,Aged,10.1007/s11055-019-00858-1,0.77,0.07,,,,,
,Cho,tCho,2019_khomenko_49,10,MCI,10.1007/s11055-019-00858-1,1.04,0.16,,,,,
,Cho,tCho,2019_khomenko_49,11,MCI,10.1007/s11055-019-00858-1,0.97,0.15,,,,,
,Cho,tCho,2019_khomenko_49,12,MCI,10.1007/s11055-019-00858-1,0.91,0.11,,,,,
,Cho,tCho,2019_khomenko_49,13,MCI,10.1007/s11055-019-00858-1,1.04,0.14,,,,,
,Cho,tCho,2019_khomenko_49,14,MCI,10.1007/s11055-019-00858-1,0.96,0.12,,,,,
,Cho,tCho,2019_khomenko_49,15,MCI,10.1007/s11055-019-00858-1,0.85,0.09,,,,,
,Cho,tCho,2019_khomenko_49,16,MCI,10.1007/s11055-019-00858-1,0.96,0.11,,,,,
,Cho,tCho,2019_khomenko_49,17,MCI,10.1007/s11055-019-00858-1,0.87,0.1,,,,,
,Cho,tCho,2019_khomenko_49,18,MCI,10.1007/s11055-019-00858-1,0.76,0.09,,,,,
,Cho,tCho,2019_khomenko_49,19,Alzheimer's Disease,10.1007/s11055-019-00858-1,0.99,0.09,,,,,
,Cho,tCho,2019_khomenko_49,20,Alzheimer's Disease,10.1007/s11055-019-00858-1,0.91,0.08,,,,,
,Cho,tCho,2019_khomenko_49,21,Alzheimer's Disease,10.1007/s11055-019-00858-1,0.81,0.08,,,,,
,Cho,tCho,2019_khomenko_49,22,Alzheimer's Disease,10.1007/s11055-019-00858-1,0.96,0.12,,,,,
,Cho,tCho,2019_khomenko_49,23,Alzheimer's Disease,10.1007/s11055-019-00858-1,0.88,0.06,,,,,
,Cho,tCho,2019_khomenko_49,24,Alzheimer's Disease,10.1007/s11055-019-00858-1,0.84,0.1,,,,,
,Cho,tCho,2019_khomenko_49,25,Alzheimer's Disease,10.1007/s11055-019-00858-1,0.96,0.08,,,,,
,Cho,tCho,2019_khomenko_49,26,Alzheimer's Disease,10.1007/s11055-019-00858-1,0.88,0.05,,,,,
,Cho,tCho,2019_khomenko_49,27,Alzheimer's Disease,10.1007/s11055-019-00858-1,0.78,0.07,,,,,
,tCho,tCho,2019_lawrence_33,1,Control,10.1080/02699052.2019.1584332,1.833,0.275,,,,,
,tCho,tCho,2019_lawrence_33,2,TBI,10.1080/02699052.2019.1584332,2.157,0.217,,,,,
,tCho,tCho,2019_lawrence_33,3,TBI,10.1080/02699052.2019.1584332,2.475,0.509,,,,,
,Cho,GPC,2019_levin_202,1,Control (Young),10.1016/j.neuroimage.2019.116050,,,1.7,0.3,,,
,Cho,GPC,2019_levin_202,2,Middle-Aged,10.1016/j.neuroimage.2019.116050,,,1.58,0.35,,,
,Cho,GPC,2019_levin_202,3,Old-Middle Aged,10.1016/j.neuroimage.2019.116050,,,1.63,0.37,,,
,Cho,GPC,2019_levin_202,4,Aged,10.1016/j.neuroimage.2019.116050,,,1.48,0.28,,,
,Cho,GPC,2019_levin_202,5,Control (Young),10.1016/j.neuroimage.2019.116050,,,1.77,0.5,,,
,Cho,GPC,2019_levin_202,6,Middle-Aged,10.1016/j.neuroimage.2019.116050,,,1.74,0.42,,,
,Cho,GPC,2019_levin_202,7,Old-Middle Aged,10.1016/j.neuroimage.2019.116050,,,1.47,0.4,,,
,Cho,GPC,2019_levin_202,8,Aged,10.1016/j.neuroimage.2019.116050,,,1.41,0.37,,,
,tCho,tCho,2018_veeramuthu_25,1,Complicated mTBI,10.1016/j.acra.2018.01.005,0.354,0.097,0.585,0.129,,,
,tCho,tCho,2018_veeramuthu_25,2,Uncomplicated mTBI,10.1016/j.acra.2018.01.005,0.397,0.035,0.666,0.046,,,
,tCho,tCho,2018_veeramuthu_25,3,Control,10.1016/j.acra.2018.01.005,0.374,0.049,0.66,0.109,,,
,tCho,tCho,2018_volk_39,1,Healthy - Evening,10.1002/hbm.24225,0.22,0.04,1.65,0.2,,,
,tCho,tCho,2018_volk_39,2,Healthy - Morning,10.1002/hbm.24225,0.22,0.04,1.62,0.24,,,
,Cho,GPC,2018_wang_277,1,OCD,10.1016/j.pscychresns.2018.05.004,0.31,0.02,,,,,
,Cho,GPC,2018_wang_277,2,OCD,10.1016/j.pscychresns.2018.05.004,0.31,0.03,,,,,
,Cho,GPC,2018_wang_277,3,Control,10.1016/j.pscychresns.2018.05.004,0.29,0.01,,,,,
,Cho,GPC,2018_wang_277,4,Control,10.1016/j.pscychresns.2018.05.004,0.27,0.08,,,,,
,Cho,GPC,2018_white_43,1,Healthy_Placebo,10.1038/s41386-018-0027-7,,,1.8,0.19,,,
,Cho,GPC,2018_white_43,2,Healthy_d-amphetamine,10.1038/s41386-018-0027-7,,,1.91,0.19,,,
,Cho,GPC,2018_white_43,3,Healthy_methamphetamine,10.1038/s41386-018-0027-7,,,1.82,0.2,,,
,tCho,tCho,2018_wu_9,1,MA dependence (Abstinent),10.3389/fpsyt.2018.00478,0.27,0.03,,,,,
,tCho,tCho,2018_wu_9,2,Control,10.3389/fpsyt.2018.00478,0.27,0.03,,,,,
,Cho,GPC,2018_yeh_30,1,Alzheimer's Disease,10.1017/S1041610217002381,0.31,0.03,,,,,
,Cho,GPC,2018_yeh_30,2,Alzheimer's Disease,10.1017/S1041610217002381,0.32,0.08,,,,,
,tCho,tCho,2018_zarinabad_79,1,Medulloblastoma,10.1002/mrm.26837,,,,,3.94,1.74,
,tCho,tCho,2018_zarinabad_79,2,Pilocytic Astrocytoma,10.1002/mrm.26837,,,,,1.4,0.709,
,tCho,tCho,2018_zarinabad_79,3,Ependymoma,10.1002/mrm.26837,,,,,1.69,0.29,
,Cho,tCho,2018_zhong_241,1,BD - with suicidal ideation,10.1016/j.jad.2018.08.031,1.15,0.21,,,,,
,Cho,tCho,2018_zhong_241,2,BD - with suicidal ideation,10.1016/j.jad.2018.08.031,1.19,0.2,,,,,
,Cho,tCho,2018_zhong_241,3,BD - with suicidal ideation,10.1016/j.jad.2018.08.031,1.17,0.19,,,,,
,Cho,tCho,2018_zhong_241,4,BD - with suicidal ideation,10.1016/j.jad.2018.08.031,1.14,0.19,,,,,
,Cho,tCho,2018_zhong_241,5,BD - with suicidal ideation,10.1016/j.jad.2018.08.031,0.85,0.36,,,,,
,Cho,tCho,2018_zhong_241,6,BD - with suicidal ideation,10.1016/j.jad.2018.08.031,0.79,0.37,,,,,
,Cho,tCho,2018_zhong_241,7,BD - with suicidal ideation,10.1016/j.jad.2018.08.031,0.89,0.18,,,,,
,Cho,tCho,2018_zhong_241,8,BD - with suicidal ideation,10.1016/j.jad.2018.08.031,0.9,0.19,,,,,
,Cho,tCho,2018_zhong_241,9,BD - without suicidal ideation,10.1016/j.jad.2018.08.031,1.18,0.32,,,,,
,Cho,tCho,2018_zhong_241,10,BD - without suicidal ideation,10.1016/j.jad.2018.08.031,1.17,0.22,,,,,
,Cho,tCho,2018_zhong_241,11,BD - without suicidal ideation,10.1016/j.jad.2018.08.031,1.27,0.38,,,,,
,Cho,tCho,2018_zhong_241,12,BD - without suicidal ideation,10.1016/j.jad.2018.08.031,1.2,0.49,,,,,
,Cho,tCho,2018_zhong_241,13,BD - without suicidal ideation,10.1016/j.jad.2018.08.031,0.88,0.35,,,,,
,Cho,tCho,2018_zhong_241,14,BD - without suicidal ideation,10.1016/j.jad.2018.08.031,1.02,1.12,,,,,
,Cho,tCho,2018_zhong_241,15,BD - without suicidal ideation,10.1016/j.jad.2018.08.031,0.87,0.21,,,,,
,Cho,tCho,2018_zhong_241,16,BD - without suicidal ideation,10.1016/j.jad.2018.08.031,0.89,0.2,,,,,
,Cho,tCho,2018_zhong_241,17,Control ,10.1016/j.jad.2018.08.031,1.49,1.3,,,,,
,Cho,tCho,2018_zhong_241,18,Control,10.1016/j.jad.2018.08.031,1.21,0.21,,,,,
,Cho,tCho,2018_zhong_241,19,Control,10.1016/j.jad.2018.08.031,1.12,0.2,,,,,
,Cho,tCho,2018_zhong_241,20,Control,10.1016/j.jad.2018.08.031,1.05,0.17,,,,,
,Cho,tCho,2018_zhong_241,21,Control,10.1016/j.jad.2018.08.031,0.8,0.46,,,,,
,Cho,tCho,2018_zhong_241,22,Control,10.1016/j.jad.2018.08.031,0.72,0.15,,,,,
,Cho,tCho,2018_zhong_241,23,Control,10.1016/j.jad.2018.08.031,0.87,0.16,,,,,
,Cho,tCho,2018_zhong_241,24,Control,10.1016/j.jad.2018.08.031,0.87,0.13,,,,,
,Cho,GPC,2017_bustillo_43,1,Control,10.1093/schbul/sbw122,,,,,6.5,1.1,
,Cho,GPC,2017_bustillo_43,2,Schizophrenia,10.1093/schbul/sbw123,,,,,6.6,1.2,
,tCho,tCho,2017_cao_42,1,Control,10.1038/npp.2017.39,,,2.27,0.07,,,
,tCho,tCho,2017_cao_42,2,Control,10.1038/npp.2017.39,,,2.48,0.07,,,
,tCho,tCho,2017_cao_42,3,Control,10.1038/npp.2017.39,,,1.59,0.1,,,
,tCho,tCho,2017_cao_42,4,Control,10.1038/npp.2017.39,,,2.46,0.07,,,
,tCho,tCho,2017_cao_42,5,BD-1 - Non Rapid Cycling,10.1038/npp.2017.39,,,2.34,0.07,,,
,tCho,tCho,2017_cao_42,6,BD-1 - Non Rapid Cycling,10.1038/npp.2017.39,,,2.55,0.07,,,
,tCho,tCho,2017_cao_42,7,BD-1 - Non Rapid Cycling,10.1038/npp.2017.39,,,1.89,0.11,,,
,tCho,tCho,2017_cao_42,8,BD-1 - Non Rapid Cycling,10.1038/npp.2017.39,,,2.65,0.08,,,
,tCho,tCho,2017_cao_42,9,BD-1- Rapid Cycling ,10.1038/npp.2017.39,,,2.65,0.1,,,
,tCho,tCho,2017_cao_42,10,BD-1- Rapid Cycling ,10.1038/npp.2017.39,,,2.92,0.1,,,
,tCho,tCho,2017_cao_42,11,BD-1- Rapid Cycling ,10.1038/npp.2017.39,,,2.14,0.13,,,
,tCho,tCho,2017_cao_42,12,BD-1- Rapid Cycling ,10.1038/npp.2017.39,,,2.91,0.1,,,
,tCho,tCho,2017_holmes_12,1,Healthy - 5 year olds,10.1371/journal.pone.0180973,0.2,0.028,1.108,0.161,,,
,tCho,tCho,2017_holmes_12,2,Healthy - 5 year olds,10.1371/journal.pone.0180973,0.194,0.017,1.149,0.113,,,
,tCho,tCho,2017_holmes_12,3,Healthy - 5 year olds,10.1371/journal.pone.0180973,0.32,0.064,1.138,0.171,,,
,tCho,tCho,2017_holmes_12,4,Healthy - 7 year olds,10.1371/journal.pone.0180973,0.205,0.022,1.11,0.137,,,
,tCho,tCho,2017_holmes_12,5,Healthy - 7 year olds,10.1371/journal.pone.0180973,0.193,0.027,1.133,0.123,,,
,tCho,tCho,2017_holmes_12,6,Healthy - 7 year olds,10.1371/journal.pone.0180973,0.32,0.07,1.12,0.16,,,
,tCho,tCho,2017_holmes_12,7,Healthy - 9 year olds,10.1371/journal.pone.0180973,0.188,0.024,1.078,0.127,,,
,tCho,tCho,2017_holmes_12,8,Healthy - 9 year olds,10.1371/journal.pone.0180973,0.198,0.497,1.141,0.106,,,
,tCho,tCho,2017_holmes_12,9,Healthy - 9 year olds,10.1371/journal.pone.0180973,0.298,0.033,1.146,0.103,,,
,Cho,GPC,2017_simoes_216,1,Control,10.1016/j.ajog.2016.09.089,0.25,0.03,,,,,
,Cho,GPC,2017_simoes_216,2,Preterm,10.1016/j.ajog.2016.09.089,0.25,0.04,,,,,
,Cho,GPC,2017_simoes_216,3,Preterm - Intra-uterine growth restricted,10.1016/j.ajog.2016.09.089,0.23,0.03,,,,,
,GPC,GPC,2018_al-iedani_108,1,Healthy,10.1016/j.ejrad.2018.09.020,0.22,0.01,,,,,
,GPC,GPC,2018_al-iedani_108,2,Healthy,10.1016/j.ejrad.2018.09.020,0.19,0.01,,,,,
,GPC,GPC,2018_bednarik_38,1,Healthy,10.1177/0271678X17695291,,,,,0.59,0.07,
,tCho,tCho,2018_kim_83,1,First-episode Psychosis,10.1016/j.biopsych.2017.08.022,0.35,0.06,3.1,0.9,,,IU estimated from bar graph
,tCho,tCho,2018_kim_83,2,First-episode Psychosis,10.1016/j.biopsych.2017.08.022,0.28,0.05,2.5,0.5,,,IU estimated from bar graph
,tCho,tCho,2018_kim_83,3,Control,10.1016/j.biopsych.2017.08.022,0.32,0.04,2.9,0.6,,,IU estimated from bar graph
,tCho,tCho,2018_kim_83,4,Control,10.1016/j.biopsych.2017.08.022,0.23,0.04,2,0.55,,,IU estimated from bar graph
,tCho,tCho,2020_boillat_40,1,Baseline,10.1177/0271678X19831022,,,0.41,0.03,,,
,tCho,tCho,2020_boillat_40,2,positive BOLD,10.1177/0271678X19831022,,,0,0.02,,,
,tCho,tCho,2020_boillat_40,3,Baseline,10.1177/0271678X19831022,,,0.42,0.03,,,
,tCho,tCho,2020_boillat_40,4,negative BOLD,10.1177/0271678X19831022,,,0,0.03,,,
,GPC,GPC,2021_akiyama_61,1,Control,10.2176/nmc.oa.2020-0274,,,1.86,0.59,,,
,GPC,GPC,2021_akiyama_61,2,NPH,10.2176/nmc.oa.2020-0274,,,1.62,0.7,,,
,GPC,GPC,2021_chaudhary_42,4,PD-CN,10.1007/s10072-020-04626-9,,,3.26,0.8,,,
,GPC,GPC,2021_chaudhary_42,19,PD-CI,10.1007/s10072-020-04626-9,,,2.53,0.79,,,
,GPC,GPC,2021_chaudhary_42,34,HC,10.1007/s10072-020-04626-9,,,2.84,0.82,,,
,GPC,GPC,2018_sheth_276,1,Veterans - Suicidal behavior,10.1016/j.pscychresns.2018.04.004,,,0.58,0.02,,,
,GPC,GPC,2018_sheth_276,2,Veterans - Suicidal behavior,10.1016/j.pscychresns.2018.04.004,,,0.46,0.01,,,
,GPC,GPC,2018_sheth_276,3,Veterans - No suicidal behavior,10.1016/j.pscychresns.2018.04.004,,,0.61,0.03,,,
,GPC,GPC,2018_sheth_276,4,Veterans - No suicidal behavior,10.1016/j.pscychresns.2018.04.004,,,0.43,0.01,,,
,tCho,tCho,2019_betinaip_39,1,Behavior - ON - 3% Visual Contrast,10.1523/JNEUROSCI.3021-18.2019,,,0.921,0.12,,,
,tCho,tCho,2019_betinaip_39,2,Behavior - ON - 12.5% Visual Contrast,10.1523/JNEUROSCI.3021-18.2019,,,0.902,0.12,,,
,tCho,tCho,2019_betinaip_39,3,Behavior - ON - 50% Visual Contrast,10.1523/JNEUROSCI.3021-18.2019,,,0.929,0.113,,,
,tCho,tCho,2019_betinaip_39,4,Behavior - ON - 100% Visual Contrast,10.1523/JNEUROSCI.3021-18.2019,,,0.923,0.114,,,
,tCho,tCho,2019_betinaip_39,5,Resting,10.1523/JNEUROSCI.3021-18.2019,,,0.938,0.133,,,
,tCho,tCho,2019_betinaip_39,6,Behavior - OFF - 3% Visual Contrast,10.1523/JNEUROSCI.3021-18.2019,,,0.916,0.117,,,
,tCho,tCho,2019_betinaip_39,7,Behavior - OFF - 12.5% Visual Contrast,10.1523/JNEUROSCI.3021-18.2019,,,0.905,0.12,,,
,tCho,tCho,2019_betinaip_39,8,Behavior - OFF - 50% Visual Contrast,10.1523/JNEUROSCI.3021-18.2019,,,0.908,0.107,,,
,tCho,tCho,2019_betinaip_39,9,Behavior - OFF - 100% Visual Contrast,10.1523/JNEUROSCI.3021-18.2019,,,0.924,0.112,,,
,tCho,tCho,2019_betinaip_39,10,Resting,10.1523/JNEUROSCI.3021-18.2019,,,0.952,0.128,,,
,GPC,GPC,2019_hansen_33,4,Control,10.1016/j.jdiacomp.2018.12.016,0.34,0.07,,,1.91,0.42,
,GPC,GPC,2019_hansen_33,3,Diabetes,10.1016/j.jdiacomp.2018.12.016,0.35,0.06,,,2.01,0.33,
,GPC,GPC,2018_veeramuthu_25,1,Complicated mTBI,10.1016/j.acra.2018.01.005,0.343,0.1,0.572,0.147,,,
,GPC,GPC,2018_veeramuthu_25,2,Uncomplicated mTBI,10.1016/j.acra.2018.01.005,0.395,0.035,0.685,0.068,,,
,GPC,GPC,2018_veeramuthu_25,3,Control,10.1016/j.acra.2018.01.005,0.374,0.049,0.66,0.109,,,
,PCho,PCho,2021_akiyama_61,1,Control,10.2176/nmc.oa.2020-0274,,,0.23,0.52,,,
,PCho,PCho,2021_akiyama_61,2,NPH,10.2176/nmc.oa.2020-0274,,,0.22,0.39,,,
,tCho,tCho,2021_akiyama_61,1,Control,10.2176/nmc.oa.2020-0274,,,2.09,0.33,,,
,tCho,tCho,2021_akiyama_61,2,NPH,10.2176/nmc.oa.2020-0274,,,1.84,0.44,,,
,tCho,tCho,2017_carlson_38,2,Control- Non-dominant Hand ,10.1002/hbm.23472,0.19,0.028,1.45,0.15,,,
,tCho,tCho,2017_carlson_38,1,Control- Dominant Hand,10.1002/hbm.23472,0.21,0.032,1.65,0.188,,,
,tCho,tCho,2017_carlson_38,4,Bipolar with Periventricular Venous Infarctions- Lesioned Side,10.1002/hbm.23472,0.19,0.023,1.55,0.15,,,
,tCho,tCho,2017_carlson_38,3,Bipolar with Periventricular Venous Infarctions- Non-lesioned Side,10.1002/hbm.23472,0.21,0.041,1.55,0.3,,,
,tCho,tCho,2017_carlson_38,5,Bipolar with Arterial Ischemic Strokes- Lesioned Side ,10.1002/hbm.23472,0.22,0.015,1.75,0.225,,,
,tCho,tCho,2017_carlson_38,6,Bipolar with Arterial Ischemic Strokes- Non-lesioned Side,10.1002/hbm.23472,0.21,0.034,1.6,0.188,,,
,Cho,GPC,2020_zheng_265,1,Control,10.1016/j.jad.2020.01.059,,,1.9,0.24,,,
,Cho,GPC,2020_zheng_265,2,Control,10.1016/j.jad.2020.01.059,,,1.99,0.23,,,
,Cho,GPC,2020_zheng_265,3,Control,10.1016/j.jad.2020.01.059,,,1.82,0.23,,,
,Cho,GPC,2020_zheng_265,4,OCD,10.1016/j.jad.2020.01.059,,,2.09,0.37,,,
,Cho,GPC,2020_zheng_265,5,OCD,10.1016/j.jad.2020.01.059,,,2.23,0.31,,,
,Cho,GPC,2020_zheng_265,6,OCD,10.1016/j.jad.2020.01.059,,,1.88,0.37,,,
,Cho,GPC,2020_zheng_265,7,OCD + SPD,10.1016/j.jad.2020.01.059,,,1.96,0.42,,,
,Cho,GPC,2020_zheng_265,8,OCD + SPD,10.1016/j.jad.2020.01.059,,,1.92,0.28,,,
,Cho,GPC,2020_zheng_265,9,OCD + SPD,10.1016/j.jad.2020.01.059,,,1.98,0.48,,,
,Cho,GPC,2021_gramegna_8,2,Patients with MELAS,10.1002/acn3.51329,0.16,0.02,,,,,
,Cho,GPC,2021_gramegna_8,3,Patients with MELAS,10.1002/acn3.51329,0.33,0.06,,,,,
,Cho,GPC,2021_gramegna_8,4,Patients with MELAS,10.1002/acn3.51329,0.24,0.03,,,,,
,Cho,GPC,2021_gramegna_8,6,Patients with MELAS,10.1002/acn3.51329,0.17,0.02,,,,,
,Cho,GPC,2021_gramegna_8,7,Patients with MELAS,10.1002/acn3.51329,0.37,0.04,,,,,
,Cho,GPC,2021_gramegna_8,8,Patients with MELAS,10.1002/acn3.51329,0.29,0.03,,,,,
,tCho,tCho,2020_kahl_101,1,Control,10.1016/j.pnpbp.2020.109916,,,2.22,0.03,,,
,tCho,tCho,2020_kahl_101,2,Control,10.1016/j.pnpbp.2020.109916,,,2.19,0.04,,,
,tCho,tCho,2020_kahl_101,3,Control,10.1016/j.pnpbp.2020.109916,,,1.95,0.04,,,
,tCho,tCho,2020_kahl_101,4,Control,10.1016/j.pnpbp.2020.109916,,,2.02,0.03,,,
,tCho,tCho,2020_kahl_101,5,Control,10.1016/j.pnpbp.2020.109916,,,1.9,0.03,,,
,tCho,tCho,2020_kahl_101,6,Control,10.1016/j.pnpbp.2020.109916,,,1.95,0.04,,,
,tCho,tCho,2020_kahl_101,7,Control,10.1016/j.pnpbp.2020.109916,,,1.5,0.03,,,
,tCho,tCho,2020_kahl_101,8,Control,10.1016/j.pnpbp.2020.109916,,,1.57,0.03,,,
,tCho,tCho,2020_kahl_101,9,Control,10.1016/j.pnpbp.2020.109916,,,2.39,0.04,,,
,tCho,tCho,2020_kahl_101,10,MDD,10.1016/j.pnpbp.2020.109916,,,2.08,0.04,,,
,tCho,tCho,2020_kahl_101,11,MDD,10.1016/j.pnpbp.2020.109916,,,2.09,0.04,,,
,tCho,tCho,2020_kahl_101,12,MDD,10.1016/j.pnpbp.2020.109916,,,1.89,0.03,,,
,tCho,tCho,2020_kahl_101,13,MDD,10.1016/j.pnpbp.2020.109916,,,1.95,0.04,,,
,tCho,tCho,2020_kahl_101,14,MDD,10.1016/j.pnpbp.2020.109916,,,1.8,0.03,,,
,tCho,tCho,2020_kahl_101,15,MDD,10.1016/j.pnpbp.2020.109916,,,1.9,0.03,,,
,tCho,tCho,2020_kahl_101,16,MDD,10.1016/j.pnpbp.2020.109916,,,1.5,0.03,,,
,tCho,tCho,2020_kahl_101,17,MDD,10.1016/j.pnpbp.2020.109916,,,1.59,0.03,,,
,tCho,tCho,2020_kahl_101,18,MDD,10.1016/j.pnpbp.2020.109916,,,1.39,0.05,,,
,tCho,tCho,2020_zhang_33,1,Healthy,10.1002/nbm.4313,0.6,0.1,6.5,0.7,,,
,tCho,tCho,2020_zhang_33,2,Healthy,10.1002/nbm.4313,0.6,0.1,7.1,1.1,,,
,tCho,tCho,2020_zhang_33,3,Healthy,10.1002/nbm.4313,0.6,0.1,7.6,1.1,,,
,tCho,tCho,2020_zhang_33,4,Healthy,10.1002/nbm.4313,0.6,0.1,7.3,1.1,,,
,tCho,tCho,2020_zhang_33,5,Healthy,10.1002/nbm.4313,0.6,0.1,7.6,1.1,,,
,tCho,tCho,2020_zhang_33,6,Healthy,10.1002/nbm.4313,0.6,0.1,8.1,1.6,,,
,tCho,tCho,2020_zhang_33,7,Healthy,10.1002/nbm.4313,0.6,0.1,8,1.2,,,
,tCho,tCho,2020_zhang_33,8,Healthy,10.1002/nbm.4313,0.6,0.1,7.4,1.1,,,
,tCho,tCho,2020_zhang_33,9,Healthy,10.1002/nbm.4313,0.7,0.1,8.4,1.5,,,
,tCho,tCho,2020_zhang_33,10,Healthy,10.1002/nbm.4313,0.7,0.1,9.8,1.9,,,
,tCho,tCho,2020_zhang_33,11,Healthy,10.1002/nbm.4313,0.7,0.1,10,1.9,,,
,tCho,tCho,2020_zhang_33,12,Healthy,10.1002/nbm.4313,0.7,0.1,9.3,1.9,,,
,tCho,tCho,2020_zhang_33,13,Healthy,10.1002/nbm.4313,0.6,0.1,7.8,0.8,,,
,tCho,tCho,2020_zhang_33,14,Healthy,10.1002/nbm.4313,0.6,0.1,8.1,0.8,,,
,tCho,tCho,2020_zhang_33,15,Healthy,10.1002/nbm.4313,0.6,0.1,5.9,1,,,
,tCho,tCho,2020_zhang_33,16,Healthy,10.1002/nbm.4313,0.6,0.1,5.8,0.7,,,
,tCho,tCho,2020_zhang_33,17,Healthy,10.1002/nbm.4313,0.7,0.1,6,1,,,
,tCho,tCho,2020_zhang_33,18,Healthy,10.1002/nbm.4313,0.7,0.1,7.1,1.3,,,
,tCho,tCho,2020_zhang_33,19,Healthy,10.1002/nbm.4313,0.4,0.1,6,1,,,
,tCho,tCho,2020_zhang_33,20,Healthy,10.1002/nbm.4313,0.5,0.1,6.3,1,,,
,tCho,tCho,2020_zhang_33,21,Healthy,10.1002/nbm.4313,0.5,0.1,6.1,1.1,,,
,tCho,tCho,2020_zhang_33,22,Healthy,10.1002/nbm.4313,0.5,0.1,6.1,1.1,,,
,tCho,tCho,2020_zhang_33,23,Healthy,10.1002/nbm.4313,0.5,0.1,5.7,0.9,,,
,tCho,tCho,2020_zhang_33,24,Healthy,10.1002/nbm.4313,0.5,0.1,6,0.9,,,
,tCho,tCho,2020_zhang_33,25,Healthy,10.1002/nbm.4313,0.5,0.1,6.4,0.8,,,
,tCho,tCho,2020_zhang_33,26,Healthy,10.1002/nbm.4313,0.5,0.1,6.1,1,,,
,tCho,tCho,2020_zhang_33,27,Healthy,10.1002/nbm.4313,0.6,0.1,6,0.9,,,
,tCho,tCho,2020_zhang_33,28,Healthy,10.1002/nbm.4313,0.6,0.1,6.4,1,,,
,tCho,tCho,2020_zhang_33,29,Healthy,10.1002/nbm.4313,0.6,0.1,6.6,0.7,,,
,tCho,tCho,2020_zhang_33,30,Healthy,10.1002/nbm.4313,0.5,0.1,7,0.7,,,
,tCho,tCho,2020_zhang_33,31,Healthy,10.1002/nbm.4313,0.5,0.1,6.7,0.7,,,
,tCho,tCho,2020_zhang_33,32,Healthy,10.1002/nbm.4313,0.5,0.1,6.8,0.9,,,
,tCho,tCho,2020_zhang_33,33,Healthy,10.1002/nbm.4313,0.5,0.1,6.4,0.8,,,
,tCho,tCho,2020_zhang_33,34,Healthy,10.1002/nbm.4313,0.5,0.1,6.4,0.8,,,
,tCho,tCho,2020_zhang_33,35,Healthy,10.1002/nbm.4313,0.6,0.1,6.3,1,,,
,tCho,tCho,2020_zhang_33,36,Healthy,10.1002/nbm.4313,0.5,0.1,6.4,0.8,,,
,tCho,tCho,2020_zhang_33,37,Healthy,10.1002/nbm.4313,0.7,0.1,8.4,1.7,,,
,tCho,tCho,2020_zhang_33,38,Healthy,10.1002/nbm.4313,0.7,0.1,8.8,1.9,,,
,tCho,tCho,2020_zhang_33,39,Healthy,10.1002/nbm.4313,0.6,0.1,6.5,1.4,,,
,tCho,tCho,2020_zhang_33,40,Healthy,10.1002/nbm.4313,0.6,0.1,7.8,1.8,,,
,tCho,tCho,2020_zhang_33,41,Healthy,10.1002/nbm.4313,0.6,0.1,5.9,1.7,,,
,tCho,tCho,2020_zhang_33,42,Healthy,10.1002/nbm.4313,0.5,0.1,6.2,1.9,,,
,tCho,tCho,2020_zhang_33,43,Healthy,10.1002/nbm.4313,0.7,0.1,6.5,1.4,,,
,tCho,tCho,2020_zhang_33,44,Healthy,10.1002/nbm.4313,0.7,0.1,7.1,1.4,,,
,tCho,tCho,2020_zhang_33,45,Healthy,10.1002/nbm.4313,0.6,0.1,6.5,0.8,,,
,tCho,tCho,2020_zhang_33,46,Healthy,10.1002/nbm.4313,0.6,0.1,6.9,1.1,,,
,tCho,tCho,2020_zhang_33,47,Healthy,10.1002/nbm.4313,0.6,0.1,8.1,1.3,,,
,Cho,tCho,2020_gules_79,1,MDD,10.1159/000505782,0.94,0.24,4.3,1.06,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2020_gules_79,2,Healthy Control,10.1159/000505782,1.21,0.18,3.27,1.51,,,Assumed Total (tCho) based on Analysis
,Cho,GPC,2021_malaspina_42,1,Schizophrenia,10.3174/ajnr.A6879,,,,,2.6,0.86,
,Cho,GPC,2017_cao_660,1,Control ,10.1016/j.neulet.2017.08.050,1.2,0.05,,,,,Brain Region: Medulla Oblongata 
,Cho,GPC,2017_cao_660,1,Control ,10.1016/j.neulet.2017.08.050,1,0.1,,,,,Brain Region: Substantia Nigra  
,Cho,GPC,2017_cao_660,1,Control,10.1016/j.neulet.2017.08.050,1,0.05,,,,,Brain Region: Putamen 
,Cho,GPC,2017_cao_660,1,Control,10.1016/j.neulet.2017.08.050,0.9,0.1,,,,,Brain Region: Motor Cortex
,Cho,GPC,2017_cao_660,2,Parkinson's Disease,10.1016/j.neulet.2017.08.050,1.2,0.15,,,,,Brain Region: Medulla Oblongata 
,Cho,GPC,2017_cao_660,2,Parkinson's Disease,10.1016/j.neulet.2017.08.050,1.15,0.05,,,,,Brain Region: Substantia Nigra  
,Cho,GPC,2017_cao_660,2,Parkinson's Disease,10.1016/j.neulet.2017.08.050,1.1,0.025,,,,,Brain Region: Putamen 
,Cho,GPC,2017_cao_660,2,Parkinson's Disease,10.1016/j.neulet.2017.08.050,1.2,0.05,,,,,Brain Region: Motor Cortex
,Cho,tCho,2016_guo_69,1,Control,10.1016/j.comppsych.2016.06.001,0.86,0.11,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2016_guo_69,2,Control,10.1016/j.comppsych.2016.06.001,0.87,0.14,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2016_guo_69,3,Control,10.1016/j.comppsych.2016.06.001,0.78,0.16,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2016_guo_69,4,Control,10.1016/j.comppsych.2016.06.001,0.78,0.19,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2016_guo_69,5,Amnestic mild cognitive impairment,10.1016/j.comppsych.2016.06.001,0.87,0.14,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2016_guo_69,6,Amnestic mild cognitive impairment,10.1016/j.comppsych.2016.06.001,0.82,0.011,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2016_guo_69,7,Amnestic mild cognitive impairment,10.1016/j.comppsych.2016.06.001,0.73,0.08,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2016_guo_69,8,Amnestic mild cognitive impairment,10.1016/j.comppsych.2016.06.001,0.69,0.16,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2016_guo_69,9,Alzheimer's disease,10.1016/j.comppsych.2016.06.001,0.91,0.12,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2016_guo_69,10,Alzheimer's disease,10.1016/j.comppsych.2016.06.001,0.83,0.16,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2016_guo_69,11,Alzheimer's disease,10.1016/j.comppsych.2016.06.001,0.68,0.15,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2016_guo_69,12,Alzheimer's disease,10.1016/j.comppsych.2016.06.001,0.71,0.23,,,,,Assumed Total (tCho) based on Analysis
,tCho,tCho,2016_howells_31,1,In utero alcohol exposure,10.1007/s11011-016-9850-x,0.48,0.07,,,1.28,0.37,
,tCho,tCho,2016_howells_31,2,In utero alcohol exposure,10.1007/s11011-016-9850-x,0.43,0.06,,,1.51,0.23,
,tCho,tCho,2016_howells_31,3,In utero alcohol exposure - Female,10.1007/s11011-016-9850-x,0.49,0.09,,,1.23,0.4,
,tCho,tCho,2016_howells_31,4,In utero alcohol exposure - Female,10.1007/s11011-016-9850-x,0.44,0.07,,,1.49,0.22,
,tCho,tCho,2016_howells_31,5,In utero alcohol exposure - Male,10.1007/s11011-016-9850-x,0.47,0.05,,,1.33,0.36,
,tCho,tCho,2016_howells_31,6,In utero alcohol exposure - Male,10.1007/s11011-016-9850-x,0.43,0.05,,,1.52,0.25,
,tCho,tCho,2016_howells_31,7,Infants - Control,10.1007/s11011-016-9850-x,0.45,0.06,,,1.39,0.27,
,tCho,tCho,2016_howells_31,8,Infants - Control,10.1007/s11011-016-9850-x,0.43,0.04,,,1.47,0.26,
,tCho,tCho,2016_howells_31,9,Infants - Control_Female,10.1007/s11011-016-9850-x,0.45,0.06,,,1.35,0.27,
,tCho,tCho,2016_howells_31,10,Infants - Control_Female,10.1007/s11011-016-9850-x,0.45,0.05,,,1.34,0.35,
,tCho,tCho,2016_howells_31,11,Infants - Control_Male,10.1007/s11011-016-9850-x,0.46,0.06,,,1.45,0.28,
,tCho,tCho,2016_howells_31,12,Infants - Control_Male,10.1007/s11011-016-9850-x,0.42,0.03,,,1.53,0.19,
,tCho,tCho,2016_koob_11,1,Premature Neonates,10.1371/journal.pone.0160990,,,0.045,0.018,,,
,tCho,tCho,2016_koob_11,2,Premature Neonates,10.1371/journal.pone.0160990,,,0.03,0.006,,,
,tCho,tCho,2016_koob_11,3,Infants - Control,10.1371/journal.pone.0160990,,,0.049,0.014,,,
,tCho,tCho,2016_koob_11,4,Infants - Control,10.1371/journal.pone.0160990,,,0.032,0.006,,,
,GPC,GPC,2020_su_71,1,Healthy Controls,10.1016/j.jocn.2019.11.021,,,5.11,1.59,,,
,GPC,GPC,2020_su_71,2,Methamphetamine Dependence,10.1016/j.jocn.2019.11.021,,,3.96,0.61,,,
,GPC + PCh,tCho,2020_su_71,1,Healthy Controls,10.1016/j.jocn.2019.11.021,,,3.96,0.61,,,
,GPC + PCh,tCho,2020_su_71,2,Methamphetamine Dependence,10.1016/j.jocn.2019.11.021,,,3.15,0.7,,,
,tCho,tCho,2016_mazuel_278,1,Parkinson's Disease - Drug-on,10.1148/radiol.2015142764,,,2,2.7,,,
,tCho,tCho,2016_mazuel_278,2,Parkinson's Disease - Drug-off,10.1148/radiol.2015142764,,,1.9,2.2,,,
,tCho,tCho,2016_mazuel_278,3,Control,10.1148/radiol.2015142764,,,2.1,2.2,,,
,tCho,tCho,2019_marjanska_68,1,Alzheimer's disease,10.3233/JAD-180861,,,,,1.65,0.16,
,tCho,tCho,2019_marjanska_68,2,Alzheimer's disease,10.3233/JAD-180861,,,,,1.24,0.16,
,tCho,tCho,2019_marjanska_68,3,Control,10.3233/JAD-180861,,,,,1.47,0.172,
,tCho,tCho,2019_marjanska_68,4,Control,10.3233/JAD-180861,,,,,1.16,0.172,
,Cho,GPC,2020_basu_10,1,Preterm Infants,10.1038/s41598-020-67188-y,,,1.99,0.05,,,
,Cho,GPC,2020_basu_10,4,Preterm Infants,10.1038/s41598-020-67188-y,,,2.08,0.05,,,
,Cho,GPC,2020_basu_10,7,Preterm Infants,10.1038/s41598-020-67188-y,,,1.9,0.07,,,
,Cho,GPC,2020_basu_10,10,Preterm Infants,10.1038/s41598-020-67188-y,,,2.1,0.05,,,
,Cho,GPC,2020_basu_10,13,Preterm Infants,10.1038/s41598-020-67188-y,,,1.9,0.06,,,
,tCho,tCho,2019_meyer_10,1,Control,10.3389/fneur.2019.00556,,,,,22.21,2.87,
,tCho,tCho,2019_meyer_10,2,Control,10.3389/fneur.2019.00556,,,,,25.19,6.54,
,tCho,tCho,2019_meyer_10,3,Concussion,10.3389/fneur.2019.00556,,,,,22.43,3.8,
,tCho,tCho,2019_meyer_10,4,Concussion,10.3389/fneur.2019.00556,,,,,26.01,13.52,
,tCho,tCho,2019_meyer_10,5,Concussion,10.3389/fneur.2019.00556,,,,,24.04,5.68,
,tCho,tCho,2019_meyer_10,6,Concussion,10.3389/fneur.2019.00556,,,,,21.66,8.74,
,tCho,tCho,2019_meyer_10,7,Concussion,10.3389/fneur.2019.00556,,,,,24.72,4.6,
,tCho,tCho,2019_meyer_10,8,Concussion,10.3389/fneur.2019.00556,,,,,21.8,11.38,
,Cho,tCho,2020_wang_21,1,ESRD,10.1186/s12882-020-01863-0,1.24,0.12,,,,,
,Cho,tCho,2020_wang_21,2,ESRD,10.1186/s12882-020-01863-0,1.2,0.12,,,,,
,Cho,tCho,2020_wang_21,3,ESRD,10.1186/s12882-020-01863-0,1.28,0.16,,,,,
,Cho,tCho,2020_wang_21,4,ESRD,10.1186/s12882-020-01863-0,1.3,0.18,,,,,
,Cho,tCho,2020_wang_21,5,ESRD,10.1186/s12882-020-01863-0,1.19,0.15,,,,,
,Cho,tCho,2020_wang_21,6,ESRD,10.1186/s12882-020-01863-0,1.22,0.16,,,,,
,Cho,tCho,2020_wang_21,7,ESRD,10.1186/s12882-020-01863-0,1.1,0.17,,,,,
,Cho,tCho,2020_wang_21,8,ESRD,10.1186/s12882-020-01863-0,1.08,0.13,,,,,
,Cho,tCho,2020_wang_21,9,Control,10.1186/s12882-020-01863-0,1,0.12,,,,,
,Cho,tCho,2020_wang_21,10,Control,10.1186/s12882-020-01863-0,1.02,0.14,,,,,
,tCho,tCho,2019_monnig_54,1,Healthy - Baseline,10.1093/alcalc/agz062,0.353,0.045,,,,,
,tCho,tCho,2019_monnig_54,2,Healthy - Descending limb,10.1093/alcalc/agz062,0.365,0.053,,,,,
,tCho,tCho,2019_monnig_54,3,Healthy - Baseline,10.1093/alcalc/agz062,0.285,0.036,,,,,
,tCho,tCho,2019_monnig_54,4,Healthy - Descending limb,10.1093/alcalc/agz062,0.311,0.038,,,,,
,tCho,tCho,2019_parmar_73,1,Obsessive-compulsive disorder - Unmedicated - 10mg escitalopram - Baseline,10.1111/pcn.12850,,,1.68,0.24,,,
,tCho,tCho,2019_parmar_73,2,Obsessive-compulsive disorder - Unmedicated - 10mg escitalopram - 12wk,10.1111/pcn.12850,,,1.56,,,,"Median,IQR (1.56, .22)"
,tCho,tCho,2019_parmar_73,3,Control,10.1111/pcn.12850,,,1.8,0.35,,,
,tCho,tCho,2019_parmar_73,4,Obsessive-compulsive disorder - Unmedicated - 10mg escitalopram - Baseline,10.1111/pcn.12850,,,1.65,0.31,,,
,tCho,tCho,2019_parmar_73,5,Obsessive-compulsive disorder - Unmedicated - 10mg escitalopram - 12wk,10.1111/pcn.12850,,,1.52,,,,"Median,IQR (1.52, .22)"
,tCho,tCho,2019_parmar_73,6,Control,10.1111/pcn.12850,,,1.47,0.22,,,
,tCho,tCho,2019_parmar_73,7,Obsessive-compulsive disorder - Unmedicated - 10mg escitalopram - Baseline,10.1111/pcn.12850,,,1.77,0.31,,,
,tCho,tCho,2019_parmar_73,8,Obsessive-compulsive disorder - Unmedicated - 10mg escitalopram - 12wk,10.1111/pcn.12850,,,1.52,,,,"Median,IQR (1.52, .17)"
,tCho,tCho,2019_parmar_73,9,Control,10.1111/pcn.12850,,,1.49,0.24,,,
,Cho,GPC,2019_pflugrad_14,1,Chronic liver disease - Before OLT,10.1371/journal.pone.0221626,,,0.91,0.13,,,
,Cho,GPC,2019_pflugrad_14,2,Chronic liver disease - Before OLT,10.1371/journal.pone.0221626,,,0.99,,,,"Median,IQR (0.99, .36)"
,Cho,GPC,2019_pflugrad_14,3,Chronic liver disease - Before OLT,10.1371/journal.pone.0221626,,,0.94,0.14,,,
,Cho,GPC,2019_pflugrad_14,4,Chronic liver disease - Before OLT_PTE,10.1371/journal.pone.0221626,,,0.9,0.12,,,
,Cho,GPC,2019_pflugrad_14,5,Chronic liver disease - Before OLT_PTE,10.1371/journal.pone.0221626,,,0.96,,,,"Median,IQR (.96, .28)"
,Cho,GPC,2019_pflugrad_14,6,Chronic liver disease - Before OLT_PTE,10.1371/journal.pone.0221626,,,0.98,0.13,,,
,Cho,GPC,2019_pflugrad_14,7,Chronic liver disease - Before OLT_no PTE,10.1371/journal.pone.0221626,,,0.94,0.13,,,
,Cho,GPC,2019_pflugrad_14,8,Chronic liver disease - Before OLT_no PTE,10.1371/journal.pone.0221626,,,1,,,,"Median,IQR (1.00, .30)"
,Cho,GPC,2019_pflugrad_14,9,Chronic liver disease - Before OLT_no PTE,10.1371/journal.pone.0221626,,,0.92,0.13,,,
,Cho,GPC,2019_pflugrad_14,10,Control,10.1371/journal.pone.0221626,,,1.02,0.14,,,
,Cho,GPC,2019_pflugrad_14,11,Control,10.1371/journal.pone.0221626,,,1,,,,"Median,IQR (1.00, .12)"
,Cho,GPC,2019_pflugrad_14,12,Control,10.1371/journal.pone.0221626,,,1.08,0.15,,,
,Cho,GPC,2019_pflugrad_14,13,Chronic liver disease - After OLT,10.1371/journal.pone.0221626,,,1.11,0.2,,,
,Cho,GPC,2019_pflugrad_14,14,Chronic liver disease - After OLT,10.1371/journal.pone.0221626,,,1.26,,,,"Median,IQR (1.26, .43)"
,Cho,GPC,2019_pflugrad_14,15,Chronic liver disease - After OLT,10.1371/journal.pone.0221626,,,1.05,0.25,,,
,Cho,GPC,2019_pflugrad_14,16,Chronic liver disease - After OLT_PTE,10.1371/journal.pone.0221626,,,1.1,0.22,,,
,Cho,GPC,2019_pflugrad_14,17,Chronic liver disease - After OLT_PTE,10.1371/journal.pone.0221626,,,1.14,,,,"Median,IQR (1.14, .43)"
,Cho,GPC,2019_pflugrad_14,18,Chronic liver disease - After OLT_PTE,10.1371/journal.pone.0221626,,,0.98,0.23,,,
,Cho,GPC,2019_pflugrad_14,19,Chronic liver disease - After OLT_no PTE,10.1371/journal.pone.0221626,,,1.11,0.2,,,
,Cho,GPC,2019_pflugrad_14,20,Chronic liver disease - After OLT_no PTE,10.1371/journal.pone.0221626,,,1.26,,,,"Median,IQR (1.26, .42)"
,Cho,GPC,2019_pflugrad_14,21,Chronic liver disease - After OLT_no PTE,10.1371/journal.pone.0221626,,,1.09,0.26,,,
,Cho,GPC,2021_rowe_133,1,LOGG,10.1016/j.ymgme.2021.06.008,,,,,1.96,0.1,
,Cho,GPC,2021_rowe_133,4,LOTS,10.1016/j.ymgme.2021.06.008,,,,,1.95,0.12,
,Cho,GPC,2021_rowe_133,7,LOSD,10.1016/j.ymgme.2021.06.008,,,,,1.98,0.07,
,Cho,GPC,2021_rowe_133,10,Control,10.1016/j.ymgme.2021.06.008,,,,,2.08,0.14,
,tCho,tCho,2021_shiga_30,1,Non-progression,10.1016/j.jstrokecerebrovasdis.2021.105747,0.345,0.04,,,,,
,tCho,tCho,2021_shiga_30,2,Non-progression,10.1016/j.jstrokecerebrovasdis.2021.105747,0.98,0.09,,,,,
,tCho,tCho,2021_shiga_30,3,Progression,10.1016/j.jstrokecerebrovasdis.2021.105747,0.366,0.029,,,,,
,tCho,tCho,2021_shiga_30,4,Progression,10.1016/j.jstrokecerebrovasdis.2021.105747,1.04,0.11,,,,,
,Cho,GPC,2021_siegel-ramsay_313,1,Control,10.1016/j.pscychresns.2021.111302,,,1.89,0.25,,,
,Cho,GPC,2021_siegel-ramsay_313,2,Autism,10.1016/j.pscychresns.2021.111302,,,2,0.34,,,
,Cho,GPC,2021_soeiro-de-souza_49,1,Bipolar,10.1016/j.euroneuro.2021.03.020,0.23,0.03,,,,,
,Cho,GPC,2021_soeiro-de-souza_49,2,Control,10.1016/j.euroneuro.2021.03.020,0.21,0.27,,,,,
,GPC + PCh,tCho,2020_colizzi_25,1,Healthy,10.1038/s41380-019-0374-8,,,4.44,1.46,,,
,GPC + PCh,tCho,2020_colizzi_25,2,Healthy,10.1038/s41380-019-0374-8,,,3.25,0.45,,,
,GPC + PCh,tCho,2020_colizzi_25,3,Healthy,10.1038/s41380-019-0374-8,,,4.19,0.83,,,
,GPC + PCh,tCho,2020_colizzi_25,4,Psychosis ,10.1038/s41380-019-0374-8,,,4.31,0.79,,,
,GPC + PCh,tCho,2020_colizzi_25,5,Psychosis ,10.1038/s41380-019-0374-8,,,3.25,0.58,,,
,GPC + PCh,tCho,2020_colizzi_25,6,Psychosis ,10.1038/s41380-019-0374-8,,,4.06,0.44,,,
,GPC + PCh,tCho,2021_steinegger_26,1,Control,10.1111/adb.13027,,,,,2.91,0.34,
,GPC + PCh,tCho,2021_steinegger_26,4,Smokers,10.1111/adb.13027,,,,,2.71,0.42,
,GPC + PCh,tCho,2021_steinegger_26,6,Baseline,10.1111/adb.13027,,,,,2.76,0.43,
,GPC + PCh,tCho,2021_steinegger_26,7,Withdrawal,10.1111/adb.13027,,,,,2.66,0.4,
,GPC + PCh,tCho,2021_steinegger_26,8,Satiation,10.1111/adb.13027,,,,,2.83,0.26,
,Cho,GPC,2021_wang_59,1,Control,10.1016/j.mito.2021.06.012,0.24,0.32,,,1.58,0.16,
,Cho,GPC,2021_wang_59,2,Control,10.1016/j.mito.2021.06.013,0.24,0.32,,,1.58,0.16,
,Cho,GPC,2021_wang_59,3,MELAS,10.1016/j.mito.2021.06.014,0.95,0.33,,,6.32,2.56,
,Cho,tCho,2021_yao_45,1,low-grade gliomas,10.1097/RCT.0000000000001130,1.971,0.742,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2021_yao_45,2,high-grade gliomas,10.1097/RCT.0000000000001130,2.724,1.382,,,,,Assumed Total (tCho) based on Analysis
,Cho,GPC,2021_henigsberg_238,1,AD discontinuation,10.1007/s00213-019-05303-2,0.63,0.2,,,,,
,Cho,GPC,2021_henigsberg_238,2,Episode recurrence,10.1007/s00213-019-05303-2,0.52,0.2,,,,,
,GPC + PC,tCho,2021_mansur_281,1,Placebo,10.1016/j.jad.2020.11.128,,,,,1.34,0.21,
,GPC + PC,tCho,2021_mansur_281,2,Infliximab,10.1016/j.jad.2020.11.128,,,,,1.44,0.29,
,Cho,tCho,2019_piccardo_46,1,Pediatric diffuse midline glioma - H3K27M-mutant,10.1007/s00259-019-04333-4,3.35,2.14,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2019_piccardo_46,2,Pediatric diffuse midline glioma - H3K27M-wildtype,10.1007/s00259-019-04333-4,2.67,2.56,,,,,Assumed Total (tCho) based on Analysis
,Cho,GPC,2019_prisci_43,1,Alcohol use disorder ,10.1111/acer.13931,,,1.09,0.12,,,
,Cho,GPC,2019_prisci_43,2,Control,10.1111/acer.13931,,,1.01,0.19,,,
,tCho,tCho,2019_schmitz_49,1,Control,10.1111/apt.15256,,,1.13,0.141,,,
,tCho,tCho,2019_schmitz_49,2,Liver transplantation - Calcineurin inhibitor free,10.1111/apt.15256,,,1.035,0.166,,,
,tCho,tCho,2019_schmitz_49,3,Liver transplantation - Calcineurin inhibitor low-dose,10.1111/apt.15256,,,1.096,0.195,,,
,tCho,tCho,2019_schmitz_49,4,Liver transplantation - Calcineurin inhibitor standard-dose,10.1111/apt.15256,,,1.077,0.183,,,
,tCho,tCho,2019_sheth_248,1,PTSD,10.1016/j.jad.2019.01.037,0.28,0.05,0.57,0,,,
,tCho,tCho,2019_sheth_248,2,Trauma-exposed ,10.1016/j.jad.2019.01.037,0.29,0.04,0.6,0,,,
,tCho,tCho,2019_sheth_248,3,Control,10.1016/j.jad.2019.01.037,0.29,0.03,0.62,0,,,
,Cho,GPC,2020_lyros_87,1,Healthy Control,10.1016/j.neurobiolaging.2019.11.012,0.28,0.04,,,,,
,Cho,GPC,2020_lyros_87,2,Healthy Control ,10.1016/j.neurobiolaging.2019.11.012,0.31,0.03,,,,,
,Cho,GPC,2020_lyros_87,3,Alzheimer's disease,10.1016/j.neurobiolaging.2019.11.012,0.31,0.03,,,,,
,Cho,GPC,2020_lyros_87,4,Vascular Dementia ,10.1016/j.neurobiolaging.2019.11.012,0.3,0.05,,,,,
,Cho,GPC,2020_lyros_87,5,Mixed Type AD and VaD,10.1016/j.neurobiolaging.2019.11.012,0.31,0.04,,,,,
,Cho,GPC,2020_lyros_87,6,FTLD,10.1016/j.neurobiolaging.2019.11.012,0.34,0.02,,,,,
,Cho,GPC,2020_lyros_87,7,Mild cognitive impairment,10.1016/j.neurobiolaging.2019.11.012,0.33,0.05,,,,,
,Cho,GPC,2020_lyros_87,8,Healthy Control,10.1016/j.neurobiolaging.2019.11.012,0.23,0.03,,,,,
,Cho,GPC,2020_lyros_87,9,Healthy Control ,10.1016/j.neurobiolaging.2019.11.012,0.23,0.02,,,,,
,Cho,GPC,2020_lyros_87,10,Alzheimer's disease,10.1016/j.neurobiolaging.2019.11.012,0.24,0.03,,,,,
,Cho,GPC,2020_lyros_87,11,Vascular Dementia ,10.1016/j.neurobiolaging.2019.11.012,0.22,0.04,,,,,
,Cho,GPC,2020_lyros_87,12,Mixed Type AD and VaD,10.1016/j.neurobiolaging.2019.11.012,0.23,0.03,,,,,
,Cho,GPC,2020_lyros_87,13,FTLD,10.1016/j.neurobiolaging.2019.11.012,0.22,0.03,,,,,
,Cho,GPC,2020_lyros_87,14,Mild cognitive impairment,10.1016/j.neurobiolaging.2019.11.012,0.23,0.02,,,,,
,GPC+PCh,tCho,2019_smaragdi_93,1,ASPD - DLPFC,10.1016/j.pnpbp.2019.04.002,,,,,2.28,0.33,
,GPC+PCh,tCho,2019_smaragdi_93,2,ASPD - ACC,10.1016/j.pnpbp.2019.04.002,,,,,3.27,0.4,
,GPC+PCh,tCho,2019_smaragdi_93,3,BD - DLPFC,10.1016/j.pnpbp.2019.04.002,,,,,2.23,0.3,
,GPC+PCh,tCho,2019_smaragdi_93,4,BD - ACC,10.1016/j.pnpbp.2019.04.002,,,,,3.17,0.42,
,GPC+PCh,tCho,2019_smaragdi_93,5,HC - DLPFC,10.1016/j.pnpbp.2019.04.002,,,,,2.31,0.29,
,GPC+PCh,tCho,2019_smaragdi_93,6,HC - ACC,10.1016/j.pnpbp.2019.04.002,,,,,3.42,0.45,
,Cho,GPC,2019_simmonite_26,1,Healthy - Young adults,10.1016/j.acra.2018.07.024,0.16,0.01,,,,,
,Cho,GPC,2019_simmonite_26,2,Healthy - Older adults,10.1016/j.acra.2018.07.024,0.16,0.02,,,,,
,tCho,tCho,2019_wagoner_317,1,Non-OI,10.1152/ajpheart.00680.2018,,,1.6,0.529,,,
,tCho,tCho,2019_wagoner_317,2,OI,10.1152/ajpheart.00680.2018,,,2.2,0.332,,,
,tCho,tCho,2019_wang_28,1,PTSD,10.1007/s00787-018-1241-x,,,,,2.83,0.34,
,tCho,tCho,2019_wang_28,2,PTSD,10.1007/s00787-018-1241-x,,,,,2.9,0.41,
,tCho,tCho,2019_wang_28,3,Non-PTSD,10.1007/s00787-018-1241-x,,,,,2.87,0.35,
,tCho,tCho,2019_wang_28,4,Non-PTSD,10.1007/s00787-018-1241-x,,,,,2.54,0.35,
,Cho,GPC,2019_zawadzki_9,1,Control,10.1038/s41598-019-39352-6,0.337,0.062,,,,,
,Cho,GPC,2019_zawadzki_9,2,Control,10.1038/s41598-019-39352-6,0.332,0.034,,,,,
,Cho,GPC,2019_zawadzki_9,3,Control,10.1038/s41598-019-39352-6,0.311,0.145,,,,,
,Cho,GPC,2019_zawadzki_9,4,Control,10.1038/s41598-019-39352-6,0.273,0.062,,,,,
,Cho,GPC,2019_zawadzki_9,5,Control,10.1038/s41598-019-39352-6,0.311,0.039,,,,,
,Cho,GPC,2019_zawadzki_9,6,Control,10.1038/s41598-019-39352-6,0.312,0.038,,,,,
,Cho,GPC,2019_zawadzki_9,7,TBE,10.1038/s41598-019-39352-6,0.358,0.038,,,,,
,Cho,GPC,2019_zawadzki_9,8,TBE,10.1038/s41598-019-39352-6,0.365,0.051,,,,,
,Cho,GPC,2019_zawadzki_9,9,TBE,10.1038/s41598-019-39352-6,0.288,0.044,,,,,
,Cho,GPC,2019_zawadzki_9,10,TBE,10.1038/s41598-019-39352-6,0.279,0.035,,,,,
,Cho,GPC,2019_zawadzki_9,11,TBE,10.1038/s41598-019-39352-6,0.326,0.065,,,,,
,Cho,GPC,2019_zawadzki_9,12,TBE,10.1038/s41598-019-39352-6,0.342,0.048,,,,,
,Cho,tCho,2018_gu_11,1,Control,10.2147/JPR.S162696,0.95,0.16,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2018_gu_11,2,Control,10.2147/JPR.S162696,1.04,0.13,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2018_gu_11,3,Control,10.2147/JPR.S162696,0.98,0.14,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2018_gu_11,4,Control,10.2147/JPR.S162696,1.01,0.09,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2018_gu_11,5,Control,10.2147/JPR.S162696,0.97,0.08,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2018_gu_11,6,Control,10.2147/JPR.S162696,0.95,0.08,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2018_gu_11,7,Control,10.2147/JPR.S162696,0.76,0.06,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2018_gu_11,8,Control,10.2147/JPR.S162696,0.78,0.08,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2018_gu_11,9,Migraine,10.2147/JPR.S162696,1,0.08,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2018_gu_11,10,Migraine,10.2147/JPR.S162696,1.05,0.13,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2018_gu_11,11,Migraine,10.2147/JPR.S162696,1,0.07,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2018_gu_11,12,Migraine,10.2147/JPR.S162696,1.04,0.1,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2018_gu_11,13,Migraine,10.2147/JPR.S162696,1,0.14,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2018_gu_11,14,Migraine,10.2147/JPR.S162696,1.05,0.13,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2018_gu_11,15,Migraine,10.2147/JPR.S162696,0.76,0.06,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2018_gu_11,16,Migraine,10.2147/JPR.S162696,0.79,0.07,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2018_gu_11,17,Cervicogenic Headache,10.2147/JPR.S162696,1.08,0.09,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2018_gu_11,18,Cervicogenic Headache,10.2147/JPR.S162696,1.01,0.06,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2018_gu_11,19,Cervicogenic Headache,10.2147/JPR.S162696,1.08,0.06,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2018_gu_11,20,Cervicogenic Headache,10.2147/JPR.S162696,1.04,0.07,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2018_gu_11,21,Cervicogenic Headache,10.2147/JPR.S162696,1.04,0.06,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2018_gu_11,22,Cervicogenic Headache,10.2147/JPR.S162696,1.06,0.08,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2018_gu_11,23,Cervicogenic Headache,10.2147/JPR.S162696,0.81,0.03,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2018_gu_11,24,Cervicogenic Headache,10.2147/JPR.S162696,0.78,0.78,,,,,Assumed Total (tCho) based on Analysis
,Cho,GPC,2018_horowitz-kraus_12,1,Control,10.3389/fnhum.2018.00466,,,,,1.66,0.15,
,Cho,GPC,2018_horowitz-kraus_12,2,Dyslexia,10.3389/fnhum.2018.00466,,,,,1.63,0.11,
,tCho,tCho,2018_povazan_79,1,Healthy,10.1002/mrm.26778,,,3.02,0.39,,,
,tCho,tCho,2018_povazan_79,2,Healthy,10.1002/mrm.26778,,,2.79,0.34,,,
,tCho,tCho,2018_povazan_79,3,Healthy,10.1002/mrm.26778,,,2.74,0.39,,,
,tCho,tCho,2018_povazan_79,4,Healthy,10.1002/mrm.26778,,,2.98,0.39,,,
,tCho,tCho,2018_povazan_79,5,Healthy,10.1002/mrm.26778,,,2.98,0.43,,,
,tCho,tCho,2018_povazan_79,6,Healthy,10.1002/mrm.26778,,,2.93,0.68,,,
,tCho,tCho,2018_povazan_79,7,Healthy,10.1002/mrm.26778,,,2.74,0.39,,,
,Cho,GPC,2020_mazibuko_10,1,Control,10.3390/diagnostics10070482,,,2.06,0.33,,,
,Cho,GPC,2020_mazibuko_10,2,Control,10.3390/diagnostics10070482,,,2,0.21,,,
,Cho,GPC,2020_mazibuko_10,3,Subacute Ischemic Stroke,10.3390/diagnostics10070482,,,2.33,0.35,,,
,Cho,GPC,2020_mazibuko_10,4,Subacute Ischemic Stroke,10.3390/diagnostics10070482,,,1.98,0.28,,,
,Cho,GPC,2020_mazibuko_10,5,Subacute Ischemic Stroke ,10.3390/diagnostics10070482,,,2.51,1.17,,,
,Cho,GPC,2020_mazibuko_10,6,Subacute Ischemic Stroke ,10.3390/diagnostics10070482,,,2.4,0.9,,,
,Cho,GPC,2020_mazibuko_10,7,Subacute Ischemic Stroke ,10.3390/diagnostics10070482,,,2.82,0.58,,,
,Cho,GPC,2020_mazibuko_10,8,Subacute Ischemic Stroke ,10.3390/diagnostics10070482,,,2.56,1.18,,,
,tCho,tCho,2020_menshchikov_84,1,Control,10.1002/mrm.28332,0.282,0.026,,,1.96,0.2,
,tCho,tCho,2020_menshchikov_84,2,Mild Traumatic Brain Injury ,10.1002/mrm.28332,0.282,0.022,,,1.98,0.19,
,tCho,tCho,2019_wiegers_62,1,Control,10.1007/s00125-019-4862-9,,,,,1.79,0.16,
,tCho,tCho,2019_wiegers_62,2,Type 1 diabetes - Normal awareness of hypoglycaemia,10.1007/s00125-019-4862-9,,,,,1.9,0.39,
,tCho,tCho,2019_wiegers_62,3,Type 1 diabetes,10.1007/s00125-019-4862-9,,,,,1.97,0.31,
,Cho,tCho,2019_xu_98,1,Non-alcoholic fatty liver disease - No mild cognitive impairment,10.1097/MD.0000000000018189,1.01,0.19,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2019_xu_98,2,Non-alcoholic fatty liver disease - No mild cognitive impairment,10.1097/MD.0000000000018189,0.94,0.31,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2019_xu_98,3,Non-alcoholic fatty liver disease - No mild cognitive impairment,10.1097/MD.0000000000018189,1.03,0.38,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2019_xu_98,4,Non-alcoholic fatty liver disease - No mild cognitive impairment,10.1097/MD.0000000000018189,0.95,0.2,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2019_xu_98,5,Non-alcoholic fatty liver disease - No mild cognitive impairment,10.1097/MD.0000000000018189,0.91,0.13,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2019_xu_98,6,Non-alcoholic fatty liver disease - No mild cognitive impairment,10.1097/MD.0000000000018189,1.04,0.29,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2019_xu_98,7,Non-alcoholic fatty liver disease - Mild cognitive impairment,10.1097/MD.0000000000018189,1.08,0.12,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2019_xu_98,8,Non-alcoholic fatty liver disease - Mild cognitive impairment,10.1097/MD.0000000000018189,1.27,0.25,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2019_xu_98,9,Non-alcoholic fatty liver disease - Mild cognitive impairment,10.1097/MD.0000000000018189,1.02,0.06,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2019_xu_98,10,Non-alcoholic fatty liver disease - Mild cognitive impairment,10.1097/MD.0000000000018189,1.16,0.22,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2019_xu_98,11,Non-alcoholic fatty liver disease - Mild cognitive impairment,10.1097/MD.0000000000018189,0.94,0.12,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2019_xu_98,12,Non-alcoholic fatty liver disease - Mild cognitive impairment,10.1097/MD.0000000000018189,1.12,0.23,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2018_shan_227,1,Control,10.1016/j.jad.2017.10.030,1.3,0.47,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2018_shan_227,2,Control,10.1016/j.jad.2017.10.030,1.21,0.22,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2018_shan_227,3,Control,10.1016/j.jad.2017.10.030,0.81,0.5,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2018_shan_227,4,Control,10.1016/j.jad.2017.10.030,0.72,0.16,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2018_shan_227,5,Depression,10.1016/j.jad.2017.10.030,1.17,0.2,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2018_shan_227,6,Depression,10.1016/j.jad.2017.10.030,1.21,0.18,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2018_shan_227,7,Depression,10.1016/j.jad.2017.10.030,0.81,0.22,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2018_shan_227,8,Depression,10.1016/j.jad.2017.10.030,0.81,0.33,,,,,Assumed Total (tCho) based on Analysis
,Cho,GPC,2018_soeiro-de-souza_241,1,Control,10.1016/j.jad.2018.08.039,,,,,2.763,0.396,
,Cho,GPC,2018_soeiro-de-souza_241,2,Bipolar,10.1016/j.jad.2018.08.039,,,,,2.857,0.429,
,Cho,GPC,2018_soeiro-de-souza_241,3,Bipolar,10.1016/j.jad.2018.08.039,,,,,2.883,0.412,
,Cho,GPC,2018_soeiro-de-souza_241,4,Bipolar,10.1016/j.jad.2018.08.039,,,,,2.994,0.548,
,Cho,GPC,2018_su_241,1,Control,10.1016/j.jad.2018.08.018,,,,,2.52,0.37,
,Cho,GPC,2018_su_241,2,Control,10.1016/j.jad.2018.08.018,,,,,2.89,0.59,
,Cho,GPC,2018_su_241,3,Control,10.1016/j.jad.2018.08.018,,,,,2.82,0.5,
,Cho,GPC,2018_su_241,4,PTSD,10.1016/j.jad.2018.08.018,,,,,2.38,0.47,
,Cho,GPC,2018_su_241,5,PTSD,10.1016/j.jad.2018.08.018,,,,,3.16,0.57,
,Cho,GPC,2018_su_241,6,PTSD,10.1016/j.jad.2018.08.018,,,,,2.98,0.43,
,Cho,GPC,2019_nery_21,1,At risk for bipolar disorder,10.1111/bdi.12770,,,,,1.65,0.31,
,Cho,GPC,2019_nery_21,2,At risk for bipolar disorder,10.1111/bdi.12770,,,,,1.88,0.29,
,Cho,GPC,2019_nery_21,3,At risk for bipolar disorder,10.1111/bdi.12770,,,,,1.86,0.35,
,Cho,GPC,2019_nery_21,4,Control,10.1111/bdi.12770,,,,,1.71,0.36,
,Cho,GPC,2019_nery_21,5,Control,10.1111/bdi.12770,,,,,1.94,0.32,
,Cho,GPC,2019_nery_21,6,Control,10.1111/bdi.12770,,,,,1.9,0.46,
,Cho,GPC,2019_nery_21,7,At risk for bipolar disorder - Before first mood episode,10.1111/bdi.12770,,,,,1.5,1.73,
,Cho,GPC,2019_nery_21,8,At risk for bipolar disorder - Before first mood episode,10.1111/bdi.12770,,,,,1.71,0.3,
,Cho,GPC,2019_nery_21,9,At risk for bipolar disorder - Before first mood episode,10.1111/bdi.12770,,,,,1.8,0.33,
,Cho,GPC,2019_nery_21,10,At risk for bipolar disorder - After first mood episode,10.1111/bdi.12770,,,,,1.61,0.25,
,Cho,GPC,2019_nery_21,11,At risk for bipolar disorder - After first mood episode,10.1111/bdi.12770,,,,,1.83,0.27,
,Cho,GPC,2019_nery_21,12,At risk for bipolar disorder - After first mood episode,10.1111/bdi.12770,,,,,1.96,0.33,
,Cho,GPC,2019_nery_21,13,Control,10.1111/bdi.12770,,,,,1.56,0.2,
,Cho,GPC,2019_nery_21,14,Control,10.1111/bdi.12770,,,,,1.83,0.22,
,Cho,GPC,2019_nery_21,15,Control,10.1111/bdi.12770,,,,,1.79,0.42,
,Cho,GPC,2019_nery_21,16,Control,10.1111/bdi.12770,,,,,1.59,0.33,
,Cho,GPC,2019_nery_21,17,Control,10.1111/bdi.12770,,,,,1.78,0.25,
,Cho,GPC,2019_nery_21,18,Control,10.1111/bdi.12770,,,,,1.72,0.33,
,Cho,GPC,2019_oneill_111,1,Control,10.1002/bdr2.1460,,,1.4,0.4,,,
,Cho,GPC,2019_oneill_111,2,ADHD,10.1002/bdr2.1460,,,1.1,0.2,,,
,Cho,GPC,2019_oneill_111,3,ADHD,10.1002/bdr2.1460,,,1.5,0.2,,,
,Cho,GPC,2019_oneill_111,4,ADHD,10.1002/bdr2.1460,,,1.3,0.1,,,
,Cho,GPC,2019_oneill_111,5,ADHD,10.1002/bdr2.1460,,,1.4,0.2,,,
,Cho,GPC,2019_oneill_111,6,ADHD,10.1002/bdr2.1460,,,1.4,0.3,,,
,Cho,GPC,2019_oneill_111,7,Control,10.1002/bdr2.1460,,,1.3,0.2,,,
,Cho,GPC,2019_oneill_111,8,ADHD,10.1002/bdr2.1460,,,1.3,0.2,,,
,Cho,GPC,2019_oneill_111,9,ADHD,10.1002/bdr2.1460,,,1.3,0.2,,,
,Cho,GPC,2019_oneill_111,10,ADHD,10.1002/bdr2.1460,,,1.2,0.2,,,
,Cho,GPC,2019_oneill_111,11,ADHD,10.1002/bdr2.1460,,,1.3,0.2,,,
,Cho,GPC,2019_oneill_111,12,ADHD,10.1002/bdr2.1460,,,1.3,0.2,,,
,Cho,GPC,2019_polacek_163,1,Control,10.5507/bp.2018.036,0.39,0.059,,,,,Assumed 15% StdDev
,Cho,GPC,2019_polacek_163,2,Multiple Sclerosis,10.5507/bp.2018.036,0.35,0.053,,,,,Assumed 15% StdDev
,tCho,tCho,2019_reid_45,1,Control,10.1093/schbul/sbx190,,,1.3,0.17,,,
,tCho,tCho,2019_reid_45,2,Schizophrenia,10.1093/schbul/sbx190,,,1.34,0.16,,,
,Cho,GPC,2019_tamrazi_40,1,Pediatric atypical teratoid/rhabdoid tumors - ASCL1 Pos.,10.3174/ajnr.A6024,,,3.2,0.8,,,
,Cho,GPC,2019_tamrazi_40,2,Pediatric atypical teratoid/rhabdoid tumors - ASCL1 Neg.,10.3174/ajnr.A6024,,,3.8,2.1,,,
,Cho,GPC,2020_demnitz_295,1,Addiction ,10.1016/j.pscychresns.2019.111019,,,,,2.43,0.46,
,Cho,tCho,2020_liu_99,1,Healthy Controls,10.1016/j.pnpbp.2019.109828,1.17,0.19,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2020_liu_99,2,Healthy Controls,10.1016/j.pnpbp.2019.109828,1.12,0.17,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2020_liu_99,3,Healthy Controls,10.1016/j.pnpbp.2019.109828,0.93,0.51,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2020_liu_99,4,Healthy Controls,10.1016/j.pnpbp.2019.109828,0.83,0.28,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2020_liu_99,5,MDD,10.1016/j.pnpbp.2019.109828,1.15,0.22,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2020_liu_99,6,MDD,10.1016/j.pnpbp.2019.109828,1.13,0.18,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2020_liu_99,7,MDD,10.1016/j.pnpbp.2019.109828,0.86,0.27,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2020_liu_99,8,MDD,10.1016/j.pnpbp.2019.109828,0.8,0.2,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2020_didehdar_189,1,Nonspecific low back pain - Lumbopelvic manipulation - Baseline,10.1007/s11845-019-02140-2,0.73,0.095,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2020_didehdar_189,2,Nonspecific low back pain - Lumbopelvic manipulation - Baseline,10.1007/s11845-019-02140-2,0.872,0.066,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2020_didehdar_189,3,Nonspecific low back pain - Lumbopelvic manipulation - Baseline,10.1007/s11845-019-02140-2,0.621,0.057,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2020_didehdar_189,4,Nonspecific low back pain - Lumbopelvic manipulation - Baseline,10.1007/s11845-019-02140-2,0.682,0.057,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2020_didehdar_189,5,Nonspecific low back pain - Lumbopelvic manipulation - Baseline,10.1007/s11845-019-02140-2,0.521,0.076,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2020_didehdar_189,6,Nonspecific low back pain - Lumbopelvic manipulation - 5 wks,10.1007/s11845-019-02140-2,0.858,0.105,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2020_didehdar_189,7,Nonspecific low back pain - Lumbopelvic manipulation - 5 wks,10.1007/s11845-019-02140-2,0.948,0.097,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2020_didehdar_189,8,Nonspecific low back pain - Lumbopelvic manipulation - 5 wks,10.1007/s11845-019-02140-2,0.642,0.067,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2020_didehdar_189,9,Nonspecific low back pain - Lumbopelvic manipulation - 5 wks,10.1007/s11845-019-02140-2,0.649,0.06,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2020_didehdar_189,10,Nonspecific low back pain - Lumbopelvic manipulation - 5 wks,10.1007/s11845-019-02140-2,0.627,0.067,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2020_didehdar_189,11,Nonspecific low back pain - Sham - Baseline,10.1007/s11845-019-02140-2,0.673,0.071,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2020_didehdar_189,12,Nonspecific low back pain - Sham - Baseline,10.1007/s11845-019-02140-2,0.858,0.085,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2020_didehdar_189,13,Nonspecific low back pain - Sham - Baseline,10.1007/s11845-019-02140-2,0.616,0.052,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2020_didehdar_189,14,Nonspecific low back pain - Sham - Baseline,10.1007/s11845-019-02140-2,0.607,0.075,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2020_didehdar_189,15,Nonspecific low back pain - Sham - Baseline,10.1007/s11845-019-02140-2,0.512,0.071,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2020_didehdar_189,16,Nonspecific low back pain - Sham - 5 wks,10.1007/s11845-019-02140-2,0.657,0.074,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2020_didehdar_189,17,Nonspecific low back pain - Sham - 5 wks,10.1007/s11845-019-02140-2,0.858,0.097,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2020_didehdar_189,18,Nonspecific low back pain - Sham - 5 wks,10.1007/s11845-019-02140-2,0.552,0.052,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2020_didehdar_189,19,Nonspecific low back pain - Sham - 5 wks,10.1007/s11845-019-02140-2,0.59,0.067,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2020_didehdar_189,20,Nonspecific low back pain - Sham - 5 wks,10.1007/s11845-019-02140-2,0.507,0.083,,,,,Assumed Total (tCho) based on Analysis
,tCho,tCho,2020_lind_40,1,Control,10.1523/JNEUROSCI.2883-19.2020,,,,,1.44,0.16,
,tCho,tCho,2020_lind_40,2,Aging,10.1523/JNEUROSCI.2883-19.2020,,,,,1.63,0.22,
,tCho,tCho,2020_lind_40,3,Aging,10.1523/JNEUROSCI.2883-19.2020,,,,,1.71,0.19,
,tCho,tCho,2020_lind_40,4,Control,10.1523/JNEUROSCI.2883-19.2020,,,,,1.36,0.2,
,tCho,tCho,2020_lind_40,5,Aging,10.1523/JNEUROSCI.2883-19.2020,,,,,1.51,0.23,
,tCho,tCho,2020_lind_40,6,Aging,10.1523/JNEUROSCI.2883-19.2020,,,,,1.49,0.17,
,tCho,tCho,2020_lind_40,7,Control,10.1523/JNEUROSCI.2883-19.2020,,,,,1.52,0.2,
,tCho,tCho,2020_lind_40,8,Aging,10.1523/JNEUROSCI.2883-19.2020,,,,,1.63,0.23,
,tCho,tCho,2020_lind_40,9,Aging,10.1523/JNEUROSCI.2883-19.2020,,,,,1.83,0.24,
,tCho,tCho,2020_lind_40,10,Control,10.1523/JNEUROSCI.2883-19.2020,,,,,1.54,0.23,
,tCho,tCho,2020_lind_40,11,Aging,10.1523/JNEUROSCI.2883-19.2020,,,,,1.54,0.24,
,tCho,tCho,2020_lind_40,12,Aging,10.1523/JNEUROSCI.2883-19.2020,,,,,1.6,0.27,
,Cho,GPC,2020_macmaster_35,1,Orthopedic Injury,10.1097/HTR.0000000000000535,,,,,1.67,0.17,
,Cho,GPC,2020_macmaster_35,2,Concussion,10.1097/HTR.0000000000000535,,,,,1.64,0.17,
,Cho,GPC,2020_macmaster_35,3,Single Concussion,10.1097/HTR.0000000000000535,,,,,1.64,0.15,
,Cho,GPC,2020_macmaster_35,4,Multiple Concussion,10.1097/HTR.0000000000000535,,,,,1.64,0.18,
,Cho,GPC,2020_macmaster_35,5,Orthopedic Injury,10.1097/HTR.0000000000000535,,,,,1.79,0.16,
,Cho,GPC,2020_macmaster_35,6,Concussion,10.1097/HTR.0000000000000535,,,,,1.78,0.17,
,Cho,GPC,2020_macmaster_35,7,Single Concussion,10.1097/HTR.0000000000000535,,,,,1.83,0.15,
,Cho,GPC,2020_macmaster_35,8,Multiple Concussion,10.1097/HTR.0000000000000535,,,,,1.74,0.18,
,Cho,tCho,2020_simani_112,1,Healthy Controls,10.1016/j.yebeh.2020.107480,0.69,0.01,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2020_simani_112,2,Idiopathic Generalized Epilepsy,10.1016/j.yebeh.2020.107480,0.65,0.02,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2020_simani_112,3,Psychogenic Nonepileptic Seizure,10.1016/j.yebeh.2020.107480,0.7,0.01,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2020_simani_112,4,Healthy Controls,10.1016/j.yebeh.2020.107480,0.71,0.12,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2020_simani_112,5,Idiopathic Generalized Epilepsy,10.1016/j.yebeh.2020.107480,0.68,0.15,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2020_simani_112,6,Psychogenic Nonepileptic Seizure,10.1016/j.yebeh.2020.107480,0.69,0.08,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2020_simani_112,7,Healthy Controls,10.1016/j.yebeh.2020.107480,0.8,0.07,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2020_simani_112,8,Idiopathic Generalized Epilepsy,10.1016/j.yebeh.2020.107480,0.77,0.08,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2020_simani_112,9,Psychogenic Nonepileptic Seizure,10.1016/j.yebeh.2020.107480,0.81,0.07,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2020_simani_112,10,Healthy Controls,10.1016/j.yebeh.2020.107480,0.79,0.1,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2020_simani_112,11,Idiopathic Generalized Epilepsy,10.1016/j.yebeh.2020.107480,0.74,0.13,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2020_simani_112,12,Psychogenic Nonepileptic Seizure,10.1016/j.yebeh.2020.107480,0.76,0.13,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2020_simani_112,13,Healthy Controls,10.1016/j.yebeh.2020.107480,1.33,0.09,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2020_simani_112,14,Idiopathic Generalized Epilepsy,10.1016/j.yebeh.2020.107480,0.93,0.07,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2020_simani_112,15,Psychogenic Nonepileptic Seizure,10.1016/j.yebeh.2020.107480,0.99,0.07,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2020_simani_112,16,Healthy Controls,10.1016/j.yebeh.2020.107480,0.91,0.19,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2020_simani_112,17,Idiopathic Generalized Epilepsy,10.1016/j.yebeh.2020.107480,0.95,0.31,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2020_simani_112,18,Psychogenic Nonepileptic Seizure,10.1016/j.yebeh.2020.107480,0.89,0.51,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2020_simani_112,19,Healthy Controls,10.1016/j.yebeh.2020.107480,0.82,0.19,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2020_simani_112,20,Idiopathic Generalized Epilepsy,10.1016/j.yebeh.2020.107480,0.76,0.09,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2020_simani_112,21,Psychogenic Nonepileptic Seizure,10.1016/j.yebeh.2020.107480,0.77,0.13,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2020_simani_112,22,Healthy Controls,10.1016/j.yebeh.2020.107480,0.59,0.23,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2020_simani_112,23,Idiopathic Generalized Epilepsy,10.1016/j.yebeh.2020.107480,0.62,0.14,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2020_simani_112,24,Psychogenic Nonepileptic Seizure,10.1016/j.yebeh.2020.107480,0.59,0.15,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2020_ozcelik_31,1,Healthy Controls,10.5080/u25195,0.79,0.15,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2020_ozcelik_31,2,Schizophrenia,10.5080/u25195,0.77,0.22,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2020_ozcelik_31,3,Schizophrenia,10.5080/u25195,0.77,0.27,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2020_ozcelik_31,4,Healthy Controls,10.5080/u25195,0.75,0.15,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2020_ozcelik_31,5,Schizophrenia,10.5080/u25195,0.82,0.19,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2020_ozcelik_31,6,Schizophrenia,10.5080/u25195,0.84,0.2,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2020_ozcelik_31,7,Healthy Controls,10.5080/u25195,0.88,0.22,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2020_ozcelik_31,8,Schizophrenia,10.5080/u25195,0.88,0.26,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2020_ozcelik_31,9,Schizophrenia,10.5080/u25195,1.01,0.25,,,,,Assumed Total (tCho) based on Analysis
,tCho,tCho,2020_jasek_54,1,Multiple scclerosis - Late onset,10.5603/PJNNS.a2020.0036,,,1.59,0.41,,,
,tCho,tCho,2020_jasek_54,2,Multiple scclerosis - Typical onset,10.5603/PJNNS.a2020.0036,,,1.65,0.31,,,
,tCho,tCho,2021_imrich_31,1,MS,10.1007/s10286-021-00790-w,0.43,0.02,,,,,
,tCho,tCho,2021_imrich_32,2,MS,10.1007/s10286-021-00790-w,0.43,0.01,,,,,
,tCho,tCho,2021_imrich_33,3,Control,10.1007/s10286-021-00790-w,0.43,0.02,,,,,
,GPC,GPC,2018_giapitzakis_79,1,Healthy,10.1002/mrm.26873,,,,,0.58,0.534,Med/Quartile --> Mean/Std Greco 2015
,GPC,GPC,2018_giapitzakis_79,2,Healthy,10.1002/mrm.26873,,,,,1.01,0.303,Med/Quartile --> Mean/Std Wan 2014
,tCh,tCho,2018_giapitzakis_79,1,Healthy,10.1002/mrm.26873,,,,,1.26,0.147,Med/Quartile --> Mean/Std Wan 2014
,tCh,tCho,2018_giapitzakis_79,2,Healthy,10.1002/mrm.26873,,,,,1.24,0.282,Med/Quartile --> Mean/Std Greco 2015
,Cho,tCho,2020_mohamadi_101,1,Tension-type headache - Positional release technique - Baseline,10.1016/j.apmr.2020.05.028,0.89,0.26,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2020_mohamadi_101,2,Tension-type headache - Positional release technique - 5wks,10.1016/j.apmr.2020.05.028,0.86,0.28,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2020_mohamadi_101,3,Tension-type headache - Positional release technique - Baseline,10.1016/j.apmr.2020.05.028,0.76,0.06,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2020_mohamadi_101,4,Tension-type headache - Positional release technique - 5wks,10.1016/j.apmr.2020.05.028,0.78,0.06,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2020_mohamadi_101,5,Tension-type headache - Positional release technique - Baseline,10.1016/j.apmr.2020.05.028,0.51,0.09,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2020_mohamadi_101,6,Tension-type headache - Positional release technique - 5wks,10.1016/j.apmr.2020.05.028,0.54,0.06,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2020_mohamadi_101,7,Tension-type headache - Control - Baseline,10.1016/j.apmr.2020.05.028,0.73,0.19,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2020_mohamadi_101,8,Tension-type headache - Control - 5wks,10.1016/j.apmr.2020.05.028,0.78,0.14,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2020_mohamadi_101,9,Tension-type headache - Control - Baseline,10.1016/j.apmr.2020.05.028,0.78,0.11,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2020_mohamadi_101,10,Tension-type headache - Control - 5wks,10.1016/j.apmr.2020.05.028,0.8,0.11,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2020_mohamadi_101,11,Tension-type headache - Control - Baseline,10.1016/j.apmr.2020.05.028,0.48,0.11,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2020_mohamadi_101,12,Tension-type headache - Control - 5wks,10.1016/j.apmr.2020.05.028,0.52,0.12,,,,,Assumed Total (tCho) based on Analysis
,Cho,GPC,2021_egerton_47,1,Psychosis - Antipsychotic responder,10.1093/schbul/sbaa128,,,3.36,0.75,,,
,Cho,GPC,2021_egerton_47,2,Psychosis - Antipsychotic responder,10.1093/schbul/sbaa128,,,2.35,0.32,,,
,Cho,GPC,2021_egerton_47,3,Psychosis - Antipsychotic responder,10.1093/schbul/sbaa128,,,2.26,0.47,,,
,Cho,GPC,2021_egerton_47,4,Psychosis - Antipsychotic responder,10.1093/schbul/sbaa128,,,2.27,0.5,,,
,Cho,GPC,2021_egerton_47,5,Psychosis - Antipsychotic responder,10.1093/schbul/sbaa128,,,3,0,,,
,Cho,GPC,2021_egerton_47,6,Psychosis - Antipsychotic responder,10.1093/schbul/sbaa128,,,3.07,0.26,,,
,Cho,GPC,2021_egerton_47,7,Psychosis - Antipsychotic responder,10.1093/schbul/sbaa128,,,2.8,0.45,,,
,Cho,GPC,2021_egerton_47,8,Psychosis - Antipsychotic responder,10.1093/schbul/sbaa128,,,2.11,0.31,,,
,Cho,GPC,2021_egerton_47,9,Psychosis - Antipsychotic non-responder,10.1093/schbul/sbaa128,,,2.28,0.28,,,
,Cho,GPC,2021_egerton_47,10,Psychosis - Antipsychotic non-responder,10.1093/schbul/sbaa128,,,1.92,0.26,,,
,Cho,GPC,2021_egerton_47,11,Psychosis - Antipsychotic non-responder,10.1093/schbul/sbaa128,,,2.24,0.43,,,n=6
,Cho,GPC,2021_egerton_47,12,Psychosis - Antipsychotic non-responder,10.1093/schbul/sbaa128,,,1.37,0.59,,,
,Cho,GPC,2021_egerton_47,13,Psychosis - Antipsychotic non-responder,10.1093/schbul/sbaa128,,,2.15,0.26,,,
,Cho,GPC,2021_egerton_47,14,Psychosis - Antipsychotic non-responder,10.1093/schbul/sbaa128,,,1.87,0.17,,,
,Cho,GPC,2021_egerton_47,15,Psychosis - Antipsychotic non-responder,10.1093/schbul/sbaa128,,,1.82,0.29,,,n=4
,Cho,GPC,2021_egerton_47,16,Psychosis - Antipsychotic non-responder,10.1093/schbul/sbaa128,,,2,0.11,,,n=4
,Cho,tCho,2015_guo_15,1,Alzheimer's disease - Depressed,10.1186/s12888-015-0691-7,0.94,0.25,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2015_guo_15,2,Alzheimer's disease - Depressed,10.1186/s12888-015-0691-7,0.89,0.18,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2015_guo_15,3,Alzheimer's disease - Non-depressed,10.1186/s12888-015-0691-7,0.89,0.14,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2015_guo_15,4,Alzheimer's disease - Non-depressed,10.1186/s12888-015-0691-7,0.87,0.12,,,,,Assumed Total (tCho) based on Analysis
,tCho,tCho,2018_raschke_39,1,Healthy,10.3174/ajnr.A5457,0.194,0.015,3.374,0.32,,,Med/Quartile --> Mean/Std Greco 2015; Greco 2015
,tCho,tCho,2018_raschke_39,2,Healthy,10.3174/ajnr.A5457,0.265,0.016,6.122,1.045,,,Med/Quartile --> Mean/Std Greco 2015; Greco 2015
,GPC,GPC,2016_lopezkolkovsky_75,1,Healthy_Rodent,10.1002/mrm.25602,,,,,0.6,0.1,
,PCh,PCh,2016_lopezkolkovsky_75,1,Healthy_Rodent,10.1002/mrm.25602,,,,,0.3,0.1,
,tCho,tCho,2016_lopezkolkovsky_75,1,Healthy_Rodent,10.1002/mrm.25602,,,,,0.9,0.2,
,tCho,tCho,2018_an_79,1,Glioma - IDH1-mutated grade-II oligodendroglioma,10.1002/mrm.26884,,,1.53,0.331,,,
,tCho,tCho,2018_an_79,2,Glioma - IDH1-mutated grade-II oligodendroglioma,10.1002/mrm.26884,,,1.966,0.923,,,
,tCho,tCho,2018_an_79,3,Glioma - Radiographically suggested glioma,10.1002/mrm.26884,,,1.31,0.367,,,
,tCho,tCho,2018_an_79,4,Glioma - Radiographically suggested glioma,10.1002/mrm.26884,,,1.834,0.472,,,
,tCho,tCho,2018_an_79,5,Glioma - IDH wild-type glioblastoma,10.1002/mrm.26884,,,2.014,0.371,,,
,tCho,tCho,2018_an_79,6,Glioma - IDH wild-type glioblastoma,10.1002/mrm.26884,,,3.869,0.477,,,
,Cho,GPC,2021_mitolo_82,1,PPA,10.3233/JAD-210211,0.2,0.02,,,,,
,Cho,GPC,2021_mitolo_82,2,AD,10.3233/JAD-210211,0.21,0.03,,,,,
,Cho,GPC,2021_mitolo_82,3,Healthy controls,10.3233/JAD-210211,0.19,0.02,,,,,
,GPC,GPC,2021_oneill_35,1,PSY-PLB (placebo),10.1177/02698811211001107,,,,,2.41,0.28,
,GPC,GPC,2021_oneill_35,2,PSY-CBD,10.1177/02698811211001107,,,,,2.37,0.29,
,Cho,GPC,2020_tarumi_45,1,Healthy Control,10.1038/s41386-019-0589-z,,,2.19,0.28,,,
,Cho,GPC,2020_tarumi_45,2,Treatment Resistant Schizophrenia ,10.1038/s41386-019-0589-z,,,2.28,0.27,,,
,Cho,GPC,2020_tarumi_45,3,Non-treatment Resistant Schizophrenia ,10.1038/s41386-019-0589-z,,,2.34,0.22,,,
,Cho,GPC,2020_tarumi_45,4,Healthy Control,10.1038/s41386-019-0589-z,,,3.15,0.42,,,
,Cho,GPC,2020_tarumi_45,5,Treatment Resistant Schizophrenia ,10.1038/s41386-019-0589-z,,,3.41,0.47,,,
,Cho,GPC,2020_tarumi_45,6,Non-treatment Resistant Schizophrenia ,10.1038/s41386-019-0589-z,,,3.45,0.41,,,
,tCho,tCho,2018_burger_185,1,Addiction - Methamphetamine Acute Abstinence,10.1016/j.drugalcdep.2017.11.029,0.285,0.032,,,,,
,tCho,tCho,2018_burger_185,2,Addiction - Methamphetamine Acute Abstinence,10.1016/j.drugalcdep.2017.11.029,0.281,0.004,,,,,
,tCho,tCho,2018_burger_185,3,Addiction - Methamphetamine Acute Abstinence,10.1016/j.drugalcdep.2017.11.029,0.285,0.049,,,,,
,tCho,tCho,2018_burger_185,4,Addiction - Methamphetamine Acute Abstinence,10.1016/j.drugalcdep.2017.11.029,0.308,0.032,,,,,
,tCho,tCho,2018_burger_185,5,Addiction - Methamphetamine Acute Abstinence,10.1016/j.drugalcdep.2017.11.029,0.236,0.023,,,,,
,tCho,tCho,2018_burger_185,6,Addiction - Methamphetamine Acute Abstinence,10.1016/j.drugalcdep.2017.11.029,0.262,0.029,,,,,
,tCho,tCho,2018_burger_185,7,Addiction - Methamphetamine Short-term Abstinence,10.1016/j.drugalcdep.2017.11.029,0.292,0.039,,,,,
,tCho,tCho,2018_burger_185,8,Addiction - Methamphetamine Short-term Abstinence,10.1016/j.drugalcdep.2017.11.029,0.292,0.032,,,,,
,tCho,tCho,2018_burger_185,9,Addiction - Methamphetamine Short-term Abstinence,10.1016/j.drugalcdep.2017.11.029,0.253,0.039,,,,,
,tCho,tCho,2018_burger_185,10,Addiction - Methamphetamine Short-term Abstinence,10.1016/j.drugalcdep.2017.11.029,0.26,0.032,,,,,
,tCho,tCho,2018_burger_185,11,Addiction - Methamphetamine Short-term Abstinence,10.1016/j.drugalcdep.2017.11.029,0.31,0.028,,,,,
,tCho,tCho,2018_burger_185,12,Addiction - Methamphetamine Short-term Abstinence,10.1016/j.drugalcdep.2017.11.029,0.278,0.021,,,,,
,tCho,tCho,2018_burger_185,13,Control,10.1016/j.drugalcdep.2017.11.029,0.239,0.036,,,,,
,tCho,tCho,2018_burger_185,14,Control,10.1016/j.drugalcdep.2017.11.029,0.268,0.033,,,,,
,tCho,tCho,2018_burger_185,15,Control,10.1016/j.drugalcdep.2017.11.029,0.281,0.043,,,,,
,tCho,tCho,2018_burger_185,16,Control,10.1016/j.drugalcdep.2017.11.029,0.304,0.036,,,,,
,tCho,tCho,2018_burger_185,17,Control,10.1016/j.drugalcdep.2017.11.029,0.291,0.043,,,,,
,tCho,tCho,2018_burger_185,18,Control,10.1016/j.drugalcdep.2017.11.029,0.308,0.032,,,,,
,tCho,tCho,2018_deelchand_79,1,Healthy,10.1002/mrm.26788,,,,,1.633,0.346,
,tCho,tCho,2018_deelchand_79,2,Healthy,10.1002/mrm.26788,,,,,1.731,0.297,
,Cho,tCho,2018_guo_27,1,Open-angle glaucoma - Early,10.1097/IJG.0000000000001098,0.982,0.342,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2018_guo_27,2,Control,10.1097/IJG.0000000000001098,1.131,0.241,,,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2018_karczewska-kupczewska_103,1,Drug - Intralipid/Heparin Baseline,10.1210/jc.2018-00107,0.887,0.194,0.226,0.063,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2018_karczewska-kupczewska_103,2,Drug - Intralipid/Heparin Baseline,10.1210/jc.2018-00107,0.911,0.182,0.181,0.069,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2018_karczewska-kupczewska_103,3,Drug - Intralipid/Heparin Baseline,10.1210/jc.2018-00107,1.008,0.389,0.192,0.086,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2018_karczewska-kupczewska_103,4,Drug - Intralipid/Heparin 4 hour infusion,10.1210/jc.2018-00107,0.984,0.273,0.277,0.136,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2018_karczewska-kupczewska_103,5,Drug - Intralipid/Heparin 4 hour infusion,10.1210/jc.2018-00107,1.026,0.261,0.206,0.117,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2018_karczewska-kupczewska_103,6,Drug - Intralipid/Heparin 4 hour infusion,10.1210/jc.2018-00107,0.887,0.139,0.186,0.053,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2018_karczewska-kupczewska_103,7,Control - Saline Baseline,10.1210/jc.2018-00107,0.826,0.182,0.204,0.067,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2018_karczewska-kupczewska_103,8,Control - Saline Baseline,10.1210/jc.2018-00107,0.868,0.152,0.186,0.064,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2018_karczewska-kupczewska_103,9,Control - Saline Baseline,10.1210/jc.2018-00107,1.081,0.194,0.229,0.055,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2018_karczewska-kupczewska_103,10,Control - Saline 4 hour infusion,10.1210/jc.2018-00107,0.966,0.212,0.227,0.062,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2018_karczewska-kupczewska_103,11,Control - Saline 4 hour infusion,10.1210/jc.2018-00107,0.899,0.486,0.226,0.055,,,Assumed Total (tCho) based on Analysis
,Cho,tCho,2018_karczewska-kupczewska_103,12,Control - Saline 4 hour infusion,10.1210/jc.2018-00107,1.026,0.207,0.178,0.031,,,Assumed Total (tCho) based on Analysis
,PC,PC,2018_bednarik_38,1,Healthy,10.1177/0271678X17695291,,,,,0.33,0.03,
,PC,PC,2020_dehghani_83,1,Control ,10.1002/mrm.28066,,,0.27,0.23,,,
,PC,PC,2020_dehghani_83,2,Control ,10.1002/mrm.28066,,,0.3,0.12,,,
,Gpc+PC,tCho,2020_sheth_123,1,Traumatic Brain Injury,10.1152/jn.00765.2019,,,0.61,0.02,,,
,Gpc+PC,tCho,2020_sheth_123,2,Non Traumatic Brain Injury,10.1152/jn.00765.2019,,,0.57,0.03,,,
,Cr,Cre,2017_sijens_42,2,control (normal development),10.1016/j.mri.2017.06.001,0.26,0.03,,,,,
,Cr,Cre,2017_sijens_42,6,mild disability,10.1016/j.mri.2017.06.001,0.24,0.05,,,,,
,Cr,Cre,2017_sijens_42,10,deceased,10.1016/j.mri.2017.06.001,0.27,0.04,,,,,
,Cr,Cre,2017_sijens_42,14,control (normal development),10.1016/j.mri.2017.06.001,0.25,0.03,,,,,
,Cr,Cre,2017_sijens_42,18,mild disability,10.1016/j.mri.2017.06.001,0.25,0.01,,,,,
,Cr,Cre,2017_sijens_42,22,deceased,10.1016/j.mri.2017.06.001,0.26,0.04,,,,,
,Cre,Cre,2019_barbagallo_62,1,Control,10.1016/j.parkreldis.2018.12.008,,,5,0.4,,,
,Cre,Cre,2019_barbagallo_62,2,Progressive Supranuclear Palsy,10.1016/j.parkreldis.2018.12.008,,,4.05,0.05,,,
,Cre,Cre,2020_benson_274,10,Control,10.1016/j.jad.2020.05.026,,,,,,,
,Cre,Cre,2020_benson_274,3,Control,10.1016/j.jad.2020.05.026,,,,,,,
,Cre,Cre,2020_benson_274,5,Insomnia,10.1016/j.jad.2020.05.026,,,,,,,
,Cre,Cre,2020_benson_274,6,Insomnia,10.1016/j.jad.2020.05.026,,,,,,,
,Cre,Cre,2020_benson_274,12,Depression,10.1016/j.jad.2020.05.026,,,,,,,
,Cre,Cre,2020_benson_274,9,Depression,10.1016/j.jad.2020.05.026,,,,,,,
,tCr,tCr,2019_bell_39,1,Behavior,10.1523/JNEUROSCI.2110-18.2019,,,,,11.58,1.74,
,tCr,tCr,2019_bell_39,2,Behavior,10.1523/JNEUROSCI.2110-18.2019,,,,,12.02,2.26,
,tCr,tCr,2019_bell_39,3,Behavior,10.1523/JNEUROSCI.2110-18.2019,,,,,,,
,tCr,tCr,2019_bell_39,4,No-Behavior,10.1523/JNEUROSCI.2110-18.2019,,,,,11.8,2.31,
,tCr,tCr,2019_bell_39,5,No-Behavior,10.1523/JNEUROSCI.2110-18.2019,,,,,11.13,3.95,
,tCr,tCr,2019_bell_39,6,No-Behavior,10.1523/JNEUROSCI.2110-18.2019,,,,,,,
,Cre,Cre,2019_borgelt_21,1,Bipolar - First,10.1111/bdi.12782,,,,,7.17,1.62,
,Cre,Cre,2019_borgelt_21,2,Bipolar - First,10.1111/bdi.12782,,,,,7.9,1.04,
,Cre,Cre,2019_borgelt_21,3,Bipolar - First,10.1111/bdi.12782,,,,,6.92,1.24,
,Cre,Cre,2019_borgelt_21,4,Bipolar - Multiple,10.1111/bdi.12782,,,,,6.68,1.36,
,Cre,Cre,2019_borgelt_21,5,Bipolar - Multiple,10.1111/bdi.12782,,,,,8.18,1.12,
,Cre,Cre,2019_borgelt_21,6,Bipolar - Multiple,10.1111/bdi.12782,,,,,6.83,0.96,
,Cre,Cre,2019_bossong_76,1,Control,10.1001/jamapsychiatry.2018.3252,,,,,7.42,1.1,
,Cre,Cre,2019_bossong_76,2,Psychosis - HighRisk,10.1001/jamapsychiatry.2018.3252,,,,,7.32,1.09,
,Cre,Cre,2019_bossong_76,3,Psychosis,10.1001/jamapsychiatry.2018.3252,,,,,8.18,0.74,
,tCr,tCr,2019_bustillo_246,1,Control <40 GM,10.1016/j.jad.2018.12.064,,,,,15.7,1.5,
,tCr,tCr,2019_bustillo_246,2,Control <40 WM,10.1016/j.jad.2018.12.064,,,,,10.8,1,
,tCr,tCr,2019_bustillo_246,3,Control >40 GM,10.1016/j.jad.2018.12.064,,,,,16.8,1.8,
,tCr,tCr,2019_bustillo_246,4,Control >40 WM,10.1016/j.jad.2018.12.064,,,,,11.7,1.5,
,tCr,tCr,2019_bustillo_246,5,Bipolar <40 GM,10.1016/j.jad.2018.12.064,,,,,15.5,1.6,
,tCr,tCr,2019_bustillo_246,6,Bipolar <40 WM,10.1016/j.jad.2018.12.064,,,,,10.7,1.1,
,tCr,tCr,2019_bustillo_246,7,Bipolar >40 GM,10.1016/j.jad.2018.12.064,,,,,16.7,1.9,
,tCr,tCr,2019_bustillo_246,8,Bipolar >40 WM,10.1016/j.jad.2018.12.064,,,,,11.3,1.2,
,tCr,tCr,2019_bustillo_246,9,Schizophrenia <40 GM,10.1016/j.jad.2018.12.064,,,,,15.6,1.5,
,tCr,tCr,2019_bustillo_246,10,Schizophrenia <40 WM,10.1016/j.jad.2018.12.064,,,,,10.6,1.3,
,tCr,tCr,2019_bustillo_246,11,Schizophrenia >40 GM,10.1016/j.jad.2018.12.064,,,,,16.4,1.9,
,tCr,tCr,2019_bustillo_246,12,Schizophrenia >40 WM,10.1016/j.jad.2018.12.064,,,,,11.1,1.5,
,Cre+PCr,tCr,2019_basu_9,1,Premature Infant,10.1038/s41598-018-37203-4,,,5.171,2.377,,,
,Cre+PCr,tCr,2019_basu_9,5,Premature Infant,10.1038/s41598-018-37203-4,,,2.936,0.899,,,
,tCr,tCr,2019_cheong_90,1,Control - Visit 1,10.1136/jnnp-2018-318795,,,,,5.875,0.557,
,tCr,tCr,2019_cheong_90,2,Control - Visit 2,10.1136/jnnp-2018-318795,,,,,6.237,0.473,
,tCr,tCr,2019_cheong_90,3,Control - Visit 3,10.1136/jnnp-2018-318795,,,,,6.042,0.417,
,tCr,tCr,2019_cheong_90,4,Control - Visit 1,10.1136/jnnp-2018-318795,,,,,6.194,0.516,
,tCr,tCr,2019_cheong_90,5,Control - Visit 2,10.1136/jnnp-2018-318795,,,,,6.226,0.58,
,tCr,tCr,2019_cheong_90,6,Control - Visit 3,10.1136/jnnp-2018-318795,,,,,6.516,0.452,
,tCr,tCr,2019_cheong_90,7,ALS - Visit 1,10.1136/jnnp-2018-318795,,,,,5.712,0.494,
,tCr,tCr,2019_cheong_90,8,ALS - Visit 2,10.1136/jnnp-2018-318795,,,,,5.794,0.632,
,tCr,tCr,2019_cheong_90,9,ALS - Visit 3,10.1136/jnnp-2018-318795,,,,,5.959,0.329,
,tCr,tCr,2019_cheong_90,10,ALS - Visit 1,10.1136/jnnp-2018-318795,,,,,5.769,0.648,
,tCr,tCr,2019_cheong_90,11,ALS - Visit 2,10.1136/jnnp-2018-318795,,,,,5.931,0.875,
,tCr,tCr,2019_cheong_90,12,ALS - Visit 3,10.1136/jnnp-2018-318795,,,,,6.222,0.778,
,Cre,Cre,2019_davies_29,1,High-Risk Psychosis,10.1016/j.euroneuro.2019.03.008,,,7.25,1.13,,,
,Cre,Cre,2019_davies_29,2,High-Risk Psychosis,10.1016/j.euroneuro.2019.03.008,,,11.42,0.96,,,
,Cre,Cre,2019_davies_29,3,High-Risk Psychosis,10.1016/j.euroneuro.2019.03.008,,,7.44,0.72,,,
,Cre,Cre,2019_davies_29,4,High-Risk Psychosis,10.1016/j.euroneuro.2019.03.008,,,7.42,0.86,,,
,Cre,Cre,2019_davies_29,5,High-Risk Psychosis,10.1016/j.euroneuro.2019.03.008,,,11.6,1.05,,,
,Cre,Cre,2019_davies_29,6,High-Risk Psychosis,10.1016/j.euroneuro.2019.03.008,,,7.44,0.44,,,
,tCr,tCr,2018_adanyeguh_31,2,Healthy,10.1002/nbm.3880,,,,,6.6,0.4,Estimated Bar Graph
,tCr,tCr,2018_adanyeguh_31,4,HD,10.1002/nbm.3880,,,,,7,0.5,Estimated Bar Graph
,tCr,tCr,2018_adanyeguh_31,1,Healthy,10.1002/nbm.3880,,,,,7,0.4,Estimated Bar Graph
,tCr,tCr,2018_adanyeguh_31,3,HD,10.1002/nbm.3880,,,,,6.5,0.5,Estimated Bar Graph
,Cre,Cre,2018_al-iedani_108,1,Healthy,10.1016/j.ejrad.2018.09.020,0.43,0.02,,,,,
,Cre,Cre,2018_al-iedani_108,2,Healthy,10.1016/j.ejrad.2018.09.020,0.44,0.01,,,,,
,tCr,tCr,2018_atagun_235,1,BD-I,10.1016/j.jad.2018.04.010,,,1.12,0.14,,,
,tCr,tCr,2018_atagun_235,2,BD-I,10.1016/j.jad.2018.04.010,,,0.71,0.11,,,
,tCr,tCr,2018_atagun_235,3,BD-II,10.1016/j.jad.2018.04.010,,,1.27,0.19,,,
,tCr,tCr,2018_atagun_235,4,BD-II,10.1016/j.jad.2018.04.010,,,0.9,0.19,,,
,tCr,tCr,2018_atagun_235,5,Control,10.1016/j.jad.2018.04.010,,,1.18,0.18,,,
,tCr,tCr,2018_atagun_235,6,Control,10.1016/j.jad.2018.04.010,,,0.81,0.1,,,
,tCr,tCr,2018_barbagallo_47,4,Control,10.1016/j.parkreldis.2017.11.345,,,7.15,0.78,,,
,tCr,tCr,2018_barbagallo_47,5,Control,10.1016/j.parkreldis.2017.11.345,,,7.05,0.95,,,
,tCr,tCr,2018_barbagallo_47,6,Control,10.1016/j.parkreldis.2017.11.345,,,7.24,1.21,,,
,tCr,tCr,2018_barbagallo_47,1,Essential Tremor,10.1016/j.parkreldis.2017.11.345,,,7.06,0.74,,,
,tCr,tCr,2018_barbagallo_47,2,Essential Tremor,10.1016/j.parkreldis.2017.11.345,,,6.97,1.05,,,
,tCr,tCr,2018_barbagallo_47,3,Essential Tremor,10.1016/j.parkreldis.2017.11.345,,,7.15,0.9,,,
,tCr,tCr,2018_bauer_19,1,Healthy,10.1080/15622975.2016.1262060,,,8.2,0.95,,,
,tCr,tCr,2018_bauer_19,2,Healthy,10.1080/15622975.2016.1262060,,,6.29,0.82,,,
,tCr,tCr,2018_bauer_19,3,ADHD,10.1080/15622975.2016.1262060,,,8.3,1.14,,,
,tCr,tCr,2018_bauer_19,4,ADHD,10.1080/15622975.2016.1262060,,,6.85,1.06,,,
,Cre,Cre,2018_bednarik_38,1,Healthy,10.1177/0271678X17695291,,,,,4.18,0.21,
,Cre,Cre,2021_akiyama_61,1,Control,10.2176/nmc.oa.2020-0274,,,6.55,0.69,,,
,Cre,Cre,2021_akiyama_61,2,NPH,10.2176/nmc.oa.2020-0274,,,5.94,1.78,,,
,Cre,Cre,2018_caravaggio_28,1,Healthy,10.1016/j.euroneuro.2017.12.002,,,7.04,1.07,,,
,Cre,Cre,2018_caravaggio_28,2,Healthy,10.1016/j.euroneuro.2017.12.002,,,6.56,1.35,,,
,Cre,Cre,2018_caravaggio_28,3,Healthy,10.1016/j.euroneuro.2017.12.002,,,7.56,0.86,,,
,Cre,Cre,2018_caravaggio_28,4,Healthy,10.1016/j.euroneuro.2017.12.002,,,7.28,0.6,,,
,Cre,Cre,2018_chiu_193,3,First-episode Schizophrenia,10.1016/j.schres.2017.07.021,,,,,14.74,1.88,
,Cre,Cre,2018_chiu_193,4,Healthy,10.1016/j.schres.2017.07.021,,,,,14.71,1.75,
,tCr,tCr,2018_ding_38,1,Healthy - Pre-fasting,10.1177/0271678X17697721,,,8.68,0.42,,,
,tCr,tCr,2018_ding_38,2,Healthy - Pre-fasting,10.1177/0271678X17697721,,,9,0.57,,,
,tCr,tCr,2018_ding_38,3,Healthy - Pre-fasting,10.1177/0271678X17697721,,,7.81,0.48,,,
,tCr,tCr,2018_ding_38,4,Healthy - Pre-fasting,10.1177/0271678X17697721,,,7.99,0.47,,,
,tCr,tCr,2018_ding_38,5,Healthy - Pre-fasting,10.1177/0271678X17697721,,,8.67,0.42,,,
,tCr,tCr,2018_ding_38,6,Healthy - Pre-fasting,10.1177/0271678X17697721,,,8.68,0.37,,,
,tCr,tCr,2018_ding_38,7,Healthy - Pre-fasting,10.1177/0271678X17697721,,,8.58,0.54,,,
,tCr,tCr,2018_ding_38,8,Healthy - Pre-fasting,10.1177/0271678X17697721,,,8.8,0.52,,,
,tCr,tCr,2018_ding_38,9,Healthy - Pre-fasting,10.1177/0271678X17697721,,,10.74,0.69,,,
,tCr,tCr,2018_ding_38,10,Healthy - Post-fasting,10.1177/0271678X17697721,,,8.36,0.53,,,
,tCr,tCr,2018_ding_38,11,Healthy - Post-fasting,10.1177/0271678X17697721,,,8.56,0.52,,,
,tCr,tCr,2018_ding_38,12,Healthy - Post-fasting,10.1177/0271678X17697721,,,7.49,0.32,,,
,tCr,tCr,2018_ding_38,13,Healthy - Post-fasting,10.1177/0271678X17697721,,,7.78,0.44,,,
,tCr,tCr,2018_ding_38,14,Healthy - Post-fasting,10.1177/0271678X17697721,,,8.41,0.47,,,
,tCr,tCr,2018_ding_38,15,Healthy - Post-fasting,10.1177/0271678X17697721,,,8.45,0.51,,,
,tCr,tCr,2018_ding_38,16,Healthy - Post-fasting,10.1177/0271678X17697721,,,8.42,0.56,,,
,tCr,tCr,2018_ding_38,17,Healthy - Post-fasting,10.1177/0271678X17697721,,,8.52,0.49,,,
,tCr,tCr,2018_ding_38,18,Healthy - Post-fasting,10.1177/0271678X17697721,,,10.23,0.64,,,
,tCr,tCr,2018_ding_38,19,Healthy - Non-fasting,10.1177/0271678X17697721,,,8.78,0.55,,,
,tCr,tCr,2018_ding_38,20,Healthy - Non-fasting,10.1177/0271678X17697721,,,8.91,0.8,,,
,tCr,tCr,2018_ding_38,21,Healthy - Non-fasting,10.1177/0271678X17697721,,,7.62,0.49,,,
,tCr,tCr,2018_ding_38,22,Healthy - Non-fasting,10.1177/0271678X17697721,,,8.12,0.5,,,
,tCr,tCr,2018_ding_38,23,Healthy - Non-fasting,10.1177/0271678X17697721,,,8.39,0.62,,,
,tCr,tCr,2018_ding_38,24,Healthy - Non-fasting,10.1177/0271678X17697721,,,8.57,0.63,,,
,tCr,tCr,2018_ding_38,25,Healthy - Non-fasting,10.1177/0271678X17697721,,,8.34,0.48,,,
,tCr,tCr,2018_ding_38,26,Healthy - Non-fasting,10.1177/0271678X17697721,,,8.82,0.66,,,
,tCr,tCr,2018_ding_38,27,Healthy - Non-fasting,10.1177/0271678X17697721,,,10.37,0.82,,,
,Cre,Cre,2018_egerton_23,1,Healthy - Baseline,10.1038/s41380-018-0082-9,,,,,6.48,0.45,
,Cre,Cre,2018_egerton_23,2,Healthy - Baseline,10.1038/s41380-018-0082-9,,,,,5.07,0.37,
,Cre,Cre,2018_egerton_23,3,Healthy - Baseline,10.1038/s41380-018-0082-9,,,,,5.22,0.25,
,Cre,Cre,2018_egerton_23,4,Healthy - Baseline,10.1038/s41380-018-0082-9,,,,,7.17,0.57,
,Cre,Cre,2018_egerton_23,5,Healthy - Baseline,10.1038/s41380-018-0082-9,,,,,5.34,0.3,
,Cre,Cre,2018_egerton_23,6,Healthy - Baseline,10.1038/s41380-018-0082-9,,,,,4.91,0.22,
,Cre,Cre,2018_egerton_23,7,Healthy - After Amisulpride,10.1038/s41380-018-0082-9,,,,,6.4,0.48,
,Cre,Cre,2018_egerton_23,8,Healthy - After Amisulpride,10.1038/s41380-018-0082-9,,,,,5.06,0.37,
,Cre,Cre,2018_egerton_23,9,Healthy - After Amisulpride,10.1038/s41380-018-0082-9,,,,,5.23,0.3,
,Cre,Cre,2018_egerton_23,10,Healthy - After Amisulpride,10.1038/s41380-018-0082-9,,,,,7.11,0.42,
,Cre,Cre,2018_egerton_23,11,Healthy - After Amisulpride,10.1038/s41380-018-0082-9,,,,,5.4,0.6,
,Cre,Cre,2018_egerton_23,12,Healthy - After Amisulpride,10.1038/s41380-018-0082-9,,,,,4.83,0.13,
,Cre,Cre,2018_egerton_23,13,First Episode Psychosis - Baseline,10.1038/s41380-018-0082-9,,,,,6.17,1.19,
,Cre,Cre,2018_egerton_23,14,First Episode Psychosis - Baseline,10.1038/s41380-018-0082-9,,,,,5.25,0.39,
,Cre,Cre,2018_egerton_23,15,First Episode Psychosis - Baseline,10.1038/s41380-018-0082-9,,,,,5.01,0.36,
,Cre,Cre,2018_egerton_23,16,First Episode Psychosis - Baseline,10.1038/s41380-018-0082-9,,,,,7.09,0.61,
,Cre,Cre,2018_egerton_23,17,First Episode Psychosis - Baseline,10.1038/s41380-018-0082-9,,,,,5.53,0.52,
,Cre,Cre,2018_egerton_23,18,First Episode Psychosis - Baseline,10.1038/s41380-018-0082-9,,,,,4.75,0.9,
,Cre,Cre,2018_egerton_23,19,First Episode Psychosis - After Amisulpride,10.1038/s41380-018-0082-9,,,,,6.61,0.79,
,Cre,Cre,2018_egerton_23,20,First Episode Psychosis - After Amisulpride,10.1038/s41380-018-0082-9,,,,,5.19,0.34,
,Cre,Cre,2018_egerton_23,21,First Episode Psychosis - After Amisulpride,10.1038/s41380-018-0082-9,,,,,4.86,0.32,
,Cre,Cre,2018_egerton_23,22,First Episode Psychosis - After Amisulpride,10.1038/s41380-018-0082-9,,,,,6.95,0.47,
,Cre,Cre,2018_egerton_23,23,First Episode Psychosis - After Amisulpride,10.1038/s41380-018-0082-9,,,,,5.49,0.35,
,Cre,Cre,2018_egerton_23,24,First Episode Psychosis - After Amisulpride,10.1038/s41380-018-0082-9,,,,,5.03,0.48,
,Cre,Cre,2018_egerton_23,25,First Episode Psychosis - Remission (Baseline),10.1038/s41380-018-0082-9,,,,,6.11,1.47,
,Cre,Cre,2018_egerton_23,26,First Episode Psychosis - Remission (Baseline),10.1038/s41380-018-0082-9,,,,,5.38,0.33,
,Cre,Cre,2018_egerton_23,27,First Episode Psychosis - Remission (Baseline),10.1038/s41380-018-0082-9,,,,,5.04,0.38,
,Cre,Cre,2018_egerton_23,28,First Episode Psychosis - Remission (Baseline),10.1038/s41380-018-0082-9,,,,,7.15,0.72,
,Cre,Cre,2018_egerton_23,29,First Episode Psychosis - Remission (Baseline),10.1038/s41380-018-0082-9,,,,,5.53,0.44,
,Cre,Cre,2018_egerton_23,30,First Episode Psychosis - Remission (Baseline),10.1038/s41380-018-0082-9,,,,,5.01,0.45,
,Cre,Cre,2018_egerton_23,31,First Episode Psychosis - Remission (After Amisulpride),10.1038/s41380-018-0082-9,,,,,6.73,0.84,
,Cre,Cre,2018_egerton_23,32,First Episode Psychosis - Remission (After Amisulpride),10.1038/s41380-018-0082-9,,,,,5.25,0.34,
,Cre,Cre,2018_egerton_23,33,First Episode Psychosis - Remission (After Amisulpride),10.1038/s41380-018-0082-9,,,,,4.89,0.35,
,Cre,Cre,2018_egerton_23,34,First Episode Psychosis - Remission (After Amisulpride),10.1038/s41380-018-0082-9,,,,,6.98,0.53,
,Cre,Cre,2018_egerton_23,35,First Episode Psychosis - Remission (After Amisulpride),10.1038/s41380-018-0082-9,,,,,5.47,0.37,
,Cre,Cre,2018_egerton_23,36,First Episode Psychosis - Remission (After Amisulpride),10.1038/s41380-018-0082-9,,,,,4.88,0.49,
,Cre,Cre,2018_egerton_23,37,First Episode Psychosis - No Remission (Baseline),10.1038/s41380-018-0082-9,,,,,6.09,0.16,
,Cre,Cre,2018_egerton_23,38,First Episode Psychosis - No Remission (Baseline),10.1038/s41380-018-0082-9,,,,,5.14,0.41,
,Cre,Cre,2018_egerton_23,39,First Episode Psychosis - No Remission (Baseline),10.1038/s41380-018-0082-9,,,,,4.95,0.38,
,Cre,Cre,2018_egerton_23,40,First Episode Psychosis - No Remission (Baseline),10.1038/s41380-018-0082-9,,,,,7.05,0.31,
,Cre,Cre,2018_egerton_23,41,First Episode Psychosis - No Remission (Baseline),10.1038/s41380-018-0082-9,,,,,5.57,0.68,
,Cre,Cre,2018_egerton_23,42,First Episode Psychosis - No Remission (Baseline),10.1038/s41380-018-0082-9,,,,,4.72,1.19,
,Cre,Cre,2018_egerton_23,43,First Episode Psychosis - No Remission (After Amisulpride),10.1038/s41380-018-0082-9,,,,,6.42,0.73,
,Cre,Cre,2018_egerton_23,44,First Episode Psychosis - No Remission (After Amisulpride),10.1038/s41380-018-0082-9,,,,,5.07,0.32,
,Cre,Cre,2018_egerton_23,45,First Episode Psychosis - No Remission (After Amisulpride),10.1038/s41380-018-0082-9,,,,,4.81,0.3,
,Cre,Cre,2018_egerton_23,46,First Episode Psychosis - No Remission (After Amisulpride),10.1038/s41380-018-0082-9,,,,,6.99,0.28,
,Cre,Cre,2018_egerton_23,47,First Episode Psychosis - No Remission (After Amisulpride),10.1038/s41380-018-0082-9,,,,,5.53,0.31,
,Cre,Cre,2018_egerton_23,48,First Episode Psychosis - No Remission (After Amisulpride),10.1038/s41380-018-0082-9,,,,,5.4,0.6,
,Cre,Cre,2018_elmaki_36,1,Parkinson's Disease,10.1007/s11604-017-0714-z,,,6.64,0.91,,,
,Cre,Cre,2018_elmaki_36,2,Healthy,10.1007/s11604-017-0714-z,,,7.37,1.01,,,
,tCr,tCr,2018_ford_10,1,Healthy - Vitamin B (Baseline),10.3390/nu10121860,,,7.97,0.19,,,
,tCr,tCr,2018_ford_10,2,Healthy - Placebo (Baseline),10.3390/nu10121860,,,7.74,0.15,,,
,tCr,tCr,2018_ford_10,3,Healthy - Vitamin B (6 Months),10.3390/nu10121860,,,8.23,0.12,,,
,tCr,tCr,2018_ford_10,4,Healthy - Placebo (6 Months),10.3390/nu10121860,,,7.96,0.13,,,
,tCr,tCr,2018_galinska-skok_2018,1,Schizophrenia,10.1155/2018/3654894,,,0.27,0.07,,,
,tCr,tCr,2018_galinska-skok_2018,2,Schizophrenia,10.1155/2018/3654894,,,0.25,0.06,,,
,tCr,tCr,2018_galinska-skok_2018,3,Bipolar Disorder,10.1155/2018/3654894,,,0.26,0.05,,,
,tCr,tCr,2018_galinska-skok_2018,4,Bipolar Disorder,10.1155/2018/3654894,,,0.24,0.04,,,
,tCr,tCr,2018_galinska-skok_2018,5,Control,10.1155/2018/3654894,,,0.26,0.03,,,
,tCr,tCr,2018_galinska-skok_2018,6,Control,10.1155/2018/3654894,,,0.23,0.05,,,
,tCr,tCr,2018_gasparovic_48,1,Preterm Birth - Placebo (Scan 1),10.1007/s00247-017-4052-1,,,12.09,1.17,,,
,tCr,tCr,2018_gasparovic_48,2,Preterm Birth - Placebo (Scan 1),10.1007/s00247-017-4052-1,,,9.89,0.89,,,
,tCr,tCr,2018_gasparovic_48,3,Preterm Birth - Placebo (Scan 2),10.1007/s00247-017-4052-1,,,12.26,1.29,,,
,tCr,tCr,2018_gasparovic_48,4,Preterm Birth - Placebo (Scan 2),10.1007/s00247-017-4052-1,,,9.28,0.6,,,
,tCr,tCr,2018_gasparovic_48,5,Preterm Birth - Erythropoiesis Stimulating Agent (Scan 1),10.1007/s00247-017-4052-1,,,12.29,0.91,,,
,tCr,tCr,2018_gasparovic_48,6,Preterm Birth - Erythropoiesis Stimulating Agent (Scan 1),10.1007/s00247-017-4052-1,,,9.51,1.02,,,
,tCr,tCr,2018_gasparovic_48,7,Preterm Birth - Erythropoiesis Stimulating Agent (Scan 2),10.1007/s00247-017-4052-1,,,12.47,0.84,,,
,tCr,tCr,2018_gasparovic_48,8,Preterm Birth - Erythropoiesis Stimulating Agent (Scan 2),10.1007/s00247-017-4052-1,,,9.87,0.63,,,
,tCr,tCr,2018_gasparovic_48,9,Control - Scan 1,10.1007/s00247-017-4052-1,,,12,0.96,,,
,tCr,tCr,2018_gasparovic_48,10,Control - Scan 1,10.1007/s00247-017-4052-1,,,9.5,1.49,,,
,tCr,tCr,2018_gasparovic_48,11,Control - Scan 2,10.1007/s00247-017-4052-1,,,12.3,0.8,,,
,tCr,tCr,2018_gasparovic_48,12,Control - Scan 3,10.1007/s00247-017-4052-1,,,9.55,0.82,,,
,Cre,Cre,2018_gong_47,1,Parkinson's Disease - Postural Instability Gait Difficulty,10.1002/jmri.25865,,,7.54,1.3,,,
,Cre,Cre,2018_gong_47,2,Parkinson's Disease - Tremor-dominant,10.1002/jmri.25865,,,7.05,0.87,,,
,Cre,Cre,2018_gong_47,3,Control,10.1002/jmri.25865,,,8.87,1.41,,,
,tCr,tCr,2018_gramegna_39,1,Mitochondrial Neurogastrointestinal Encephalopathy,10.3174/ajnr.A5507,,,,,4.15,0.48,
,tCr,tCr,2018_gramegna_39,2,Control,10.3174/ajnr.A5507,,,,,4.97,0.55,
,Cre,Cre,2018_harper_17,1,Urologic Chronic Pelvic Pain Syndrome,10.1016/j.nicl.2017.11.014,0.48,0.07,2.7,0.52,,,
,Cre,Cre,2018_harper_17,2,Urologic Chronic Pelvic Pain Syndrome,10.1016/j.nicl.2017.11.014,0.48,0.09,2.91,0.49,,,
,Cre,Cre,2018_harper_17,3,Urologic Chronic Pelvic Pain Syndrome,10.1016/j.nicl.2017.11.014,0.48,0.14,2.82,0.97,,,
,Cre,Cre,2018_harper_17,4,Urologic Chronic Pelvic Pain Syndrome,10.1016/j.nicl.2017.11.014,0.42,0.08,2.65,0.64,,,
,Cre,Cre,2018_harper_17,5,Control,10.1016/j.nicl.2017.11.014,0.48,0.07,2.7,0.47,,,
,Cre,Cre,2018_harper_17,6,Control,10.1016/j.nicl.2017.11.014,0.47,0.08,2.85,0.61,,,
,Cre,Cre,2018_harper_17,7,Control,10.1016/j.nicl.2017.11.014,0.49,0.08,2.88,0.53,,,
,Cre,Cre,2018_harper_17,8,Control,10.1016/j.nicl.2017.11.014,0.43,0.04,2.63,0.26,,,
,Cre,Cre,2018_hegarty_48,1,Autism Spectrum Disorder,10.1007/s10803-018-3613-y,,,15.82,2.35,,,
,Cre,Cre,2018_hegarty_48,2,Autism Spectrum Disorder,10.1007/s10803-018-3613-y,,,10.1,0.47,,,
,Cre,Cre,2018_hegarty_48,3,Control,10.1007/s10803-018-3613-y,,,16.4,1.1,,,
,Cre,Cre,2018_hegarty_48,4,Control,10.1007/s10803-018-3613-y,,,10.41,0.51,,,
,Cre,Cre,2018_hjelmervik_172,1,Healthy - Menstrual Phase,10.1016/j.neuroimage.2018.01.043,,,5.54,0.81,,,
,Cre,Cre,2018_hjelmervik_172,2,Healthy - Menstrual Phase,10.1016/j.neuroimage.2018.01.043,,,4.85,0.81,,,
,Cre,Cre,2018_hjelmervik_172,3,Healthy - Follicular Phase,10.1016/j.neuroimage.2018.01.043,,,5.934,0.9,,,
,Cre,Cre,2018_hjelmervik_172,4,Healthy - Follicular Phase,10.1016/j.neuroimage.2018.01.043,,,4.68,0.98,,,
,Cre,Cre,2018_hjelmervik_172,5,Healthy - Luteal Phase,10.1016/j.neuroimage.2018.01.043,,,5.42,1.26,,,
,Cre,Cre,2018_hjelmervik_172,6,Healthy - Luteal Phase,10.1016/j.neuroimage.2018.01.043,,,5.15,0.93,,,
,Cre,Cre,2018_hjelmervik_172,7,Healthy - Total,10.1016/j.neuroimage.2018.01.043,,,5.26,0.54,,,
,Cre,Cre,2018_hjelmervik_172,8,Healthy - Session 1,10.1016/j.neuroimage.2018.01.043,,,5.41,0.78,,,
,Cre,Cre,2018_hjelmervik_172,9,Healthy - Session 1,10.1016/j.neuroimage.2018.01.043,,,5,0.81,,,
,Cre,Cre,2018_hjelmervik_172,10,Healthy - Session 2,10.1016/j.neuroimage.2018.01.043,,,5.2,0.85,,,
,Cre,Cre,2018_hjelmervik_172,11,Healthy - Session 2,10.1016/j.neuroimage.2018.01.043,,,4.87,0.72,,,
,Cre,Cre,2018_hjelmervik_172,12,Healthy - Session 3,10.1016/j.neuroimage.2018.01.043,,,5.35,0.73,,,
,Cre,Cre,2018_hjelmervik_172,13,Healthy - Session 3,10.1016/j.neuroimage.2018.01.043,,,4.68,0.96,,,
,Cre,Cre,2018_hjelmervik_172,14,Healthy - Total,10.1016/j.neuroimage.2018.01.043,,,5.08,0.5,,,
,Cre,Cre,2018_horder_8,1,Control,10.1038/s41398-018-0155-1,,,8.51,0.84,,,
,Cre,Cre,2018_horder_8,2,Control,10.1038/s41398-018-0155-1,,,8.13,0.84,,,
,Cre,Cre,2018_horder_8,3,Autism Spectrum Disorder,10.1038/s41398-018-0155-1,,,8.63,0.7,,,
,Cre,Cre,2018_horder_8,4,Autism Spectrum Disorder,10.1038/s41398-018-0155-1,,,8.5,0.5,,,
,Cre,Cre,2018_huber_225,1,Bipolar Disorder,10.1016/j.jad.2017.07.052,,,6.47,0.44,,,
,Cre,Cre,2018_huber_225,2,Bipolar Disorder,10.1016/j.jad.2017.07.052,,,6.29,1.02,,,
,Cre,Cre,2018_huber_225,3,Control,10.1016/j.jad.2017.07.052,,,6.49,0.6,,,
,Cre,Cre,2018_huber_225,4,Control,10.1016/j.jad.2017.07.052,,,6.81,0.46,,,
,Cre,Cre,2018_kim_23,1,Methamphetamine Dependence ,10.1111/adb.12473,,,5.05,0.8,,,
,Cre,Cre,2018_kim_23,2,Control,10.1111/adb.12473,,,5.02,0.73,,,
,tCr,tCr,2018_kim_83,1,First-episode Psychosis,10.1016/j.biopsych.2017.08.022,,,9.15,2.2,,,Estimated Bar Graph
,tCr,tCr,2018_kim_83,2,First-episode Psychosis,10.1016/j.biopsych.2017.08.022,,,9.05,1.95,,,Estimated Bar Graph
,tCr,tCr,2018_kim_83,3,Control,10.1016/j.biopsych.2017.08.022,,,9.2,1.8,,,Estimated Bar Graph
,tCr,tCr,2018_kim_83,4,Control,10.1016/j.biopsych.2017.08.022,,,9.35,2,,,Estimated Bar Graph
,Cre,Cre,2020_blest-hopley_25,1,Current CU,10.1111/adb.12827,,,7.329,1.022,,,
,Cre,Cre,2020_blest-hopley_25,2,Healthy,10.1111/adb.12827,,,7.665,0.784,,,
,Cre,Cre,2018_kirov_139,1,Epilepsy,10.1016/j.eplepsyres.2017.11.017,,,,,7.1,1.1,
,Cre,Cre,2018_kirov_139,2,Control,10.1016/j.eplepsyres.2017.11.017,,,,,7.7,0.7,
,tCr,tCr,2018_kroll_19,1,Asthma,10.1016/j.nicl.2018.04.012,,,9.15,1.46,,,
,tCr,tCr,2018_kroll_19,2,Control,10.1016/j.nicl.2018.04.012,,,10.57,1.06,,,
,Cre,Cre,2020_boillat_40,1,Baseline,10.1177/0271678X19831022,,,2.51,0.11,,,
,Cre,Cre,2020_boillat_40,2,positive BOLD,10.1177/0271678X19831022,,,0.03,0.07,,,
,Cre,Cre,2020_boillat_40,3,Baseline,10.1177/0271678X19831022,,,2.58,0.1,,,
,Cre,Cre,2020_boillat_40,4,negative BOLD,10.1177/0271678X19831022,,,0.01,0.11,,,
,Cre,Cre,2018_marshall_265,1,Secondary Progressive Multiple Sclerosis,10.1007/s00415-018-8903-y,,,809,14,,,
,Cre,Cre,2018_marshall_265,2,Secondary Progressive Multiple Sclerosis,10.1007/s00415-018-8903-y,,,958,32,,,
,Cre,Cre,2018_marshall_265,3,Secondary Progressive Multiple Sclerosis,10.1007/s00415-018-8903-y,,,858,15,,,
,Cre,Cre,2018_mcqueen_235,1,Schizophrenia - Placebo,10.1007/s00213-018-4997-2,,,11.48,1.64,,,
,Cre,Cre,2018_mcqueen_235,2,Schizophrenia - Placebo,10.1007/s00213-018-4997-2,,,9.43,1.46,,,
,Cre,Cre,2018_mcqueen_235,3,Schizophrenia - N-Acetylcysteine ,10.1007/s00213-018-4997-2,,,12.19,1.13,,,
,Cre,Cre,2018_mcqueen_235,4,Schizophrenia - N-Acetylcysteine ,10.1007/s00213-018-4997-2,,,10.62,4.36,,,
,Cre,Cre,2018_modinos_48,1,Healthy - Low Schizotypy,10.1017/S0033291717003403,,,12.15,1.45,,,
,Cre,Cre,2018_modinos_48,2,Healthy - High Schizotypy,10.1017/S0033291717003403,,,12.05,1.17,,,
,tCr,tCr,2018_plitman_273,1,Schizophrenia,10.1016/j.pscychresns.2018.01.004,,,8.58,0.87,,,
,tCr,tCr,2018_plitman_273,2,Control,10.1016/j.pscychresns.2018.01.004,,,8.2,1.05,,,
,tCr,tCr,2018_plitman_273,3,Schizophrenia - Point 1,10.1016/j.pscychresns.2018.01.004,,,8.55,0.47,,,
,tCr,tCr,2018_plitman_273,4,Schizophrenia - Point 2,10.1016/j.pscychresns.2018.01.004,,,9.15,0.54,,,
,tCr,tCr,2018_plitman_273,5,Control - Point 1,10.1016/j.pscychresns.2018.01.004,,,8.84,1.59,,,
,tCr,tCr,2018_plitman_273,6,Control - Point 2,10.1016/j.pscychresns.2018.01.004,,,8.71,1.16,,,
,tCr,tCr,2018_ryan_13,1,Healthy - Sham,10.1371/journal.pone.0198053,,,,,10.9,0.4,
,tCr,tCr,2018_ryan_13,2,Healthy - Transcranial direct current stimulation,10.1371/journal.pone.0198053,,,,,10.1,0.3,
,tCr,tCr,2021_bednarik_15,1,Healthy,10.3389/fnins.2021.609485,,,,,8.2,0.2,
,tCr,tCr,2021_bednarik_15,2,Healthy,10.3389/fnins.2021.609485,,,,,8.1,0.2,
,tCr,tCr,2018_schmitz_28,1,Healthy - <30 yrs,10.1111/jon.12514,,,10.13,0.35,,,
,tCr,tCr,2018_schmitz_28,2,Healthy - 30-39 yrs,10.1111/jon.12514,,,9.92,0.32,,,
,tCr,tCr,2018_schmitz_28,3,Healthy - 40-49 yrs,10.1111/jon.12514,,,10.48,0.35,,,
,tCr,tCr,2018_schmitz_28,4,Healthy - 50-59 yrs,10.1111/jon.12514,,,10.18,0.28,,,
,tCr,tCr,2018_schmitz_28,5,Healthy - >60 yrs,10.1111/jon.12514,,,10.27,0.52,,,
,tCr,tCr,2018_schmitz_28,6,Healthy,10.1111/jon.12514,,,10.19,0.41,,,
,tCr,tCr,2021_chaudhary_42,2,PD-CN,10.1007/s10072-020-04626-9,,,11.84,4.14,,,
,tCr,tCr,2021_chaudhary_42,17,PD-CI,10.1007/s10072-020-04626-9,,,8.56,2.32,,,
,tCr,tCr,2021_chaudhary_42,32,HC,10.1007/s10072-020-04626-9,,,10.69,2.63,,,
,Cre,Cre,2021_chaudhary_42,10,PD-CN,10.1007/s10072-020-04626-9,,,8.77,2.82,,,
,Cre,Cre,2021_chaudhary_42,25,PD-CI,10.1007/s10072-020-04626-9,,,6.77,2.47,,,
,Cre,Cre,2021_chaudhary_42,40,HC,10.1007/s10072-020-04626-9,,,8.26,2.43,,,
,tCr,tCr,2021_chaudhary_42,13,PD-CN,10.1007/s10072-020-04626-9,,,9.61,1.65,,,
,tCr,tCr,2021_chaudhary_42,28,PD-CI,10.1007/s10072-020-04626-9,,,8.37,1.22,,,
,tCr,tCr,2021_chaudhary_42,43,HC,10.1007/s10072-020-04626-9,,,9.46,1.66,,,
,tCr,tCr,2021_chaudhary_42,14,PD-CN,10.1007/s10072-020-04626-9,,,8.92,1.63,,,
,tCr,tCr,2021_chaudhary_42,29,PD-CI,10.1007/s10072-020-04626-9,,,8.05,1.87,,,
,tCr,tCr,2021_chaudhary_42,44,HC,10.1007/s10072-020-04626-9,,,8.06,1.47,,,
,Cre,Cre,2021_chenji_282,1,Control,10.1016/j.jad.2020.12.176,,,6.23,0.89,,,
,Cre,Cre,2021_chenji_282,3,MDD-Normal BMI,10.1016/j.jad.2020.12.176,,,6.51,0.86,,,
,Cre,Cre,2021_chenji_282,5,MDD-High BMI,10.1016/j.jad.2020.12.176,,,6.07,0.85,,,
,Cre,Cre,2021_chenji_282,2,Control,10.1016/j.jad.2020.12.176,,,6.76,0.98,,,
,Cre,Cre,2021_chenji_282,4,MDD-Normal BMI,10.1016/j.jad.2020.12.176,,,6.48,1,,,
,Cre,Cre,2021_chenji_282,6,MDD-High BMI,10.1016/j.jad.2020.12.176,,,6.19,1.07,,,
,tCr,tCr,2018_shakory_43,1,Control,10.1038/s41386-018-0163-0,,,7.17,0.7,,,
,tCr,tCr,2018_shakory_43,2,Clinical high risk of psychosis,10.1038/s41386-018-0163-0,,,6.88,0.68,,,
,tCr,tCr,2018_shakory_43,3,First Episode Psychosis,10.1038/s41386-018-0163-0,,,7.14,0.68,,,
,Cre,Cre,2021_faulkner_26,1,Nonsmokers,10.1111/adb.12986,,,,,7.229,0.136,
,Cre,Cre,2021_faulkner_26,2,Intermittent smokers,10.1111/adb.12986,,,,,5.899,0.121,
,Cre,Cre,2021_faulkner_26,3,Smokers,10.1111/adb.12986,,,,,5.96,0.136,
,tCr,tCr,2018_sheth_276,1,Veterans - Suicidal behavior,10.1016/j.pscychresns.2018.04.004,,,2.16,0.08,,,
,tCr,tCr,2018_sheth_276,2,Veterans - Suicidal behavior,10.1016/j.pscychresns.2018.04.004,,,1.95,0.04,,,
,tCr,tCr,2018_sheth_276,3,Veterans - No suicidal behavior,10.1016/j.pscychresns.2018.04.004,,,2.12,0.13,,,
,tCr,tCr,2018_sheth_276,4,Veterans - No suicidal behavior,10.1016/j.pscychresns.2018.04.004,,,1.88,0.06,,,
,Cre,Cre,2018_sivaraman_281,1,Control,10.1016/j.pscychresns.2018.06.003,,,0.37,0.07,,,
,Cre,Cre,2018_sivaraman_281,2,First episode psychosis,10.1016/j.pscychresns.2018.06.003,,,0.38,0.06,,,
,Cre,Cre,2018_tan_28,1,Control,10.1007/s00330-018-5443-x,,,,,5.8,0.5,
,Cre,Cre,2018_tan_28,2,Control,10.1007/s00330-018-5443-x,,,,,5.8,0.5,
,Cre,Cre,2018_tan_28,3,Control,10.1007/s00330-018-5443-x,,,,,5.8,0.4,
,Cre,Cre,2018_tan_28,4,Temporal lobe epilespsy,10.1007/s00330-018-5443-x,,,,,5.6,0.5,
,Cre,Cre,2018_tan_28,5,Temporal lobe epilespsy,10.1007/s00330-018-5443-x,,,,,5.5,0.4,
,Cre,Cre,2018_tan_28,6,Temporal lobe epilespsy - Left seizure foci,10.1007/s00330-018-5443-x,,,,,5.7,0.6,
,Cre,Cre,2018_tan_28,7,Temporal lobe epilespsy - Left seizure foci,10.1007/s00330-018-5443-x,,,,,5.5,0.4,
,Cre,Cre,2018_tan_28,8,Temporal lobe epilespsy - Right seizure foci,10.1007/s00330-018-5443-x,,,,,5.5,0.3,
,Cre,Cre,2018_tan_28,9,Temporal lobe epilespsy - Right seizure foci,10.1007/s00330-018-5443-x,,,,,5.5,0.4,
,tCr,tCr,2018_van_89,1,Control,10.1136/jnnp-2017-316364,,,,,3.77,0.38,
,tCr,tCr,2018_van_89,2,Metachromatic leukodystrophy - Good outcome,10.1136/jnnp-2017-316364,,,,,4.8,0.52,
,tCr,tCr,2018_van_89,3,Metachromatic leukodystrophy - Moderate outcome,10.1136/jnnp-2017-316364,,,,,4.61,0.58,
,tCr,tCr,2018_van_89,4,Metachromatic leukodystrophy - Poor outcome,10.1136/jnnp-2017-316364,,,,,3.12,0.82,
,Cre,Cre,2019_betinaip_39,1,Behavior - ON - 3% Visual Contrast,10.1523/JNEUROSCI.3021-18.2019,,,3.988,0.462,,,
,Cre,Cre,2019_betinaip_39,2,Behavior - ON - 12.5% Visual Contrast,10.1523/JNEUROSCI.3021-18.2019,,,3.963,0.44,,,
,Cre,Cre,2019_betinaip_39,3,Behavior - ON - 50% Visual Contrast,10.1523/JNEUROSCI.3021-18.2019,,,4.013,0.505,,,
,Cre,Cre,2019_betinaip_39,4,Behavior - ON - 100% Visual Contrast,10.1523/JNEUROSCI.3021-18.2019,,,3.915,0.378,,,
,Cre,Cre,2019_betinaip_39,5,Resting,10.1523/JNEUROSCI.3021-18.2019,,,3.985,0.556,,,
,Cre,Cre,2019_betinaip_39,6,Behavior - OFF - 3% Visual Contrast,10.1523/JNEUROSCI.3021-18.2019,,,3.966,0.439,,,
,Cre,Cre,2019_betinaip_39,7,Behavior - OFF - 12.5% Visual Contrast,10.1523/JNEUROSCI.3021-18.2019,,,3.994,0.482,,,
,Cre,Cre,2019_betinaip_39,8,Behavior - OFF - 50% Visual Contrast,10.1523/JNEUROSCI.3021-18.2019,,,3.896,0.48,,,
,Cre,Cre,2019_betinaip_39,9,Behavior - OFF - 100% Visual Contrast,10.1523/JNEUROSCI.3021-18.2019,,,3.908,0.415,,,
,Cre,Cre,2019_betinaip_39,10,Resting,10.1523/JNEUROSCI.3021-18.2019,,,4.052,0.625,,,
,tCr,tCr,2019_betinaip_39,1,Behavior - ON - 3% Visual Contrast,10.1523/JNEUROSCI.3021-18.2019,,,8.038,0.802,,,
,tCr,tCr,2019_betinaip_39,2,Behavior - ON - 12.5% Visual Contrast,10.1523/JNEUROSCI.3021-18.2019,,,7.997,0.801,,,
,tCr,tCr,2019_betinaip_39,3,Behavior - ON - 50% Visual Contrast,10.1523/JNEUROSCI.3021-18.2019,,,8.05,0.799,,,
,tCr,tCr,2019_betinaip_39,4,Behavior - ON - 100% Visual Contrast,10.1523/JNEUROSCI.3021-18.2019,,,7.962,0.733,,,
,tCr,tCr,2019_betinaip_39,5,Resting,10.1523/JNEUROSCI.3021-18.2019,,,8.116,0.702,,,
,tCr,tCr,2019_betinaip_39,6,Behavior - OFF - 3% Visual Contrast,10.1523/JNEUROSCI.3021-18.2019,,,8.033,0.798,,,
,tCr,tCr,2019_betinaip_39,7,Behavior - OFF - 12.5% Visual Contrast,10.1523/JNEUROSCI.3021-18.2019,,,7.991,0.775,,,
,tCr,tCr,2019_betinaip_39,8,Behavior - OFF - 50% Visual Contrast,10.1523/JNEUROSCI.3021-18.2019,,,7.979,0.799,,,
,tCr,tCr,2019_betinaip_39,9,Behavior - OFF - 100% Visual Contrast,10.1523/JNEUROSCI.3021-18.2019,,,8.035,0.746,,,
,tCr,tCr,2019_betinaip_39,10,Resting,10.1523/JNEUROSCI.3021-18.2019,,,8.172,0.715,,,
,Cre,Cre,2019_davitz_50,1,TBI (Post-Concussive),10.1002/jmri.26718,,,,,6.2,1.2,
,Cre,Cre,2019_davitz_50,2,TBI (Post-Concussive),10.1002/jmri.26718,,,,,4.4,0.7,
,Cre,Cre,2019_davitz_50,3,TBI (Post-Concussive),10.1002/jmri.26718,,,,,6.2,0.9,
,Cre,Cre,2019_davitz_50,4,TBI (Post-Concussive),10.1002/jmri.26718,,,,,5.9,1.2,
,Cre,Cre,2019_davitz_50,5,TBI (Post-Concussive),10.1002/jmri.26718,,,,,4.9,0.9,
,Cre,Cre,2019_davitz_50,6,Control,10.1002/jmri.26718,,,,,5.2,2.1,
,Cre,Cre,2019_davitz_50,7,Control,10.1002/jmri.26718,,,,,4.2,1.2,
,Cre,Cre,2019_davitz_50,8,Control,10.1002/jmri.26718,,,,,6.5,1.3,
,Cre,Cre,2019_davitz_50,9,Control,10.1002/jmri.26718,,,,,5.9,1.5,
,Cre,Cre,2019_davitz_50,10,Control,10.1002/jmri.26718,,,,,4.8,1,
,tCr,tCr,2019_ferland_237,1,Healthy TMS,10.1007/s00221-019-05691-z,,,,,17.259,1.647,
,tCr,tCr,2019_ferland_237,2,Healthy TMS,10.1007/s00221-019-05691-z,,,,,17.695,0.857,
,tCr,tCr,2019_giapitzakis_81,1,Healthy,10.1002/mrm.27467,,,,,7.8,0.5,
,tCr,tCr,2019_giapitzakis_81,2,Healthy,10.1002/mrm.27467,,,,,6.4,0.6,
,tCr,tCr,2019_graf_32,1,Healthy,10.1002/nbm.4083,,,5.9,1.71,,,Med/Quartile --> Mean/Std Wan 2014
,Cre,Cre,2019_hansen_33,1,Control,10.1016/j.jdiacomp.2018.12.016,,,,,5.55,0.52,
,Cre,Cre,2019_hansen_33,2,Diabetes,10.1016/j.jdiacomp.2018.12.016,,,,,5.82,0.41,
,Cre,Cre,2019_iwata_85,1,Control,10.1016/j.biopsych.2018.09.009,,,8.77,0.84,,,
,Cre,Cre,2019_iwata_85,2,Control,10.1016/j.biopsych.2018.09.009,,,9.86,0.92,,,
,Cre,Cre,2019_iwata_85,3,Control,10.1016/j.biopsych.2018.09.009,,,8.71,0.87,,,
,Cre,Cre,2019_iwata_85,4,Schizophrenia Ultra-Resistant,10.1016/j.biopsych.2018.09.009,,,8.79,1.18,,,
,Cre,Cre,2019_iwata_85,5,Schizophrenia Ultra-Resistant,10.1016/j.biopsych.2018.09.009,,,10.42,0.85,,,
,Cre,Cre,2019_iwata_85,6,Schizophrenia Ultra-Resistant,10.1016/j.biopsych.2018.09.009,,,8.93,1.01,,,
,Cre,Cre,2019_iwata_85,7,Schizophrenia Non-Ultra Resistant,10.1016/j.biopsych.2018.09.009,,,9.26,0.89,,,
,Cre,Cre,2019_iwata_85,8,Schizophrenia Non-Ultra Resistant,10.1016/j.biopsych.2018.09.009,,,10.37,0.76,,,
,Cre,Cre,2019_iwata_85,9,Schizophrenia Non-Ultra Resistant,10.1016/j.biopsych.2018.09.009,,,9.02,1.28,,,
,Cre,Cre,2019_iwata_85,10,Schizophrenia Non-Treatment Resistant,10.1016/j.biopsych.2018.09.009,,,9.29,1.14,,,
,Cre,Cre,2019_iwata_85,11,Schizophrenia Non-Treatment Resistant,10.1016/j.biopsych.2018.09.009,,,9.87,0.89,,,
,Cre,Cre,2019_iwata_85,12,Schizophrenia Non-Treatment Resistant,10.1016/j.biopsych.2018.09.009,,,9.37,1,,,
,Cre,Cre,2019_joe_13,1,Predisposed Alzheimer's Mutation Carriers,10.1007/s11682-018-9913-1,,,5.13,0.5,,,
,Cre,Cre,2019_joe_13,2,Predisposed Alzheimer's Mutation Carriers,10.1007/s11682-018-9913-1,,,5.71,0.91,,,
,Cre,Cre,2019_joe_13,3,Predisposed Alzheimer's Mutation Carriers,10.1007/s11682-018-9913-1,,,6.76,1.22,,,
,Cre,Cre,2019_joe_13,4,Predisposed Alzheimer's Mutation Carriers,10.1007/s11682-018-9913-1,,,6.09,0.45,,,
,Cre,Cre,2019_joe_13,5,Predisposed Alzheimer's Non-Carriers,10.1007/s11682-018-9913-1,,,5.37,1.12,,,
,Cre,Cre,2019_joe_13,6,Predisposed Alzheimer's Non-Carriers,10.1007/s11682-018-9913-1,,,5.59,1.28,,,
,Cre,Cre,2019_joe_13,7,Predisposed Alzheimer's Non-Carriers,10.1007/s11682-018-9913-1,,,6.82,0.99,,,
,Cre,Cre,2019_joe_13,8,Predisposed Alzheimer's Non-Carriers,10.1007/s11682-018-9913-1,,,6.3,0.75,,,
,Cr,Cre,2019_levin_202,1,Control (Young),10.1016/j.neuroimage.2019.116050,,,6.2,0.81,,,
,Cr,Cre,2019_levin_202,2,Middle-Aged,10.1016/j.neuroimage.2019.116050,,,5.97,0.84,,,
,Cr,Cre,2019_levin_202,3,Old-Middle Aged,10.1016/j.neuroimage.2019.116050,,,5.89,0.87,,,
,Cr,Cre,2019_levin_202,4,Aged,10.1016/j.neuroimage.2019.116050,,,5.39,0.69,,,
,Cr,Cre,2019_levin_202,5,Control (Young),10.1016/j.neuroimage.2019.116050,,,6.22,1.06,,,
,Cr,Cre,2019_levin_202,6,Middle-Aged,10.1016/j.neuroimage.2019.116050,,,6.06,0.92,,,
,Cr,Cre,2019_levin_202,7,Old-Middle Aged,10.1016/j.neuroimage.2019.116050,,,5.19,1.02,,,
,Cr,Cre,2019_levin_202,8,Aged,10.1016/j.neuroimage.2019.116050,,,5.29,1.15,,,
,tCr,tCr,2018_veeramuthu_25,1,Complicated mTBI,10.1016/j.acra.2018.01.005,,,1.702,0.34,,,
,tCr,tCr,2018_veeramuthu_25,2,Uncomplicated mTBI,10.1016/j.acra.2018.01.005,,,1.693,0.217,,,
,tCr,tCr,2018_veeramuthu_25,3,Control,10.1016/j.acra.2018.01.005,,,1.766,0.225,,,
,tCr,tCr,2018_volk_39,1,Healthy - Evening,10.1002/hbm.24225,,,7.54,0.56,,,
,tCr,tCr,2018_volk_39,2,Healthy - Morning,10.1002/hbm.24225,,,7.48,0.56,,,
,tCr,tCr,2018_white_43,1,Healthy_Placebo,10.1038/s41386-018-0027-7,,,6.28,0.54,,,
,tCr,tCr,2018_white_43,2,Healthy_d-amphetamine,10.1038/s41386-018-0027-7,,,6.56,0.64,,,
,tCr,tCr,2018_white_43,3,Healthy_methamphetamine,10.1038/s41386-018-0027-7,,,6.34,0.53,,,
,tCr,tCr,2018_wu_9,1,MA dependence (Abstinent),10.3389/fpsyt.2018.00478,,,6.47,0.83,,,
,tCr,tCr,2018_wu_9,2,Control,10.3389/fpsyt.2018.00478,,,6.58,0.7,,,
,tCr,tCr,2018_younis_19,1,Healthy - Sildenafil_Baseline,10.1186/s10194-018-0870-2,,,,,4.25,0.35,
,tCr,tCr,2018_younis_19,2,Healthy - Sildenafil_40min,10.1186/s10194-018-0870-2,,,,,4.33,0.32,
,tCr,tCr,2018_younis_19,3,Healthy - Sildenafil_140min,10.1186/s10194-018-0870-2,,,,,4.23,0.28,
,tCr,tCr,2018_younis_19,4,Healthy - Calcitonin gene-related peptide_Baseline,10.1186/s10194-018-0870-2,,,,,4.38,0.38,
,tCr,tCr,2018_younis_19,5,Healthy - Calcitonin gene-related peptide_40min,10.1186/s10194-018-0870-2,,,,,4.39,0.53,
,tCr,tCr,2018_younis_19,6,Healthy - Calcitonin gene-related peptide_140min,10.1186/s10194-018-0870-2,,,,,4.5,0.33,
,tCr,tCr,2018_younis_19,7,Healthy - Placebo_Baseline,10.1186/s10194-018-0870-2,,,,,4.24,0.33,
,tCr,tCr,2018_younis_19,8,Healthy - Placebo_40min,10.1186/s10194-018-0870-2,,,,,4.33,0.47,
,tCr,tCr,2018_younis_19,9,Healthy - Placebo_140min,10.1186/s10194-018-0870-2,,,,,4.21,0.32,
,tCr,tCr,2018_zarinabad_79,1,Medulloblastoma,10.1002/mrm.26837,,,,,3.91,1.5,
,tCr,tCr,2018_zarinabad_79,2,Pilocytic Astrocytoma,10.1002/mrm.26837,,,,,2.29,2.22,
,tCr,tCr,2018_zarinabad_79,3,Ependymoma,10.1002/mrm.26837,,,,,1.69,0.79,
,tCr,tCr,2017_bustillo_43,1,Control,10.1093/schbul/sbw122,,,,,5.7,0.8,
,tCr,tCr,2017_bustillo_43,2,Schizophrenia,10.1093/schbul/sbw123,,,,,5.9,0.9,
,tCr,tCr,2017_holmes_12,1,Healthy - 5 year olds,10.1371/journal.pone.0180973,,,5.356,0.44,,,
,tCr,tCr,2017_holmes_12,2,Healthy - 5 year olds,10.1371/journal.pone.0180973,,,5.94,0.454,,,
,tCr,tCr,2017_holmes_12,3,Healthy - 5 year olds,10.1371/journal.pone.0180973,,,3.619,0.445,,,
,tCr,tCr,2017_holmes_12,4,Healthy - 7 year olds,10.1371/journal.pone.0180973,,,5.419,0.459,,,
,tCr,tCr,2017_holmes_12,5,Healthy - 7 year olds,10.1371/journal.pone.0180973,,,5.899,0.537,,,
,tCr,tCr,2017_holmes_12,6,Healthy - 7 year olds,10.1371/journal.pone.0180973,,,6.8,0.93,,,
,tCr,tCr,2017_holmes_12,7,Healthy - 9 year olds,10.1371/journal.pone.0180973,,,5.743,0.532,,,
,tCr,tCr,2017_holmes_12,8,Healthy - 9 year olds,10.1371/journal.pone.0180973,,,5.783,0.415,,,
,tCr,tCr,2017_holmes_12,9,Healthy - 9 year olds,10.1371/journal.pone.0180973,,,3.859,0.172,,,
,PCr,PCr,2018_al-iedani_108,1,Healthy,10.1016/j.ejrad.2018.09.020,,,0.57,0.02,,,
,PCr,PCr,2018_al-iedani_108,2,Healthy,10.1016/j.ejrad.2018.09.020,,,0.56,0.01,,,
,PCr,PCr,2018_bednarik_38,1,Healthy,10.1177/0271678X17695291,,,,,3.42,0.24,
,PCr,PCr,2020_boillat_40,1,Baseline,10.1177/0271678X19831022,,,1.95,0.12,,,
,PCr,PCr,2020_boillat_40,2,positive BOLD,10.1177/0271678X19831022,,,0.03,0.08,,,
,PCr,PCr,2020_boillat_40,3,Baseline,10.1177/0271678X19831022,,,1.93,0.09,,,
,PCr,PCr,2020_boillat_40,4,negative BOLD,10.1177/0271678X19831022,,,0.04,0.09,,,
,PCr,PCr,2019_betinaip_39,1,Behavior - ON - 3% Visual Contrast,10.1523/JNEUROSCI.3021-18.2019,,,4.05,0.422,,,
,PCr,PCr,2019_betinaip_39,2,Behavior - ON - 12.5% Visual Contrast,10.1523/JNEUROSCI.3021-18.2019,,,4.034,0.502,,,
,PCr,PCr,2019_betinaip_39,3,Behavior - ON - 50% Visual Contrast,10.1523/JNEUROSCI.3021-18.2019,,,4.037,0.511,,,
,PCr,PCr,2019_betinaip_39,4,Behavior - ON - 100% Visual Contrast,10.1523/JNEUROSCI.3021-18.2019,,,4.048,0.503,,,
,PCr,PCr,2019_betinaip_39,5,Resting,10.1523/JNEUROSCI.3021-18.2019,,,4.131,0.392,,,
,PCr,PCr,2019_betinaip_39,6,Behavior - OFF - 3% Visual Contrast,10.1523/JNEUROSCI.3021-18.2019,,,4.066,0.432,,,
,PCr,PCr,2019_betinaip_39,7,Behavior - OFF - 12.5% Visual Contrast,10.1523/JNEUROSCI.3021-18.2019,,,3.997,0.476,,,
,PCr,PCr,2019_betinaip_39,8,Behavior - OFF - 50% Visual Contrast,10.1523/JNEUROSCI.3021-18.2019,,,4.083,0.509,,,
,PCr,PCr,2019_betinaip_39,9,Behavior - OFF - 100% Visual Contrast,10.1523/JNEUROSCI.3021-18.2019,,,4.127,0.515,,,
,PCr,PCr,2019_betinaip_39,10,Resting,10.1523/JNEUROSCI.3021-18.2019,,,4.12,0.387,,,
,tCr,tCr,2017_cao_42,1,Control,10.1038/npp.2017.39,,,9.36,0.21,,,
,tCr,tCr,2017_cao_42,2,Control,10.1038/npp.2017.39,,,9.96,0.25,,,
,tCr,tCr,2017_cao_42,3,Control,10.1038/npp.2017.39,,,5.78,0.28,,,
,tCr,tCr,2017_cao_42,4,Control,10.1038/npp.2017.39,,,11.23,0.34,,,
,tCr,tCr,2017_cao_42,5,BD-1-Non Rapid Cycle  ,10.1038/npp.2017.39,,,9.55,0.22,,,
,tCr,tCr,2017_cao_42,6,BD-1-Non Rapid Cycle  ,10.1038/npp.2017.39,,,10.17,0.25,,,
,tCr,tCr,2017_cao_42,7,BD-1-Non Rapid Cycle  ,10.1038/npp.2017.39,,,6.64,0.31,,,
,tCr,tCr,2017_cao_42,8,BD-1-Non Rapid Cycle  ,10.1038/npp.2017.39,,,11.72,0.39,,,
,tCr,tCr,2017_cao_42,9,BD-1-Rapid Cycle ,10.1038/npp.2017.39,,,10.02,0.33,,,
,tCr,tCr,2017_cao_42,10,BD-1-Rapid Cycle ,10.1038/npp.2017.39,,,10.72,0.34,,,
,tCr,tCr,2017_cao_42,11,BD-1-Rapid Cycle ,10.1038/npp.2017.39,,,6.7,0.36,,,
,tCr,tCr,2017_cao_42,12,BD-1-Rapid Cycle ,10.1038/npp.2017.39,,,11.96,0.47,,,
,tCr,tCr,2017_carlson_38,2,Control- Non-dominant Hand ,10.1002/hbm.23472,,,7.8,0.75,,,
,tCr,tCr,2017_carlson_38,1,Control- Dominant Hand,10.1002/hbm.23472,,,8.1,0.75,,,
,tCr,tCr,2017_carlson_38,4,Bipolar with Periventricular Venous Infarctions- Lesioned Side,10.1002/hbm.23472,,,8.05,0.9,,,
,tCr,tCr,2017_carlson_38,3,Bipolar with Periventricular Venous Infarctions- Non-lesioned Side,10.1002/hbm.23472,,,7.8,1.125,,,
,tCr,tCr,2017_carlson_38,5,Bipolar with Arterial Ischemic Strokes- Lesioned Side ,10.1002/hbm.23472,,,8,0.938,,,
,tCr,tCr,2017_carlson_38,6,Bipolar with Arterial Ischemic Strokes- Non-lesioned Side,10.1002/hbm.23472,,,7.75,0.75,,,
,Cr,Cre,2020_zheng_265,1,Control,10.1016/j.jad.2020.01.059,,,8.07,1.07,,,
,Cr,Cre,2020_zheng_265,2,Control,10.1016/j.jad.2020.01.059,,,8.53,1.33,,,
,Cr,Cre,2020_zheng_265,3,Control,10.1016/j.jad.2020.01.059,,,7.66,0.58,,,
,Cr,Cre,2020_zheng_265,4,OCD,10.1016/j.jad.2020.01.059,,,8.1,1.15,,,
,Cr,Cre,2020_zheng_265,5,OCD,10.1016/j.jad.2020.01.059,,,8.69,1.17,,,
,Cr,Cre,2020_zheng_265,6,OCD,10.1016/j.jad.2020.01.059,,,7.27,0.37,,,
,Cr,Cre,2020_zheng_265,7,OCD + SPD,10.1016/j.jad.2020.01.059,,,7.41,2.25,,,
,Cr,Cre,2020_zheng_265,8,OCD + SPD,10.1016/j.jad.2020.01.059,,,8.16,1.13,,,
,Cr,Cre,2020_zheng_265,9,OCD + SPD,10.1016/j.jad.2020.01.059,,,7.08,2.6,,,
,tCr,tCr,2020_kahl_101,1,Control,10.1016/j.pnpbp.2020.109916,,,9.46,0.13,,,
,tCr,tCr,2020_kahl_101,2,Control,10.1016/j.pnpbp.2020.109916,,,9.48,0.15,,,
,tCr,tCr,2020_kahl_101,3,Control,10.1016/j.pnpbp.2020.109916,,,8.45,0.11,,,
,tCr,tCr,2020_kahl_101,4,Control,10.1016/j.pnpbp.2020.109916,,,8.73,0.13,,,
,tCr,tCr,2020_kahl_101,5,Control,10.1016/j.pnpbp.2020.109916,,,9,0.1,,,
,tCr,tCr,2020_kahl_101,6,Control,10.1016/j.pnpbp.2020.109916,,,9.14,0.14,,,
,tCr,tCr,2020_kahl_101,7,Control,10.1016/j.pnpbp.2020.109916,,,9.16,0.12,,,
,tCr,tCr,2020_kahl_101,8,Control,10.1016/j.pnpbp.2020.109916,,,9.57,0.14,,,
,tCr,tCr,2020_kahl_101,9,Control,10.1016/j.pnpbp.2020.109916,,,11.07,0.19,,,
,tCr,tCr,2020_kahl_101,10,MDD,10.1016/j.pnpbp.2020.109916,,,8.98,0.11,,,
,tCr,tCr,2020_kahl_101,11,MDD,10.1016/j.pnpbp.2020.109916,,,9.09,0.13,,,
,tCr,tCr,2020_kahl_101,12,MDD,10.1016/j.pnpbp.2020.109916,,,8.26,0.1,,,
,tCr,tCr,2020_kahl_101,13,MDD,10.1016/j.pnpbp.2020.109916,,,8.5,0.12,,,
,tCr,tCr,2020_kahl_101,14,MDD,10.1016/j.pnpbp.2020.109916,,,8.68,0.08,,,
,tCr,tCr,2020_kahl_101,15,MDD,10.1016/j.pnpbp.2020.109916,,,9.06,0.13,,,
,tCr,tCr,2020_kahl_101,16,MDD,10.1016/j.pnpbp.2020.109916,,,9.2,0.14,,,
,tCr,tCr,2020_kahl_101,17,MDD,10.1016/j.pnpbp.2020.109916,,,9.59,0.12,,,
,tCr,tCr,2020_kahl_101,18,MDD,10.1016/j.pnpbp.2020.109916,,,10.92,0.16,,,
,tCr,tCr,2020_zhang_33,1,Healthy,10.1002/nbm.4313,,,11.3,0.7,,,
,tCr,tCr,2020_zhang_33,2,Healthy,10.1002/nbm.4313,,,12.8,1.2,,,
,tCr,tCr,2020_zhang_33,3,Healthy,10.1002/nbm.4313,,,12,1.1,,,
,tCr,tCr,2020_zhang_33,4,Healthy,10.1002/nbm.4313,,,12.2,0.9,,,
,tCr,tCr,2020_zhang_33,5,Healthy,10.1002/nbm.4313,,,12.8,1.3,,,
,tCr,tCr,2020_zhang_33,6,Healthy,10.1002/nbm.4313,,,13.8,1.9,,,
,tCr,tCr,2020_zhang_33,7,Healthy,10.1002/nbm.4313,,,13,1.1,,,
,tCr,tCr,2020_zhang_33,8,Healthy,10.1002/nbm.4313,,,12.2,1,,,
,tCr,tCr,2020_zhang_33,9,Healthy,10.1002/nbm.4313,,,12.2,1.2,,,
,tCr,tCr,2020_zhang_33,10,Healthy,10.1002/nbm.4313,,,14.8,1.7,,,
,tCr,tCr,2020_zhang_33,11,Healthy,10.1002/nbm.4313,,,14.7,2.1,,,
,tCr,tCr,2020_zhang_33,12,Healthy,10.1002/nbm.4313,,,13.9,2.3,,,
,tCr,tCr,2020_zhang_33,13,Healthy,10.1002/nbm.4313,,,12.7,1,,,
,tCr,tCr,2020_zhang_33,14,Healthy,10.1002/nbm.4313,,,13,0.9,,,
,tCr,tCr,2020_zhang_33,15,Healthy,10.1002/nbm.4313,,,10.6,1.4,,,
,tCr,tCr,2020_zhang_33,16,Healthy,10.1002/nbm.4313,,,10.4,1.7,,,
,tCr,tCr,2020_zhang_33,17,Healthy,10.1002/nbm.4313,,,8.2,1,,,
,tCr,tCr,2020_zhang_33,18,Healthy,10.1002/nbm.4313,,,9.7,1.4,,,
,tCr,tCr,2020_zhang_33,19,Healthy,10.1002/nbm.4313,,,13.3,1.4,,,
,tCr,tCr,2020_zhang_33,20,Healthy,10.1002/nbm.4313,,,12.9,1.5,,,
,tCr,tCr,2020_zhang_33,21,Healthy,10.1002/nbm.4313,,,13.5,1.5,,,
,tCr,tCr,2020_zhang_33,22,Healthy,10.1002/nbm.4313,,,13.1,1.8,,,
,tCr,tCr,2020_zhang_33,23,Healthy,10.1002/nbm.4313,,,12,1,,,
,tCr,tCr,2020_zhang_33,24,Healthy,10.1002/nbm.4313,,,12.4,1.2,,,
,tCr,tCr,2020_zhang_33,25,Healthy,10.1002/nbm.4313,,,12.7,1.3,,,
,tCr,tCr,2020_zhang_33,26,Healthy,10.1002/nbm.4313,,,12.4,1.1,,,
,tCr,tCr,2020_zhang_33,27,Healthy,10.1002/nbm.4313,,,10.6,1.1,,,
,tCr,tCr,2020_zhang_33,28,Healthy,10.1002/nbm.4313,,,11,1.2,,,
,tCr,tCr,2020_zhang_33,29,Healthy,10.1002/nbm.4313,,,11.9,0.7,,,
,tCr,tCr,2020_zhang_33,30,Healthy,10.1002/nbm.4313,,,13.1,1.1,,,
,tCr,tCr,2020_zhang_33,31,Healthy,10.1002/nbm.4313,,,12.3,0.7,,,
,tCr,tCr,2020_zhang_33,32,Healthy,10.1002/nbm.4313,,,12.8,0.7,,,
,tCr,tCr,2020_zhang_33,33,Healthy,10.1002/nbm.4313,,,12.5,1.1,,,
,tCr,tCr,2020_zhang_33,34,Healthy,10.1002/nbm.4313,,,12.2,1,,,
,tCr,tCr,2020_zhang_33,35,Healthy,10.1002/nbm.4313,,,11.4,0.9,,,
,tCr,tCr,2020_zhang_33,36,Healthy,10.1002/nbm.4313,,,12,1.3,,,
,tCr,tCr,2020_zhang_33,37,Healthy,10.1002/nbm.4313,,,12.2,2.2,,,
,tCr,tCr,2020_zhang_33,38,Healthy,10.1002/nbm.4313,,,13,2.1,,,
,tCr,tCr,2020_zhang_33,39,Healthy,10.1002/nbm.4313,,,10.6,1.8,,,
,tCr,tCr,2020_zhang_33,40,Healthy,10.1002/nbm.4313,,,12.5,1.9,,,
,tCr,tCr,2020_zhang_33,41,Healthy,10.1002/nbm.4313,,,9.6,2,,,
,tCr,tCr,2020_zhang_33,42,Healthy,10.1002/nbm.4313,,,11.1,2,,,
,tCr,tCr,2020_zhang_33,43,Healthy,10.1002/nbm.4313,,,9.5,1.1,,,
,tCr,tCr,2020_zhang_33,44,Healthy,10.1002/nbm.4313,,,10.4,1,,,
,tCr,tCr,2020_zhang_33,45,Healthy,10.1002/nbm.4313,,,11.3,0.7,,,
,tCr,tCr,2020_zhang_33,46,Healthy,10.1002/nbm.4313,,,11.9,0.9,,,
,tCr,tCr,2020_zhang_33,47,Healthy,10.1002/nbm.4313,,,13.4,1.6,,,
,Cre,tCr,2020_gules_79,1,MDD,10.1159/000505782,,,4.82,1.52,,,Assumed Total (tCr) based on Analysis
,Cre,tCr,2020_gules_79,2,Healthy Control,10.1159/000505782,,,2.73,1.27,,,Assumed Total (tCr) based on Analysis
,tCr,tCr,2016_howells_31,1,In utero alcohol exposure,10.1007/s11011-016-9850-x,,,,,2.81,0.93,
,tCr,tCr,2016_howells_31,2,In utero alcohol exposure,10.1007/s11011-016-9850-x,,,,,3.49,0.49,
,tCr,tCr,2016_howells_31,3,In utero alcohol exposure - Female,10.1007/s11011-016-9850-x,,,,,2.72,1.06,
,tCr,tCr,2016_howells_31,4,In utero alcohol exposure - Female,10.1007/s11011-016-9850-x,,,,,3.45,0.57,
,tCr,tCr,2016_howells_31,5,In utero alcohol exposure - Male,10.1007/s11011-016-9850-x,,,,,2.91,0.82,
,tCr,tCr,2016_howells_31,6,In utero alcohol exposure - Male,10.1007/s11011-016-9850-x,,,,,3.52,0.42,
,tCr,tCr,2016_howells_31,7,Infants - Control,10.1007/s11011-016-9850-x,,,,,3.1,0.54,
,tCr,tCr,2016_howells_31,8,Infants - Control,10.1007/s11011-016-9850-x,,,,,3.45,0.63,
,tCr,tCr,2016_howells_31,9,Infants - Control_Female,10.1007/s11011-016-9850-x,,,,,2.99,0.55,
,tCr,tCr,2016_howells_31,10,Infants - Control_Female,10.1007/s11011-016-9850-x,,,,,3.01,0.79,
,tCr,tCr,2016_howells_31,11,Infants - Control_Male,10.1007/s11011-016-9850-x,,,,,3.27,0.5,
,tCr,tCr,2016_howells_31,12,Infants - Control_Male,10.1007/s11011-016-9850-x,,,,,3.64,0.44,
,Cr,Cre,2020_su_71,1,Healthy Controls,10.1016/j.jocn.2019.11.021,,,3.85,0.93,,,
,Cr,Cre,2020_su_71,2,Methamphetamine Dependence,10.1016/j.jocn.2019.11.021,,,3.19,1.16,,,
,PCr,PCr,2020_su_71,1,Healthy Controls,10.1016/j.jocn.2019.11.021,,,6.17,1.08,,,
,Pcr,PCr,2020_su_71,2,Methamphetamine Dependence,10.1016/j.jocn.2019.11.021,,,5.11,1.59,,,
,tCr,tCr,2016_koob_11,1,Premature Neonates,10.1371/journal.pone.0160990,,,0.099,0.018,,,
,tCr,tCr,2016_koob_11,2,Premature Neonates,10.1371/journal.pone.0160990,,,0.053,0.012,,,
,tCr,tCr,2016_koob_11,3,Infants - Control,10.1371/journal.pone.0160990,,,0.112,0.027,,,
,tCr,tCr,2016_koob_11,4,Infants - Control,10.1371/journal.pone.0160990,,,0.064,0.011,,,
,Cr + PCr,tCr,2020_su_71,1,Healthy Controls,10.1016/j.jocn.2019.11.021,,,9.81,1.1,,,
,Cr + PCr,tCr,2020_su_71,2,Methamphetamine Dependence,10.1016/j.jocn.2019.11.021,,,7.81,1,,,
,tCr,tCr,2016_mazuel_278,1,Parkinson's Disease - Drug-on,10.1148/radiol.2015142764,,,8.1,1.3,,,
,tCr,tCr,2016_mazuel_278,2,Parkinson's Disease - Drug-off,10.1148/radiol.2015142764,,,7.5,0.9,,,
,tCr,tCr,2016_mazuel_278,3,Control,10.1148/radiol.2015142764,,,8.3,1.3,,,
,tCr,tCr,2019_marjanska_68,1,Alzheimer's disease,10.3233/JAD-180861,,,,,9.86,1,
,tCr,tCr,2019_marjanska_68,2,Alzheimer's disease,10.3233/JAD-180861,,,,,9.84,1,
,tCr,tCr,2019_marjanska_68,3,Control,10.3233/JAD-180861,,,,,9.7,0.977,
,tCr,tCr,2019_marjanska_68,4,Control,10.3233/JAD-180861,,,,,9.62,0.977,
,Cr,Cre,2020_basu_10,1,Preterm Infants,10.1038/s41598-020-67188-y,,,3.54,0.11,,,
,Cr,Cre,2020_basu_10,4,Preterm Infants,10.1038/s41598-020-67188-y,,,3.73,0.15,,,
,Cr,Cre,2020_basu_10,7,Preterm Infants,10.1038/s41598-020-67188-y,,,3.34,0.14,,,
,Cr,Cre,2020_basu_10,10,Preterm Infants,10.1038/s41598-020-67188-y,,,3.68,0.15,,,
,Cr,Cre,2020_basu_10,13,Preterm Infants,10.1038/s41598-020-67188-y,,,3.43,0.15,,,
,tCr,tCr,2020_archibald_10,1,Baseline,10.1038/s41598-020-76263-3,,,,,7.65,0.15,
,tCr,tCr,2020_archibald_10,2,Baseline 2,10.1038/s41598-020-76263-3,,,,,8.07,0.16,
,tCr,tCr,2020_archibald_10,3,Baseline 4,10.1038/s41598-020-76263-3,,,,,7.69,0.15,
,tCr,tCr,2020_archibald_10,4,Baseline 6,10.1038/s41598-020-76263-3,,,,,7.79,0.16,
,tCr,tCr,2020_archibald_10,5,Baseline 8,10.1038/s41598-020-76263-3,,,,,7.63,0.15,
,tCr,tCr,2020_archibald_10,6,Heat 10,10.1038/s41598-020-76263-3,,,,,7.54,0.15,
,tCr,tCr,2020_archibald_10,7,Heat 12,10.1038/s41598-020-76263-3,,,,,7.62,0.15,
,tCr,tCr,2020_archibald_10,8,Post Heat 14,10.1038/s41598-020-76263-3,,,,,7.26,0.14,
,tCr,tCr,2020_archibald_10,9,Post Heat 16,10.1038/s41598-020-76263-3,,,,,7.81,0.16,
,tCr,tCr,2020_archibald_10,10,Post Heat 18,10.1038/s41598-020-76263-3,,,,,7.56,0.15,
,tCr,tCr,2020_archibald_10,11,Post Heat 20,10.1038/s41598-020-76263-3,,,,,7.67,0.15,
,tCr,tCr,2019_mellen_27,1,Bipolar disorder - Older age bipolar depression,10.1016/j.jagp.2019.02.017,,,,,,,
,tCr,tCr,2019_mellen_27,2,Bipolar disorder - Older age bipolar depression,10.1016/j.jagp.2019.02.017,,,,,,,
,tCr,tCr,2019_mellen_27,3,Control,10.1016/j.jagp.2019.02.017,,,,,,,
,tCr,tCr,2019_mellen_27,4,Control,10.1016/j.jagp.2019.02.017,,,,,,,
,tCr,tCr,2019_meyer_10,1,Control,10.3389/fneur.2019.00556,,,,,71.87,11.15,
,tCr,tCr,2019_meyer_10,2,Control,10.3389/fneur.2019.00556,,,,,71.2,17.8,
,tCr,tCr,2019_meyer_10,3,Concussion,10.3389/fneur.2019.00556,,,,,61.88,40.68,
,tCr,tCr,2019_meyer_10,4,Concussion,10.3389/fneur.2019.00556,,,,,69.49,11.56,
,tCr,tCr,2019_meyer_10,5,Concussion,10.3389/fneur.2019.00556,,,,,69.69,10.2,
,tCr,tCr,2019_meyer_10,6,Concussion,10.3389/fneur.2019.00556,,,,,61.72,11.49,
,tCr,tCr,2019_meyer_10,7,Concussion,10.3389/fneur.2019.00556,,,,,66.31,6.16,
,tCr,tCr,2019_meyer_10,8,Concussion,10.3389/fneur.2019.00556,,,,,63.37,15.47,
,Cre,tCr,2019_mikkelsen_191,1,Healthy,10.1016/j.neuroimage.2019.02.059,,,15.78,1.36,,,
,Cre,tCr,2019_mikkelsen_191,2,Healthy,10.1016/j.neuroimage.2019.02.059,,,15.21,0.84,,,
,Cre,tCr,2019_mikkelsen_191,3,Healthy,10.1016/j.neuroimage.2019.02.059,,,13.77,0.99,,,
,Cre,tCr,2019_mikkelsen_191,4,Healthy,10.1016/j.neuroimage.2019.02.059,,,14.28,0.72,,,
,Cre,tCr,2019_mikkelsen_191,5,Healthy,10.1016/j.neuroimage.2019.02.059,,,13.91,0.54,,,
,Cre,tCr,2019_mikkelsen_191,6,Healthy,10.1016/j.neuroimage.2019.02.059,,,13.17,1.04,,,
,Cre,tCr,2019_mikkelsen_191,7,Healthy,10.1016/j.neuroimage.2019.02.059,,,15.2,0.79,,,
,Cre,tCr,2019_mikkelsen_191,8,Healthy,10.1016/j.neuroimage.2019.02.059,,,14.96,0.58,,,
,Cre,tCr,2019_mikkelsen_191,9,Healthy,10.1016/j.neuroimage.2019.02.059,,,14.58,1.2,,,
,Cre,tCr,2019_mikkelsen_191,10,Healthy,10.1016/j.neuroimage.2019.02.059,,,15.49,0.95,,,
,Cre,tCr,2019_mikkelsen_191,11,Healthy,10.1016/j.neuroimage.2019.02.059,,,15.7,0.92,,,
,Cre,tCr,2019_mikkelsen_191,12,Healthy,10.1016/j.neuroimage.2019.02.059,,,15.25,1.29,,,
,Cre,tCr,2019_mikkelsen_191,13,Healthy,10.1016/j.neuroimage.2019.02.059,,,16.02,0.74,,,
,Cre,tCr,2019_mikkelsen_191,14,Healthy,10.1016/j.neuroimage.2019.02.059,,,15.27,1.07,,,
,Cre,tCr,2019_mikkelsen_191,15,Healthy,10.1016/j.neuroimage.2019.02.059,,,17.81,1.58,,,
,Cre,tCr,2019_mikkelsen_191,16,Healthy,10.1016/j.neuroimage.2019.02.059,,,16.02,0.51,,,
,Cre,tCr,2019_mikkelsen_191,17,Healthy,10.1016/j.neuroimage.2019.02.059,,,18.69,0.69,,,
,Cre,tCr,2019_mikkelsen_191,18,Healthy,10.1016/j.neuroimage.2019.02.059,,,15.09,1.26,,,
,Cre,tCr,2019_mikkelsen_191,19,Healthy,10.1016/j.neuroimage.2019.02.059,,,16.16,1.55,,,
,Cre,tCr,2019_mikkelsen_191,20,Healthy,10.1016/j.neuroimage.2019.02.059,,,20.13,1.12,,,
,Cre,tCr,2019_mikkelsen_191,21,Healthy,10.1016/j.neuroimage.2019.02.059,,,23.57,0.44,,,
,Cre,tCr,2019_mikkelsen_191,22,Healthy,10.1016/j.neuroimage.2019.02.059,,,20.28,1.33,,,
,Cre,tCr,2019_mikkelsen_191,23,Healthy,10.1016/j.neuroimage.2019.02.059,,,19.02,0.71,,,
,Cre,tCr,2019_mikkelsen_191,24,Healthy,10.1016/j.neuroimage.2019.02.059,,,19.66,2.21,,,
,Cre,tCr,2019_mikkelsen_191,25,Healthy,10.1016/j.neuroimage.2019.02.059,,,19.77,0.73,,,
,Cre,tCr,2019_mikkelsen_191,26,Healthy,10.1016/j.neuroimage.2019.02.059,,,18.81,1.22,,,
,Cre,tCr,2019_mikkelsen_191,27,Healthy,10.1016/j.neuroimage.2019.02.059,,,21.08,0.7,,,
,Cre,tCr,2019_mikkelsen_191,28,Healthy,10.1016/j.neuroimage.2019.02.059,,,20.03,1.64,,,
,Cre,tCr,2019_mikkelsen_191,29,Healthy,10.1016/j.neuroimage.2019.02.059,,,16.83,2.66,,,
,tCr,tCr,2019_parmar_73,1,Obsessive-compulsive disorder - Unmedicated - 10mg escitalopram - Baseline,10.1111/pcn.12850,,,8.03,0.69,,,
,tCr,tCr,2019_parmar_73,2,Obsessive-compulsive disorder - Unmedicated - 10mg escitalopram - 12wk,10.1111/pcn.12850,,,8.3,1.29,,,
,tCr,tCr,2019_parmar_73,3,Control,10.1111/pcn.12850,,,8.6,1.09,,,
,tCr,tCr,2019_parmar_73,4,Obsessive-compulsive disorder - Unmedicated - 10mg escitalopram - Baseline,10.1111/pcn.12850,,,6.57,1.21,,,
,tCr,tCr,2019_parmar_73,5,Obsessive-compulsive disorder - Unmedicated - 10mg escitalopram - 12wk,10.1111/pcn.12850,,,6.74,1.15,,,
,tCr,tCr,2019_parmar_73,6,Control,10.1111/pcn.12850,,,6.54,0.96,,,
,tCr,tCr,2019_parmar_73,7,Obsessive-compulsive disorder - Unmedicated - 10mg escitalopram - Baseline,10.1111/pcn.12850,,,6.88,1.07,,,
,tCr,tCr,2019_parmar_73,8,Obsessive-compulsive disorder - Unmedicated - 10mg escitalopram - 12wk,10.1111/pcn.12850,,,6.71,0.97,,,
,tCr,tCr,2019_parmar_73,9,Control,10.1111/pcn.12850,,,6.56,1.12,,,
,Cre,Cre,2019_pflugrad_14,1,Chronic liver disease - Before OLT,10.1371/journal.pone.0221626,,,3.61,0.5,,,
,Cre,Cre,2019_pflugrad_14,2,Chronic liver disease - Before OLT,10.1371/journal.pone.0221626,,,4.32,0.49,,,
,Cre,Cre,2019_pflugrad_14,3,Chronic liver disease - Before OLT,10.1371/journal.pone.0221626,,,3.3,,,,"Median,IQR (3.3, .50)"
,Cre,Cre,2019_pflugrad_14,4,Chronic liver disease - Before OLT_PTE,10.1371/journal.pone.0221626,,,3.47,0.48,,,
,Cre,Cre,2019_pflugrad_14,5,Chronic liver disease - Before OLT_PTE,10.1371/journal.pone.0221626,,,4.17,0.34,,,
,Cre,Cre,2019_pflugrad_14,6,Chronic liver disease - Before OLT_PTE,10.1371/journal.pone.0221626,,,3.34,,,,"Median,IQR (3.34, .30)"
,Cre,Cre,2019_pflugrad_14,7,Chronic liver disease - Before OLT_no PTE,10.1371/journal.pone.0221626,,,3.77,0.47,,,
,Cre,Cre,2019_pflugrad_14,8,Chronic liver disease - Before OLT_no PTE,10.1371/journal.pone.0221626,,,4.45,0.53,,,
,Cre,Cre,2019_pflugrad_14,9,Chronic liver disease - Before OLT_no PTE,10.1371/journal.pone.0221626,,,3.25,,,,"Median,IQR (3.25, .58)"
,Cre,Cre,2019_pflugrad_14,10,Control,10.1371/journal.pone.0221626,,,3.41,0.39,,,
,Cre,Cre,2019_pflugrad_14,11,Control,10.1371/journal.pone.0221626,,,3.83,0.36,,,
,Cre,Cre,2019_pflugrad_14,12,Control,10.1371/journal.pone.0221626,,,3.23,,,,"Median,IQR (3.23, .26)"
,Cre,Cre,2019_pflugrad_14,13,Chronic liver disease - After OLT,10.1371/journal.pone.0221626,,,3.34,0.38,,,
,Cre,Cre,2019_pflugrad_14,14,Chronic liver disease - After OLT,10.1371/journal.pone.0221626,,,3.99,0.82,,,
,Cre,Cre,2019_pflugrad_14,15,Chronic liver disease - After OLT,10.1371/journal.pone.0221626,,,3.26,,,,"Median,IQR (3.26, .47)"
,Cre,Cre,2019_pflugrad_14,16,Chronic liver disease - After OLT_PTE,10.1371/journal.pone.0221626,,,3.32,0.38,,,
,Cre,Cre,2019_pflugrad_14,17,Chronic liver disease - After OLT_PTE,10.1371/journal.pone.0221626,,,3.86,0.75,,,
,Cre,Cre,2019_pflugrad_14,18,Chronic liver disease - After OLT_PTE,10.1371/journal.pone.0221626,,,3.28,,,,"Median,IQR (3.28, .56)"
,Cre,Cre,2019_pflugrad_14,19,Chronic liver disease - After OLT_no PTE,10.1371/journal.pone.0221626,,,3.36,0.4,,,
,Cre,Cre,2019_pflugrad_14,20,Chronic liver disease - After OLT_no PTE,10.1371/journal.pone.0221626,,,4.06,0.86,,,
,Cre,Cre,2019_pflugrad_14,21,Chronic liver disease - After OLT_no PTE,10.1371/journal.pone.0221626,,,3.25,,,,"Median,IQR (3.25, .46)"
,Cr,Cre,2021_rowe_133,1,LOGG,10.1016/j.ymgme.2021.06.008,,,,,8.2,0.71,
,Cr,Cre,2021_rowe_133,4,LOTS,10.1016/j.ymgme.2021.06.008,,,,,7.82,0.41,
,Cr,Cre,2021_rowe_133,7,LOSD,10.1016/j.ymgme.2021.06.008,,,,,9.09,0.27,
,Cr,Cre,2021_rowe_133,10,Control,10.1016/j.ymgme.2021.06.008,,,,,8.69,0.51,
,tCr,tCr,2021_shiga_30,1,Non-progression,10.1016/j.jstrokecerebrovasdis.2021.105747,,,,,1.25,0.13,
,tCr,tCr,2021_shiga_30,2,Non-progression,10.1016/j.jstrokecerebrovasdis.2021.105747,1.02,0.19,,,,,
,tCr,tCr,2021_shiga_30,3,Progression,10.1016/j.jstrokecerebrovasdis.2021.105747,,,,,1.25,0.09,
,tCr,tCr,2021_shiga_30,4,Progression,10.1016/j.jstrokecerebrovasdis.2021.105747,1.01,0.1,,,,,
,Cre,Cre,2021_siegel-ramsay_313,1,Control,10.1016/j.pscychresns.2021.111302,,,7.54,0.56,,,
,Cre,Cre,2021_siegel-ramsay_313,2,Autism,10.1016/j.pscychresns.2021.111302,,,7.47,0.91,,,
,Cr,Cre,2020_colizzi_25,1,Healthy,10.1038/s41380-019-0374-8,,,3.5,0.89,,,
,Cr,Cre,2020_colizzi_25,2,Healthy,10.1038/s41380-019-0374-8,,,2.62,0.62,,,
,Cr,Cre,2020_colizzi_25,3,Healthy,10.1038/s41380-019-0374-8,,,4.19,0.75,,,
,Cr,Cre,2020_colizzi_25,4,Psychosis ,10.1038/s41380-019-0374-8,,,3.37,0.62,,,
,Cr,Cre,2020_colizzi_25,5,Psychosis ,10.1038/s41380-019-0374-8,,,2.75,0.45,,,
,Cr,Cre,2020_colizzi_25,6,Psychosis ,10.1038/s41380-019-0374-8,,,4.06,0.68,,,
,Cr,Cre,2021_steinegger_26,1,Control,10.1111/adb.13027,,,,,11,0.82,
,Cr,Cre,2021_steinegger_26,4,Smokers,10.1111/adb.13027,,,,,10.48,0.87,
,Cr,Cre,2021_steinegger_26,6,Baseline,10.1111/adb.13027,,,,,10.44,0.97,
,Cr,Cre,2021_steinegger_26,7,Withdrawal,10.1111/adb.13027,,,,,10.49,2.22,
,Cr,Cre,2021_steinegger_26,8,Satiation,10.1111/adb.13027,,,,,10.71,1.15,
,Cr,Cre,2021_wang_59,1,Control,10.1016/j.mito.2021.06.012,,,,,6.57,0.52,
,Cr,Cre,2021_wang_59,2,Control,10.1016/j.mito.2021.06.013,,,,,6.57,0.52,
,Cr,Cre,2021_wang_59,3,MELAS,10.1016/j.mito.2021.06.014,,,,,6.73,1.36,
,Cr,Cre,2021_wood_11,1,ASD,10.1038/s41398-020-01154-0,,,,,2,0.19,
,Cr,Cre,2021_wood_11,2,ASD,10.1038/s41398-020-01154-0,,,,,4,0.63,
,Cr,Cre,2021_wood_11,3,TD,10.1038/s41398-020-01154-0,,,,,2,0.14,
,Cr,Cre,2021_wood_11,4,TD,10.1038/s41398-020-01154-0,,,,,4,0.52,
,Cr,Cre,2021_younis_41,1,Baseline,10.1177/0271678X20906902,,,,,4.57,0.09,
,Cr,Cre,2021_younis_41,2,Migraine attack ,10.1177/0271678X20906902,,,,,4.73,0.08,
,Cr,Cre,2021_mansur_281,1,Placebo,10.1016/j.jad.2020.11.128,,,,,4.25,0.21,
,Cr,Cre,2021_mansur_281,2,Infliximab,10.1016/j.jad.2020.11.128,,,,,4.27,0.39,
,Cre,Cre,2019_prisci_43,1,Alcohol use disorder ,10.1111/acer.13931,,,3.6,0.36,,,
,Cre,Cre,2019_prisci_43,2,Control,10.1111/acer.13931,,,3.4,0.67,,,
,tCr,tCr,2019_schmitz_49,1,Control,10.1111/apt.15256,,,4.305,0.381,,,
,tCr,tCr,2019_schmitz_49,2,Liver transplantation - Calcineurin inhibitor free,10.1111/apt.15256,,,4.371,0.593,,,
,tCr,tCr,2019_schmitz_49,3,Liver transplantation - Calcineurin inhibitor low-dose,10.1111/apt.15256,,,4.319,0.558,,,
,tCr,tCr,2019_schmitz_49,4,Liver transplantation - Calcineurin inhibitor standard-dose,10.1111/apt.15256,,,4.377,0.506,,,
,tCr,tCr,2019_sheth_248,1,PTSD,10.1016/j.jad.2019.01.037,,,2.11,,,,
,tCr,tCr,2019_sheth_248,2,Trauma-exposed ,10.1016/j.jad.2019.01.037,,,2.15,,,,
,tCr,tCr,2019_sheth_248,3,Control,10.1016/j.jad.2019.01.037,,,2.19,,,,
,Cr+PCr,tCr,2019_smaragdi_93,1,ASPD - DLPFC,10.1016/j.pnpbp.2019.04.002,,,,,8.59,0.85,
,Cr+PCr,tCr,2019_smaragdi_93,2,ASPD - ACC,10.1016/j.pnpbp.2019.04.002,,,,,9.54,1.32,
,Cr+PCr,tCr,2019_smaragdi_93,3,BD - DLPFC,10.1016/j.pnpbp.2019.04.002,,,,,8.14,0.91,
,Cr+PCr,tCr,2019_smaragdi_93,4,BD - ACC,10.1016/j.pnpbp.2019.04.002,,,,,9.57,0.81,
,Cr+PCr,tCr,2019_smaragdi_93,5,HC - DLPFC,10.1016/j.pnpbp.2019.04.002,,,,,8.11,0.91,
,Cr+PCr,tCr,2019_smaragdi_93,6,HC - ACC,10.1016/j.pnpbp.2019.04.002,,,,,9.48,0.65,
,tCr,tCr,2019_starmose_20,1,Control,10.1186/s10194-019-1059-z,,,6.241,0.369,,,
,tCr,tCr,2019_starmose_20,2,Control,10.1186/s10194-019-1059-z,,,5.937,0.388,,,
,tCr,tCr,2019_starmose_20,3,Migraine with aura,10.1186/s10194-019-1059-z,,,6.009,0.446,,,
,tCr,tCr,2019_starmose_20,4,Migraine with aura,10.1186/s10194-019-1059-z,,,5.747,0.264,,,
,Cr,Cre,2019_su_29,1,PTSD,10.1007/s00330-018-5615-8,,,,,8.3,1.12,
,Cr,Cre,2019_su_29,4,non-PTSD,10.1007/s00330-018-5615-8,,,,,8.19,1.33,
,Cr,Cre,2019_su_29,2,PTSD,10.1007/s00330-018-5615-8,,,,,9.03,1.56,
,Cr,Cre,2019_su_29,5,non-PTSD,10.1007/s00330-018-5615-8,,,,,7.82,1.14,
,Cr,Cre,2019_su_29,3,PTSD,10.1007/s00330-018-5615-8,,,,,8.65,1.65,
,Cr,Cre,2019_su_29,6,non-PTSD,10.1007/s00330-018-5615-8,,,,,7.89,1.2,
,Cr,Cre,2019_wagoner_317,1,Non-OI,10.1152/ajpheart.00680.2018,,,4.4,1.852,,,
,Cr,Cre,2019_wagoner_317,2,OI,10.1152/ajpheart.00680.2018,,,5.4,0.663,,,
,tCr,tCr,2019_wang_28,1,PTSD,10.1007/s00787-018-1241-x,,,,,8.25,1.44,
,tCr,tCr,2019_wang_28,2,PTSD,10.1007/s00787-018-1241-x,,,,,8.7,1.62,
,tCr,tCr,2019_wang_28,3,Non-PTSD,10.1007/s00787-018-1241-x,,,,,8.39,1.45,
,tCr,tCr,2019_wang_28,4,Non-PTSD,10.1007/s00787-018-1241-x,,,,,7.13,1.1,
,Cre,Cre,2018_horowitz-kraus_12,1,Control,10.3389/fnhum.2018.00466,,,,,7.99,0.55,
,Cre,Cre,2018_horowitz-kraus_12,2,Dyslexia,10.3389/fnhum.2018.00466,,,,,8.08,0.39,
,tCr,tCr,2018_povazan_79,1,Healthy,10.1002/mrm.26778,,,9.4,0.96,,,
,tCr,tCr,2018_povazan_79,2,Healthy,10.1002/mrm.26778,,,10.07,1.02,,,
,tCr,tCr,2018_povazan_79,3,Healthy,10.1002/mrm.26778,,,9.93,1.16,,,
,tCr,tCr,2018_povazan_79,4,Healthy,10.1002/mrm.26778,,,9.79,0.92,,,
,tCr,tCr,2018_povazan_79,5,Healthy,10.1002/mrm.26778,,,9.4,0.82,,,
,tCr,tCr,2018_povazan_79,6,Healthy,10.1002/mrm.26778,,,9.01,1.92,,,
,tCr,tCr,2018_povazan_79,7,Healthy,10.1002/mrm.26778,,,9.35,0.76,,,
,Cre,Cre,2020_mazibuko_10,1,Control,10.3390/diagnostics10070482,,,7.08,0.66,,,
,Cre,Cre,2020_mazibuko_10,2,Control,10.3390/diagnostics10070482,,,6.92,2.14,,,
,Cre,Cre,2020_mazibuko_10,3,Subacute Ischemic Stroke,10.3390/diagnostics10070482,,,5.63,0.36,,,
,Cre,Cre,2020_mazibuko_10,4,Subacute Ischemic Stroke,10.3390/diagnostics10070482,,,6.63,2.19,,,
,Cre,Cre,2020_mazibuko_10,5,Subacute Ischemic Stroke ,10.3390/diagnostics10070482,,,6.31,1.33,,,
,Cre,Cre,2020_mazibuko_10,6,Subacute Ischemic Stroke ,10.3390/diagnostics10070482,,,6.86,2.82,,,
,Cre,Cre,2020_mazibuko_10,7,Subacute Ischemic Stroke ,10.3390/diagnostics10070482,,,7.38,1.75,,,
,Cre,Cre,2020_mazibuko_10,8,Subacute Ischemic Stroke ,10.3390/diagnostics10070482,,,6.14,3.2,,,
,tCre,tCr,2020_menshchikov_84,2,Mild Traumatic Brain Injury ,10.1002/mrm.28332,,,,,7.08,0.43,
,tCre,tCr,2020_menshchikov_84,1,Control,10.1002/mrm.28332,,,,,6.98,0.48,
,tCre,tCr,2019_wiegers_62,1,Control,10.1007/s00125-019-4862-9,,,,,6.94,0.41,
,tCre,tCr,2019_wiegers_62,2,Type 1 diabetes - Normal awareness of hypoglycaemia,10.1007/s00125-019-4862-9,,,,,6.92,0.51,
,tCre,tCr,2019_wiegers_62,3,Type 1 diabetes,10.1007/s00125-019-4862-9,,,,,7.07,0.44,
,tCr,tCr,2020_gonen_14,1,Healthy,10.3389/fnins.2020.566643,,,,,8.94,0.78,
,tCr,tCr,2020_gonen_14,2,Healthy,10.3389/fnins.2020.566643,,,,,8.54,0.67,
,tCr,tCr,2020_gonen_14,3,Healthy,10.3389/fnins.2020.566643,,,,,8.81,0.63,
,tCr,tCr,2020_gonen_14,4,Healthy,10.3389/fnins.2020.566643,,,,,9,1.34,
,Cre,Cre,2019_morgenroth_117,4,Trait Anxiety,10.1016/j.cortex.2019.02.021,,,6.47,0.52,,,
,Cre,Cre,2019_morgenroth_117,5,Trait Anxiety - Low trait anxiety,10.1016/j.cortex.2019.02.021,,,6.57,0.44,,,
,Cre,Cre,2019_morgenroth_117,6,Trait Anxiety - High trait anxiety,10.1016/j.cortex.2019.02.021,,,6.37,0.59,,,
,Cr,Cre,2018_su_241,1,Control,10.1016/j.jad.2018.08.018,,,,,8.19,1.33,
,Cr,Cre,2018_su_241,2,Control,10.1016/j.jad.2018.08.018,,,,,7.82,1.14,
,Cr,Cre,2018_su_241,3,Control,10.1016/j.jad.2018.08.018,,,,,7.89,1.2,
,Cr,Cre,2018_su_241,4,PTSD,10.1016/j.jad.2018.08.018,,,,,8.3,1.12,
,Cr,Cre,2018_su_241,5,PTSD,10.1016/j.jad.2018.08.018,,,,,9.03,1.56,
,Cr,Cre,2018_su_241,6,PTSD,10.1016/j.jad.2018.08.018,,,,,8.65,1.65,
,tCr,tCr,2019_nery_21,1,At risk for bipolar disorder,10.1111/bdi.12770,,,,,6.63,1.03,
,tCr,tCr,2019_nery_21,2,At risk for bipolar disorder,10.1111/bdi.12770,,,,,7.4,1.13,
,tCr,tCr,2019_nery_21,3,At risk for bipolar disorder,10.1111/bdi.12770,,,,,6.91,1.12,
,tCr,tCr,2019_nery_21,4,Control,10.1111/bdi.12770,,,,,6.73,1.13,
,tCr,tCr,2019_nery_21,5,Control,10.1111/bdi.12770,,,,,7.58,1.06,
,tCr,tCr,2019_nery_21,6,Control,10.1111/bdi.12770,,,,,6.91,1.24,
,tCr,tCr,2019_nery_21,7,At risk for bipolar disorder - Before first mood episode,10.1111/bdi.12770,,,,,6.03,0.92,
,tCr,tCr,2019_nery_21,8,At risk for bipolar disorder - Before first mood episode,10.1111/bdi.12770,,,,,6.69,1.26,
,tCr,tCr,2019_nery_21,9,At risk for bipolar disorder - Before first mood episode,10.1111/bdi.12770,,,,,6.56,1.13,
,tCr,tCr,2019_nery_21,10,At risk for bipolar disorder - After first mood episode,10.1111/bdi.12770,,,,,6.57,0.74,
,tCr,tCr,2019_nery_21,11,At risk for bipolar disorder - After first mood episode,10.1111/bdi.12770,,,,,7.02,0.72,
,tCr,tCr,2019_nery_21,12,At risk for bipolar disorder - After first mood episode,10.1111/bdi.12770,,,,,7.15,1.4,
,tCr,tCr,2019_nery_21,13,Control,10.1111/bdi.12770,,,,,6.5,0.74,
,tCr,tCr,2019_nery_21,14,Control,10.1111/bdi.12770,,,,,7.53,0.87,
,tCr,tCr,2019_nery_21,15,Control,10.1111/bdi.12770,,,,,6.99,1.65,
,tCr,tCr,2019_nery_21,16,Control,10.1111/bdi.12770,,,,,6.4,1.03,
,tCr,tCr,2019_nery_21,17,Control,10.1111/bdi.12770,,,,,6.88,1.3,
,tCr,tCr,2019_nery_21,18,Control,10.1111/bdi.12770,,,,,6.58,1.09,
,tCr,tCr,2018_tiwari_80,1,Healthy,10.1002/mrm.27142,,,,,8,0.57,
,tCr,tCr,2018_tiwari_80,2,Healthy,10.1002/mrm.27142,,,,,6.05,0.43,
,tCr,tCr,2018_tiwari_80,3,Healthy,10.1002/mrm.27142,,,,,8.3,0.66,
,tCr,tCr,2018_tiwari_80,4,Healthy,10.1002/mrm.27142,,,,,7.81,0.66,
,tCr,tCr,2018_tiwari_80,5,Healthy,10.1002/mrm.27142,,,,,8.08,0.48,
,tCr,tCr,2018_tiwari_80,6,Healthy,10.1002/mrm.27142,,,,,6.28,0.2,Assumed the Reported .02 was a type and that the StdDev was actually .20. This would bring the StdDevs within the range of the other StdDevs reported.
,tCr,tCr,2019_oneill_111,1,Control,10.1002/bdr2.1460,,,3.6,0.9,,,
,tCr,tCr,2019_oneill_111,2,ADHD,10.1002/bdr2.1460,,,3.3,1.1,,,
,tCr,tCr,2019_oneill_111,3,ADHD,10.1002/bdr2.1460,,,3.7,0.6,,,
,tCr,tCr,2019_oneill_111,4,ADHD,10.1002/bdr2.1460,,,4,0.4,,,
,tCr,tCr,2019_oneill_111,5,ADHD,10.1002/bdr2.1460,,,3.8,0.5,,,
,tCr,tCr,2019_oneill_111,6,ADHD,10.1002/bdr2.1460,,,3.7,0.7,,,
,Cre,Cre,2019_reid_45,1,Control,10.1093/schbul/sbx190,,,2.39,0.22,,,
,Cre,Cre,2019_reid_45,2,Schizophrenia,10.1093/schbul/sbx190,,,2.33,0.34,,,
,PCr,PCr,2019_reid_45,1,Control,10.1093/schbul/sbx190,,,3.36,0.35,,,
,PCr,PCr,2019_reid_45,2,Schizophrenia,10.1093/schbul/sbx190,,,3.44,0.43,,,
,tCr,tCr,2019_reid_45,1,Control,10.1093/schbul/sbx190,,,5.74,0.38,,,
,tCr,tCr,2019_reid_45,2,Schizophrenia,10.1093/schbul/sbx190,,,5.73,0.42,,,
,Cre,Cre,2019_tamrazi_40,1,Pediatric atypical teratoid/rhabdoid tumors - ASCL1 Pos.,10.3174/ajnr.A6024,,,3.4,1.1,,,
,Cre,Cre,2019_tamrazi_40,2,Pediatric atypical teratoid/rhabdoid tumors - ASCL1 Neg.,10.3174/ajnr.A6024,,,1.8,0.8,,,
,Cre,Cre,2020_dehghani_83,1,Protocol 1,10.1002/mrm.28066,,,2.33,0.25,,,
,Cre (CH3),,2020_dehghani_83,2,Protocol 2,10.1002/mrm.28066,,,1.28,0.69,,,
,Cre (CH2),,2020_dehghani_83,2,Protocol 2,10.1002/mrm.28066,,,0.7,0.14,,,
,Cre (CH3),,2020_dehghani_83,3,Protocol 3,10.1002/mrm.28066,,,1.35,0.56,,,
,Cre (CH2),,2020_dehghani_83,3,Protocol 3,10.1002/mrm.28066,,,0.67,0.2,,,
,Cre,Cre,2020_demnitz_295,1,Addiction ,10.1016/j.pscychresns.2019.111019,,,,,9.23,1.53,
,Cre,Cre,2020_coughlin_26,1,Control,10.1038/s41380-020-00901-5,,,5.14,0.46,,,
,Cre,Cre,2020_coughlin_26,4,Schizophrenia,10.1038/s41380-020-00901-5,,,4.87,0.8,,,
,tCr,tCr,2020_lind_40,1,Control,10.1523/JNEUROSCI.2883-19.2020,,,,,6.96,0.34,
,tCr,tCr,2020_lind_40,2,Aging,10.1523/JNEUROSCI.2883-19.2020,,,,,7.2,0.71,
,tCr,tCr,2020_lind_40,3,Aging,10.1523/JNEUROSCI.2883-19.2020,,,,,7.6,0.5,
,tCr,tCr,2020_lind_40,4,Control,10.1523/JNEUROSCI.2883-19.2020,,,,,6.79,0.5,
,tCr,tCr,2020_lind_40,5,Aging,10.1523/JNEUROSCI.2883-19.2020,,,,,6.99,0.49,
,tCr,tCr,2020_lind_40,6,Aging,10.1523/JNEUROSCI.2883-19.2020,,,,,7.07,0.48,
,tCr,tCr,2020_lind_40,7,Control,10.1523/JNEUROSCI.2883-19.2020,,,,,6.29,0.51,
,tCr,tCr,2020_lind_40,8,Aging,10.1523/JNEUROSCI.2883-19.2020,,,,,6.12,0.51,
,tCr,tCr,2020_lind_40,9,Aging,10.1523/JNEUROSCI.2883-19.2020,,,,,6.99,0.74,
,tCr,tCr,2020_lind_40,10,Control,10.1523/JNEUROSCI.2883-19.2020,,,,,6.13,0.67,
,tCr,tCr,2020_lind_40,11,Aging,10.1523/JNEUROSCI.2883-19.2020,,,,,5.84,0.52,
,tCr,tCr,2020_lind_40,12,Aging,10.1523/JNEUROSCI.2883-19.2020,,,,,6.13,0.9,
,Cre,Cre,2020_draganov_266,1,Control,10.1016/j.jad.2020.01.138,,,,,5.67,0.9,
,Cre,Cre,2020_draganov_266,2,Depression,10.1016/j.jad.2020.01.138,,,,,5.67,0.8,
,Cre,Cre,2020_draganov_266,3,Depression,10.1016/j.jad.2020.01.138,,,,,5.64,0.7,
,Cre,Cre,2020_draganov_266,4,Depression,10.1016/j.jad.2020.01.138,,,,,5.76,0.66,
,Cre,Cre,2020_macmaster_35,1,Orthopedic Injury,10.1097/HTR.0000000000000535,,,,,6.3,0.48,
,Cre,Cre,2020_macmaster_35,2,Concussion,10.1097/HTR.0000000000000535,,,,,6.29,0.44,
,Cre,Cre,2020_macmaster_35,3,Single Concussion,10.1097/HTR.0000000000000535,,,,,6.32,0.5,
,Cre,Cre,2020_macmaster_35,4,Multiple Concussion,10.1097/HTR.0000000000000535,,,,,6.26,0.4,
,Cre,Cre,2020_macmaster_35,5,Orthopedic Injury,10.1097/HTR.0000000000000535,,,,,6.46,0.51,
,Cre,Cre,2020_macmaster_35,6,Concussion,10.1097/HTR.0000000000000535,,,,,6.48,0.45,
,Cre,Cre,2020_macmaster_35,7,Single Concussion,10.1097/HTR.0000000000000535,,,,,6.54,0.43,
,Cre,Cre,2020_macmaster_35,8,Multiple Concussion,10.1097/HTR.0000000000000535,,,,,6.44,0.48,
,Cr,Cre,2021_jung_17b,1,Control,10.1177/17448069211012833,0.634,0.264,,,,,
,Cr,Cre,2021_jung_17b,2,Fibromyalgia,10.1177/17448069211012833,0.718,0.199,,,,,
,Cr,Cre,2021_jung_17b,3,Control,10.1177/17448069211012833,0.853,0.223,,,,,
,Cr,Cre,2021_jung_17b,4,Fibromyalgia,10.1177/17448069211012833,0.817,0.233,,,,,
,Cr,Cre,2021_jung_17b,5,Control,10.1177/17448069211012833,0.884,0.141,,,,,
,Cr,Cre,2021_jung_17b,6,Fibromyalgia,10.1177/17448069211012833,0.876,0.169,,,,,
,Cr,Cre,2021_jung_17b,7,Control,10.1177/17448069211012833,0.58,0.155,,,,,
,Cr,Cre,2021_jung_17b,8,Fibromyalgia,10.1177/17448069211012833,0.78,0.185,,,,,
,Cr,Cre,2021_jung_17b,9,Control,10.1177/17448069211012833,0.681,0.234,,,,,
,Cr,Cre,2021_jung_17b,10,Fibromyalgia,10.1177/17448069211012833,0.728,0.225,,,,,
,PCr,PCr,2021_jung_17b,1,Control,10.1177/17448069211012833,0.728,0.164,,,,,
,PCr,PCr,2021_jung_17b,2,Fibromyalgia,10.1177/17448069211012833,0.477,0.103,,,,,
,PCr,PCr,2021_jung_17b,7,Control,10.1177/17448069211012833,0.737,0.234,,,,,
,PCr,PCr,2021_jung_17b,8,Fibromyalgia,10.1177/17448069211012833,0.423,0.023,,,,,
,PCr,PCr,2021_jung_17b,9,Control,10.1177/17448069211012833,0.661,0.22,,,,,
,PCr,PCr,2021_jung_17b,10,Fibromyalgia,10.1177/17448069211012833,0.553,0.24,,,,,
,Cre,Cre,2020_kaminski_87,1,Control,10.1016/j.biopsych.2019.07.011,,,4.6,1.02,,,
,Cre,Cre,2020_kaminski_87,2,Schizophrenia - Medicated,10.1016/j.biopsych.2019.07.011,,,4.37,1.01,,,
,Cre,Cre,2020_kaminski_87,3,Schizophrenia - Unmedicated,10.1016/j.biopsych.2019.07.011,,,4.51,0.9,,,
,Cre+PCr,tCr,2020_sheth_123,1,Traumatic Brain Injury,10.1152/jn.00765.2019,,,2.22,0.08,,,
,Cre+PCr,tCr,2020_sheth_123,2,Non Traumatic Brain Injury,10.1152/jn.00765.2019,,,2.04,0.11,,,
,Cr,Cr,2018_giapitzakis_79,1,Healthy,10.1002/mrm.26873,,,,,5.5,1.038,Med/Quartile --> Mean/Std Wan 2014
,Cr,Cr,2018_giapitzakis_79,2,Healthy,10.1002/mrm.26873,,,,,3.76,0.928,Med/Quartile --> Mean/Std Greco 2015
,PCr,PCr,2018_giapitzakis_79,1,Healthy,10.1002/mrm.26873,,,,,4.18,0.875,Med/Quartile --> Mean/Std Greco 2015
,PCr,PCr,2018_giapitzakis_79,2,Healthy,10.1002/mrm.26873,,,,,4.96,1.341,Med/Quartile --> Mean/Std Wan 2014
,tCr,tCr,2018_giapitzakis_79,1,Healthy,10.1002/mrm.26873,,,,,9.8,0.367,Med/Quartile --> Mean/Std Wan 2014
,tCr,tCr,2018_giapitzakis_79,2,Healthy,10.1002/mrm.26873,,,,,8.76,0.593,Med/Quartile --> Mean/Std Greco 2015
,Cre,Cre,2021_egerton_47,1,Psychosis - Antipsychotic responder,10.1093/schbul/sbaa128,,,12.18,2.15,,,
,Cre,Cre,2021_egerton_47,2,Psychosis - Antipsychotic responder,10.1093/schbul/sbaa128,,,9.83,0.99,,,
,Cre,Cre,2021_egerton_47,3,Psychosis - Antipsychotic responder,10.1093/schbul/sbaa128,,,8.83,1.38,,,
,Cre,Cre,2021_egerton_47,4,Psychosis - Antipsychotic responder,10.1093/schbul/sbaa128,,,8.99,1.46,,,
,Cre,Cre,2021_egerton_47,5,Psychosis - Antipsychotic responder,10.1093/schbul/sbaa128,,,12.66,1.51,,,
,Cre,Cre,2021_egerton_47,6,Psychosis - Antipsychotic responder,10.1093/schbul/sbaa128,,,10.1,1.04,,,
,Cre,Cre,2021_egerton_47,7,Psychosis - Antipsychotic responder,10.1093/schbul/sbaa128,,,9.6,0.79,,,
,Cre,Cre,2021_egerton_47,8,Psychosis - Antipsychotic responder,10.1093/schbul/sbaa128,,,8.49,1.24,,,
,Cre,Cre,2021_egerton_47,9,Psychosis - Antipsychotic non-responder,10.1093/schbul/sbaa128,,,8.79,0.89,,,
,Cre,Cre,2021_egerton_47,10,Psychosis - Antipsychotic non-responder,10.1093/schbul/sbaa128,,,7.85,0.64,,,
,Cre,Cre,2021_egerton_47,11,Psychosis - Antipsychotic non-responder,10.1093/schbul/sbaa128,,,6.83,1.16,,,n=6
,Cre,Cre,2021_egerton_47,12,Psychosis - Antipsychotic non-responder,10.1093/schbul/sbaa128,,,4.96,2.67,,,
,Cre,Cre,2021_egerton_47,13,Psychosis - Antipsychotic non-responder,10.1093/schbul/sbaa128,,,8.69,0.85,,,
,Cre,Cre,2021_egerton_47,14,Psychosis - Antipsychotic non-responder,10.1093/schbul/sbaa128,,,7.6,0.56,,,
,Cre,Cre,2021_egerton_47,15,Psychosis - Antipsychotic non-responder,10.1093/schbul/sbaa128,,,5.73,1.06,,,n=4
,Cre,Cre,2021_egerton_47,16,Psychosis - Antipsychotic non-responder,10.1093/schbul/sbaa128,,,7.14,0.45,,,n=4
,Cre,Cre,2016_lopezkolkovsky_75,1,Healthy_Rodent,10.1002/mrm.25602,,,,,4.1,0.4,
,PCr,PCr,2016_lopezkolkovsky_75,1,Healthy_Rodent,10.1002/mrm.25602,,,,,4.9,0.3,
,tCr,tCr,2016_lopezkolkovsky_75,1,Healthy_Rodent,10.1002/mrm.25602,,,,,8.9,0.6,
,tCr,tCr,2018_an_79,1,Glioma - IDH1-mutated grade-II oligodendroglioma,10.1002/mrm.26884,,,6.103,0.443,,,
,tCr,tCr,2018_an_79,2,Glioma - IDH1-mutated grade-II oligodendroglioma,10.1002/mrm.26884,,,3.825,1.38,,,
,tCr,tCr,2018_an_79,3,Glioma - Radiographically suggested glioma,10.1002/mrm.26884,,,6.969,0.996,,,
,tCr,tCr,2018_an_79,4,Glioma - Radiographically suggested glioma,10.1002/mrm.26884,,,5.031,0.524,,,
,tCr,tCr,2018_an_79,5,Glioma - IDH wild-type glioblastoma,10.1002/mrm.26884,,,5.989,1.272,,,
,tCr,tCr,2018_an_79,6,Glioma - IDH wild-type glioblastoma,10.1002/mrm.26884,,,7.473,1.644,,,
,Cr,Cre,2020_tarumi_45,4,Healthy Control,10.1038/s41386-019-0589-z,,,10.45,0.82,,,
,Cr,Cre,2020_tarumi_45,5,Treatment Resistant Schizophrenia ,10.1038/s41386-019-0589-z,,,11.1,0.76,,,
,Cr,Cre,2020_tarumi_45,6,Non-treatment Resistant Schizophrenia ,10.1038/s41386-019-0589-z,,,10.96,0.8,,,
,tCr,tCr,2018_deelchand_79,1,Healthy,10.1002/mrm.26788,,,,,8.385,0.816,
,tCr,tCr,2018_deelchand_79,2,Healthy,10.1002/mrm.26788,,,,,8.731,0.916,
,Cystathionine,CSH,2019_branzoli_21,1,Control,10.1093/neuonc/noz031,,,,,0,0,
,Cystathionine,CSH,2019_branzoli_21,2,IDH_COD,10.1093/neuonc/noz031,,,,,2.6,,0.2–4.1
,Cystathionine,CSH,2019_branzoli_21,3,IDH_Non_COD,10.1093/neuonc/noz031,,,,,1.25,,0.0–3.6
,Cystathionine,CSH,2019_branzoli_82,1,,10.1002/mrm.27810,,,,,2.467,1.277,
,EA,EA,2016_lopezkolkovsky_75,1,Healthy_Rodent,10.1002/mrm.25602,,,,,0.6,0.1,
,GABA+,GABA,2020_benson_274,1,Control,10.1016/j.jad.2020.05.026,0.19,0.03,,,,,
,GABA+,GABA,2020_benson_274,3,Control,10.1016/j.jad.2020.05.026,0.21,0.03,,,,,
,GABA+,GABA,2020_benson_274,4,Insomnia,10.1016/j.jad.2020.05.026,0.19,0.06,,,,,
,GABA+,GABA,2020_benson_274,6,Insomnia,10.1016/j.jad.2020.05.026,0.2,0.05,,,,,
,GABA+,GABA,2020_benson_274,7,Depression,10.1016/j.jad.2020.05.026,0.18,0.04,,,,,
,GABA+,GABA,2020_benson_274,9,Depression,10.1016/j.jad.2020.05.026,0.22,0.04,,,,,
,GABA+,GABA,2019_chan_14,1,Control,10.1371/journal.pone.0208666,,,3.308,0.325,,,
,GABA+,GABA,2019_chan_14,2,Migraine,10.1371/journal.pone.0208666,,,3.42,0.237,,,
,GABA+,GABA,2019_costigan_40,3,Healthy,10.1002/hbm.24566,,,,,1.85,0.27,
,GABA+,GABA,2019_costigan_40,5,Healthy,10.1002/hbm.24566,,,,,1.97,0.19,
,GABA,GABA,2018_adanyeguh_31,1,Healthy,10.1002/nbm.3880,,,,,2.2,1,Estimated Bar Graph
,GABA,GABA,2018_adanyeguh_31,3,HD,10.1002/nbm.3880,,,,,2.4,0.9,Estimated Bar Graph
,GABA+,GABA,2020_li_74,2,POA,10.1111/pcn.12940,,,,,1.34,0.12,
,GABA+,GABA,2020_li_74,3,Control,10.1111/pcn.12940,,,,,1.76,0.27,
,GABA,GABA,2018_an_80,1,Healthy,10.1002/mrm.27172,0.13,0.03,,,,,
,GABA,GABA,2018_bednarik_38,1,Healthy,10.1177/0271678X17695291,,,,,1.12,0.24,
,GABA,GABA,2018_bradley_86,1,Major Depressive Disorder,10.1016/j.pnpbp.2018.06.004,0.005,0.001,,,,,
,GABA,GABA,2018_bradley_86,2,Major Depressive Disorder,10.1016/j.pnpbp.2018.06.004,0.003,0,,,,,
,GABA,GABA,2018_bradley_86,3,Healthy,10.1016/j.pnpbp.2018.06.004,0.004,0,,,,,
,GABA,GABA,2018_bradley_86,4,Healthy,10.1016/j.pnpbp.2018.06.004,0.003,0.001,,,,,
,GABA+,GABA,2018_cao_28,1,Relapsing-Remitting Multiple Sclerosis,10.1007/s00330-017-5064-9,,,1.06,0.15,,,
,GABA+,GABA,2018_cao_28,2,Relapsing-Remitting Multiple Sclerosis,10.1007/s00330-017-5064-9,,,1.04,0.17,,,
,GABA+,GABA,2018_cao_28,3,Relapsing-Remitting Multiple Sclerosis,10.1007/s00330-017-5064-9,,,1.18,0.23,,,
,GABA+,GABA,2018_cao_28,4,Healthy,10.1007/s00330-017-5064-9,,,1.14,0.13,,,
,GABA+,GABA,2018_cao_28,5,Healthy,10.1007/s00330-017-5064-9,,,1.1,0.27,,,
,GABA+,GABA,2018_cao_28,6,Healthy,10.1007/s00330-017-5064-9,,,1.33,0.27,,,
,GABA,GABA,2018_chiu_193,1,First-episode Schizophrenia,10.1016/j.schres.2017.07.021,,,,,2.11,0.28,
,GABA,GABA,2018_chiu_193,2,Healthy,10.1016/j.schres.2017.07.021,,,,,2.32,0.22,
,GABA,GABA,2018_dejaeger_9,1,Painful Diabetic Polyneuropathy - Pregabalin Visit 1,10.1007/s13300-018-0460-y,,,,,0.29,0.14,
,GABA,GABA,2018_dejaeger_9,2,Painful Diabetic Polyneuropathy - Pregabalin Visit 1,10.1007/s13300-018-0460-y,,,,,0.29,0.12,
,GABA,GABA,2018_dejaeger_9,3,Painful Diabetic Polyneuropathy - Pregabalin Visit 1,10.1007/s13300-018-0460-y,,,,,0.41,0.26,
,GABA,GABA,2018_dejaeger_9,4,Painful Diabetic Polyneuropathy - Pregabalin Visit 1,10.1007/s13300-018-0460-y,,,,,0.28,0.21,
,GABA,GABA,2018_dejaeger_9,5,Painful Diabetic Polyneuropathy - Pregabalin Visit 3,10.1007/s13300-018-0460-y,,,,,0.38,0.24,
,GABA,GABA,2018_dejaeger_9,6,Painful Diabetic Polyneuropathy - Pregabalin Visit 3,10.1007/s13300-018-0460-y,,,,,0.26,0.2,
,GABA,GABA,2018_dejaeger_9,7,Painful Diabetic Polyneuropathy - Pregabalin Visit 3,10.1007/s13300-018-0460-y,,,,,0.35,0.19,
,GABA,GABA,2018_dejaeger_9,8,Painful Diabetic Polyneuropathy - Pregabalin Visit 3,10.1007/s13300-018-0460-y,,,,,0.36,0.27,
,GABA,GABA,2018_dejaeger_9,9,Painful Diabetic Polyneuropathy - Pregabalin Visit 5,10.1007/s13300-018-0460-y,,,,,0.37,0.3,
,GABA,GABA,2018_dejaeger_9,10,Painful Diabetic Polyneuropathy - Pregabalin Visit 5,10.1007/s13300-018-0460-y,,,,,0.25,0.14,
,GABA,GABA,2018_dejaeger_9,11,Painful Diabetic Polyneuropathy - Pregabalin Visit 5,10.1007/s13300-018-0460-y,,,,,0.91,0.47,
,GABA,GABA,2018_dejaeger_9,12,Painful Diabetic Polyneuropathy - Pregabalin Visit 5,10.1007/s13300-018-0460-y,,,,,0.25,0.1,
,GABA,GABA,2018_dejaeger_9,13,Painful Diabetic Polyneuropathy - Pregabalin Visit 7,10.1007/s13300-018-0460-y,,,,,0.31,0.13,
,GABA,GABA,2018_dejaeger_9,14,Painful Diabetic Polyneuropathy - Pregabalin Visit 7,10.1007/s13300-018-0460-y,,,,,0.24,0.16,
,GABA,GABA,2018_dejaeger_9,15,Painful Diabetic Polyneuropathy - Pregabalin Visit 7,10.1007/s13300-018-0460-y,,,,,0.48,0.26,
,GABA,GABA,2018_dejaeger_9,16,Painful Diabetic Polyneuropathy - Pregabalin Visit 7,10.1007/s13300-018-0460-y,,,,,0.35,0.16,
,GABA,GABA,2018_dejaeger_9,17,Painful Diabetic Polyneuropathy - Placebo Visit 1,10.1007/s13300-018-0460-y,,,,,0.33,0.15,
,GABA,GABA,2018_dejaeger_9,18,Painful Diabetic Polyneuropathy - Placebo Visit 1,10.1007/s13300-018-0460-y,,,,,0.35,0.194,
,GABA,GABA,2018_dejaeger_9,19,Painful Diabetic Polyneuropathy - Placebo Visit 1,10.1007/s13300-018-0460-y,,,,,0.47,0.32,
,GABA,GABA,2018_dejaeger_9,20,Painful Diabetic Polyneuropathy - Placebo Visit 1,10.1007/s13300-018-0460-y,,,,,0.37,0.2,
,GABA,GABA,2018_dejaeger_9,21,Painful Diabetic Polyneuropathy - Placebo Visit 3,10.1007/s13300-018-0460-y,,,,,0.4,0.19,
,GABA,GABA,2018_dejaeger_9,22,Painful Diabetic Polyneuropathy - Placebo Visit 3,10.1007/s13300-018-0460-y,,,,,0.35,0.16,
,GABA,GABA,2018_dejaeger_9,23,Painful Diabetic Polyneuropathy - Placebo Visit 3,10.1007/s13300-018-0460-y,,,,,0.47,0.21,
,GABA,GABA,2018_dejaeger_9,24,Painful Diabetic Polyneuropathy - Placebo Visit 3,10.1007/s13300-018-0460-y,,,,,0.58,0.62,
,GABA,GABA,2018_dejaeger_9,25,Painful Diabetic Polyneuropathy - Placebo Visit 5,10.1007/s13300-018-0460-y,,,,,0.26,0.17,
,GABA,GABA,2018_dejaeger_9,26,Painful Diabetic Polyneuropathy - Placebo Visit 5,10.1007/s13300-018-0460-y,,,,,0.37,0.09,
,GABA,GABA,2018_dejaeger_9,27,Painful Diabetic Polyneuropathy - Placebo Visit 5,10.1007/s13300-018-0460-y,,,,,0.89,0.67,
,GABA,GABA,2018_dejaeger_9,28,Painful Diabetic Polyneuropathy - Placebo Visit 5,10.1007/s13300-018-0460-y,,,,,0.37,0.29,
,GABA,GABA,2018_dejaeger_9,29,Painful Diabetic Polyneuropathy - Placebo Visit 7,10.1007/s13300-018-0460-y,,,,,0.58,0.48,
,GABA,GABA,2018_dejaeger_9,30,Painful Diabetic Polyneuropathy - Placebo Visit 7,10.1007/s13300-018-0460-y,,,,,0.43,0.2,
,GABA,GABA,2018_dejaeger_9,31,Painful Diabetic Polyneuropathy - Placebo Visit 7,10.1007/s13300-018-0460-y,,,,,0.37,0.15,
,GABA,GABA,2018_dejaeger_9,32,Painful Diabetic Polyneuropathy - Placebo Visit 7,10.1007/s13300-018-0460-y,,,,,0.32,0.27,
,GABA,GABA,2018_dejaeger_9,33,Painful Diabetic Polyneuropathy - Pregabalin 0 mg,10.1007/s13300-018-0460-y,,,,,0.36,0.24,
,GABA,GABA,2018_dejaeger_9,34,Painful Diabetic Polyneuropathy - Pregabalin 0 mg,10.1007/s13300-018-0460-y,,,,,0.37,0.16,
,GABA,GABA,2018_dejaeger_9,35,Painful Diabetic Polyneuropathy - Pregabalin 0 mg,10.1007/s13300-018-0460-y,,,,,0.53,0.4,
,GABA,GABA,2018_dejaeger_9,36,Painful Diabetic Polyneuropathy - Pregabalin 0 mg,10.1007/s13300-018-0460-y,,,,,0.39,0.34,
,GABA,GABA,2018_dejaeger_9,37,Painful Diabetic Polyneuropathy - Pregabalin 75 mg,10.1007/s13300-018-0460-y,,,,,0.53,0.51,
,GABA,GABA,2018_dejaeger_9,38,Painful Diabetic Polyneuropathy - Pregabalin 75 mg,10.1007/s13300-018-0460-y,,,,,0.32,0.18,
,GABA,GABA,2018_dejaeger_9,39,Painful Diabetic Polyneuropathy - Pregabalin 75 mg,10.1007/s13300-018-0460-y,,,,,0.41,0.16,
,GABA,GABA,2018_dejaeger_9,40,Painful Diabetic Polyneuropathy - Pregabalin 75 mg,10.1007/s13300-018-0460-y,,,,,0.31,0.19,
,GABA,GABA,2018_dejaeger_9,41,Painful Diabetic Polyneuropathy - Pregabalin 225 mg,10.1007/s13300-018-0460-y,,,,,0.28,0.19,
,GABA,GABA,2018_dejaeger_9,42,Painful Diabetic Polyneuropathy - Pregabalin 225 mg,10.1007/s13300-018-0460-y,,,,,0.38,0.22,
,GABA,GABA,2018_dejaeger_9,43,Painful Diabetic Polyneuropathy - Pregabalin 225 mg,10.1007/s13300-018-0460-y,,,,,0.63,0.39,
,GABA,GABA,2018_dejaeger_9,44,Painful Diabetic Polyneuropathy - Pregabalin 225 mg,10.1007/s13300-018-0460-y,,,,,0.36,0.17,
,GABA,GABA,2018_dejaeger_9,45,Painful Diabetic Polyneuropathy - Pregabalin 450 mg,10.1007/s13300-018-0460-y,,,,,0.28,0.15,
,GABA,GABA,2018_dejaeger_9,46,Painful Diabetic Polyneuropathy - Pregabalin 450 mg,10.1007/s13300-018-0460-y,,,,,0.33,0.16,
,GABA,GABA,2018_dejaeger_9,47,Painful Diabetic Polyneuropathy - Pregabalin 450 mg,10.1007/s13300-018-0460-y,,,,,0.45,0.24,
,GABA,GABA,2018_dejaeger_9,48,Painful Diabetic Polyneuropathy - Pregabalin 450 mg,10.1007/s13300-018-0460-y,,,,,0.39,0.17,
,GABA,GABA,2017_atagun_637,1,Healthy Control,10.1016/j.neulet.2016.11.051,0.18,0.027,,,,,Assumed 15% StdDev
,GABA,GABA,2017_atagun_637,2,Healthy Control,10.1016/j.neulet.2016.11.051,0.12,0.018,,,,,Assumed 15% StdDev
,GABA,GABA,2017_atagun_637,3,Schizophrenia,10.1016/j.neulet.2016.11.051,0.23,0.035,,,,,Assumed 15% StdDev
,GABA,GABA,2017_atagun_637,4,Schizophrenia,10.1016/j.neulet.2016.11.051,0.12,0.018,,,,,Assumed 15% StdDev
,GABA,GABA,2017_atagun_637,5,Bipolar I,10.1016/j.neulet.2016.11.051,0.18,0.027,,,,,Assumed 15% StdDev
,GABA,GABA,2017_atagun_637,6,Bipolar I,10.1016/j.neulet.2016.11.051,0.11,0.017,,,,,Assumed 15% StdDev
,GABA,GABA,2017_atagun_637,7,Bipolar II,10.1016/j.neulet.2016.11.051,0.18,0.027,,,,,Assumed 15% StdDev
,GABA,GABA,2017_atagun_637,8,Bipolar II,10.1016/j.neulet.2016.11.051,0.13,0.02,,,,,Assumed 15% StdDev
,GABA+,GABA,2018_elmaki_36,1,Parkinson's Disease,10.1007/s11604-017-0714-z,,,1.305,0.213,,,
,GABA+,GABA,2018_elmaki_36,2,Healthy,10.1007/s11604-017-0714-z,,,1.608,0.224,,,
,GABA+,GABA,2018_gong_47,1,Parkinson's Disease - Tremor-dominant,10.1002/jmri.25865,,,1.36,0.18,,,
,GABA+,GABA,2018_gong_47,2,,10.1002/jmri.25865,,,1.15,0.16,,,
,GABA+,GABA,2018_gong_47,3,Control,10.1002/jmri.25865,,,1.56,0.23,,,
,GABA,GABA,2018_harper_17,9,Urologic Chronic Pelvic Pain Syndrome,10.1016/j.nicl.2017.11.014,,,1.14,0.31,,,
,GABA,GABA,2018_harper_17,10,Urologic Chronic Pelvic Pain Syndrome,10.1016/j.nicl.2017.11.014,,,1.33,0.31,,,
,GABA,GABA,2018_harper_17,11,Urologic Chronic Pelvic Pain Syndrome,10.1016/j.nicl.2017.11.014,,,1.14,0.22,,,
,GABA,GABA,2018_harper_17,12,Urologic Chronic Pelvic Pain Syndrome,10.1016/j.nicl.2017.11.014,,,1.28,0.45,,,
,GABA,GABA,2018_harper_17,13,Control,10.1016/j.nicl.2017.11.014,,,1.35,0.23,,,
,GABA,GABA,2018_harper_17,14,Control,10.1016/j.nicl.2017.11.014,,,1.33,0.31,,,
,GABA,GABA,2018_harper_17,15,Control,10.1016/j.nicl.2017.11.014,,,1.2,0.23,,,
,GABA,GABA,2018_harper_17,16,Control,10.1016/j.nicl.2017.11.014,,,1.17,0.29,,,
,GABA,GABA,2018_hegarty_48,5,Autism Spectrum Disorder,10.1007/s10803-018-3613-y,,,3.39,0.64,,,
,GABA,GABA,2018_hegarty_48,6,Autism Spectrum Disorder,10.1007/s10803-018-3613-y,,,1.78,0.37,,,
,GABA,GABA,2018_hegarty_48,7,Control,10.1007/s10803-018-3613-y,,,3.41,0.65,,,
,GABA,GABA,2018_hegarty_48,8,Control,10.1007/s10803-018-3613-y,,,2.16,0.92,,,
,GABA,GABA,2018_horder_8,1,Control,10.1038/s41398-018-0155-1,,,3.9,0.42,,,
,GABA,GABA,2018_horder_8,2,Control,10.1038/s41398-018-0155-1,,,3.74,0.72,,,
,GABA,GABA,2018_horder_8,3,Autism Spectrum Disorder,10.1038/s41398-018-0155-1,,,3.84,0.45,,,
,GABA,GABA,2018_horder_8,4,Autism Spectrum Disorder,10.1038/s41398-018-0155-1,,,3.71,0.65,,,
,GABA,GABA,2018_huber_225,1,Bipolar Disorder,10.1016/j.jad.2017.07.052,,,1.07,0.27,,,
,GABA,GABA,2018_huber_225,2,Bipolar Disorder,10.1016/j.jad.2017.07.052,,,1.02,0.32,,,
,GABA,GABA,2018_huber_225,3,Control,10.1016/j.jad.2017.07.052,,,1.14,0.29,,,
,GABA,GABA,2018_huber_225,4,Control,10.1016/j.jad.2017.07.052,,,1.2,0.29,,,
,GABA,GABA,2020_hjelmervik_46,1,Schizophrenia,10.1093/schbul/sbz099,,,4.95,0.97,,,
,GABA,GABA,2020_hjelmervik_46,2,Schizophrenia,10.1093/schbul/sbz099,,,4.63,1.13,,,
,GABA,GABA,2020_hjelmervik_46,3,Schizophrenia,10.1093/schbul/sbz099,,,4.44,0.83,,,
,GABA,GABA,2020_hjelmervik_46,4,Schizophrenia,10.1093/schbul/sbz099,,,5.47,0.77,,,
,GABA,GABA,2020_hjelmervik_46,5,Control,10.1093/schbul/sbz099,,,4.82,1.08,,,
,GABA,GABA,2020_hjelmervik_46,6,Control,10.1093/schbul/sbz099,,,4.43,1.28,,,
,GABA,GABA,2020_hjelmervik_46,7,Control,10.1093/schbul/sbz099,,,4.59,0.82,,,
,GABA,GABA,2020_hjelmervik_46,8,Control,10.1093/schbul/sbz099,,,5.4,0.84,,,
,GABA,GABA,2020_boillat_40,1,Baseline,10.1177/0271678X19831022,,,1.37,0.08,,,
,GABA,GABA,2020_boillat_40,2,positive BOLD,10.1177/0271678X19831022,,,0.06,0.22,,,
,GABA,GABA,2020_boillat_40,3,Baseline,10.1177/0271678X19831022,,,1.46,0.06,,,
,GABA,GABA,2020_boillat_40,4,negative BOLD,10.1177/0271678X19831022,,,0.12,0.18,,,
,GABA,GABA,2021_akiyama_61,1,Control,10.2176/nmc.oa.2020-0274,,,1.17,0.59,,,
,GABA,GABA,2021_akiyama_61,2,NPH,10.2176/nmc.oa.2020-0274,,,0.43,0.35,,,
,GABA+,GABA,2018_li_29,1,Migraine - Pretreatment,10.1097/WNR.0000000000001067,,,0.098,0.025,,,
,GABA+,GABA,2018_li_29,2,Migraine - Pretreatment,10.1097/WNR.0000000000001067,,,0.094,0.01,,,
,GABA+,GABA,2018_li_29,3,Migraine - After Levetiracetam Treatment,10.1097/WNR.0000000000001067,,,0.084,0.022,,,
,GABA+,GABA,2018_li_29,4,Migraine - After Levetiracetam Treatment,10.1097/WNR.0000000000001067,,,0.084,0.006,,,
,GABA+,GABA,2018_louis_17,1,Essential Tremor,10.1007/s12311-017-0891-4,,,1.68,0.49,,,
,GABA+,GABA,2018_louis_17,2,Essential Tremor,10.1007/s12311-017-0891-4,,,2.01,0.45,,,
,GABA+,GABA,2018_louis_17,3,Control,10.1007/s12311-017-0891-4,,,1.8,0.53,,,
,GABA+,GABA,2018_louis_17,4,Control,10.1007/s12311-017-0891-4,,,1.86,0.53,,,
,GABA+,GABA,2018_mahone_273,1,Tourrette Syndrom,10.1016/j.pscychresns.2017.12.005,,,2.87,1.05,,,
,GABA+,GABA,2018_mahone_273,2,Tourrette Syndrom,10.1016/j.pscychresns.2017.12.005,,,2.8,1.35,,,
,GABA+,GABA,2018_mahone_273,3,Tourrette Syndrom,10.1016/j.pscychresns.2017.12.005,,,2.59,1.04,,,
,GABA+,GABA,2018_mahone_273,4,Tourrette Syndrom,10.1016/j.pscychresns.2017.12.005,,,2.99,0.74,,,
,GABA+,GABA,2018_mahone_273,5,Control,10.1016/j.pscychresns.2017.12.005,,,2.41,0.37,,,
,GABA+,GABA,2018_mahone_273,6,Control,10.1016/j.pscychresns.2017.12.005,,,2.49,0.86,,,
,GABA+,GABA,2018_mahone_273,7,Control,10.1016/j.pscychresns.2017.12.005,,,2.34,0.65,,,
,GABA+,GABA,2018_mahone_273,8,Control,10.1016/j.pscychresns.2017.12.005,,,2.87,0.6,,,
,GABA+,GABA,2018_marenco_43,1,Healthy,10.1038/s41386-018-0134-5,0.096,0.009,0.001,0,,,
,GABA+,GABA,2018_marenco_43,2,Healthy,10.1038/s41386-018-0134-5,0.106,0.011,0.001,0,,,
,GABA+,GABA,2018_modinos_43,1,Ultra-high Risk for Psychosis,10.1038/s41386-017-0004-6,,,3.9,0.7,,,
,GABA+,GABA,2018_modinos_43,2,Ultra-high Risk for Psychosis - Did not develop psychosis,10.1038/s41386-017-0004-6,,,3.8,0.6,,,
,GABA+,GABA,2018_modinos_43,3,Ultra-high Risk for Psychosis - Developed psychosis,10.1038/s41386-017-0004-6,,,4.2,0.9,,,
,GABA+,GABA,2018_morley_9,5,Alcohol Dependence - Placebo,10.3389/fpsyt.2018.00412,,,0.55,0.04,,,
,GABA+,GABA,2018_morley_9,6,Alcohol Dependence - Baclofen,10.3389/fpsyt.2018.00412,,,0.53,0.09,,,
,GABA+,GABA,2018_morley_9,7,"Alcohol Dependence - Recent alcohol consumption, placebo",10.3389/fpsyt.2018.00412,,,0.53,0.04,,,
,GABA+,GABA,2018_morley_9,8,"Alcohol Dependence - Recent alcohol consumption, Baclofen",10.3389/fpsyt.2018.00412,,,0.59,0.05,,,
,GABA,GABA,2018_saleh_80,1,Healthy,10.1002/mrm.27044,,,1.051,0.254,,,
,GABA,GABA,2018_saleh_80,2,Healthy,10.1002/mrm.27044,,,1.053,0.248,,,
,GABA,GABA,2020_cen_54,1,Healthy Controls,10.1177/0004867419898520,,,2.43,0.49,,,
,GABA,GABA,2020_cen_54,2,FEP,10.1177/0004867419898520,,,2.87,0.92,,,
,GABA,GABA,2018_sheth_276,1,Veterans - Suicidal behavior,10.1016/j.pscychresns.2018.04.004,,,0.37,0.03,,,
,GABA,GABA,2018_sheth_276,2,Veterans - Suicidal behavior,10.1016/j.pscychresns.2018.04.004,,,0.35,0.01,,,
,GABA,GABA,2018_sheth_276,3,Veterans - No suicidal behavior,10.1016/j.pscychresns.2018.04.004,,,0.37,0.03,,,
,GABA,GABA,2018_sheth_276,4,Veterans - No suicidal behavior,10.1016/j.pscychresns.2018.04.004,,,0.34,0.01,,,
,GABA,GABA,2019_betinaip_39,1,Behavior - ON - 3% Visual Contrast,10.1523/JNEUROSCI.3021-18.2019,,,0.758,0.179,,,
,GABA,GABA,2019_betinaip_39,2,Behavior - ON - 12.5% Visual Contrast,10.1523/JNEUROSCI.3021-18.2019,,,0.778,0.136,,,
,GABA,GABA,2019_betinaip_39,3,Behavior - ON - 50% Visual Contrast,10.1523/JNEUROSCI.3021-18.2019,,,0.74,0.158,,,
,GABA,GABA,2019_betinaip_39,4,Behavior - ON - 100% Visual Contrast,10.1523/JNEUROSCI.3021-18.2019,,,0.771,0.187,,,
,GABA,GABA,2019_betinaip_39,5,Resting,10.1523/JNEUROSCI.3021-18.2019,,,0.795,0.166,,,
,GABA,GABA,2019_betinaip_39,6,Behavior - OFF - 3% Visual Contrast,10.1523/JNEUROSCI.3021-18.2019,,,0.77,0.189,,,
,GABA,GABA,2019_betinaip_39,7,Behavior - OFF - 12.5% Visual Contrast,10.1523/JNEUROSCI.3021-18.2019,,,0.729,0.147,,,
,GABA,GABA,2019_betinaip_39,8,Behavior - OFF - 50% Visual Contrast,10.1523/JNEUROSCI.3021-18.2019,,,0.73,0.158,,,
,GABA,GABA,2019_betinaip_39,9,Behavior - OFF - 100% Visual Contrast,10.1523/JNEUROSCI.3021-18.2019,,,0.76,0.196,,,
,GABA,GABA,2019_betinaip_39,10,Resting,10.1523/JNEUROSCI.3021-18.2019,,,0.762,0.143,,,
,GABA+,GABA,2019_duncan_50,1,Healthy,10.1002/jmri.26706,,,5.5,0.4,,,
,GABA+,GABA,2019_duncan_50,2,Healthy,10.1002/jmri.26706,,,5.7,0.5,,,
,GABA,GABA,2019_duncan_50,3,Healthy,10.1002/jmri.26706,,,2.9,0.6,,,
,GABA,GABA,2019_duncan_50,4,Healthy,10.1002/jmri.26706,,,3.3,0.4,,,
,GABA,GABA,2019_ferland_237,1,Healthy TMS,10.1007/s00221-019-05691-z,0.049,0.016,,,0.834,0.239,
,GABA,GABA,2019_ferland_237,2,Healthy TMS,10.1007/s00221-019-05691-z,0.05,0.015,,,0.888,0.254,
,GABA,GABA,2019_flores-ramos_242,1,Depression,10.1016/j.jad.2018.08.033,,,,,1.72,1.54,
,GABA,GABA,2019_flores-ramos_242,2,Depression,10.1016/j.jad.2018.08.033,,,,,1.94,0.7,
,GABA,GABA,2019_giapitzakis_81,1,Healthy,10.1002/mrm.27467,,,,,0.8,0.2,
,GABA,GABA,2019_giapitzakis_81,2,Healthy,10.1002/mrm.27467,,,,,0.8,0.4,
,GABA,GABA,2019_gradinger_160,1,Control,10.1097/j.pain.0000000000001641,0.23,0.04,,,,,
,GABA,GABA,2019_gradinger_160,2,Borderline Personality Disorder,10.1097/j.pain.0000000000001641,0.23,0.04,,,,,
,GABA,GABA,2019_hong_14,1,Healthy,10.1371/journal.pone.0223702,0.13,0.06,,,,,
,GABA,GABA,2019_hong_14,2,Healthy,10.1371/journal.pone.0223702,0.22,0.09,,,,,
,GABA,GABA,2019_hong_14,3,Healthy,10.1371/journal.pone.0223702,0.16,0.03,,,,,
,GABA,GABA,2019_hong_14,4,Healthy,10.1371/journal.pone.0223702,0.28,0.03,,,,,
,GABA,GABA,2019_hong_14,5,Healthy,10.1371/journal.pone.0223702,0.26,0.09,,,,,
,GABA,GABA,2019_hong_14,6,Healthy,10.1371/journal.pone.0223702,0.25,0.05,,,,,
,GABA,GABA,2019_hong_14,7,Healthy,10.1371/journal.pone.0223702,0.07,0.03,,,,,
,GABA,GABA,2019_hong_14,8,Healthy,10.1371/journal.pone.0223702,0.1,0.02,,,,,
,GABA,GABA,2019_hong_14,9,Healthy,10.1371/journal.pone.0223702,0.11,0.05,,,,,
,GABA,GABA,2019_hong_14,10,Healthy,10.1371/journal.pone.0223702,0.19,0.04,,,,,
,GABA,GABA,2019_hong_14,11,Healthy,10.1371/journal.pone.0223702,0.18,0.04,,,,,
,GABA,GABA,2019_hong_14,12,Healthy,10.1371/journal.pone.0223702,0.18,0.03,,,,,
,GABA+,GABA,2019_kim_13,1,Control,10.3389/fnhum.2019.00193,0.109,0.008,,,,,
,GABA+,GABA,2019_kim_13,2,TBI (Boxers),10.3389/fnhum.2019.00193,0.103,0.007,,,,,
,GABA,GABA,2018_wyss_21,1,Healthy,10.1093/ijnp/pyy056,,,1.45,0.24,,,
,GABA+,GABA,2018_xia_34,1,Schizophrenia - Drug_Baseline,10.1097/YCT.0000000000000507,0.149,0.052,,,,,
,GABA+,GABA,2018_xia_34,2,Schizophrenia - Drug_4wk,10.1097/YCT.0000000000000507,0.196,0.103,,,,,
,GABA+,GABA,2018_xia_34,3,Schizophrenia - Electroconvulsive therapy_Baseline,10.1097/YCT.0000000000000507,0.137,0.048,,,,,
,GABA+,GABA,2018_xia_34,4,Schizophrenia - Electroconvulsive therapy_4wk,10.1097/YCT.0000000000000507,0.21,0.097,,,,,
,GABA+,GABA,2018_xia_34,5,Control,10.1097/YCT.0000000000000507,0.194,0.098,,,,,
,GABA,GABA,2020_savic_30,1,Control,10.1093/cercor/bhz340,,,,,1.2,1,
,GABA,GABA,2020_savic_30,2,Control,10.1093/cercor/bhz340,,,,,2.1,0.6,
,GABA,GABA,2020_savic_30,3,Control,10.1093/cercor/bhz340,,,,,1.1,0.6,
,GABA,GABA,2020_savic_30,4,Control,10.1093/cercor/bhz340,,,,,2.2,0.7,
,GABA,GABA,2020_savic_30,5,ES Patients,10.1093/cercor/bhz340,,,,,1.5,1.1,
,GABA,GABA,2020_savic_30,6,ES Patients,10.1093/cercor/bhz340,,,,,2,0.7,
,GABA,GABA,2020_savic_30,7,ES Patients,10.1093/cercor/bhz340,,,,,1.3,0.8,
,GABA,GABA,2020_savic_30,8,ES Patients,10.1093/cercor/bhz340,,,,,2.5,0.5,
,GABA,GABA,2020_su_71,1,Healthy Controls,10.1016/j.jocn.2019.11.021,,,,,1.28,0.2,
,GABA,GABA,2020_su_71,2,Methamphetamine Dependence,10.1016/j.jocn.2019.11.021,,,,,1.16,0.22,
,GABA,GABA,2020_wenneberg_5,1,Ultra High Risk for Psychosis,10.1016/j.bpsc.2019.12.005,,,2.79,0.34,,,
,GABA,GABA,2020_wenneberg_5,3,Healthy Control,10.1016/j.bpsc.2019.12.005,,,2.78,0.33,,,
,GABA,GABA,2020_wenneberg_5,5,Ultra High Risk for Psychosis,10.1016/j.bpsc.2019.12.005,,,2.21,0.22,,,
,GABA,GABA,2020_wenneberg_5,7,Ultra High Risk for Psychosis,10.1016/j.bpsc.2019.12.005,,,2.11,0.25,,,
,GABA,GABA,2019_marjanska_68,1,Alzheimer's disease,10.3233/JAD-180861,,,,,0.78,0.28,
,GABA,GABA,2019_marjanska_68,2,Alzheimer's disease,10.3233/JAD-180861,,,,,0.95,0.28,
,GABA,GABA,2019_marjanska_68,3,Control,10.3233/JAD-180861,,,,,0.87,0.23,
,GABA,GABA,2019_marjanska_68,4,Control,10.3233/JAD-180861,,,,,1.04,0.23,
,GABA+,GABA,2020_basu_10,1,Preterm Infants,10.1038/s41598-020-67188-y,0.42,0.02,1.5,0.07,,,
,GABA+,GABA,2020_basu_10,4,Preterm Infants,10.1038/s41598-020-67188-y,0.44,0.02,1.66,0.07,,,
,GABA+,GABA,2020_basu_10,7,Preterm Infants,10.1038/s41598-020-67188-y,0.39,0.04,1.33,0.11,,,
,GABA+,GABA,2020_basu_10,10,Preterm Infants,10.1038/s41598-020-67188-y,0.45,0.02,1.67,0.07,,,
,GABA+,GABA,2020_basu_10,13,Preterm Infants,10.1038/s41598-020-67188-y,0.39,0.03,1.35,0.11,,,
,GABA,GABA,2019_mason_29,1,Occasional cannabis user - Full dose THC - Visit 1,10.1016/j.euroneuro.2018.12.003,0.19,0.03,,,,,
,GABA,GABA,2019_mason_29,2,Occasional cannabis user - Full dose THC - Visit 2,10.1016/j.euroneuro.2018.12.003,0.16,0.03,,,,,
,GABA,GABA,2019_mason_29,3,Occasional cannabis user - Full dose THC - Visit 1,10.1016/j.euroneuro.2018.12.003,0.18,0.03,,,,,
,GABA,GABA,2019_mason_29,4,Occasional cannabis user - Full dose THC - Visit 1,10.1016/j.euroneuro.2018.12.003,0.22,0.03,,,,,
,GABA,GABA,2019_mason_29,5,Occasional cannabis user - Full dose THC - Visit 2,10.1016/j.euroneuro.2018.12.003,0.25,0.13,,,,,
,GABA,GABA,2019_mason_29,6,Occasional cannabis user - Full dose THC - Visit 1,10.1016/j.euroneuro.2018.12.003,0.21,0.09,,,,,
,GABA,GABA,2019_mason_29,7,Occasional cannabis user - Full dose placebo - Visit 1,10.1016/j.euroneuro.2018.12.003,0.15,0.03,,,,,
,GABA,GABA,2019_mason_29,8,Occasional cannabis user - Full dose placebo - Visit 2,10.1016/j.euroneuro.2018.12.003,0.14,0.03,,,,,
,GABA,GABA,2019_mason_29,9,Occasional cannabis user - Full dose placebo - Visit 3,10.1016/j.euroneuro.2018.12.003,0.15,0.06,,,,,
,GABA,GABA,2019_mason_29,10,Occasional cannabis user - Full dose placebo - Visit 1,10.1016/j.euroneuro.2018.12.003,0.22,0.16,,,,,
,GABA,GABA,2019_mason_29,11,Occasional cannabis user - Full dose placebo - Visit 2,10.1016/j.euroneuro.2018.12.003,0.21,0.09,,,,,
,GABA,GABA,2019_mason_29,12,Occasional cannabis user - Full dose placebo - Visit 3,10.1016/j.euroneuro.2018.12.003,0.19,0.09,,,,,
,GABA,GABA,2019_mason_29,13,Occasional cannabis user - Divided dose THC - Visit 1,10.1016/j.euroneuro.2018.12.003,0.14,0.03,,,,,
,GABA,GABA,2019_mason_29,14,Occasional cannabis user - Divided dose THC - Visit 2,10.1016/j.euroneuro.2018.12.003,0.14,0.03,,,,,
,GABA,GABA,2019_mason_29,15,Occasional cannabis user - Divided dose THC - Visit 3,10.1016/j.euroneuro.2018.12.003,0.15,0.03,,,,,
,GABA,GABA,2019_mason_29,16,Occasional cannabis user - Divided dose THC - Visit 1,10.1016/j.euroneuro.2018.12.003,0.21,0.13,,,,,
,GABA,GABA,2019_mason_29,17,Occasional cannabis user - Divided dose THC - Visit 2,10.1016/j.euroneuro.2018.12.003,0.19,0.13,,,,,
,GABA,GABA,2019_mason_29,19,Occasional cannabis user - Divided dose placebo - Visit 1,10.1016/j.euroneuro.2018.12.003,0.15,0.06,,,,,
,GABA,GABA,2019_mason_29,20,Occasional cannabis user - Divided dose placebo - Visit 2,10.1016/j.euroneuro.2018.12.003,0.16,0.03,,,,,
,GABA,GABA,2019_mason_29,21,Occasional cannabis user - Divided dose placebo - Visit 3,10.1016/j.euroneuro.2018.12.003,0.16,0.06,,,,,
,GABA,GABA,2019_mason_29,22,Occasional cannabis user - Divided dose placebo - Visit 1,10.1016/j.euroneuro.2018.12.003,0.24,0.09,,,,,
,GABA,GABA,2019_mason_29,23,Occasional cannabis user - Divided dose placebo - Visit 2,10.1016/j.euroneuro.2018.12.003,0.19,0.09,,,,,
,GABA+,GABA,2019_mikkelsen_191,1,Healthy,10.1016/j.neuroimage.2019.02.059,,,3.33,0.2,,,
,GABA+,GABA,2019_mikkelsen_191,2,Healthy,10.1016/j.neuroimage.2019.02.059,,,3.7,0.26,,,
,GABA+,GABA,2019_mikkelsen_191,3,Healthy,10.1016/j.neuroimage.2019.02.059,,,2.92,0.26,,,
,GABA+,GABA,2019_mikkelsen_191,4,Healthy,10.1016/j.neuroimage.2019.02.059,,,3.31,0.39,,,
,GABA+,GABA,2019_mikkelsen_191,5,Healthy,10.1016/j.neuroimage.2019.02.059,,,2.96,0.2,,,
,GABA+,GABA,2019_mikkelsen_191,6,Healthy,10.1016/j.neuroimage.2019.02.059,,,3.22,0.59,,,
,GABA+,GABA,2019_mikkelsen_191,7,Healthy,10.1016/j.neuroimage.2019.02.059,,,3.44,0.38,,,
,GABA+,GABA,2019_mikkelsen_191,8,Healthy,10.1016/j.neuroimage.2019.02.059,,,3.46,0.41,,,
,GABA+,GABA,2019_mikkelsen_191,9,Healthy,10.1016/j.neuroimage.2019.02.059,,,3.32,0.42,,,
,GABA+,GABA,2019_mikkelsen_191,10,Healthy,10.1016/j.neuroimage.2019.02.059,,,3.3,0.37,,,
,GABA+,GABA,2019_mikkelsen_191,11,Healthy,10.1016/j.neuroimage.2019.02.059,,,3.18,0.25,,,
,GABA+,GABA,2019_mikkelsen_191,12,Healthy,10.1016/j.neuroimage.2019.02.059,,,3.29,0.26,,,
,GABA+,GABA,2019_mikkelsen_191,13,Healthy,10.1016/j.neuroimage.2019.02.059,,,3.48,0.58,,,
,GABA+,GABA,2019_mikkelsen_191,14,Healthy,10.1016/j.neuroimage.2019.02.059,,,3.03,0.25,,,
,GABA+,GABA,2019_mikkelsen_191,15,Healthy,10.1016/j.neuroimage.2019.02.059,,,3.56,0.27,,,
,GABA+,GABA,2019_mikkelsen_191,16,Healthy,10.1016/j.neuroimage.2019.02.059,,,3.1,0.22,,,
,GABA+,GABA,2019_mikkelsen_191,17,Healthy,10.1016/j.neuroimage.2019.02.059,,,3.59,0.33,,,
,GABA+,GABA,2019_mikkelsen_191,18,Healthy,10.1016/j.neuroimage.2019.02.059,,,3.31,0.22,,,
,GABA+,GABA,2019_mikkelsen_191,19,Healthy,10.1016/j.neuroimage.2019.02.059,,,3.32,0.36,,,
,GABA+,GABA,2019_mikkelsen_191,20,Healthy,10.1016/j.neuroimage.2019.02.059,,,4.17,0.23,,,
,GABA+,GABA,2019_mikkelsen_191,21,Healthy,10.1016/j.neuroimage.2019.02.059,,,4.74,0.39,,,
,GABA+,GABA,2019_mikkelsen_191,22,Healthy,10.1016/j.neuroimage.2019.02.059,,,3.87,0.41,,,
,GABA+,GABA,2019_mikkelsen_191,23,Healthy,10.1016/j.neuroimage.2019.02.059,,,4.28,0.48,,,
,GABA+,GABA,2019_mikkelsen_191,24,Healthy,10.1016/j.neuroimage.2019.02.059,,,4.46,0.72,,,
,GABA+,GABA,2019_mikkelsen_191,25,Healthy,10.1016/j.neuroimage.2019.02.059,,,4.08,0.17,,,
,GABA+,GABA,2019_mikkelsen_191,26,Healthy,10.1016/j.neuroimage.2019.02.059,,,4.43,0.34,,,
,GABA+,GABA,2019_mikkelsen_191,27,Healthy,10.1016/j.neuroimage.2019.02.059,,,4.5,0.5,,,
,GABA+,GABA,2019_mikkelsen_191,28,Healthy,10.1016/j.neuroimage.2019.02.059,,,4.29,0.49,,,
,GABA+,GABA,2019_mikkelsen_191,29,Healthy,10.1016/j.neuroimage.2019.02.059,,,3.61,0.61,,,
,GABA+,GABA,2019_mikkelsen_191,30,Healthy,10.1016/j.neuroimage.2019.02.059,,,4.4,0.61,,,
,GABA+,GABA,2019_mikkelsen_191,31,Healthy,10.1016/j.neuroimage.2019.02.059,,,4.04,0.78,,,
,GABA+,GABA,2019_mikkelsen_191,33,Healthy,10.1016/j.neuroimage.2019.02.059,,,2.95,0.93,,,
,GABA+,GABA,2019_mikkelsen_191,34,Healthy,10.1016/j.neuroimage.2019.02.059,,,2.23,0.54,,,
,GABA+,GABA,2019_mikkelsen_191,36,Healthy,10.1016/j.neuroimage.2019.02.059,,,2.83,0.84,,,
,GABA+,GABA,2019_mikkelsen_191,37,Healthy,10.1016/j.neuroimage.2019.02.059,,,2.81,0.43,,,
,GABA+,GABA,2019_mikkelsen_191,38,Healthy,10.1016/j.neuroimage.2019.02.059,,,3.22,1.02,,,
,GABA+,GABA,2019_mikkelsen_191,39,Healthy,10.1016/j.neuroimage.2019.02.059,,,3.47,0.33,,,
,GABA+,GABA,2019_mikkelsen_191,40,Healthy,10.1016/j.neuroimage.2019.02.059,,,3.16,0.71,,,
,GABA+,GABA,2019_mikkelsen_191,41,Healthy,10.1016/j.neuroimage.2019.02.059,,,3.66,0.88,,,
,GABA+,GABA,2019_mikkelsen_191,42,Healthy,10.1016/j.neuroimage.2019.02.059,,,2.05,0.65,,,
,GABA+,GABA,2019_mikkelsen_191,43,Healthy,10.1016/j.neuroimage.2019.02.059,,,2.61,0.32,,,
,GABA+,GABA,2019_mikkelsen_191,44,Healthy,10.1016/j.neuroimage.2019.02.059,,,4.07,1.42,,,
,GABA+,GABA,2019_mikkelsen_191,45,Healthy,10.1016/j.neuroimage.2019.02.059,,,2.87,0.55,,,
,GABA+,GABA,2019_mikkelsen_191,46,Healthy,10.1016/j.neuroimage.2019.02.059,,,5.7,0.4,,,
,GABA+,GABA,2019_mikkelsen_191,47,Healthy,10.1016/j.neuroimage.2019.02.059,,,4.1,0.4,,,
,GABA+,GABA,2019_mikkelsen_191,48,Healthy,10.1016/j.neuroimage.2019.02.059,,,3.52,1.2,,,
,GABA+,GABA,2019_mikkelsen_191,49,Healthy,10.1016/j.neuroimage.2019.02.059,,,3.39,0.56,,,
,GABA+,GABA,2019_mikkelsen_191,50,Healthy,10.1016/j.neuroimage.2019.02.059,,,3.76,0.52,,,
,GABA+,GABA,2019_mikkelsen_191,51,Healthy,10.1016/j.neuroimage.2019.02.059,,,3.75,0.76,,,
,GABA+,GABA,2019_mikkelsen_191,52,Healthy,10.1016/j.neuroimage.2019.02.059,,,3.22,0.55,,,
,GABA+,GABA,2019_mikkelsen_191,53,Healthy,10.1016/j.neuroimage.2019.02.059,,,3.73,0.63,,,
,GABA+,GABA,2019_mikkelsen_191,54,Healthy,10.1016/j.neuroimage.2019.02.059,,,3.86,0.37,,,
,GABA+,GABA,2019_mikkelsen_191,55,Healthy,10.1016/j.neuroimage.2019.02.059,,,3.55,0.52,,,
,GABA+,GABA,2019_mikkelsen_191,56,Healthy,10.1016/j.neuroimage.2019.02.059,,,3.46,0.61,,,
,GABA+,GABA,2019_mikkelsen_191,57,Healthy,10.1016/j.neuroimage.2019.02.059,,,3.6,0.59,,,
,GABA+,GABA,2019_mikkelsen_191,58,Healthy,10.1016/j.neuroimage.2019.02.059,,,3.46,1,,,
,GABA,GABA,2019_patel_9,1,Healthy - Anodal transcranial direct current stimulation - Baseline,10.1038/s41598-019-39262-7,,,,,1.68,0.34,
,GABA,GABA,2019_patel_9,2,Healthy - Anodal transcranial direct current stimulation - Baseline,10.1038/s41598-019-39262-7,,,,,1.67,0.29,
,GABA,GABA,2019_patel_9,3,Healthy - Anodal transcranial direct current stimulation - 20min,10.1038/s41598-019-39262-7,,,,,1.47,0.45,
,GABA,GABA,2019_patel_9,4,Healthy - Anodal transcranial direct current stimulation - 26 min,10.1038/s41598-019-39262-7,,,,,1.53,0.42,
,GABA,GABA,2019_patel_9,5,Healthy - Anodal transcranial direct current stimulation - 33 min,10.1038/s41598-019-39262-7,,,,,1.61,0.34,
,GABA,GABA,2019_patel_9,6,Healthy - Anodal transcranial direct current stimulation - 40 min,10.1038/s41598-019-39262-7,,,,,1.5,0.48,
,GABA,GABA,2019_patel_9,7,Healthy - Anodal transcranial direct current stimulation - 46 min,10.1038/s41598-019-39262-7,,,,,1.49,0.44,
,GABA,GABA,2019_patel_9,8,Healthy - Anodal transcranial direct current stimulation - 53 min,10.1038/s41598-019-39262-7,,,,,1.53,0.46,
,GABA,GABA,2019_patel_9,9,Healthy - Anodal transcranial direct current stimulation - 60 min,10.1038/s41598-019-39262-7,,,,,1.53,0.52,
,GABA,GABA,2019_patel_9,10,Healthy - Anodal transcranial direct current stimulation - 66 min,10.1038/s41598-019-39262-7,,,,,1.49,0.45,
,GABA,GABA,2019_patel_9,11,Healthy - Anodal transcranial direct current stimulation - 73 min,10.1038/s41598-019-39262-7,,,,,1.48,0.48,
,GABA,GABA,2019_patel_9,12,Healthy - Anodal transcranial direct current stimulation - 79 min,10.1038/s41598-019-39262-7,,,,,1.42,0.45,
,GABA,GABA,2019_patel_9,13,Healthy - Sham - Baseline,10.1038/s41598-019-39262-7,,,,,1.76,0.19,
,GABA,GABA,2019_patel_9,14,Healthy - Sham - Baseline,10.1038/s41598-019-39262-7,,,,,1.67,0.18,
,GABA,GABA,2019_patel_9,15,Healthy - Sham - 20min,10.1038/s41598-019-39262-7,,,,,1.76,0.23,
,GABA,GABA,2019_patel_9,16,Healthy - Sham - 26 min,10.1038/s41598-019-39262-7,,,,,1.71,0.25,
,GABA,GABA,2019_patel_9,17,Healthy - Sham - 33 min,10.1038/s41598-019-39262-7,,,,,1.66,0.2,
,GABA,GABA,2019_patel_9,18,Healthy - Sham - 40 min,10.1038/s41598-019-39262-7,,,,,1.68,0.25,
,GABA,GABA,2019_patel_9,19,Healthy - Sham - 46 min,10.1038/s41598-019-39262-7,,,,,1.66,0.24,
,GABA,GABA,2019_patel_9,20,Healthy - Sham - 53 min,10.1038/s41598-019-39262-7,,,,,1.72,0.24,
,GABA,GABA,2019_patel_9,21,Healthy - Sham - 60 min,10.1038/s41598-019-39262-7,,,,,1.7,0.22,
,GABA,GABA,2019_patel_9,22,Healthy - Sham - 66 min,10.1038/s41598-019-39262-7,,,,,1.65,0.22,
,GABA,GABA,2019_patel_9,23,Healthy - Sham- 73 min,10.1038/s41598-019-39262-7,,,,,1.7,0.31,
,GABA,GABA,2019_patel_9,24,Healthy - Sham - 79 min,10.1038/s41598-019-39262-7,,,,,1.71,0.27,
,GABA,GABA,2021_steinegger_26,1,Control,10.1111/adb.13027,,,,,4.38,0.75,
,GABA,GABA,2021_steinegger_26,4,Smokers,10.1111/adb.13027,,,,,4.06,0.52,
,GABA,GABA,2021_steinegger_26,6,Baseline,10.1111/adb.13027,,,,,4.01,0.54,
,GABA,GABA,2021_steinegger_26,7,Withdrawal,10.1111/adb.13027,,,,,3.77,1.26,
,GABA,GABA,2021_steinegger_26,8,Satiation,10.1111/adb.13027,,,,,4.19,0.57,
,GABA,GABA,2021_wood_11,1,ASD,10.1038/s41398-020-01154-0,0.2,0.06,,,,,
,GABA,GABA,2021_wood_11,2,ASD,10.1038/s41398-020-01154-0,0.17,0.07,,,,,
,GABA,GABA,2021_wood_11,3,TD,10.1038/s41398-020-01154-0,0.21,0.09,,,,,
,GABA,GABA,2021_wood_11,4,TD,10.1038/s41398-020-01154-0,0.14,0.05,,,,,
,GABA,GABA,2019_prisci_43,1,Alcohol use disorder ,10.1111/acer.13931,,,0.52,0.06,,,
,GABA,GABA,2019_prisci_43,2,Control,10.1111/acer.13931,,,0.59,0.11,,,
,GABA,GABA,2019_sheth_248,1,PTSD,10.1016/j.jad.2019.01.037,0.17,0.05,0.31,0,,,
,GABA,GABA,2019_sheth_248,2,Trauma-exposed ,10.1016/j.jad.2019.01.037,0.16,0.04,0.31,0,,,
,GABA,GABA,2019_sheth_248,3,Control,10.1016/j.jad.2019.01.037,0.19,0.05,2.1,0,,,
,GABA+,GABA,2020_ford_98,1,Symptoms of the autism and schizophrenia,10.1016/j.pnpbp.2019.109769,,,2.545,0.165,,,
,GABA+,GABA,2020_ford_98,2,Symptoms of the autism and schizophrenia,10.1016/j.pnpbp.2019.109769,,,2.58,0.54,,,
,GABA+,GABA,2020_ford_98,3,Symptoms of the autism and schizophrenia,10.1016/j.pnpbp.2019.109769,,,2.68,0.2,,,
,GABA+,GABA,2020_ford_98,4,Symptoms of the autism and schizophrenia,10.1016/j.pnpbp.2019.109769,,,2.16,0.16,,,
,GABA+,GABA,2020_ford_98,5,Symptoms of the autism and schizophrenia,10.1016/j.pnpbp.2019.109769,,,2.41,0.13,,,
,GABA+,GABA,2020_ford_98,6,Symptoms of the autism and schizophrenia,10.1016/j.pnpbp.2019.109769,,,3,0.38,,,
,GABA+,GABA,2019_simmonite_26,3,Healthy - Young adults,10.1016/j.acra.2018.07.024,0.1,0.01,,,,,
,GABA+,GABA,2019_simmonite_26,4,Healthy - Older adults,10.1016/j.acra.2018.07.024,0.09,0.01,,,,,
,GABA,GABA,2020_hai_3,1,ADHD,10.1001/jamanetworkopen.2020.20973,,,,,2.45,0.34,
,GABA,GABA,2020_hai_3,2,Control,10.1001/jamanetworkopen.2020.20973,,,,,2.49,0.26,
,GABA,GABA,2019_starmose_20,1,Control,10.1186/s10194-019-1059-z,0.305,0.054,1.891,0.284,,,
,GABA,GABA,2019_starmose_20,2,Control,10.1186/s10194-019-1059-z,0.27,0.038,1.597,0.183,,,
,GABA,GABA,2019_starmose_20,3,Migraine with aura,10.1186/s10194-019-1059-z,0.298,0.055,1.78,0.271,,,
,GABA,GABA,2019_starmose_20,4,Migraine with aura,10.1186/s10194-019-1059-z,0.286,0.045,1.638,0.225,,,
,GABA,GABA,2019_strasser_29,1,Healthy,10.1016/j.euroneuro.2018.12.015,,,,,2.22,0.53,
,GABA,GABA,2019_strasser_29,2,Healthy,10.1016/j.euroneuro.2018.12.015,,,,,1.87,0.29,
,GABA,GABA,2019_wang_76,1,FEP,10.1001/jamapsychiatry.2018.3637,,,1.7,0.2,,,
,GABA,GABA,2019_wang_76,2,FEP,10.1001/jamapsychiatry.2018.3637,,,1.65,0.15,,,
,GABA,GABA,2019_wang_76,3,FEP,10.1001/jamapsychiatry.2018.3637,,,1.55,0.2,,,
,GABA,GABA,2019_wang_76,4,FEP,10.1001/jamapsychiatry.2018.3637,,,1.5,0.12,,,
,GABA,GABA,2019_wang_76,5,FEP,10.1001/jamapsychiatry.2018.3637,,,2.1,0.2,,,
,GABA,GABA,2019_wang_76,6,Control,10.1001/jamapsychiatry.2018.3637,,,1.72,0.15,,,
,GABA,GABA,2019_wang_76,7,Control,10.1001/jamapsychiatry.2018.3637,,,1.65,0.22,,,
,GABA,GABA,2019_wang_76,8,Control,10.1001/jamapsychiatry.2018.3637,,,1.55,0.21,,,
,GABA,GABA,2019_wang_76,9,Control,10.1001/jamapsychiatry.2018.3637,,,1.5,0.23,,,
,GABA,GABA,2019_wang_76,10,Control,10.1001/jamapsychiatry.2018.3637,,,2,0.18,,,
,GABA,GABA,2018_modinos_21,1,Control,10.1093/ijnp/pyx076,0.4,0.1,,,,,
,GABA,GABA,2018_modinos_21,2,Psychosis,10.1093/ijnp/pyx076,0.3,0.05,,,,,
,GABA+,GABA,2018_prescot_43,1,Control,10.1038/npp.2017.156,,,,,0.988,0.094,
,GABA+,GABA,2018_prescot_43,2,Control,10.1038/npp.2017.156,,,,,0.778,0.034,
,GABA+,GABA,2018_prescot_43,3,Control,10.1038/npp.2017.156,,,,,0.81,0.023,
,GABA+,GABA,2018_prescot_43,4,Control,10.1038/npp.2017.156,,,,,0.862,0.061,
,GABA+,GABA,2018_prescot_43,5,Control,10.1038/npp.2017.156,,,,,0.922,0.027,
,GABA+,GABA,2018_prescot_43,6,Control,10.1038/npp.2017.156,,,,,0.835,0.054,
,GABA+,GABA,2018_prescot_43,7,Control,10.1038/npp.2017.156,,,,,0.932,0.01,
,GABA+,GABA,2018_prescot_43,8,Control,10.1038/npp.2017.156,,,,,0.805,0.023,
,GABA+,GABA,2018_prescot_43,9,Drug,10.1038/npp.2017.156,,,,,0.839,0.05,
,GABA+,GABA,2018_prescot_43,10,Drug,10.1038/npp.2017.156,,,,,0.851,0.083,
,GABA+,GABA,2018_prescot_43,11,Drug,10.1038/npp.2017.156,,,,,1.475,0.092,
,GABA+,GABA,2018_prescot_43,12,Drug,10.1038/npp.2017.156,,,,,1.481,0.149,
,GABA+,GABA,2018_prescot_43,13,Drug,10.1038/npp.2017.156,,,,,1.381,0.223,
,GABA+,GABA,2018_prescot_43,14,Drug,10.1038/npp.2017.156,,,,,1.387,0.257,
,GABA+,GABA,2018_prescot_43,15,Drug,10.1038/npp.2017.156,,,,,0.94,0.015,
,GABA+,GABA,2018_prescot_43,16,Drug,10.1038/npp.2017.156,,,,,0.88,0.068,
,GABA,GABA,2018_povazan_79,1,Healthy,10.1002/mrm.26778,,,1.33,0.16,,,
,GABA,GABA,2018_povazan_79,2,Healthy,10.1002/mrm.26778,,,1.82,0.23,,,
,GABA,GABA,2018_povazan_79,3,Healthy,10.1002/mrm.26778,,,2.55,0.33,,,
,GABA,GABA,2018_povazan_79,4,Healthy,10.1002/mrm.26778,,,2.1,0.45,,,
,GABA,GABA,2018_povazan_79,5,Healthy,10.1002/mrm.26778,,,1.77,0.45,,,
,GABA,GABA,2018_povazan_79,6,Healthy,10.1002/mrm.26778,,,3.21,0.45,,,
,GABA,GABA,2018_povazan_79,7,Healthy,10.1002/mrm.26778,,,2.49,0.4,,,
,GABA,GABA,2020_gonen_14,1,Healthy,10.3389/fnins.2020.566643,0.17,0.02,,,1.52,0.2,
,GABA,GABA,2020_gonen_14,2,Healthy,10.3389/fnins.2020.566643,0.17,0.03,,,1.48,0.31,
,GABA,GABA,2020_gonen_14,3,Healthy,10.3389/fnins.2020.566643,0.18,0.03,,,1.57,0.31,
,GABA,GABA,2020_gonen_14,4,Healthy,10.3389/fnins.2020.566643,0.18,0.02,,,1.65,0.26,
,GABA,GABA,2020_gonen_14,5,Healthy,10.3389/fnins.2020.566643,0.18,0.03,,,1.56,0.27,
,GABA,GABA,2019_morgenroth_117,1,Trait Anxiety,10.1016/j.cortex.2019.02.021,0.28,0.05,1.78,0.28,,,
,GABA,GABA,2019_morgenroth_117,2,Trait Anxiety - Low trait anxiety,10.1016/j.cortex.2019.02.021,0.26,0.03,1.73,0.22,,,
,GABA,GABA,2019_morgenroth_117,3,Trait Anxiety - High trait anxiety,10.1016/j.cortex.2019.02.021,0.29,0.06,1.83,0.33,,,
,GABA,GABA,2019_morgenroth_117,4,Trait Anxiety,10.1016/j.cortex.2019.02.021,,,2.06,0.35,,,
,GABA,GABA,2019_morgenroth_117,5,Trait Anxiety - Low trait anxiety,10.1016/j.cortex.2019.02.021,,,1.97,0.27,,,
,GABA,GABA,2019_morgenroth_117,6,Trait Anxiety - High trait anxiety,10.1016/j.cortex.2019.02.021,,,2.14,0.4,,,
,GABA,GABA,2018_tiwari_80,1,Healthy,10.1002/mrm.27142,,,,,0.8,0.06,
,GABA,GABA,2018_tiwari_80,2,Healthy,10.1002/mrm.27142,,,,,0.51,0.07,
,GABA,GABA,2018_tiwari_80,3,Healthy,10.1002/mrm.27142,,,,,0.87,0.06,
,GABA,GABA,2018_tiwari_80,4,Healthy,10.1002/mrm.27142,,,,,0.66,0.04,
,GABA,GABA,2018_tiwari_80,5,Healthy,10.1002/mrm.27142,,,,,1.08,0.08,
,GABA,GABA,2018_tiwari_80,6,Healthy,10.1002/mrm.27142,,,,,0.46,0.03,
,GABA,GABA,2019_levitt_44,1,Depression,10.1503/jpn.180230,,,2,0.4,,,
,GABA,GABA,2019_levitt_44,2,Depression,10.1503/jpn.180230,,,2.2,0.4,,,
,GABA,GABA,2019_reid_45,1,Control,10.1093/schbul/sbx190,,,0.93,0.18,,,
,GABA,GABA,2019_reid_45,2,Schizophrenia,10.1093/schbul/sbx190,,,0.91,0.18,,,
,GABA,GABA,2020_draganov_266,1,Control,10.1016/j.jad.2020.01.138,,,,,1.11,0.8,
,GABA,GABA,2020_draganov_266,2,Depression,10.1016/j.jad.2020.01.138,,,,,1.74,1.3,
,GABA,GABA,2020_draganov_266,3,Depression,10.1016/j.jad.2020.01.138,,,,,2,1.61,
,GABA,GABA,2020_draganov_266,4,Depression,10.1016/j.jad.2020.01.138,,,,,1.42,0.67,
,GABA,GABA,2020_prisci_65,1,Healthy,10.1016/j.mri.2019.10.004,,,3.77,0.58,,,
,GABA,GABA,2020_prisci_65,2,Healthy,10.1016/j.mri.2019.10.004,,,3.91,0.76,,,
,GABA,GABA,2020_yasen_11,5,Control ,10.3389/fneur.2020.00683,0.015,0.005,,,,,
,GABA,GABA,2020_yasen_11,6,mTBI - Acute,10.3389/fneur.2020.00683,0.014,0.002,,,,,
,GABA,GABA,2020_yasen_11,7,mTBI - Chronic asymptomatic,10.3389/fneur.2020.00683,0.012,0.003,,,,,
,GABA,GABA,2020_yasen_11,8,mTBI - Chronic symptomatic,10.3389/fneur.2020.00683,0.012,0.002,,,,,
,GABA,GABA,2020_yasen_38,3,Healthy - ApoE4 non-carrier,10.1097/WNP.0000000000000738,0.012,0.003,,,,,
,GABA,GABA,2020_yasen_38,4,Healthy - ApoE4 carrier,10.1097/WNP.0000000000000738,0.012,0.003,,,,,
,GABA,GABA,2021_kantrowitz_11,1,MDD,10.1038/s41398-021-01541-1,0.098,0.02,,,,,
,GABA,GABA,2021_kantrowitz_11,2,Healthy Control,10.1038/s41398-021-01541-1,0.119,0.03,,,,,
,GABA+,GABA,2020_pizzi_35,1,Healthy Control,10.1002/mds.28221,0.082,0.02,,,,,
,GABA+,GABA,2020_pizzi_35,2,Somatic Symptom Disorder,10.1002/mds.28221,0.112,0.026,,,,,
,GABA+,GABA,2020_pizzi_35,3,Parkinson’s Disease,10.1002/mds.28221,0.085,0.02,,,,,
,GABA+,GABA,2020_pizzi_35,4,SSD + PD,10.1002/mds.28221,0.11,0.027,,,,,
,GABA,GABA,2020_sheth_123,1,Traumatic Brain Injury,10.1152/jn.00765.2019,,,0.37,0.03,,,
,GABA,GABA,2020_sheth_123,2,Non Traumatic Brain Injury,10.1152/jn.00765.2019,,,0.41,0.05,,,
,GABA,GABA,2018_giapitzakis_79,1,Healthy,10.1002/mrm.26873,,,,,1.07,0.697,Med/Quartile --> Mean/Std Greco 2015
,GABA,GABA,2018_giapitzakis_79,2,Healthy,10.1002/mrm.26873,,,,,1.52,1.314,Med/Quartile --> Mean/Std Wan 2014
,GABA,GABA,2020_vingerhoets_34,1,Healthy Control,10.1177/0269881120922977,,,0.93,0.18,,,
,GABA,GABA,2020_vingerhoets_34,7,George syndrome,10.1177/0269881120922977,,,0.89,0.28,,,
,GABA,GABA,2020_vingerhoets_34,3,Healthy Control,10.1177/0269881120922977,,,0.938,0.25,,,
,GABA,GABA,2020_vingerhoets_34,4,Healthy Control,10.1177/0269881120922977,,,0.775,0.16,,,
,GABA,GABA,2020_vingerhoets_34,9,George syndrome,10.1177/0269881120922977,,,0.975,0.34,,,
,GABA,GABA,2020_vingerhoets_34,10,George syndrome,10.1177/0269881120922977,,,0.874,0.19,,,
,GABA,GABA,2020_rafique_10,1,Healthy - Single rTMS - Pre-rTMS,10.1002/brb3.1845,,,3.662,0.727,,,
,GABA,GABA,2020_rafique_10,2,Healthy - Single rTMS - Immediate post-rTMS,10.1002/brb3.1845,,,3.919,0.88,,,
,GABA,GABA,2020_rafique_10,3,Healthy - Single rTMS - 1hr post-rTMS,10.1002/brb3.1845,,,0.757,0.919,,,
,GABA,GABA,2020_rafique_10,4,Healthy - 5 accelerated rTMS - Pre-rTMS,10.1002/brb3.1845,,,3.606,0.314,,,
,GABA,GABA,2020_rafique_10,5,Healthy - 5 accelerated rTMS - Immediate post-rTMS,10.1002/brb3.1845,,,3.317,0.351,,,
,GABA,GABA,2020_rafique_10,6,Healthy - 5 accelerated rTMS - 24hr post-rTMS,10.1002/brb3.1845,,,3.372,0.274,,,
,GABA,GABA,2020_rafique_10,7,Healthy - 5 accelerated rTMS - 1wk post-rTMS,10.1002/brb3.1845,,,3.798,0.506,,,
,GABA,GABA,2021_kozhuharova_238,1,Schizotypy - Low schizotypy,10.1007/s00213-021-05867-y,,,2.356,1.32,,,N_exclusions=21; StdDev calculated from SEM
,GABA,GABA,2021_kozhuharova_238,2,Schizotypy - High schizotypy,10.1007/s00213-021-05867-y,,,1.715,1.861,,,N_exclusions=19; StdDev calculated from SEM
,GABA+,GABA,2021_mawla_73,5,Fibromyalgia - Electroacupuncture - Pre-treatment,10.1002/art.41620,0.083,0.012,3.26,0.48,,,
,GABA+,GABA,2021_mawla_73,6,Fibromyalgia - Electroacupuncture - Post-treatment,10.1002/art.41620,0.083,0.02,3.21,0.83,,,
,GABA+,GABA,2021_mawla_73,7,Fibromyalgia - Sham - Pre-treatment,10.1002/art.41620,0.084,0.027,3.25,0.91,,,
,GABA+,GABA,2021_mawla_73,8,Fibromyalgia - Sham - Post-treatment,10.1002/art.41620,0.08,0.018,3.13,0.67,,,
,GABA,GABA,2016_lopezkolkovsky_75,1,Healthy_Rodent,10.1002/mrm.25602,,,,,2,0.3,
,GABA,GABA,2021_wijtenburg_12,1,Healthy Controls,10.3389/fpsyt.2021.644271,,,0.95,0.2,,,
,GABA,GABA,2021_wijtenburg_12,2,Schizophrenia,10.3389/fpsyt.2021.644271,,,0.87,0.2,,,
,GABA+,GABA,2021_persson_315,1,MDD,10.1016/j.pscychresns.2021.111327,0.101,0.01,,,,,
,GABA+,GABA,2021_persson_315,2,HC,10.1016/j.pscychresns.2021.111327,0.099,0.01,,,,,
,GABA+/Glu,GABA,2021_persson_315,1,MDD,10.1016/j.pscychresns.2021.111327,,,,,0.142,0.02,
,GABA+/Glu,GABA,2021_persson_315,2,HC,10.1016/j.pscychresns.2021.111327,,,,,0.139,0.02,
,GABA,GABA,2021_seger_36,1,PD patients,10.1002/mds.28674,,,1.5,0.26,,,
,GABA,GABA,2021_seger_36,2,Healthy controls,10.1002/mds.28674,,,1.26,0.31,,,
,GABA,GABA,2018_deelchand_79,1,Healthy,10.1002/mrm.26788,,,,,1.88,0.668,
,GABA,GABA,2018_maeshima_29,1,Healthy - Absolute pitch possessors,10.1097/WNR.0000000000001137,0.1,0.012,0.852,0.115,,,
,GABA,GABA,2018_maeshima_29,2,Healthy - Absolute pitch possessors,10.1097/WNR.0000000000001137,0.101,0.011,0.879,0.088,,,
,GABA,GABA,2018_maeshima_29,3,Healthy - Absolute pitch non-possessors,10.1097/WNR.0000000000001137,0.124,0.014,1.077,0.118,,,
,GABA,GABA,2018_maeshima_29,4,Healthy - Absolute pitch non-possessors,10.1097/WNR.0000000000001137,0.125,0.012,1.127,0.088,,,
,GABA+,GABA,2021_peek_22,1,Migraine,10.1016/j.jpain.2021.06.005,,,4.89,0.62,,,
,GABA+,GABA,2021_peek_22,2,Migraine,10.1016/j.jpain.2021.06.005,,,4.51,0.38,,,
,GABA+,GABA,2021_peek_22,3,Migraine,10.1016/j.jpain.2021.06.005,,,6.16,1.23,,,
,GABA+,GABA,2021_peek_22,4,Pain - Whiplash,10.1016/j.jpain.2021.06.005,,,4.78,0.43,,,
,GABA+,GABA,2021_peek_22,5,Pain - Whiplash,10.1016/j.jpain.2021.06.005,,,4.47,0.79,,,
,GABA+,GABA,2021_peek_22,6,Pain - Whiplash,10.1016/j.jpain.2021.06.005,,,6.08,0.79,,,
,GABA+,GABA,2021_peek_22,7,Pain - Back pain,10.1016/j.jpain.2021.06.005,,,4.88,0.44,,,
,GABA+,GABA,2021_peek_22,8,Pain - Back pain,10.1016/j.jpain.2021.06.005,,,4.6,0.47,,,
,GABA+,GABA,2021_peek_22,9,Pain - Back pain,10.1016/j.jpain.2021.06.005,,,6.55,1.78,,,
,GABA+,GABA,2021_peek_22,10,Control,10.1016/j.jpain.2021.06.005,,,4.62,0.38,,,
,GABA+,GABA,2021_peek_22,11,Control,10.1016/j.jpain.2021.06.005,,,4.59,0.51,,,
,GABA+,GABA,2021_peek_22,12,Control,10.1016/j.jpain.2021.06.005,,,5.75,0.78,,,
,GABA+,GABA,2021_peek_22,13,Control,10.1016/j.jpain.2021.06.005,,,4.63,0.44,,,
,GABA+,GABA,2021_peek_22,14,Control,10.1016/j.jpain.2021.06.005,,,4.69,0.99,,,
,GABA+,GABA,2021_peek_22,15,Control,10.1016/j.jpain.2021.06.005,,,5.61,0.91,,,
,GABA+,GABA,2021_peek_22,16,Control,10.1016/j.jpain.2021.06.005,,,4.6,0.32,,,
,GABA+,GABA,2021_peek_22,17,Control,10.1016/j.jpain.2021.06.005,,,4.47,0.5,,,
,GABA+,GABA,2021_peek_22,18,Control,10.1016/j.jpain.2021.06.005,,,5.53,0.8,,,
,Glc,Glc,2018_bednarik_38,1,Healthy,10.1177/0271678X17695291,,,,,0.8,0.48,
,Glc,Glc,2018_dejaeger_9,1,Painful Diabetic Polyneuropathy - Pregabalin Visit 1,10.1007/s13300-018-0460-y,,,,,1.18,0.62,
,Glc,Glc,2018_dejaeger_9,2,Painful Diabetic Polyneuropathy - Pregabalin Visit 1,10.1007/s13300-018-0460-y,,,,,1.71,0.49,
,Glc,Glc,2018_dejaeger_9,3,Painful Diabetic Polyneuropathy - Pregabalin Visit 1,10.1007/s13300-018-0460-y,,,,,1.66,0.51,
,Glc,Glc,2018_dejaeger_9,4,Painful Diabetic Polyneuropathy - Pregabalin Visit 1,10.1007/s13300-018-0460-y,,,,,2.45,0.66,
,Glc,Glc,2018_dejaeger_9,5,Painful Diabetic Polyneuropathy - Pregabalin Visit 3,10.1007/s13300-018-0460-y,,,,,1.17,0.58,
,Glc,Glc,2018_dejaeger_9,6,Painful Diabetic Polyneuropathy - Pregabalin Visit 3,10.1007/s13300-018-0460-y,,,,,1.74,0.97,
,Glc,Glc,2018_dejaeger_9,7,Painful Diabetic Polyneuropathy - Pregabalin Visit 3,10.1007/s13300-018-0460-y,,,,,2.05,0.51,
,Glc,Glc,2018_dejaeger_9,8,Painful Diabetic Polyneuropathy - Pregabalin Visit 3,10.1007/s13300-018-0460-y,,,,,2.07,0.7,
,Glc,Glc,2018_dejaeger_9,9,Painful Diabetic Polyneuropathy - Pregabalin Visit 5,10.1007/s13300-018-0460-y,,,,,0.92,0.54,
,Glc,Glc,2018_dejaeger_9,10,Painful Diabetic Polyneuropathy - Pregabalin Visit 5,10.1007/s13300-018-0460-y,,,,,1.48,0.79,
,Glc,Glc,2018_dejaeger_9,11,Painful Diabetic Polyneuropathy - Pregabalin Visit 5,10.1007/s13300-018-0460-y,,,,,1.58,0.69,
,Glc,Glc,2018_dejaeger_9,12,Painful Diabetic Polyneuropathy - Pregabalin Visit 5,10.1007/s13300-018-0460-y,,,,,2.13,0.57,
,Glc,Glc,2018_dejaeger_9,13,Painful Diabetic Polyneuropathy - Pregabalin Visit 7,10.1007/s13300-018-0460-y,,,,,1.21,0.77,
,Glc,Glc,2018_dejaeger_9,14,Painful Diabetic Polyneuropathy - Pregabalin Visit 7,10.1007/s13300-018-0460-y,,,,,1.63,0.92,
,Glc,Glc,2018_dejaeger_9,15,Painful Diabetic Polyneuropathy - Pregabalin Visit 7,10.1007/s13300-018-0460-y,,,,,1.64,0.91,
,Glc,Glc,2018_dejaeger_9,16,Painful Diabetic Polyneuropathy - Pregabalin Visit 7,10.1007/s13300-018-0460-y,,,,,2.24,0.98,
,Glc,Glc,2018_dejaeger_9,17,Painful Diabetic Polyneuropathy - Placebo Visit 1,10.1007/s13300-018-0460-y,,,,,1.66,0.59,
,Glc,Glc,2018_dejaeger_9,18,Painful Diabetic Polyneuropathy - Placebo Visit 1,10.1007/s13300-018-0460-y,,,,,1.39,0.61,
,Glc,Glc,2018_dejaeger_9,19,Painful Diabetic Polyneuropathy - Placebo Visit 1,10.1007/s13300-018-0460-y,,,,,2.15,0.92,
,Glc,Glc,2018_dejaeger_9,20,Painful Diabetic Polyneuropathy - Placebo Visit 1,10.1007/s13300-018-0460-y,,,,,2.18,0.65,
,Glc,Glc,2018_dejaeger_9,21,Painful Diabetic Polyneuropathy - Placebo Visit 3,10.1007/s13300-018-0460-y,,,,,1.28,0.52,
,Glc,Glc,2018_dejaeger_9,22,Painful Diabetic Polyneuropathy - Placebo Visit 3,10.1007/s13300-018-0460-y,,,,,1.36,0.73,
,Glc,Glc,2018_dejaeger_9,23,Painful Diabetic Polyneuropathy - Placebo Visit 3,10.1007/s13300-018-0460-y,,,,,1.69,0.65,
,Glc,Glc,2018_dejaeger_9,24,Painful Diabetic Polyneuropathy - Placebo Visit 3,10.1007/s13300-018-0460-y,,,,,2.24,0.89,
,Glc,Glc,2018_dejaeger_9,25,Painful Diabetic Polyneuropathy - Placebo Visit 5,10.1007/s13300-018-0460-y,,,,,1.46,0.53,
,Glc,Glc,2018_dejaeger_9,26,Painful Diabetic Polyneuropathy - Placebo Visit 5,10.1007/s13300-018-0460-y,,,,,1.32,0.56,
,Glc,Glc,2018_dejaeger_9,27,Painful Diabetic Polyneuropathy - Placebo Visit 5,10.1007/s13300-018-0460-y,,,,,1.89,1.1,
,Glc,Glc,2018_dejaeger_9,28,Painful Diabetic Polyneuropathy - Placebo Visit 5,10.1007/s13300-018-0460-y,,,,,2.03,0.92,
,Glc,Glc,2018_dejaeger_9,29,Painful Diabetic Polyneuropathy - Placebo Visit 7,10.1007/s13300-018-0460-y,,,,,1.29,0.59,
,Glc,Glc,2018_dejaeger_9,30,Painful Diabetic Polyneuropathy - Placebo Visit 7,10.1007/s13300-018-0460-y,,,,,1.32,0.73,
,Glc,Glc,2018_dejaeger_9,31,Painful Diabetic Polyneuropathy - Placebo Visit 7,10.1007/s13300-018-0460-y,,,,,2.37,0.91,
,Glc,Glc,2018_dejaeger_9,32,Painful Diabetic Polyneuropathy - Placebo Visit 7,10.1007/s13300-018-0460-y,,,,,2.46,1.27,
,Glc,Glc,2018_dejaeger_9,33,Painful Diabetic Polyneuropathy - Pregabalin 0 mg,10.1007/s13300-018-0460-y,,,,,1.36,0.56,
,Glc,Glc,2018_dejaeger_9,34,Painful Diabetic Polyneuropathy - Pregabalin 0 mg,10.1007/s13300-018-0460-y,,,,,1.4,0.63,
,Glc,Glc,2018_dejaeger_9,35,Painful Diabetic Polyneuropathy - Pregabalin 0 mg,10.1007/s13300-018-0460-y,,,,,1.95,0.85,
,Glc,Glc,2018_dejaeger_9,36,Painful Diabetic Polyneuropathy - Pregabalin 0 mg,10.1007/s13300-018-0460-y,,,,,2.2,0.9,
,Glc,Glc,2018_dejaeger_9,37,Painful Diabetic Polyneuropathy - Pregabalin 75 mg,10.1007/s13300-018-0460-y,,,,,1.27,0.57,
,Glc,Glc,2018_dejaeger_9,38,Painful Diabetic Polyneuropathy - Pregabalin 75 mg,10.1007/s13300-018-0460-y,,,,,1.81,0.73,
,Glc,Glc,2018_dejaeger_9,39,Painful Diabetic Polyneuropathy - Pregabalin 75 mg,10.1007/s13300-018-0460-y,,,,,2.19,0.83,
,Glc,Glc,2018_dejaeger_9,40,Painful Diabetic Polyneuropathy - Pregabalin 75 mg,10.1007/s13300-018-0460-y,,,,,2.23,1.01,
,Glc,Glc,2018_dejaeger_9,41,Painful Diabetic Polyneuropathy - Pregabalin 225 mg,10.1007/s13300-018-0460-y,,,,,1.07,0.66,
,Glc,Glc,2018_dejaeger_9,42,Painful Diabetic Polyneuropathy - Pregabalin 225 mg,10.1007/s13300-018-0460-y,,,,,1.47,0.73,
,Glc,Glc,2018_dejaeger_9,43,Painful Diabetic Polyneuropathy - Pregabalin 225 mg,10.1007/s13300-018-0460-y,,,,,1.65,0.65,
,Glc,Glc,2018_dejaeger_9,44,Painful Diabetic Polyneuropathy - Pregabalin 225 mg,10.1007/s13300-018-0460-y,,,,,2.22,0.71,
,Glc,Glc,2018_dejaeger_9,45,Painful Diabetic Polyneuropathy - Pregabalin 450 mg,10.1007/s13300-018-0460-y,,,,,1.21,0.68,
,Glc,Glc,2018_dejaeger_9,46,Painful Diabetic Polyneuropathy - Pregabalin 450 mg,10.1007/s13300-018-0460-y,,,,,1.36,0.74,
,Glc,Glc,2018_dejaeger_9,47,Painful Diabetic Polyneuropathy - Pregabalin 450 mg,10.1007/s13300-018-0460-y,,,,,1.59,0.71,
,Glc,Glc,2018_dejaeger_9,48,Painful Diabetic Polyneuropathy - Pregabalin 450 mg,10.1007/s13300-018-0460-y,,,,,1.9,0.94,
,Glc,Glc,2021_akiyama_61,1,Control,10.2176/nmc.oa.2020-0274,,,1.23,0.52,,,
,Glc,Glc,2021_akiyama_61,2,NPH,10.2176/nmc.oa.2020-0274,,,1.06,1.05,,,
,Glc + Tau,GlcTau,2019_betinaip_39,1,Behavior - ON - 3% Visual Contrast,10.1523/JNEUROSCI.3021-18.2019,,,1.458,0.275,,,
,Glc + Tau,GlcTau,2019_betinaip_39,2,Behavior - ON - 12.5% Visual Contrast,10.1523/JNEUROSCI.3021-18.2019,,,1.534,0.328,,,
,Glc + Tau,GlcTau,2019_betinaip_39,3,Behavior - ON - 50% Visual Contrast,10.1523/JNEUROSCI.3021-18.2019,,,1.535,0.332,,,
,Glc + Tau,GlcTau,2019_betinaip_39,4,Behavior - ON - 100% Visual Contrast,10.1523/JNEUROSCI.3021-18.2019,,,1.493,0.318,,,
,Glc + Tau,GlcTau,2019_betinaip_39,5,Resting,10.1523/JNEUROSCI.3021-18.2019,,,1.58,0.396,,,
,Glc + Tau,GlcTau,2019_betinaip_39,6,Behavior - OFF - 3% Visual Contrast,10.1523/JNEUROSCI.3021-18.2019,,,1.427,0.294,,,
,Glc + Tau,GlcTau,2019_betinaip_39,7,Behavior - OFF - 12.5% Visual Contrast,10.1523/JNEUROSCI.3021-18.2019,,,1.519,0.321,,,
,Glc + Tau,GlcTau,2019_betinaip_39,8,Behavior - OFF - 50% Visual Contrast,10.1523/JNEUROSCI.3021-18.2019,,,1.489,0.287,,,
,Glc + Tau,GlcTau,2019_betinaip_39,9,Behavior - OFF - 100% Visual Contrast,10.1523/JNEUROSCI.3021-18.2019,,,1.516,0.353,,,
,Glc + Tau,GlcTau,2019_betinaip_39,10,Resting,10.1523/JNEUROSCI.3021-18.2019,,,1.631,0.343,,,
,Glc,Glc ,2019_giapitzakis_81,1,Healthy,10.1002/mrm.27467,,,,,2.4,0.7,
,Glc,Glc ,2019_giapitzakis_81,2,Healthy,10.1002/mrm.27467,,,,,1.3,0.8,
,Glc,Glc ,2018_zarinabad_79,1,Medulloblastoma,10.1002/mrm.26837,,,,,0.56,0.31,
,Glc,Glc ,2018_zarinabad_79,2,Pilocytic Astrocytoma,10.1002/mrm.26837,,,,,0.47,0.48,
,Glc,Glc ,2018_zarinabad_79,3,Ependymoma,10.1002/mrm.26837,,,,,0.96,0.21,
,b-Glc,Glc ,2016_koob_11,1,Premature Neonates,10.1371/journal.pone.0160990,,,0.072,0.033,,,
,b-Glc,Glc ,2016_koob_11,3,Infants - Control,10.1371/journal.pone.0160990,,,0.088,0.045,,,
,Glc ,Glc ,2020_dehghani_83,2,Protocol 2,10.1002/mrm.28066,,,,,0.17,0.06,
,Glc ,Glc ,2018_giapitzakis_79,1,Healthy,10.1002/mrm.26873,,,,,0.63,1.586,Med/Quartile --> Mean/Std Greco 2015
,Glc ,Glc ,2018_giapitzakis_79,2,Healthy,10.1002/mrm.26873,,,,,0.66,0.698,Med/Quartile --> Mean/Std Wan 2014
,Glc + Tau,GlcTau,2019_cheong_90,1,Control - Visit 1,10.1136/jnnp-2018-318795,,,,,1.643,0.417,
,Glc + Tau,GlcTau,2019_cheong_90,2,Control - Visit 2,10.1136/jnnp-2018-318795,,,,,1.754,0.334,
,Glc + Tau,GlcTau,2019_cheong_90,3,Control - Visit 3,10.1136/jnnp-2018-318795,,,,,1.643,0.306,
,Glc + Tau,GlcTau,2019_cheong_90,7,ALS - Visit 1,10.1136/jnnp-2018-318795,,,,,1.624,0.385,
,Glc + Tau,GlcTau,2019_cheong_90,8,ALS - Visit 2,10.1136/jnnp-2018-318795,,,,,1.706,0.303,
,Glc + Tau,GlcTau,2019_cheong_90,9,ALS - Visit 3,10.1136/jnnp-2018-318795,,,,,1.954,0.578,
,Glc,Glc ,2016_lopezkolkovsky_75,1,Healthy_Rodent,10.1002/mrm.25602,,,,,2.2,0.6,
,Glc + Tau,GlcTau,2018_deelchand_79,1,Healthy,10.1002/mrm.26788,,,,,2.325,0.866,
,Glc + Tau,GlcTau,2018_deelchand_79,2,Healthy,10.1002/mrm.26788,,,,,4.205,1.41,
,Gln,Gln,2019_borgan_9,1,Control,10.1038/s41598-019-45018-0,,,,,4.92,2.55,
,Gln,Gln,2019_borgan_9,2,Psychosis,10.1038/s41598-019-45018-0,,,,,5.29,2.8,
,Gln,Gln,2019_brown_29,1,Corticosteroid,10.1016/j.euroneuro.2018.12.012,0.56,0.17,,,,,
,Gln,Gln,2019_brown_29,2,Corticosteroid,10.1016/j.euroneuro.2018.12.012,0.6,0.23,,,,,
,Gln,Gln,2019_brown_29,3,Corticosteroid,10.1016/j.euroneuro.2018.12.012,0.44,0.2,,,,,
,Gln,Gln,2019_brown_29,4,Corticosteroid,10.1016/j.euroneuro.2018.12.012,0.57,0.22,,,,,
,Gln,Gln,2019_brown_29,5,Corticosteroid,10.1016/j.euroneuro.2018.12.012,0.5,0.13,,,,,
,Gln,Gln,2019_brown_29,6,Corticosteroid,10.1016/j.euroneuro.2018.12.012,0.47,0.18,,,,,
,Gln,Gln,2019_brown_29,7,Corticosteroid,10.1016/j.euroneuro.2018.12.012,0.56,0.22,,,,,
,Gln,Gln,2019_brown_29,8,Corticosteroid,10.1016/j.euroneuro.2018.12.012,0.59,0.26,,,,,
,Gln,Gln,2019_cheong_90,1,Control - Visit 1,10.1136/jnnp-2018-318795,,,,,2.394,0.362,
,Gln,Gln,2019_cheong_90,2,Control - Visit 2,10.1136/jnnp-2018-318795,,,,,2.116,0.473,
,Gln,Gln,2019_cheong_90,3,Control - Visit 3,10.1136/jnnp-2018-318795,,,,,2.478,0.306,
,Gln,Gln,2019_cheong_90,7,ALS - Visit 1,10.1136/jnnp-2018-318795,,,,,2.307,0.302,
,Gln,Gln,2019_cheong_90,8,ALS - Visit 2,10.1136/jnnp-2018-318795,,,,,2.224,0.33,
,Gln,Gln,2019_cheong_90,9,ALS - Visit 3,10.1136/jnnp-2018-318795,,,,,2.471,0.22,
,Gln,Gln,2017_li_42,1,Control,10.1038/npp.2016.184,,,2.01,0.86,,,
,Gln,Gln,2017_li_42,2,Control,10.1038/npp.2016.184,,,2.37,0.63,,,
,Gln,Gln,2017_li_42,3,Control,10.1038/npp.2016.184,,,2.02,0.78,,,
,Gln,Gln,2017_li_42,4,Control,10.1038/npp.2016.184,,,1.52,0.49,,,
,Gln,Gln,2017_li_42,5,Control,10.1038/npp.2016.184,,,1.64,0.51,,,
,Gln,Gln,2017_li_42,6,Control,10.1038/npp.2016.184,,,1.69,0.49,,,
,Gln,Gln,2017_li_42,7,Ketamine,10.1038/npp.2016.184,,,1.91,0.47,,,
,Gln,Gln,2017_li_42,8,Ketamine,10.1038/npp.2016.184,,,2.2,0.88,,,
,Gln,Gln,2017_li_42,9,Ketamine,10.1038/npp.2016.184,,,2.3,0.42,,,
,Gln,Gln,2017_li_42,10,Ketamine,10.1038/npp.2016.184,,,1.42,0.53,,,
,Gln,Gln,2017_li_42,11,Ketamine,10.1038/npp.2016.184,,,1.6,0.42,,,
,Gln,Gln,2017_li_42,12,Ketamine,10.1038/npp.2016.184,,,1.5,0.41,,,
,Gln,Gln,2018_adanyeguh_31,2,Healthy,10.1002/nbm.3880,,,,,2,0.6,Estimated Bar Graph
,Gln,Gln,2018_adanyeguh_31,4,HD,10.1002/nbm.3880,,,,,2.2,0.2,Estimated Bar Graph
,Gln,Gln,2018_adanyeguh_31,1,Healthy,10.1002/nbm.3880,,,,,3.1,0.7,Estimated Bar Graph
,Gln,Gln,2018_adanyeguh_31,3,HD,10.1002/nbm.3880,,,,,2.7,0.5,Estimated Bar Graph
,Gln,Gln,2018_an_80,1,Healthy,10.1002/mrm.27172,0.33,0.06,,,,,
,Gln,Gln,2018_bednarik_38,1,Healthy,10.1177/0271678X17695291,,,,,2.45,0.42,
,Gln,Gln,2020_kumar_25,1,Healthy,10.1038/s41380-018-0104-7,,,,,1.66,0.31,
,Gln,Gln,2020_kumar_25,2,Healthy,10.1038/s41380-018-0104-7,,,,,1.2,0.23,
,Gln,Gln,2020_kumar_25,3,Healthy,10.1038/s41380-018-0104-7,,,,,1.57,0.28,
,Gln,Gln,2020_kumar_25,4,Schizophrenia,10.1038/s41380-018-0104-7,,,,,1.48,0.36,
,Gln,Gln,2020_kumar_25,5,Schizophrenia,10.1038/s41380-018-0104-7,,,,,1.22,0.25,
,Gln,Gln,2020_kumar_25,6,Schizophrenia,10.1038/s41380-018-0104-7,,,,,1.59,0.3,
,Gln,Gln,2020_kumar_25,7,Residual SZ,10.1038/s41380-018-0104-7,,,,,1.4,0.3,
,Gln,Gln,2020_kumar_25,8,Residual SZ,10.1038/s41380-018-0104-7,,,,,1.19,0.3,
,Gln,Gln,2020_kumar_25,9,Residual SZ,10.1038/s41380-018-0104-7,,,,,1.56,0.24,
,Gln,Gln,2018_evans_43,1,Control - Baseline,10.1038/s41386-018-0057-1,0.29,0.02,,,,,
,Gln,Gln,2018_evans_43,2,Control - Ketamine,10.1038/s41386-018-0057-1,0.31,0.03,,,,,
,Gln,Gln,2018_evans_43,3,Control - Placebo,10.1038/s41386-018-0057-1,0.28,0.03,,,,,
,Gln,Gln,2018_evans_43,4,Major Depressive Disorder - Baseline,10.1038/s41386-018-0057-1,0.29,0.02,,,,,
,Gln,Gln,2018_evans_43,5,Major Depressive Disorder - Ketamine,10.1038/s41386-018-0057-1,0.3,0.02,,,,,
,Gln,Gln,2018_evans_43,6,Major Depressive Disorder - Placebo,10.1038/s41386-018-0057-1,0.31,0.02,,,,,
,Gln,Gln,2018_godlewska_48,1,Major Depression,10.1017/S0033291717003373,,,3.48,0.857,,,
,Gln,Gln,2018_godlewska_48,2,Major Depression,10.1017/S0033291717003373,,,6.19,0.762,,,
,Gln,Gln,2018_godlewska_48,3,Major Depression,10.1017/S0033291717003373,,,4.73,0.849,,,
,Gln,Gln,2018_godlewska_48,4,Control,10.1017/S0033291717003373,,,3.21,0.47,,,
,Gln,Gln,2018_godlewska_48,5,Control,10.1017/S0033291717003373,,,6.3,0.831,,,
,Gln,Gln,2018_godlewska_48,6,Control,10.1017/S0033291717003373,,,4.17,0.754,,,
,Gln,Gln,2018_harper_17,1,Urologic Chronic Pelvic Pain Syndrome,10.1016/j.nicl.2017.11.014,0.25,0.1,1.27,0.51,,,
,Gln,Gln,2018_harper_17,2,Urologic Chronic Pelvic Pain Syndrome,10.1016/j.nicl.2017.11.014,0.27,0.13,1.64,0.77,,,
,Gln,Gln,2018_harper_17,3,Urologic Chronic Pelvic Pain Syndrome,10.1016/j.nicl.2017.11.014,0.25,0.16,1.47,1.07,,,
,Gln,Gln,2018_harper_17,4,Urologic Chronic Pelvic Pain Syndrome,10.1016/j.nicl.2017.11.014,0.25,0.1,1.6,0.65,,,
,Gln,Gln,2018_harper_17,5,Control,10.1016/j.nicl.2017.11.014,0.23,0.08,1.33,0.47,,,
,Gln,Gln,2018_harper_17,6,Control,10.1016/j.nicl.2017.11.014,0.3,0.1,1.81,0.62,,,
,Gln,Gln,2018_harper_17,7,Control,10.1016/j.nicl.2017.11.014,0.24,0.1,1.42,0.58,,,
,Gln,Gln,2018_harper_17,8,Control,10.1016/j.nicl.2017.11.014,0.24,0.11,1.5,0.67,,,
,Gln,Gln,2018_horder_8,1,Control,10.1038/s41398-018-0155-1,,,1.94,1.14,,,
,Gln,Gln,2018_horder_8,2,Control,10.1038/s41398-018-0155-1,,,1.98,0.36,,,
,Gln,Gln,2018_horder_8,3,Autism Spectrum Disorder,10.1038/s41398-018-0155-1,,,1.68,1.15,,,
,Gln,Gln,2018_horder_8,4,Autism Spectrum Disorder,10.1038/s41398-018-0155-1,,,1.97,0.45,,,
,Gln,Gln,2020_hjelmervik_46,1,Schizophrenia,10.1093/schbul/sbz099,,,3.6,2.54,,,
,Gln,Gln,2020_hjelmervik_46,2,Schizophrenia,10.1093/schbul/sbz099,,,6.95,3.49,,,
,Gln,Gln,2020_hjelmervik_46,3,Schizophrenia,10.1093/schbul/sbz099,,,4.22,2.39,,,
,Gln,Gln,2020_hjelmervik_46,4,Schizophrenia,10.1093/schbul/sbz099,,,3.12,1.64,,,
,Gln,Gln,2020_hjelmervik_46,5,Control,10.1093/schbul/sbz099,,,4.06,2.63,,,
,Gln,Gln,2020_hjelmervik_46,6,Control,10.1093/schbul/sbz099,,,7.08,3.66,,,
,Gln,Gln,2020_hjelmervik_46,7,Control,10.1093/schbul/sbz099,,,4.31,2.28,,,
,Gln,Gln,2020_hjelmervik_46,8,Control,10.1093/schbul/sbz099,,,2.75,1.5,,,
,Gln,Gln,2020_boillat_40,1,Baseline,10.1177/0271678X19831022,,,1.15,0.08,,,
,Gln,Gln,2020_boillat_40,2,positive BOLD,10.1177/0271678X19831022,,,0.01,0.11,,,
,Gln,Gln,2020_boillat_40,3,Baseline,10.1177/0271678X19831022,,,1.13,0.06,,,
,Gln,Gln,2020_boillat_40,4,negative BOLD,10.1177/0271678X19831022,,,0.06,0.14,,,
,Gln,Gln,2018_modinos_48,1,Healthy - Low Schizotypy,10.1017/S0033291717003403,,,7.04,1.41,,,n=7
,Gln,Gln,2018_modinos_48,2,Healthy - High Schizotypy,10.1017/S0033291717003403,,,6.7,1.72,,,n=11
,Gln,Gln,2021_akiyama_61,1,Control,10.2176/nmc.oa.2020-0274,,,1.42,1.31,,,
,Gln,Gln,2021_akiyama_61,2,NPH,10.2176/nmc.oa.2020-0274,,,2.33,2.65,,,
,Gln,Gln,2021_bednarik_15,1,Healthy,10.3389/fnins.2021.609485,,,,,2.83,0.21,
,Gln,Gln,2021_bednarik_15,2,Healthy,10.3389/fnins.2021.609485,,,,,2.43,0.21,
,Gln,Gln,2018_sheth_276,1,Veterans - Suicidal behavior,10.1016/j.pscychresns.2018.04.004,,,0.52,0.03,,,
,Gln,Gln,2018_sheth_276,2,Veterans - Suicidal behavior,10.1016/j.pscychresns.2018.04.004,,,0.54,0.02,,,
,Gln,Gln,2018_sheth_276,3,Veterans - No suicidal behavior,10.1016/j.pscychresns.2018.04.004,,,0.48,0.05,,,
,Gln,Gln,2018_sheth_276,4,Veterans - No suicidal behavior,10.1016/j.pscychresns.2018.04.004,,,0.55,0.05,,,
,Gln,Gln,2017_brennan_269,1,Control,10.1016/j.pscychresns.2017.08.009,0.27,0.05,,,,,
,Gln,Gln,2017_brennan_269,2,MDD,10.1016/j.pscychresns.2017.08.009,0.27,0.05,,,,,
,Gln,Gln,2017_brennan_269,3,MDD,10.1016/j.pscychresns.2017.08.009,0.28,0.08,,,,,
,Gln,Gln,2017_brennan_269,4,MDD,10.1016/j.pscychresns.2017.08.009,0.27,0.09,,,,,
,Gln,Gln,2017_brennan_269,5,MDD,10.1016/j.pscychresns.2017.08.009,0.23,0.06,,,,,
,Gln,Gln,2019_betinaip_39,1,Behavior - ON - 3% Visual Contrast,10.1523/JNEUROSCI.3021-18.2019,,,3.283,0.71,,,
,Gln,Gln,2019_betinaip_39,2,Behavior - ON - 12.5% Visual Contrast,10.1523/JNEUROSCI.3021-18.2019,,,3.048,0.599,,,
,Gln,Gln,2019_betinaip_39,3,Behavior - ON - 50% Visual Contrast,10.1523/JNEUROSCI.3021-18.2019,,,3.124,0.917,,,
,Gln,Gln,2019_betinaip_39,4,Behavior - ON - 100% Visual Contrast,10.1523/JNEUROSCI.3021-18.2019,,,3.158,0.816,,,
,Gln,Gln,2019_betinaip_39,5,Resting,10.1523/JNEUROSCI.3021-18.2019,,,3.191,0.799,,,
,Gln,Gln,2019_betinaip_39,6,Behavior - OFF - 3% Visual Contrast,10.1523/JNEUROSCI.3021-18.2019,,,3.277,0.725,,,
,Gln,Gln,2019_betinaip_39,7,Behavior - OFF - 12.5% Visual Contrast,10.1523/JNEUROSCI.3021-18.2019,,,3.025,0.613,,,
,Gln,Gln,2019_betinaip_39,8,Behavior - OFF - 50% Visual Contrast,10.1523/JNEUROSCI.3021-18.2019,,,3.018,0.771,,,
,Gln,Gln,2019_betinaip_39,9,Behavior - OFF - 100% Visual Contrast,10.1523/JNEUROSCI.3021-18.2019,,,3.143,0.819,,,
,Gln,Gln,2019_betinaip_39,10,Resting,10.1523/JNEUROSCI.3021-18.2019,,,3.147,0.72,,,
,Gln,Gln,2019_giapitzakis_81,1,Healthy,10.1002/mrm.27467,,,,,1.9,0.3,
,Gln,Gln,2019_giapitzakis_81,2,Healthy,10.1002/mrm.27467,,,,,1.7,0.4,
,Gln,Gln,2018_white_43,1,Healthy_Placebo,10.1038/s41386-018-0027-7,,,4.41,0.87,,,
,Gln,Gln,2018_white_43,2,Healthy_d-amphetamine,10.1038/s41386-018-0027-7,,,4.59,0.85,,,
,Gln,Gln,2018_white_43,3,Healthy_methamphetamine,10.1038/s41386-018-0027-7,,,4.42,0.95,,,
,Gln,Gln,2018_zarinabad_79,1,Medulloblastoma,10.1002/mrm.26837,,,,,2.6,1.53,
,Gln,Gln,2018_zarinabad_79,2,Pilocytic Astrocytoma,10.1002/mrm.26837,,,,,2.2,2.6,
,Gln,Gln,2018_zarinabad_79,3,Ependymoma,10.1002/mrm.26837,,,,,1.69,0.11,
,Gln,Gln,2020_zheng_265,1,Control,10.1016/j.jad.2020.01.059,,,6.32,3.04,,,
,Gln,Gln,2020_zheng_265,2,Control,10.1016/j.jad.2020.01.059,,,6.41,2.45,,,
,Gln,Gln,2020_zheng_265,3,Control,10.1016/j.jad.2020.01.059,,,6.24,3.65,,,
,Gln,Gln,2020_zheng_265,4,OCD,10.1016/j.jad.2020.01.059,,,6.94,4.43,,,
,Gln,Gln,2020_zheng_265,5,OCD,10.1016/j.jad.2020.01.059,,,8.2,4.99,,,
,Gln,Gln,2020_zheng_265,6,OCD,10.1016/j.jad.2020.01.059,,,5.15,2.96,,,
,Gln,Gln,2020_zheng_265,7,OCD + SPD,10.1016/j.jad.2020.01.059,,,8.24,4.67,,,
,Gln,Gln,2020_zheng_265,8,OCD + SPD,10.1016/j.jad.2020.01.059,,,9.54,6.02,,,
,Gln,Gln,2020_zheng_265,9,OCD + SPD,10.1016/j.jad.2020.01.059,,,7.67,4.24,,,
,Gln,Gln,2021_godlewska_11,1,Psychosis,10.1038/s41398-021-01477-6,,,3.39,0.599,,,
,Gln,Gln,2021_godlewska_11,2,Psychosis,10.1038/s41398-021-01477-6,,,2.48,0.56,,,
,Gln,Gln,2021_godlewska_11,3,Psychosis,10.1038/s41398-021-01477-6,,,3.22,0.711,,,
,Gln,Gln,2021_godlewska_11,4,Control,10.1038/s41398-021-01477-6,,,3.93,0.467,,,
,Gln,Gln,2021_godlewska_11,5,Control,10.1038/s41398-021-01477-6,,,2.8,0.424,,,
,Gln,Gln,2021_godlewska_11,6,Control,10.1038/s41398-021-01477-6,,,3.01,0.6,,,
,Gln,Gln,2020_savic_30,1,Control,10.1093/cercor/bhz340,,,,,3.1,1.7,
,Gln,Gln,2020_savic_30,2,Control,10.1093/cercor/bhz340,,,,,2.3,0.6,
,Gln,Gln,2020_savic_30,3,Control,10.1093/cercor/bhz340,,,,,1.5,1.3,
,Gln,Gln,2020_savic_30,4,Control,10.1093/cercor/bhz340,,,,,2.2,0.7,
,Gln,Gln,2020_savic_30,5,ES Patients,10.1093/cercor/bhz340,,,,,3.2,1.8,
,Gln,Gln,2020_savic_30,6,ES Patients,10.1093/cercor/bhz340,,,,,2.1,0.8,
,Gln,Gln,2020_savic_30,7,ES Patients,10.1093/cercor/bhz340,,,,,1.4,1.7,
,Gln,Gln,2020_savic_30,8,ES Patients,10.1093/cercor/bhz340,,,,,2.7,0.6,
,Gln,Gln,2019_marjanska_68,1,Alzheimer's disease,10.3233/JAD-180861,,,,,3.52,0.44,
,Gln,Gln,2019_marjanska_68,2,Alzheimer's disease,10.3233/JAD-180861,,,,,3.18,0.44,
,Gln,Gln,2019_marjanska_68,3,Control,10.3233/JAD-180861,,,,,3.35,0.402,
,Gln,Gln,2019_marjanska_68,4,Control,10.3233/JAD-180861,,,,,2.97,0.402,
,Gln,Gln,2019_mellen_27,1,Bipolar disorder - Older age bipolar depression,10.1016/j.jagp.2019.02.017,0.45,0.23,,,,,
,Gln,Gln,2019_mellen_27,2,Bipolar disorder - Older age bipolar depression,10.1016/j.jagp.2019.02.017,0.26,0.12,,,,,
,Gln,Gln,2019_mellen_27,3,Control,10.1016/j.jagp.2019.02.017,0.38,0.14,,,,,
,Gln,Gln,2019_mellen_27,4,Control,10.1016/j.jagp.2019.02.017,0.29,0.1,,,,,
,Gln,Gln,2021_steinegger_26,1,Control,10.1111/adb.13027,,,,,5.12,1.87,
,Gln,Gln,2021_steinegger_26,3,Smokers,10.1111/adb.13027,,,,,5.27,1.75,
,Gln,Gln,2021_steinegger_26,6,Baseline,10.1111/adb.13027,,,,,5.05,1.52,
,Gln,Gln,2021_steinegger_26,7,Withdrawal,10.1111/adb.13027,,,,,5.74,2.35,
,Gln,Gln,2021_steinegger_26,8,Satiation,10.1111/adb.13027,,,,,5.43,2.17,
,Gln,Gln,2019_prisci_43,1,Alcohol use disorder ,10.1111/acer.13931,,,0.81,0.18,,,
,Gln,Gln,2019_prisci_43,2,Control,10.1111/acer.13931,,,0.99,0.21,,,
,Gln,Gln,2019_sheth_248,1,PTSD,10.1016/j.jad.2019.01.037,0.23,0.05,0.46,0,,,
,Gln,Gln,2019_sheth_248,2,Trauma-exposed ,10.1016/j.jad.2019.01.037,0.26,0.08,0.48,0,,,
,Gln,Gln,2019_sheth_248,3,Control,10.1016/j.jad.2019.01.037,0.27,0.05,0.58,0,,,
,Gln,Gln,2019_strasser_29,1,Healthy,10.1016/j.euroneuro.2018.12.015,,,,,4.45,1.05,
,Gln,Gln,2019_strasser_29,2,Healthy,10.1016/j.euroneuro.2018.12.015,,,,,2.11,0.41,
,Gln,Gln,2019_wagoner_317,1,Non-OI,10.1152/ajpheart.00680.2018,,,3.3,1.852,,,
,Gln,Gln,2019_wagoner_317,2,OI,10.1152/ajpheart.00680.2018,,,3.5,0.663,,,
,Gln,Gln,2019_wang_76,1,FEP,10.1001/jamapsychiatry.2018.3637,,,1.8,0.22,,,
,Gln,Gln,2019_wang_76,2,FEP,10.1001/jamapsychiatry.2018.3637,,,1,0.2,,,
,Gln,Gln,2019_wang_76,3,FEP,10.1001/jamapsychiatry.2018.3637,,,1.4,0.2,,,
,Gln,Gln,2019_wang_76,4,FEP,10.1001/jamapsychiatry.2018.3637,,,1.5,0.2,,,
,Gln,Gln,2019_wang_76,5,FEP,10.1001/jamapsychiatry.2018.3637,,,1.5,1,,,
,Gln,Gln,2019_wang_76,6,Control,10.1001/jamapsychiatry.2018.3637,,,1.8,0.25,,,
,Gln,Gln,2019_wang_76,7,Control,10.1001/jamapsychiatry.2018.3637,,,1,0.15,,,
,Gln,Gln,2019_wang_76,8,Control,10.1001/jamapsychiatry.2018.3637,,,1.4,0.22,,,
,Gln,Gln,2019_wang_76,9,Control,10.1001/jamapsychiatry.2018.3637,,,1.52,0.18,,,
,Gln,Gln,2019_wang_76,10,Control,10.1001/jamapsychiatry.2018.3637,,,1.4,0.8,,,
,Gln,Gln,2018_povazan_79,1,Healthy,10.1002/mrm.26778,,,4.67,0.54,,,
,Gln,Gln,2018_povazan_79,2,Healthy,10.1002/mrm.26778,,,3.22,0.34,,,
,Gln,Gln,2018_povazan_79,3,Healthy,10.1002/mrm.26778,,,3.07,0.39,,,
,Gln,Gln,2018_povazan_79,4,Healthy,10.1002/mrm.26778,,,3.32,0.43,,,
,Gln,Gln,2018_povazan_79,5,Healthy,10.1002/mrm.26778,,,4.14,0.53,,,
,Gln,Gln,2018_povazan_79,6,Healthy,10.1002/mrm.26778,,,2.93,0.68,,,
,Gln,Gln,2018_povazan_79,7,Healthy,10.1002/mrm.26778,,,2.7,0.57,,,
,Gln,Gln,2019_wiegers_62,1,Control,10.1007/s00125-019-4862-9,,,,,1.32,0.44,
,Gln,Gln,2019_wiegers_62,2,Type 1 diabetes - Normal awareness of hypoglycaemia,10.1007/s00125-019-4862-9,,,,,1.45,0.57,
,Gln,Gln,2019_wiegers_62,3,Type 1 diabetes,10.1007/s00125-019-4862-9,,,,,1.64,0.68,
,Gln,Gln,2020_gonen_14,1,Healthy,10.3389/fnins.2020.566643,,,,,2.27,0.49,
,Gln,Gln,2020_gonen_14,2,Healthy,10.3389/fnins.2020.566643,,,,,2.13,0.49,
,Gln,Gln,2020_gonen_14,3,Healthy,10.3389/fnins.2020.566643,,,,,2.28,0.23,
,Gln,Gln,2020_gonen_14,4,Healthy,10.3389/fnins.2020.566643,,,,,2.19,0.42,
,Gln,Gln,2019_morgenroth_117,4,Trait Anxiety,10.1016/j.cortex.2019.02.021,,,0.2,0.06,,,
,Gln,Gln,2019_morgenroth_117,5,Trait Anxiety - Low trait anxiety,10.1016/j.cortex.2019.02.021,,,0.19,0.05,,,
,Gln,Gln,2019_morgenroth_117,6,Trait Anxiety - High trait anxiety,10.1016/j.cortex.2019.02.021,,,0.21,0.07,,,
,Gln,Gln,2019_reid_45,1,Control,10.1093/schbul/sbx190,,,1.91,0.23,,,
,Gln,Gln,2019_reid_45,2,Schizophrenia,10.1093/schbul/sbx190,,,1.82,0.32,,,
,Gln,Gln,2020_demnitz_295,1,Addiction ,10.1016/j.pscychresns.2019.111019,,,,,4.05,1.12,
,Gln,Gln,2020_lind_40,7,Aging,10.1523/JNEUROSCI.2883-19.2020,,,,,1.96,0.49,
,Gln,Gln,2020_lind_40,8,Aging,10.1523/JNEUROSCI.2883-19.2020,,,,,2.1,0.67,
,Gln,Gln,2020_lind_40,9,Aging,10.1523/JNEUROSCI.2883-19.2020,,,,,2.47,0.63,
,Gln,Gln,2020_sheth_123,1,Traumatic Brain Injury,10.1152/jn.00765.2019,,,0.54,0.03,,,
,Gln,Gln,2020_sheth_123,2,Non Traumatic Brain Injury,10.1152/jn.00765.2019,,,0.5,0.04,,,
,Gln,Gln,2018_giapitzakis_79,1,Healthy,10.1002/mrm.26873,,,,,2.3,0.505,Med/Quartile --> Mean/Std Wan 2014
,Gln,Gln,2018_giapitzakis_79,2,Healthy,10.1002/mrm.26873,,,,,2.01,1.571,Med/Quartile --> Mean/Std Wan 2014
,Gln,Gln,2020_vingerhoets_34,1,Healthy Control,10.1177/0269881120922977,,,0.816,0.2,,,
,Gln,Gln,2020_vingerhoets_34,2,Healthy Control,10.1177/0269881120922977,,,1.181,0.32,,,
,Gln,Gln,2020_vingerhoets_34,3,Healthy Control,10.1177/0269881120922977,,,0.816,0.2,,,
,Gln,Gln,2020_vingerhoets_34,4,Healthy Control,10.1177/0269881120922977,,,0.832,0.23,,,
,Gln,Gln,2020_vingerhoets_34,5,Healthy Control,10.1177/0269881120922977,,,1.151,0.32,,,
,Gln,Gln,2020_vingerhoets_34,6,Healthy Control,10.1177/0269881120922977,,,1.137,0.36,,,
,Gln,Gln,2020_vingerhoets_34,7,George syndrome,10.1177/0269881120922977,,,0.801,0.23,,,
,Gln,Gln,2020_vingerhoets_34,8,George syndrome,10.1177/0269881120922977,,,1.132,0.42,,,
,Gln,Gln,2020_vingerhoets_34,9,George syndrome,10.1177/0269881120922977,,,0.785,0.22,,,
,Gln,Gln,2020_vingerhoets_34,10,George syndrome,10.1177/0269881120922977,,,0.794,0.25,,,
,Gln,Gln,2020_vingerhoets_34,11,George syndrome,10.1177/0269881120922977,,,1.025,0.23,,,
,Gln,Gln,2020_vingerhoets_34,12,George syndrome,10.1177/0269881120922977,,,0.95,0.3,,,
,Gln,Gln,2021_egerton_47,1,Psychosis - Antipsychotic responder,10.1093/schbul/sbaa128,,,7.99,2.23,,,n=9
,Gln,Gln,2021_egerton_47,2,Psychosis - Antipsychotic responder,10.1093/schbul/sbaa128,,,6.11,0.9,,,n=16
,Gln,Gln,2021_egerton_47,3,Psychosis - Antipsychotic responder,10.1093/schbul/sbaa128,,,6.24,1.38,,,n=6
,Gln,Gln,2021_egerton_47,4,Psychosis - Antipsychotic responder,10.1093/schbul/sbaa128,,,3.71,0.62,,,n=3
,Gln,Gln,2021_egerton_47,5,Psychosis - Antipsychotic responder,10.1093/schbul/sbaa128,,,8.39,1.73,,,n=10
,Gln,Gln,2021_egerton_47,6,Psychosis - Antipsychotic responder,10.1093/schbul/sbaa128,,,6.04,1.1,,,n=13
,Gln,Gln,2021_egerton_47,7,Psychosis - Antipsychotic responder,10.1093/schbul/sbaa128,,,6.29,1.2,,,n=5
,Gln,Gln,2021_egerton_47,8,Psychosis - Antipsychotic responder,10.1093/schbul/sbaa128,,,3.99,0.38,,,n=3
,Gln,Gln,2021_egerton_47,9,Psychosis - Antipsychotic non-responder,10.1093/schbul/sbaa128,,,5.68,0.55,,,n=4
,Gln,Gln,2021_egerton_47,10,Psychosis - Antipsychotic non-responder,10.1093/schbul/sbaa128,,,4.95,0.68,,,n=12
,Gln,Gln,2021_egerton_47,11,Psychosis - Antipsychotic non-responder,10.1093/schbul/sbaa128,,,9.26,4.94,,,n=4
,Gln,Gln,2021_egerton_47,12,Psychosis - Antipsychotic non-responder,10.1093/schbul/sbaa128,,,4.67,0.882,,,n=1 Assumed 15% StdDev
,Gln,Gln,2021_egerton_47,13,Psychosis - Antipsychotic non-responder,10.1093/schbul/sbaa128,,,5.88,0.34,,,n=1
,Gln,Gln,2021_egerton_47,14,Psychosis - Antipsychotic non-responder,10.1093/schbul/sbaa128,,,5.03,1.88,,,n=11
,Gln,Gln,2021_egerton_47,15,Psychosis - Antipsychotic non-responder,10.1093/schbul/sbaa128,,,6.27,1.07,,,n=3
,Gln,Gln,2021_egerton_47,16,Psychosis - Antipsychotic non-responder,10.1093/schbul/sbaa128,,,5.96,2.06,,,n=2
,Gln,Gln,2016_lopezkolkovsky_75,1,Healthy_Rodent,10.1002/mrm.25602,,,,,4.6,0.4,
,Gln,Gln,2021_wijtenburg_12,1,Healthy Controls,10.3389/fpsyt.2021.644271,,,1.8,0.4,,,
,Gln,Gln,2021_wijtenburg_12,2,Schizophrenia,10.3389/fpsyt.2021.644271,,,2.2,0.6,,,
,Gln,Gln,2018_deelchand_79,1,Healthy,10.1002/mrm.26788,,,,,2.721,1.014,
,Gln,Gln,2018_deelchand_79,2,Healthy,10.1002/mrm.26788,,,,,1.905,0.593,
,Glu,Glu,2020_benson_274,2,Control,10.1016/j.jad.2020.05.026,1,0.2,,,,,Glutamate (Not Glx Model) Quantified from MEGA-PRESS Off Spectra
,Glu,Glu,2020_benson_274,3,Control,10.1016/j.jad.2020.05.026,0.83,0.1,,,,,Glutamate (Not Glx Model) Quantified from MEGA-PRESS Off Spectra
,Glu,Glu,2020_benson_274,5,Insomnia,10.1016/j.jad.2020.05.026,0.93,0.19,,,,,Glutamate (Not Glx Model) Quantified from MEGA-PRESS Off Spectra
,Glu,Glu,2020_benson_274,6,Insomnia,10.1016/j.jad.2020.05.026,0.79,0.13,,,,,Glutamate (Not Glx Model) Quantified from MEGA-PRESS Off Spectra
,Glu,Glu,2020_benson_274,8,Depression,10.1016/j.jad.2020.05.026,0.86,0.18,,,,,Glutamate (Not Glx Model) Quantified from MEGA-PRESS Off Spectra
,Glu,Glu,2020_benson_274,10,Depression,10.1016/j.jad.2020.05.026,0.84,0.08,,,,,Glutamate (Not Glx Model) Quantified from MEGA-PRESS Off Spectra
,Glu,Glu,2019_borgelt_21,1,Bipolar - First,10.1111/bdi.12782,,,,,5.3,1.2,
,Glu,Glu,2019_borgelt_21,2,Bipolar - First,10.1111/bdi.12782,,,,,6.27,1.15,
,Glu,Glu,2019_borgelt_21,3,Bipolar - First,10.1111/bdi.12782,,,,,5.35,0.9,
,Glu,Glu,2019_borgelt_21,4,Bipolar - Multiple,10.1111/bdi.12782,,,,,4.88,1.16,
,Glu,Glu,2019_borgelt_21,5,Bipolar - Multiple,10.1111/bdi.12782,,,,,5.99,0.97,
,Glu,Glu,2019_borgelt_21,6,Bipolar - Multiple,10.1111/bdi.12782,,,,,5.28,1.02,
,Glu,Glu,2019_bossong_76,1,Control,10.1001/jamapsychiatry.2018.3252,,,,,8.31,1.12,
,Glu,Glu,2019_bossong_76,2,Psychosis - HighRisk,10.1001/jamapsychiatry.2018.3252,,,,,8.33,1.48,
,Glu,Glu,2019_bossong_76,3,Psychosis,10.1001/jamapsychiatry.2018.3252,,,,,9.16,1.28,
,Glu,Glu,2019_brown_29,1,Corticosteroid,10.1016/j.euroneuro.2018.12.012,0.89,0.13,,,,,
,Glu,Glu,2019_brown_29,2,Corticosteroid,10.1016/j.euroneuro.2018.12.012,0.92,0.15,,,,,
,Glu,Glu,2019_brown_29,3,Corticosteroid,10.1016/j.euroneuro.2018.12.012,0.84,0.1,,,,,
,Glu,Glu,2019_brown_29,4,Corticosteroid,10.1016/j.euroneuro.2018.12.012,0.94,0.12,,,,,
,Glu,Glu,2019_brown_29,5,Corticosteroid,10.1016/j.euroneuro.2018.12.012,0.86,0.11,,,,,
,Glu,Glu,2019_brown_29,6,Corticosteroid,10.1016/j.euroneuro.2018.12.012,0.92,0.13,,,,,
,Glu,Glu,2019_brown_29,7,Corticosteroid,10.1016/j.euroneuro.2018.12.012,0.86,0.13,,,,,
,Glu,Glu,2019_brown_29,8,Corticosteroid,10.1016/j.euroneuro.2018.12.012,0.98,0.2,,,,,
,Glu,Glu,2019_cheong_90,1,Control - Visit 1,10.1136/jnnp-2018-318795,,,,,6.042,0.417,
,Glu,Glu,2019_cheong_90,2,Control - Visit 2,10.1136/jnnp-2018-318795,,,,,6.07,0.445,
,Glu,Glu,2019_cheong_90,3,Control - Visit 3,10.1136/jnnp-2018-318795,,,,,6.237,0.417,
,Glu,Glu,2019_cheong_90,7,ALS - Visit 1,10.1136/jnnp-2018-318795,,,,,5.876,0.55,
,Glu,Glu,2019_cheong_90,8,ALS - Visit 2,10.1136/jnnp-2018-318795,,,,,5.767,0.659,
,Glu,Glu,2019_cheong_90,9,ALS - Visit 3,10.1136/jnnp-2018-318795,,,,,6.014,0.412,
,Glu,Glu,2017_li_42,1,Control,10.1038/npp.2016.184,,,6.22,0.88,,,
,Glu,Glu,2017_li_42,2,Control,10.1038/npp.2016.184,,,5.99,0.67,,,
,Glu,Glu,2017_li_42,3,Control,10.1038/npp.2016.184,,,6.5,0.9,,,
,Glu,Glu,2017_li_42,4,Control,10.1038/npp.2016.184,,,6.23,0.49,,,
,Glu,Glu,2017_li_42,5,Control,10.1038/npp.2016.184,,,6.12,0.42,,,
,Glu,Glu,2017_li_42,6,Control,10.1038/npp.2016.184,,,6,0.55,,,
,Glu,Glu,2017_li_42,7,Ketamine,10.1038/npp.2016.184,,,6.04,0.9,,,
,Glu,Glu,2017_li_42,8,Ketamine,10.1038/npp.2016.184,,,5.89,0.73,,,
,Glu,Glu,2017_li_42,9,Ketamine,10.1038/npp.2016.184,,,5.23,0.97,,,
,Glu,Glu,2017_li_42,10,Ketamine,10.1038/npp.2016.184,,,6.52,1.05,,,
,Glu,Glu,2017_li_42,11,Ketamine,10.1038/npp.2016.184,,,6.04,0.64,,,
,Glu,Glu,2017_li_42,12,Ketamine,10.1038/npp.2016.184,,,5.99,0.39,,,
,Glu,Glu,2019_craig_121,1,Control,10.1016/j.cortex.2019.08.017,,,11.5,3.9,,,
,Glu,Glu,2019_craig_121,2,Control,10.1016/j.cortex.2019.08.017,,,10.6,2.4,,,
,Glu,Glu,2019_craig_121,3,Control,10.1016/j.cortex.2019.08.017,,,7.8,2,,,
,Glu,Glu,2019_craig_121,4,Control,10.1016/j.cortex.2019.08.017,,,7.8,2.6,,,
,Glu,Glu,2019_craig_121,5,Psychiatric,10.1016/j.cortex.2019.08.017,,,11.7,3.8,,,
,Glu,Glu,2019_craig_121,6,Psychiatric,10.1016/j.cortex.2019.08.017,,,10.6,2.2,,,
,Glu,Glu,2019_craig_121,7,Psychiatric,10.1016/j.cortex.2019.08.017,,,8.2,2.1,,,
,Glu,Glu,2019_craig_121,8,Psychiatric,10.1016/j.cortex.2019.08.017,,,7.6,2.1,,,
,Glu,Glu,2019_davies_29,1,High-Risk Psychosis,10.1016/j.euroneuro.2019.03.008,1.07,0.17,8.92,1.62,,,
,Glu,Glu,2019_davies_29,2,High-Risk Psychosis,10.1016/j.euroneuro.2019.03.008,1.36,0.16,5.18,0.43,,,
,Glu,Glu,2019_davies_29,3,High-Risk Psychosis,10.1016/j.euroneuro.2019.03.008,0.98,0.16,9.21,2.11,,,
,Glu,Glu,2019_davies_29,4,High-Risk Psychosis,10.1016/j.euroneuro.2019.03.008,1.01,0.16,9.62,2.17,,,
,Glu,Glu,2019_davies_29,5,High-Risk Psychosis,10.1016/j.euroneuro.2019.03.008,1.33,0.11,5.04,0.43,,,
,Glu,Glu,2019_davies_29,6,High-Risk Psychosis,10.1016/j.euroneuro.2019.03.008,0.98,0.18,9.25,2.27,,,
,Glu,Glu,2018_adanyeguh_31,2,Healthy,10.1002/nbm.3880,,,,,7,0.6,Estimated Bar Graph
,Glu,Glu,2018_adanyeguh_31,4,HD,10.1002/nbm.3880,,,,,7.1,0.4,Estimated Bar Graph
,Glu,Glu,2018_adanyeguh_31,1,Healthy,10.1002/nbm.3880,,,,,6.5,0.7,Estimated Bar Graph
,Glu,Glu,2018_adanyeguh_31,3,HD,10.1002/nbm.3880,,,,,5.3,0.5,Estimated Bar Graph
,Glu ,Glu,2020_li_74,1,POA,10.1111/pcn.12940,,,,,9.84,1.83,
,Glu,Glu,2020_li_74,3,Control,10.1111/pcn.12940,,,,,8.09,1.05,
,Glu,Glu,2018_al-iedani_108,1,Healthy,10.1016/j.ejrad.2018.09.020,1.15,0.04,,,,,
,Glu,Glu,2018_al-iedani_108,2,Healthy,10.1016/j.ejrad.2018.09.020,1.06,0.02,,,,,
,Glu,Glu,2018_an_80,1,Healthy,10.1002/mrm.27172,1.26,0.13,,,,,
,Glu,Glu,2018_atagun_235,1,BD-I,10.1016/j.jad.2018.04.010,,,1.31,0.16,,,
,Glu,Glu,2018_atagun_235,2,BD-I,10.1016/j.jad.2018.04.010,,,0.82,0.11,,,
,Glu,Glu,2018_atagun_235,3,BD-II,10.1016/j.jad.2018.04.010,,,1.46,0.24,,,
,Glu,Glu,2018_atagun_235,4,BD-II,10.1016/j.jad.2018.04.010,,,0.99,0.25,,,
,Glu,Glu,2018_atagun_235,5,Control,10.1016/j.jad.2018.04.010,,,1.43,0.18,,,
,Glu,Glu,2018_atagun_235,6,Control,10.1016/j.jad.2018.04.010,,,0.95,0.13,,,
,Glu,Glu,2018_bauer_19,1,Healthy,10.1080/15622975.2016.1262060,,,10.9,1.61,,,
,Glu,Glu,2018_bauer_19,2,Healthy,10.1080/15622975.2016.1262060,,,9.39,1.62,,,
,Glu,Glu,2018_bauer_19,3,ADHD,10.1080/15622975.2016.1262060,,,12.19,1.69,,,
,Glu,Glu,2018_bauer_19,4,ADHD,10.1080/15622975.2016.1262060,,,9.75,2.03,,,
,Glu,Glu,2018_bednarik_38,1,Healthy,10.1177/0271678X17695291,,,,,8.53,0.59,
,Glu,Glu,2018_caravaggio_28,1,Healthy,10.1016/j.euroneuro.2017.12.002,,,8.88,1.31,,,
,Glu,Glu,2018_caravaggio_28,2,Healthy,10.1016/j.euroneuro.2017.12.002,,,8.41,1.81,,,
,Glu,Glu,2018_caravaggio_28,3,Healthy,10.1016/j.euroneuro.2017.12.002,,,12.11,1.68,,,
,Glu,Glu,2018_caravaggio_28,4,Healthy,10.1016/j.euroneuro.2017.12.002,,,11.59,1.33,,,
,Glu,Glu,2018_de_239,1,Postpartum Depression,10.1016/j.jad.2018.07.028,1.4,0.2,,,,,
,Glu,Glu,2018_de_239,2,Postpartum Euthymic ,10.1016/j.jad.2018.07.028,1.5,0.2,,,,,
,Glu,Glu,2020_kumar_25,1,Healthy,10.1038/s41380-018-0104-7,,,,,6.21,0.81,
,Glu,Glu,2020_kumar_25,2,Healthy,10.1038/s41380-018-0104-7,,,,,5.4,0.51,
,Glu,Glu,2020_kumar_25,3,Healthy,10.1038/s41380-018-0104-7,,,,,6.44,0.51,
,Glu,Glu,2020_kumar_25,4,Schizophrenia,10.1038/s41380-018-0104-7,,,,,6.01,0.66,
,Glu,Glu,2020_kumar_25,5,Schizophrenia,10.1038/s41380-018-0104-7,,,,,5.3,0.51,
,Glu,Glu,2020_kumar_25,6,Schizophrenia,10.1038/s41380-018-0104-7,,,,,6.39,0.68,
,Glu,Glu,2020_kumar_25,7,Residual SZ,10.1038/s41380-018-0104-7,,,,,5.68,0.73,
,Glu,Glu,2020_kumar_25,8,Residual SZ,10.1038/s41380-018-0104-7,,,,,5.37,0.55,
,Glu,Glu,2020_kumar_25,9,Residual SZ,10.1038/s41380-018-0104-7,,,,,6.56,0.6,
,Glu,Glu,2018_egerton_23,1,Healthy - Baseline,10.1038/s41380-018-0082-9,1.33,0.15,,,,,
,Glu,Glu,2018_egerton_23,2,Healthy - Baseline,10.1038/s41380-018-0082-9,1.36,0.11,,,,,
,Glu,Glu,2018_egerton_23,3,Healthy - Baseline,10.1038/s41380-018-0082-9,1.34,0.12,,,,,
,Glu,Glu,2018_egerton_23,4,Healthy - Baseline,10.1038/s41380-018-0082-9,1.07,0.12,,,,,
,Glu,Glu,2018_egerton_23,5,Healthy - Baseline,10.1038/s41380-018-0082-9,1.19,0.17,,,,,
,Glu,Glu,2018_egerton_23,6,Healthy - Baseline,10.1038/s41380-018-0082-9,1.02,0.25,,,,,
,Glu,Glu,2018_egerton_23,7,Healthy - After Amisulpride,10.1038/s41380-018-0082-9,1.27,0.16,,,,,
,Glu,Glu,2018_egerton_23,8,Healthy - After Amisulpride,10.1038/s41380-018-0082-9,1.42,0.08,,,,,
,Glu,Glu,2018_egerton_23,9,Healthy - After Amisulpride,10.1038/s41380-018-0082-9,1.3,0.11,,,,,
,Glu,Glu,2018_egerton_23,10,Healthy - After Amisulpride,10.1038/s41380-018-0082-9,1,0.18,,,,,
,Glu,Glu,2018_egerton_23,11,Healthy - After Amisulpride,10.1038/s41380-018-0082-9,1.28,0.19,,,,,
,Glu,Glu,2018_egerton_23,12,Healthy - After Amisulpride,10.1038/s41380-018-0082-9,1.04,0.19,,,,,
,Glu,Glu,2018_egerton_23,13,First Episode Psychosis - Baseline,10.1038/s41380-018-0082-9,1.33,0.17,,,,,
,Glu,Glu,2018_egerton_23,14,First Episode Psychosis - Baseline,10.1038/s41380-018-0082-9,1.37,0.17,,,,,
,Glu,Glu,2018_egerton_23,15,First Episode Psychosis - Baseline,10.1038/s41380-018-0082-9,1.26,0.1,,,,,
,Glu,Glu,2018_egerton_23,16,First Episode Psychosis - Baseline,10.1038/s41380-018-0082-9,1.02,0.13,,,,,
,Glu,Glu,2018_egerton_23,17,First Episode Psychosis - Baseline,10.1038/s41380-018-0082-9,1.11,0.19,,,,,
,Glu,Glu,2018_egerton_23,18,First Episode Psychosis - Baseline,10.1038/s41380-018-0082-9,1.2,0.21,,,,,
,Glu,Glu,2018_egerton_23,19,First Episode Psychosis - After Amisulpride,10.1038/s41380-018-0082-9,1.23,0.25,,,,,
,Glu,Glu,2018_egerton_23,20,First Episode Psychosis - After Amisulpride,10.1038/s41380-018-0082-9,1.32,0.1,,,,,
,Glu,Glu,2018_egerton_23,21,First Episode Psychosis - After Amisulpride,10.1038/s41380-018-0082-9,1.25,0.19,,,,,
,Glu,Glu,2018_egerton_23,22,First Episode Psychosis - After Amisulpride,10.1038/s41380-018-0082-9,1.02,0.16,,,,,
,Glu,Glu,2018_egerton_23,23,First Episode Psychosis - After Amisulpride,10.1038/s41380-018-0082-9,1.15,0.2,,,,,
,Glu,Glu,2018_egerton_23,24,First Episode Psychosis - After Amisulpride,10.1038/s41380-018-0082-9,1,0.23,,,,,
,Glu,Glu,2018_egerton_23,25,First Episode Psychosis - Remission (Baseline),10.1038/s41380-018-0082-9,1.28,0.14,,,,,
,Glu,Glu,2018_egerton_23,26,First Episode Psychosis - Remission (Baseline),10.1038/s41380-018-0082-9,1.35,0.16,,,,,
,Glu,Glu,2018_egerton_23,27,First Episode Psychosis - Remission (Baseline),10.1038/s41380-018-0082-9,1.26,0.11,,,,,
,Glu,Glu,2018_egerton_23,28,First Episode Psychosis - Remission (Baseline),10.1038/s41380-018-0082-9,1,0.15,,,,,
,Glu,Glu,2018_egerton_23,29,First Episode Psychosis - Remission (Baseline),10.1038/s41380-018-0082-9,1.12,0.15,,,,,
,Glu,Glu,2018_egerton_23,30,First Episode Psychosis - Remission (Baseline),10.1038/s41380-018-0082-9,1.23,0.23,,,,,
,Glu,Glu,2018_egerton_23,31,First Episode Psychosis - Remission (After Amisulpride),10.1038/s41380-018-0082-9,1.18,0.22,,,,,
,Glu,Glu,2018_egerton_23,32,First Episode Psychosis - Remission (After Amisulpride),10.1038/s41380-018-0082-9,1.31,0.12,,,,,
,Glu,Glu,2018_egerton_23,33,First Episode Psychosis - Remission (After Amisulpride),10.1038/s41380-018-0082-9,1.2,0.09,,,,,
,Glu,Glu,2018_egerton_23,34,First Episode Psychosis - Remission (After Amisulpride),10.1038/s41380-018-0082-9,0.98,0.15,,,,,
,Glu,Glu,2018_egerton_23,35,First Episode Psychosis - Remission (After Amisulpride),10.1038/s41380-018-0082-9,1.12,0.18,,,,,
,Glu,Glu,2018_egerton_23,36,First Episode Psychosis - Remission (After Amisulpride),10.1038/s41380-018-0082-9,1.03,0.27,,,,,
,Glu,Glu,2018_egerton_23,37,First Episode Psychosis - No Remission (Baseline),10.1038/s41380-018-0082-9,1.57,0.07,,,,,
,Glu,Glu,2018_egerton_23,38,First Episode Psychosis - No Remission (Baseline),10.1038/s41380-018-0082-9,1.38,0.19,,,,,
,Glu,Glu,2018_egerton_23,39,First Episode Psychosis - No Remission (Baseline),10.1038/s41380-018-0082-9,1.26,0.11,,,,,
,Glu,Glu,2018_egerton_23,40,First Episode Psychosis - No Remission (Baseline),10.1038/s41380-018-0082-9,1.12,0.22,,,,,
,Glu,Glu,2018_egerton_23,41,First Episode Psychosis - No Remission (Baseline),10.1038/s41380-018-0082-9,1.12,0.05,,,,,
,Glu,Glu,2018_egerton_23,42,First Episode Psychosis - No Remission (Baseline),10.1038/s41380-018-0082-9,1.12,0.14,,,,,
,Glu,Glu,2018_egerton_23,43,First Episode Psychosis - No Remission (After Amisulpride),10.1038/s41380-018-0082-9,1.31,0.32,,,,,
,Glu,Glu,2018_egerton_23,44,First Episode Psychosis - No Remission (After Amisulpride),10.1038/s41380-018-0082-9,1.33,0.04,,,,,
,Glu,Glu,2018_egerton_23,45,First Episode Psychosis - No Remission (After Amisulpride),10.1038/s41380-018-0082-9,1.39,0.36,,,,,
,Glu,Glu,2018_egerton_23,46,First Episode Psychosis - No Remission (After Amisulpride),10.1038/s41380-018-0082-9,1.13,0.18,,,,,
,Glu,Glu,2018_egerton_23,47,First Episode Psychosis - No Remission (After Amisulpride),10.1038/s41380-018-0082-9,1.22,0.24,,,,,
,Glu,Glu,2018_egerton_23,48,First Episode Psychosis - No Remission (After Amisulpride),10.1038/s41380-018-0082-9,0.93,0.07,,,,,
,Glu,Glu,2018_evans_43,1,Control - Baseline,10.1038/s41386-018-0057-1,1.25,0.02,,,,,
,Glu,Glu,2018_evans_43,2,Control - Ketamine,10.1038/s41386-018-0057-1,1.28,0.03,,,,,
,Glu,Glu,2018_evans_43,3,Control - Placebo,10.1038/s41386-018-0057-1,1.27,0.03,,,,,
,Glu,Glu,2018_evans_43,4,Major Depressive Disorder - Baseline,10.1038/s41386-018-0057-1,1.29,0.02,,,,,
,Glu,Glu,2018_evans_43,5,Major Depressive Disorder - Ketamine,10.1038/s41386-018-0057-1,1.36,0.02,,,,,
,Glu,Glu,2018_evans_43,6,Major Depressive Disorder - Placebo,10.1038/s41386-018-0057-1,1.32,0.02,,,,,
,Glu,Glu,2018_godlewska_48,1,Major Depression,10.1017/S0033291717003373,,,9.11,1,,,
,Glu,Glu,2018_godlewska_48,2,Major Depression,10.1017/S0033291717003373,,,5.61,0.693,,,
,Glu,Glu,2018_godlewska_48,3,Major Depression,10.1017/S0033291717003373,,,8.73,0.778,,,
,Glu,Glu,2018_godlewska_48,4,Control,10.1017/S0033291717003373,,,9.24,0.939,,,
,Glu,Glu,2018_godlewska_48,5,Control,10.1017/S0033291717003373,,,4.77,0.693,,,
,Glu,Glu,2018_godlewska_48,6,Control,10.1017/S0033291717003373,,,8.73,0.891,,,
,Glu,Glu,2018_harper_17,1,Urologic Chronic Pelvic Pain Syndrome,10.1016/j.nicl.2017.11.014,1.07,0.23,4.96,1.35,,,
,Glu,Glu,2018_harper_17,2,Urologic Chronic Pelvic Pain Syndrome,10.1016/j.nicl.2017.11.014,1.16,0.12,6.96,0.46,,,
,Glu,Glu,2018_harper_17,3,Urologic Chronic Pelvic Pain Syndrome,10.1016/j.nicl.2017.11.014,1,0.11,5.84,0.64,,,
,Glu,Glu,2018_harper_17,4,Urologic Chronic Pelvic Pain Syndrome,10.1016/j.nicl.2017.11.014,0.88,0.16,5.54,1.03,,,
,Glu,Glu,2018_harper_17,5,Control,10.1016/j.nicl.2017.11.014,1.1,0.15,6.18,0.81,,,
,Glu,Glu,2018_harper_17,6,Control,10.1016/j.nicl.2017.11.014,1.2,0.12,7.18,0.93,,,
,Glu,Glu,2018_harper_17,7,Control,10.1016/j.nicl.2017.11.014,1.08,0.12,6.34,0.68,,,
,Glu,Glu,2018_harper_17,8,Control,10.1016/j.nicl.2017.11.014,0.93,0.11,5.74,0.76,,,
,Glu,Glu,2018_horder_8,1,Control,10.1038/s41398-018-0155-1,,,4.02,0.78,,,
,Glu,Glu,2018_horder_8,2,Control,10.1038/s41398-018-0155-1,,,4.78,0.72,,,
,Glu,Glu,2018_horder_8,3,Autism Spectrum Disorder,10.1038/s41398-018-0155-1,,,3.52,0.9,,,
,Glu,Glu,2018_horder_8,4,Autism Spectrum Disorder,10.1038/s41398-018-0155-1,,,4.99,0.65,,,
,Glu,Glu,2018_kim_83,1,First-episode Psychosis,10.1016/j.biopsych.2017.08.022,1.42,0.24,12.65,3.05,,,IU estimated from bar graph
,Glu,Glu,2018_kim_83,2,First-episode Psychosis,10.1016/j.biopsych.2017.08.022,1.48,0.26,13.55,3.45,,,IU estimated from bar graph
,Glu,Glu,2018_kim_83,3,Control,10.1016/j.biopsych.2017.08.022,1.24,0.18,11.2,2.3,,,IU estimated from bar graph
,Glu,Glu,2018_kim_83,4,Control,10.1016/j.biopsych.2017.08.022,1.18,0.22,11,3,,,IU estimated from bar graph
,Glu,Glu,2018_kim_83,5,First-episode Psychosis - Antipsychotic-free,10.1016/j.biopsych.2017.08.022,,,12.31,2.77,,,
,Glu,Glu,2018_kim_83,6,First-episode Psychosis - Antipsychotic-free,10.1016/j.biopsych.2017.08.022,,,14.69,3.29,,,
,Glu,Glu,2018_kim_83,7,First-episode Psychosis - Antipsychotic Treatment,10.1016/j.biopsych.2017.08.022,,,12.86,3.14,,,
,Glu,Glu,2018_kim_83,8,First-episode Psychosis - Antipsychotic Treatment,10.1016/j.biopsych.2017.08.022,,,12.92,3.05,,,
,Glu,Glu,2018_kim_83,9,First-episode Psychosis - Lithium-free,10.1016/j.biopsych.2017.08.022,,,12.75,2.97,,,
,Glu,Glu,2018_kim_83,10,First-episode Psychosis - Lithium-free,10.1016/j.biopsych.2017.08.022,,,13.67,3.25,,,
,Glu,Glu,2018_kim_83,11,First-episode Psychosis - Lithium Treatment,10.1016/j.biopsych.2017.08.022,,,12.62,3.2,,,
,Glu,Glu,2018_kim_83,12,First-episode Psychosis - Lithium Treatment,10.1016/j.biopsych.2017.08.022,,,13.06,3.18,,,
,Glu,Glu,2020_bhogal_10,1,Healthy,10.1002/brb3.1852,0.73,0.13,,,,,
,Glu,Glu,2020_bhogal_10,2,Healthy,10.1002/brb3.1852,0.68,0.11,,,,,
,Glu,Glu,2020_bhogal_10,3,Healthy,10.1002/brb3.1852,0.72,0.07,,,,,
,Glu,Glu,2020_bhogal_10,4,Healthy,10.1002/brb3.1852,0.66,0.12,,,,,
,Glu,Glu,2020_bhogal_10,5,Healthy,10.1002/brb3.1852,0.58,0.1,,,,,
,Glu,Glu,2020_bhogal_10,6,Healthy,10.1002/brb3.1852,0.78,0.1,,,,,
,Glu,Glu,2020_bhogal_10,7,Healthy,10.1002/brb3.1852,0.75,0.1,,,,,
,Glu,Glu,2020_bhogal_10,8,Healthy,10.1002/brb3.1852,0.89,0.11,,,,,
,Glu,Glu,2020_bhogal_10,9,Healthy,10.1002/brb3.1852,0.98,0.12,,,,,
,Glu,Glu,2020_bhogal_10,10,Healthy,10.1002/brb3.1852,0.97,0.2,,,,,
,Glu,Glu,2020_hjelmervik_46,1,Schizophrenia,10.1093/schbul/sbz099,,,13.23,2.13,,,
,Glu,Glu,2020_hjelmervik_46,2,Schizophrenia,10.1093/schbul/sbz099,,,16.4,1.96,,,
,Glu,Glu,2020_hjelmervik_46,3,Schizophrenia,10.1093/schbul/sbz099,,,20.18,3.33,,,
,Glu,Glu,2020_hjelmervik_46,4,Schizophrenia,10.1093/schbul/sbz099,,,16.93,2.86,,,
,Glu,Glu,2020_hjelmervik_46,5,Control,10.1093/schbul/sbz099,,,13.61,2,,,
,Glu,Glu,2020_hjelmervik_46,6,Control,10.1093/schbul/sbz099,,,15.34,2.51,,,
,Glu,Glu,2020_hjelmervik_46,7,Control,10.1093/schbul/sbz099,,,19.83,3.59,,,
,Glu,Glu,2020_hjelmervik_46,8,Control,10.1093/schbul/sbz099,,,16.18,3.23,,,
,Glu,Glu,2018_kroll_19,1,Asthma,10.1016/j.nicl.2018.04.012,1.04,0.15,9.52,2.01,,,
,Glu,Glu,2018_kroll_19,2,Control,10.1016/j.nicl.2018.04.012,0.98,0.1,10.33,0.75,,,
,Glu,Glu,2020_boillat_40,1,Baseline,10.1177/0271678X19831022,,,6.92,0.17,,,
,Glu,Glu,2020_boillat_40,2,positive BOLD,10.1177/0271678X19831022,,,0.11,0.15,,,
,Glu,Glu,2020_boillat_40,3,Baseline,10.1177/0271678X19831022,,,6.83,0.17,,,
,Glu,Glu,2020_boillat_40,4,negative BOLD,10.1177/0271678X19831022,,,0.09,0.12,,,
,Glu,Glu,2017_barbagallo_43,1,Control,10.1016/j.parkreldis.2017.07.028,2.42,1.09,,,,,Right
,Glu,Glu,2017_barbagallo_43,2,Control,10.1016/j.parkreldis.2017.07.028,1.94,0.59,,,,,Left
,Glu,Glu,2017_barbagallo_43,3,Control,10.1016/j.parkreldis.2017.07.028,2.18,0.65,,,,,Both
,Glu,Glu,2017_barbagallo_43,4,Parkinson's Disease,10.1016/j.parkreldis.2017.07.028,2.27,0.35,,,,,Contralateral
,Glu,Glu,2017_barbagallo_43,5,Parkinson's Disease,10.1016/j.parkreldis.2017.07.028,2.27,0.44,,,,,Ipsilateral
,Glu,Glu,2017_barbagallo_43,6,Parkinson's Disease,10.1016/j.parkreldis.2017.07.028,2.29,0.4,,,,,Both
,Glu,Glu,2017_barbagallo_43,7,Essential Tremor,10.1016/j.parkreldis.2017.07.028,2.11,0.46,,,,,Contralateral
,Glu,Glu,2017_barbagallo_43,8,Essential Tremor,10.1016/j.parkreldis.2017.07.028,1.96,0.54,,,,,Ipsilateral
,Glu,Glu,2017_barbagallo_43,9,Essential Tremor,10.1016/j.parkreldis.2017.07.028,2.03,0.33,,,,,Both
,Glu,Glu,2018_lynn_172,1,Healthy - Relaxed with eyes closed,10.1016/j.neuroimage.2018.01.069,,,,,11.9,1.1,
,Glu,Glu,2018_lynn_172,2,Healthy - Passive visual fixation crosshair,10.1016/j.neuroimage.2018.01.069,,,,,11.6,0.9,
,Glu,Glu,2018_lynn_172,3,Healthy - Finger tapping,10.1016/j.neuroimage.2018.01.069,,,,,12,0.9,
,Glu,Glu,2018_lynn_172,4,Healthy - Visual flashing checkerboard,10.1016/j.neuroimage.2018.01.069,,,,,12.2,0.9,
,Glu,Glu,2018_mahone_273,1,Tourrette Syndrom,10.1016/j.pscychresns.2017.12.005,,,13.36,3.74,,,
,Glu,Glu,2018_mahone_273,2,Tourrette Syndrom,10.1016/j.pscychresns.2017.12.005,,,19.31,25.78,,,
,Glu,Glu,2018_mahone_273,3,Tourrette Syndrom,10.1016/j.pscychresns.2017.12.005,,,12.75,3.47,,,
,Glu,Glu,2018_mahone_273,4,Tourrette Syndrom,10.1016/j.pscychresns.2017.12.005,,,10.81,2.57,,,
,Glu,Glu,2018_mahone_273,5,Control,10.1016/j.pscychresns.2017.12.005,,,11.77,2.99,,,
,Glu,Glu,2018_mahone_273,6,Control,10.1016/j.pscychresns.2017.12.005,,,11.94,3.96,,,
,Glu,Glu,2018_mahone_273,7,Control,10.1016/j.pscychresns.2017.12.005,,,10.81,2.69,,,
,Glu,Glu,2018_mahone_273,8,Control,10.1016/j.pscychresns.2017.12.005,,,10.18,2.2,,,
,Glu,Glu,2018_mcqueen_235,1,Schizophrenia - Placebo,10.1007/s00213-018-4997-2,1.29,0.2,14.67,2.67,,,
,Glu,Glu,2018_mcqueen_235,2,Schizophrenia - Placebo,10.1007/s00213-018-4997-2,1.2,0.11,11.2,1.47,,,
,Glu,Glu,2018_mcqueen_235,3,Schizophrenia - N-Acetylcysteine ,10.1007/s00213-018-4997-2,1.22,0.18,14.77,2.67,,,
,Glu,Glu,2018_mcqueen_235,4,Schizophrenia - N-Acetylcysteine ,10.1007/s00213-018-4997-2,1.19,0.19,12.66,6.04,,,
,Glu,Glu,2018_modinos_48,1,Healthy - Low Schizotypy,10.1017/S0033291717003403,,,15.67,2.51,,,
,Glu,Glu,2018_modinos_48,2,Healthy - High Schizotypy,10.1017/S0033291717003403,,,16.14,2.07,,,
,Glu,Glu,2018_morley_9,1,Alcohol Dependence - Placebo,10.3389/fpsyt.2018.00412,1.5,0.07,,,,,
,Glu,Glu,2018_morley_9,2,Alcohol Dependence - Baclofen,10.3389/fpsyt.2018.00412,1.47,0.09,,,,,
,Glu,Glu,2018_morley_9,3,"Alcohol Dependence - Recent alcohol consumption, placebo",10.3389/fpsyt.2018.00412,1.47,0.06,,,,,
,Glu,Glu,2018_morley_9,4,"Alcohol Dependence - Recent alcohol consumption, Baclofen",10.3389/fpsyt.2018.00412,1.55,0.08,,,,,
,Glu,Glu,2018_plitman_273,1,Schizophrenia,10.1016/j.pscychresns.2018.01.004,,,11.28,1.18,,,
,Glu,Glu,2018_plitman_273,2,Control,10.1016/j.pscychresns.2018.01.004,,,11.69,1.19,,,
,Glu,Glu,2018_plitman_273,3,Schizophrenia - Point 1,10.1016/j.pscychresns.2018.01.004,,,11.65,0.92,,,
,Glu,Glu,2018_plitman_273,4,Schizophrenia - Point 2,10.1016/j.pscychresns.2018.01.004,,,11.79,1.49,,,
,Glu,Glu,2018_plitman_273,5,Control - Point 1,10.1016/j.pscychresns.2018.01.004,,,11.92,1.45,,,
,Glu,Glu,2018_plitman_273,6,Control - Point 2,10.1016/j.pscychresns.2018.01.004,,,12.61,1.62,,,
,Glu,Glu,2021_akiyama_61,1,Control,10.2176/nmc.oa.2020-0274,,,7.41,1.56,,,
,Glu,Glu,2021_akiyama_61,22,NPH,10.2176/nmc.oa.2020-0274,,,6.85,1.05,,,
,Glu,Glu,2021_bloomfield_6,1,THC,10.1016/j.bpsc.2021.04.013,,,5.93,0.9,,,
,Glu,Glu,2021_bloomfield_6,2,Placebo,10.1016/j.bpsc.2021.04.013,,,6.39,1.01,,,
,Glu,Glu,2018_ryan_13,1,Healthy - Sham,10.1371/journal.pone.0198053,0.71,0.06,,,7.9,0.71,
,Glu,Glu,2018_ryan_13,2,Healthy - Transcranial direct current stimulation,10.1371/journal.pone.0198053,0.79,0.07,,,8.2,0.79,
,Glu,Glu,2021_bednarik_15,1,Healthy,10.3389/fnins.2021.609485,,,,,10.1,0.28,
,Glu,Glu,2021_bednarik_15,2,Healthy,10.3389/fnins.2021.609485,,,,,9.87,0.28,
,Glu,Glu,2021_chaudhary_42,3,PD-CN,10.1007/s10072-020-04626-9,,,14.96,4.98,,,
,Glu,Glu,2021_chaudhary_42,18,PD-CI,10.1007/s10072-020-04626-9,,,11.77,3.48,,,
,Glu,Glu,2021_chaudhary_42,33,HC,10.1007/s10072-020-04626-9,,,13.25,3.56,,,
,Glu,Glu,2021_chenji_282,1,Control,10.1016/j.jad.2020.12.176,,,7.59,1.36,,,
,Glu,Glu,2021_chenji_282,3,MDD-Normal BMI,10.1016/j.jad.2020.12.176,,,8.07,1.34,,,
,Glu,Glu,2021_chenji_282,5,MDD-High BMI,10.1016/j.jad.2020.12.176,,,7.58,1.34,,,
,Glu,Glu,2021_chenji_282,2,Control,10.1016/j.jad.2020.12.176,,,7.87,1.41,,,
,Glu,Glu,2021_chenji_282,4,MDD-Normal BMI,10.1016/j.jad.2020.12.176,,,8.18,1.44,,,
,Glu,Glu,2021_chenji_282,6,MDD-High BMI,10.1016/j.jad.2020.12.176,,,7.65,1.54,,,
,Glu,Glu,2018_shakory_43,1,Control,10.1038/s41386-018-0163-0,,,10.492,1.377,,,
,Glu,Glu,2018_shakory_43,2,Clinical high risk of psychosis,10.1038/s41386-018-0163-0,,,9.724,0.824,,,
,Glu,Glu,2018_shakory_43,3,First Episode Psychosis,10.1038/s41386-018-0163-0,,,10.295,1.167,,,
,Glu,Glu,2018_shakory_43,4,Clinical high risk of psychosis - No antipsychotic,10.1038/s41386-018-0163-0,,,9.86,0.78,,,
,Glu,Glu,2018_shakory_43,5,Clinical high risk of psychosis - Antipsychotic,10.1038/s41386-018-0163-0,,,9.35,1.02,,,
,Glu,Glu,2018_shakory_43,6,First Episode Psychosis - No antipsychotic,10.1038/s41386-018-0163-0,,,10.34,1.21,,,
,Glu,Glu,2018_shakory_43,7,First Episode Psychosis - Antipsychotic,10.1038/s41386-018-0163-0,,,10.16,1.44,,,
,Glu,Glu,2018_shakory_43,8,Control - Cannabis non-user,10.1038/s41386-018-0163-0,,,10.41,1.47,,,
,Glu,Glu,2018_shakory_43,9,Control - Cannabis user,10.1038/s41386-018-0163-0,,,10.65,1.34,,,
,Glu,Glu,2018_shakory_43,10,Schizophrenia,10.1038/s41386-018-0163-0,,,10.12,1.15,,,
,Glu,Glu,2018_shakory_43,11,Schizophreniform,10.1038/s41386-018-0163-0,,,10.48,1.7,,,
,Glu,Glu,2020_poletti_11,1,Bipolar Disorder,10.3389/fpsyt.2020.590095,,,8.11,0.99,,,
,Glu,Glu,2020_poletti_11,2,Healthy Controls,10.3389/fpsyt.2020.590095,,,7.68,1.04,,,
,Glu,Glu,2021_faulkner_26,1,Nonsmokers,10.1111/adb.12986,,,,,7.448,0.188,
,Glu,Glu,2021_faulkner_26,2,Intermittent smokers,10.1111/adb.12986,,,,,6.667,0.094,
,Glu,Glu,2021_faulkner_26,3,Smokers,10.1111/adb.12986,,,,,6.573,0.188,
,Glu,Glu,2018_sheth_276,1,Veterans - Suicidal behavior,10.1016/j.pscychresns.2018.04.004,,,2.34,0.1,,,
,Glu,Glu,2018_sheth_276,2,Veterans - Suicidal behavior,10.1016/j.pscychresns.2018.04.004,,,2.07,0.04,,,
,Glu,Glu,2018_sheth_276,3,Veterans - No suicidal behavior,10.1016/j.pscychresns.2018.04.004,,,2.34,0.12,,,
,Glu,Glu,2018_sheth_276,4,Veterans - No suicidal behavior,10.1016/j.pscychresns.2018.04.004,,,2.06,0.06,,,
,Glu,Glu,2018_singh_60,1,Control,10.1007/s00234-017-1954-4,1.24,0.21,,,,,
,Glu,Glu,2018_singh_60,2,Schizophrenia,10.1007/s00234-017-1954-4,1.15,0.16,,,,,
,Glu,Glu,2018_smesny_227,1,Control - Voxel 1,10.1016/j.jad.2017.10.044,,,,,9.52,1.1,
,Glu,Glu,2018_smesny_227,2,Control - Voxel 2,10.1016/j.jad.2017.10.044,,,,,9.87,1.17,
,Glu,Glu,2018_smesny_227,3,Control - Voxel 3,10.1016/j.jad.2017.10.044,,,,,10.1,1.44,
,Glu,Glu,2018_smesny_227,4,Control - Voxel 4,10.1016/j.jad.2017.10.044,,,,,10.59,1.65,
,Glu,Glu,2018_smesny_227,5,Control - Voxel 5,10.1016/j.jad.2017.10.044,,,,,8.75,1.08,
,Glu,Glu,2018_smesny_227,6,Control - Voxel 6,10.1016/j.jad.2017.10.044,,,,,8.63,1.26,
,Glu,Glu,2018_smesny_227,7,Cluster B personality disorder - Voxel 1,10.1016/j.jad.2017.10.044,,,,,10.12,1.4,
,Glu,Glu,2018_smesny_227,8,Cluster B personality disorder - Voxel 2,10.1016/j.jad.2017.10.044,,,,,10.15,1.66,
,Glu,Glu,2018_smesny_227,9,Cluster B personality disorder - Voxel 3,10.1016/j.jad.2017.10.044,,,,,10.45,1.77,
,Glu,Glu,2018_smesny_227,10,Cluster B personality disorder - Voxel 4,10.1016/j.jad.2017.10.044,,,,,11.22,2.11,
,Glu,Glu,2018_smesny_227,11,Cluster B personality disorder - Voxel 5,10.1016/j.jad.2017.10.044,,,,,8.64,1.53,
,Glu,Glu,2018_smesny_227,12,Cluster B personality disorder - Voxel 6,10.1016/j.jad.2017.10.044,,,,,8.74,1.29,
,Glu,Glu,2018_smesny_227,13,Cluster C personality disorder - Voxel 1,10.1016/j.jad.2017.10.044,,,,,8.72,1.72,
,Glu,Glu,2018_smesny_227,14,Cluster C personality disorder - Voxel 2,10.1016/j.jad.2017.10.044,,,,,9.38,1.46,
,Glu,Glu,2018_smesny_227,15,Cluster C personality disorder - Voxel 3,10.1016/j.jad.2017.10.044,,,,,9.13,1.98,
,Glu,Glu,2018_smesny_227,16,Cluster C personality disorder - Voxel 4,10.1016/j.jad.2017.10.044,,,,,9.63,2,
,Glu,Glu,2018_smesny_227,17,Cluster C personality disorder - Voxel 5,10.1016/j.jad.2017.10.044,,,,,8.72,1.23,
,Glu,Glu,2018_smesny_227,18,Cluster C personality disorder - Voxel 6,10.1016/j.jad.2017.10.044,,,,,8.35,1.42,
,Glu,Glu,2018_soeiro-de-souza_3,1,Control,10.1016/j.bpsc.2018.02.007,0.99,0.11,,,,,
,Glu,Glu,2018_soeiro-de-souza_3,2,Euthymic Bipolar I Disorder,10.1016/j.bpsc.2018.02.007,1.01,0.11,,,,,
,Glu,Glu,2018_soeiro-de-souza_3,3,Euthymic Bipolar I Disorder - Anticonvulsant,10.1016/j.bpsc.2018.02.007,0.97,0.12,,,,,
,Glu,Glu,2018_soeiro-de-souza_3,4,Euthymic Bipolar I Disorder - Non-anticonvulsant,10.1016/j.bpsc.2018.02.007,1.03,0.11,,,,,
,Glu,Glu,2018_soeiro-de-souza_3,5,Euthymic Bipolar I Disorder - Lithium,10.1016/j.bpsc.2018.02.007,1.01,0.12,,,,,
,Glu,Glu,2018_soeiro-de-souza_3,6,Euthymic Bipolar I Disorder - Non-lithium,10.1016/j.bpsc.2018.02.007,0.99,0.1,,,,,
,Glu,Glu,2018_soeiro-de-souza_3,7,Euthymic Bipolar I Disorder - Antipsychotics,10.1016/j.bpsc.2018.02.007,1,0.11,,,,,
,Glu,Glu,2018_soeiro-de-souza_3,8,Euthymic Bipolar I Disorder - Non-antipsychotics,10.1016/j.bpsc.2018.02.007,1,0.12,,,,,
,Glu,Glu,2017_brennan_269,1,Control,10.1016/j.pscychresns.2017.08.009,0.98,0.14,,,,,
,Glu,Glu,2017_brennan_269,2,MDD,10.1016/j.pscychresns.2017.08.009,0.89,0.11,,,,,
,Glu,Glu,2017_brennan_269,3,MDD,10.1016/j.pscychresns.2017.08.009,0.88,0.17,,,,,
,Glu,Glu,2017_brennan_269,4,MDD,10.1016/j.pscychresns.2017.08.009,0.92,0.15,,,,,
,Glu,Glu,2017_brennan_269,5,MDD,10.1016/j.pscychresns.2017.08.009,0.91,0.16,,,,,
,Glu,Glu,2018_van_89,1,Control,10.1136/jnnp-2017-316364,,,,,4.68,0.5,
,Glu,Glu,2018_van_89,2,Metachromatic leukodystrophy - Good outcome,10.1136/jnnp-2017-316364,,,,,4.8,0.8,
,Glu,Glu,2018_van_89,3,Metachromatic leukodystrophy - Moderate outcome,10.1136/jnnp-2017-316364,,,,,4.46,0.75,
,Glu,Glu,2018_van_89,4,Metachromatic leukodystrophy - Poor outcome,10.1136/jnnp-2017-316364,,,,,1.68,0.55,
,Glu,Glu,2019_betinaip_39,1,Behavior - ON - 3% Visual Contrast,10.1523/JNEUROSCI.3021-18.2019,,,7.484,0.653,,,
,Glu,Glu,2019_betinaip_39,2,Behavior - ON - 12.5% Visual Contrast,10.1523/JNEUROSCI.3021-18.2019,,,7.51,0.644,,,
,Glu,Glu,2019_betinaip_39,3,Behavior - ON - 50% Visual Contrast,10.1523/JNEUROSCI.3021-18.2019,,,7.445,0.596,,,
,Glu,Glu,2019_betinaip_39,4,Behavior - ON - 100% Visual Contrast,10.1523/JNEUROSCI.3021-18.2019,,,7.51,0.606,,,
,Glu,Glu,2019_betinaip_39,5,Resting,10.1523/JNEUROSCI.3021-18.2019,,,7.483,0.84,,,
,Glu,Glu,2019_betinaip_39,6,Behavior - OFF - 3% Visual Contrast,10.1523/JNEUROSCI.3021-18.2019,,,7.543,0.623,,,
,Glu,Glu,2019_betinaip_39,7,Behavior - OFF - 12.5% Visual Contrast,10.1523/JNEUROSCI.3021-18.2019,,,7.546,0.706,,,
,Glu,Glu,2019_betinaip_39,8,Behavior - OFF - 50% Visual Contrast,10.1523/JNEUROSCI.3021-18.2019,,,7.51,0.667,,,
,Glu,Glu,2019_betinaip_39,9,Behavior - OFF - 100% Visual Contrast,10.1523/JNEUROSCI.3021-18.2019,,,7.462,0.649,,,
,Glu,Glu,2019_betinaip_39,10,Resting,10.1523/JNEUROSCI.3021-18.2019,,,7.6,0.791,,,
,Glu,Glu,2019_giapitzakis_81,1,Healthy,10.1002/mrm.27467,,,,,6.7,0.8,
,Glu,Glu,2019_giapitzakis_81,2,Healthy,10.1002/mrm.27467,,,,,5.8,0.4,
,Glu,Glu,2019_girgis_275,1,Control - Baseline - dAC,10.1016/j.psychres.2019.03.018,,,0.128,0.014,,,
,Glu,Glu,2019_girgis_275,2,Control - Baseline - mPFC,10.1016/j.psychres.2019.03.018,,,0.1,0.013,,,
,Glu,Glu,2019_girgis_275,3,Schizophrenia - Baseline - dAC,10.1016/j.psychres.2019.03.018,,,0.127,0.015,,,
,Glu,Glu,2019_girgis_275,4,Schizophrenia - Baseline - mPFC,10.1016/j.psychres.2019.03.018,,,0.099,0.013,,,
,Glu,Glu,2019_girgis_275,5,Control - Treatment - dAC,10.1016/j.psychres.2019.03.018,,,0.127,0.078,,,
,Glu,Glu,2019_girgis_275,6,Controll - Treatment - mPFC,10.1016/j.psychres.2019.03.018,,,0.099,0.077,,,
,Glu,Glu,2019_girgis_275,7,Schizophrenial - Treatment - dAC,10.1016/j.psychres.2019.03.018,,,0.129,0.048,,,
,Glu,Glu,2019_girgis_275,8,Schizophrenial - Treatment - mPFC,10.1016/j.psychres.2019.03.018,,,0.1,0.078,,,
,Glu,Glu,2019_gradinger_160,1,Control,10.1097/j.pain.0000000000001641,0.77,0.08,,,,,Reported as Glutamate (not glx)
,Glu,Glu,2019_gradinger_160,2,Borderline Personality Disorder,10.1097/j.pain.0000000000001641,0.74,0.07,,,,,
,Glu,Glu,2019_graf_32,1,Healthy,10.1002/nbm.4083,,,6.6,2.011,,,Med/Quartile --> Mean/Std Wan 2014
,Glu,Glu,2019_hansen_33,1,Control,10.1016/j.jdiacomp.2018.12.016,0.87,0.18,,,4.79,0.99,
,Glu,Glu,2019_hansen_33,3,Diabetes,10.1016/j.jdiacomp.2018.12.016,0.84,0.12,,,4.91,0.69,
,Glu,Glu,2019_iwata_85,1,Control,10.1016/j.biopsych.2018.09.009,,,11.5,2.2,,,
,Glu,Glu,2019_iwata_85,2,Control,10.1016/j.biopsych.2018.09.009,,,15.98,1.74,,,
,Glu,Glu,2019_iwata_85,3,Control,10.1016/j.biopsych.2018.09.009,,,13.94,1.32,,,
,Glu,Glu,2019_iwata_85,4,Schizophrenia Ultra-Resistant,10.1016/j.biopsych.2018.09.009,,,11.36,1.71,,,
,Glu,Glu,2019_iwata_85,5,Schizophrenia Ultra-Resistant,10.1016/j.biopsych.2018.09.009,,,17.16,1.97,,,
,Glu,Glu,2019_iwata_85,6,Schizophrenia Ultra-Resistant,10.1016/j.biopsych.2018.09.009,,,13.55,1.6,,,
,Glu,Glu,2019_iwata_85,7,Schizophrenia Non-Ultra Resistant,10.1016/j.biopsych.2018.09.009,,,11.95,1.74,,,
,Glu,Glu,2019_iwata_85,8,Schizophrenia Non-Ultra Resistant,10.1016/j.biopsych.2018.09.009,,,16.92,1.39,,,
,Glu,Glu,2019_iwata_85,9,Schizophrenia Non-Ultra Resistant,10.1016/j.biopsych.2018.09.009,,,13.87,1.62,,,
,Glu,Glu,2019_iwata_85,10,Schizophrenia Non-Treatment Resistant,10.1016/j.biopsych.2018.09.009,,,12.13,1.78,,,
,Glu,Glu,2019_iwata_85,11,Schizophrenia Non-Treatment Resistant,10.1016/j.biopsych.2018.09.009,,,16.7,1.51,,,
,Glu,Glu,2019_iwata_85,12,Schizophrenia Non-Treatment Resistant,10.1016/j.biopsych.2018.09.009,,,14.65,1.26,,,
,Glu,Glu,2019_jelen_29,1,Control 0-Back,10.1016/j.euroneuro.2018.12.005,0.9,0.13,,,,,IU Values Referenced to Creatine | Estimated by Graph
,Glu,Glu,2019_jelen_29,2,Schizophrenia 0-Back,10.1016/j.euroneuro.2018.12.005,0.89,0.14,,,,,IU Values Referenced to Creatine | Estimated by Graph
,Glu,Glu,2019_jelen_29,3,Bipolar (Bipolar 2) 0-Back,10.1016/j.euroneuro.2018.12.005,0.91,0.12,,,,,IU Values Referenced to Creatine | Estimated by Graph
,Glu,Glu,2019_jelen_29,10,Control 2-Back,10.1016/j.euroneuro.2018.12.005,0.92,0.11,,,,,IU Values Referenced to Creatine | Estimated by Graph
,Glu,Glu,2019_jelen_29,11,Schizophrenia 2-Back,10.1016/j.euroneuro.2018.12.005,0.89,0.08,,,,,IU Values Referenced to Creatine | Estimated by Graph
,Glu,Glu,2019_jelen_29,12,Bipolar (Bipolar 2) 2-Back,10.1016/j.euroneuro.2018.12.005,0.92,0.1,,,,,IU Values Referenced to Creatine | Estimated by Graph
,Glu,Glu,2019_jelen_29,7,Control,10.1016/j.euroneuro.2018.12.005,0.86,0.1,,,,,IU Values Referenced to Creatine | Estimated by Graph
,Glu,Glu,2019_jelen_29,8,Schizophrenia,10.1016/j.euroneuro.2018.12.005,0.98,0.13,,,,,IU Values Referenced to Creatine | Estimated by Graph
,Glu,Glu,2019_jelen_29,9,Bipolar (Bipolar 2),10.1016/j.euroneuro.2018.12.005,0.88,0.08,,,,,IU Values Referenced to Creatine | Estimated by Graph
,Glu,Glu,2019_jelen_29,10,Control,10.1016/j.euroneuro.2018.12.005,0.97,0.07,,,,,IU Values Referenced to Creatine | Estimated by Graph
,Glu,Glu,2019_jelen_29,11,Schizophrenia,10.1016/j.euroneuro.2018.12.005,0.94,0.06,,,,,IU Values Referenced to Creatine | Estimated by Graph
,Glu,Glu,2019_jelen_29,12,Bipolar (Bipolar 2),10.1016/j.euroneuro.2018.12.005,0.94,0.15,,,,,IU Values Referenced to Creatine | Estimated by Graph
,Glu,Glu,2019_kaur_113,1,Bipolar,10.1016/j.jpsychires.2019.03.018,1.8,0.4,,,,,Reported Glu (not glx)
,Glu,Glu,2019_kaur_113,2,Bipolar,10.1016/j.jpsychires.2019.03.018,1.6,0.3,,,,,Reported Glu (not glx)
,Glu,Glu,2019_kaur_113,3,Schizophrenia,10.1016/j.jpsychires.2019.03.018,1.7,0.2,,,,,Reported Glu (not glx)
,Glu,Glu,2019_kaur_113,4,Schizophrenia,10.1016/j.jpsychires.2019.03.018,1.4,0.2,,,,,Reported Glu (not glx)
,Glu,Glu,2018_veeramuthu_25,1,Complicated mTBI,10.1016/j.acra.2018.01.005,1.699,0.293,2.817,0.387,,,
,Glu,Glu,2018_veeramuthu_25,2,Uncomplicated mTBI,10.1016/j.acra.2018.01.005,1.782,0.25,2.988,0.371,,,
,Glu,Glu,2018_veeramuthu_25,3,Control,10.1016/j.acra.2018.01.005,1.567,0.215,2.736,0.272,,,
,Glu,Glu,2018_white_43,1,Healthy_Placebo,10.1038/s41386-018-0027-7,,,8.62,0.84,,,
,Glu,Glu,2018_white_43,2,Healthy_d-amphetamine,10.1038/s41386-018-0027-7,,,9.32,1.01,,,
,Glu,Glu,2018_white_43,3,Healthy_methamphetamine,10.1038/s41386-018-0027-7,,,8.8,1.08,,,
,Glu,Glu,2018_wu_9,1,MA dependence (Abstinent),10.3389/fpsyt.2018.00478,1.03,0.15,,,,,
,Glu,Glu,2018_wu_9,2,Control,10.3389/fpsyt.2018.00478,0.95,0.14,,,,,
,Glu,Glu,2018_wyss_21,1,Healthy,10.1093/ijnp/pyy056,,,18.25,2.68,,,
,Glu,Glu,2018_zarinabad_79,1,Medulloblastoma,10.1002/mrm.26837,,,,,2.4,2.2,
,Glu,Glu,2018_zarinabad_79,2,Pilocytic Astrocytoma,10.1002/mrm.26837,,,,,3.2,2.3,
,Glu,Glu,2018_zarinabad_79,3,Ependymoma,10.1002/mrm.26837,,,,,1.13,0.94,
,Glu,Glu,2017_cao_42,1,Control,10.1038/npp.2017.39,,,9.01,0.24,,,
,Glu,Glu,2017_cao_42,2,Control,10.1038/npp.2017.39,,,9.86,0.26,,,
,Glu,Glu,2017_cao_42,3,Control,10.1038/npp.2017.39,,,5.69,0.31,,,
,Glu,Glu,2017_cao_42,4,Control,10.1038/npp.2017.39,,,10.66,0.73,,,
,Glu,Glu,2017_cao_42,5,BD-1-Non Rapid Cycling ,10.1038/npp.2017.39,,,8.69,0.25,,,
,Glu,Glu,2017_cao_42,6,BD-1-Non Rapid Cycling ,10.1038/npp.2017.39,,,9.59,0.26,,,
,Glu,Glu,2017_cao_42,7,BD-1-Non Rapid Cycling ,10.1038/npp.2017.39,,,5.9,0.32,,,
,Glu,Glu,2017_cao_42,8,BD-1-Non Rapid Cycling ,10.1038/npp.2017.39,,,10.22,0.62,,,
,Glu,Glu,2017_cao_42,9,BD-1-Rapid Cycling,10.1038/npp.2017.40,,,9.52,0.37,,,
,Glu,Glu,2017_cao_42,10,BD-1-Rapid Cycling,10.1038/npp.2017.41,,,10.14,0.37,,,
,Glu,Glu,2017_cao_42,11,BD-1-Rapid Cycling,10.1038/npp.2017.42,,,5.92,0.39,,,
,Glu,Glu,2017_cao_42,12,BD-1-Rapid Cycling,10.1038/npp.2017.43,,,10.2,0.75,,,
,Glu,Glu,2017_holmes_12,1,Healthy - 5 year olds,10.1371/journal.pone.0180973,1.716,0.198,9.195,1.362,,,
,Glu,Glu,2017_holmes_12,2,Healthy - 5 year olds,10.1371/journal.pone.0180973,1.377,0.145,8.18,0.889,,,
,Glu,Glu,2017_holmes_12,3,Healthy - 5 year olds,10.1371/journal.pone.0180973,1.478,0.225,5.353,1.07,,,
,Glu,Glu,2017_holmes_12,4,Healthy - 7 year olds,10.1371/journal.pone.0180973,1.73,0.174,9.342,0.942,,,
,Glu,Glu,2017_holmes_12,5,Healthy - 7 year olds,10.1371/journal.pone.0180973,1.316,0.188,7.718,1.02,,,
,Glu,Glu,2017_holmes_12,6,Healthy - 7 year olds,10.1371/journal.pone.0180973,1.52,0.24,5.52,1.1,,,
,Glu,Glu,2017_holmes_12,7,Healthy - 9 year olds,10.1371/journal.pone.0180973,1.701,0.229,9.712,1.097,,,
,Glu,Glu,2017_holmes_12,8,Healthy - 9 year olds,10.1371/journal.pone.0180973,1.264,0.293,7.294,1.745,,,
,Glu,Glu,2017_holmes_12,9,Healthy - 9 year olds,10.1371/journal.pone.0180973,1.559,0.292,6.01,1.108,,,
,Glu,Glu,2020_zheng_265,1,Control,10.1016/j.jad.2020.01.059,,,10.58,2.38,,,
,Glu,Glu,2020_zheng_265,2,Control,10.1016/j.jad.2020.01.059,,,11.43,1.62,,,
,Glu,Glu,2020_zheng_265,3,Control,10.1016/j.jad.2020.01.059,,,9.83,2.77,,,
,Glu,Glu,2020_zheng_265,4,OCD,10.1016/j.jad.2020.01.059,,,12.1,3.9,,,
,Glu,Glu,2020_zheng_265,5,OCD,10.1016/j.jad.2020.01.059,,,12.07,4.85,,,
,Glu,Glu,2020_zheng_265,6,OCD,10.1016/j.jad.2020.01.059,,,12.13,2.28,,,
,Glu,Glu,2020_zheng_265,7,OCD + SPD,10.1016/j.jad.2020.01.059,,,7.53,2.92,,,
,Glu,Glu,2020_zheng_265,8,OCD + SPD,10.1016/j.jad.2020.01.059,,,7.03,2.87,,,
,Glu,Glu,2020_zheng_265,9,OCD + SPD,10.1016/j.jad.2020.01.059,,,7.76,3.09,,,
,Glu,Glu,2021_godlewska_11,1,Psychosis,10.1038/s41398-021-01477-6,,,11.54,1.01,,,
,Glu,Glu,2021_godlewska_11,2,Psychosis,10.1038/s41398-021-01477-6,,,8.87,0.68,,,
,Glu,Glu,2021_godlewska_11,3,Psychosis,10.1038/s41398-021-01477-6,,,9.57,0.898,,,
,Glu,Glu,2021_godlewska_11,4,Control,10.1038/s41398-021-01477-6,,,12.24,0.721,,,
,Glu,Glu,2021_godlewska_11,5,Control,10.1038/s41398-021-01477-6,,,9,2.758,,,
,Glu,Glu,2021_godlewska_11,6,Control,10.1038/s41398-021-01477-6,,,9.67,0.96,,,
,Glu,Glu,2020_korenic_120,1,Schizophrenia,10.1016/j.jpsychires.2019.10.006,,,13.2,1.2,,,
,Glu,Glu,2020_korenic_120,2,Schizophrenia,10.1016/j.jpsychires.2019.10.006,,,8.2,1.3,,,
,Glu,Glu,2020_korenic_120,3,Schizophrenia,10.1016/j.jpsychires.2019.10.006,,,10.3,1.1,,,
,Glu,Glu,2020_korenic_120,4,Control,10.1016/j.jpsychires.2019.10.006,,,13.3,1.3,,,
,Glu,Glu,2020_korenic_120,5,Control,10.1016/j.jpsychires.2019.10.006,,,8.5,1.3,,,
,Glu,Glu,2020_korenic_120,6,Control,10.1016/j.jpsychires.2019.10.006,,,10.7,1.4,,,
,Glu,Glu,2021_mcqueen_47,1,Baseline,10.1093/schbul/sbaa156,,,,,14.43,2.41,
,Glu,Glu,2020_lewis_10,1,Healthy Control,10.1038/s41398-020-0792-z,,,85.04,4.19,,,
,Glu,Glu,2020_lewis_10,2,Depressed,10.1038/s41398-020-0792-z,,,78.44,3.71,,,
,Glu,Glu,2020_lewis_10,3,Depressed,10.1038/s41398-020-0792-z,,,88.43,3.93,,,
,Glu,Glu,2021_mcqueen_47,2,Baseline,10.1093/schbul/sbaa156,,,,,12.08,3.69,
,Glu,Glu,2021_mcqueen_47,3,12 weeks,10.1093/schbul/sbaa156,,,,,15.46,3.68,
,Glu,Glu,2021_mcqueen_47,4,12 weeks,10.1093/schbul/sbaa156,,,,,10.85,1.58,
,Glu,Glu,2021_onwordi_11,1,Schizophrenia,10.1038/s41398-021-01515-3,1.06,0.085,,,,,
,Glu,Glu,2015_simoes_213,1,Control,10.1016/j.ajog.2015.04.011,,,,,6,0.8,
,Glu,Glu,2015_simoes_213,2,Small-born infants,10.1016/j.ajog.2015.04.011,,,,,6.6,1.1,
,Glu,Glu,2015_simoes_213,3,Small-born infants - Small for gestational age,10.1016/j.ajog.2015.04.011,,,,,7.1,1.4,
,Glu,Glu,2015_simoes_213,4,Small-born infants - Late intrauterine growth restriction,10.1016/j.ajog.2015.04.011,,,,,6.4,0.9,
,Glu,Glu,2021_onwordi_11,2,Schizophrenia,10.1038/s41398-021-01515-3,0.93,0.17,,,,,
,Glu,Glu,2021_onwordi_11,3,Control,10.1038/s41398-021-01515-3,1.1,0.094,,,,,
,Glu,Glu,2016_howells_31,1,In utero alcohol exposure,10.1007/s11011-016-9850-x,1.36,0.34,,,3.79,0.61,
,Glu,Glu,2016_howells_31,2,In utero alcohol exposure,10.1007/s11011-016-9850-x,1.51,0.25,,,5.12,0.69,
,Glu,Glu,2016_howells_31,3,In utero alcohol exposure - Female,10.1007/s11011-016-9850-x,1.49,0.39,,,4.1,0.67,
,Glu,Glu,2016_howells_31,4,In utero alcohol exposure - Female,10.1007/s11011-016-9850-x,1.58,0.27,,,5.12,0.67,
,Glu,Glu,2016_howells_31,5,In utero alcohol exposure - Male,10.1007/s11011-016-9850-x,1.23,0.23,,,3.45,0.3,
,Glu,Glu,2016_howells_31,6,In utero alcohol exposure - Male,10.1007/s11011-016-9850-x,1.45,0.21,,,5.12,0.73,
,Glu,Glu,2016_howells_31,7,Infants - Control,10.1007/s11011-016-9850-x,1.42,0.32,,,4.1,0.81,
,Glu,Glu,2016_howells_31,8,Infants - Control,10.1007/s11011-016-9850-x,1.53,0.27,,,5.14,0.71,
,Glu,Glu,2016_howells_31,9,Infants - Control_Female,10.1007/s11011-016-9850-x,1.49,0.36,,,4.16,0.92,
,Glu,Glu,2016_howells_31,10,Infants - Control_Female,10.1007/s11011-016-9850-x,1.74,0.19,,,5.04,0.88,
,Glu,Glu,2016_howells_31,11,Infants - Control_Male,10.1007/s11011-016-9850-x,1.32,0.21,,,4,0.66,
,Glu,Glu,2016_howells_31,12,Infants - Control_Male,10.1007/s11011-016-9850-x,1.43,0.25,,,5.19,0.65,
,Glu,Glu,2020_savic_30,1,Control,10.1093/cercor/bhz340,,,,,13.6,1.7,
,Glu,Glu,2020_savic_30,2,Control,10.1093/cercor/bhz340,,,,,15.5,2.8,
,Glu,Glu,2020_savic_30,3,Control,10.1093/cercor/bhz340,,,,,12.6,2.2,
,Glu,Glu,2020_savic_30,4,Control,10.1093/cercor/bhz340,,,,,15,1.6,
,Glu,Glu,2020_savic_30,5,ES Patients,10.1093/cercor/bhz340,,,,,15.1,1.8,
,Glu,Glu,2020_savic_30,6,ES Patients,10.1093/cercor/bhz340,,,,,14.9,2.5,
,Glu,Glu,2020_savic_30,7,ES Patients,10.1093/cercor/bhz340,,,,,12.9,2.5,
,Glu,Glu,2020_savic_30,8,ES Patients,10.1093/cercor/bhz340,,,,,15.3,1.1,
,Glu,Glu,2020_wenneberg_5,1,Ultra High Risk for Psychosis,10.1016/j.bpsc.2019.12.005,,,9.27,0.8,,,
,Glu,Glu,2020_wenneberg_5,2,Ultra High Risk for Psychosis,10.1016/j.bpsc.2019.12.005,,,6.51,0.82,,,
,Glu,Glu,2020_wenneberg_5,3,Healthy Control,10.1016/j.bpsc.2019.12.005,,,9.27,0.86,,,
,Glu,Glu,2020_wenneberg_5,4,Healthy Control,10.1016/j.bpsc.2019.12.005,,,6.57,0.79,,,
,Glu,Glu,2020_wenneberg_5,5,Ultra High Risk for Psychosis,10.1016/j.bpsc.2019.12.005,,,9.13,0.87,,,
,Glu,Glu,2020_wenneberg_5,6,Ultra High Risk for Psychosis,10.1016/j.bpsc.2019.12.005,,,6.5,0.83,,,
,Glu,Glu,2020_wenneberg_5,7,Ultra High Risk for Psychosis,10.1016/j.bpsc.2019.12.005,,,9.41,0.73,,,
,Glu,Glu,2020_wenneberg_5,8,Ultra High Risk for Psychosis,10.1016/j.bpsc.2019.12.005,,,6.47,0.79,,,
,Glu,Glu,2021_onwordi_11,4,Control,10.1038/s41398-021-01515-3,0.97,0.141,,,,,
,Glu,Glu,2019_marjanska_68,1,Alzheimer's disease,10.3233/JAD-180861,,,,,9.83,0.96,
,Glu,Glu,2019_marjanska_68,2,Alzheimer's disease,10.3233/JAD-180861,,,,,8.95,0.96,
,Glu,Glu,2019_marjanska_68,3,Control,10.3233/JAD-180861,,,,,10.13,0.919,
,Glu,Glu,2019_marjanska_68,4,Control,10.3233/JAD-180861,,,,,8.95,0.919,
,Glu,Glu,2020_basu_10,2,Preterm Infants,10.1038/s41598-020-67188-y,0.73,0.03,2.64,0.15,,,
,Glu,Glu,2020_basu_10,3,Preterm Infants,10.1038/s41598-020-67188-y,,,3.09,0.2,,,
,Glu,Glu,2020_basu_10,5,Preterm Infants,10.1038/s41598-020-67188-y,0.75,0.03,2.82,0.18,,,
,Glu,Glu,2020_basu_10,6,Preterm Infants,10.1038/s41598-020-67188-y,,,3.19,0.24,,,
,Glu,Glu,2020_basu_10,8,Preterm Infants,10.1038/s41598-020-67188-y,0.71,0.06,2.44,0.23,,,
,Glu,Glu,2020_basu_10,9,Preterm Infants,10.1038/s41598-020-67188-y,,,2.92,0.31,,,
,Glu,Glu,2020_basu_10,11,Preterm Infants,10.1038/s41598-020-67188-y,,,2.89,0.19,,,
,Glu,Glu,2020_basu_10,12,Preterm Infants,10.1038/s41598-020-67188-y,,,3.06,0.31,,,
,Glu,Glu,2020_basu_10,14,Preterm Infants,10.1038/s41598-020-67188-y,,,2.44,0.2,,,
,Glu,Glu,2020_basu_10,15,Preterm Infants,10.1038/s41598-020-67188-y,,,3.11,0.23,,,
,Glu,Glu,2020_archibald_10,1,Baseline,10.1038/s41598-020-76263-3,,,,,9.9,0.42,
,Glu,Glu,2020_archibald_10,2,Baseline 2,10.1038/s41598-020-76263-3,,,,,10.23,0.46,
,Glu,Glu,2020_archibald_10,3,Baseline 4,10.1038/s41598-020-76263-3,,,,,9.54,0.43,
,Glu,Glu,2020_archibald_10,4,Baseline 6,10.1038/s41598-020-76263-3,,,,,9.97,0.46,
,Glu,Glu,2020_archibald_10,5,Baseline 8,10.1038/s41598-020-76263-3,,,,,9.73,0.43,
,Glu,Glu,2020_archibald_10,6,Heat 10,10.1038/s41598-020-76263-3,,,,,10.06,0.42,
,Glu,Glu,2020_archibald_10,7,Heat 12,10.1038/s41598-020-76263-3,,,,,9.82,0.43,
,Glu,Glu,2020_archibald_10,8,Post Heat 14,10.1038/s41598-020-76263-3,,,,,9.43,0.42,
,Glu,Glu,2020_archibald_10,9,Post Heat 16,10.1038/s41598-020-76263-3,,,,,9.92,0.42,
,Glu,Glu,2020_archibald_10,10,Post Heat 18,10.1038/s41598-020-76263-3,,,,,9.61,0.41,
,Glu,Glu,2020_archibald_10,11,Post Heat 20,10.1038/s41598-020-76263-3,,,,,9.79,0.41,
,Glu,Glu,2020_bell_34,1,Healthy,10.1002/nbm.4245,,,,,15.5,2,
,Glu,Glu,2020_bell_34,2,Healthy,10.1002/nbm.4245,,,,,13.1,1.5,
,Glu,Glu,2020_bell_34,3,Healthy,10.1002/nbm.4245,,,,,13.8,3,
,Glu,Glu,2020_bell_34,4,Healthy,10.1002/nbm.4245,,,,,13.8,1.2,
,Glu,Glu,2020_bell_34,5,Healthy,10.1002/nbm.4245,,,,,11.8,3,
,Glu,Glu,2020_bell_34,6,Healthy,10.1002/nbm.4245,,,,,9.6,1,
,Glu,Glu,2020_bell_34,7,Healthy,10.1002/nbm.4245,,,,,5.3,3,
,Glu,Glu,2020_bell_34,8,Healthy,10.1002/nbm.4245,,,,,6.1,0.5,
,Glu,Glu,2020_bell_34,9,Healthy,10.1002/nbm.4245,,,,,2.6,3,
,Glu,Glu,2020_bell_34,10,Healthy,10.1002/nbm.4245,,,,,2.8,0.4,
,Glu,Glu,2019_mason_29,1,Occasional cannabis user - Full dose THC - Visit 1,10.1016/j.euroneuro.2018.12.003,1.09,0.19,,,,,
,Glu,Glu,2019_mason_29,2,Occasional cannabis user - Full dose THC - Visit 2,10.1016/j.euroneuro.2018.12.003,1.09,0.13,,,,,
,Glu,Glu,2019_mason_29,3,Occasional cannabis user - Full dose THC - Visit 1,10.1016/j.euroneuro.2018.12.003,1.08,0.19,,,,,
,Glu,Glu,2019_mason_29,4,Occasional cannabis user - Full dose THC - Visit 1,10.1016/j.euroneuro.2018.12.003,1.05,0.13,,,,,
,Glu,Glu,2019_mason_29,5,Occasional cannabis user - Full dose THC - Visit 2,10.1016/j.euroneuro.2018.12.003,1.12,0.16,,,,,
,Glu,Glu,2019_mason_29,6,Occasional cannabis user - Full dose THC - Visit 1,10.1016/j.euroneuro.2018.12.003,1.13,0.13,,,,,
,Glu,Glu,2019_mason_29,7,Occasional cannabis user - Full dose placebo - Visit 1,10.1016/j.euroneuro.2018.12.003,1.03,0.16,,,,,
,Glu,Glu,2019_mason_29,8,Occasional cannabis user - Full dose placebo - Visit 2,10.1016/j.euroneuro.2018.12.003,1.07,0.09,,,,,
,Glu,Glu,2019_mason_29,9,Occasional cannabis user - Full dose placebo - Visit 3,10.1016/j.euroneuro.2018.12.003,1.08,0.19,,,,,
,Glu,Glu,2019_mason_29,10,Occasional cannabis user - Full dose placebo - Visit 1,10.1016/j.euroneuro.2018.12.003,0.95,0.25,,,,,
,Glu,Glu,2019_mason_29,11,Occasional cannabis user - Full dose placebo - Visit 2,10.1016/j.euroneuro.2018.12.003,0.95,0.09,,,,,
,Glu,Glu,2019_mason_29,12,Occasional cannabis user - Full dose placebo - Visit 3,10.1016/j.euroneuro.2018.12.003,0.99,0.25,,,,,
,Glu,Glu,2019_mason_29,13,Occasional cannabis user - Divided dose THC - Visit 1,10.1016/j.euroneuro.2018.12.003,1.11,0.13,,,,,
,Glu,Glu,2019_mason_29,14,Occasional cannabis user - Divided dose THC - Visit 2,10.1016/j.euroneuro.2018.12.003,1.08,0.09,,,,,
,Glu,Glu,2019_mason_29,15,Occasional cannabis user - Divided dose THC - Visit 3,10.1016/j.euroneuro.2018.12.003,1.08,0.09,,,,,
,Glu,Glu,2019_mason_29,16,Occasional cannabis user - Divided dose THC - Visit 1,10.1016/j.euroneuro.2018.12.003,1.1,0.22,,,,,
,Glu,Glu,2019_mason_29,17,Occasional cannabis user - Divided dose THC - Visit 2,10.1016/j.euroneuro.2018.12.003,1.13,0.16,,,,,
,Glu,Glu,2019_mason_29,18,Occasional cannabis user - Divided dose THC - Visit 3,10.1016/j.euroneuro.2018.12.003,1.06,0.22,,,,,
,Glu,Glu,2019_mason_29,19,Occasional cannabis user - Divided dose placebo - Visit 1,10.1016/j.euroneuro.2018.12.003,1.09,0.09,,,,,
,Glu,Glu,2019_mason_29,20,Occasional cannabis user - Divided dose placebo - Visit 2,10.1016/j.euroneuro.2018.12.003,1.09,0.09,,,,,
,Glu,Glu,2019_mason_29,21,Occasional cannabis user - Divided dose placebo - Visit 3,10.1016/j.euroneuro.2018.12.003,1.08,0.13,,,,,
,Glu,Glu,2019_mason_29,22,Occasional cannabis user - Divided dose placebo - Visit 1,10.1016/j.euroneuro.2018.12.003,1.09,0.09,,,,,
,Glu,Glu,2019_mason_29,23,Occasional cannabis user - Divided dose placebo - Visit 2,10.1016/j.euroneuro.2018.12.003,1,0.13,,,,,
,Glu,Glu,2019_mason_29,24,Occasional cannabis user - Divided dose placebo - Visit 3,10.1016/j.euroneuro.2018.12.003,1,0.16,,,,,
,Glu,Glu,2019_mellen_27,1,Bipolar disorder - Older age bipolar depression,10.1016/j.jagp.2019.02.017,0.79,0.24,,,,,
,Glu,Glu,2019_mellen_27,2,Bipolar disorder - Older age bipolar depression,10.1016/j.jagp.2019.02.017,0.9,0.26,,,,,
,Glu,Glu,2019_mellen_27,3,Control,10.1016/j.jagp.2019.02.017,0.94,0.17,,,,,
,Glu,Glu,2019_mellen_27,4,Control,10.1016/j.jagp.2019.02.017,0.97,0.12,,,,,
,Glu,Glu,2019_ousdal_49,1,Trauma-exposed - Youths,10.1017/S0033291718002519,1.85,0.17,,,,,
,Glu,Glu,2019_ousdal_49,2,Control - Youths,10.1017/S0033291718002519,1.87,0.14,,,,,
,Glu,Glu,2019_ousdal_49,3,Trauma-exposed - Youths,10.1017/S0033291718002519,1.63,0.56,,,,,
,Glu,Glu,2019_ousdal_49,4,Control - Youths,10.1017/S0033291718002519,1.86,0.39,,,,,
,Glu,Glu,2021_siegel-ramsay_313,1,Control,10.1016/j.pscychresns.2021.111302,,,9,1.83,,,
,Glu,Glu,2020_colizzi_25,1,Healthy,10.1038/s41380-019-0374-8,,,5.94,1.06,,,
,Glu,Glu,2020_colizzi_25,2,Healthy,10.1038/s41380-019-0374-8,,,9.94,2.52,,,
,Glu,Glu,2020_colizzi_25,3,Healthy,10.1038/s41380-019-0374-8,,,9.87,1.82,,,
,Glu,Glu,2020_colizzi_25,4,Psychosis ,10.1038/s41380-019-0374-8,,,9.25,2.35,,,
,Glu,Glu,2020_colizzi_25,5,Psychosis ,10.1038/s41380-019-0374-8,,,5.69,0.79,,,
,Glu,Glu,2020_colizzi_25,6,Psychosis ,10.1038/s41380-019-0374-8,,,9.87,1.82,,,
,Glu,Glu,2021_siegel-ramsay_313,2,Autism,10.1016/j.pscychresns.2021.111302,,,8.31,1.58,,,
,Glu,Glu,2021_steinegger_26,1,Control,10.1111/adb.13027,,,,,11.89,1.28,
,Glu,Glu,2021_steinegger_26,4,Smokers,10.1111/adb.13027,,,,,11.77,1.29,
,Glu,Glu,2021_steinegger_26,5,Baseline,10.1111/adb.13027,,,,,11.67,1.25,
,Glu,Glu,2021_steinegger_26,7,Withdrawal,10.1111/adb.13027,,,,,12.27,1.76,
,Glu,Glu,2021_steinegger_26,8,Satiation,10.1111/adb.13027,,,,,12.13,2.02,
,Glu,Glu,2021_younis_41,1,Baseline,10.1177/0271678X20906902,,,,,8.3,0.19,
,Glu,Glu,2021_younis_41,2,Migraine attack ,10.1177/0271678X20906902,,,,,8.33,0.19,
,Glu,Glu,2019_prisci_43,1,Alcohol use disorder ,10.1111/acer.13931,,,4.13,0.47,,,
,Glu,Glu,2019_prisci_43,2,Control,10.1111/acer.13931,,,4.16,0.7,,,
,Glu,Glu,2019_sheth_248,1,PTSD,10.1016/j.jad.2019.01.037,1.12,0.1,2.37,0,,,
,Glu,Glu,2019_sheth_248,2,Trauma-exposed ,10.1016/j.jad.2019.01.037,1.12,0.13,2.39,0,,,
,Glu,Glu,2019_sheth_248,3,Control,10.1016/j.jad.2019.01.037,1.13,0.16,2.37,0,,,
,Glu,Glu,2020_ford_98,7,Symptoms of the autism and schizophrenia,10.1016/j.pnpbp.2019.109769,,,6.095,0.23,,,
,Glu,Glu,2020_ford_98,8,Symptoms of the autism and schizophrenia,10.1016/j.pnpbp.2019.109769,,,4.96,0.175,,,
,Glu,Glu,2020_ford_98,9,Symptoms of the autism and schizophrenia,10.1016/j.pnpbp.2019.109769,,,6.04,0.26,,,
,Glu,Glu,2020_ford_98,10,Symptoms of the autism and schizophrenia,10.1016/j.pnpbp.2019.109769,,,5.09,0.15,,,
,Glu,Glu,2020_ford_98,11,Symptoms of the autism and schizophrenia,10.1016/j.pnpbp.2019.109769,,,6.15,0.2,,,
,Glu,Glu,2020_ford_98,12,Symptoms of the autism and schizophrenia,10.1016/j.pnpbp.2019.109769,,,4.83,0.2,,,
,Glu,Glu,2020_hai_3,3,ADHD,10.1001/jamanetworkopen.2020.20973,,,,,9.37,1.29,
,Glu,Glu,2020_hai_3,4,Control,10.1001/jamanetworkopen.2020.20973,,,,,9.43,1.06,
,Glu,Glu,2020_corcoran_10,1,Healthy Controls,10.1002/brb3.1616,,,8.64,2.11,,,
,Glu,Glu,2020_corcoran_10,2,Healthy Controls,10.1002/brb3.1616,,,8.2,1.36,,,
,Glu,Glu,2020_corcoran_10,3,Healthy Controls,10.1002/brb3.1616,,,7.79,1.71,,,
,Glu,Glu,2020_corcoran_10,4,Psychosis ,10.1002/brb3.1616,,,8.04,1.46,,,
,Glu,Glu,2020_corcoran_10,5,Psychosis ,10.1002/brb3.1616,,,7.41,1.37,,,
,Glu,Glu,2020_corcoran_10,6,Psychosis ,10.1002/brb3.1616,,,7.17,1.87,,,
,Glu,Glu,2019_strasser_29,1,Healthy,10.1016/j.euroneuro.2018.12.015,,,,,9.79,1.09,
,Glu,Glu,2019_strasser_29,2,Healthy,10.1016/j.euroneuro.2018.12.015,,,,,10.4,0.86,
,Glu,Glu,2019_wagoner_317,1,Non-OI,10.1152/ajpheart.00680.2018,,,4.9,1.587,,,
,Glu,Glu,2019_wagoner_317,2,OI,10.1152/ajpheart.00680.2018,,,5.4,1.99,,,
,Glu + Gln,Glx,2019_wagoner_317,1,Non-OI,10.1152/ajpheart.00680.2018,,,6.2,3.175,,,
,Glu + Gln,Glx,2019_wagoner_317,2,OI,10.1152/ajpheart.00680.2018,,,7.6,2.322,,,
,Glu,Glu,2019_wang_76,1,FEP,10.1001/jamapsychiatry.2018.3637,,,7.8,1.8,,,
,Glu,Glu,2019_wang_76,2,FEP,10.1001/jamapsychiatry.2018.3637,,,5.2,1,,,
,Glu,Glu,2019_wang_76,3,FEP,10.1001/jamapsychiatry.2018.3637,,,6.3,2,,,
,Glu,Glu,2019_wang_76,4,FEP,10.1001/jamapsychiatry.2018.3637,,,5.6,1,,,
,Glu,Glu,2019_wang_76,5,FEP,10.1001/jamapsychiatry.2018.3637,,,6.3,1.8,,,
,Glu,Glu,2019_wang_76,6,Control,10.1001/jamapsychiatry.2018.3637,,,8.2,1.6,,,
,Glu,Glu,2019_wang_76,7,Control,10.1001/jamapsychiatry.2018.3637,,,5.1,0.8,,,
,Glu,Glu,2019_wang_76,8,Control,10.1001/jamapsychiatry.2018.3637,,,6.6,1.6,,,
,Glu,Glu,2019_wang_76,9,Control,10.1001/jamapsychiatry.2018.3637,,,5.5,1.2,,,
,Glu,Glu,2019_wang_76,10,Control,10.1001/jamapsychiatry.2018.3637,,,6.3,1.6,,,
,Glu,Glu,2018_horowitz-kraus_12,1,Control,10.3389/fnhum.2018.00466,,,,,8.24,0.59,
,Glu,Glu,2018_horowitz-kraus_12,2,Dyslexia,10.3389/fnhum.2018.00466,,,,,8.19,0.51,
,Glu,Glu,2018_modinos_21,1,Control,10.1093/ijnp/pyx076,0.5,1,,,,,
,Glu,Glu,2018_modinos_21,2,Psychosis,10.1093/ijnp/pyx076,0.55,0.1,,,,,Assumed Typo of 5.5 to be .55
,Glu,Glu,2018_posporelis_3,1,Control,10.1016/j.bpsc.2017.04.003,1.33,0.14,7.56,1.18,,,
,Glu,Glu,2018_posporelis_3,2,Schizophrenia,10.1016/j.bpsc.2017.04.003,1.29,0.1,7.56,1.34,,,
,Glu,Glu,2018_posporelis_3,3,Control,10.1016/j.bpsc.2017.04.003,,,9.03,1.94,,,
,Glu,Glu,2018_posporelis_3,4,Schizophrenia,10.1016/j.bpsc.2017.04.003,,,8.38,1.24,,,
,Glu,Glu,2018_povazan_79,1,Healthy,10.1002/mrm.26778,,,10.75,1.01,,,
,Glu,Glu,2018_povazan_79,2,Healthy,10.1002/mrm.26778,,,11.43,0.96,,,
,Glu,Glu,2018_povazan_79,3,Healthy,10.1002/mrm.26778,,,11.76,1.21,,,
,Glu,Glu,2018_povazan_79,4,Healthy,10.1002/mrm.26778,,,12.58,1.11,,,
,Glu,Glu,2018_povazan_79,5,Healthy,10.1002/mrm.26778,,,13.3,0.96,,,
,Glu,Glu,2018_povazan_79,6,Healthy,10.1002/mrm.26778,,,10.41,2.41,,,
,Glu,Glu,2018_povazan_79,7,Healthy,10.1002/mrm.26778,,,10.29,1.44,,,
,Glu,Glu,2020_menshchikov_84,1,Control,10.1002/mrm.28332,0.977,0.045,,,7.08,0.52,
,Glu,Glu,2020_menshchikov_84,2,Mild Traumatic Brain Injury ,10.1002/mrm.28332,0.959,0.056,,,6.91,0.41,
,Glu,Glu,2019_wiegers_62,1,Control,10.1007/s00125-019-4862-9,,,,,6.1,0.74,
,Glu,Glu,2019_wiegers_62,2,Type 1 diabetes - Normal awareness of hypoglycaemia,10.1007/s00125-019-4862-9,,,,,7.04,0.86,
,Glu,Glu,2019_wiegers_62,3,Type 1 diabetes,10.1007/s00125-019-4862-9,,,,,7.29,0.93,
,Glu,Glu,2020_gonen_14,1,Healthy,10.3389/fnins.2020.566643,1.16,0.07,,,10.34,0.93,
,Glu,Glu,2020_gonen_14,2,Healthy,10.3389/fnins.2020.566643,1.13,0.06,,,9.69,0.95,
,Glu,Glu,2020_gonen_14,3,Healthy,10.3389/fnins.2020.566643,1.16,0.07,,,10.24,0.66,
,Glu,Glu,2020_gonen_14,4,Healthy,10.3389/fnins.2020.566643,1.17,0.09,,,10.45,1.3,
,Glu,Glu,2020_gonen_14,5,Healthy,10.3389/fnins.2020.566643,1.16,0.07,,,10.18,1,
,Glu,Glu,2019_morgenroth_117,4,Trait Anxiety,10.1016/j.cortex.2019.02.021,,,6.59,0.58,,,
,Glu,Glu,2019_morgenroth_117,5,Trait Anxiety - Low trait anxiety,10.1016/j.cortex.2019.02.021,,,6.54,0.46,,,
,Glu,Glu,2019_morgenroth_117,6,Trait Anxiety - High trait anxiety,10.1016/j.cortex.2019.02.021,,,6.64,0.68,,,
,Glu,Glu,2019_nery_21,1,At risk for bipolar disorder,10.1111/bdi.12770,,,,,5.61,1,
,Glu,Glu,2019_nery_21,2,At risk for bipolar disorder,10.1111/bdi.12770,,,,,6.21,1.13,
,Glu,Glu,2019_nery_21,3,At risk for bipolar disorder,10.1111/bdi.12770,,,,,5.44,1.1,
,Glu,Glu,2019_nery_21,4,Control,10.1111/bdi.12770,,,,,5.89,0.96,
,Glu,Glu,2019_nery_21,5,Control,10.1111/bdi.12770,,,,,6.3,1.01,
,Glu,Glu,2019_nery_21,6,Control,10.1111/bdi.12770,,,,,5.53,1.07,
,Glu,Glu,2019_nery_21,7,At risk for bipolar disorder - Before first mood episode,10.1111/bdi.12770,,,,,5.43,0.8,
,Glu,Glu,2019_nery_21,8,At risk for bipolar disorder - Before first mood episode,10.1111/bdi.12770,,,,,5.94,1.2,
,Glu,Glu,2019_nery_21,9,At risk for bipolar disorder - Before first mood episode,10.1111/bdi.12770,,,,,5.46,0.98,
,Glu,Glu,2019_nery_21,10,At risk for bipolar disorder - After first mood episode,10.1111/bdi.12770,,,,,5.44,0.88,
,Glu,Glu,2019_nery_21,11,At risk for bipolar disorder - After first mood episode,10.1111/bdi.12770,,,,,5.93,0.96,
,Glu,Glu,2019_nery_21,12,At risk for bipolar disorder - After first mood episode,10.1111/bdi.12770,,,,,5.35,1.02,
,Glu,Glu,2019_nery_21,13,Control,10.1111/bdi.12770,,,,,5.7,0.88,
,Glu,Glu,2019_nery_21,14,Control,10.1111/bdi.12770,,,,,6.14,0.99,
,Glu,Glu,2019_nery_21,15,Control,10.1111/bdi.12770,,,,,5.75,1.33,
,Glu,Glu,2019_nery_21,16,Control,10.1111/bdi.12770,,,,,5.35,0.99,
,Glu,Glu,2019_nery_21,17,Control,10.1111/bdi.12770,,,,,6.11,0.79,
,Glu,Glu,2019_nery_21,18,Control,10.1111/bdi.12770,,,,,5.22,0.9,
,Glu,Glu,2018_tiwari_80,1,Healthy,10.1002/mrm.27142,,,,,9.2,0.6,
,Glu,Glu,2018_tiwari_80,2,Healthy,10.1002/mrm.27142,,,,,6.44,0.44,
,Glu,Glu,2018_tiwari_80,3,Healthy,10.1002/mrm.27142,,,,,10.3,0.9,
,Glu,Glu,2018_tiwari_80,4,Healthy,10.1002/mrm.27142,,,,,10.12,0.74,
,Glu,Glu,2018_tiwari_80,5,Healthy,10.1002/mrm.27142,,,,,9.15,0.81,
,Glu,Glu,2018_tiwari_80,6,Healthy,10.1002/mrm.27142,,,,,7.19,0.55,
,Glu,Glu,2019_reid_45,1,Control,10.1093/schbul/sbx190,,,6.93,0.5,,,
,Glu,Glu,2019_reid_45,2,Schizophrenia,10.1093/schbul/sbx190,,,6.57,0.5,,,
,Glu,Glu,2020_bolo_69,1,Control ,10.2337/db19-0936,,,,,12.8,1.6,
,Glu,Glu,2020_bolo_69,2,Control ,10.2337/db19-0936,,,,,12.6,1.1,
,Glu,Glu,2020_bolo_69,3,T1D,10.2337/db19-0936,,,,,12.3,0.9,
,Glu,Glu,2020_bolo_69,4,T1D,10.2337/db19-0936,,,,,13.5,2,
,Glu,Glu,2020_bolo_69,5,Control ,10.2337/db19-0936,,,,,7.4,0.7,
,Glu,Glu,2020_bolo_69,6,Control ,10.2337/db19-0936,,,,,7.7,0.8,
,Glu,Glu,2020_bolo_69,7,T1D,10.2337/db19-0936,,,,,7.9,0.6,
,Glu,Glu,2020_bolo_69,8,T1D,10.2337/db19-0936,,,,,7.8,0.8,
,Glu,Glu,2020_demnitz_295,1,Addiction ,10.1016/j.pscychresns.2019.111019,,,,,7.12,1.43,
,Glu,Glu,2020_dehghani_83,1,Protocol 1,10.1002/mrm.28066,,,,,6.37,0.48,
,Glu,Glu,2020_dehghani_83,2,Protocol 2,10.1002/mrm.28066,,,,,2.74,0.36,
,Glu,Glu,2020_dehghani_83,3,Protocol 3,10.1002/mrm.28066,,,,,3.51,0.63,
,Glu,Glu,2020_lind_40,1,Control,10.1523/JNEUROSCI.2883-19.2020,,,,,9.62,0.36,
,Glu,Glu,2020_lind_40,2,Aging,10.1523/JNEUROSCI.2883-19.2020,,,,,9.59,1.02,
,Glu,Glu,2020_lind_40,3,Aging,10.1523/JNEUROSCI.2883-19.2020,,,,,9.2,0.6,
,Glu,Glu,2020_lind_40,4,Control,10.1523/JNEUROSCI.2883-19.2020,,,,,7.07,0.55,
,Glu,Glu,2020_lind_40,5,Aging,10.1523/JNEUROSCI.2883-19.2020,,,,,6.55,0.88,
,Glu,Glu,2020_lind_40,6,Aging,10.1523/JNEUROSCI.2883-19.2020,,,,,6.39,0.79,
,Glu,Glu,2020_lind_40,7,Control,10.1523/JNEUROSCI.2883-19.2020,,,,,6.68,0.52,
,Glu,Glu,2020_lind_40,8,Aging,10.1523/JNEUROSCI.2883-19.2020,,,,,6.5,0.66,
,Glu,Glu,2020_lind_40,9,Aging,10.1523/JNEUROSCI.2883-19.2020,,,,,6.68,0.83,
,Glu,Glu,2020_lind_40,10,Control,10.1523/JNEUROSCI.2883-19.2020,,,,,6.04,0.7,
,Glu,Glu,2020_lind_40,11,Aging,10.1523/JNEUROSCI.2883-19.2020,,,,,5.51,0.84,
,Glu,Glu,2020_lind_40,12,Aging,10.1523/JNEUROSCI.2883-19.2020,,,,,5.09,0.99,
,Glu,Glu,2020_draganov_266,1,Control,10.1016/j.jad.2020.01.138,,,,,8.74,1.7,
,Glu,Glu,2020_draganov_266,2,Depression,10.1016/j.jad.2020.01.138,,,,,8.01,1.8,
,Glu,Glu,2020_draganov_266,3,Depression,10.1016/j.jad.2020.01.138,,,,,7.91,1.62,
,Glu,Glu,2020_draganov_266,4,Depression,10.1016/j.jad.2020.01.138,,,,,8.08,1.57,
,Glu,Glu,2020_wiers_305,1,Alcohol use disorder,10.1016/j.pscychresns.2020.111185,,,9.377,0.66,,,
,Glu,Glu,2020_wiers_305,2,Alcohol use disorder,10.1016/j.pscychresns.2020.111185,,,8.205,0.513,,,
,Glu,Glu,2020_wiers_305,3,Control,10.1016/j.pscychresns.2020.111185,,,8.059,0.879,,,
,Glu,Glu,2020_wiers_305,4,Control,10.1016/j.pscychresns.2020.111185,,,6.886,0.293,,,
,Glu,Glu,2020_wong_73,1,Control,10.3233/JAD-190773,,,,,5.593,1.009,
,Glu,Glu,2020_wong_73,2,Mild cognitive impairment,10.3233/JAD-190773,,,,,2.201,0.939,
,Glu,Glu,2020_wong_73,3,Alzheimer's disease,10.3233/JAD-190773,,,,,2.063,1.146,
,Glu,Glu,2020_yasen_11,1,Control ,10.3389/fneur.2020.00683,0.736,0.057,,,,,
,Glu,Glu,2020_yasen_11,2,mTBI - Acute,10.3389/fneur.2020.00683,0.727,0.042,,,,,
,Glu,Glu,2020_yasen_11,3,mTBI - Chronic asymptomatic,10.3389/fneur.2020.00683,0.714,0.1,,,,,
,Glu,Glu,2020_yasen_11,4,mTBI - Chronic symptomatic,10.3389/fneur.2020.00683,0.733,0.107,,,,,
,Glu,Glu,2020_yasen_38,1,Healthy - ApoE4 non-carrier,10.1097/WNP.0000000000000738,0.73,0.076,,,,,
,Glu,Glu,2020_yasen_38,2,Healthy - ApoE4 carrier,10.1097/WNP.0000000000000738,0.733,0.114,,,,,
,Glu,Glu,2020_oleson_23,1,APOE 4 Non Carriers,10.1080/1028415X.2018.1547857,1.23,0.11,,,,,
,Glu,Glu,2020_oleson_23,2,APOE 4 Carriers,10.1080/1028415X.2018.1547857,1.28,0.13,,,,,
,Glu,Glu,2021_borgan_271,1,Healthy,10.1007/s00406-020-01191-2,,,,,15.38,1.85,
,Glu,Glu,2021_borgan_271,2,Psychosis patients,10.1007/s00406-020-01191-2,,,,,16.36,1.9,
,Glu,Glu,2021_kantrowitz_11,1,MDD,10.1038/s41398-021-01541-1,0.835,0.3,,,,,
,Glu,Glu,2021_kantrowitz_11,2,Healthy Control,10.1038/s41398-021-01541-1,0.718,0.8,,,,,
,Glu,Glu,2020_kaminski_87,1,Control,10.1016/j.biopsych.2019.07.011,,,8.22,0.9,,,
,Glu,Glu,2020_kaminski_87,2,Schizophrenia - Medicated,10.1016/j.biopsych.2019.07.011,,,7.94,1.22,,,
,Glu,Glu,2020_kaminski_87,3,Schizophrenia - Unmedicated,10.1016/j.biopsych.2019.07.011,,,7.89,0.84,,,
,Glu,Glu,2020_sheth_123,1,Traumatic Brain Injury,10.1152/jn.00765.2019,,,2.45,0.09,,,
,Glu,Glu,2020_sheth_123,2,Non Traumatic Brain Injury,10.1152/jn.00765.2019,,,2.26,0.13,,,
,Glu,Glu,2018_giapitzakis_79,1,Healthy,10.1002/mrm.26873,,,,,8.42,0.836,Med/Quartile --> Mean/Std Wan 2014
,Glu,Glu,2018_giapitzakis_79,2,Healthy,10.1002/mrm.26873,,,,,8.44,1.24,Med/Quartile --> Mean/Std Wan 2014
,Glu,Glu,2020_vingerhoets_34,1,Healthy Control,10.1177/0269881120922977,,,6.659,0.66,,,
,Glu,Glu,2020_vingerhoets_34,2,Healthy Control,10.1177/0269881120922977,,,4.419,0.63,,,
,Glu,Glu,2020_vingerhoets_34,3,Healthy Control,10.1177/0269881120922977,,,6.659,0.66,,,
,Glu,Glu,2020_vingerhoets_34,4,Healthy Control,10.1177/0269881120922977,,,6.477,0.64,,,
,Glu,Glu,2020_vingerhoets_34,5,Healthy Control,10.1177/0269881120922977,,,4.419,0.63,,,
,Glu,Glu,2020_vingerhoets_34,6,Healthy Control,10.1177/0269881120922977,,,4.389,0.7,,,
,Glu,Glu,2020_vingerhoets_34,7,George syndrome,10.1177/0269881120922977,,,7.061,0.85,,,
,Glu,Glu,2020_vingerhoets_34,8,George syndrome,10.1177/0269881120922977,,,4.628,0.8,,,
,Glu,Glu,2020_vingerhoets_34,9,George syndrome,10.1177/0269881120922977,,,7.061,0.85,,,
,Glu,Glu,2020_vingerhoets_34,10,George syndrome,10.1177/0269881120922977,,,6.8,0.63,,,
,Glu,Glu,2020_vingerhoets_34,11,George syndrome,10.1177/0269881120922977,,,4.674,0.8,,,
,Glu,Glu,2020_vingerhoets_34,12,George syndrome,10.1177/0269881120922977,,,4.62,0.76,,,
,Glu,Glu,2020_vijayakumari_14,1,Healthy Controls,10.1007/s11682-019-00122-7,,,8.77,1.06,,,
,Glu,Glu,2020_vijayakumari_14,2,Healthy Controls,10.1007/s11682-019-00122-7,,,9.24,1.22,,,
,Glu,Glu,2020_vijayakumari_14,3,Healthy Controls,10.1007/s11682-019-00122-7,,,8.72,1.13,,,
,Glu,Glu,2020_vijayakumari_14,4,Mild Cognitive Impairment,10.1007/s11682-019-00122-7,,,8.29,1.3,,,
,Glu,Glu,2020_vijayakumari_14,5,Mild Cognitive Impairment,10.1007/s11682-019-00122-7,,,8.18,1.02,,,
,Glu,Glu,2020_vijayakumari_14,6,Mild Cognitive Impairment,10.1007/s11682-019-00122-7,,,8.15,1.43,,,
,Glu,Glu,2021_egerton_47,1,Psychosis - Antipsychotic responder,10.1093/schbul/sbaa128,,,19.39,3.56,,,
,Glu,Glu,2021_egerton_47,2,Psychosis - Antipsychotic responder,10.1093/schbul/sbaa128,,,13.74,1.75,,,
,Glu,Glu,2021_egerton_47,3,Psychosis - Antipsychotic responder,10.1093/schbul/sbaa128,,,12.57,1.18,,,
,Glu,Glu,2021_egerton_47,4,Psychosis - Antipsychotic responder,10.1093/schbul/sbaa128,,,11.65,1.68,,,
,Glu,Glu,2021_egerton_47,5,Psychosis - Antipsychotic responder,10.1093/schbul/sbaa128,,,20.29,2.63,,,
,Glu,Glu,2021_egerton_47,6,Psychosis - Antipsychotic responder,10.1093/schbul/sbaa128,,,14.28,1.59,,,
,Glu,Glu,2021_egerton_47,7,Psychosis - Antipsychotic responder,10.1093/schbul/sbaa128,,,13.33,0.9,,,
,Glu,Glu,2021_egerton_47,8,Psychosis - Antipsychotic responder,10.1093/schbul/sbaa128,,,11.57,2.22,,,
,Glu,Glu,2021_egerton_47,9,Psychosis - Antipsychotic non-responder,10.1093/schbul/sbaa128,,,10.78,1.47,,,
,Glu,Glu,2021_egerton_47,10,Psychosis - Antipsychotic non-responder,10.1093/schbul/sbaa128,,,8.35,1.12,,,
,Glu,Glu,2021_egerton_47,11,Psychosis - Antipsychotic non-responder,10.1093/schbul/sbaa128,,,8.67,1.13,,,n=5
,Glu,Glu,2021_egerton_47,12,Psychosis - Antipsychotic non-responder,10.1093/schbul/sbaa128,,,9,3.15,,,n=4
,Glu,Glu,2021_egerton_47,13,Psychosis - Antipsychotic non-responder,10.1093/schbul/sbaa128,,,11.07,1.62,,,
,Glu,Glu,2021_egerton_47,14,Psychosis - Antipsychotic non-responder,10.1093/schbul/sbaa128,,,7.89,1.01,,,
,Glu,Glu,2021_egerton_47,15,Psychosis - Antipsychotic non-responder,10.1093/schbul/sbaa128,,,7.41,1.21,,,n=4
,Glu,Glu,2021_egerton_47,16,Psychosis - Antipsychotic non-responder,10.1093/schbul/sbaa128,,,8.58,1.43,,,n=4
,Glu,Glu,2021_kozhuharova_238,1,Schizotypy - Low schizotypy,10.1007/s00213-021-05867-y,,,6.673,4.477,,,StdDev calculated from SEM
,Glu,Glu,2021_kozhuharova_238,2,Schizotypy - High schizotypy,10.1007/s00213-021-05867-y,,,5.356,5.17,,,StdDev calculated from SEM
,Glu,Glu,2016_lopezkolkovsky_75,1,Healthy_Rodent,10.1002/mrm.25602,,,,,9.6,0.9,
,Glu,Glu,2021_oneill_35,1,PSY-PLB (placebo),10.1177/02698811211001107,,,,,7.84,0.9,
,Glu,Glu,2021_oneill_35,2,PSY-CBD,10.1177/02698811211001107,,,,,8.27,1.023,
,Glu+Gln,Glx,2021_oneill_35,1,PSY-PLB (placebo),10.1177/02698811211001107,,,,,11,1.92,
,Glu+Gln,Glx,2021_oneill_35,2,PSY-CBD,10.1177/02698811211001107,,,,,11.46,1.19,
,Glu,Glu,2021_wijtenburg_12,1,Healthy Controls,10.3389/fpsyt.2021.644271,,,6.6,0.7,,,
,Glu,Glu,2021_wijtenburg_12,2,Schizophrenia,10.3389/fpsyt.2021.644271,,,7.4,1.3,,,
,Glu,Glu,2021_persson_315,1,MDD,10.1016/j.pscychresns.2021.111327,0.714,0.07,,,,,
,Glu,Glu,2021_persson_315,2,HC,10.1016/j.pscychresns.2021.111327,0.714,0.07,,,,,
,Glu,Glu,2020_tarumi_45,1,Healthy Control,10.1038/s41386-019-0589-z,,,9.28,1.89,,,
,Glu,Glu,2020_tarumi_45,2,Treatment Resistant Schizophrenia ,10.1038/s41386-019-0589-z,,,10.2,1.3,,,
,Glu,Glu,2020_tarumi_45,3,Non-treatment Resistant Schizophrenia ,10.1038/s41386-019-0589-z,,,9.89,1.51,,,
,Glu,Glu,2020_tarumi_45,4,Healthy Control,10.1038/s41386-019-0589-z,,,14.88,1.6,,,
,Glu,Glu,2020_tarumi_45,5,Treatment Resistant Schizophrenia ,10.1038/s41386-019-0589-z,,,16.14,2.13,,,
,Glu,Glu,2020_tarumi_45,6,Non-treatment Resistant Schizophrenia ,10.1038/s41386-019-0589-z,,,16.01,1.44,,,
,Glu,Glu,2018_burger_185,1,Addiction - Methamphetamine Acute Abstinence,10.1016/j.drugalcdep.2017.11.029,1.368,0.229,,,,,
,Glu,Glu,2018_burger_185,2,Addiction - Methamphetamine Acute Abstinence,10.1016/j.drugalcdep.2017.11.029,1.368,0.173,,,,,
,Glu,Glu,2018_burger_185,3,Addiction - Methamphetamine Acute Abstinence,10.1016/j.drugalcdep.2017.11.029,1.371,0.193,,,,,
,Glu,Glu,2018_burger_185,4,Addiction - Methamphetamine Acute Abstinence,10.1016/j.drugalcdep.2017.11.029,1.279,0.177,,,,,
,Glu,Glu,2018_burger_185,5,Addiction - Methamphetamine Acute Abstinence,10.1016/j.drugalcdep.2017.11.029,1.162,0.189,,,,,
,Glu,Glu,2018_burger_185,6,Addiction - Methamphetamine Acute Abstinence,10.1016/j.drugalcdep.2017.11.029,1.207,0.351,,,,,
,Glu,Glu,2018_burger_185,7,Addiction - Methamphetamine Short-term Abstinence,10.1016/j.drugalcdep.2017.11.029,1.335,0.234,,,,,
,Glu,Glu,2018_burger_185,8,Addiction - Methamphetamine Short-term Abstinence,10.1016/j.drugalcdep.2017.11.029,1.31,0.156,,,,,
,Glu,Glu,2018_burger_185,9,Addiction - Methamphetamine Short-term Abstinence,10.1016/j.drugalcdep.2017.11.029,1.27,0.285,,,,,
,Glu,Glu,2018_burger_185,10,Addiction - Methamphetamine Short-term Abstinence,10.1016/j.drugalcdep.2017.11.029,1.342,0.259,,,,,
,Glu,Glu,2018_burger_185,11,Addiction - Methamphetamine Short-term Abstinence,10.1016/j.drugalcdep.2017.11.029,1.217,0.221,,,,,
,Glu,Glu,2018_burger_185,12,Addiction - Methamphetamine Short-term Abstinence,10.1016/j.drugalcdep.2017.11.029,1.256,0.431,,,,,
,Glu,Glu,2018_burger_185,13,Control,10.1016/j.drugalcdep.2017.11.029,1.293,0.166,,,,,
,Glu,Glu,2018_burger_185,14,Control,10.1016/j.drugalcdep.2017.11.029,1.329,0.18,,,,,
,Glu,Glu,2018_burger_185,15,Control,10.1016/j.drugalcdep.2017.11.029,1.417,0.255,,,,,
,Glu,Glu,2018_burger_185,16,Control,10.1016/j.drugalcdep.2017.11.029,1.286,0.223,,,,,
,Glu,Glu,2018_burger_185,17,Control,10.1016/j.drugalcdep.2017.11.029,1.165,0.17,,,,,
,Glu,Glu,2018_burger_185,18,Control,10.1016/j.drugalcdep.2017.11.029,1.247,0.232,,,,,
,Glu,Glu,2018_deelchand_79,1,Healthy,10.1002/mrm.26788,,,,,10.24,1.559,
,Glu,Glu,2018_deelchand_79,2,Healthy,10.1002/mrm.26788,,,,,9.127,1.113,
,Glu,Glu,2018_kameda_34,1,Chronic Low Back Pain,10.1097/AJP.0000000000000583,1.38,0.163,9.642,1.213,,,
,Glu,Glu,2018_kameda_34,2,Control,10.1097/AJP.0000000000000583,1.385,0.125,10.127,0.763,,,
,Gly,Gly,2018_kim_83,1,First-episode Psychosis,10.1016/j.biopsych.2017.08.022,0.27,0.1,2.5,1,,,IU estimated from bar graph
,Gly,Gly,2018_kim_83,2,First-episode Psychosis,10.1016/j.biopsych.2017.08.022,0.25,0.07,2.15,0.75,,,IU estimated from bar graph
,Gly,Gly,2018_kim_83,3,Control,10.1016/j.biopsych.2017.08.022,0.22,0.06,2,0.7,,,IU estimated from bar graph
,Gly,Gly,2018_kim_83,4,Control,10.1016/j.biopsych.2017.08.022,0.2,0.04,1.7,0.35,,,IU estimated from bar graph
,Gly,Gly,2018_kim_83,5,First-episode Psychosis - Antipsychotic-free,10.1016/j.biopsych.2017.08.022,,,2.17,0.73,,,
,Gly,Gly,2018_kim_83,6,First-episode Psychosis - Antipsychotic-free,10.1016/j.biopsych.2017.08.022,,,2.24,0.74,,,
,Gly,Gly,2018_kim_83,7,First-episode Psychosis - Antipsychotic Treatment,10.1016/j.biopsych.2017.08.022,,,2.62,1.18,,,
,Gly,Gly,2018_kim_83,8,First-episode Psychosis - Antipsychotic Treatment,10.1016/j.biopsych.2017.08.022,,,2.32,0.66,,,
,Gly,Gly,2018_kim_83,9,First-episode Psychosis - Lithium-free,10.1016/j.biopsych.2017.08.022,,,2.49,1.25,,,
,Gly,Gly,2018_kim_83,10,First-episode Psychosis - Lithium-free,10.1016/j.biopsych.2017.08.022,,,2.36,0.63,,,
,Gly,Gly,2018_kim_83,11,First-episode Psychosis - Lithium Treatment,10.1016/j.biopsych.2017.08.022,,,2.48,0.79,,,
,Gly,Gly,2018_kim_83,12,First-episode Psychosis - Lithium Treatment,10.1016/j.biopsych.2017.08.022,,,2.08,0.67,,,
,Gly,Gly,2019_giapitzakis_81,1,Healthy,10.1002/mrm.27467,,,,,1.8,0.3,
,Gly,Gly,2019_giapitzakis_81,2,Healthy,10.1002/mrm.27467,,,,,1.4,0.3,
,Gly,Gly,2018_zarinabad_79,1,Medulloblastoma,10.1002/mrm.26837,,,,,3.7,2.08,
,Gly,Gly,2018_zarinabad_79,2,Pilocytic Astrocytoma,10.1002/mrm.26837,,,,,0.73,0.76,
,Gly,Gly,2018_zarinabad_79,3,Ependymoma,10.1002/mrm.26837,,,,,1.92,0.5,
,Gly,Gly,2021_steinegger_26,1,Control,10.1111/adb.13027,,,,,6.34,2,
,Gly,Gly,2021_steinegger_26,4,Smokers,10.1111/adb.13027,,,,,5.7,1.78,
,Gly,Gly,2021_steinegger_26,6,Baseline,10.1111/adb.13027,,,,,5.62,1.74,
,Gly,Gly,2021_steinegger_26,7,Withdrawal,10.1111/adb.13027,,,,,7.33,2.01,
,Gly,Gly,2021_steinegger_26,8,Satiation,10.1111/adb.13027,,,,,7.28,1.63,
,Gly,Gly,2020_dehghani_83,1,Protocol 1,10.1002/mrm.28066,,,,,0.38,0.14,
,Gly,Gly,2020_dehghani_83,3,Protocol 3,10.1002/mrm.28066,,,,,0.22,0.07,
,Gly,Gly,2018_giapitzakis_79,1,Healthy,10.1002/mrm.26873,,,,,1.61,0.597,Med/Quartile --> Mean/Std Wan 2014
,Gly,Gly,2018_giapitzakis_79,2,Healthy,10.1002/mrm.26873,,,,,0.71,1.185,Med/Quartile --> Mean/Std Wan 2014
,Gly,Gly,2016_lopezkolkovsky_75,1,Healthy_Rodent,10.1002/mrm.25602,,,,,0.2,0.04,
,Glx,Glx,2017_hanquinet_27,1,control,10.1007/s00330-017-4808-x,0.1,0.1,,,,,
,Glx,Glx,2017_hanquinet_27,2,isointense,10.1007/s00330-017-4808-x,0.1,0.1,,,,,
,Glx,Glx,2017_hanquinet_27,3,hyperintense,10.1007/s00330-017-4808-x,0.1,0.1,,,,,
,Glx,Glx,2017_hanquinet_27,4,much more hyperintense,10.1007/s00330-017-4808-x,0.1,0.1,,,,,
,Glx,Glx,2019_andrade_13,1,Control,10.3389/fnhum.2019.00186,1.32,0.23,,,,,
,Glx,Glx,2019_andrade_13,2,OCD,10.3389/fnhum.2019.00186,1.51,0.27,,,,,
,Glx,Glx,2019_barbagallo_62,1,Control,10.1016/j.parkreldis.2018.12.008,2.005,0.1,9.85,0.5,,,
,Glx,Glx,2019_barbagallo_62,2,Progressive Supranuclear Palsy,10.1016/j.parkreldis.2018.12.008,2.033,0.18,8.35,1.317,,,
,Glx,Glx,2019_borgan_9,1,Control,10.1038/s41598-019-45018-0,,,,,18.12,3.65,
,Glx,Glx,2019_borgan_9,2,Psychosis,10.1038/s41598-019-45018-0,,,,,18.4,3.82,
,Glx,Glx,2019_bossong_76,1,Control,10.1001/jamapsychiatry.2018.3252,,,,,11.61,2.23,
,Glx,Glx,2019_bossong_76,2,Psychosis - HighRisk,10.1001/jamapsychiatry.2018.3252,,,,,11.43,2.48,
,Glx,Glx,2019_bossong_76,3,Psychosis,10.1001/jamapsychiatry.2018.3252,,,,,12.44,2.16,
,Glx,Glx,2019_bustillo_246,1,Control <40 GM,10.1016/j.jad.2018.12.064,,,,,25.3,3.3,
,Glx,Glx,2019_bustillo_246,2,Control <40 WM,10.1016/j.jad.2018.12.064,,,,,14.5,2.3,
,Glx,Glx,2019_bustillo_246,3,Control >40 GM,10.1016/j.jad.2018.12.064,,,,,26.1,4.7,
,Glx,Glx,2019_bustillo_246,4,Control >40 WM,10.1016/j.jad.2018.12.064,,,,,15.5,3.5,
,Glx,Glx,2019_bustillo_246,5,Bipolar <40 GM,10.1016/j.jad.2018.12.064,,,,,25.3,3.7,
,Glx,Glx,2019_bustillo_246,6,Bipolar <40 WM,10.1016/j.jad.2018.12.064,,,,,15.1,2.9,
,Glx,Glx,2019_bustillo_246,7,Bipolar >40 GM,10.1016/j.jad.2018.12.064,,,,,27.1,4.6,
,Glx,Glx,2019_bustillo_246,8,Bipolar >40 WM,10.1016/j.jad.2018.12.064,,,,,15.4,3,
,Glx,Glx,2019_bustillo_246,9,Schizophrenia <40 GM,10.1016/j.jad.2018.12.064,,,,,25.5,3.4,
,Glx,Glx,2019_bustillo_246,10,Schizophrenia <40 WM,10.1016/j.jad.2018.12.064,,,,,14.9,3,
,Glx,Glx,2019_bustillo_246,11,Schizophrenia >40 GM,10.1016/j.jad.2018.12.064,,,,,27.6,4.9,
,Glx,Glx,2019_bustillo_246,12,Schizophrenia >40 WM,10.1016/j.jad.2018.12.064,,,,,15.4,3,
,Glx,Glx,2019_chan_14,1,Control,10.1371/journal.pone.0208666,,,1.902,0.269,,,
,Glx,Glx,2019_chan_14,2,Migraine,10.1371/journal.pone.0208666,,,1.604,0.122,,,
,Glx,Glx,2019_costigan_40,2,Healthy,10.1002/hbm.24566,,,,,20.93,2.87,
,Glx,Glx,2019_costigan_40,4,Healthy,10.1002/hbm.24566,,,,,21.64,2.75,
,Glx,Glx,2019_davies_29,1,High-Risk Psychosis,10.1016/j.euroneuro.2019.03.008,1.42,0.24,10.19,1.81,,,
,Glx,Glx,2019_davies_29,2,High-Risk Psychosis,10.1016/j.euroneuro.2019.03.008,1.72,0.23,19.51,2.53,,,
,Glx,Glx,2019_davies_29,3,High-Risk Psychosis,10.1016/j.euroneuro.2019.03.008,1.24,0.27,9.16,1.96,,,
,Glx,Glx,2019_davies_29,4,High-Risk Psychosis,10.1016/j.euroneuro.2019.03.008,1.4,0.24,10.37,2.08,,,
,Glx,Glx,2019_davies_29,5,High-Risk Psychosis,10.1016/j.euroneuro.2019.03.008,1.7,0.17,19.65,2.51,,,
,Glx,Glx,2019_davies_29,6,High-Risk Psychosis,10.1016/j.euroneuro.2019.03.008,1.19,0.28,8.88,2.06,,,
,Glx,Glx,2018_al-iedani_108,1,Healthy,10.1016/j.ejrad.2018.09.020,1.29,0.04,,,,,
,Glx,Glx,2018_al-iedani_108,2,Healthy,10.1016/j.ejrad.2018.09.020,1.25,0.01,,,,,
,Glx,Glx,2018_atagun_235,1,BD-I,10.1016/j.jad.2018.04.010,,,1.87,0.26,,,
,Glx,Glx,2018_atagun_235,2,BD-I,10.1016/j.jad.2018.04.010,,,1.11,0.18,,,
,Glx,Glx,2018_atagun_235,3,BD-II,10.1016/j.jad.2018.04.010,,,1.98,0.26,,,
,Glx,Glx,2018_atagun_235,4,BD-II,10.1016/j.jad.2018.04.010,,,1.36,0.37,,,
,Glx,Glx,2018_atagun_235,5,Control,10.1016/j.jad.2018.04.010,,,1.95,0.26,,,
,Glx,Glx,2018_atagun_235,6,Control,10.1016/j.jad.2018.04.010,,,1.25,0.18,,,
,Glx,Glx,2018_barbagallo_47,4,Control,10.1016/j.parkreldis.2017.11.345,2.08,0.57,14.6,3.39,,,
,Glx,Glx,2018_barbagallo_47,5,Control,10.1016/j.parkreldis.2017.11.345,2.12,1.02,14.3,5.33,,,
,Glx,Glx,2018_barbagallo_47,6,Control,10.1016/j.parkreldis.2017.11.345,2.03,0.51,15,4.19,,,
,Glx,Glx,2018_barbagallo_47,1,Essential Tremor,10.1016/j.parkreldis.2017.11.345,2.61,0.53,18.1,3.34,,,
,Glx,Glx,2018_barbagallo_47,2,Essential Tremor,10.1016/j.parkreldis.2017.11.345,2.75,0.87,17.5,3.44,,,
,Glx,Glx,2018_barbagallo_47,3,Essential Tremor,10.1016/j.parkreldis.2017.11.345,2.48,0.55,18.7,4.96,,,
,Glx,Glx,2018_bauer_19,1,Healthy,10.1080/15622975.2016.1262060,,,16.69,1.61,,,
,Glx,Glx,2018_bauer_19,2,Healthy,10.1080/15622975.2016.1262060,,,13.55,2.59,,,
,Glx,Glx,2018_bauer_19,3,ADHD,10.1080/15622975.2016.1262060,,,17.65,2.25,,,
,Glx,Glx,2018_bauer_19,4,ADHD,10.1080/15622975.2016.1262060,,,13.58,2.54,,,
,Glx,Glx,2020_mohamadi_10,1,TTH,10.31661/jbpe.v0i0.1039,0.86,0.18,,,,,
,Glx,Glx,2020_mohamadi_10,2,TTH,10.31661/jbpe.v0i0.1039,0.93,0.41,,,,,
,Glx,Glx,2020_mohamadi_10,3,TTH,10.31661/jbpe.v0i0.1039,1.08,0.27,,,,,
,Glx,Glx,2018_bossong_21,1,Healthy,10.1093/ijnp/pyy011,,,9.95,1.96,,,
,Glx,Glx,2018_caravaggio_28,1,Healthy,10.1016/j.euroneuro.2017.12.002,,,12.37,1.83,,,
,Glx,Glx,2018_caravaggio_28,2,Healthy,10.1016/j.euroneuro.2017.12.002,,,11.98,2.2,,,
,Glx,Glx,2018_caravaggio_28,3,Healthy,10.1016/j.euroneuro.2017.12.002,,,14.4,1.6,,,
,Glx,Glx,2018_caravaggio_28,4,Healthy,10.1016/j.euroneuro.2017.12.002,,,14.23,1.28,,,
,Glx,Glx,2018_chiu_193,3,First-episode Schizophrenia,10.1016/j.schres.2017.07.021,,,,,12.86,3.25,
,Glx,Glx,2018_chiu_193,4,Healthy,10.1016/j.schres.2017.07.021,,,,,7.88,1.39,
,Glx,Glx,2018_cirstea_97,1,Healthy,10.1097/PHM.0000000000000791,,,,,12.4,2.5,
,Glx,Glx,2018_cirstea_97,2,Healthy,10.1097/PHM.0000000000000791,,,,,13.5,3.8,
,Glx,Glx,2018_cirstea_97,3,Healthy,10.1097/PHM.0000000000000791,,,,,14.7,2.3,
,Glx,Glx,2018_cirstea_97,4,Healthy,10.1097/PHM.0000000000000791,,,,,11.2,2.6,
,Glx,Glx,2018_cirstea_97,5,Healthy,10.1097/PHM.0000000000000791,,,,,12.8,2.7,
,Glx,Glx,2018_cirstea_97,6,Healthy,10.1097/PHM.0000000000000791,,,,,13.2,3,
,Glx,Glx,2018_cirstea_97,7,Stroke,10.1097/PHM.0000000000000791,,,,,10.9,2.2,
,Glx,Glx,2018_cirstea_97,8,Stroke,10.1097/PHM.0000000000000791,,,,,12.5,2.5,
,Glx,Glx,2018_cirstea_97,9,Stroke,10.1097/PHM.0000000000000791,,,,,15.2,3.5,
,Glx,Glx,2018_cirstea_97,10,Stroke,10.1097/PHM.0000000000000791,,,,,11.7,2.6,
,Glx,Glx,2018_cirstea_97,11,Stroke,10.1097/PHM.0000000000000791,,,,,14.3,2.9,
,Glx,Glx,2018_cirstea_97,12,Stroke,10.1097/PHM.0000000000000791,,,,,14,3,
,Glx,Glx,2018_de_239,1,Postpartum Depression,10.1016/j.jad.2018.07.028,1.5,0.2,,,,,
,Glx,Glx,2018_de_239,2,Postpartum Euthymic ,10.1016/j.jad.2018.07.028,1.6,0.3,,,,,
,Glx,Glx,2018_dejaeger_9,1,Painful Diabetic Polyneuropathy - Pregabalin Visit 1,10.1007/s13300-018-0460-y,,,,,5.93,2.75,
,Glx,Glx,2018_dejaeger_9,2,Painful Diabetic Polyneuropathy - Pregabalin Visit 1,10.1007/s13300-018-0460-y,,,,,6.36,1.07,
,Glx,Glx,2018_dejaeger_9,3,Painful Diabetic Polyneuropathy - Pregabalin Visit 1,10.1007/s13300-018-0460-y,,,,,6.34,1.66,
,Glx,Glx,2018_dejaeger_9,4,Painful Diabetic Polyneuropathy - Pregabalin Visit 1,10.1007/s13300-018-0460-y,,,,,5.92,1.99,
,Glx,Glx,2018_dejaeger_9,5,Painful Diabetic Polyneuropathy - Pregabalin Visit 3,10.1007/s13300-018-0460-y,,,,,5.52,3.02,
,Glx,Glx,2018_dejaeger_9,6,Painful Diabetic Polyneuropathy - Pregabalin Visit 3,10.1007/s13300-018-0460-y,,,,,5.63,1.78,
,Glx,Glx,2018_dejaeger_9,7,Painful Diabetic Polyneuropathy - Pregabalin Visit 3,10.1007/s13300-018-0460-y,,,,,7.17,2.09,
,Glx,Glx,2018_dejaeger_9,8,Painful Diabetic Polyneuropathy - Pregabalin Visit 3,10.1007/s13300-018-0460-y,,,,,5.78,1.29,
,Glx,Glx,2018_dejaeger_9,9,Painful Diabetic Polyneuropathy - Pregabalin Visit 5,10.1007/s13300-018-0460-y,,,,,8.47,3.87,
,Glx,Glx,2018_dejaeger_9,10,Painful Diabetic Polyneuropathy - Pregabalin Visit 5,10.1007/s13300-018-0460-y,,,,,6.55,0.84,
,Glx,Glx,2018_dejaeger_9,11,Painful Diabetic Polyneuropathy - Pregabalin Visit 5,10.1007/s13300-018-0460-y,,,,,5.84,1.78,
,Glx,Glx,2018_dejaeger_9,12,Painful Diabetic Polyneuropathy - Pregabalin Visit 5,10.1007/s13300-018-0460-y,,,,,5.42,1.19,
,Glx,Glx,2018_dejaeger_9,13,Painful Diabetic Polyneuropathy - Pregabalin Visit 7,10.1007/s13300-018-0460-y,,,,,6.32,2.83,
,Glx,Glx,2018_dejaeger_9,14,Painful Diabetic Polyneuropathy - Pregabalin Visit 7,10.1007/s13300-018-0460-y,,,,,6.28,1.98,
,Glx,Glx,2018_dejaeger_9,15,Painful Diabetic Polyneuropathy - Pregabalin Visit 7,10.1007/s13300-018-0460-y,,,,,7.04,3.87,
,Glx,Glx,2018_dejaeger_9,16,Painful Diabetic Polyneuropathy - Pregabalin Visit 7,10.1007/s13300-018-0460-y,,,,,6.61,1.35,
,Glx,Glx,2018_dejaeger_9,17,Painful Diabetic Polyneuropathy - Placebo Visit 1,10.1007/s13300-018-0460-y,,,,,6.58,3.26,
,Glx,Glx,2018_dejaeger_9,18,Painful Diabetic Polyneuropathy - Placebo Visit 1,10.1007/s13300-018-0460-y,,,,,5.98,1.88,
,Glx,Glx,2018_dejaeger_9,19,Painful Diabetic Polyneuropathy - Placebo Visit 1,10.1007/s13300-018-0460-y,,,,,5.15,1.67,
,Glx,Glx,2018_dejaeger_9,20,Painful Diabetic Polyneuropathy - Placebo Visit 1,10.1007/s13300-018-0460-y,,,,,6.68,1.59,
,Glx,Glx,2018_dejaeger_9,21,Painful Diabetic Polyneuropathy - Placebo Visit 3,10.1007/s13300-018-0460-y,,,,,5.5,2.74,
,Glx,Glx,2018_dejaeger_9,22,Painful Diabetic Polyneuropathy - Placebo Visit 3,10.1007/s13300-018-0460-y,,,,,6.29,1.89,
,Glx,Glx,2018_dejaeger_9,23,Painful Diabetic Polyneuropathy - Placebo Visit 3,10.1007/s13300-018-0460-y,,,,,5.69,1.68,
,Glx,Glx,2018_dejaeger_9,24,Painful Diabetic Polyneuropathy - Placebo Visit 3,10.1007/s13300-018-0460-y,,,,,5.29,0.93,
,Glx,Glx,2018_dejaeger_9,25,Painful Diabetic Polyneuropathy - Placebo Visit 5,10.1007/s13300-018-0460-y,,,,,5.96,1.91,
,Glx,Glx,2018_dejaeger_9,26,Painful Diabetic Polyneuropathy - Placebo Visit 5,10.1007/s13300-018-0460-y,,,,,5.29,1.77,
,Glx,Glx,2018_dejaeger_9,27,Painful Diabetic Polyneuropathy - Placebo Visit 5,10.1007/s13300-018-0460-y,,,,,5.05,2.17,
,Glx,Glx,2018_dejaeger_9,28,Painful Diabetic Polyneuropathy - Placebo Visit 5,10.1007/s13300-018-0460-y,,,,,6.08,2.26,
,Glx,Glx,2018_dejaeger_9,29,Painful Diabetic Polyneuropathy - Placebo Visit 7,10.1007/s13300-018-0460-y,,,,,5.83,2.54,
,Glx,Glx,2018_dejaeger_9,30,Painful Diabetic Polyneuropathy - Placebo Visit 7,10.1007/s13300-018-0460-y,,,,,5.49,1.39,
,Glx,Glx,2018_dejaeger_9,31,Painful Diabetic Polyneuropathy - Placebo Visit 7,10.1007/s13300-018-0460-y,,,,,6.31,1.43,
,Glx,Glx,2018_dejaeger_9,32,Painful Diabetic Polyneuropathy - Placebo Visit 7,10.1007/s13300-018-0460-y,,,,,7.83,3.01,
,Glx,Glx,2018_dejaeger_9,33,Painful Diabetic Polyneuropathy - Pregabalin 0 mg,10.1007/s13300-018-0460-y,,,,,5.92,2.61,
,Glx,Glx,2018_dejaeger_9,34,Painful Diabetic Polyneuropathy - Pregabalin 0 mg,10.1007/s13300-018-0460-y,,,,,5.8,1.66,
,Glx,Glx,2018_dejaeger_9,35,Painful Diabetic Polyneuropathy - Pregabalin 0 mg,10.1007/s13300-018-0460-y,,,,,5.72,1.76,
,Glx,Glx,2018_dejaeger_9,36,Painful Diabetic Polyneuropathy - Pregabalin 0 mg,10.1007/s13300-018-0460-y,,,,,6.22,2.15,
,Glx,Glx,2018_dejaeger_9,37,Painful Diabetic Polyneuropathy - Pregabalin 75 mg,10.1007/s13300-018-0460-y,,,,,5.77,2.52,
,Glx,Glx,2018_dejaeger_9,38,Painful Diabetic Polyneuropathy - Pregabalin 75 mg,10.1007/s13300-018-0460-y,,,,,6.53,1.85,
,Glx,Glx,2018_dejaeger_9,39,Painful Diabetic Polyneuropathy - Pregabalin 75 mg,10.1007/s13300-018-0460-y,,,,,7.19,2.81,
,Glx,Glx,2018_dejaeger_9,40,Painful Diabetic Polyneuropathy - Pregabalin 75 mg,10.1007/s13300-018-0460-y,,,,,6.19,1.27,
,Glx,Glx,2018_dejaeger_9,41,Painful Diabetic Polyneuropathy - Pregabalin 225 mg,10.1007/s13300-018-0460-y,,,,,7.49,3.16,
,Glx,Glx,2018_dejaeger_9,42,Painful Diabetic Polyneuropathy - Pregabalin 225 mg,10.1007/s13300-018-0460-y,,,,,6.77,2.09,
,Glx,Glx,2018_dejaeger_9,43,Painful Diabetic Polyneuropathy - Pregabalin 225 mg,10.1007/s13300-018-0460-y,,,,,5.92,1.94,
,Glx,Glx,2018_dejaeger_9,44,Painful Diabetic Polyneuropathy - Pregabalin 225 mg,10.1007/s13300-018-0460-y,,,,,6.06,1.45,
,Glx,Glx,2018_dejaeger_9,45,Painful Diabetic Polyneuropathy - Pregabalin 450 mg,10.1007/s13300-018-0460-y,,,,,6.5,2.31,
,Glx,Glx,2018_dejaeger_9,46,Painful Diabetic Polyneuropathy - Pregabalin 450 mg,10.1007/s13300-018-0460-y,,,,,5.92,1.94,
,Glx,Glx,2018_dejaeger_9,47,Painful Diabetic Polyneuropathy - Pregabalin 450 mg,10.1007/s13300-018-0460-y,,,,,6.42,2.86,
,Glx,Glx,2018_dejaeger_9,48,Painful Diabetic Polyneuropathy - Pregabalin 450 mg,10.1007/s13300-018-0460-y,,,,,6.53,2,
,Glx,Glx,2018_ding_38,1,Healthy - Pre-fasting,10.1177/0271678X17697721,,,8.05,0.61,,,
,Glx,Glx,2018_ding_38,2,Healthy - Pre-fasting,10.1177/0271678X17697721,,,8.52,0.91,,,
,Glx,Glx,2018_ding_38,3,Healthy - Pre-fasting,10.1177/0271678X17697721,,,7.74,0.53,,,
,Glx,Glx,2018_ding_38,4,Healthy - Pre-fasting,10.1177/0271678X17697721,,,7.9,0.63,,,
,Glx,Glx,2018_ding_38,5,Healthy - Pre-fasting,10.1177/0271678X17697721,,,7.55,0.77,,,
,Glx,Glx,2018_ding_38,6,Healthy - Pre-fasting,10.1177/0271678X17697721,,,7.66,0.78,,,
,Glx,Glx,2018_ding_38,7,Healthy - Pre-fasting,10.1177/0271678X17697721,,,7.97,1.19,,,
,Glx,Glx,2018_ding_38,8,Healthy - Pre-fasting,10.1177/0271678X17697721,,,7.93,1.15,,,
,Glx,Glx,2018_ding_38,9,Healthy - Pre-fasting,10.1177/0271678X17697721,,,8.54,0.69,,,
,Glx,Glx,2018_ding_38,10,Healthy - Post-fasting,10.1177/0271678X17697721,,,6.68,0.78,,,
,Glx,Glx,2018_ding_38,11,Healthy - Post-fasting,10.1177/0271678X17697721,,,7.35,0.89,,,
,Glx,Glx,2018_ding_38,12,Healthy - Post-fasting,10.1177/0271678X17697721,,,6.39,0.55,,,
,Glx,Glx,2018_ding_38,13,Healthy - Post-fasting,10.1177/0271678X17697721,,,6.72,0.98,,,
,Glx,Glx,2018_ding_38,14,Healthy - Post-fasting,10.1177/0271678X17697721,,,6.16,0.56,,,
,Glx,Glx,2018_ding_38,15,Healthy - Post-fasting,10.1177/0271678X17697721,,,6.28,0.76,,,
,Glx,Glx,2018_ding_38,16,Healthy - Post-fasting,10.1177/0271678X17697721,,,6.51,0.73,,,
,Glx,Glx,2018_ding_38,17,Healthy - Post-fasting,10.1177/0271678X17697721,,,6.27,0.71,,,
,Glx,Glx,2018_ding_38,18,Healthy - Post-fasting,10.1177/0271678X17697721,,,7.19,0.69,,,
,Glx,Glx,2018_ding_38,19,Healthy - Non-fasting,10.1177/0271678X17697721,,,8.09,0.55,,,
,Glx,Glx,2018_ding_38,20,Healthy - Non-fasting,10.1177/0271678X17697721,,,8.48,0.5,,,
,Glx,Glx,2018_ding_38,21,Healthy - Non-fasting,10.1177/0271678X17697721,,,7.4,0.49,,,
,Glx,Glx,2018_ding_38,22,Healthy - Non-fasting,10.1177/0271678X17697721,,,8.01,0.53,,,
,Glx,Glx,2018_ding_38,23,Healthy - Non-fasting,10.1177/0271678X17697721,,,7.54,0.44,,,
,Glx,Glx,2018_ding_38,24,Healthy - Non-fasting,10.1177/0271678X17697721,,,7.86,0.5,,,
,Glx,Glx,2018_ding_38,25,Healthy - Non-fasting,10.1177/0271678X17697721,,,7.64,0.57,,,
,Glx,Glx,2018_ding_38,26,Healthy - Non-fasting,10.1177/0271678X17697721,,,7.76,0.49,,,
,Glx,Glx,2018_ding_38,27,Healthy - Non-fasting,10.1177/0271678X17697721,,,8.34,0.37,,,
,Glx,Glx,2017_aleks_282,1,Control - Baseline,10.1148/radiol.2016152083,0.59,0.01,,,,,
,Glx,Glx,2017_aleks_282,2,Control - Follow-Up,10.1148/radiol.2016152083,0.62,0.04,,,,,
,Glx,Glx,2017_aleks_282,3,Cervical Spondylotic Myelopathy - Preoperative,10.1148/radiol.2016152083,0.67,0.04,,,,,
,Glx,Glx,2017_aleks_282,4,Cervical Spondylotic Myelopathy - Postoperative,10.1148/radiol.2016152083,0.58,0.03,,,,,
,Glx,Glx,2018_egerton_23,1,Healthy - Baseline,10.1038/s41380-018-0082-9,1.94,0.24,,,,,
,Glx,Glx,2018_egerton_23,2,Healthy - Baseline,10.1038/s41380-018-0082-9,1.54,0.23,,,,,
,Glx,Glx,2018_egerton_23,3,Healthy - Baseline,10.1038/s41380-018-0082-9,1.6,0.23,,,,,
,Glx,Glx,2018_egerton_23,4,Healthy - Baseline,10.1038/s41380-018-0082-9,1.37,0.31,,,,,
,Glx,Glx,2018_egerton_23,5,Healthy - Baseline,10.1038/s41380-018-0082-9,1.54,0.17,,,,,
,Glx,Glx,2018_egerton_23,6,Healthy - Baseline,10.1038/s41380-018-0082-9,1.43,0.4,,,,,
,Glx,Glx,2018_egerton_23,7,Healthy - After Amisulpride,10.1038/s41380-018-0082-9,1.86,0.31,,,,,
,Glx,Glx,2018_egerton_23,8,Healthy - After Amisulpride,10.1038/s41380-018-0082-9,1.71,0.22,,,,,
,Glx,Glx,2018_egerton_23,9,Healthy - After Amisulpride,10.1038/s41380-018-0082-9,1.42,0.15,,,,,
,Glx,Glx,2018_egerton_23,10,Healthy - After Amisulpride,10.1038/s41380-018-0082-9,1.28,0.27,,,,,
,Glx,Glx,2018_egerton_23,11,Healthy - After Amisulpride,10.1038/s41380-018-0082-9,1.79,0.3,,,,,
,Glx,Glx,2018_egerton_23,12,Healthy - After Amisulpride,10.1038/s41380-018-0082-9,1.31,0.43,,,,,
,Glx,Glx,2018_egerton_23,13,First Episode Psychosis - Baseline,10.1038/s41380-018-0082-9,1.9,0.26,,,,,
,Glx,Glx,2018_egerton_23,14,First Episode Psychosis - Baseline,10.1038/s41380-018-0082-9,1.62,0.32,,,,,
,Glx,Glx,2018_egerton_23,15,First Episode Psychosis - Baseline,10.1038/s41380-018-0082-9,1.48,0.18,,,,,
,Glx,Glx,2018_egerton_23,16,First Episode Psychosis - Baseline,10.1038/s41380-018-0082-9,1.31,0.28,,,,,
,Glx,Glx,2018_egerton_23,17,First Episode Psychosis - Baseline,10.1038/s41380-018-0082-9,1.56,0.31,,,,,
,Glx,Glx,2018_egerton_23,18,First Episode Psychosis - Baseline,10.1038/s41380-018-0082-9,1.59,0.33,,,,,
,Glx,Glx,2018_egerton_23,19,First Episode Psychosis - After Amisulpride,10.1038/s41380-018-0082-9,1.82,0.38,,,,,
,Glx,Glx,2018_egerton_23,20,First Episode Psychosis - After Amisulpride,10.1038/s41380-018-0082-9,1.51,0.19,,,,,
,Glx,Glx,2018_egerton_23,21,First Episode Psychosis - After Amisulpride,10.1038/s41380-018-0082-9,1.48,0.34,,,,,
,Glx,Glx,2018_egerton_23,22,First Episode Psychosis - After Amisulpride,10.1038/s41380-018-0082-9,1.34,0.25,,,,,
,Glx,Glx,2018_egerton_23,23,First Episode Psychosis - After Amisulpride,10.1038/s41380-018-0082-9,1.67,0.29,,,,,
,Glx,Glx,2018_egerton_23,24,First Episode Psychosis - After Amisulpride,10.1038/s41380-018-0082-9,1.29,0.51,,,,,
,Glx,Glx,2018_egerton_23,25,First Episode Psychosis - Remission (Baseline),10.1038/s41380-018-0082-9,1.62,0.34,,,,,
,Glx,Glx,2018_egerton_23,26,First Episode Psychosis - Remission (Baseline),10.1038/s41380-018-0082-9,1.84,0.11,,,,,
,Glx,Glx,2018_egerton_23,27,First Episode Psychosis - Remission (Baseline),10.1038/s41380-018-0082-9,1.51,0.16,,,,,
,Glx,Glx,2018_egerton_23,28,First Episode Psychosis - Remission (Baseline),10.1038/s41380-018-0082-9,1.27,0.21,,,,,
,Glx,Glx,2018_egerton_23,29,First Episode Psychosis - Remission (Baseline),10.1038/s41380-018-0082-9,1.63,0.25,,,,,
,Glx,Glx,2018_egerton_23,30,First Episode Psychosis - Remission (Baseline),10.1038/s41380-018-0082-9,1.68,0.35,,,,,
,Glx,Glx,2018_egerton_23,31,First Episode Psychosis - Remission (After Amisulpride),10.1038/s41380-018-0082-9,1.73,0.36,,,,,
,Glx,Glx,2018_egerton_23,32,First Episode Psychosis - Remission (After Amisulpride),10.1038/s41380-018-0082-9,1.49,0.21,,,,,
,Glx,Glx,2018_egerton_23,33,First Episode Psychosis - Remission (After Amisulpride),10.1038/s41380-018-0082-9,1.34,0.07,,,,,
,Glx,Glx,2018_egerton_23,34,First Episode Psychosis - Remission (After Amisulpride),10.1038/s41380-018-0082-9,1.61,0.26,,,,,
,Glx,Glx,2018_egerton_23,35,First Episode Psychosis - Remission (After Amisulpride),10.1038/s41380-018-0082-9,1.28,0.27,,,,,
,Glx,Glx,2018_egerton_23,36,First Episode Psychosis - Remission (After Amisulpride),10.1038/s41380-018-0082-9,1.35,0.6,,,,,
,Glx,Glx,2018_egerton_23,37,First Episode Psychosis - No Remission (Baseline),10.1038/s41380-018-0082-9,2.17,0.32,,,,,
,Glx,Glx,2018_egerton_23,38,First Episode Psychosis - No Remission (Baseline),10.1038/s41380-018-0082-9,1.61,0.32,,,,,
,Glx,Glx,2018_egerton_23,39,First Episode Psychosis - No Remission (Baseline),10.1038/s41380-018-0082-9,1.43,0.23,,,,,
,Glx,Glx,2018_egerton_23,40,First Episode Psychosis - No Remission (Baseline),10.1038/s41380-018-0082-9,1.6,0.33,,,,,
,Glx,Glx,2018_egerton_23,41,First Episode Psychosis - No Remission (Baseline),10.1038/s41380-018-0082-9,1.43,0.36,,,,,
,Glx,Glx,2018_egerton_23,42,First Episode Psychosis - No Remission (Baseline),10.1038/s41380-018-0082-9,1.45,0.27,,,,,
,Glx,Glx,2018_egerton_23,43,First Episode Psychosis - No Remission (After Amisulpride),10.1038/s41380-018-0082-9,1.88,0.27,,,,,
,Glx,Glx,2018_egerton_23,44,First Episode Psychosis - No Remission (After Amisulpride),10.1038/s41380-018-0082-9,1.54,0.12,,,,,
,Glx,Glx,2018_egerton_23,45,First Episode Psychosis - No Remission (After Amisulpride),10.1038/s41380-018-0082-9,1.83,0.58,,,,,
,Glx,Glx,2018_egerton_23,46,First Episode Psychosis - No Remission (After Amisulpride),10.1038/s41380-018-0082-9,1.5,0.16,,,,,
,Glx,Glx,2018_egerton_23,47,First Episode Psychosis - No Remission (After Amisulpride),10.1038/s41380-018-0082-9,1.81,0.35,,,,,
,Glx,Glx,2018_egerton_23,48,First Episode Psychosis - No Remission (After Amisulpride),10.1038/s41380-018-0082-9,1.16,0.33,,,,,
,Glx,Glx,2018_ford_10,1,Healthy - Vitamin B (Baseline),10.3390/nu10121860,,,13.56,0.7,,,
,Glx,Glx,2018_ford_10,2,Healthy - Placebo (Baseline),10.3390/nu10121860,,,11.44,0.47,,,
,Glx,Glx,2018_ford_10,3,Healthy - Vitamin B (6 Months),10.3390/nu10121860,,,12.05,0.37,,,
,Glx,Glx,2018_ford_10,4,Healthy - Placebo (6 Months),10.3390/nu10121860,,,11.82,0.64,,,
,Glx,Glx,2018_galinska-skok_2018,1,Schizophrenia,10.1155/2018/3654894,1.98,0.29,0.54,0.08,,,
,Glx,Glx,2018_galinska-skok_2018,2,Schizophrenia,10.1155/2018/3654894,2.24,0.44,0.62,0.07,,,
,Glx,Glx,2018_galinska-skok_2018,3,Bipolar Disorder,10.1155/2018/3654894,1.93,0.56,0.5,0.12,,,
,Glx,Glx,2018_galinska-skok_2018,4,Bipolar Disorder,10.1155/2018/3654894,2.18,0.58,0.53,0.14,,,
,Glx,Glx,2018_galinska-skok_2018,5,Control,10.1155/2018/3654894,2.17,0.39,0.56,0.1,,,
,Glx,Glx,2018_galinska-skok_2018,6,Control,10.1155/2018/3654894,2.24,0.66,0.54,0.15,,,
,Glx,Glx,2018_gasparovic_48,1,Preterm Birth - Placebo (Scan 1),10.1007/s00247-017-4052-1,,,18.02,2.24,,,
,Glx,Glx,2018_gasparovic_48,2,Preterm Birth - Placebo (Scan 1),10.1007/s00247-017-4052-1,,,13.18,1.89,,,
,Glx,Glx,2018_gasparovic_48,3,Preterm Birth - Placebo (Scan 2),10.1007/s00247-017-4052-1,,,19.87,4.26,,,
,Glx,Glx,2018_gasparovic_48,4,Preterm Birth - Placebo (Scan 2),10.1007/s00247-017-4052-1,,,13.47,1.52,,,
,Glx,Glx,2018_gasparovic_48,5,Preterm Birth - Erythropoiesis Stimulating Agent (Scan 1),10.1007/s00247-017-4052-1,,,19.41,2.58,,,
,Glx,Glx,2018_gasparovic_48,6,Preterm Birth - Erythropoiesis Stimulating Agent (Scan 1),10.1007/s00247-017-4052-1,,,12.78,1.52,,,
,Glx,Glx,2018_gasparovic_48,7,Preterm Birth - Erythropoiesis Stimulating Agent (Scan 2),10.1007/s00247-017-4052-1,,,19.89,1.64,,,
,Glx,Glx,2018_gasparovic_48,8,Preterm Birth - Erythropoiesis Stimulating Agent (Scan 2),10.1007/s00247-017-4052-1,,,13.22,2.39,,,
,Glx,Glx,2018_gasparovic_48,9,Control - Scan 1,10.1007/s00247-017-4052-1,,,17.86,1.39,,,
,Glx,Glx,2018_gasparovic_48,10,Control - Scan 1,10.1007/s00247-017-4052-1,,,13.26,2.44,,,
,Glx,Glx,2018_gasparovic_48,11,Control - Scan 2,10.1007/s00247-017-4052-1,,,18.84,1.6,,,
,Glx,Glx,2018_gasparovic_48,12,Control - Scan 3,10.1007/s00247-017-4052-1,,,12.93,1.34,,,
,Glx,Glx,2018_harper_17,1,Urologic Chronic Pelvic Pain Syndrome,10.1016/j.nicl.2017.11.014,1.32,0.22,7.33,1.34,,,
,Glx,Glx,2018_harper_17,2,Urologic Chronic Pelvic Pain Syndrome,10.1016/j.nicl.2017.11.014,1.43,0.19,8.6,0.99,,,
,Glx,Glx,2018_harper_17,3,Urologic Chronic Pelvic Pain Syndrome,10.1016/j.nicl.2017.11.014,1.24,0.17,7.31,1.17,,,
,Glx,Glx,2018_harper_17,4,Urologic Chronic Pelvic Pain Syndrome,10.1016/j.nicl.2017.11.014,1.13,0.2,7.14,1.26,,,
,Glx,Glx,2018_harper_17,5,Control,10.1016/j.nicl.2017.11.014,1.33,0.16,7.5,0.94,,,
,Glx,Glx,2018_harper_17,6,Control,10.1016/j.nicl.2017.11.014,1.5,0.16,8.99,1.25,,,
,Glx,Glx,2018_harper_17,7,Control,10.1016/j.nicl.2017.11.014,1.32,0.17,7.76,0.9,,,
,Glx,Glx,2018_harper_17,8,Control,10.1016/j.nicl.2017.11.014,1.17,0.16,7.23,1.01,,,
,Glx,Glx,2018_hegarty_48,1,Autism Spectrum Disorder,10.1007/s10803-018-3613-y,,,8.75,2.21,,,
,Glx,Glx,2018_hegarty_48,2,Autism Spectrum Disorder,10.1007/s10803-018-3613-y,,,9.41,0.61,,,
,Glx,Glx,2018_hegarty_48,3,Control,10.1007/s10803-018-3613-y,,,9.06,1.54,,,
,Glx,Glx,2018_hegarty_48,4,Control,10.1007/s10803-018-3613-y,,,9.62,0.92,,,
,Glx,Glx,2018_hegarty_81,1,Autism Spectrum Disorder,10.1016/j.pnpbp.2017.09.016,1.82,0.64,,,,,
,Glx,Glx,2018_hegarty_81,2,Autism Spectrum Disorder,10.1016/j.pnpbp.2017.09.016,2.09,0.52,,,,,
,Glx,Glx,2018_hegarty_81,3,Control,10.1016/j.pnpbp.2017.09.016,1.86,0.32,,,,,
,Glx,Glx,2018_hegarty_81,4,Control,10.1016/j.pnpbp.2017.09.016,2.16,0.43,,,,,
,Glx,Glx,2018_hegarty_81,5,Autism Spectrum Disorder,10.1016/j.pnpbp.2017.09.016,1.88,0.54,,,,,
,Glx,Glx,2018_hegarty_81,6,Autism Spectrum Disorder,10.1016/j.pnpbp.2017.09.016,2.14,0.36,,,,,
,Glx,Glx,2018_hegarty_81,7,Control,10.1016/j.pnpbp.2017.09.016,2.09,0.39,,,,,
,Glx,Glx,2018_hegarty_81,8,Control,10.1016/j.pnpbp.2017.09.016,2.06,0.41,,,,,
,Glx,Glx,2018_hjelmervik_172,1,Healthy - Menstrual Phase,10.1016/j.neuroimage.2018.01.043,,,10.44,2.88,,,
,Glx,Glx,2018_hjelmervik_172,2,Healthy - Menstrual Phase,10.1016/j.neuroimage.2018.01.043,,,11.02,2.7,,,
,Glx,Glx,2018_hjelmervik_172,3,Healthy - Follicular Phase,10.1016/j.neuroimage.2018.01.043,,,12.31,2.93,,,
,Glx,Glx,2018_hjelmervik_172,4,Healthy - Follicular Phase,10.1016/j.neuroimage.2018.01.043,,,11.93,2.13,,,
,Glx,Glx,2018_hjelmervik_172,5,Healthy - Luteal Phase,10.1016/j.neuroimage.2018.01.043,,,9.96,2.82,,,
,Glx,Glx,2018_hjelmervik_172,6,Healthy - Luteal Phase,10.1016/j.neuroimage.2018.01.043,,,11.93,3.14,,,
,Glx,Glx,2018_hjelmervik_172,7,Healthy - Total,10.1016/j.neuroimage.2018.01.043,,,11.26,1.38,,,
,Glx,Glx,2018_hjelmervik_172,8,Healthy - Session 1,10.1016/j.neuroimage.2018.01.043,,,11.89,2.53,,,
,Glx,Glx,2018_hjelmervik_172,9,Healthy - Session 1,10.1016/j.neuroimage.2018.01.043,,,11.58,2.96,,,
,Glx,Glx,2018_hjelmervik_172,10,Healthy - Session 2,10.1016/j.neuroimage.2018.01.043,,,10.8,3.11,,,
,Glx,Glx,2018_hjelmervik_172,11,Healthy - Session 2,10.1016/j.neuroimage.2018.01.043,,,11.08,1.98,,,
,Glx,Glx,2018_hjelmervik_172,12,Healthy - Session 3,10.1016/j.neuroimage.2018.01.043,,,10.67,2.69,,,
,Glx,Glx,2018_hjelmervik_172,13,Healthy - Session 3,10.1016/j.neuroimage.2018.01.043,,,10.92,2.48,,,
,Glx,Glx,2018_hjelmervik_172,14,Healthy - Total,10.1016/j.neuroimage.2018.01.043,,,11.16,1.35,,,
,Glx,Glx,2018_horder_8,1,Control,10.1038/s41398-018-0155-1,,,5.8,1.5,,,
,Glx,Glx,2018_horder_8,2,Control,10.1038/s41398-018-0155-1,,,6.77,0.84,,,
,Glx,Glx,2018_horder_8,3,Autism Spectrum Disorder,10.1038/s41398-018-0155-1,,,4.92,1.75,,,
,Glx,Glx,2018_horder_8,4,Autism Spectrum Disorder,10.1038/s41398-018-0155-1,,,6.93,0.8,,,
,Glx,Glx,2020_bhogal_10,1,Healthy,10.1002/brb3.1852,0.9,0.16,,,,,
,Glx,Glx,2020_bhogal_10,2,Healthy,10.1002/brb3.1852,0.86,0.14,,,,,
,Glx,Glx,2020_bhogal_10,3,Healthy,10.1002/brb3.1852,1,0.07,,,,,
,Glx,Glx,2020_bhogal_10,4,Healthy,10.1002/brb3.1852,0.85,0.16,,,,,
,Glx,Glx,2020_bhogal_10,5,Healthy,10.1002/brb3.1852,0.71,0.12,,,,,
,Glx,Glx,2020_bhogal_10,6,Healthy,10.1002/brb3.1852,0.97,0.13,,,,,
,Glx,Glx,2020_bhogal_10,7,Healthy,10.1002/brb3.1852,0.93,0.12,,,,,
,Glx,Glx,2020_bhogal_10,8,Healthy,10.1002/brb3.1852,1.1,0.16,,,,,
,Glx,Glx,2020_bhogal_10,9,Healthy,10.1002/brb3.1852,1.2,0.16,,,,,
,Glx,Glx,2020_bhogal_10,10,Healthy,10.1002/brb3.1852,1.2,0.27,,,,,
,Glx,Glx,2020_hjelmervik_46,1,Schizophrenia,10.1093/schbul/sbz099,,,15.73,4.1,,,
,Glx,Glx,2020_hjelmervik_46,2,Schizophrenia,10.1093/schbul/sbz099,,,22.3,3.25,,,
,Glx,Glx,2020_hjelmervik_46,3,Schizophrenia,10.1093/schbul/sbz099,,,20.18,3.33,,,
,Glx,Glx,2020_hjelmervik_46,4,Schizophrenia,10.1093/schbul/sbz099,,,16.93,2.86,,,
,Glx,Glx,2020_hjelmervik_46,5,Control,10.1093/schbul/sbz099,,,15.87,4.19,,,
,Glx,Glx,2020_hjelmervik_46,6,Control,10.1093/schbul/sbz099,,,21.14,4.31,,,
,Glx,Glx,2020_hjelmervik_46,7,Control,10.1093/schbul/sbz099,,,19.83,3.59,,,
,Glx,Glx,2020_hjelmervik_46,8,Control,10.1093/schbul/sbz099,,,16.18,3.23,,,
,Glx,Glx,2018_lu_29,1,Liver Cirrhosis,10.1097/WNR.0000000000001063,1.1,0.3,,,,,
,Glx,Glx,2018_lu_29,2,Liver Cirrhosis with Hepatic Encephalopathy,10.1097/WNR.0000000000001063,1.1,0.3,,,,,
,Glx,Glx,2018_lu_29,3,Liver Cirrhosis without Hepatic Encephalopathy,10.1097/WNR.0000000000001063,1.1,0.2,,,,,
,Glx,Glx,2018_lu_29,4,Control,10.1097/WNR.0000000000001063,1.1,0.3,,,,,
,Glx,Glx,2018_marshall_265,1,Secondary Progressive Multiple Sclerosis,10.1007/s00415-018-8903-y,1.46,0.02,1164,21,,,
,Glx,Glx,2018_marshall_265,2,Secondary Progressive Multiple Sclerosis,10.1007/s00415-018-8903-y,1.26,0.05,1220,53,,,
,Glx,Glx,2018_marshall_265,3,Secondary Progressive Multiple Sclerosis,10.1007/s00415-018-8903-y,1.64,0.02,1390,24,,,
,Glx,Glx,2018_mcqueen_235,1,Schizophrenia - Placebo,10.1007/s00213-018-4997-2,1.86,0.43,22.55,6.33,,,
,Glx,Glx,2018_mcqueen_235,2,Schizophrenia - Placebo,10.1007/s00213-018-4997-2,1.69,0.29,15.87,3.24,,,
,Glx,Glx,2018_mcqueen_235,3,Schizophrenia - N-Acetylcysteine ,10.1007/s00213-018-4997-2,1.63,0.3,19.8,4.13,,,
,Glx,Glx,2018_mcqueen_235,4,Schizophrenia - N-Acetylcysteine ,10.1007/s00213-018-4997-2,1.7,0.37,18.68,12,,,
,Glx,Glx,2018_modinos_48,1,Healthy - Low Schizotypy,10.1017/S0033291717003403,,,20.36,3.67,,,
,Glx,Glx,2018_modinos_48,2,Healthy - High Schizotypy,10.1017/S0033291717003403,,,21.27,3.48,,,
,β·ɣ-Glx,Glx,2018_moon_227,1,Obsessive-compulsive Disorder,10.1016/j.jad.2017.11.059,1,0.23,,,,,
,β·ɣ-Glx,Glx,2018_moon_227,2,Control,10.1016/j.jad.2017.11.059,0.86,0.1,,,,,
,⍺-Glx,Glx,2018_moon_227,1,Obsessive-compulsive Disorder,10.1016/j.jad.2017.11.059,0.51,0.25,,,,,
,⍺-Glx,Glx,2018_moon_227,2,Control,10.1016/j.jad.2017.11.059,0.46,0.08,,,,,
,Glx,Glx,2018_plitman_273,1,Schizophrenia,10.1016/j.pscychresns.2018.01.004,,,15.32,1.87,,,
,Glx,Glx,2018_plitman_273,2,Control,10.1016/j.pscychresns.2018.01.004,,,15.83,1.78,,,
,Glx,Glx,2018_plitman_273,3,Schizophrenia - Point 1,10.1016/j.pscychresns.2018.01.004,,,15.72,1.14,,,
,Glx,Glx,2018_plitman_273,4,Schizophrenia - Point 2,10.1016/j.pscychresns.2018.01.004,,,17.23,2.17,,,
,Glx,Glx,2018_plitman_273,5,Control - Point 1,10.1016/j.pscychresns.2018.01.004,,,16.03,2.3,,,n=9
,Glx,Glx,2018_plitman_273,6,Control - Point 2,10.1016/j.pscychresns.2018.01.004,,,16.62,1.56,,,n=9
,Glx,Glx,2018_rudler_48,1,"Cirrhosis - Before TIPSS, no MHE",10.1111/apt.14938,,,,,9.8,3.3,
,Glx,Glx,2018_rudler_48,2,"Cirrhosis - Before TIPSS, no MHE",10.1111/apt.14938,,,,,12.1,3.2,
,Glx,Glx,2018_rudler_48,3,"Cirrhosis - Before TIPSS, MHE",10.1111/apt.14938,,,,,16.3,6.1,
,Glx,Glx,2018_rudler_48,4,"Cirrhosis - Before TIPSS, MHE",10.1111/apt.14938,,,,,16.3,5.4,
,Glx,Glx,2018_rudler_48,5,"Cirrhosis - Before TIPSS, no development of HE after TIPSS",10.1111/apt.14938,,,,,10.7,5.2,
,Glx,Glx,2018_rudler_48,6,"Cirrhosis - Before TIPSS, no development of HE after TIPSS",10.1111/apt.14938,,,,,13,4.3,
,Glx,Glx,2018_rudler_48,7,"Cirrhosis - Before TIPSS, development of HE after TIPSS",10.1111/apt.14938,,,,,13.5,4.7,
,Glx,Glx,2018_rudler_48,8,"Cirrhosis - Before TIPSS, development of HE after TIPSS",10.1111/apt.14938,,,,,13.7,4.2,
,Glx,Glx,2018_rudler_48,9,"Cirrhosis - After TIPSS, no development of HE",10.1111/apt.14938,,,,,14.9,4.9,
,Glx,Glx,2018_rudler_48,10,"Cirrhosis - After TIPSS, no development of HE",10.1111/apt.14938,,,,,16.9,4.8,
,Glx,Glx,2018_rudler_48,11,"Cirrhosis - After TIPSS, development of HE",10.1111/apt.14938,,,,,17.1,6.1,
,Glx,Glx,2018_rudler_48,12,"Cirrhosis - After TIPSS, development of HE",10.1111/apt.14938,,,,,15,5.5,
,Glx,Glx,2021_bloomfield_6,1,THC,10.1016/j.bpsc.2021.04.013,,,7.5,1.35,,,
,Glx,Glx,2021_bloomfield_6,2,Placebo,10.1016/j.bpsc.2021.04.013,,,7.88,1.6,,,
,Glx,Glx,2021_bednarik_15,1,Healthy,10.3389/fnins.2021.609485,,,,,12.28,0.43,
,Glx,Glx,2021_bednarik_15,2,Healthy,10.3389/fnins.2021.609485,,,,,12.1,0.43,
,Glx,Glx,2021_chenji_282,1,Control,10.1016/j.jad.2020.12.176,,,10.46,2.81,,,
,Glx,Glx,2021_chenji_282,3,MDD-Normal BMI,10.1016/j.jad.2020.12.176,,,11.44,1.68,,,
,Glx,Glx,2021_chenji_282,5,MDD-High BMI,10.1016/j.jad.2020.12.176,,,10.41,1.65,,,
,Glx,Glx,2021_chenji_282,2,Control,10.1016/j.jad.2020.12.176,,,10.95,1.88,,,
,Glx,Glx,2021_chenji_282,4,MDD-Normal BMI,10.1016/j.jad.2020.12.176,,,11.65,1.92,,,
,Glx,Glx,2021_chenji_282,6,MDD-High BMI,10.1016/j.jad.2020.12.176,,,10.64,1.97,,,
,Glx,Glx,2020_briend_10,1,Control,10.1038/s41398-020-0812-z,,,12.6,,,,Estimated by Graph
,Glx,Glx,2020_briend_10,2,FEP,10.1038/s41398-020-0812-z,,,13.1,,,,Estimated by Graph
,Glx,Glx,2020_cen_54,1,Healthy Controls,10.1177/0004867419898520,,,5.05,0.7,,,
,Glx,Glx,2020_cen_54,2,FEP,10.1177/0004867419898520,,,5.27,0.91,,,
,Glx,Glx,2020_chen_131,1,Healthy Controls,10.1016/j.ejrad.2020.109252,1.74,1.13,,,,,
,Glx,Glx,2020_chen_131,2,NHE,10.1016/j.ejrad.2020.109252,2.48,1.25,,,,,
,Glx,Glx,2020_chen_131,3,Minimal Hepatic Encephalopathy,10.1016/j.ejrad.2020.109252,2.73,1.18,,,,,
,Glx,Glx,2018_shakory_43,1,Control,10.1038/s41386-018-0163-0,,,13.63,1.55,,,
,Glx,Glx,2018_shakory_43,2,Clinical high risk of psychosis,10.1038/s41386-018-0163-0,,,12.403,1.113,,,
,Glx,Glx,2018_shakory_43,3,First Episode Psychosis,10.1038/s41386-018-0163-0,,,13.454,1.064,,,
,Glx,Glx,2018_shakory_43,4,Clinical high risk of psychosis - No antipsychotic,10.1038/s41386-018-0163-0,,,12.47,1.08,,,
,Glx,Glx,2018_shakory_43,5,Clinical high risk of psychosis - Antipsychotic,10.1038/s41386-018-0163-0,,,12.19,1.37,,,
,Glx,Glx,2018_shakory_43,6,First Episode Psychosis - No antipsychotic,10.1038/s41386-018-0163-0,,,13.47,1.14,,,
,Glx,Glx,2018_shakory_43,7,First Episode Psychosis - Antipsychotic,10.1038/s41386-018-0163-0,,,13.36,1.12,,,
,Glx,Glx,2018_shakory_43,8,Control - Cannabis non-user,10.1038/s41386-018-0163-0,,,13.55,1.74,,,
,Glx,Glx,2018_shakory_43,9,Control - Cannabis user,10.1038/s41386-018-0163-0,,,13.75,1.3,,,
,Glx,Glx,2018_shakory_43,10,Schizophrenia,10.1038/s41386-018-0163-0,,,13.23,1.15,,,
,Glx,Glx,2018_shakory_43,11,Schizophreniform,10.1038/s41386-018-0163-0,,,13.89,1.15,,,
,Glx,Glx,2020_poletti_11,1,Bipolar Disorder,10.3389/fpsyt.2020.590095,,,9.9,1.31,,,
,Glx,Glx,2020_poletti_11,2,Healthy Controls,10.3389/fpsyt.2020.590095,,,9.2,1.17,,,
,Glx,Glx,2018_singh_60,1,Control,10.1007/s00234-017-1954-4,2.07,0.4,,,,,
,Glx,Glx,2018_singh_60,2,Schizophrenia,10.1007/s00234-017-1954-4,1.97,0.43,,,,,
,Glx,Glx,2018_sivaraman_281,1,Control,10.1016/j.pscychresns.2018.06.003,,,0.23,0.06,,,n=16
,Glx,Glx,2018_sivaraman_281,2,First episode psychosis,10.1016/j.pscychresns.2018.06.003,,,0.22,0.03,,,n=13
,Glx,Glx,2018_soeiro-de-souza_3,1,Control,10.1016/j.bpsc.2018.02.007,1.03,0.14,,,,,
,Glx,Glx,2018_soeiro-de-souza_3,2,Euthymic Bipolar I Disorder,10.1016/j.bpsc.2018.02.007,1.08,0.15,,,,,
,Glx,Glx,2018_soeiro-de-souza_3,3,Euthymic Bipolar I Disorder - Anticonvulsant,10.1016/j.bpsc.2018.02.007,1.06,0.16,,,,,
,Glx,Glx,2018_soeiro-de-souza_3,4,Euthymic Bipolar I Disorder - Non-anticonvulsant,10.1016/j.bpsc.2018.02.007,1.09,0.14,,,,,
,Glx,Glx,2018_soeiro-de-souza_3,5,Euthymic Bipolar I Disorder - Lithium,10.1016/j.bpsc.2018.02.007,1.08,0.15,,,,,
,Glx,Glx,2018_soeiro-de-souza_3,6,Euthymic Bipolar I Disorder - Non-lithium,10.1016/j.bpsc.2018.02.007,1.06,0.13,,,,,
,Glx,Glx,2018_soeiro-de-souza_3,7,Euthymic Bipolar I Disorder - Antipsychotics,10.1016/j.bpsc.2018.02.007,1.07,0.14,,,,,
,Glx,Glx,2018_soeiro-de-souza_3,8,Euthymic Bipolar I Disorder - Non-antipsychotics,10.1016/j.bpsc.2018.02.007,1.06,0.15,,,,,
,Glx,Glx,2018_tan_28,1,Control,10.1007/s00330-018-5443-x,,,,,9.9,1.4,
,Glx,Glx,2018_tan_28,2,Control,10.1007/s00330-018-5443-x,,,,,10.2,1.2,
,Glx,Glx,2018_tan_28,3,Control,10.1007/s00330-018-5443-x,,,,,10.1,1,
,Glx,Glx,2018_tan_28,4,Temporal lobe epilespsy,10.1007/s00330-018-5443-x,,,,,9.7,1.5,
,Glx,Glx,2018_tan_28,5,Temporal lobe epilespsy,10.1007/s00330-018-5443-x,,,,,10.5,1.8,
,Glx,Glx,2018_tan_28,6,Temporal lobe epilespsy - Left seizure foci,10.1007/s00330-018-5443-x,,,,,9.9,1.5,
,Glx,Glx,2018_tan_28,7,Temporal lobe epilespsy - Left seizure foci,10.1007/s00330-018-5443-x,,,,,10.8,2,
,Glx,Glx,2018_tan_28,8,Temporal lobe epilespsy - Right seizure foci,10.1007/s00330-018-5443-x,,,,,9.6,1.5,
,Glx,Glx,2018_tan_28,9,Temporal lobe epilespsy - Right seizure foci,10.1007/s00330-018-5443-x,,,,,10.3,1.2,
,Glx,Glx,2018_van_89,1,Control,10.1136/jnnp-2017-316364,,,,,6.88,0.59,
,Glx,Glx,2018_van_89,2,Metachromatic leukodystrophy - Good outcome,10.1136/jnnp-2017-316364,,,,,8.43,0.38,
,Glx,Glx,2018_van_89,3,Metachromatic leukodystrophy - Moderate outcome,10.1136/jnnp-2017-316364,,,,,6.5,0.89,
,Glx,Glx,2018_van_89,4,Metachromatic leukodystrophy - Poor outcome,10.1136/jnnp-2017-316364,,,,,4.82,1.28,
,Glx,Glx,2019_betinaip_39,1,Behavior - ON - 3% Visual Contrast,10.1523/JNEUROSCI.3021-18.2019,,,10.767,1.053,,,
,Glx,Glx,2019_betinaip_39,2,Behavior - ON - 12.5% Visual Contrast,10.1523/JNEUROSCI.3021-18.2019,,,10.558,1.059,,,
,Glx,Glx,2019_betinaip_39,3,Behavior - ON - 50% Visual Contrast,10.1523/JNEUROSCI.3021-18.2019,,,10.569,1.07,,,
,Glx,Glx,2019_betinaip_39,4,Behavior - ON - 100% Visual Contrast,10.1523/JNEUROSCI.3021-18.2019,,,10.668,1.059,,,
,Glx,Glx,2019_betinaip_39,5,Resting,10.1523/JNEUROSCI.3021-18.2019,,,10.674,1.178,,,
,Glx,Glx,2019_betinaip_39,6,Behavior - OFF - 3% Visual Contrast,10.1523/JNEUROSCI.3021-18.2019,,,10.82,1.001,,,
,Glx,Glx,2019_betinaip_39,7,Behavior - OFF - 12.5% Visual Contrast,10.1523/JNEUROSCI.3021-18.2019,,,10.571,1.058,,,
,Glx,Glx,2019_betinaip_39,8,Behavior - OFF - 50% Visual Contrast,10.1523/JNEUROSCI.3021-18.2019,,,10.527,1.122,,,
,Glx,Glx,2019_betinaip_39,9,Behavior - OFF - 100% Visual Contrast,10.1523/JNEUROSCI.3021-18.2019,,,10.605,1.137,,,
,Glx,Glx,2019_betinaip_39,10,Resting,10.1523/JNEUROSCI.3021-18.2019,,,10.746,1.059,,,
,Glx,Glx,2019_fayed_32,2,Fibromyalgia - Baseline,10.1177/1971400919857544,2.03,0.27,,,,,
,Glx,Glx,2019_fayed_32,3,Fibromyalgia - Baseline,10.1177/1971400919857544,1.77,0.34,,,,,
,Glx,Glx,2019_fayed_32,7,Fibromyalgia - Treatment,10.1177/1971400919857544,2.17,0.34,,,,,
,Glx,Glx,2019_fayed_32,8,Fibromyalgia - Treatment,10.1177/1971400919857544,2,0.12,,,,,
,Glx,Glx,2019_ferland_237,1,Healthy TMS,10.1007/s00221-019-05691-z,0.85,0.137,,,14.495,1.232,
,Glx,Glx,2019_ferland_237,2,Healthy TMS,10.1007/s00221-019-05691-z,0.803,0.05,,,14.18,0.73,
,Glx,Glx,2019_godlewska_246,1,Bipolar,10.1016/j.jad.2018.12.092,,,14,0.9,,,
,Glx,Glx,2019_godlewska_246,2,Bipolar,10.1016/j.jad.2018.12.092,,,14.9,0.99,,,
,Glx,Glx,2019_godlewska_246,3,Bipolar,10.1016/j.jad.2018.12.092,,,14.8,1.3,,,
,Glx,Glx,2019_godlewska_246,4,Bipolar,10.1016/j.jad.2018.12.092,,,14.3,0.98,,,
,Glx,Glx,2019_hnilicova_407,1,Control,10.1016/j.jns.2019.116458,2.185,0.96,,,,,
,Glx,Glx,2019_hnilicova_407,2,Multiple Sclerosis,10.1016/j.jns.2019.116458,2.513,0.91,,,,,
,Glx,Glx,2019_iwata_85,1,Control,10.1016/j.biopsych.2018.09.009,,,15.76,2.2,,,
,Glx,Glx,2019_iwata_85,2,Control,10.1016/j.biopsych.2018.09.009,,,20.06,2.06,,,
,Glx,Glx,2019_iwata_85,3,Control,10.1016/j.biopsych.2018.09.009,,,17,1.68,,,
,Glx,Glx,2019_iwata_85,4,Schizophrenia Ultra-Resistant,10.1016/j.biopsych.2018.09.009,,,16.34,2.85,,,
,Glx,Glx,2019_iwata_85,5,Schizophrenia Ultra-Resistant,10.1016/j.biopsych.2018.09.009,,,21.92,3.14,,,
,Glx,Glx,2019_iwata_85,6,Schizophrenia Ultra-Resistant,10.1016/j.biopsych.2018.09.009,,,16.96,2.5,,,
,Glx,Glx,2019_iwata_85,7,Schizophrenia Non-Ultra Resistant,10.1016/j.biopsych.2018.09.009,,,16.21,1.87,,,
,Glx,Glx,2019_iwata_85,8,Schizophrenia Non-Ultra Resistant,10.1016/j.biopsych.2018.09.009,,,21.3,1.61,,,
,Glx,Glx,2019_iwata_85,9,Schizophrenia Non-Ultra Resistant,10.1016/j.biopsych.2018.09.009,,,17.12,2.13,,,
,Glx,Glx,2019_iwata_85,10,Schizophrenia Non-Treatment Resistant,10.1016/j.biopsych.2018.09.009,,,16.9,2.32,,,
,Glx,Glx,2019_iwata_85,11,Schizophrenia Non-Treatment Resistant,10.1016/j.biopsych.2018.09.009,,,20.71,2.46,,,
,Glx,Glx,2019_iwata_85,12,Schizophrenia Non-Treatment Resistant,10.1016/j.biopsych.2018.09.009,,,18.05,1.8,,,
,Glx,Glx,2019_jelen_29,1,Control 0-Back 1st Spectra,10.1016/j.euroneuro.2018.12.005,1.109,0.167,,,,,IU Values Referenced to Creatine | Estimated by Graph
,Glx,Glx,2019_jelen_29,2,Schizophrenia 0-Back 1st Spectra,10.1016/j.euroneuro.2018.12.005,1.047,0.151,,,,,IU Values Referenced to Creatine | Estimated by Graph
,Glx,Glx,2019_jelen_29,3,Bipolar (Bipolar 2) 0-Back 1st Spectra,10.1016/j.euroneuro.2018.12.005,1.081,0.128,,,,,IU Values Referenced to Creatine | Estimated by Graph
,Glx,Glx,2019_jelen_29,4,Control 0-Back 2nd Spectra,10.1016/j.euroneuro.2018.12.005,1.039,0.097,,,,,IU Values Referenced to Creatine | Estimated by Graph
,Glx,Glx,2019_jelen_29,5,Schizophrenia 0-Back 2nd Spectra,10.1016/j.euroneuro.2018.12.005,1.077,0.128,,,,,IU Values Referenced to Creatine | Estimated by Graph
,Glx,Glx,2019_jelen_29,6,Bipolar (Bipolar 2) 0-Back 2nd Spectra,10.1016/j.euroneuro.2018.12.005,1.059,0.134,,,,,IU Values Referenced to Creatine | Estimated by Graph
,Glx,Glx,2019_jelen_29,7,Control 0-Back 3rd Spectra,10.1016/j.euroneuro.2018.12.005,1.016,0.099,,,,,IU Values Referenced to Creatine | Estimated by Graph
,Glx,Glx,2019_jelen_29,8,Schizophrenia 0-Back 3rd Spectra,10.1016/j.euroneuro.2018.12.005,1.106,0.234,,,,,IU Values Referenced to Creatine | Estimated by Graph
,Glx,Glx,2019_jelen_29,9,Bipolar (Bipolar 2) 0-Back 3rd Spectra,10.1016/j.euroneuro.2018.12.005,1.044,0.123,,,,,IU Values Referenced to Creatine | Estimated by Graph
,Glx,Glx,2019_jelen_29,10,Control 2-Back 1st Spectra,10.1016/j.euroneuro.2018.12.005,1.153,0.122,,,,,IU Values Referenced to Creatine | Estimated by Graph
,Glx,Glx,2019_jelen_29,11,Schizophrenia 2-Back 1st Spectra,10.1016/j.euroneuro.2018.12.005,1.139,0.157,,,,,IU Values Referenced to Creatine | Estimated by Graph
,Glx,Glx,2019_jelen_29,12,Bipolar (Bipolar 2) 2-Back 1st Spectra,10.1016/j.euroneuro.2018.12.005,1.138,0.168,,,,,IU Values Referenced to Creatine | Estimated by Graph
,Glx,Glx,2019_jelen_29,13,Control 2-Back 2nd Spectra,10.1016/j.euroneuro.2018.12.005,1.05,0.116,,,,,IU Values Referenced to Creatine | Estimated by Graph
,Glx,Glx,2019_jelen_29,14,Schizophrenia 2-Back 2nd Spectra,10.1016/j.euroneuro.2018.12.005,1.106,0.165,,,,,IU Values Referenced to Creatine | Estimated by Graph
,Glx,Glx,2019_jelen_29,15,Bipolar (Bipolar 2) 2-Back 2nd Spectra,10.1016/j.euroneuro.2018.12.005,1.113,0.155,,,,,IU Values Referenced to Creatine | Estimated by Graph
,Glx,Glx,2019_jelen_29,16,Control 2-Back 3rd Spectra,10.1016/j.euroneuro.2018.12.005,1.094,0.174,,,,,IU Values Referenced to Creatine | Estimated by Graph
,Glx,Glx,2019_jelen_29,17,Schizophrenia 2-Back 3rd Spectra,10.1016/j.euroneuro.2018.12.005,1.072,0.17,,,,,IU Values Referenced to Creatine | Estimated by Graph
,Glx,Glx,2019_jelen_29,18,Bipolar (Bipolar 2) 2-Back 3rd Spectra,10.1016/j.euroneuro.2018.12.005,1.063,0.114,,,,,IU Values Referenced to Creatine | Estimated by Graph
,Glx,Glx,2019_joe_13,1,Predisposed Alzheimer's Mutation Carriers,10.1007/s11682-018-9913-1,2.58,0.45,12.84,1.99,,,
,Glx,Glx,2019_joe_13,2,Predisposed Alzheimer's Mutation Carriers,10.1007/s11682-018-9913-1,2.61,0.49,14.54,2.66,,,
,Glx,Glx,2019_joe_13,3,Predisposed Alzheimer's Mutation Carriers,10.1007/s11682-018-9913-1,1.91,0.33,12.5,1.44,,,
,Glx,Glx,2019_joe_13,4,Predisposed Alzheimer's Mutation Carriers,10.1007/s11682-018-9913-1,2.38,0.15,14.1,1.09,,,
,Glx,Glx,2019_joe_13,5,Predisposed Alzheimer's Non-Carriers,10.1007/s11682-018-9913-1,2.65,0.79,13.55,2.53,,,
,Glx,Glx,2019_joe_13,6,Predisposed Alzheimer's Non-Carriers,10.1007/s11682-018-9913-1,2.51,0.49,13.37,1.31,,,
,Glx,Glx,2019_joe_13,7,Predisposed Alzheimer's Non-Carriers,10.1007/s11682-018-9913-1,1.94,0.26,13.08,2.36,,,
,Glx,Glx,2019_joe_13,8,Predisposed Alzheimer's Non-Carriers,10.1007/s11682-018-9913-1,2.29,0.27,14.12,1.58,,,
,Glx,Glx,2019_kaplan_160,1,Control,10.1097/j.pain.0000000000001480,,,10.97,1.48,,,
,Glx,Glx,2019_kaplan_160,2,Fibromyalgia,10.1097/j.pain.0000000000001480,,,11.92,1.57,,,
,Glx,Glx,2019_kim_13,1,Control,10.3389/fnhum.2019.00193,0.092,0.006,,,,,
,Glx,Glx,2019_kim_13,2,TBI (Boxers),10.3389/fnhum.2019.00193,0.094,0.01,,,,,
,Glx,Glx,2019_levin_202,1,Control (Young),10.1016/j.neuroimage.2019.116050,,,7.81,1.44,,,
,Glx,Glx,2019_levin_202,2,Middle-Aged,10.1016/j.neuroimage.2019.116050,,,7.41,1.43,,,
,Glx,Glx,2019_levin_202,3,Old-Middle Aged,10.1016/j.neuroimage.2019.116050,,,7.27,1.44,,,
,Glx,Glx,2019_levin_202,4,Aged,10.1016/j.neuroimage.2019.116050,,,6.52,1.21,,,
,Glx,Glx,2019_levin_202,5,Control (Young),10.1016/j.neuroimage.2019.116050,,,8.43,2.22,,,
,Glx,Glx,2019_levin_202,6,Middle-Aged,10.1016/j.neuroimage.2019.116050,,,8.24,2.02,,,
,Glx,Glx,2019_levin_202,7,Old-Middle Aged,10.1016/j.neuroimage.2019.116050,,,6.85,1.64,,,
,Glx,Glx,2019_levin_202,8,Aged,10.1016/j.neuroimage.2019.116050,,,6.41,1.67,,,
,Glx,Glx,2018_veeramuthu_25,1,Complicated mTBI,10.1016/j.acra.2018.01.005,2.464,0.435,4.195,0.831,,,
,Glx,Glx,2018_veeramuthu_25,2,Uncomplicated mTBI,10.1016/j.acra.2018.01.005,2.352,0.376,4.15,0.422,,,
,Glx,Glx,2018_veeramuthu_25,3,Control,10.1016/j.acra.2018.01.005,2.051,0.336,3.634,0.328,,,
,Glx,Glx,2018_volk_39,1,Healthy - Evening,10.1002/hbm.24225,1.72,0.2,12.55,0.88,,,
,Glx,Glx,2018_volk_39,2,Healthy - Morning,10.1002/hbm.24225,1.59,0.16,11.69,0.8,,,
,Glx,Glx,2018_wang_277,1,OCD,10.1016/j.pscychresns.2018.05.004,1.72,0.29,,,,,
,Glx,Glx,2018_wang_277,2,OCD,10.1016/j.pscychresns.2018.05.004,1.75,0.28,,,,,
,Glx,Glx,2018_wang_277,3,Control,10.1016/j.pscychresns.2018.05.004,1.85,0.31,,,,,
,Glx,Glx,2018_wang_277,4,Control,10.1016/j.pscychresns.2018.05.004,1.7,0.55,,,,,
,Glx,Glx,2018_white_43,1,Healthy - Placebo,10.1038/s41386-018-0027-7,,,12.92,1.44,,,
,Glx,Glx,2018_white_43,2,Health - d-amphetamine,10.1038/s41386-018-0027-7,,,13.91,1.51,,,
,Glx,Glx,2018_white_43,3,Healthy - methamphetamine,10.1038/s41386-018-0027-7,,,13.16,1.49,,,
,Glx,Glx,2018_younis_19,1,Healthy - Sildenafil_Baseline,10.1186/s10194-018-0870-2,,,,,7.77,0.65,
,Glx,Glx,2018_younis_19,2,Healthy - Sildenafil_40min,10.1186/s10194-018-0870-2,,,,,8.21,0.53,
,Glx,Glx,2018_younis_19,3,Healthy - Sildenafil_140min,10.1186/s10194-018-0870-2,,,,,8.06,0.77,
,Glx,Glx,2018_younis_19,4,Healthy - Calcitonin gene-related peptide_Baseline,10.1186/s10194-018-0870-2,,,,,7.92,1.11,
,Glx,Glx,2018_younis_19,5,Healthy - Calcitonin gene-related peptide_40min,10.1186/s10194-018-0870-2,,,,,7.49,0.88,
,Glx,Glx,2018_younis_19,6,Healthy - Calcitonin gene-related peptide_140min,10.1186/s10194-018-0870-2,,,,,8.08,0.73,
,Glx,Glx,2018_younis_19,7,Healthy - Placebo_Baseline,10.1186/s10194-018-0870-2,,,,,7.96,0.5,
,Glx,Glx,2018_younis_19,8,Healthy - Placebo_40min,10.1186/s10194-018-0870-2,,,,,7.72,0.61,
,Glx,Glx,2018_younis_19,9,Healthy - Placebo_140min,10.1186/s10194-018-0870-2,,,,,7.7,0.65,
,Glx,Glx,2017_bustillo_43,1,Control,10.1093/schbul/sbw122,,,,,15.6,2.4,
,Glx,Glx,2017_bustillo_43,2,Schizophrenia,10.1093/schbul/sbw123,,,,,15.8,2.3,
,Glx,Glx,2017_holmes_12,1,Healthy - 5 year olds,10.1371/journal.pone.0180973,2.057,0.258,11.031,1.746,,,
,Glx,Glx,2017_holmes_12,2,Healthy - 5 year olds,10.1371/journal.pone.0180973,1.74,0.22,10.319,1.369,,,
,Glx,Glx,2017_holmes_12,3,Healthy - 5 year olds,10.1371/journal.pone.0180973,1.738,0.269,6.256,1.05,,,
,Glx,Glx,2017_holmes_12,4,Healthy - 7 year olds,10.1371/journal.pone.0180973,2.101,0.252,11.345,1.379,,,
,Glx,Glx,2017_holmes_12,5,Healthy - 7 year olds,10.1371/journal.pone.0180973,1.787,0.253,10.502,1.552,,,
,Glx,Glx,2017_holmes_12,6,Healthy - 7 year olds,10.1371/journal.pone.0180973,1.94,0.41,6.99,1.52,,,
,Glx,Glx,2017_holmes_12,7,Healthy - 9 year olds,10.1371/journal.pone.0180973,2.16,0.315,12.32,1.603,,,
,Glx,Glx,2017_holmes_12,8,Healthy - 9 year olds,10.1371/journal.pone.0180973,1.832,0.369,10.524,1.824,,,
,Glx,Glx,2017_holmes_12,9,Healthy - 9 year olds,10.1371/journal.pone.0180973,2.018,0.286,7.776,1.075,,,
,Glx,Glx,2021_akiyama_61,1,Control,10.2176/nmc.oa.2020-0274,,,8.83,2.31,,,
,Glx,Glx,2021_akiyama_61,2,NPH,10.2176/nmc.oa.2020-0274,,,9.19,3.26,,,
,Glx,Glx,2017_carlson_38,2,Control- Non-dominant Hand ,10.1002/hbm.23472,2.25,0.338,16.5,1.125,,,
,Glx,Glx,2017_carlson_38,1,Control- Dominant Hand,10.1002/hbm.23472,1.95,0.225,16,1.875,,,
,Glx,Glx,2017_carlson_38,4,Bipolar with Periventricular Venous Infarctions- Lesioned Side,10.1002/hbm.23472,2.1,0.131,17,1.5,,,
,Glx,Glx,2017_carlson_38,3,Bipolar with Periventricular Venous Infarctions- Non-lesioned Side,10.1002/hbm.23472,2.05,0.259,15.5,3.75,,,
,Glx,Glx,2017_carlson_38,5,Bipolar with Arterial Ischemic Strokes- Lesioned Side ,10.1002/hbm.23472,2.05,0.3,16,2.63,,,
,Glx,Glx,2017_carlson_38,6,Bipolar with Arterial Ischemic Strokes- Non-lesioned Side,10.1002/hbm.23472,2.15,0.3,16.5,3,,,
,Glx,Glx,2020_zheng_265,1,Control,10.1016/j.jad.2020.01.059,,,16.9,2.64,,,
,Glx,Glx,2020_zheng_265,2,Control,10.1016/j.jad.2020.01.059,,,17.84,3.2,,,
,Glx,Glx,2020_zheng_265,3,Control,10.1016/j.jad.2020.01.059,,,16.07,1.83,,,
,Glx,Glx,2020_zheng_265,4,OCD,10.1016/j.jad.2020.01.059,,,19.04,4.86,,,
,Glx,Glx,2020_zheng_265,5,OCD,10.1016/j.jad.2020.01.059,,,20.27,5.21,,,
,Glx,Glx,2020_zheng_265,6,OCD,10.1016/j.jad.2020.01.059,,,17.28,4.02,,,
,Glx,Glx,2020_zheng_265,7,OCD + SPD,10.1016/j.jad.2020.01.059,,,15.78,6.11,,,
,Glx,Glx,2020_zheng_265,8,OCD + SPD,10.1016/j.jad.2020.01.059,,,14.67,3.71,,,
,Glx,Glx,2020_zheng_265,9,OCD + SPD,10.1016/j.jad.2020.01.059,,,16.27,7.07,,,
,Glx,Glx,2021_mcqueen_47,1,Baseline,10.1093/schbul/sbaa156,,,,,19.94,4.42,
,Glx,Glx,2021_mcqueen_47,2,Baseline,10.1093/schbul/sbaa156,,,,,17.39,5.56,
,Glx,Glx,2021_mcqueen_47,3,12 weeks,10.1093/schbul/sbaa156,,,,,21.4,5.57,
,Glx,Glx,2021_mcqueen_47,4,12 weeks,10.1093/schbul/sbaa156,,,,,14.9,2.81,
,Glx,Glx,2021_onwordi_11,1,Schizophrenia,10.1038/s41398-021-01515-3,1.31,0.212,,,,,
,Glx,Glx,2020_lewis_10,1,Healthy Control,10.1038/s41398-020-0792-z,,,110.13,6.1,,,
,Glx,Glx,2020_lewis_10,2,Depressed,10.1038/s41398-020-0792-z,,,95.64,5.51,,,
,Glx,Glx,2020_lewis_10,3,Depressed,10.1038/s41398-020-0792-z,,,120.13,5.67,,,
,Glx,Glx,2015_simoes_213,1,Control,10.1016/j.ajog.2015.04.011,,,,,6.5,1,
,Glx,Glx,2015_simoes_213,2,Small-born infants,10.1016/j.ajog.2015.04.011,,,,,7.2,1.4,
,Glx,Glx,2015_simoes_213,3,Small-born infants - Small for gestational age,10.1016/j.ajog.2015.04.011,,,,,7.9,1.4,
,Glx,Glx,2015_simoes_213,4,Small-born infants - Late intrauterine growth restriction,10.1016/j.ajog.2015.04.011,,,,,7,1.2,
,Glx,Glx,2021_onwordi_11,2,Schizophrenia,10.1038/s41398-021-01515-3,1.28,0.297,,,,,
,Glx,Glx,2021_onwordi_11,3,Control,10.1038/s41398-021-01515-3,1.29,0.141,,,,,
,Glx,Glx,2016_howells_31,1,In utero alcohol exposure,10.1007/s11011-016-9850-x,1.9,0.57,,,5.03,0.93,
,Glx,Glx,2016_howells_31,2,In utero alcohol exposure,10.1007/s11011-016-9850-x,1.89,0.39,,,6.49,1.16,
,Glx,Glx,2016_howells_31,3,In utero alcohol exposure - Female,10.1007/s11011-016-9850-x,2.02,0.62,,,5.38,0.89,
,Glx,Glx,2016_howells_31,4,In utero alcohol exposure - Female,10.1007/s11011-016-9850-x,1.99,0.37,,,6.55,1.2,
,Glx,Glx,2016_howells_31,5,In utero alcohol exposure - Male,10.1007/s11011-016-9850-x,1.78,0.52,,,4.64,0.85,
,Glx,Glx,2016_howells_31,6,In utero alcohol exposure - Male,10.1007/s11011-016-9850-x,1.81,0.4,,,6.45,1.17,
,Glx,Glx,2016_howells_31,7,Infants - Control,10.1007/s11011-016-9850-x,2,0.63,,,5.68,0.85,
,Glx,Glx,2016_howells_31,8,Infants - Control,10.1007/s11011-016-9850-x,1.84,0.43,,,6.23,1.02,
,Glx,Glx,2016_howells_31,9,Infants - Control_Female,10.1007/s11011-016-9850-x,2.09,0.79,,,5.77,0.97,
,Glx,Glx,2016_howells_31,10,Infants - Control_Female,10.1007/s11011-016-9850-x,2.17,0.48,,,6.16,0.99,
,Glx,Glx,2016_howells_31,11,Infants - Control_Male,10.1007/s11011-016-9850-x,1.87,0.21,,,5.53,0.66,
,Glx,Glx,2016_howells_31,12,Infants - Control_Male,10.1007/s11011-016-9850-x,1.7,0.32,,,6.26,1.05,
,Glx,Glx,2020_su_71,1,Healthy Controls,10.1016/j.jocn.2019.11.021,,,,,3.91,0.7,
,Glx,Glx,2020_su_71,2,Methamphetamine Dependence,10.1016/j.jocn.2019.11.021,,,,,3.92,0.55,
,Glx,Glx,2016_koob_11,1,Premature Neonates,10.1371/journal.pone.0160990,,,0.255,0.082,,,
,Glx,Glx,2016_koob_11,2,Premature Neonates,10.1371/journal.pone.0160990,,,0.053,0.028,,,
,Glx,Glx,2016_koob_11,3,Infants - Control,10.1371/journal.pone.0160990,,,0.321,0.086,,,
,Glx,Glx,2016_koob_11,4,Infants - Control,10.1371/journal.pone.0160990,,,0.079,0.025,,,
,Glx,Glx,2020_wenneberg_5,1,Ultra High Risk for Psychosis,10.1016/j.bpsc.2019.12.005,,,12.38,1.29,,,
,Glx,Glx,2020_wenneberg_5,2,Ultra High Risk for Psychosis,10.1016/j.bpsc.2019.12.005,,,9.11,1.22,,,
,Glx,Glx,2020_wenneberg_5,3,Healthy Control,10.1016/j.bpsc.2019.12.005,,,12.42,1.29,,,
,Glx,Glx,2020_wenneberg_5,4,Healthy Control,10.1016/j.bpsc.2019.12.005,,,9.29,1.34,,,
,Glx,Glx,2020_wenneberg_5,5,Ultra High Risk for Psychosis,10.1016/j.bpsc.2019.12.005,,,12.19,1.37,,,
,Glx,Glx,2020_wenneberg_5,6,Ultra High Risk for Psychosis,10.1016/j.bpsc.2019.12.005,,,9.05,1.24,,,
,Glx,Glx,2020_wenneberg_5,7,Ultra High Risk for Psychosis,10.1016/j.bpsc.2019.12.005,,,12.57,1.23,,,
,Glx,Glx,2020_wenneberg_5,8,Ultra High Risk for Psychosis,10.1016/j.bpsc.2019.12.005,,,9.08,1.17,,,
,Glx,Glx,2016_mazuel_278,1,Parkinson's Disease - Drug-on,10.1148/radiol.2015142764,,,15.2,21.5,,,
,Glx,Glx,2016_mazuel_278,2,Parkinson's Disease - Drug-off,10.1148/radiol.2015142764,,,14.4,13.4,,,
,Glx,Glx,2016_mazuel_278,3,Control,10.1148/radiol.2015142764,,,14.9,16.5,,,
,Glx,Glx,2021_onwordi_11,4,Control,10.1038/s41398-021-01515-3,1.38,0.281,,,,,
,Glx,Glx,2020_basu_10,2,Preterm Infants,10.1038/s41598-020-67188-y,,,3.84,0.27,,,
,Glx,Glx,2020_basu_10,3,Preterm Infants,10.1038/s41598-020-67188-y,,,4.43,0.19,,,
,Glx,Glx,2020_basu_10,5,Preterm Infants,10.1038/s41598-020-67188-y,,,4.54,0.4,,,
,Glx,Glx,2020_basu_10,6,Preterm Infants,10.1038/s41598-020-67188-y,,,4.66,0.24,,,
,Glx,Glx,2020_basu_10,8,Preterm Infants,10.1038/s41598-020-67188-y,,,3.07,0.26,,,
,Glx,Glx,2020_basu_10,9,Preterm Infants,10.1038/s41598-020-67188-y,,,4.18,0.28,,,
,Glx,Glx,2020_basu_10,11,Preterm Infants,10.1038/s41598-020-67188-y,,,4.57,0.39,,,
,Glx,Glx,2020_basu_10,12,Preterm Infants,10.1038/s41598-020-67188-y,,,4.38,0.24,,,
,Glx,Glx,2020_basu_10,14,Preterm Infants,10.1038/s41598-020-67188-y,,,3.3,0.29,,,
,Glx,Glx,2020_basu_10,15,Preterm Infants,10.1038/s41598-020-67188-y,,,4.47,0.29,,,
,Glx,Glx,2020_archibald_10,1,Baseline,10.1038/s41598-020-76263-3,,,,,14.06,0.55,
,Glx,Glx,2020_archibald_10,2,Baseline 2,10.1038/s41598-020-76263-3,,,,,15.17,0.59,
,Glx,Glx,2020_archibald_10,3,Baseline 4,10.1038/s41598-020-76263-3,,,,,13.54,0.52,
,Glx,Glx,2020_archibald_10,4,Baseline 6,10.1038/s41598-020-76263-3,,,,,14.51,0.56,
,Glx,Glx,2020_archibald_10,5,Baseline 8,10.1038/s41598-020-76263-3,,,,,13.86,0.56,
,Glx,Glx,2020_archibald_10,6,Heat 10,10.1038/s41598-020-76263-3,,,,,14.24,0.55,
,Glx,Glx,2020_archibald_10,7,Heat 12,10.1038/s41598-020-76263-3,,,,,13.96,0.54,
,Glx,Glx,2020_archibald_10,8,Post Heat 14,10.1038/s41598-020-76263-3,,,,,13.67,0.52,
,Glx,Glx,2020_archibald_10,9,Post Heat 16,10.1038/s41598-020-76263-3,,,,,14.41,0.53,
,Glx,Glx,2020_archibald_10,10,Post Heat 18,10.1038/s41598-020-76263-3,,,,,13.96,0.53,
,Glx,Glx,2020_archibald_10,11,Post Heat 20,10.1038/s41598-020-76263-3,,,,,13.95,0.55,
,Glx,Glx,2020_bell_34,1,Healthy,10.1002/nbm.4245,,,,,18.8,2.3,
,Glx,Glx,2020_bell_34,2,Healthy,10.1002/nbm.4245,,,,,13.1,1.5,
,Glx,Glx,2020_bell_34,3,Healthy,10.1002/nbm.4245,,,,,15.6,3,
,Glx,Glx,2020_bell_34,4,Healthy,10.1002/nbm.4245,,,,,13.8,1.2,
,Glx,Glx,2020_bell_34,5,Healthy,10.1002/nbm.4245,,,,,12.8,2.2,
,Glx,Glx,2020_bell_34,6,Healthy,10.1002/nbm.4245,,,,,9.6,1,
,Glx,Glx,2020_bell_34,7,Healthy,10.1002/nbm.4245,,,,,7.4,0.7,
,Glx,Glx,2020_bell_34,8,Healthy,10.1002/nbm.4245,,,,,6.1,0.5,
,Glx,Glx,2020_bell_34,9,Healthy,10.1002/nbm.4245,,,,,2.9,0.5,
,Glx,Glx,2020_bell_34,10,Healthy,10.1002/nbm.4245,,,,,2.8,0.4,
,Glx,Glx,2019_meyer_10,1,Control,10.3389/fneur.2019.00556,,,,,72.75,9.23,
,Glx,Glx,2019_meyer_10,2,Control,10.3389/fneur.2019.00556,,,,,68.8,29,
,Glx,Glx,2019_meyer_10,3,Concussion,10.3389/fneur.2019.00556,,,,,65.07,31.19,
,Glx,Glx,2019_meyer_10,4,Concussion,10.3389/fneur.2019.00556,,,,,79.29,53.18,
,Glx,Glx,2019_meyer_10,5,Concussion,10.3389/fneur.2019.00556,,,,,63.87,21.36,
,Glx,Glx,2019_meyer_10,6,Concussion,10.3389/fneur.2019.00556,,,,,78.4,16.82,
,Glx,Glx,2019_meyer_10,7,Concussion,10.3389/fneur.2019.00556,,,,,70.34,12.84,
,Glx,Glx,2019_meyer_10,8,Concussion,10.3389/fneur.2019.00556,,,,,81.89,7.73,
,Glx,Glx,2019_monnig_54,1,Healthy - Baseline,10.1093/alcalc/agz062,1.402,0.125,,,,,
,Glx,Glx,2019_monnig_54,2,Healthy - Descending limb,10.1093/alcalc/agz062,1.529,0.215,,,,,
,Glx,Glx,2019_monnig_54,3,Healthy - Baseline,10.1093/alcalc/agz062,1.698,0.158,,,,,
,Glx,Glx,2019_monnig_54,4,Healthy - Descending limb,10.1093/alcalc/agz062,1.88,0.154,,,,,
,Glx,Glx,2019_parmar_73,1,Obsessive-compulsive disorder - Unmedicated - 10mg escitalopram - Baseline,10.1111/pcn.12850,,,15.88,3.16,,,
,Glx,Glx,2019_parmar_73,2,Obsessive-compulsive disorder - Unmedicated - 10mg escitalopram - 12wk,10.1111/pcn.12850,,,14.06,1.66,,,
,Glx,Glx,2019_parmar_73,3,Control,10.1111/pcn.12850,,,14.43,2.91,,,
,Glx,Glx,2019_parmar_73,4,Obsessive-compulsive disorder - Unmedicated - 10mg escitalopram - Baseline,10.1111/pcn.12850,,,15.98,3.6,,,
,Glx,Glx,2019_parmar_73,5,Obsessive-compulsive disorder - Unmedicated - 10mg escitalopram - 12wk,10.1111/pcn.12850,,,14.39,2.42,,,
,Glx,Glx,2019_parmar_73,6,Control,10.1111/pcn.12850,,,14.14,2.18,,,
,Glx,Glx,2019_parmar_73,7,Obsessive-compulsive disorder - Unmedicated - 10mg escitalopram - Baseline,10.1111/pcn.12850,,,15.01,3.12,,,
,Glx,Glx,2019_parmar_73,8,Obsessive-compulsive disorder - Unmedicated - 10mg escitalopram - 12wk,10.1111/pcn.12850,,,13.15,2.1,,,
,Glx,Glx,2019_parmar_73,9,Control,10.1111/pcn.12850,,,13.07,2.95,,,
,Glx,Glx,2019_pflugrad_14,2,Chronic liver disease - Before OLT,10.1371/journal.pone.0221626,,,9.37,1.74,,,
,Glx,Glx,2019_pflugrad_14,5,Chronic liver disease - Before OLT_PTE,10.1371/journal.pone.0221626,,,10.41,1.9,,,
,Glx,Glx,2019_pflugrad_14,8,Chronic liver disease - Before OLT_no PTE,10.1371/journal.pone.0221626,,,9.07,1.47,,,
,Glx,Glx,2019_pflugrad_14,11,Control,10.1371/journal.pone.0221626,,,6.57,0.86,,,
,Glx,Glx,2019_pflugrad_14,14,Chronic liver disease - After OLT,10.1371/journal.pone.0221626,,,7.92,1.81,,,
,Glx,Glx,2019_pflugrad_14,17,Chronic liver disease - After OLT_PTE,10.1371/journal.pone.0221626,,,8.01,1.47,,,
,Glx,Glx,2019_pflugrad_14,20,Chronic liver disease - After OLT_no PTE,10.1371/journal.pone.0221626,,,7.88,2,,,
,Glx,Glx,2021_rowe_133,1,LOGG,10.1016/j.ymgme.2021.06.008,,,,,10.41,2.59,
,Glx,Glx,2021_rowe_133,4,LOTS,10.1016/j.ymgme.2021.06.008,,,,,9.32,2.04,
,Glx,Glx,2021_rowe_133,7,LOSD,10.1016/j.ymgme.2021.06.008,,,,,12.94,2,
,Glx,Glx,2021_rowe_133,10,Control,10.1016/j.ymgme.2021.06.008,,,,,12.52,0.74,
,Glx,Glx,2021_shiga_30,1,Non-progression,10.1016/j.jstrokecerebrovasdis.2021.105747,1.77,0.26,,,,,
,Glx,Glx,2021_shiga_30,2,Non-progression,10.1016/j.jstrokecerebrovasdis.2021.105747,1.01,0.2,,,,,
,Glx,Glx,2021_shiga_30,3,Progression,10.1016/j.jstrokecerebrovasdis.2021.105747,1.81,0.24,,,,,
,Glx,Glx,2021_shiga_30,4,Progression,10.1016/j.jstrokecerebrovasdis.2021.105747,1.03,0.22,,,,,
,Glx,Glx,2021_siegel-ramsay_313,1,Control,10.1016/j.pscychresns.2021.111302,,,10.42,0.79,,,
,Glx,Glx,2021_siegel-ramsay_313,2,Autism,10.1016/j.pscychresns.2021.111302,,,9.55,1.79,,,
,Glx,Glx,2020_colizzi_25,1,Healthy,10.1038/s41380-019-0374-8,,,10.87,2.58,,,
,Glx,Glx,2020_colizzi_25,2,Healthy,10.1038/s41380-019-0374-8,,,6.75,1.06,,,
,Glx,Glx,2020_colizzi_25,3,Healthy,10.1038/s41380-019-0374-8,,,10.31,2.73,,,
,Glx,Glx,2020_colizzi_25,4,Psychosis ,10.1038/s41380-019-0374-8,,,9.25,2.35,,,
,Glx,Glx,2020_colizzi_25,5,Psychosis ,10.1038/s41380-019-0374-8,,,6.31,0.87,,,
,Glx,Glx,2020_colizzi_25,6,Psychosis ,10.1038/s41380-019-0374-8,,,9.5,2.85,,,
,Glx,Glx,2021_steinegger_26,1,Control,10.1111/adb.13027,,,,,17.01,2.56,
,Glx,Glx,2021_steinegger_26,3,Smokers,10.1111/adb.13027,,,,,17.04,2.46,
,Glx,Glx,2021_steinegger_26,5,Baseline,10.1111/adb.13027,,,,,16.72,2.09,
,Glx,Glx,2021_steinegger_26,7,Withdrawal,10.1111/adb.13027,,,,,18,2.94,
,Glx,Glx,2021_steinegger_26,8,Satiation,10.1111/adb.13027,,,,,17.56,3.07,
,Glx,Glx,2021_wang_59,1,Control,10.1016/j.mito.2021.06.012,2.02,0.4,,,13.17,2.23,
,Glx,Glx,2021_wang_59,2,Control,10.1016/j.mito.2021.06.013,2.02,0.4,,,13.17,2.23,
,Glx,Glx,2021_wang_59,3,MELAS,10.1016/j.mito.2021.06.014,1.63,0.68,,,10.51,3.31,
,Glx,Glx,2021_wood_11,1,ASD,10.1038/s41398-020-01154-0,0.12,0.05,,,,,
,Glx,Glx,2021_wood_11,2,ASD,10.1038/s41398-020-01154-0,0.15,0.03,,,,,
,Glx,Glx,2021_wood_11,3,TD,10.1038/s41398-020-01154-0,0.12,0.06,,,,,
,Glx,Glx,2021_wood_11,4,TD,10.1038/s41398-020-01154-0,0.14,0.02,,,,,
,Glx,Glx,2021_henigsberg_238,1,AD discontinuation,10.1007/s00213-019-05303-2,1.8,0.2,,,,,
,Glx,Glx,2021_henigsberg_238,2,Episode recurrence,10.1007/s00213-019-05303-2,1.98,0.3,,,,,
,Glx,Glx,2021_mansur_281,1,Placebo,10.1016/j.jad.2020.11.128,,,,,7.8,3.18,
,Glx,Glx,2021_mansur_281,2,Infliximab,10.1016/j.jad.2020.11.128,,,,,6.3,1.16,
,Glx,Glx,2019_schmitz_49,1,Control,10.1111/apt.15256,,,5.371,1.634,,,
,Glx,Glx,2019_schmitz_49,2,Liver transplantation - Calcineurin inhibitor free,10.1111/apt.15256,,,4.821,1.505,,,
,Glx,Glx,2019_schmitz_49,3,Liver transplantation - Calcineurin inhibitor low-dose,10.1111/apt.15256,,,5.283,0.931,,,
,Glx,Glx,2019_schmitz_49,4,Liver transplantation - Calcineurin inhibitor standard-dose,10.1111/apt.15256,,,5.129,0.739,,,
,Glx,Glx,2020_ford_98,7,Symptoms of the autism and schizophrenia,10.1016/j.pnpbp.2019.109769,,,6.875,0.29,,,
,Glx,Glx,2020_ford_98,8,Symptoms of the autism and schizophrenia,10.1016/j.pnpbp.2019.109769,,,5.63,0.23,,,
,Glx,Glx,2020_ford_98,9,Symptoms of the autism and schizophrenia,10.1016/j.pnpbp.2019.109769,,,6.72,0.32,,,
,Glx,Glx,2020_ford_98,10,Symptoms of the autism and schizophrenia,10.1016/j.pnpbp.2019.109769,,,5.75,0.22,,,
,Glx,Glx,2020_ford_98,11,Symptoms of the autism and schizophrenia,10.1016/j.pnpbp.2019.109769,,,7.03,0.26,,,
,Glx,Glx,2020_ford_98,12,Symptoms of the autism and schizophrenia,10.1016/j.pnpbp.2019.109769,,,5.51,0.24,,,
,Glx,Glx,2019_smaragdi_93,1,ASPD,10.1016/j.pnpbp.2019.04.002,,,,,19.04,1.4,
,Glx,Glx,2019_smaragdi_93,2,ASPD,10.1016/j.pnpbp.2019.04.002,,,,,21.84,4.26,
,Glx,Glx,2019_smaragdi_93,3,BD,10.1016/j.pnpbp.2019.04.002,,,,,16.89,1.55,
,Glx,Glx,2019_smaragdi_93,4,BD,10.1016/j.pnpbp.2019.04.002,,,,,21.21,1.64,
,Glx,Glx,2019_smaragdi_93,5,HC,10.1016/j.pnpbp.2019.04.002,,,,,17.1,1.4,
,Glx,Glx,2019_smaragdi_93,6,HC,10.1016/j.pnpbp.2019.04.002,,,,,21.43,1.95,
,Glx,Glx,2019_simmonite_26,1,Healthy - Young adults,10.1016/j.acra.2018.07.024,1.61,0.18,,,,,
,Glx,Glx,2019_simmonite_26,2,Healthy - Older adults,10.1016/j.acra.2018.07.024,1.52,0.23,,,,,
,Glx,Glx,2020_hai_3,3,ADHD,10.1001/jamanetworkopen.2020.20973,,,,,11.59,3.11,
,Glx,Glx,2020_hai_3,4,Control,10.1001/jamanetworkopen.2020.20973,,,,,11.18,1.43,
,Glx,Glx,2020_burger_51,1,Healthy,10.1111/ejn.14583,1.48,0.28,,,,,
,Glx,Glx,2020_burger_51,2,Healthy,10.1111/ejn.14583,1.56,0.24,,,,,
,Glx,Glx,2020_burger_51,3,Healthy,10.1111/ejn.14583,1.48,0.3,,,,,
,Glx,Glx,2020_burger_51,4,Healthy,10.1111/ejn.14583,1.36,0.28,,,,,
,Glx,Glx,2020_burger_51,5,Healthy,10.1111/ejn.14583,1.19,0.21,,,,,
,Glx,Glx,2020_burger_51,6,Healthy,10.1111/ejn.14583,1.27,0.25,,,,,
,Glx,Glx,2020_burger_51,7,Healthy,10.1111/ejn.14583,1.6,0.27,,,,,
,Glx,Glx,2020_burger_51,8,Healthy,10.1111/ejn.14583,1.71,0.27,,,,,
,Glx,Glx,2020_burger_51,9,Healthy,10.1111/ejn.14583,1.58,0.44,,,,,
,Glx,Glx,2020_burger_51,10,Healthy,10.1111/ejn.14583,1.45,0.28,,,,,
,Glx,Glx,2020_burger_51,11,Healthy,10.1111/ejn.14583,1.16,0.22,,,,,
,Glx,Glx,2020_burger_51,12,Healthy,10.1111/ejn.14583,1.19,0.22,,,,,
,Glx,Glx,2019_starmose_20,1,Control,10.1186/s10194-019-1059-z,1.271,0.094,7.991,0.704,,,
,Glx,Glx,2019_starmose_20,2,Control,10.1186/s10194-019-1059-z,1.244,0.105,7.362,0.548,,,
,Glx,Glx,2019_starmose_20,3,Migraine with aura,10.1186/s10194-019-1059-z,1.278,0.097,7.646,0.345,,,
,Glx,Glx,2019_starmose_20,4,Migraine with aura,10.1186/s10194-019-1059-z,1.314,0.129,7.536,0.662,,,
,Glx,Glx,2019_su_29,1,PTSD,10.1007/s00330-018-5615-8,,,,,15.79,2.24,
,Glx,Glx,2019_su_29,4,non-PTSD,10.1007/s00330-018-5615-8,,,,,16.32,3.02,
,Glx,Glx,2019_su_29,2,PTSD,10.1007/s00330-018-5615-8,,,,,18.29,2.61,
,Glx,Glx,2019_su_29,5,non-PTSD,10.1007/s00330-018-5615-8,,,,,16.92,3.17,
,Glx,Glx,2019_su_29,3,PTSD,10.1007/s00330-018-5615-8,,,,,16.89,2.44,
,Glx,Glx,2019_su_29,6,non-PTSD,10.1007/s00330-018-5615-8,,,,,17.04,3.35,
,Glx,Glx,2018_horowitz-kraus_12,1,Control,10.3389/fnhum.2018.00466,,,,,11.41,0.84,
,Glx,Glx,2018_horowitz-kraus_12,2,Dyslexia,10.3389/fnhum.2018.00466,,,,,11.12,0.68,
,Glx,Glx,2018_modinos_21,1,Control,10.1093/ijnp/pyx076,0.8,0.1,,,,,
,Glx,Glx,2018_modinos_21,2,Psychosis,10.1093/ijnp/pyx076,0.8,0.1,,,,,
,Glx,Glx,2020_menshchikov_84,1,Control,10.1002/mrm.28332,1.464,0.143,,,10.21,0.8,
,Glx,Glx,2020_menshchikov_84,2,Mild Traumatic Brain Injury ,10.1002/mrm.28332,1.462,0.132,,,10.32,0.8,
,Glx,Glx,2018_su_241,1,Control,10.1016/j.jad.2018.08.018,,,,,16.32,3.02,
,Glx,Glx,2018_su_241,2,Control,10.1016/j.jad.2018.08.018,,,,,16.92,3.17,
,Glx,Glx,2018_su_241,3,Control,10.1016/j.jad.2018.08.018,,,,,17.04,3.35,
,Glx,Glx,2018_su_241,4,PTSD,10.1016/j.jad.2018.08.018,,,,,15.79,2.24,
,Glx,Glx,2018_su_241,5,PTSD,10.1016/j.jad.2018.08.018,,,,,18.29,2.61,
,Glx,Glx,2018_su_241,6,PTSD,10.1016/j.jad.2018.08.018,,,,,16.89,2.44,
,Glx,Glx,2019_oneill_111,1,Control,10.1002/bdr2.1460,,,9.2,2.2,,,
,Glx,Glx,2019_oneill_111,2,ADHD,10.1002/bdr2.1460,,,9.4,2.1,,,
,Glx,Glx,2019_oneill_111,3,ADHD,10.1002/bdr2.1460,,,10.3,1.6,,,
,Glx,Glx,2019_oneill_111,4,ADHD,10.1002/bdr2.1460,,,9.1,0.9,,,
,Glx,Glx,2019_oneill_111,5,ADHD,10.1002/bdr2.1460,,,9.6,0.9,,,
,Glx,Glx,2019_oneill_111,6,ADHD,10.1002/bdr2.1460,,,9.6,1.7,,,
,Glx,Glx,2019_polacek_163,1,Control,10.5507/bp.2018.036,2.3,0.345,,,,,Assumed 15% StdDev
,Glx,Glx,2019_polacek_163,2,Multiple Sclerosis,10.5507/bp.2018.036,2.22,0.333,,,,,Assumed 15% StdDev
,Glx,Glx,2019_rogdaki_29,1,22q11.2 deletion,10.1016/j.euroneuro.2019.09.005,,,19.83,3.09,,,
,Glx,Glx,2019_rogdaki_29,2,22q11.2 deletion,10.1016/j.euroneuro.2019.09.005,,,12.11,3.17,,,
,Glx,Glx,2019_rogdaki_29,3,22q11.2 deletion,10.1016/j.euroneuro.2019.09.005,,,10.25,3.47,,,
,Glx,Glx,2019_rogdaki_29,4,22q11.2 deletion - antipsychotic naïve,10.1016/j.euroneuro.2019.09.005,,,19.97,3,,,
,Glx,Glx,2019_rogdaki_29,5,22q11.2 deletion - antipsychotic naïve,10.1016/j.euroneuro.2019.09.005,,,11.92,3.3,,,
,Glx,Glx,2019_rogdaki_29,6,22q11.2 deletion - antipsychotic naïve,10.1016/j.euroneuro.2019.09.005,,,10.42,3.5,,,
,Glx,Glx,2019_rogdaki_29,7,Control,10.1016/j.euroneuro.2019.09.005,,,21.09,3.85,,,
,Glx,Glx,2019_rogdaki_29,8,Control,10.1016/j.euroneuro.2019.09.005,,,11.49,2.76,,,
,Glx,Glx,2019_rogdaki_29,9,Control,10.1016/j.euroneuro.2019.09.005,,,10.06,2.87,,,
,Glx,Glx,2020_didehdar_189,1,Nonspecific low back pain - Lumbopelvic manipulation - Baseline,10.1007/s11845-019-02140-2,0.54,0.394,,,,,
,Glx,Glx,2020_didehdar_189,2,Nonspecific low back pain - Lumbopelvic manipulation - Baseline,10.1007/s11845-019-02140-2,0.858,0.133,,,,,
,Glx,Glx,2020_didehdar_189,3,Nonspecific low back pain - Lumbopelvic manipulation - Baseline,10.1007/s11845-019-02140-2,0.858,0.095,,,,,
,Glx,Glx,2020_didehdar_189,4,Nonspecific low back pain - Lumbopelvic manipulation - Baseline,10.1007/s11845-019-02140-2,0.995,0.12,,,,,
,Glx,Glx,2020_didehdar_189,5,Nonspecific low back pain - Lumbopelvic manipulation - Baseline,10.1007/s11845-019-02140-2,1.043,0.184,,,,,
,Glx,Glx,2020_didehdar_189,6,Nonspecific low back pain - Lumbopelvic manipulation - 5 wks,10.1007/s11845-019-02140-2,0.903,0.269,,,,,
,Glx,Glx,2020_didehdar_189,7,Nonspecific low back pain - Lumbopelvic manipulation - 5 wks,10.1007/s11845-019-02140-2,0.925,0.112,,,,,
,Glx,Glx,2020_didehdar_189,8,Nonspecific low back pain - Lumbopelvic manipulation - 5 wks,10.1007/s11845-019-02140-2,0.828,0.12,,,,,
,Glx,Glx,2020_didehdar_189,9,Nonspecific low back pain - Lumbopelvic manipulation - 5 wks,10.1007/s11845-019-02140-2,1.022,0.179,,,,,
,Glx,Glx,2020_didehdar_189,10,Nonspecific low back pain - Lumbopelvic manipulation - 5 wks,10.1007/s11845-019-02140-2,1.06,0.112,,,,,
,Glx,Glx,2020_didehdar_189,11,Nonspecific low back pain - Sham - Baseline,10.1007/s11845-019-02140-2,0.678,0.137,,,,,
,Glx,Glx,2020_didehdar_189,12,Nonspecific low back pain - Sham - Baseline,10.1007/s11845-019-02140-2,0.962,0.095,,,,,
,Glx,Glx,2020_didehdar_189,13,Nonspecific low back pain - Sham - Baseline,10.1007/s11845-019-02140-2,0.967,0.109,,,,,
,Glx,Glx,2020_didehdar_189,14,Nonspecific low back pain - Sham - Baseline,10.1007/s11845-019-02140-2,1.142,0.104,,,,,
,Glx,Glx,2020_didehdar_189,15,Nonspecific low back pain - Sham - Baseline,10.1007/s11845-019-02140-2,1.123,0.176,,,,,
,Glx,Glx,2020_didehdar_189,16,Nonspecific low back pain - Sham - 5 wks,10.1007/s11845-019-02140-2,0.784,0.246,,,,,
,Glx,Glx,2020_didehdar_189,17,Nonspecific low back pain - Sham - 5 wks,10.1007/s11845-019-02140-2,0.881,0.067,,,,,
,Glx,Glx,2020_didehdar_189,18,Nonspecific low back pain - Sham - 5 wks,10.1007/s11845-019-02140-2,0.91,0.112,,,,,
,Glx,Glx,2020_didehdar_189,19,Nonspecific low back pain - Sham - 5 wks,10.1007/s11845-019-02140-2,1.097,0.104,,,,,
,Glx,Glx,2020_didehdar_189,20,Nonspecific low back pain - Sham - 5 wks,10.1007/s11845-019-02140-2,1.097,0.127,,,,,
,Glx,Glx,2020_coughlin_26,2,Control,10.1038/s41380-020-00901-5,1.58,0.21,,,,,
,Glx,Glx,2020_coughlin_26,5,Schizophrenia,10.1038/s41380-020-00901-5,1.49,0.21,,,,,
,Glx,Glx,2020_draganov_266,1,Control,10.1016/j.jad.2020.01.138,,,,,14.83,2.4,
,Glx,Glx,2020_draganov_266,2,Depression,10.1016/j.jad.2020.01.138,,,,,13.57,3.6,
,Glx,Glx,2020_draganov_266,3,Depression,10.1016/j.jad.2020.01.138,,,,,12.9,2.84,
,Glx,Glx,2020_draganov_266,4,Depression,10.1016/j.jad.2020.01.138,,,,,13.98,1.55,
,Glx,Glx,2020_macmaster_35,1,Orthopedic Injury,10.1097/HTR.0000000000000535,,,,,12.83,1.17,
,Glx,Glx,2020_macmaster_35,2,Concussion,10.1097/HTR.0000000000000535,,,,,12.53,1.29,
,Glx,Glx,2020_macmaster_35,3,Single Concussion,10.1097/HTR.0000000000000535,,,,,12.58,1.29,
,Glx,Glx,2020_macmaster_35,4,Multiple Concussion,10.1097/HTR.0000000000000535,,,,,12.48,1.33,
,Glx,Glx,2020_macmaster_35,5,Orthopedic Injury,10.1097/HTR.0000000000000535,,,,,13.28,1.37,
,Glx,Glx,2020_macmaster_35,6,Concussion,10.1097/HTR.0000000000000535,,,,,12.8,1.87,
,Glx,Glx,2020_macmaster_35,7,Single Concussion,10.1097/HTR.0000000000000535,,,,,2.73,1.69,
,Glx,Glx,2020_macmaster_35,8,Multiple Concussion,10.1097/HTR.0000000000000535,,,,,12.85,2.06,
,Glx,Glx,2020_prisci_65,1,Healthy,10.1016/j.mri.2019.10.004,,,14.58,1.48,,,
,Glx,Glx,2020_prisci_65,2,Healthy,10.1016/j.mri.2019.10.004,,,14.05,1.19,,,
,Glx,Glx,2020_simani_112,1,Healthy Controls,10.1016/j.yebeh.2020.107480,0.44,0.17,,,,,
,Glx,Glx,2020_simani_112,2,Idiopathic Generalized Epilepsy,10.1016/j.yebeh.2020.107480,0.39,0.13,,,,,
,Glx,Glx,2020_simani_112,3,Psychogenic Nonepileptic Seizure,10.1016/j.yebeh.2020.107480,0.41,0.12,,,,,
,Glx,Glx,2020_simani_112,4,Healthy Controls,10.1016/j.yebeh.2020.107480,0.43,0.08,,,,,
,Glx,Glx,2020_simani_112,5,Idiopathic Generalized Epilepsy,10.1016/j.yebeh.2020.107480,0.42,0.14,,,,,
,Glx,Glx,2020_simani_112,6,Psychogenic Nonepileptic Seizure,10.1016/j.yebeh.2020.107480,0.39,0.12,,,,,
,Glx,Glx,2020_simani_112,7,Healthy Controls,10.1016/j.yebeh.2020.107480,0.44,0.01,,,,,
,Glx,Glx,2020_simani_112,8,Idiopathic Generalized Epilepsy,10.1016/j.yebeh.2020.107480,0.46,0.01,,,,,
,Glx,Glx,2020_simani_112,9,Psychogenic Nonepileptic Seizure,10.1016/j.yebeh.2020.107480,0.43,0.02,,,,,
,Glx,Glx,2020_simani_112,10,Healthy Controls,10.1016/j.yebeh.2020.107480,0.42,0.15,,,,,
,Glx,Glx,2020_simani_112,11,Idiopathic Generalized Epilepsy,10.1016/j.yebeh.2020.107480,0.35,0.13,,,,,
,Glx,Glx,2020_simani_112,12,Psychogenic Nonepileptic Seizure,10.1016/j.yebeh.2020.107480,0.37,0.09,,,,,
,Glx,Glx,2020_simani_112,13,Healthy Controls,10.1016/j.yebeh.2020.107480,0.5,0.07,,,,,
,Glx,Glx,2020_simani_112,14,Idiopathic Generalized Epilepsy,10.1016/j.yebeh.2020.107480,0.71,0.06,,,,,
,Glx,Glx,2020_simani_112,15,Psychogenic Nonepileptic Seizure,10.1016/j.yebeh.2020.107480,0.64,0.05,,,,,
,Glx,Glx,2020_simani_112,16,Healthy Controls,10.1016/j.yebeh.2020.107480,0.45,0.23,,,,,
,Glx,Glx,2020_simani_112,17,Idiopathic Generalized Epilepsy,10.1016/j.yebeh.2020.107480,0.77,0.67,,,,,
,Glx,Glx,2020_simani_112,18,Psychogenic Nonepileptic Seizure,10.1016/j.yebeh.2020.107480,0.55,0.37,,,,,
,Glx,Glx,2020_simani_112,19,Healthy Controls,10.1016/j.yebeh.2020.107480,0.44,0.04,,,,,
,Glx,Glx,2020_simani_112,20,Idiopathic Generalized Epilepsy,10.1016/j.yebeh.2020.107480,0.39,0.03,,,,,
,Glx,Glx,2020_simani_112,21,Psychogenic Nonepileptic Seizure,10.1016/j.yebeh.2020.107480,0.42,0.03,,,,,
,Glx,Glx,2020_simani_112,22,Healthy Controls,10.1016/j.yebeh.2020.107480,0.48,0.25,,,,,
,Glx,Glx,2020_simani_112,23,Idiopathic Generalized Epilepsy,10.1016/j.yebeh.2020.107480,0.45,0.27,,,,,
,Glx,Glx,2020_simani_112,24,Psychogenic Nonepileptic Seizure,10.1016/j.yebeh.2020.107480,0.38,0.22,,,,,
,Glx,Glx,2021_imrich_31,1,MS,10.1007/s10286-021-00790-w,0.51,0.1,,,,,
,Glx,Glx,2021_imrich_32,2,MS,10.1007/s10286-021-00790-w,0.48,0.07,,,,,
,Glx,Glx,2021_imrich_33,3,Control,10.1007/s10286-021-00790-w,0.46,0.09,,,,,
,Glx,Glx,2021_coughlin_26,1,Schizophrenia,10.1038/s41380-020-00901-5,1.49,0.21,,,,,"Author List nmol/ml, but methods show referenced to Cre"
,Glx,Glx,2021_coughlin_26,2,Healthy controls,10.1038/s41380-020-00901-5,1.58,0.21,,,,,"Author List nmol/ml, but methods show referenced to Cre"
,Glx,Glx,2021_kantrowitz_11,1,MDD,10.1038/s41398-021-01541-1,1.925,0.6,,,,,
,Glx,Glx,2021_kantrowitz_11,2,Healthy Control,10.1038/s41398-021-01541-1,1.585,0.4,,,,,
,Glx,Glx,2020_pizzi_35,1,Healthy Control,10.1002/mds.28221,0.0776,0.0315,,,,,
,Glx,Glx,2020_pizzi_35,2,Somatic Symptom Disorder,10.1002/mds.28221,0.0941,0.0152,,,,,
,Glx,Glx,2020_pizzi_35,3,Parkinson’s Disease,10.1002/mds.28221,0.0972,0.0437,,,,,
,Glx,Glx,2020_pizzi_35,4,SSD + PD,10.1002/mds.28221,0.0904,0.0186,,,,,
,Glx,Glx,2020_mcqueen_237,1,Schizophrenia - Placebo,10.1007/s00213-019-05382-1,1.86,0.43,,,,,
,Glx,Glx,2020_mcqueen_237,2,Schizophrenia - 2400mg NAC,10.1007/s00213-019-05382-1,1.63,0.3,,,,,
,Glx,Glx,2020_mohamadi_101,1,Tension-type headache - Positional release technique - Baseline,10.1016/j.apmr.2020.05.028,0.95,0.38,,,,,
,Glx,Glx,2020_mohamadi_101,2,Tension-type headache - Positional release technique - 5wks,10.1016/j.apmr.2020.05.028,1.07,0.4,,,,,
,Glx,Glx,2020_mohamadi_101,3,Tension-type headache - Positional release technique - Baseline,10.1016/j.apmr.2020.05.028,0.84,0.17,,,,,
,Glx,Glx,2020_mohamadi_101,4,Tension-type headache - Positional release technique - 5wks,10.1016/j.apmr.2020.05.028,0.91,0.18,,,,,
,Glx,Glx,2020_mohamadi_101,5,Tension-type headache - Positional release technique - Baseline,10.1016/j.apmr.2020.05.028,1.04,0.34,,,,,
,Glx,Glx,2020_mohamadi_101,6,Tension-type headache - Positional release technique - 5wks,10.1016/j.apmr.2020.05.028,0.98,0.34,,,,,
,Glx,Glx,2020_mohamadi_101,7,Tension-type headache - Control - Baseline,10.1016/j.apmr.2020.05.028,0.87,0.43,,,,,
,Glx,Glx,2020_mohamadi_101,8,Tension-type headache - Control - 5wks,10.1016/j.apmr.2020.05.028,0.77,0.3,,,,,
,Glx,Glx,2020_mohamadi_101,9,Tension-type headache - Control - Baseline,10.1016/j.apmr.2020.05.028,0.82,0.23,,,,,
,Glx,Glx,2020_mohamadi_101,10,Tension-type headache - Control - 5wks,10.1016/j.apmr.2020.05.028,0.92,0.22,,,,,
,Glx,Glx,2020_mohamadi_101,11,Tension-type headache - Control - Baseline,10.1016/j.apmr.2020.05.028,1.06,0.2,,,,,
,Glx,Glx,2020_mohamadi_101,12,Tension-type headache - Control - 5wks,10.1016/j.apmr.2020.05.028,0.93,0.19,,,,,
,Glx,Glx,2020_provenzano_87,1,Control,10.1016/j.biopsych.2019.09.022,8.778,1.12,,,,,
,Glx,Glx,2020_provenzano_87,2,High-risk for psychosis,10.1016/j.biopsych.2019.09.022,10.121,1.8,,,,,
,Glx,Glx,2020_provenzano_87,3,High-risk for psychosis - Converters,10.1016/j.biopsych.2019.09.022,10.07,1.93,,,,,
,Glx,Glx,2020_provenzano_87,4,High-risk for psychosis - Non-converters,10.1016/j.biopsych.2019.09.022,10.241,1.51,,,,,
,Glx,Glx,2020_rafique_10,1,Healthy - Single rTMS - Pre-rTMS,10.1002/brb3.1845,,,7.842,1.239,,,
,Glx,Glx,2020_rafique_10,2,Healthy - Single rTMS - Immediate post-rTMS,10.1002/brb3.1845,,,7.966,0.467,,,
,Glx,Glx,2020_rafique_10,3,Healthy - Single rTMS - 1hr post-rTMS,10.1002/brb3.1845,,,7.815,1.318,,,
,Glx,Glx,2020_rafique_10,4,Healthy - 5 accelerated rTMS - Pre-rTMS,10.1002/brb3.1845,,,7.41,0.506,,,
,Glx,Glx,2020_rafique_10,5,Healthy - 5 accelerated rTMS - Immediate post-rTMS,10.1002/brb3.1845,,,7.09,0.741,,,
,Glx,Glx,2020_rafique_10,6,Healthy - 5 accelerated rTMS - 24hr post-rTMS,10.1002/brb3.1845,,,7.272,0.778,,,
,Glx,Glx,2020_rafique_10,7,Healthy - 5 accelerated rTMS - 1wk post-rTMS,10.1002/brb3.1845,,,7.576,0.86,,,
,Glx,Glx,2021_egerton_47,1,Psychosis - Antipsychotic responder,10.1093/schbul/sbaa128,,,25.86,5.28,,,
,Glx,Glx,2021_egerton_47,2,Psychosis - Antipsychotic responder,10.1093/schbul/sbaa128,,,19.67,2.56,,,
,Glx,Glx,2021_egerton_47,3,Psychosis - Antipsychotic responder,10.1093/schbul/sbaa128,,,18.596,1.61,,,
,Glx,Glx,2021_egerton_47,4,Psychosis - Antipsychotic responder,10.1093/schbul/sbaa128,,,14.82,2.15,,,
,Glx,Glx,2021_egerton_47,5,Psychosis - Antipsychotic responder,10.1093/schbul/sbaa128,,,26.85,4.28,,,
,Glx,Glx,2021_egerton_47,6,Psychosis - Antipsychotic responder,10.1093/schbul/sbaa128,,,20.17,1.87,,,
,Glx,Glx,2021_egerton_47,7,Psychosis - Antipsychotic responder,10.1093/schbul/sbaa128,,,19.62,1.87,,,
,Glx,Glx,2021_egerton_47,8,Psychosis - Antipsychotic responder,10.1093/schbul/sbaa128,,,15.56,2.14,,,
,Glx,Glx,2021_egerton_47,9,Psychosis - Antipsychotic non-responder,10.1093/schbul/sbaa128,,,15.08,2.65,,,
,Glx,Glx,2021_egerton_47,10,Psychosis - Antipsychotic non-responder,10.1093/schbul/sbaa128,,,13.34,1.81,,,
,Glx,Glx,2021_egerton_47,11,Psychosis - Antipsychotic non-responder,10.1093/schbul/sbaa128,,,16.69,5.84,,,n=5
,Glx,Glx,2021_egerton_47,12,Psychosis - Antipsychotic non-responder,10.1093/schbul/sbaa128,,,11.75,3.53,,,n=4
,Glx,Glx,2021_egerton_47,13,Psychosis - Antipsychotic non-responder,10.1093/schbul/sbaa128,,,14.27,3.15,,,
,Glx,Glx,2021_egerton_47,14,Psychosis - Antipsychotic non-responder,10.1093/schbul/sbaa128,,,12.89,2.33,,,
,Glx,Glx,2021_egerton_47,15,Psychosis - Antipsychotic non-responder,10.1093/schbul/sbaa128,,,12.7,3.2,,,n=4
,Glx,Glx,2021_egerton_47,16,Psychosis - Antipsychotic non-responder,10.1093/schbul/sbaa128,,,14.1,3.41,,,
,Glx,Glx,2021_mawla_73,1,Fibromyalgia - Electroacupuncture - Pre-treatment,10.1002/art.41620,,,12.11,1.94,,,
,Glx,Glx,2021_mawla_73,2,Fibromyalgia - Electroacupuncture - Post-treatment,10.1002/art.41620,,,11.88,1.57,,,
,Glx,Glx,2021_mawla_73,3,Fibromyalgia - Sham - Pre-treatment,10.1002/art.41620,,,11.91,1,,,
,Glx,Glx,2021_mawla_73,4,Fibromyalgia - Sham - Post-treatment,10.1002/art.41620,,,11.82,1.04,,,
,Glx,Glx,2019_cheong_90,4,Control - Visit 1,10.1136/jnnp-2018-318795,,,,,4.645,0.871,
,Glx,Glx,2019_cheong_90,5,Control - Visit 2,10.1136/jnnp-2018-318795,,,,,4.839,0.871,
,Glx,Glx,2019_cheong_90,6,Control - Visit 3,10.1136/jnnp-2018-318795,,,,,5.226,0.709,
,Glx,Glx,2019_cheong_90,10,ALS - Visit 1,10.1136/jnnp-2018-318795,,,,,4.019,0.907,
,Glx,Glx,2019_cheong_90,11,ALS - Visit 2,10.1136/jnnp-2018-318795,,,,,4.343,0.713,
,Glx,Glx,2019_cheong_90,12,ALS - Visit 3,10.1136/jnnp-2018-318795,,,,,4.667,0.972,
,Glx,Glx,2018_raschke_39,1,Healthy,10.3174/ajnr.A5457,0.987,0.081,17.454,0.295,,,Med/Quartile --> Mean/Std Wan 2014; Greco 2015
,Glx,Glx,2018_raschke_39,2,Healthy,10.3174/ajnr.A5457,0.537,0.058,12.589,1.389,,,Med/Quartile --> Mean/Std Greco 2015; Wan 2014
,Glx,Glx,2018_an_79,1,Glioma - IDH1-mutated grade-II oligodendroglioma,10.1002/mrm.26884,,,6.699,1.415,,,
,Glx,Glx,2018_an_79,2,Glioma - IDH1-mutated grade-II oligodendroglioma,10.1002/mrm.26884,,,3.967,1.394,,,
,Glx,Glx,2018_an_79,3,Glioma - Radiographically suggested glioma,10.1002/mrm.26884,,,5.293,1.729,,,
,Glx,Glx,2018_an_79,4,Glioma - Radiographically suggested glioma,10.1002/mrm.26884,,,5.083,2.83,,,
,Glx,Glx,2018_an_79,5,Glioma - IDH wild-type glioblastoma,10.1002/mrm.26884,,,7.686,2.756,,,
,Glx,Glx,2018_an_79,6,Glioma - IDH wild-type glioblastoma,10.1002/mrm.26884,,,12.297,2.438,,,
,Glx,Glx,2018_cadena_9,1,Schizophrenia - Baseline unmedicated,10.3389/fpsyt.2018.00632,0.67,0.007,,,,,
,Glx,Glx,2018_cadena_9,2,Schizophrenia - 6 wks medicated,10.3389/fpsyt.2018.00632,0.68,0.05,,,,,
,Glx,Glx,2018_cadena_9,3,Control - Baseline,10.3389/fpsyt.2018.00632,0.7,0.07,,,,,
,Glx,Glx,2018_cadena_9,4,Control - 6 wks,10.3389/fpsyt.2018.00632,0.72,0.07,,,,,
,Glx,Glx,2018_burger_185,1,Addiction - Methamphetamine Acute Abstinence,10.1016/j.drugalcdep.2017.11.029,1.499,0.288,,,,,
,Glx,Glx,2018_burger_185,2,Addiction - Methamphetamine Acute Abstinence,10.1016/j.drugalcdep.2017.11.029,1.502,0.245,,,,,
,Glx,Glx,2018_burger_185,3,Addiction - Methamphetamine Acute Abstinence,10.1016/j.drugalcdep.2017.11.029,1.584,0.275,,,,,
,Glx,Glx,2018_burger_185,4,Addiction - Methamphetamine Acute Abstinence,10.1016/j.drugalcdep.2017.11.029,1.479,0.314,,,,,
,Glx,Glx,2018_burger_185,5,Addiction - Methamphetamine Acute Abstinence,10.1016/j.drugalcdep.2017.11.029,1.273,0.245,,,,,
,Glx,Glx,2018_burger_185,6,Addiction - Methamphetamine Acute Abstinence,10.1016/j.drugalcdep.2017.11.029,1.394,0.53,,,,,
,Glx,Glx,2018_burger_185,7,Addiction - Methamphetamine Short-term Abstinence,10.1016/j.drugalcdep.2017.11.029,1.537,0.292,,,,,
,Glx,Glx,2018_burger_185,8,Addiction - Methamphetamine Short-term Abstinence,10.1016/j.drugalcdep.2017.11.029,1.477,0.235,,,,,
,Glx,Glx,2018_burger_185,9,Addiction - Methamphetamine Short-term Abstinence,10.1016/j.drugalcdep.2017.11.029,1.399,0.334,,,,,
,Glx,Glx,2018_burger_185,10,Addiction - Methamphetamine Short-term Abstinence,10.1016/j.drugalcdep.2017.11.029,1.459,0.324,,,,,
,Glx,Glx,2018_burger_185,11,Addiction - Methamphetamine Short-term Abstinence,10.1016/j.drugalcdep.2017.11.029,1.32,0.264,,,,,
,Glx,Glx,2018_burger_185,12,Addiction - Methamphetamine Short-term Abstinence,10.1016/j.drugalcdep.2017.11.029,1.459,0.541,,,,,
,Glx,Glx,2018_burger_185,13,Control,10.1016/j.drugalcdep.2017.11.029,1.443,0.232,,,,,
,Glx,Glx,2018_burger_185,14,Control,10.1016/j.drugalcdep.2017.11.029,1.489,0.249,,,,,
,Glx,Glx,2018_burger_185,15,Control,10.1016/j.drugalcdep.2017.11.029,1.587,0.367,,,,,
,Glx,Glx,2018_burger_185,16,Control,10.1016/j.drugalcdep.2017.11.029,1.417,0.301,,,,,
,Glx,Glx,2018_burger_185,17,Control,10.1016/j.drugalcdep.2017.11.029,1.319,0.212,,,,,
,Glx,Glx,2018_burger_185,18,Control,10.1016/j.drugalcdep.2017.11.029,1.404,0.347,,,,,
,Glx,Glx,2018_guo_27,1,Open-angle glaucoma - Early,10.1097/IJG.0000000000001098,2.064,0.891,,,,,
,Glx,Glx,2018_guo_27,2,Control,10.1097/IJG.0000000000001098,1.374,0.503,,,,,
,Glx,Glx,2018_kameda_34,1,Chronic Low Back Pain,10.1097/AJP.0000000000000583,1.933,0.293,13.526,1.873,,,
,Glx,Glx,2018_kameda_34,2,Control,10.1097/AJP.0000000000000583,1.846,0.192,13.387,1.388,,,
,Glx,Glx,2018_karczewska-kupczewska_103,1,Drug - Intralipid/Heparin Baseline,10.1210/jc.2018-00107,3.516,1.397,0.819,0.356,,,
,Glx,Glx,2018_karczewska-kupczewska_103,2,Drug - Intralipid/Heparin Baseline,10.1210/jc.2018-00107,3.018,1.397,0.662,0.36,,,
,Glx,Glx,2018_karczewska-kupczewska_103,3,Drug - Intralipid/Heparin Baseline,10.1210/jc.2018-00107,2.35,1.731,0.46,0.241,,,
,Glx,Glx,2018_karczewska-kupczewska_103,4,Drug - Intralipid/Heparin 4 hour infusion,10.1210/jc.2018-00107,1.634,1.19,0.548,0.234,,,
,Glx,Glx,2018_karczewska-kupczewska_103,5,Drug - Intralipid/Heparin 4 hour infusion,10.1210/jc.2018-00107,1.822,1.081,0.388,0.128,,,
,Glx,Glx,2018_karczewska-kupczewska_103,6,Drug - Intralipid/Heparin 4 hour infusion,10.1210/jc.2018-00107,2.824,1.633,0.536,0.274,,,
,Glx,Glx,2018_karczewska-kupczewska_103,7,Control - Saline Baseline,10.1210/jc.2018-00107,2.781,0.966,0.658,0.231,,,
,Glx,Glx,2018_karczewska-kupczewska_103,8,Control - Saline Baseline,10.1210/jc.2018-00107,2.49,0.753,0.616,0.457,,,
,Glx,Glx,2018_karczewska-kupczewska_103,9,Control - Saline Baseline,10.1210/jc.2018-00107,3.03,1.676,0.538,0.231,,,
,Glx,Glx,2018_karczewska-kupczewska_103,10,Control - Saline 4 hour infusion,10.1210/jc.2018-00107,2.49,1.111,0.797,0.414,,,
,Glx,Glx,2018_karczewska-kupczewska_103,11,Control - Saline 4 hour infusion,10.1210/jc.2018-00107,3.188,0.844,0.749,0.361,,,
,Glx,Glx,2018_karczewska-kupczewska_103,12,Control - Saline 4 hour infusion,10.1210/jc.2018-00107,2.557,0.959,0.48,0.17,,,
,Glx,Glx,2018_menshchikov_67,2,Healthy,10.1007/s11172-018-2119-2,0.361,0.011,,,,,
,Gua,Gua,2021_akiyama_61,1,Control,10.2176/nmc.oa.2020-0274,,,1.16,1.25,,,
,Gua,Gua,2021_akiyama_61,2,NPH,10.2176/nmc.oa.2020-0274,,,0.79,0.81,,,
,GSH,GSH,2019_barbagallo_62,1,Control,10.1016/j.parkreldis.2018.12.008,0.48,0.02,2.4,0.15,,,
,GSH,GSH,2019_barbagallo_62,2,Progressive Supranuclear Palsy,10.1016/j.parkreldis.2018.12.008,0.47,0.05,1.9,0.225,,,
,GSH,GSH,2019_cheong_90,1,Control - Visit 1,10.1136/jnnp-2018-318795,,,,,0.891,0.195,
,GSH,GSH,2019_cheong_90,2,Control - Visit 2,10.1136/jnnp-2018-318795,,,,,0.974,0.14,
,GSH,GSH,2019_cheong_90,3,Control - Visit 3,10.1136/jnnp-2018-318795,,,,,0.891,0.167,
,GSH,GSH,2019_cheong_90,7,ALS - Visit 1,10.1136/jnnp-2018-318795,,,,,0.934,0.192,
,GSH,GSH,2019_cheong_90,8,ALS - Visit 2,10.1136/jnnp-2018-318795,,,,,0.879,0.219,
,GSH,GSH,2019_cheong_90,9,ALS - Visit 3,10.1136/jnnp-2018-318795,,,,,0.879,0.219,
,GSH,GSH,2018_adanyeguh_31,2,Healthy,10.1002/nbm.3880,,,,,1.1,0.1,Estimated Bar Graph
,GSH,GSH,2018_adanyeguh_31,4,HD,10.1002/nbm.3880,,,,,1,0.2,Estimated Bar Graph
,GSH,GSH,2018_adanyeguh_31,1,Healthy,10.1002/nbm.3880,,,,,1.5,0.2,Estimated Bar Graph
,GSH,GSH,2018_adanyeguh_31,3,HD,10.1002/nbm.3880,,,,,1.4,0.2,Estimated Bar Graph
,GSH,GSH,2018_al-iedani_108,1,Healthy,10.1016/j.ejrad.2018.09.020,0.19,0.01,,,,,
,GSH,GSH,2018_al-iedani_108,2,Healthy,10.1016/j.ejrad.2018.09.020,0.21,0,,,,,
,GSH,GSH,2018_an_80,1,Healthy,10.1002/mrm.27172,0.27,0.03,,,,,
,GSH,GSH,2018_bednarik_38,1,Healthy,10.1177/0271678X17695291,,,,,1.13,0.07,
,GSH,GSH,2020_kumar_25,1,Healthy,10.1038/s41380-018-0104-7,,,,,1.75,0.31,
,GSH,GSH,2020_kumar_25,2,Healthy,10.1038/s41380-018-0104-7,,,,,1.5,0.17,
,GSH,GSH,2020_kumar_25,3,Healthy,10.1038/s41380-018-0104-7,,,,,1.72,0.2,
,GSH,GSH,2020_kumar_25,4,Schizophrenia,10.1038/s41380-018-0104-7,,,,,1.55,0.26,
,GSH,GSH,2020_kumar_25,5,Schizophrenia,10.1038/s41380-018-0104-7,,,,,1.47,0.2,
,GSH,GSH,2020_kumar_25,6,Schizophrenia,10.1038/s41380-018-0104-7,,,,,1.68,0.26,
,GSH,GSH,2020_kumar_25,7,Residual SZ,10.1038/s41380-018-0104-7,,,,,1.49,0.23,
,GSH,GSH,2020_kumar_25,8,Residual SZ,10.1038/s41380-018-0104-7,,,,,1.46,0.24,
,GSH,GSH,2020_kumar_25,9,Residual SZ,10.1038/s41380-018-0104-7,,,,,1.7,0.24,
,GSH,GSH,2018_evans_43,1,Control - Baseline,10.1038/s41386-018-0057-1,0.24,0.02,,,,,
,GSH,GSH,2018_evans_43,2,Control - Ketamine,10.1038/s41386-018-0057-1,0.24,0.03,,,,,
,GSH,GSH,2018_evans_43,3,Control - Placebo,10.1038/s41386-018-0057-1,0.25,0.03,,,,,
,GSH,GSH,2018_evans_43,4,Major Depressive Disorder - Baseline,10.1038/s41386-018-0057-1,0.25,0.02,,,,,
,GSH,GSH,2018_evans_43,5,Major Depressive Disorder - Ketamine,10.1038/s41386-018-0057-1,0.26,0.02,,,,,
,GSH,GSH,2018_evans_43,6,Major Depressive Disorder - Placebo,10.1038/s41386-018-0057-1,0.25,0.02,,,,,
,GSH,GSH,2018_hermens_268,1,Unipolar Depression,10.1007/s00406-017-0788-8,,,,,2.23,0.63,
,GSH,GSH,2018_hermens_268,2,Unipolar Depression,10.1007/s00406-017-0788-8,,,,,2.07,0.6,
,GSH,GSH,2018_hermens_268,3,Bipolar Disorder,10.1007/s00406-017-0788-8,,,,,2.24,0.67,
,GSH,GSH,2018_hermens_268,4,Bipolar Disorder,10.1007/s00406-017-0788-8,,,,,2.13,0.54,
,GSH,GSH,2018_hermens_268,5,Control,10.1007/s00406-017-0788-8,,,,,2.04,0.56,
,GSH,GSH,2018_hermens_268,6,Control,10.1007/s00406-017-0788-8,,,,,1.97,0.48,
,GSH,GSH,2020_bhogal_10,1,Healthy,10.1002/brb3.1852,0.17,0.04,,,,,
,GSH,GSH,2020_bhogal_10,2,Healthy,10.1002/brb3.1852,0.16,0.03,,,,,
,GSH,GSH,2020_bhogal_10,3,Healthy,10.1002/brb3.1852,0.21,0.07,,,,,
,GSH,GSH,2020_bhogal_10,4,Healthy,10.1002/brb3.1852,0.18,0.05,,,,,
,GSH,GSH,2020_bhogal_10,5,Healthy,10.1002/brb3.1852,0.15,0.04,,,,,
,GSH,GSH,2020_bhogal_10,6,Healthy,10.1002/brb3.1852,0.15,0.03,,,,,
,GSH,GSH,2020_bhogal_10,7,Healthy,10.1002/brb3.1852,0.15,0.02,,,,,
,GSH,GSH,2020_bhogal_10,8,Healthy,10.1002/brb3.1852,0.12,0.02,,,,,
,GSH,GSH,2020_bhogal_10,9,Healthy,10.1002/brb3.1852,0.14,0.03,,,,,
,GSH,GSH,2020_bhogal_10,10,Healthy,10.1002/brb3.1852,0.15,0.06,,,,,
,GSH,GSH,2020_boillat_40,1,Baseline,10.1177/0271678X19831022,,,0.48,0.04,,,
,GSH,GSH,2020_boillat_40,2,positive BOLD,10.1177/0271678X19831022,,,0.01,0.07,,,
,GSH,GSH,2020_boillat_40,3,Baseline,10.1177/0271678X19831022,,,0.49,0.03,,,
,GSH,GSH,2020_boillat_40,4,negative BOLD,10.1177/0271678X19831022,,,0.02,0.05,,,
,GSH,GSH,2018_morley_9,1,Alcohol Dependence - Placebo,10.3389/fpsyt.2018.00412,0.43,0.03,,,,,
,GSH,GSH,2018_morley_9,2,Alcohol Dependence - Baclofen,10.3389/fpsyt.2018.00412,0.45,0.03,,,,,
,GSH,GSH,2018_morley_9,3,"Alcohol Dependence - Recent alcohol consumption, placebo",10.3389/fpsyt.2018.00412,0.42,0.02,,,,,
,GSH,GSH,2018_morley_9,4,"Alcohol Dependence - Recent alcohol consumption, Baclofen",10.3389/fpsyt.2018.00412,0.47,0.01,,,,,
,GSH,GSH,2018_ryan_13,1,Healthy - Sham,10.1371/journal.pone.0198053,1.28,0.05,,,2.4,0.18,
,GSH,GSH,2018_ryan_13,2,Healthy - Transcranial direct current stimulation,10.1371/journal.pone.0198053,1.4,0.06,,,2.4,0.13,
,GSH,GSH,2018_saleh_80,1,Healthy,10.1002/mrm.27044,,,0.3,0.091,,,
,GSH,GSH,2018_saleh_80,2,Healthy,10.1002/mrm.27044,,,0.302,0.093,,,
,GSH,GSH,2021_bednarik_15,1,Healthy,10.3389/fnins.2021.609485,,,,,1.7,0.1,
,GSH,GSH,2021_bednarik_15,2,Healthy,10.3389/fnins.2021.609485,,,,,1.7,0.1,
,GSH,GSH,2020_poletti_11,1,Bipolar Disorder,10.3389/fpsyt.2020.590095,,,1.7,0.26,,,
,GSH,GSH,2020_poletti_11,2,Healthy Controls,10.3389/fpsyt.2020.590095,,,1.54,0.16,,,
,GSH,GSH,2019_betinaip_39,1,Behavior - ON - 3% Visual Contrast,10.1523/JNEUROSCI.3021-18.2019,,,1.086,0.314,,,
,GSH,GSH,2019_betinaip_39,2,Behavior - ON - 12.5% Visual Contrast,10.1523/JNEUROSCI.3021-18.2019,,,1.075,0.269,,,
,GSH,GSH,2019_betinaip_39,3,Behavior - ON - 50% Visual Contrast,10.1523/JNEUROSCI.3021-18.2019,,,1.089,0.312,,,
,GSH,GSH,2019_betinaip_39,4,Behavior - ON - 100% Visual Contrast,10.1523/JNEUROSCI.3021-18.2019,,,1.105,0.299,,,
,GSH,GSH,2019_betinaip_39,5,Resting,10.1523/JNEUROSCI.3021-18.2019,,,1.124,0.296,,,
,GSH,GSH,2019_betinaip_39,6,Behavior - OFF - 3% Visual Contrast,10.1523/JNEUROSCI.3021-18.2019,,,1.075,0.289,,,
,GSH,GSH,2019_betinaip_39,7,Behavior - OFF - 12.5% Visual Contrast,10.1523/JNEUROSCI.3021-18.2019,,,1.046,0.271,,,
,GSH,GSH,2019_betinaip_39,8,Behavior - OFF - 50% Visual Contrast,10.1523/JNEUROSCI.3021-18.2019,,,1.062,0.327,,,
,GSH,GSH,2019_betinaip_39,9,Behavior - OFF - 100% Visual Contrast,10.1523/JNEUROSCI.3021-18.2019,,,1.12,0.327,,,
,GSH,GSH,2019_betinaip_39,10,Resting,10.1523/JNEUROSCI.3021-18.2019,,,1.138,0.303,,,
,GSH,GSH,2019_giapitzakis_81,1,Healthy,10.1002/mrm.27467,,,,,1.9,0.1,
,GSH,GSH,2019_giapitzakis_81,2,Healthy,10.1002/mrm.27467,,,,,1.5,0.2,
,GSH,GSH,2019_girgis_275,1,Control - Baseline - dAC,10.1016/j.psychres.2019.03.018,,,0.002,0,,,
,GSH,GSH,2019_girgis_275,3,Schizophrenia - Baseline - dAC,10.1016/j.psychres.2019.03.018,,,0.002,0.001,,,
,GSH,GSH,2019_girgis_275,5,Control - Treatment - dAC,10.1016/j.psychres.2019.03.018,,,0.002,0.214,,,
,GSH,GSH,2019_girgis_275,7,Schizophrenial - Treatment - dAC,10.1016/j.psychres.2019.03.018,,,0.002,0.232,,,
,GSH,GSH,2018_zarinabad_79,1,Medulloblastoma,10.1002/mrm.26837,,,,,1.8,0.8,
,GSH,GSH,2018_zarinabad_79,2,Pilocytic Astrocytoma,10.1002/mrm.26837,,,,,0.66,0.6,
,GSH,GSH,2018_zarinabad_79,3,Ependymoma,10.1002/mrm.26837,,,,,1.12,0.32,
,GSH,GSH,2017_simoes_216,1,Control,10.1016/j.ajog.2016.09.089,0.33,0.09,,,,,
,GSH,GSH,2017_simoes_216,2,Preterm,10.1016/j.ajog.2016.09.089,0.3,0.07,,,,,
,GSH,GSH,2017_simoes_216,3,Preterm - Intra-uterine growth restricted,10.1016/j.ajog.2016.09.089,0.25,0.04,,,,,
,GSH,GSH,2021_godlewska_11,1,Psychosis,10.1038/s41398-021-01477-6,,,1.38,0.3367,,,
,GSH,GSH,2021_godlewska_11,2,Psychosis,10.1038/s41398-021-01477-6,,,1.3,0.2816,,,
,GSH,GSH,2021_godlewska_11,3,Psychosis,10.1038/s41398-021-01477-6,,,1.25,0.337,,,
,GSH,GSH,2021_godlewska_11,4,Control,10.1038/s41398-021-01477-6,,,1.29,0.255,,,
,GSH,GSH,2021_godlewska_11,5,Control,10.1038/s41398-021-01477-6,,,1.3,0.255,,,
,GSH,GSH,2021_godlewska_11,6,Control,10.1038/s41398-021-01477-6,,,1.43,2.88,,,
,GSH,GSH,2015_simoes_213,1,Control,10.1016/j.ajog.2015.04.011,,,,,1.4,0.3,
,GSH,GSH,2015_simoes_213,3,Small-born infants - Small for gestational age,10.1016/j.ajog.2015.04.011,,,,,1.4,0.6,
,GSH,GSH,2015_simoes_213,4,Small-born infants - Late intrauterine growth restriction,10.1016/j.ajog.2015.04.011,,,,,1.2,0.2,
,GSH,GSH,2020_su_71,1,Healthy Controls,10.1016/j.jocn.2019.11.021,,,,,0.55,0.09,
,GSH,GSH,2020_su_71,2,Methamphetamine Dependence,10.1016/j.jocn.2019.11.021,,,,,0.85,0.46,
,GSH,GSH,2019_marjanska_68,1,Alzheimer's disease,10.3233/JAD-180861,,,,,1.21,0.12,
,GSH,GSH,2019_marjanska_68,2,Alzheimer's disease,10.3233/JAD-180861,,,,,1.12,0.12,
,GSH,GSH,2019_marjanska_68,3,Control,10.3233/JAD-180861,,,,,1.14,0.115,
,GSH,GSH,2019_marjanska_68,4,Control,10.3233/JAD-180861,,,,,1.05,0.115,
,GSH,GSH,2019_monnig_54,1,Healthy - Baseline,10.1093/alcalc/agz062,0.349,0.048,,,,,
,GSH,GSH,2019_monnig_54,2,Healthy - Descending limb,10.1093/alcalc/agz062,0.397,0.088,,,,,
,GSH,GSH,2019_monnig_54,3,Healthy - Baseline,10.1093/alcalc/agz062,0.328,0.047,,,,,
,GSH,GSH,2019_monnig_54,4,Healthy - Descending limb,10.1093/alcalc/agz062,0.394,0.081,,,,,
,GSH,GSH,2020_mastaloudis_153,1,Control ,10.1016/j.freeradbiomed.2020.04.017,0.195,0.01,0.0037,0.0002,,,
,GSH,GSH,2020_mastaloudis_153,2,Control ,10.1016/j.freeradbiomed.2020.04.017,0.19,0.01,0.0039,0.0002,,,
,GSH,GSH,2020_mastaloudis_153,3,Experimental ,10.1016/j.freeradbiomed.2020.04.017,0.19,0.01,0.0038,0.0001,,,
,GSH,GSH,2020_mastaloudis_153,4,Experimental ,10.1016/j.freeradbiomed.2020.04.017,0.21,0.005,0.0041,0.0003,,,
,GSH,GSH,2019_wagoner_317,1,Non-OI,10.1152/ajpheart.00680.2018,,,4.2,5.556,,,
,GSH,GSH,2019_wagoner_317,2,OI,10.1152/ajpheart.00680.2018,,,2,0.663,,,
,GSH,GSH,2019_wang_76,1,FEP,10.1001/jamapsychiatry.2018.3637,,,1.6,0.22,,,
,GSH,GSH,2019_wang_76,2,FEP,10.1001/jamapsychiatry.2018.3637,,,1.2,0.4,,,
,GSH,GSH,2019_wang_76,3,FEP,10.1001/jamapsychiatry.2018.3637,,,1.18,0.22,,,
,GSH,GSH,2019_wang_76,4,FEP,10.1001/jamapsychiatry.2018.3637,,,1.2,0.25,,,
,GSH,GSH,2019_wang_76,5,FEP,10.1001/jamapsychiatry.2018.3637,,,1.32,0.25,,,
,GSH,GSH,2019_wang_76,6,Control,10.1001/jamapsychiatry.2018.3637,,,1.65,0.22,,,
,GSH,GSH,2019_wang_76,7,Control,10.1001/jamapsychiatry.2018.3637,,,1.2,0.2,,,
,GSH,GSH,2019_wang_76,8,Control,10.1001/jamapsychiatry.2018.3637,,,1.18,0.2,,,
,GSH,GSH,2019_wang_76,9,Control,10.1001/jamapsychiatry.2018.3637,,,1.21,0.23,,,
,GSH,GSH,2019_wang_76,10,Control,10.1001/jamapsychiatry.2018.3637,,,1.42,0.23,,,
,GSH,GSH,2018_povazan_79,1,Healthy,10.1002/mrm.26778,,,2.38,0.27,,,
,GSH,GSH,2018_povazan_79,2,Healthy,10.1002/mrm.26778,,,1.71,0.27,,,
,GSH,GSH,2018_povazan_79,3,Healthy,10.1002/mrm.26778,,,1.6,0.28,,,
,GSH,GSH,2018_povazan_79,4,Healthy,10.1002/mrm.26778,,,1.33,0.27,,,
,GSH,GSH,2018_povazan_79,5,Healthy,10.1002/mrm.26778,,,1.65,0.23,,,
,GSH,GSH,2018_povazan_79,6,Healthy,10.1002/mrm.26778,,,2.27,0.72,,,
,GSH,GSH,2018_povazan_79,7,Healthy,10.1002/mrm.26778,,,2.27,0.28,,,
,GSH,GSH,2019_wijtenburg_49,1,Healthy,10.1002/jmri.26046,,,2.32,0.14,,,
,GSH,GSH,2019_wijtenburg_49,2,Healthy,10.1002/jmri.26046,,,2.26,0.18,,,
,GSH,GSH,2019_wijtenburg_49,3,Healthy,10.1002/jmri.26046,,,2.37,0.13,,,
,GSH,GSH,2019_wijtenburg_49,4,Healthy,10.1002/jmri.26046,,,2.23,0.41,,,
,GSH,GSH,2019_wijtenburg_49,5,Healthy,10.1002/jmri.26046,,,1.69,0.18,,,
,GSH,GSH,2019_wijtenburg_49,6,Healthy,10.1002/jmri.26046,,,1.7,0.09,,,
,GSH,GSH,2019_wijtenburg_49,7,Healthy,10.1002/jmri.26046,,,1.99,0.32,,,
,GSH,GSH,2019_wijtenburg_49,8,Healthy,10.1002/jmri.26046,,,1.76,0.41,,,
,GSH,GSH,2019_wiegers_62,1,Control,10.1007/s00125-019-4862-9,,,,,0.94,0.12,
,GSH,GSH,2019_wiegers_62,2,Type 1 diabetes - Normal awareness of hypoglycaemia,10.1007/s00125-019-4862-9,,,,,1.02,0.13,
,GSH,GSH,2019_wiegers_62,3,Type 1 diabetes,10.1007/s00125-019-4862-9,,,,,1.22,0.57,
,GSH,GSH,2020_gonen_14,1,Healthy,10.3389/fnins.2020.566643,0.21,0.02,,,1.86,0.27,
,GSH,GSH,2020_gonen_14,2,Healthy,10.3389/fnins.2020.566643,0.22,0.03,,,1.83,0.25,
,GSH,GSH,2020_gonen_14,3,Healthy,10.3389/fnins.2020.566643,0.2,0.03,,,1.8,0.21,
,GSH,GSH,2020_gonen_14,4,Healthy,10.3389/fnins.2020.566643,0.2,0.02,,,1.84,0.37,
,GSH,GSH,2020_gonen_14,5,Healthy,10.3389/fnins.2020.566643,0.21,0.02,,,1.83,0.27,
,GSH,GSH,2019_reid_45,1,Control,10.1093/schbul/sbx190,,,0.75,0.1,,,
,GSH,GSH,2019_reid_45,2,Schizophrenia,10.1093/schbul/sbx190,,,0.7,0.11,,,
,GSH,GSH,2020_coughlin_26,3,Control,10.1038/s41380-020-00901-5,0.068,0.01,,,,,
,GSH,GSH,2020_coughlin_26,6,Schizophrenia,10.1038/s41380-020-00901-5,0.062,0.01,,,,,
,GSH,GSH,2020_draganov_266,1,Control,10.1016/j.jad.2020.01.138,,,,,1.09,0.4,
,GSH,GSH,2020_draganov_266,2,Depression,10.1016/j.jad.2020.01.138,,,,,1.12,0.4,
,GSH,GSH,2020_draganov_266,3,Depression,10.1016/j.jad.2020.01.138,,,,,1.08,0.4,
,GSH,GSH,2020_draganov_266,4,Depression,10.1016/j.jad.2020.01.138,,,,,1.25,0.39,
,GSH,GSH,2020_prisci_65,1,Healthy,10.1016/j.mri.2019.10.004,,,1.9,0.52,,,
,GSH,GSH,2020_prisci_65,2,Healthy,10.1016/j.mri.2019.10.004,,,2.02,0.47,,,
,GSH,GSH,2020_prisci_65,3,Healthy,10.1016/j.mri.2019.10.004,,,3.91,0.48,,,
,GSH,GSH,2020_prisci_65,4,Healthy,10.1016/j.mri.2019.10.004,,,3.83,0.39,,,
,GSH,GSH,2021_coughlin_26,1,Schizophrenia,10.1038/s41380-020-00901-5,0.062,0.01,,,,,"Author List nmol/ml, but methods show referenced to Cre"
,GSH,GSH,2021_coughlin_26,3,Healthy controls,10.1038/s41380-020-00901-5,0.068,0.01,,,,,"Author List nmol/ml, but methods show referenced to Cre"
,GSH,GSH,2020_su_8,5,Methamphetamine use disorder,10.21037/atm.2020.02.95,0.3,0.07,,,,,
,GSH,GSH,2020_su_8,6,Methamphetamine use disorder,10.21037/atm.2020.02.95,0.27,0.08,,,,,
,GSH,GSH,2020_su_8,7,Methamphetamine use disorder,10.21037/atm.2020.02.95,0.27,0.05,,,,,
,GSH,GSH,2020_su_8,8,Methamphetamine use disorder,10.21037/atm.2020.02.95,0.26,0.07,,,,,
,GSH,GSH,2018_giapitzakis_79,1,Healthy,10.1002/mrm.26873,,,,,2.39,0.386,Med/Quartile --> Mean/Std Wan 2014
,GSH,GSH,2018_giapitzakis_79,2,Healthy,10.1002/mrm.26873,,,,,2.52,0.504,Med/Quartile --> Mean/Std Greco 2015
,GSH,GSH,2018_raschke_39,1,Healthy,10.3174/ajnr.A5457,0.118,0.007,2.089,0.15,,,Med/Quartile --> Mean/Std Greco 2015; Greco 2015
,GSH,GSH,2018_raschke_39,2,Healthy,10.3174/ajnr.A5457,0.118,0.014,2.768,0.328,,,Med/Quartile --> Mean/Std Greco 2015; Wan 2014
,GSH,GSH,2016_lopezkolkovsky_75,1,Healthy_Rodent,10.1002/mrm.25602,,,,,1,0.1,
,GSH,GSH,2018_deelchand_79,1,Healthy,10.1002/mrm.26788,,,,,1.88,0.643,
,GSH,GSH,2018_deelchand_79,2,Healthy,10.1002/mrm.26788,,,,,1.261,0.322,
,Lact,Lac,2017_sijens_42,4,control (normal development),10.1016/j.mri.2017.06.001,0.06,0.02,,,,,
,Lact,Lac,2017_sijens_42,8,mild disability,10.1016/j.mri.2017.06.001,0.06,0.03,,,,,
,Lact,Lac,2017_sijens_42,12,deceased,10.1016/j.mri.2017.06.001,0.07,0.03,,,,,
,Lact,Lac,2017_sijens_42,16,control (normal development),10.1016/j.mri.2017.06.001,0.07,0.02,,,,,
,Lact,Lac,2017_sijens_42,20,mild disability,10.1016/j.mri.2017.06.001,0.07,0.03,,,,,
,Lact,Lac,2017_sijens_42,24,deceased,10.1016/j.mri.2017.06.001,0.06,0.03,,,,,
,Lac,Lac,2019_basu_9,3,Premature Infant,10.1038/s41598-018-37203-4,,,1.93,0.657,,,
,Lac,Lac,2019_basu_9,7,Premature Infant,10.1038/s41598-018-37203-4,,,1.442,0.348,,,
,Lac,Lac,2018_bednarik_38,1,Healthy,10.1177/0271678X17695291,,,,,0.93,0.21,
,Lac,Lac,2018_cichocka_83,1,Healthy,10.5114/pjr.2018.74536,0.24,0.108,,,,,
,Lac,Lac,2018_cichocka_83,2,Healthy,10.5114/pjr.2018.74536,0.25,0.091,,,,,
,Lac,Lac,2018_cichocka_83,3,Healthy,10.5114/pjr.2018.74536,0.23,0.12,,,,,
,Lac,Lac,2018_cichocka_83,4,Healthy,10.5114/pjr.2018.74536,0.19,0.096,,,,,
,Lac,Lac,2018_cichocka_83,5,Healthy,10.5114/pjr.2018.74536,0.2,0.081,,,,,
,Lac,Lac,2018_cichocka_83,6,Healthy,10.5114/pjr.2018.74536,0.23,0.118,,,,,
,Lac,Lac,2018_cichocka_83,7,Healthy,10.5114/pjr.2018.74536,0.17,0.071,,,,,
,Lac,Lac,2018_cichocka_83,8,Healthy,10.5114/pjr.2018.74536,0.24,0.108,,,,,
,Lac,Lac,2018_cichocka_83,9,Healthy,10.5114/pjr.2018.74536,0.28,93,,,,,
,Lac,Lac,2018_cichocka_83,10,Healthy,10.5114/pjr.2018.74536,0.2,0.092,,,,,
,Lac,Lac,2018_cichocka_83,11,Healthy,10.5114/pjr.2018.74536,0.25,0.099,,,,,
,Lac,Lac,2018_cichocka_83,12,Healthy,10.5114/pjr.2018.74536,0.23,0.093,,,,,
,Lac,Lac,2018_cichocka_83,13,Healthy,10.5114/pjr.2018.74536,0.29,0.37,,,,,
,Lac,Lac,2018_cichocka_83,14,Healthy,10.5114/pjr.2018.74536,0.2,0.101,,,,,
,Lac,Lac,2020_boillat_40,1,Baseline,10.1177/0271678X19831022,,,0.7,0.06,,,
,Lac,Lac,2020_boillat_40,2,positive BOLD,10.1177/0271678X19831022,,,0.11,0.15,,,
,Lac,Lac,2020_boillat_40,3,Baseline,10.1177/0271678X19831022,,,0.67,0.05,,,
,Lac,Lac,2020_boillat_40,4,negative BOLD,10.1177/0271678X19831022,,,0.07,0.09,,,
,Lac,Lac,2018_moon_227,1,Obsessive-compulsive Disorder,10.1016/j.jad.2017.11.059,0.19,0.05,,,,,
,Lac,Lac,2018_moon_227,2,Control,10.1016/j.jad.2017.11.059,0.18,0.06,,,,,
,Lac,Lac,2021_akiyama_61,1,Control,10.2176/nmc.oa.2020-0274,,,0.7,0.69,,,
,Lac,Lac,2021_akiyama_61,2,NPH,10.2176/nmc.oa.2020-0274,,,0.58,1.05,,,
,Lac,Lac,2018_van_89,1,Control,10.1136/jnnp-2017-316364,,,,,0.33,0.08,
,Lac,Lac,2018_van_89,2,Metachromatic leukodystrophy - Good outcome,10.1136/jnnp-2017-316364,,,,,0.59,0.14,
,Lac,Lac,2018_van_89,3,Metachromatic leukodystrophy - Moderate outcome,10.1136/jnnp-2017-316364,,,,,0.8,0.4,
,Lac,Lac,2018_van_89,4,Metachromatic leukodystrophy - Poor outcome,10.1136/jnnp-2017-316364,,,,,1.57,0.66,
,Lac,Lac,2019_giapitzakis_81,1,Healthy,10.1002/mrm.27467,,,,,0.7,0.6,
,Lac,Lac,2019_giapitzakis_81,2,Healthy,10.1002/mrm.27467,,,,,0.4,0.3,
,Lac,Lac,2019_koush_184,1,Healthy (No Behavior),10.1016/j.neuroimage.2018.09.008,,,,,0.82,0.04,
,Lac,Lac,2019_koush_184,2,Healthy (Behavior),10.1016/j.neuroimage.2018.09.008,,,,,0.89,0.04,
,Lac,Lac,2018_younis_19,1,Healthy - Sildenafil_Baseline,10.1186/s10194-018-0870-2,,,,,0.9,0.21,
,Lac,Lac,2018_younis_19,2,Healthy - Sildenafil_40min,10.1186/s10194-018-0870-2,,,,,0.45,0.41,
,Lac,Lac,2018_younis_19,3,Healthy - Sildenafil_140min,10.1186/s10194-018-0870-2,,,,,0.43,0.33,
,Lac,Lac,2018_younis_19,4,Healthy - Calcitonin gene-related peptide_Baseline,10.1186/s10194-018-0870-2,,,,,0.71,0.51,
,Lac,Lac,2018_younis_19,5,Healthy - Calcitonin gene-related peptide_40min,10.1186/s10194-018-0870-2,,,,,0.49,0.44,
,Lac,Lac,2018_younis_19,6,Healthy - Calcitonin gene-related peptide_140min,10.1186/s10194-018-0870-2,,,,,0.42,0.41,
,Lac,Lac,2018_younis_19,7,Healthy - Placebo_Baseline,10.1186/s10194-018-0870-2,,,,,0.75,0.65,
,Lac,Lac,2018_younis_19,8,Healthy - Placebo_40min,10.1186/s10194-018-0870-2,,,,,0.89,0.68,
,Lac,Lac,2018_younis_19,9,Healthy - Placebo_140min,10.1186/s10194-018-0870-2,,,,,0.62,0.42,
,Lac,Lac,2018_zarinabad_79,1,Medulloblastoma,10.1002/mrm.26837,,,,,1.65,1.7,
,Lac,Lac,2018_zarinabad_79,2,Pilocytic Astrocytoma,10.1002/mrm.26837,,,,,0.65,0.74,
,Lac,Lac,2018_zarinabad_79,3,Ependymoma,10.1002/mrm.26837,,,,,1.39,0.68,
,Lac,Lac,2016_koob_11,1,Premature Neonates,10.1371/journal.pone.0160990,,,0.012,0.012,,,
,Lac,Lac,2016_koob_11,2,Premature Neonates,10.1371/journal.pone.0160990,,,0.007,0.006,,,
,Lac,Lac,2016_koob_11,3,Infants - Control,10.1371/journal.pone.0160990,,,0.013,0.014,,,
,Lac,Lac,2016_koob_11,4,Infants - Control,10.1371/journal.pone.0160990,,,0.008,0.008,,,
,Lac,Lac,2021_wang_59,1,Control,10.1016/j.mito.2021.06.012,0.2,0.18,,,1.35,1.32,
,Lac,Lac,2021_wang_59,2,Control,10.1016/j.mito.2021.06.013,0.2,0.18,,,1.35,1.32,
,Lac,Lac,2021_wang_59,3,MELAS,10.1016/j.mito.2021.06.014,2,0.99,,,13.45,6.68,
,Lac,Lac,2021_younis_41,1,Baseline,10.1177/0271678X20906902,,,,,0.93,0.08,
,Lac,Lac,2021_younis_41,2,Migraine attack ,10.1177/0271678X20906902,,,,,0.78,0.09,
,Lac,Lac,2020_mazibuko_10,1,Control,10.3390/diagnostics10070482,,,0.47,0.7,,,
,Lac,Lac,2020_mazibuko_10,2,Control,10.3390/diagnostics10070482,,,0.3,0.4,,,
,Lac,Lac,2020_mazibuko_10,3,Subacute Ischemic Stroke,10.3390/diagnostics10070482,,,0.9,1.11,,,
,Lac,Lac,2020_mazibuko_10,4,Subacute Ischemic Stroke,10.3390/diagnostics10070482,,,0.66,1.13,,,
,Lac,Lac,2020_mazibuko_10,5,Subacute Ischemic Stroke ,10.3390/diagnostics10070482,,,1.77,1.61,,,
,Lac,Lac,2020_mazibuko_10,6,Subacute Ischemic Stroke ,10.3390/diagnostics10070482,,,0.7,1.16,,,
,Lac,Lac,2020_mazibuko_10,7,Subacute Ischemic Stroke ,10.3390/diagnostics10070482,,,2.03,1.49,,,
,Lac,Lac,2020_mazibuko_10,8,Subacute Ischemic Stroke ,10.3390/diagnostics10070482,,,0.72,0.76,,,
,Lac,Lac,2019_tamrazi_40,1,Pediatric atypical teratoid/rhabdoid tumors - ASCL1 Pos.,10.3174/ajnr.A6024,,,5,3.9,,,
,Lac,Lac,2019_tamrazi_40,2,Pediatric atypical teratoid/rhabdoid tumors - ASCL1 Neg.,10.3174/ajnr.A6024,,,2.6,2.6,,,
,Lac,Lac,2020_lind_40,1,Aging,10.1523/JNEUROSCI.2883-19.2020,,,,,0.66,0.23,
,Lac,Lac,2020_lind_40,2,Aging,10.1523/JNEUROSCI.2883-19.2020,,,,,1.1,1.08,
,Lac,Lac,2020_lind_40,3,Aging,10.1523/JNEUROSCI.2883-19.2020,,,,,1.63,1.17,
,Lac,Lac,2020_dehghani_83,1,Protocol 1,10.1002/mrm.28066,,,,,0.54,0.08,
,Lac,Lac,2020_dehghani_83,2,Protocol 2,10.1002/mrm.28066,,,,,0.17,0.05,
,Lac,Lac,2020_dehghani_83,3,Protocol 3,10.1002/mrm.28066,,,,,0.38,0.05,
,Lac,Lac,2018_giapitzakis_79,1,Healthy,10.1002/mrm.26873,,,,,0.42,0.469,Med/Quartile --> Mean/Std Wan 2014
,Lac,Lac,2018_giapitzakis_79,2,Healthy,10.1002/mrm.26873,,,,,0.27,1.483,Med/Quartile --> Mean/Std Greco 2015
,Lac,Lac,2016_lopezkolkovsky_75,1,Healthy_Rodent,10.1002/mrm.25602,,,,,1.6,0.3,
,Lac,Lac,2018_deelchand_79,1,Healthy,10.1002/mrm.26788,,,,,1.484,1.212,
,Lac,Lac,2018_deelchand_79,2,Healthy,10.1002/mrm.26788,,,,,1.138,0.668,
,mI,Myo,2017_hanquinet_27,1,control,10.1007/s00330-017-4808-x,0.3,0.1,,,,,
,mI,Myo,2017_hanquinet_27,2,isointense,10.1007/s00330-017-4808-x,0.2,0.1,,,,,
,mI,Myo,2017_hanquinet_27,3,hyperintense,10.1007/s00330-017-4808-x,0.2,0.1,,,,,
,mI,Myo,2017_hanquinet_27,4,much more hyperintense,10.1007/s00330-017-4808-x,0.2,0.1,,,,,
,Myo,Myo,2019_barbagallo_62,1,Control,10.1016/j.parkreldis.2018.12.008,1.015,1.025,5.1,0.35,,,
,Myo,Myo,2019_barbagallo_62,2,Progressive Supranuclear Palsy,10.1016/j.parkreldis.2018.12.008,1.1,0.11,4.4,0.7,,,
,Myo,Myo,2019_boban_27,1,Control,10.3174/ajnr.A5160,0.424,0.129,,,,,
,Myo,Myo,2019_boban_27,2,Control,10.3174/ajnr.A5160,0.579,0.141,,,,,
,Myo,Myo,2019_boban_27,3,Control,10.3174/ajnr.A5160,0.538,0.125,,,,,
,Myo,Myo,2019_boban_27,4,Control,10.3174/ajnr.A5160,0.446,0.113,,,,,
,Myo,Myo,2019_boban_27,5,Control,10.3174/ajnr.A5160,0.383,0.127,,,,,
,Myo,Myo,2019_boban_27,6,Control,10.3174/ajnr.A5160,0.537,0.147,,,,,
,Myo,Myo,2019_boban_27,7,Control,10.3174/ajnr.A5160,0.402,0.115,,,,,
,Myo,Myo,2019_boban_27,8,Control,10.3174/ajnr.A5160,0.506,0.168,,,,,
,Myo,Myo,2019_boban_27,9,Control,10.3174/ajnr.A5160,0.627,0.17,,,,,
,Myo,Myo,2019_boban_27,10,Control,10.3174/ajnr.A5160,0.4,0.114,,,,,
,Myo,Myo,2019_boban_27,11,Control,10.3174/ajnr.A5160,0.605,0.167,,,,,
,Myo,Myo,2019_boban_27,12,Control,10.3174/ajnr.A5160,0.459,0.149,,,,,
,Myo,Myo,2019_boban_27,13,HIV,10.3174/ajnr.A5160,0.499,0.166,,,,,
,Myo,Myo,2019_boban_27,14,HIV,10.3174/ajnr.A5160,0.636,0.157,,,,,
,Myo,Myo,2019_boban_27,15,HIV,10.3174/ajnr.A5160,0.63,0.197,,,,,
,Myo,Myo,2019_boban_27,16,HIV,10.3174/ajnr.A5160,0.532,0.153,,,,,
,Myo,Myo,2019_boban_27,17,HIV,10.3174/ajnr.A5160,0.402,0.206,,,,,
,Myo,Myo,2019_boban_27,18,HIV,10.3174/ajnr.A5160,0.617,0.207,,,,,
,Myo,Myo,2019_boban_27,19,HIV,10.3174/ajnr.A5160,0.399,0.103,,,,,
,Myo,Myo,2019_boban_27,20,HIV,10.3174/ajnr.A5160,0.658,0.185,,,,,
,Myo,Myo,2019_boban_27,21,HIV,10.3174/ajnr.A5160,0.732,0.206,,,,,
,Myo,Myo,2019_boban_27,22,HIV,10.3174/ajnr.A5160,0.43,0.108,,,,,
,Myo,Myo,2019_boban_27,23,HIV,10.3174/ajnr.A5160,0.632,0.119,,,,,
,Myo,Myo,2019_boban_27,24,HIV,10.3174/ajnr.A5160,0.528,0.216,,,,,
,Myo,Myo,2019_boban_27,25,cART,10.3174/ajnr.A5160,0.489,0.159,,,,,
,Myo,Myo,2019_boban_27,26,cART,10.3174/ajnr.A5160,0.586,0.15,,,,,
,Myo,Myo,2019_boban_27,27,cART,10.3174/ajnr.A5160,0.685,0.214,,,,,
,Myo,Myo,2019_boban_27,28,cART,10.3174/ajnr.A5160,0.466,0.164,,,,,
,Myo,Myo,2019_boban_27,29,cART,10.3174/ajnr.A5160,0.391,0.139,,,,,
,Myo,Myo,2019_boban_27,30,cART,10.3174/ajnr.A5160,0.691,0.199,,,,,
,Myo,Myo,2019_boban_27,31,cART,10.3174/ajnr.A5160,0.382,0.125,,,,,
,Myo,Myo,2019_boban_27,32,cART,10.3174/ajnr.A5160,0.78,0.21,,,,,
,Myo,Myo,2019_boban_27,33,cART,10.3174/ajnr.A5160,0.726,0.178,,,,,
,Myo,Myo,2019_boban_27,34,cART,10.3174/ajnr.A5160,0.402,0.109,,,,,
,Myo,Myo,2019_boban_27,35,cART,10.3174/ajnr.A5160,0.602,0.121,,,,,
,Myo,Myo,2019_boban_27,36,cART,10.3174/ajnr.A5160,0.471,0.184,,,,,
,Myo,Myo,2019_boban_27,37,HIV - cART_Long,10.1038/s41598-019-56330-0,0.708,0.448,,,,,
,Myo,Myo,2019_boban_27,38,HIV - cART_Long,10.1038/s41598-019-56330-0,0.649,0.16,,,,,
,Myo,Myo,2019_boban_27,39,HIV - cART_Long,10.1038/s41598-019-56330-0,0.553,0.151,,,,,
,Myo,Myo,2019_boban_27,40,HIV - cART_Long,10.1038/s41598-019-56330-0,0.601,0.109,,,,,
,Myo,Myo,2019_boban_27,41,HIV - cART_Long,10.1038/s41598-019-56330-0,0.556,0.16,,,,,
,Myo,Myo,2019_boban_27,42,HIV - cART_Long,10.1038/s41598-019-56330-0,0.575,0.209,,,,,
,Myo,Myo,2019_boban_27,43,HIV - cART_Long,10.1038/s41598-019-56330-0,0.614,0.122,,,,,
,Myo,Myo,2019_boban_27,44,HIV - cART_Long,10.1038/s41598-019-56330-0,0.598,0.131,,,,,
,Myo,Myo,2019_boban_27,45,HIV - cART_Long,10.1038/s41598-019-56330-0,0.65,0.146,,,,,
,Myo,Myo,2019_boban_27,46,HIV - cART_Long,10.1038/s41598-019-56330-0,0.51,0.186,,,,,
,Myo,Myo,2019_boban_27,47,HIV - cART_Long,10.1038/s41598-019-56330-0,0.607,0.148,,,,,
,Myo,Myo,2019_boban_27,48,HIV - cART_Long,10.1038/s41598-019-56330-0,0.418,0.103,,,,,
,Myo,Myo,2019_borgelt_21,1,Bipolar - First,10.1111/bdi.12782,,,,,5.59,1.27,
,Myo,Myo,2019_borgelt_21,2,Bipolar - First,10.1111/bdi.12782,,,,,5.41,0.87,
,Myo,Myo,2019_borgelt_21,3,Bipolar - First,10.1111/bdi.12782,,,,,4.71,1.16,
,Myo,Myo,2019_borgelt_21,4,Bipolar - Multiple,10.1111/bdi.12782,,,,,5.37,1.11,
,Myo,Myo,2019_borgelt_21,5,Bipolar - Multiple,10.1111/bdi.12782,,,,,5.73,1.34,
,Myo,Myo,2019_borgelt_21,6,Bipolar - Multiple,10.1111/bdi.12782,,,,,4.88,0.81,
,Myo,Myo,2019_bossong_76,1,Control,10.1001/jamapsychiatry.2018.3252,,,,,6.19,1.51,
,Myo,Myo,2019_bossong_76,2,Psychosis - HighRisk,10.1001/jamapsychiatry.2018.3252,,,,,6.24,1.36,
,Myo,Myo,2019_bossong_76,3,Psychosis,10.1001/jamapsychiatry.2018.3252,,,,,7.6,1.23,
,Ins,Myo,2019_bustillo_246,1,Control <40 GM,10.1016/j.jad.2018.12.064,,,,,13,1.6,
,Ins,Myo,2019_bustillo_246,2,Control <40 WM,10.1016/j.jad.2018.12.064,,,,,8.4,1.6,
,Ins,Myo,2019_bustillo_246,3,Control >40 GM,10.1016/j.jad.2018.12.064,,,,,14.4,2.2,
,Ins,Myo,2019_bustillo_246,4,Control >40 WM,10.1016/j.jad.2018.12.064,,,,,10,1.9,
,Ins,Myo,2019_bustillo_246,5,Bipolar <40 GM,10.1016/j.jad.2018.12.064,,,,,12.6,1.7,
,Ins,Myo,2019_bustillo_246,6,Bipolar <40 WM,10.1016/j.jad.2018.12.064,,,,,8.4,1.7,
,Ins,Myo,2019_bustillo_246,7,Bipolar >40 GM,10.1016/j.jad.2018.12.064,,,,,14.1,2.4,
,Ins,Myo,2019_bustillo_246,8,Bipolar >40 WM,10.1016/j.jad.2018.12.064,,,,,9.5,1.8,
,Ins,Myo,2019_bustillo_246,9,Schizophrenia <40 GM,10.1016/j.jad.2018.12.064,,,,,12.9,2,
,Ins,Myo,2019_bustillo_246,10,Schizophrenia <40 WM,10.1016/j.jad.2018.12.064,,,,,8.3,1.8,
,Ins,Myo,2019_bustillo_246,11,Schizophrenia >40 GM,10.1016/j.jad.2018.12.064,,,,,14.2,2.8,
,Ins,Myo,2019_bustillo_246,12,Schizophrenia >40 WM,10.1016/j.jad.2018.12.064,,,,,9.4,2.3,
,Ins,Myo,2019_basu_9,4,Premature Infant,10.1038/s41598-018-37203-4,,,17.618,7.622,,,
,Ins,Myo,2019_basu_9,8,Premature Infant,10.1038/s41598-018-37203-4,,,15.017,4.653,,,
,Myo,Myo,2019_cheng_43,1,Control,10.1097/RCT.0000000000000854,0.39,0.09,,,,,
,Myo,Myo,2019_cheng_43,2,MMA-HC,10.1097/RCT.0000000000000854,0.34,0.097,,,,,
,Myo,Myo,2019_cheong_90,1,Control - Visit 1,10.1136/jnnp-2018-318795,,,,,5.039,0.613,
,Myo,Myo,2019_cheong_90,2,Control - Visit 2,10.1136/jnnp-2018-318795,,,,,5.29,0.501,
,Myo,Myo,2019_cheong_90,3,Control - Visit 3,10.1136/jnnp-2018-318795,,,,,5.067,0.474,
,Myo,Myo,2019_cheong_90,4,Control - Visit 1,10.1136/jnnp-2018-318795,,,,,7.903,0.678,
,Myo,Myo,2019_cheong_90,5,Control - Visit 2,10.1136/jnnp-2018-318795,,,,,8,0.742,
,Myo,Myo,2019_cheong_90,6,Control - Visit 3,10.1136/jnnp-2018-318795,,,,,7.968,1,
,Myo,Myo,2019_cheong_90,7,ALS - Visit 1,10.1136/jnnp-2018-318795,,,,,5.3,0.549,
,Myo,Myo,2019_cheong_90,8,ALS - Visit 2,10.1136/jnnp-2018-318795,,,,,5.355,0.494,
,Myo,Myo,2019_cheong_90,9,ALS - Visit 3,10.1136/jnnp-2018-318795,,,,,5.437,0.604,
,Myo,Myo,2019_cheong_90,10,ALS - Visit 1,10.1136/jnnp-2018-318795,,,,,7.616,1.134,
,Myo,Myo,2019_cheong_90,11,ALS - Visit 2,10.1136/jnnp-2018-318795,,,,,7.94,1.069,
,Myo,Myo,2019_cheong_90,12,ALS - Visit 3,10.1136/jnnp-2018-318795,,,,,8.329,1.328,
,Myo,Myo,2019_davies_29,1,High-Risk Psychosis,10.1016/j.euroneuro.2019.03.008,0.86,0.11,6.21,1.12,,,
,Myo,Myo,2019_davies_29,2,High-Risk Psychosis,10.1016/j.euroneuro.2019.03.008,0.75,0.06,8.57,1.05,,,
,Myo,Myo,2019_davies_29,3,High-Risk Psychosis,10.1016/j.euroneuro.2019.03.008,0.56,0.11,4.2,0.93,,,
,Myo,Myo,2019_davies_29,4,High-Risk Psychosis,10.1016/j.euroneuro.2019.03.008,0.9,0.12,6.68,1.28,,,
,Myo,Myo,2019_davies_29,5,High-Risk Psychosis,10.1016/j.euroneuro.2019.03.008,0.74,0.07,8.57,1.11,,,
,Myo,Myo,2019_davies_29,6,High-Risk Psychosis,10.1016/j.euroneuro.2019.03.008,0.58,0.09,4.29,0.62,,,
,Myo,Myo,2018_adanyeguh_31,2,Healthy,10.1002/nbm.3880,,,,,5.5,0.7,Estimated Bar Graph
,Myo,Myo,2018_adanyeguh_31,4,HD,10.1002/nbm.3880,,,,,5.8,1,Estimated Bar Graph
,Myo,Myo,2018_adanyeguh_31,1,Healthy,10.1002/nbm.3880,,,,,4.9,0.8,Estimated Bar Graph
,Myo,Myo,2018_adanyeguh_31,3,HD,10.1002/nbm.3880,,,,,5.2,1,Estimated Bar Graph
,Myo,Myo,2018_al-iedani_108,1,Healthy,10.1016/j.ejrad.2018.09.020,0.87,0.02,,,,,
,Myo,Myo,2018_al-iedani_108,2,Healthy,10.1016/j.ejrad.2018.09.020,0.82,0,,,,,
,Inocitol CC,Myo,2018_atagun_235,1,BD-I,10.1016/j.jad.2018.04.010,,,0.92,0.15,,,
,Inocitol CC,Myo,2018_atagun_235,2,BD-I,10.1016/j.jad.2018.04.010,,,0.57,0.12,,,
,Inocitol CC,Myo,2018_atagun_235,3,BD-II,10.1016/j.jad.2018.04.010,,,1.02,0.21,,,
,Inocitol CC,Myo,2018_atagun_235,4,BD-II,10.1016/j.jad.2018.04.010,,,0.72,0.17,,,
,Inocitol CC,Myo,2018_atagun_235,5,Control,10.1016/j.jad.2018.04.010,,,1.06,0.09,,,
,Inocitol CC,Myo,2018_atagun_235,6,Control,10.1016/j.jad.2018.04.010,,,0.67,0.09,,,
,Myo,Myo,2018_bednarik_38,1,Healthy,10.1177/0271678X17695291,,,,,5.89,0.59,
,Ino,Myo,2018_caravaggio_28,1,Healthy,10.1016/j.euroneuro.2017.12.002,,,4.78,1.05,,,
,Ino,Myo,2018_caravaggio_28,2,Healthy,10.1016/j.euroneuro.2017.12.002,,,4.33,1.39,,,
,Ino,Myo,2018_caravaggio_28,3,Healthy,10.1016/j.euroneuro.2017.12.002,,,5.74,0.91,,,
,Ino,Myo,2018_caravaggio_28,4,Healthy,10.1016/j.euroneuro.2017.12.002,,,5.63,0.62,,,
,Myo,Myo,2018_chiu_193,3,First-episode Schizophrenia,10.1016/j.schres.2017.07.021,,,,,5.13,2.65,
,Myo,Myo,2018_chiu_193,4,Healthy,10.1016/j.schres.2017.07.021,,,,,7.71,1.63,
,Myo,Myo,2018_cichocka_83,1,Healthy,10.5114/pjr.2018.74536,0.86,0.216,,,,,
,Myo,Myo,2018_cichocka_83,2,Healthy,10.5114/pjr.2018.74536,0.79,0.401,,,,,
,Myo,Myo,2018_cichocka_83,3,Healthy,10.5114/pjr.2018.74536,0.61,0.188,,,,,
,Myo,Myo,2018_cichocka_83,4,Healthy,10.5114/pjr.2018.74536,0.62,0.228,,,,,
,Myo,Myo,2018_cichocka_83,5,Healthy,10.5114/pjr.2018.74536,0.96,0.344,,,,,
,Myo,Myo,2018_cichocka_83,6,Healthy,10.5114/pjr.2018.74536,1.12,0.656,,,,,
,Myo,Myo,2018_cichocka_83,7,Healthy,10.5114/pjr.2018.74536,0.84,0.211,,,,,
,Myo,Myo,2018_cichocka_83,8,Healthy,10.5114/pjr.2018.74536,0.84,0.298,,,,,
,Myo,Myo,2018_cichocka_83,9,Healthy,10.5114/pjr.2018.74536,0.94,0.242,,,,,
,Myo,Myo,2018_cichocka_83,10,Healthy,10.5114/pjr.2018.74536,0.64,0.188,,,,,
,Myo,Myo,2018_cichocka_83,11,Healthy,10.5114/pjr.2018.74536,0.67,0.156,,,,,
,Myo,Myo,2018_cichocka_83,12,Healthy,10.5114/pjr.2018.74536,1.11,0.297,,,,,
,Myo,Myo,2018_cichocka_83,13,Healthy,10.5114/pjr.2018.74536,1.08,0.308,,,,,
,Myo,Myo,2018_cichocka_83,14,Healthy,10.5114/pjr.2018.74536,0.83,0.155,,,,,
,Myo,Myo,2018_cirstea_97,1,Healthy,10.1097/PHM.0000000000000791,,,,,4.9,0.8,
,Myo,Myo,2018_cirstea_97,2,Healthy,10.1097/PHM.0000000000000791,,,,,5.4,0.9,
,Myo,Myo,2018_cirstea_97,3,Healthy,10.1097/PHM.0000000000000791,,,,,6.7,1.6,
,Myo,Myo,2018_cirstea_97,4,Healthy,10.1097/PHM.0000000000000791,,,,,5.1,1.2,
,Myo,Myo,2018_cirstea_97,5,Healthy,10.1097/PHM.0000000000000791,,,,,5.8,1.1,
,Myo,Myo,2018_cirstea_97,6,Healthy,10.1097/PHM.0000000000000791,,,,,6.2,1.5,
,Myo,Myo,2018_cirstea_97,7,Stroke,10.1097/PHM.0000000000000791,,,,,5.5,0.9,
,Myo,Myo,2018_cirstea_97,8,Stroke,10.1097/PHM.0000000000000791,,,,,6.5,1.4,
,Myo,Myo,2018_cirstea_97,9,Stroke,10.1097/PHM.0000000000000791,,,,,6.6,1.4,
,Myo,Myo,2018_cirstea_97,10,Stroke,10.1097/PHM.0000000000000791,,,,,5.4,0.9,
,Myo,Myo,2018_cirstea_97,11,Stroke,10.1097/PHM.0000000000000791,,,,,6,1.5,
,Myo,Myo,2018_cirstea_97,12,Stroke,10.1097/PHM.0000000000000791,,,,,6.3,1.2,
,Myo,Myo,2018_de_239,1,Postpartum Depression,10.1016/j.jad.2018.07.028,1.1,0.3,,,,,
,Myo,Myo,2018_de_239,2,Postpartum Euthymic ,10.1016/j.jad.2018.07.028,1.2,0.1,,,,,
,Myo,Myo,2018_dejaeger_9,1,Painful Diabetic Polyneuropathy - Pregabalin Visit 1,10.1007/s13300-018-0460-y,,,,,2.95,1.74,
,Myo,Myo,2018_dejaeger_9,2,Painful Diabetic Polyneuropathy - Pregabalin Visit 1,10.1007/s13300-018-0460-y,,,,,2.26,1.29,
,Myo,Myo,2018_dejaeger_9,3,Painful Diabetic Polyneuropathy - Pregabalin Visit 1,10.1007/s13300-018-0460-y,,,,,2.15,0.76,
,Myo,Myo,2018_dejaeger_9,4,Painful Diabetic Polyneuropathy - Pregabalin Visit 1,10.1007/s13300-018-0460-y,,,,,2.85,0.93,
,Myo,Myo,2018_dejaeger_9,5,Painful Diabetic Polyneuropathy - Pregabalin Visit 3,10.1007/s13300-018-0460-y,,,,,1.72,0.83,
,Myo,Myo,2018_dejaeger_9,6,Painful Diabetic Polyneuropathy - Pregabalin Visit 3,10.1007/s13300-018-0460-y,,,,,2.17,0.76,
,Myo,Myo,2018_dejaeger_9,7,Painful Diabetic Polyneuropathy - Pregabalin Visit 3,10.1007/s13300-018-0460-y,,,,,2.49,1.01,
,Myo,Myo,2018_dejaeger_9,8,Painful Diabetic Polyneuropathy - Pregabalin Visit 3,10.1007/s13300-018-0460-y,,,,,2.52,1.13,
,Myo,Myo,2018_dejaeger_9,9,Painful Diabetic Polyneuropathy - Pregabalin Visit 5,10.1007/s13300-018-0460-y,,,,,2.73,1.55,
,Myo,Myo,2018_dejaeger_9,10,Painful Diabetic Polyneuropathy - Pregabalin Visit 5,10.1007/s13300-018-0460-y,,,,,1.91,0.59,
,Myo,Myo,2018_dejaeger_9,11,Painful Diabetic Polyneuropathy - Pregabalin Visit 5,10.1007/s13300-018-0460-y,,,,,2.17,0.82,
,Myo,Myo,2018_dejaeger_9,12,Painful Diabetic Polyneuropathy - Pregabalin Visit 5,10.1007/s13300-018-0460-y,,,,,2.55,0.88,
,Myo,Myo,2018_dejaeger_9,13,Painful Diabetic Polyneuropathy - Pregabalin Visit 7,10.1007/s13300-018-0460-y,,,,,1.88,1.1,
,Myo,Myo,2018_dejaeger_9,14,Painful Diabetic Polyneuropathy - Pregabalin Visit 7,10.1007/s13300-018-0460-y,,,,,2.13,0.97,
,Myo,Myo,2018_dejaeger_9,15,Painful Diabetic Polyneuropathy - Pregabalin Visit 7,10.1007/s13300-018-0460-y,,,,,2.63,0.82,
,Myo,Myo,2018_dejaeger_9,16,Painful Diabetic Polyneuropathy - Pregabalin Visit 7,10.1007/s13300-018-0460-y,,,,,2.33,0.96,
,Myo,Myo,2018_dejaeger_9,17,Painful Diabetic Polyneuropathy - Placebo Visit 1,10.1007/s13300-018-0460-y,,,,,2.42,1.59,
,Myo,Myo,2018_dejaeger_9,18,Painful Diabetic Polyneuropathy - Placebo Visit 1,10.1007/s13300-018-0460-y,,,,,2.21,0.68,
,Myo,Myo,2018_dejaeger_9,19,Painful Diabetic Polyneuropathy - Placebo Visit 1,10.1007/s13300-018-0460-y,,,,,2.29,1.18,
,Myo,Myo,2018_dejaeger_9,20,Painful Diabetic Polyneuropathy - Placebo Visit 1,10.1007/s13300-018-0460-y,,,,,2.81,1.17,
,Myo,Myo,2018_dejaeger_9,21,Painful Diabetic Polyneuropathy - Placebo Visit 3,10.1007/s13300-018-0460-y,,,,,2.32,0.83,
,Myo,Myo,2018_dejaeger_9,22,Painful Diabetic Polyneuropathy - Placebo Visit 3,10.1007/s13300-018-0460-y,,,,,2.21,0.82,
,Myo,Myo,2018_dejaeger_9,23,Painful Diabetic Polyneuropathy - Placebo Visit 3,10.1007/s13300-018-0460-y,,,,,2.67,1.14,
,Myo,Myo,2018_dejaeger_9,24,Painful Diabetic Polyneuropathy - Placebo Visit 3,10.1007/s13300-018-0460-y,,,,,2.21,0.89,
,Myo,Myo,2018_dejaeger_9,25,Painful Diabetic Polyneuropathy - Placebo Visit 5,10.1007/s13300-018-0460-y,,,,,2.39,0.79,
,Myo,Myo,2018_dejaeger_9,26,Painful Diabetic Polyneuropathy - Placebo Visit 5,10.1007/s13300-018-0460-y,,,,,1.92,1.36,
,Myo,Myo,2018_dejaeger_9,27,Painful Diabetic Polyneuropathy - Placebo Visit 5,10.1007/s13300-018-0460-y,,,,,2.34,0.97,
,Myo,Myo,2018_dejaeger_9,28,Painful Diabetic Polyneuropathy - Placebo Visit 5,10.1007/s13300-018-0460-y,,,,,2.47,1.08,
,Myo,Myo,2018_dejaeger_9,29,Painful Diabetic Polyneuropathy - Placebo Visit 7,10.1007/s13300-018-0460-y,,,,,2.12,0.86,
,Myo,Myo,2018_dejaeger_9,30,Painful Diabetic Polyneuropathy - Placebo Visit 7,10.1007/s13300-018-0460-y,,,,,2.06,0.93,
,Myo,Myo,2018_dejaeger_9,31,Painful Diabetic Polyneuropathy - Placebo Visit 7,10.1007/s13300-018-0460-y,,,,,2.56,1.01,
,Myo,Myo,2018_dejaeger_9,32,Painful Diabetic Polyneuropathy - Placebo Visit 7,10.1007/s13300-018-0460-y,,,,,2.46,0.7,
,Myo,Myo,2018_dejaeger_9,33,Painful Diabetic Polyneuropathy - Pregabalin 0 mg,10.1007/s13300-018-0460-y,,,,,2.42,1.21,
,Myo,Myo,2018_dejaeger_9,34,Painful Diabetic Polyneuropathy - Pregabalin 0 mg,10.1007/s13300-018-0460-y,,,,,2.12,1.01,
,Myo,Myo,2018_dejaeger_9,35,Painful Diabetic Polyneuropathy - Pregabalin 0 mg,10.1007/s13300-018-0460-y,,,,,2.47,1.14,
,Myo,Myo,2018_dejaeger_9,36,Painful Diabetic Polyneuropathy - Pregabalin 0 mg,10.1007/s13300-018-0460-y,,,,,2.5,0.89,
,Myo,Myo,2018_dejaeger_9,37,Painful Diabetic Polyneuropathy - Pregabalin 75 mg,10.1007/s13300-018-0460-y,,,,,2.04,0.85,
,Myo,Myo,2018_dejaeger_9,38,Painful Diabetic Polyneuropathy - Pregabalin 75 mg,10.1007/s13300-018-0460-y,,,,,2.38,0.89,
,Myo,Myo,2018_dejaeger_9,39,Painful Diabetic Polyneuropathy - Pregabalin 75 mg,10.1007/s13300-018-0460-y,,,,,2.61,1.25,
,Myo,Myo,2018_dejaeger_9,40,Painful Diabetic Polyneuropathy - Pregabalin 75 mg,10.1007/s13300-018-0460-y,,,,,2.37,0.88,
,Myo,Myo,2018_dejaeger_9,41,Painful Diabetic Polyneuropathy - Pregabalin 225 mg,10.1007/s13300-018-0460-y,,,,,2.23,1.1,
,Myo,Myo,2018_dejaeger_9,42,Painful Diabetic Polyneuropathy - Pregabalin 225 mg,10.1007/s13300-018-0460-y,,,,,1.92,0.88,
,Myo,Myo,2018_dejaeger_9,43,Painful Diabetic Polyneuropathy - Pregabalin 225 mg,10.1007/s13300-018-0460-y,,,,,2.38,0.95,
,Myo,Myo,2018_dejaeger_9,44,Painful Diabetic Polyneuropathy - Pregabalin 225 mg,10.1007/s13300-018-0460-y,,,,,2.58,0.86,
,Myo,Myo,2018_dejaeger_9,45,Painful Diabetic Polyneuropathy - Pregabalin 450 mg,10.1007/s13300-018-0460-y,,,,,1.58,0.94,
,Myo,Myo,2018_dejaeger_9,46,Painful Diabetic Polyneuropathy - Pregabalin 450 mg,10.1007/s13300-018-0460-y,,,,,1.59,0.85,
,Myo,Myo,2018_dejaeger_9,47,Painful Diabetic Polyneuropathy - Pregabalin 450 mg,10.1007/s13300-018-0460-y,,,,,2.43,1.09,
,Myo,Myo,2018_dejaeger_9,48,Painful Diabetic Polyneuropathy - Pregabalin 450 mg,10.1007/s13300-018-0460-y,,,,,2.25,0.99,
,Myo,Myo,2018_ding_38,1,Healthy - Pre-fasting,10.1177/0271678X17697721,,,5.22,0.84,,,
,Myo,Myo,2018_ding_38,2,Healthy - Pre-fasting,10.1177/0271678X17697721,,,5.53,1.28,,,
,Myo,Myo,2018_ding_38,3,Healthy - Pre-fasting,10.1177/0271678X17697721,,,4.99,0.77,,,
,Myo,Myo,2018_ding_38,4,Healthy - Pre-fasting,10.1177/0271678X17697721,,,5.47,0.79,,,
,Myo,Myo,2018_ding_38,5,Healthy - Pre-fasting,10.1177/0271678X17697721,,,4.86,0.73,,,
,Myo,Myo,2018_ding_38,6,Healthy - Pre-fasting,10.1177/0271678X17697721,,,4.92,0.75,,,
,Myo,Myo,2018_ding_38,7,Healthy - Pre-fasting,10.1177/0271678X17697721,,,4.94,0.7,,,
,Myo,Myo,2018_ding_38,8,Healthy - Pre-fasting,10.1177/0271678X17697721,,,4.98,0.7,,,
,Myo,Myo,2018_ding_38,9,Healthy - Pre-fasting,10.1177/0271678X17697721,,,5.33,0.64,,,
,Myo,Myo,2018_ding_38,10,Healthy - Post-fasting,10.1177/0271678X17697721,,,4.79,1.01,,,
,Myo,Myo,2018_ding_38,11,Healthy - Post-fasting,10.1177/0271678X17697721,,,5.24,1.18,,,
,Myo,Myo,2018_ding_38,12,Healthy - Post-fasting,10.1177/0271678X17697721,,,4.77,0.64,,,
,Myo,Myo,2018_ding_38,13,Healthy - Post-fasting,10.1177/0271678X17697721,,,5.29,1.07,,,
,Myo,Myo,2018_ding_38,14,Healthy - Post-fasting,10.1177/0271678X17697721,,,4.55,0.59,,,
,Myo,Myo,2018_ding_38,15,Healthy - Post-fasting,10.1177/0271678X17697721,,,4.66,0.85,,,
,Myo,Myo,2018_ding_38,16,Healthy - Post-fasting,10.1177/0271678X17697721,,,4.84,0.51,,,
,Myo,Myo,2018_ding_38,17,Healthy - Post-fasting,10.1177/0271678X17697721,,,4.69,0.46,,,
,Myo,Myo,2018_ding_38,18,Healthy - Post-fasting,10.1177/0271678X17697721,,,5.22,0.63,,,
,Myo,Myo,2018_ding_38,19,Healthy - Non-fasting,10.1177/0271678X17697721,,,5,0.6,,,
,Myo,Myo,2018_ding_38,20,Healthy - Non-fasting,10.1177/0271678X17697721,,,5.48,1.02,,,
,Myo,Myo,2018_ding_38,21,Healthy - Non-fasting,10.1177/0271678X17697721,,,5.33,0.73,,,
,Myo,Myo,2018_ding_38,22,Healthy - Non-fasting,10.1177/0271678X17697721,,,5.54,0.66,,,
,Myo,Myo,2018_ding_38,23,Healthy - Non-fasting,10.1177/0271678X17697721,,,4.74,0.6,,,
,Myo,Myo,2018_ding_38,24,Healthy - Non-fasting,10.1177/0271678X17697721,,,5.09,0.58,,,
,Myo,Myo,2018_ding_38,25,Healthy - Non-fasting,10.1177/0271678X17697721,,,4.81,0.54,,,
,Myo,Myo,2018_ding_38,26,Healthy - Non-fasting,10.1177/0271678X17697721,,,5.05,0.69,,,
,Myo,Myo,2018_ding_38,27,Healthy - Non-fasting,10.1177/0271678X17697721,,,5.59,0.85,,,
,Myo,Myo,2017_aleks_282,1,Control - Baseline,10.1148/radiol.2016152083,0.3,0.01,,,,,
,Myo,Myo,2017_aleks_282,2,Control - Follow-Up,10.1148/radiol.2016152083,0.29,0.02,,,,,
,Myo,Myo,2017_aleks_282,3,Cervical Spondylotic Myelopathy - Preoperative,10.1148/radiol.2016152083,0.32,0.01,,,,,
,Myo,Myo,2017_aleks_282,4,Cervical Spondylotic Myelopathy - Postoperative,10.1148/radiol.2016152083,0.28,0.02,,,,,
,Myo,Myo,2018_egerton_23,1,Healthy - Baseline,10.1038/s41380-018-0082-9,0.77,0.14,,,,,
,Myo,Myo,2018_egerton_23,2,Healthy - Baseline,10.1038/s41380-018-0082-9,0.72,0.06,,,,,
,Myo,Myo,2018_egerton_23,3,Healthy - Baseline,10.1038/s41380-018-0082-9,0.72,0.07,,,,,
,Myo,Myo,2018_egerton_23,4,Healthy - Baseline,10.1038/s41380-018-0082-9,0.58,0.1,,,,,
,Myo,Myo,2018_egerton_23,5,Healthy - Baseline,10.1038/s41380-018-0082-9,0.64,0.1,,,,,
,Myo,Myo,2018_egerton_23,6,Healthy - Baseline,10.1038/s41380-018-0082-9,0.65,0.08,,,,,
,Myo,Myo,2018_egerton_23,7,Healthy - After Amisulpride,10.1038/s41380-018-0082-9,0.76,0.1,,,,,
,Myo,Myo,2018_egerton_23,8,Healthy - After Amisulpride,10.1038/s41380-018-0082-9,0.69,0.1,,,,,
,Myo,Myo,2018_egerton_23,9,Healthy - After Amisulpride,10.1038/s41380-018-0082-9,0.72,0.03,,,,,
,Myo,Myo,2018_egerton_23,10,Healthy - After Amisulpride,10.1038/s41380-018-0082-9,0.56,0.1,,,,,
,Myo,Myo,2018_egerton_23,11,Healthy - After Amisulpride,10.1038/s41380-018-0082-9,0.7,0.09,,,,,
,Myo,Myo,2018_egerton_23,12,Healthy - After Amisulpride,10.1038/s41380-018-0082-9,0.67,0.1,,,,,
,Myo,Myo,2018_egerton_23,13,First Episode Psychosis - Baseline,10.1038/s41380-018-0082-9,0.75,0.14,,,,,
,Myo,Myo,2018_egerton_23,14,First Episode Psychosis - Baseline,10.1038/s41380-018-0082-9,0.7,0.06,,,,,
,Myo,Myo,2018_egerton_23,15,First Episode Psychosis - Baseline,10.1038/s41380-018-0082-9,0.72,0.06,,,,,
,Myo,Myo,2018_egerton_23,16,First Episode Psychosis - Baseline,10.1038/s41380-018-0082-9,0.57,0.07,,,,,
,Myo,Myo,2018_egerton_23,17,First Episode Psychosis - Baseline,10.1038/s41380-018-0082-9,0.63,0.08,,,,,
,Myo,Myo,2018_egerton_23,18,First Episode Psychosis - Baseline,10.1038/s41380-018-0082-9,0.69,0.08,,,,,
,Myo,Myo,2018_egerton_23,19,First Episode Psychosis - After Amisulpride,10.1038/s41380-018-0082-9,0.75,0.12,,,,,
,Myo,Myo,2018_egerton_23,20,First Episode Psychosis - After Amisulpride,10.1038/s41380-018-0082-9,0.67,0.07,,,,,
,Myo,Myo,2018_egerton_23,21,First Episode Psychosis - After Amisulpride,10.1038/s41380-018-0082-9,0.71,0.05,,,,,
,Myo,Myo,2018_egerton_23,22,First Episode Psychosis - After Amisulpride,10.1038/s41380-018-0082-9,0.55,0.11,,,,,
,Myo,Myo,2018_egerton_23,23,First Episode Psychosis - After Amisulpride,10.1038/s41380-018-0082-9,0.62,0.11,,,,,
,Myo,Myo,2018_egerton_23,24,First Episode Psychosis - After Amisulpride,10.1038/s41380-018-0082-9,0.66,0.08,,,,,
,Myo,Myo,2018_egerton_23,25,First Episode Psychosis - Remission (Baseline),10.1038/s41380-018-0082-9,0.76,0.15,,,,,
,Myo,Myo,2018_egerton_23,26,First Episode Psychosis - Remission (Baseline),10.1038/s41380-018-0082-9,0.69,0.06,,,,,
,Myo,Myo,2018_egerton_23,27,First Episode Psychosis - Remission (Baseline),10.1038/s41380-018-0082-9,0.74,0.06,,,,,
,Myo,Myo,2018_egerton_23,28,First Episode Psychosis - Remission (Baseline),10.1038/s41380-018-0082-9,0.56,0.08,,,,,
,Myo,Myo,2018_egerton_23,29,First Episode Psychosis - Remission (Baseline),10.1038/s41380-018-0082-9,0.62,0.08,,,,,
,Myo,Myo,2018_egerton_23,30,First Episode Psychosis - Remission (Baseline),10.1038/s41380-018-0082-9,0.71,0.09,,,,,
,Myo,Myo,2018_egerton_23,31,First Episode Psychosis - Remission (After Amisulpride),10.1038/s41380-018-0082-9,0.77,0.13,,,,,
,Myo,Myo,2018_egerton_23,32,First Episode Psychosis - Remission (After Amisulpride),10.1038/s41380-018-0082-9,0.67,0.07,,,,,
,Myo,Myo,2018_egerton_23,33,First Episode Psychosis - Remission (After Amisulpride),10.1038/s41380-018-0082-9,0.71,0.05,,,,,
,Myo,Myo,2018_egerton_23,34,First Episode Psychosis - Remission (After Amisulpride),10.1038/s41380-018-0082-9,0.54,0.13,,,,,
,Myo,Myo,2018_egerton_23,35,First Episode Psychosis - Remission (After Amisulpride),10.1038/s41380-018-0082-9,0.61,0.1,,,,,
,Myo,Myo,2018_egerton_23,36,First Episode Psychosis - Remission (After Amisulpride),10.1038/s41380-018-0082-9,0.67,0.09,,,,,
,Myo,Myo,2018_egerton_23,37,First Episode Psychosis - No Remission (Baseline),10.1038/s41380-018-0082-9,0.8,0.08,,,,,
,Myo,Myo,2018_egerton_23,38,First Episode Psychosis - No Remission (Baseline),10.1038/s41380-018-0082-9,0.71,0.07,,,,,
,Myo,Myo,2018_egerton_23,39,First Episode Psychosis - No Remission (Baseline),10.1038/s41380-018-0082-9,0.69,0.04,,,,,
,Myo,Myo,2018_egerton_23,40,First Episode Psychosis - No Remission (Baseline),10.1038/s41380-018-0082-9,0.58,0.05,,,,,
,Myo,Myo,2018_egerton_23,41,First Episode Psychosis - No Remission (Baseline),10.1038/s41380-018-0082-9,0.62,0.08,,,,,
,Myo,Myo,2018_egerton_23,42,First Episode Psychosis - No Remission (Baseline),10.1038/s41380-018-0082-9,0.66,0.09,,,,,
,Myo,Myo,2018_egerton_23,43,First Episode Psychosis - No Remission (After Amisulpride),10.1038/s41380-018-0082-9,0.7,0.09,,,,,
,Myo,Myo,2018_egerton_23,44,First Episode Psychosis - No Remission (After Amisulpride),10.1038/s41380-018-0082-9,0.66,0.06,,,,,
,Myo,Myo,2018_egerton_23,45,First Episode Psychosis - No Remission (After Amisulpride),10.1038/s41380-018-0082-9,0.71,0.07,,,,,
,Myo,Myo,2018_egerton_23,46,First Episode Psychosis - No Remission (After Amisulpride),10.1038/s41380-018-0082-9,0.58,0.07,,,,,
,Myo,Myo,2018_egerton_23,47,First Episode Psychosis - No Remission (After Amisulpride),10.1038/s41380-018-0082-9,0.64,0.12,,,,,
,Myo,Myo,2018_egerton_23,48,First Episode Psychosis - No Remission (After Amisulpride),10.1038/s41380-018-0082-9,0.65,0.07,,,,,
,Myo,Myo,2018_ford_10,1,Healthy - Vitamin B (Baseline),10.3390/nu10121860,,,4.95,0.21,,,
,Myo,Myo,2018_ford_10,2,Healthy - Placebo (Baseline),10.3390/nu10121860,,,4.53,0.15,,,
,Myo,Myo,2018_ford_10,3,Healthy - Vitamin B (6 Months),10.3390/nu10121860,,,4.99,0.13,,,
,Myo,Myo,2018_ford_10,4,Healthy - Placebo (6 Months),10.3390/nu10121860,,,4.73,0.15,,,
,Myo,Myo,2018_galinska-skok_2018,1,Schizophrenia,10.1155/2018/3654894,0.76,0.26,0.2,0.07,,,
,Myo,Myo,2018_galinska-skok_2018,2,Schizophrenia,10.1155/2018/3654894,0.73,0.22,0.18,0.06,,,
,Myo,Myo,2018_galinska-skok_2018,3,Bipolar Disorder,10.1155/2018/3654894,0.78,0.19,0.21,0.05,,,
,Myo,Myo,2018_galinska-skok_2018,4,Bipolar Disorder,10.1155/2018/3654894,0.73,0.27,0.17,0.06,,,
,Myo,Myo,2018_galinska-skok_2018,5,Control,10.1155/2018/3654894,0.71,0.25,0.18,0.06,,,
,Myo,Myo,2018_galinska-skok_2018,6,Control,10.1155/2018/3654894,0.72,0.24,0.17,0.07,,,
,Myo,Myo,2018_gasparovic_48,1,Preterm Birth - Placebo (Scan 1),10.1007/s00247-017-4052-1,,,10,1.57,,,
,Myo,Myo,2018_gasparovic_48,2,Preterm Birth - Placebo (Scan 1),10.1007/s00247-017-4052-1,,,7.57,1.05,,,
,Myo,Myo,2018_gasparovic_48,3,Preterm Birth - Placebo (Scan 2),10.1007/s00247-017-4052-1,,,10.2,1.55,,,
,Myo,Myo,2018_gasparovic_48,4,Preterm Birth - Placebo (Scan 2),10.1007/s00247-017-4052-1,,,7.22,1.21,,,
,Myo,Myo,2018_gasparovic_48,5,Preterm Birth - Erythropoiesis Stimulating Agent (Scan 1),10.1007/s00247-017-4052-1,,,10.51,1.14,,,
,Myo,Myo,2018_gasparovic_48,6,Preterm Birth - Erythropoiesis Stimulating Agent (Scan 1),10.1007/s00247-017-4052-1,,,7.41,0.86,,,
,Myo,Myo,2018_gasparovic_48,7,Preterm Birth - Erythropoiesis Stimulating Agent (Scan 2),10.1007/s00247-017-4052-1,,,10.74,1.39,,,
,Myo,Myo,2018_gasparovic_48,8,Preterm Birth - Erythropoiesis Stimulating Agent (Scan 2),10.1007/s00247-017-4052-1,,,8.05,0.9,,,
,Myo,Myo,2018_gasparovic_48,9,Control - Scan 1,10.1007/s00247-017-4052-1,,,10.3,1.02,,,
,Myo,Myo,2018_gasparovic_48,10,Control - Scan 1,10.1007/s00247-017-4052-1,,,7.19,1.08,,,
,Myo,Myo,2018_gasparovic_48,11,Control - Scan 2,10.1007/s00247-017-4052-1,,,10.89,1.27,,,
,Myo,Myo,2018_gasparovic_48,12,Control - Scan 3,10.1007/s00247-017-4052-1,,,7.85,1.55,,,
,Myo,Myo,2018_gramegna_39,1,Mitochondrial Neurogastrointestinal Encephalopathy,10.3174/ajnr.A5507,0.99,0.27,,,4.46,1.14,
,Myo,Myo,2018_gramegna_39,2,Control,10.3174/ajnr.A5507,0.85,0.08,,,5.44,0.76,
,Ins,Myo,2018_harper_17,1,Urologic Chronic Pelvic Pain Syndrome,10.1016/j.nicl.2017.11.014,0.85,0.11,4.71,0.58,,,
,Ins,Myo,2018_harper_17,2,Urologic Chronic Pelvic Pain Syndrome,10.1016/j.nicl.2017.11.014,0.82,0.09,4.96,0.52,,,
,Ins,Myo,2018_harper_17,3,Urologic Chronic Pelvic Pain Syndrome,10.1016/j.nicl.2017.11.014,0.79,0.07,4.64,0.47,,,
,Ins,Myo,2018_harper_17,4,Urologic Chronic Pelvic Pain Syndrome,10.1016/j.nicl.2017.11.014,0.74,0.09,4.67,0.59,,,
,Ins,Myo,2018_harper_17,5,Control,10.1016/j.nicl.2017.11.014,0.83,0.09,4.67,0.54,,,
,Ins,Myo,2018_harper_17,6,Control,10.1016/j.nicl.2017.11.014,0.81,0.07,4.8,0.48,,,
,Ins,Myo,2018_harper_17,7,Control,10.1016/j.nicl.2017.11.014,0.81,0.06,4.77,0.49,,,
,Ins,Myo,2018_harper_17,8,Control,10.1016/j.nicl.2017.11.014,0.74,0.08,4.58,0.49,,,
,Myo,Myo,2018_hegarty_48,1,Autism Spectrum Disorder,10.1007/s10803-018-3613-y,,,8.54,1.52,,,
,Myo,Myo,2018_hegarty_48,2,Autism Spectrum Disorder,10.1007/s10803-018-3613-y,,,7,0.51,,,
,Myo,Myo,2018_hegarty_48,3,Control,10.1007/s10803-018-3613-y,,,9.5,0.82,,,
,Myo,Myo,2018_hegarty_48,4,Control,10.1007/s10803-018-3613-y,,,7.05,0.62,,,
,Myo,Myo,2018_hegarty_81,1,Autism Spectrum Disorder,10.1016/j.pnpbp.2017.09.016,0.62,0.17,,,,,
,Myo,Myo,2018_hegarty_81,2,Autism Spectrum Disorder,10.1016/j.pnpbp.2017.09.016,0.92,0.34,,,,,
,Myo,Myo,2018_hegarty_81,3,Control,10.1016/j.pnpbp.2017.09.016,0.62,0.15,,,,,
,Myo,Myo,2018_hegarty_81,4,Control,10.1016/j.pnpbp.2017.09.016,0.95,0.17,,,,,
,Myo,Myo,2018_hegarty_81,5,Autism Spectrum Disorder,10.1016/j.pnpbp.2017.09.016,0.68,0.13,,,,,
,Myo,Myo,2018_hegarty_81,6,Autism Spectrum Disorder,10.1016/j.pnpbp.2017.09.016,0.94,0.15,,,,,
,Myo,Myo,2018_hegarty_81,7,Control,10.1016/j.pnpbp.2017.09.016,0.66,0.15,,,,,
,Myo,Myo,2018_hegarty_81,8,Control,10.1016/j.pnpbp.2017.09.016,0.82,0.18,,,,,
,Myo,Myo,2018_hjelmervik_172,1,Healthy - Menstrual Phase,10.1016/j.neuroimage.2018.01.043,,,3.66,0.85,,,
,Myo,Myo,2018_hjelmervik_172,2,Healthy - Menstrual Phase,10.1016/j.neuroimage.2018.01.043,,,3.07,0.98,,,
,Myo,Myo,2018_hjelmervik_172,3,Healthy - Follicular Phase,10.1016/j.neuroimage.2018.01.043,,,3.7,0.89,,,
,Myo,Myo,2018_hjelmervik_172,4,Healthy - Follicular Phase,10.1016/j.neuroimage.2018.01.043,,,3.18,0.76,,,
,Myo,Myo,2018_hjelmervik_172,5,Healthy - Luteal Phase,10.1016/j.neuroimage.2018.01.043,,,3.52,1.16,,,
,Myo,Myo,2018_hjelmervik_172,6,Healthy - Luteal Phase,10.1016/j.neuroimage.2018.01.043,,,3.51,0.96,,,
,Myo,Myo,2018_hjelmervik_172,7,Healthy - Total,10.1016/j.neuroimage.2018.01.043,,,3.44,0.52,,,
,Myo,Myo,2018_hjelmervik_172,8,Healthy - Session 1,10.1016/j.neuroimage.2018.01.043,,,3.53,0.91,,,
,Myo,Myo,2018_hjelmervik_172,9,Healthy - Session 1,10.1016/j.neuroimage.2018.01.043,,,3.8,1.12,,,
,Myo,Myo,2018_hjelmervik_172,10,Healthy - Session 2,10.1016/j.neuroimage.2018.01.043,,,3.92,1.34,,,
,Myo,Myo,2018_hjelmervik_172,11,Healthy - Session 2,10.1016/j.neuroimage.2018.01.043,,,3.21,0.98,,,
,Myo,Myo,2018_hjelmervik_172,12,Healthy - Session 3,10.1016/j.neuroimage.2018.01.043,,,4,1.47,,,
,Myo,Myo,2018_hjelmervik_172,13,Healthy - Session 3,10.1016/j.neuroimage.2018.01.043,,,3.34,0.52,,,
,Myo,Myo,2018_hjelmervik_172,14,Healthy - Total,10.1016/j.neuroimage.2018.01.043,,,3.63,0.77,,,
,Myo,Myo,2018_horder_8,1,Control,10.1038/s41398-018-0155-1,,,4.1,0.66,,,
,Myo,Myo,2018_horder_8,2,Control,10.1038/s41398-018-0155-1,,,4.89,0.84,,,
,Myo,Myo,2018_horder_8,3,Autism Spectrum Disorder,10.1038/s41398-018-0155-1,,,4.14,0.9,,,
,Myo,Myo,2018_horder_8,4,Autism Spectrum Disorder,10.1038/s41398-018-0155-1,,,5.31,0.75,,,
,Myo,Myo,2018_kim_23,1,Methamphetamine Dependence ,10.1111/adb.12473,,,4.89,1.34,,,
,Myo,Myo,2018_kim_23,2,Control,10.1111/adb.12473,,,4.61,0.84,,,
,Myo,Myo,2018_kim_83,1,First-episode Psychosis,10.1016/j.biopsych.2017.08.022,0.91,0.26,8.15,2.7,,,IU estimated from bar graph
,Myo,Myo,2018_kim_83,2,First-episode Psychosis,10.1016/j.biopsych.2017.08.022,0.81,0.24,7.4,2.5,,,IU estimated from bar graph
,Myo,Myo,2018_kim_83,3,Control,10.1016/j.biopsych.2017.08.022,0.73,0.21,6.7,2.3,,,IU estimated from bar graph
,Myo,Myo,2018_kim_83,4,Control,10.1016/j.biopsych.2017.08.022,0.67,0.14,6,1.5,,,IU estimated from bar graph
,ml-Gly,Myo,2020_bhogal_10,1,Healthy,10.1002/brb3.1852,0.45,0.09,,,,,
,ml-Gly,Myo,2020_bhogal_10,2,Healthy,10.1002/brb3.1852,0.39,0.1,,,,,
,ml-Gly,Myo,2020_bhogal_10,3,Healthy,10.1002/brb3.1852,0.42,0.15,,,,,
,ml-Gly,Myo,2020_bhogal_10,4,Healthy,10.1002/brb3.1852,0.37,0.08,,,,,
,ml-Gly,Myo,2020_bhogal_10,5,Healthy,10.1002/brb3.1852,0.31,0.06,,,,,
,ml-Gly,Myo,2020_bhogal_10,6,Healthy,10.1002/brb3.1852,0.32,0.06,,,,,
,ml-Gly,Myo,2020_bhogal_10,7,Healthy,10.1002/brb3.1852,0.36,0.09,,,,,
,ml-Gly,Myo,2020_bhogal_10,8,Healthy,10.1002/brb3.1852,0.35,0.08,,,,,
,ml-Gly,Myo,2020_bhogal_10,9,Healthy,10.1002/brb3.1852,0.38,0.1,,,,,
,ml-Gly,Myo,2020_bhogal_10,10,Healthy,10.1002/brb3.1852,0.41,0.16,,,,,
,Myo,Myo,2020_blest-hopley_25,1,Current CU,10.1111/adb.12827,,,6.172,0.98,,,
,Myo,Myo,2020_blest-hopley_25,2,Healthy,10.1111/adb.12827,,,6.761,0.99,,,
,Myo,Myo,2018_kroll_19,1,Asthma,10.1016/j.nicl.2018.04.012,1.24,1.24,11.2,2.16,,,
,Myo,Myo,2018_kroll_19,2,Control,10.1016/j.nicl.2018.04.012,1.11,0.26,11.72,2.56,,,
,Myo,Myo,2018_lu_29,1,Liver Cirrhosis,10.1097/WNR.0000000000001063,0.3,0.2,,,,,
,Myo,Myo,2018_lu_29,2,Liver Cirrhosis with Hepatic Encephalopathy,10.1097/WNR.0000000000001063,0.3,0.2,,,,,
,Myo,Myo,2018_lu_29,3,Liver Cirrhosis without Hepatic Encephalopathy,10.1097/WNR.0000000000001063,0.3,0.1,,,,,
,Myo,Myo,2018_lu_29,4,Control,10.1097/WNR.0000000000001063,0.3,0.3,,,,,
,Myo,Myo,2018_marshall_265,1,Secondary Progressive Multiple Sclerosis,10.1007/s00415-018-8903-y,0.57,0.01,463,10,,,
,Myo,Myo,2018_marshall_265,2,Secondary Progressive Multiple Sclerosis,10.1007/s00415-018-8903-y,0.73,0.02,677,24,,,
,Myo,Myo,2018_marshall_265,3,Secondary Progressive Multiple Sclerosis,10.1007/s00415-018-8903-y,0.53,0.01,469,13,,,
,Myo,Myo,2018_mcqueen_235,1,Schizophrenia - Placebo,10.1007/s00213-018-4997-2,0.72,0.1,8.19,1.53,,,
,Myo,Myo,2018_mcqueen_235,2,Schizophrenia - Placebo,10.1007/s00213-018-4997-2,0.51,0.1,4.73,0.78,,,
,Myo,Myo,2018_mcqueen_235,3,Schizophrenia - N-Acetylcysteine ,10.1007/s00213-018-4997-2,0.74,0.14,8.97,1.84,,,
,Myo,Myo,2018_mcqueen_235,4,Schizophrenia - N-Acetylcysteine ,10.1007/s00213-018-4997-2,0.49,0.1,5.13,2.13,,,
,Myo,Myo,2018_modinos_48,1,Healthy - Low Schizotypy,10.1017/S0033291717003403,,,8.54,1.6,,,
,Myo,Myo,2018_modinos_48,2,Healthy - High Schizotypy,10.1017/S0033291717003403,,,8.72,1.05,,,
,Myo,Myo,2018_moon_227,1,Obsessive-compulsive Disorder,10.1016/j.jad.2017.11.059,0.58,0.14,,,,,
,Myo,Myo,2018_moon_227,2,Control,10.1016/j.jad.2017.11.059,0.54,0.17,,,,,
,Myo,Myo,2018_mora-peris_32,1,HIV - Baseline,10.1097/QAD.0000000000001786,0.66,0.17,,,,,
,Myo,Myo,2018_mora-peris_32,2,HIV - Baseline,10.1097/QAD.0000000000001786,0.74,0.2,,,,,
,Myo,Myo,2018_mora-peris_32,3,HIV - Baseline,10.1097/QAD.0000000000001786,0.6,0.29,,,,,
,Myo,Myo,2018_mora-peris_32,4,HIV - ART Week 48,10.1097/QAD.0000000000001786,0.64,0.15,,,,,
,Myo,Myo,2018_mora-peris_32,5,HIV - ART Week 49,10.1097/QAD.0000000000001786,0.7,0.21,,,,,
,Myo,Myo,2018_mora-peris_32,6,HIV - ART Week 50,10.1097/QAD.0000000000001786,0.59,0.21,,,,,
,Myo,Myo,2018_plitman_273,1,Schizophrenia,10.1016/j.pscychresns.2018.01.004,,,6.54,1.24,,,
,Myo,Myo,2018_plitman_273,2,Control,10.1016/j.pscychresns.2018.01.004,,,5.6,1.82,,,
,Myo,Myo,2018_plitman_273,3,Schizophrenia - Point 1,10.1016/j.pscychresns.2018.01.004,,,6.47,0.83,,,
,Myo,Myo,2018_plitman_273,4,Schizophrenia - Point 2,10.1016/j.pscychresns.2018.01.004,,,6.98,0.9,,,
,Myo,Myo,2018_plitman_273,5,Control - Point 1,10.1016/j.pscychresns.2018.01.004,,,6.46,1.82,,,
,Myo,Myo,2018_plitman_273,6,Control - Point 2,10.1016/j.pscychresns.2018.01.004,,,6.49,1.26,,,
,Myo,Myo,2018_rudler_48,1,"Cirrhosis - Before TIPSS, no MHE",10.1111/apt.14938,,,,,3.7,2.3,
,Myo,Myo,2018_rudler_48,2,"Cirrhosis - Before TIPSS, no MHE",10.1111/apt.14938,,,,,3.5,2,
,Myo,Myo,2018_rudler_48,3,"Cirrhosis - Before TIPSS, MHE",10.1111/apt.14938,,,,,1.3,0.8,
,Myo,Myo,2018_rudler_48,4,"Cirrhosis - Before TIPSS, MHE",10.1111/apt.14938,,,,,1.6,0.7,
,Myo,Myo,2018_rudler_48,5,"Cirrhosis - Before TIPSS, no development of HE after TIPSS",10.1111/apt.14938,,,,,3.4,2.5,
,Myo,Myo,2018_rudler_48,6,"Cirrhosis - Before TIPSS, no development of HE after TIPSS",10.1111/apt.14938,,,,,3.4,2,
,Myo,Myo,2018_rudler_48,7,"Cirrhosis - Before TIPSS, development of HE after TIPSS",10.1111/apt.14938,,,,,2.5,1.8,
,Myo,Myo,2018_rudler_48,8,"Cirrhosis - Before TIPSS, development of HE after TIPSS",10.1111/apt.14938,,,,,2.2,1.6,
,Myo,Myo,2018_rudler_48,9,"Cirrhosis - After TIPSS, no development of HE",10.1111/apt.14938,,,,,1.2,0.8,
,Myo,Myo,2018_rudler_48,10,"Cirrhosis - After TIPSS, no development of HE",10.1111/apt.14938,,,,,1.8,0.6,
,Myo,Myo,2018_rudler_48,11,"Cirrhosis - After TIPSS, development of HE",10.1111/apt.14938,,,,,0.9,0.5,
,Myo,Myo,2018_rudler_48,12,"Cirrhosis - After TIPSS, development of HE",10.1111/apt.14938,,,,,1.3,0.7,
,Myo,Myo,2018_ryan_13,1,Healthy - Sham,10.1371/journal.pone.0198053,0.72,0.02,,,6.4,0.28,
,Myo,Myo,2018_ryan_13,2,Healthy - Transcranial direct current stimulation,10.1371/journal.pone.0198053,0.72,0.02,,,5.9,0.24,
,Myo,Myo,2021_bednarik_15,1,Healthy,10.3389/fnins.2021.609485,,,,,6.34,0.1,
,Myo,Myo,2021_bednarik_15,2,Healthy,10.3389/fnins.2021.609485,,,,,6.21,0.12,
,Myo,Myo,2021_chen_299,5,BD with anxiety,10.1016/j.psychres.2021.113859,,,,,0.51,0.9,
,Myo,Myo,2021_chen_299,6,BD with anxiety,10.1016/j.psychres.2021.113859,,,,,0.64,0.11,
,Myo,Myo,2021_chen_299,11,BD without anxiety,10.1016/j.psychres.2021.113859,,,,,0.55,0.28,
,Myo,Myo,2021_chen_299,12,BD without anxiety,10.1016/j.psychres.2021.113859,,,,,0.43,0.16,
,In,Myo,2021_chenji_282,1,Control,10.1016/j.jad.2020.12.176,,,6.16,1.22,,,
,In,Myo,2021_chenji_282,3,MDD-Normal BMI,10.1016/j.jad.2020.12.176,,,6.48,1.15,,,
,In,Myo,2021_chenji_282,5,MDD-High BMI,10.1016/j.jad.2020.12.176,,,5.8,1.16,,,
,In,Myo,2021_chenji_282,2,Control,10.1016/j.jad.2020.12.176,,,6.18,1.08,,,
,In,Myo,2021_chenji_282,4,MDD-Normal BMI,10.1016/j.jad.2020.12.176,,,6.06,1.1,,,
,In,Myo,2021_chenji_282,6,MDD-High BMI,10.1016/j.jad.2020.12.176,,,6.15,1.12,,,
,Myo,Myo,2020_chen_131,1,Healthy Controls,10.1016/j.ejrad.2020.109252,1.32,0.64,,,,,
,Myo,Myo,2020_chen_131,2,NHE,10.1016/j.ejrad.2020.109252,0.83,0.57,,,,,
,Myo,Myo,2020_chen_131,3,Minimal Hepatic Encephalopathy,10.1016/j.ejrad.2020.109252,0.25,0.36,,,,,
,Ins,Myo,2018_shakory_43,1,Control,10.1038/s41386-018-0163-0,,,7.3,1.01,,,
,Ins,Myo,2018_shakory_43,2,Clinical high risk of psychosis,10.1038/s41386-018-0163-0,,,7.02,1.33,,,
,Ins,Myo,2018_shakory_43,3,First Episode Psychosis,10.1038/s41386-018-0163-0,,,7.38,0.84,,,
,MI,Myo,2020_dehghan_33,1,Control,10.1177/1971400920932793,0.124,,,,,,
,MI,Myo,2020_dehghan_33,1,Control,10.1177/1971400920932793,0.124,,,,,,
,MI,Myo,2020_dehghan_33,2,Migraine without aura,10.1177/1971400920932793,0.474,,,,,,
,MI,Myo,2020_dehghan_33,2,Migraine without aura,10.1177/1971400920932793,0.474,,,,,,
,Myo-Ins,Myo,2020_poletti_11,1,Bipolar Disorder,10.3389/fpsyt.2020.590095,,,5.24,1.06,,,
,Myo-Ins,Myo,2020_poletti_11,2,Healthy Controls,10.3389/fpsyt.2020.590095,,,4.29,0.86,,,
,MI,Myo,2021_faulkner_26,1,Nonsmokers,10.1111/adb.12986,,,,,7.456,0.121,
,MI,Myo,2021_faulkner_26,2,Intermittent smokers,10.1111/adb.12986,,,,,6.655,0.151,
,MI,Myo,2021_faulkner_26,3,Smokers,10.1111/adb.12986,,,,,6.595,0.212,
,Myo,Myo,2018_sheth_276,1,Veterans - Suicidal behavior,10.1016/j.pscychresns.2018.04.004,,,1.54,0.06,,,
,Myo,Myo,2018_sheth_276,2,Veterans - Suicidal behavior,10.1016/j.pscychresns.2018.04.004,,,1.37,0.03,,,
,Myo,Myo,2018_sheth_276,3,Veterans - No suicidal behavior,10.1016/j.pscychresns.2018.04.004,,,1.38,0.1,,,
,Myo,Myo,2018_sheth_276,4,Veterans - No suicidal behavior,10.1016/j.pscychresns.2018.04.004,,,1.28,0.03,,,
,Myo,Myo,2018_singh_60,1,Control,10.1007/s00234-017-1954-4,0.98,0.22,,,,,
,Myo,Myo,2018_singh_60,2,Schizophrenia,10.1007/s00234-017-1954-4,0.85,0.19,,,,,
,Ins,Myo,2018_tan_28,1,Control,10.1007/s00330-018-5443-x,,,,,5,0.9,
,Ins,Myo,2018_tan_28,2,Control,10.1007/s00330-018-5443-x,,,,,5,0.7,
,Ins,Myo,2018_tan_28,3,Control,10.1007/s00330-018-5443-x,,,,,5,0.7,
,Ins,Myo,2018_tan_28,4,Temporal lobe epilespsy,10.1007/s00330-018-5443-x,,,,,4.6,0.9,
,Ins,Myo,2018_tan_28,5,Temporal lobe epilespsy,10.1007/s00330-018-5443-x,,,,,4.5,0.9,
,Ins,Myo,2018_tan_28,6,Temporal lobe epilespsy - Left seizure foci,10.1007/s00330-018-5443-x,,,,,4.4,0.9,
,Ins,Myo,2018_tan_28,7,Temporal lobe epilespsy - Left seizure foci,10.1007/s00330-018-5443-x,,,,,4.9,0.4,
,Ins,Myo,2018_tan_28,8,Temporal lobe epilespsy - Right seizure foci,10.1007/s00330-018-5443-x,,,,,4.2,1,
,Ins,Myo,2018_tan_28,9,Temporal lobe epilespsy - Right seizure foci,10.1007/s00330-018-5443-x,,,,,4.9,0.4,
,Ins,Myo,2018_van_89,1,Control,10.1136/jnnp-2017-316364,,,,,2.95,0.46,
,Ins,Myo,2018_van_89,2,Metachromatic leukodystrophy - Good outcome,10.1136/jnnp-2017-316364,,,,,6.85,1.41,
,Ins,Myo,2018_van_89,3,Metachromatic leukodystrophy - Moderate outcome,10.1136/jnnp-2017-316364,,,,,7.25,1.25,
,Ins,Myo,2018_van_89,4,Metachromatic leukodystrophy - Poor outcome,10.1136/jnnp-2017-316364,,,,,7.05,1.88,
,Ins,Myo,2019_betinaip_39,1,Behavior - ON - 3% Visual Contrast,10.1523/JNEUROSCI.3021-18.2019,,,5.949,0.703,,,
,Ins,Myo,2019_betinaip_39,2,Behavior - ON - 12.5% Visual Contrast,10.1523/JNEUROSCI.3021-18.2019,,,6.022,0.712,,,
,Ins,Myo,2019_betinaip_39,3,Behavior - ON - 50% Visual Contrast,10.1523/JNEUROSCI.3021-18.2019,,,6.034,0.745,,,
,Ins,Myo,2019_betinaip_39,4,Behavior - ON - 100% Visual Contrast,10.1523/JNEUROSCI.3021-18.2019,,,6.004,0.723,,,
,Ins,Myo,2019_betinaip_39,5,Resting,10.1523/JNEUROSCI.3021-18.2019,,,6.048,0.734,,,
,Ins,Myo,2019_betinaip_39,6,Behavior - OFF - 3% Visual Contrast,10.1523/JNEUROSCI.3021-18.2019,,,5.935,0.729,,,
,Ins,Myo,2019_betinaip_39,7,Behavior - OFF - 12.5% Visual Contrast,10.1523/JNEUROSCI.3021-18.2019,,,5.992,0.731,,,
,Ins,Myo,2019_betinaip_39,8,Behavior - OFF - 50% Visual Contrast,10.1523/JNEUROSCI.3021-18.2019,,,5.962,0.752,,,
,Ins,Myo,2019_betinaip_39,9,Behavior - OFF - 100% Visual Contrast,10.1523/JNEUROSCI.3021-18.2019,,,6.026,0.742,,,
,Ins,Myo,2019_betinaip_39,10,Resting,10.1523/JNEUROSCI.3021-18.2019,,,6.099,0.707,,,
,mI,Myo,2019_davitz_50,1,TBI (Post-Concussive),10.1002/jmri.26718,,,,,5.3,1.6,2 +/- 1 Voxels (CSI Acquistion)
,mI,Myo,2019_davitz_50,2,TBI (Post-Concussive),10.1002/jmri.26718,,,,,5,1,4 +/- 2 Voxels (CSI Acquistion)
,mI,Myo,2019_davitz_50,3,TBI (Post-Concussive),10.1002/jmri.26718,,,,,5.4,1.1,6 +/- 3 Voxels (CSI Acquistion)
,mI,Myo,2019_davitz_50,4,TBI (Post-Concussive),10.1002/jmri.26718,,,,,6.4,1.7,2 +/- 1 Voxels (CSI Acquistion)
,mI,Myo,2019_davitz_50,5,TBI (Post-Concussive),10.1002/jmri.26718,,,,,5.5,0.8,3 +/- 1 Voxels (CSI Acquistion)
,mI,Myo,2019_davitz_50,6,Control,10.1002/jmri.26718,,,,,5.2,1,2 +/- 1 Voxels (CSI Acquistion)
,mI,Myo,2019_davitz_50,7,Control,10.1002/jmri.26718,,,,,4.8,1.1,4 +/- 2 Voxels (CSI Acquistion)
,mI,Myo,2019_davitz_50,8,Control,10.1002/jmri.26718,,,,,5.6,1.2,6 +/- 4 Voxels (CSI Acquistion)
,mI,Myo,2019_davitz_50,9,Control,10.1002/jmri.26718,,,,,5.6,1.2,3 +/- 2 Voxels (CSI Acquistion)
,mI,Myo,2019_davitz_50,10,Control,10.1002/jmri.26718,,,,,5.1,1.1,5 +/- 2 Voxels (CSI Acquistion)
,mI,Myo,2019_giapitzakis_81,1,Healthy,10.1002/mrm.27467,,,,,6.4,0.5,
,mI,Myo,2019_giapitzakis_81,2,Healthy,10.1002/mrm.27467,,,,,4.7,0.9,
,Ins,Myo,2019_graf_32,1,Healthy,10.1002/nbm.4083,,,3.7,1.911,,,Med/Quartile --> Mean/Std Wan 2014
,mI,Myo,2019_hansen_33,1,Control,10.1016/j.jdiacomp.2018.12.016,0.87,0.21,,,4.82,1.21,
,mI,Myo,2019_hansen_33,3,Diabetes,10.1016/j.jdiacomp.2018.12.016,0.82,0.13,,,4.8,0.78,
,mIns,Myo,2019_hnilicova_407,1,Control,10.1016/j.jns.2019.116458,0.913,0.358,,,,,
,mIns,Myo,2019_hnilicova_407,2,Multiple Sclerosis,10.1016/j.jns.2019.116458,0.952,0.3,,,,,
,mI,Myo,2019_iwata_85,1,Control,10.1016/j.biopsych.2018.09.009,,,6.55,1.63,,,
,mI,Myo,2019_iwata_85,2,Control,10.1016/j.biopsych.2018.09.009,,,8.79,1.53,,,
,mI,Myo,2019_iwata_85,3,Control,10.1016/j.biopsych.2018.09.009,,,6.86,0.95,,,
,mI,Myo,2019_iwata_85,4,Schizophrenia Ultra-Resistant,10.1016/j.biopsych.2018.09.009,,,7.5,2.25,,,
,mI,Myo,2019_iwata_85,5,Schizophrenia Ultra-Resistant,10.1016/j.biopsych.2018.09.009,,,10.76,1.78,,,
,mI,Myo,2019_iwata_85,6,Schizophrenia Ultra-Resistant,10.1016/j.biopsych.2018.09.009,,,7.58,1.07,,,
,mI,Myo,2019_iwata_85,7,Schizophrenia Non-Ultra Resistant,10.1016/j.biopsych.2018.09.009,,,6.51,1.38,,,
,mI,Myo,2019_iwata_85,8,Schizophrenia Non-Ultra Resistant,10.1016/j.biopsych.2018.09.009,,,10.51,0.99,,,
,mI,Myo,2019_iwata_85,9,Schizophrenia Non-Ultra Resistant,10.1016/j.biopsych.2018.09.009,,,7.74,1.33,,,
,mI,Myo,2019_iwata_85,10,Schizophrenia Non-Treatment Resistant,10.1016/j.biopsych.2018.09.009,,,6.28,1.69,,,
,mI,Myo,2019_iwata_85,11,Schizophrenia Non-Treatment Resistant,10.1016/j.biopsych.2018.09.009,,,9.8,1.42,,,
,mI,Myo,2019_iwata_85,12,Schizophrenia Non-Treatment Resistant,10.1016/j.biopsych.2018.09.009,,,7.59,1.5,,,
,mI,Myo,2019_joe_13,1,Predisposed Alzheimer's Mutation Carriers,10.1007/s11682-018-9913-1,0.91,0.13,4.63,0.66,,,
,mI,Myo,2019_joe_13,2,Predisposed Alzheimer's Mutation Carriers,10.1007/s11682-018-9913-1,0.87,0.11,5.04,0.81,,,
,mI,Myo,2019_joe_13,3,Predisposed Alzheimer's Mutation Carriers,10.1007/s11682-018-9913-1,0.88,0.16,5.86,1.36,,,
,mI,Myo,2019_joe_13,4,Predisposed Alzheimer's Mutation Carriers,10.1007/s11682-018-9913-1,0.88,0.14,5.34,0.97,,,
,mI,Myo,2019_joe_13,5,Predisposed Alzheimer's Non-Carriers,10.1007/s11682-018-9913-1,0.9,0.16,4.72,0.89,,,
,mI,Myo,2019_joe_13,6,Predisposed Alzheimer's Non-Carriers,10.1007/s11682-018-9913-1,0.9,0.11,5.04,1.04,,,
,mI,Myo,2019_joe_13,7,Predisposed Alzheimer's Non-Carriers,10.1007/s11682-018-9913-1,0.79,0.05,5.33,0.62,,,
,mI,Myo,2019_joe_13,8,Predisposed Alzheimer's Non-Carriers,10.1007/s11682-018-9913-1,0.67,0.05,4.27,0.55,,,
,mI,Myo,2019_levin_202,1,Control (Young),10.1016/j.neuroimage.2019.116050,,,3.4,0.5,,,
,mI,Myo,2019_levin_202,2,Middle-Aged,10.1016/j.neuroimage.2019.116050,,,3.33,0.44,,,
,mI,Myo,2019_levin_202,3,Old-Middle Aged,10.1016/j.neuroimage.2019.116050,,,3.3,0.41,,,
,mI,Myo,2019_levin_202,4,Aged,10.1016/j.neuroimage.2019.116050,,,3.08,0.47,,,
,mI,Myo,2019_levin_202,5,Control (Young),10.1016/j.neuroimage.2019.116050,,,3.4,0.6,,,
,mI,Myo,2019_levin_202,6,Middle-Aged,10.1016/j.neuroimage.2019.116050,,,3.4,0.54,,,
,mI,Myo,2019_levin_202,7,Old-Middle Aged,10.1016/j.neuroimage.2019.116050,,,2.93,0.46,,,
,mI,Myo,2019_levin_202,8,Aged,10.1016/j.neuroimage.2019.116050,,,3.06,0.45,,,
,Ins,Myo,2018_veeramuthu_25,1,Complicated mTBI,10.1016/j.acra.2018.01.005,0.978,0.219,1.633,0.347,,,
,Ins,Myo,2018_veeramuthu_25,2,Uncomplicated mTBI,10.1016/j.acra.2018.01.005,1.05,0.101,1.759,0.147,,,
,Ins,Myo,2018_veeramuthu_25,3,Control,10.1016/j.acra.2018.01.005,0.894,0.129,1.576,0.271,,,
,Myo,Myo,2018_volk_39,1,Healthy - Evening,10.1002/hbm.24225,0.5,0.08,3.7,0.32,,,
,Myo,Myo,2018_volk_39,2,Healthy - Morning,10.1002/hbm.24225,0.48,0.08,3.58,0.44,,,
,Myo,Myo,2018_wang_277,1,OCD,10.1016/j.pscychresns.2018.05.004,0.63,0.14,,,,,
,Myo,Myo,2018_wang_277,2,OCD,10.1016/j.pscychresns.2018.05.004,0.65,0.14,,,,,
,Myo,Myo,2018_wang_277,3,Control,10.1016/j.pscychresns.2018.05.004,0.68,0.1,,,,,
,Myo,Myo,2018_wang_277,4,Control,10.1016/j.pscychresns.2018.05.004,0.6,0.2,,,,,
,Ins,Myo,2018_white_43,1,Healthy_Placebo,10.1038/s41386-018-0027-7,,,4.8,0.5,,,
,Ins,Myo,2018_white_43,2,Healthy_d-amphetamine,10.1038/s41386-018-0027-7,,,5.12,0.55,,,
,Ins,Myo,2018_white_43,3,Healthy_methamphetamine,10.1038/s41386-018-0027-7,,,4.86,0.58,,,
,Myo,Myo,2018_wu_9,1,MA dependence (Abstinent),10.3389/fpsyt.2018.00478,0.85,0.09,,,,,
,Myo,Myo,2018_wu_9,2,Control,10.3389/fpsyt.2018.00478,0.8,0.09,,,,,
,Myo,Myo,2018_yeh_30,1,Alzheimer's Disease,10.1017/S1041610217002381,0.85,0.14,,,,,
,Myo,Myo,2018_yeh_30,2,Alzheimer's Disease,10.1017/S1041610217002381,0.98,0.45,,,,,
,Myo,Myo,2018_zarinabad_79,1,Medulloblastoma,10.1002/mrm.26837,,,,,2.29,1.66,
,Myo,Myo,2018_zarinabad_79,2,Pilocytic Astrocytoma,10.1002/mrm.26837,,,,,1.94,1.73,
,Myo,Myo,2018_zarinabad_79,3,Ependymoma,10.1002/mrm.26837,,,,,4.53,2.3,
,Myo,Myo,2018_zhong_241,1,BD - with suicidal ideation,10.1016/j.jad.2018.08.031,0.14,0.07,,,,,
,Myo,Myo,2018_zhong_241,2,BD - with suicidal ideation,10.1016/j.jad.2018.08.031,0.13,0.06,,,,,
,Myo,Myo,2018_zhong_241,3,BD - with suicidal ideation,10.1016/j.jad.2018.08.031,0.15,0.06,,,,,
,Myo,Myo,2018_zhong_241,4,BD - with suicidal ideation,10.1016/j.jad.2018.08.031,0.15,0.06,,,,,
,Myo,Myo,2018_zhong_241,5,BD - with suicidal ideation,10.1016/j.jad.2018.08.031,0.21,0.25,,,,,
,Myo,Myo,2018_zhong_241,6,BD - with suicidal ideation,10.1016/j.jad.2018.08.031,0.18,0.16,,,,,
,Myo,Myo,2018_zhong_241,7,BD - with suicidal ideation,10.1016/j.jad.2018.08.031,0.12,0.05,,,,,
,Myo,Myo,2018_zhong_241,8,BD - with suicidal ideation,10.1016/j.jad.2018.08.031,0.12,0.06,,,,,
,Myo,Myo,2018_zhong_241,9,BD - without suicidal ideation,10.1016/j.jad.2018.08.031,0.13,0.06,,,,,
,Myo,Myo,2018_zhong_241,10,BD - without suicidal ideation,10.1016/j.jad.2018.08.031,0.15,0.05,,,,,
,Myo,Myo,2018_zhong_241,11,BD - without suicidal ideation,10.1016/j.jad.2018.08.031,0.22,0.31,,,,,
,Myo,Myo,2018_zhong_241,12,BD - without suicidal ideation,10.1016/j.jad.2018.08.031,0.26,0.48,,,,,
,Myo,Myo,2018_zhong_241,13,BD - without suicidal ideation,10.1016/j.jad.2018.08.031,0.21,0.32,,,,,
,Myo,Myo,2018_zhong_241,14,BD - without suicidal ideation,10.1016/j.jad.2018.08.031,0.17,0.27,,,,,
,Myo,Myo,2018_zhong_241,15,BD - without suicidal ideation,10.1016/j.jad.2018.08.031,0.12,0.05,,,,,
,Myo,Myo,2018_zhong_241,16,BD - without suicidal ideation,10.1016/j.jad.2018.08.031,0.12,0.05,,,,,
,Myo,Myo,2018_zhong_241,17,Control ,10.1016/j.jad.2018.08.031,0.2,0.27,,,,,
,Myo,Myo,2018_zhong_241,18,Control,10.1016/j.jad.2018.08.031,0.16,0.12,,,,,
,Myo,Myo,2018_zhong_241,19,Control,10.1016/j.jad.2018.08.031,0.16,0.09,,,,,
,Myo,Myo,2018_zhong_241,20,Control,10.1016/j.jad.2018.08.031,0.15,0.09,,,,,
,Myo,Myo,2018_zhong_241,21,Control,10.1016/j.jad.2018.08.031,0.17,0.18,,,,,
,Myo,Myo,2018_zhong_241,22,Control,10.1016/j.jad.2018.08.031,0.13,0.12,,,,,
,Myo,Myo,2018_zhong_241,23,Control,10.1016/j.jad.2018.08.031,0.11,0.04,,,,,
,Myo,Myo,2018_zhong_241,24,Control,10.1016/j.jad.2018.08.031,0.11,0.04,,,,,
,Myo,Myo,2017_cao_42,1,Control,10.1038/npp.2017.39,,,,,,,
,Myo,Myo,2017_cao_42,2,Control,10.1038/npp.2017.39,,,,,,,
,Myo,Myo,2017_cao_42,3,Control,10.1038/npp.2017.39,,,,,,,
,Myo,Myo,2017_cao_42,4,Control,10.1038/npp.2017.39,,,,,,,
,Myo,Myo,2017_cao_42,5,BP-1-Non Rapid Cycle ,10.1038/npp.2017.39,,,8.28,0.31,,,
,Myo,Myo,2017_cao_42,6,BP-1-Non Rapid Cycle ,10.1038/npp.2017.39,,,8.37,0.41,,,
,Myo,Myo,2017_cao_42,7,BP-1-Non Rapid Cycle ,10.1038/npp.2017.39,,,6.44,0.3,,,
,Myo,Myo,2017_cao_42,8,BP-1-Non Rapid Cycle ,10.1038/npp.2017.39,,,7.9,0.53,,,
,Myo,Myo,2017_cao_42,9,BP-1-Rapid Cycle ,10.1038/npp.2017.39,,,8.52,0.44,,,
,Myo,Myo,2017_cao_42,10,BP-1-Rapid Cycle ,10.1038/npp.2017.39,,,9.78,0.58,,,
,Myo,Myo,2017_cao_42,11,BP-1-Rapid Cycle ,10.1038/npp.2017.39,,,5.84,0.35,,,
,Myo,Myo,2017_cao_42,12,BP-1-Rapid Cycle ,10.1038/npp.2017.39,,,7.68,0.65,,,
,Ins,Myo,2017_bustillo_43,1,Control,10.1093/schbul/sbw122,,,,,13.1,2.2,
,Ins,Myo,2017_bustillo_43,2,Schizophrenia,10.1093/schbul/sbw123,,,,,13.6,2.4,
,Myo,Myo,2021_akiyama_61,1,Control,10.2176/nmc.oa.2020-0274,,,4.33,1.3,,,
,Myo,Myo,2021_akiyama_61,2,NPH,10.2176/nmc.oa.2020-0274,,,5.3,1.16,,,
,Ins ,Myo,2017_carlson_38,2,Control- Non-dominant Hand ,10.1002/hbm.23472,0.8,0.101,6,0.45,,,
,Ins ,Myo,2017_carlson_38,1,Control- Dominant Hand,10.1002/hbm.23472,0.75,0.725,6,0.3,,,
,Ins ,Myo,2017_carlson_38,4,Bipolar with Periventricular Venous Infarctions- Lesioned Side,10.1002/hbm.23472,0.76,0.075,6.2,1.35,,,
,Ins ,Myo,2017_carlson_38,3,Bipolar with Periventricular Venous Infarctions- Non-lesioned Side,10.1002/hbm.23472,0.75,0.075,5.8,0.9,,,
,Ins ,Myo,2017_carlson_38,5,Bipolar with Arterial Ischemic Strokes- Lesioned Side ,10.1002/hbm.23472,0.825,0.057,7,1.125,,,
,Ins ,Myo,2017_carlson_38,6,Bipolar with Arterial Ischemic Strokes- Non-lesioned Side,10.1002/hbm.23472,0.75,0.139,5.8,1.2,,,
,Myo-Ins,Myo,2020_zheng_265,1,Control,10.1016/j.jad.2020.01.059,,,1.78,1.6,,,
,Myo-Ins,Myo,2020_zheng_265,2,Control,10.1016/j.jad.2020.01.059,,,1.52,1.46,,,
,Myo-Ins,Myo,2020_zheng_265,3,Control,10.1016/j.jad.2020.01.059,,,2.02,1.64,,,
,Myo-Ins,Myo,2020_zheng_265,4,OCD,10.1016/j.jad.2020.01.059,,,2.22,1.53,,,
,Myo-Ins,Myo,2020_zheng_265,5,OCD,10.1016/j.jad.2020.01.059,,,2.38,1.6,,,
,Myo-Ins,Myo,2020_zheng_265,6,OCD,10.1016/j.jad.2020.01.059,,,2,1.51,,,
,Myo-Ins,Myo,2020_zheng_265,7,OCD + SPD,10.1016/j.jad.2020.01.059,,,3.32,2.91,,,
,Myo-Ins,Myo,2020_zheng_265,8,OCD + SPD,10.1016/j.jad.2020.01.059,,,2.48,1.6,,,
,Myo-Ins,Myo,2020_zheng_265,9,OCD + SPD,10.1016/j.jad.2020.01.059,,,3.7,3.43,,,
,ml,Myo,2021_gramegna_8,2,Patients with MELAS,10.1002/acn3.51329,0.81,0.27,,,,,
,ml,Myo,2021_gramegna_8,3,Patients with MELAS,10.1002/acn3.51329,1.13,0.33,,,,,
,ml,Myo,2021_gramegna_8,4,Patients with MELAS,10.1002/acn3.51329,0.72,0.13,,,,,
,ml,Myo,2021_gramegna_8,6,Patients with MELAS,10.1002/acn3.51329,0.73,0.07,,,,,
,ml,Myo,2021_gramegna_8,7,Patients with MELAS,10.1002/acn3.51329,0.91,0.19,,,,,
,ml,Myo,2021_gramegna_8,8,Patients with MELAS,10.1002/acn3.51329,0.7,0.16,,,,,
,Myo-Ins,Myo,2020_zhang_33,1,Healthy,10.1002/nbm.4313,0.6,0.1,6.4,1.1,,,
,Myo-Ins,Myo,2020_zhang_33,2,Healthy,10.1002/nbm.4313,0.6,0.1,7.3,1.3,,,
,Myo-Ins,Myo,2020_zhang_33,3,Healthy,10.1002/nbm.4313,0.6,0.1,7,1.4,,,
,Myo-Ins,Myo,2020_zhang_33,4,Healthy,10.1002/nbm.4313,0.6,0.1,7.6,1.3,,,
,Myo-Ins,Myo,2020_zhang_33,5,Healthy,10.1002/nbm.4313,0.6,0.1,8,1.8,,,
,Myo-Ins,Myo,2020_zhang_33,6,Healthy,10.1002/nbm.4313,0.6,0.2,8.8,2.8,,,
,Myo-Ins,Myo,2020_zhang_33,7,Healthy,10.1002/nbm.4313,0.6,0.1,8,2,,,
,Myo-Ins,Myo,2020_zhang_33,8,Healthy,10.1002/nbm.4313,0.6,0.1,7.6,1.4,,,
,Myo-Ins,Myo,2020_zhang_33,9,Healthy,10.1002/nbm.4313,0.6,0.1,7.6,1.9,,,
,Myo-Ins,Myo,2020_zhang_33,10,Healthy,10.1002/nbm.4313,0.7,0.2,10.6,2.9,,,
,Myo-Ins,Myo,2020_zhang_33,11,Healthy,10.1002/nbm.4313,0.7,0.1,10,3.1,,,
,Myo-Ins,Myo,2020_zhang_33,12,Healthy,10.1002/nbm.4313,0.7,0.2,9.8,3.2,,,
,Myo-Ins,Myo,2020_zhang_33,13,Healthy,10.1002/nbm.4313,0.7,0.1,8.5,1.3,,,
,Myo-Ins,Myo,2020_zhang_33,14,Healthy,10.1002/nbm.4313,0.7,0.1,8.5,1,,,
,Myo-Ins,Myo,2020_zhang_33,15,Healthy,10.1002/nbm.4313,0.7,0.1,7.1,1.4,,,
,Myo-Ins,Myo,2020_zhang_33,16,Healthy,10.1002/nbm.4313,0.7,0.2,6.9,2.2,,,
,Myo-Ins,Myo,2020_zhang_33,17,Healthy,10.1002/nbm.4313,0.7,0.2,5.8,1.5,,,
,Myo-Ins,Myo,2020_zhang_33,18,Healthy,10.1002/nbm.4313,0.7,0.1,7.2,2.1,,,
,Myo-Ins,Myo,2020_zhang_33,19,Healthy,10.1002/nbm.4313,0.6,0.1,8.5,1.2,,,
,Myo-Ins,Myo,2020_zhang_33,20,Healthy,10.1002/nbm.4313,0.6,0.1,8.3,1.1,,,
,Myo-Ins,Myo,2020_zhang_33,21,Healthy,10.1002/nbm.4313,0.6,0.1,8.4,1.6,,,
,Myo-Ins,Myo,2020_zhang_33,22,Healthy,10.1002/nbm.4313,0.6,0.1,8.2,1.3,,,
,Myo-Ins,Myo,2020_zhang_33,23,Healthy,10.1002/nbm.4313,0.6,0.1,7.8,1,,,
,Myo-Ins,Myo,2020_zhang_33,24,Healthy,10.1002/nbm.4313,0.6,0.1,7.6,0.9,,,
,Myo-Ins,Myo,2020_zhang_33,25,Healthy,10.1002/nbm.4313,0.6,0.1,8,1,,,
,Myo-Ins,Myo,2020_zhang_33,26,Healthy,10.1002/nbm.4313,0.6,0.1,7.4,0.9,,,
,Myo-Ins,Myo,2020_zhang_33,27,Healthy,10.1002/nbm.4313,0.6,0.1,6.6,1.1,,,
,Myo-Ins,Myo,2020_zhang_33,28,Healthy,10.1002/nbm.4313,0.6,0.1,6.8,0.8,,,
,Myo-Ins,Myo,2020_zhang_33,29,Healthy,10.1002/nbm.4313,0.6,0.1,7.2,1.1,,,
,Myo-Ins,Myo,2020_zhang_33,30,Healthy,10.1002/nbm.4313,0.6,0.1,7.6,1.5,,,
,Myo-Ins,Myo,2020_zhang_33,31,Healthy,10.1002/nbm.4313,0.6,0.1,7.9,1,,,
,Myo-Ins,Myo,2020_zhang_33,32,Healthy,10.1002/nbm.4313,0.6,0.1,7.7,1,,,
,Myo-Ins,Myo,2020_zhang_33,33,Healthy,10.1002/nbm.4313,0.7,0.1,8.2,1.5,,,
,Myo-Ins,Myo,2020_zhang_33,34,Healthy,10.1002/nbm.4313,0.6,0.1,7.6,1.4,,,
,Myo-Ins,Myo,2020_zhang_33,35,Healthy,10.1002/nbm.4313,0.6,0.1,6.7,1.8,,,
,Myo-Ins,Myo,2020_zhang_33,36,Healthy,10.1002/nbm.4313,0.6,0.1,7.1,1.5,,,
,Myo-Ins,Myo,2020_zhang_33,37,Healthy,10.1002/nbm.4313,0.5,0.2,6.2,3.3,,,
,Myo-Ins,Myo,2020_zhang_33,38,Healthy,10.1002/nbm.4313,0.7,0.2,8.8,3.4,,,
,Myo-Ins,Myo,2020_zhang_33,39,Healthy,10.1002/nbm.4313,0.4,0.2,4.8,2.2,,,
,Myo-Ins,Myo,2020_zhang_33,40,Healthy,10.1002/nbm.4313,0.6,0.2,7.6,2.8,,,
,Myo-Ins,Myo,2020_zhang_33,41,Healthy,10.1002/nbm.4313,0.5,0.2,5.2,2.4,,,
,Myo-Ins,Myo,2020_zhang_33,42,Healthy,10.1002/nbm.4313,0.5,0.2,6,2.7,,,
,Myo-Ins,Myo,2020_zhang_33,43,Healthy,10.1002/nbm.4313,0.6,0.2,5.4,1.7,,,
,Myo-Ins,Myo,2020_zhang_33,44,Healthy,10.1002/nbm.4313,0.6,0.1,6.3,1.5,,,
,Myo-Ins,Myo,2020_zhang_33,45,Healthy,10.1002/nbm.4313,0.6,0.1,7,0.9,,,
,Myo-Ins,Myo,2020_zhang_33,46,Healthy,10.1002/nbm.4313,0.6,0.1,7.1,1.3,,,
,Myo-Ins,Myo,2020_zhang_33,47,Healthy,10.1002/nbm.4313,0.6,0.1,8.1,1.2,,,
,Myo,Myo,2016_guo_69,1,Control,10.1016/j.comppsych.2016.06.001,0.57,0.23,,,,,
,Myo,Myo,2016_guo_69,2,Control,10.1016/j.comppsych.2016.06.001,0.58,0.19,,,,,
,Myo,Myo,2016_guo_69,3,Control,10.1016/j.comppsych.2016.06.001,0.42,0.15,,,,,
,Myo,Myo,2016_guo_69,4,Control,10.1016/j.comppsych.2016.06.001,0.4,0.18,,,,,
,Myo,Myo,2016_guo_69,5,Amnestic mild cognitive impairment,10.1016/j.comppsych.2016.06.001,0.61,0.08,,,,,
,Myo,Myo,2016_guo_69,6,Amnestic mild cognitive impairment,10.1016/j.comppsych.2016.06.001,0.54,0.06,,,,,
,Myo,Myo,2016_guo_69,7,Amnestic mild cognitive impairment,10.1016/j.comppsych.2016.06.001,0.39,0.07,,,,,
,Myo,Myo,2016_guo_69,8,Amnestic mild cognitive impairment,10.1016/j.comppsych.2016.06.001,0.38,0.11,,,,,
,Myo,Myo,2016_guo_69,9,Alzheimer's disease,10.1016/j.comppsych.2016.06.001,0.84,0.16,,,,,
,Myo,Myo,2016_guo_69,10,Alzheimer's disease,10.1016/j.comppsych.2016.06.001,0.58,0.14,,,,,
,Myo,Myo,2016_guo_69,11,Alzheimer's disease,10.1016/j.comppsych.2016.06.001,0.7,0.22,,,,,
,Myo,Myo,2016_guo_69,12,Alzheimer's disease,10.1016/j.comppsych.2016.06.001,0.43,0.11,,,,,
,Myo,Myo,2016_howells_31,1,In utero alcohol exposure,10.1007/s11011-016-9850-x,1.78,0.41,,,5,1.71,
,Myo,Myo,2016_howells_31,2,In utero alcohol exposure,10.1007/s11011-016-9850-x,2.12,0.32,,,7.28,0.85,
,Myo,Myo,2016_howells_31,3,In utero alcohol exposure - Female,10.1007/s11011-016-9850-x,1.65,0.45,,,4.68,1.91,
,Myo,Myo,2016_howells_31,4,In utero alcohol exposure - Female,10.1007/s11011-016-9850-x,2.1,0.36,,,7.11,0.9,
,Myo,Myo,2016_howells_31,5,In utero alcohol exposure - Male,10.1007/s11011-016-9850-x,1.91,0.34,,,5.37,1.5,
,Myo,Myo,2016_howells_31,6,In utero alcohol exposure - Male,10.1007/s11011-016-9850-x,2.14,0.3,,,7.44,0.79,
,Myo,Myo,2016_howells_31,7,Infants - Control,10.1007/s11011-016-9850-x,1.9,0.31,,,5.8,1.31,
,Myo,Myo,2016_howells_31,8,Infants - Control,10.1007/s11011-016-9850-x,2.15,0.4,,,7.24,0.94,
,Myo,Myo,2016_howells_31,9,Infants - Control_Female,10.1007/s11011-016-9850-x,1.93,0.33,,,5.65,1.45,
,Myo,Myo,2016_howells_31,10,Infants - Control_Female,10.1007/s11011-016-9850-x,2.43,0.36,,,7.09,1.16,
,Myo,Myo,2016_howells_31,11,Infants - Control_Male,10.1007/s11011-016-9850-x,1.87,0.29,,,6.03,1.08,
,Myo,Myo,2016_howells_31,12,Infants - Control_Male,10.1007/s11011-016-9850-x,2.03,0.36,,,7.3,0.86,
,Ins,Myo,2020_su_71,1,Healthy Controls,10.1016/j.jocn.2019.11.021,,,18.81,2.35,,,
,Ins,Myo,2020_su_71,2,Methamphetamine Dependence,10.1016/j.jocn.2019.11.021,,,14.66,33.79,,,
,Myo+Gly,Myo,2016_koob_11,1,Premature Neonates,10.1371/journal.pone.0160990,,,0.179,0.043,,,
,Myo+Gly,Myo,2016_koob_11,2,Premature Neonates,10.1371/journal.pone.0160990,,,0.095,0.024,,,
,Myo+Gly,Myo,2016_koob_11,3,Infants - Control,10.1371/journal.pone.0160990,,,0.197,0.04,,,
,Myo+Gly,Myo,2016_koob_11,4,Infants - Control,10.1371/journal.pone.0160990,,,0.104,0.033,,,
,Myo,Myo,2016_mazuel_278,1,Parkinson's Disease - Drug-on,10.1148/radiol.2015142764,,,4.3,1.3,,,
,Myo,Myo,2016_mazuel_278,2,Parkinson's Disease - Drug-off,10.1148/radiol.2015142764,,,3.8,1.3,,,
,Myo,Myo,2016_mazuel_278,3,Control,10.1148/radiol.2015142764,,,5.6,1.8,,,
,mIns,Myo,2019_marjanska_68,1,Alzheimer's disease,10.3233/JAD-180861,,,,,8.93,1.04,
,mIns,Myo,2019_marjanska_68,2,Alzheimer's disease,10.3233/JAD-180861,,,,,7.84,1.04,
,mIns,Myo,2019_marjanska_68,3,Control,10.3233/JAD-180861,,,,,7.69,1.034,
,mIns,Myo,2019_marjanska_68,4,Control,10.3233/JAD-180861,,,,,7.06,1.034,
,Ins,Myo,2020_basu_10,1,Preterm Infants,10.1038/s41598-020-67188-y,,,6.77,0.22,,,
,Ins,Myo,2020_basu_10,4,Preterm Infants,10.1038/s41598-020-67188-y,,,6.93,0.3,,,
,Ins,Myo,2020_basu_10,7,Preterm Infants,10.1038/s41598-020-67188-y,,,6.59,0.29,,,
,Ins,Myo,2020_basu_10,5,Preterm Infants,10.1038/s41598-020-67188-y,,,6.96,0.32,,,
,Ins,Myo,2020_basu_10,8,Preterm Infants,10.1038/s41598-020-67188-y,,,6.61,0.28,,,
,Myo,Myo,2019_meyer_10,1,Control,10.3389/fneur.2019.00556,,,,,54.75,7.5,
,Myo,Myo,2019_meyer_10,2,Control,10.3389/fneur.2019.00556,,,,,44.15,16.9,
,Myo,Myo,2019_meyer_10,3,Concussion,10.3389/fneur.2019.00556,,,,,47.71,12.26,
,Myo,Myo,2019_meyer_10,4,Concussion,10.3389/fneur.2019.00556,,,,,41.45,22.16,
,Myo,Myo,2019_meyer_10,5,Concussion,10.3389/fneur.2019.00556,,,,,50.17,16.25,
,Myo,Myo,2019_meyer_10,6,Concussion,10.3389/fneur.2019.00556,,,,,48.37,20.92,
,Myo,Myo,2019_meyer_10,7,Concussion,10.3389/fneur.2019.00556,,,,,49.71,5.64,
,Myo,Myo,2019_meyer_10,8,Concussion,10.3389/fneur.2019.00556,,,,,42.51,11.62,
,Myo-Ins,Myo,2020_wang_21,1,ESRD,10.1186/s12882-020-01863-0,0.74,0.1,,,,,
,Myo-Ins,Myo,2020_wang_21,2,ESRD,10.1186/s12882-020-01863-0,0.7,0.1,,,,,
,Myo-Ins,Myo,2020_wang_21,3,ESRD,10.1186/s12882-020-01863-0,0.76,0.13,,,,,
,Myo-Ins,Myo,2020_wang_21,4,ESRD,10.1186/s12882-020-01863-0,0.7,0.14,,,,,
,Myo-Ins,Myo,2020_wang_21,5,ESRD,10.1186/s12882-020-01863-0,0.73,0.15,,,,,
,Myo-Ins,Myo,2020_wang_21,6,ESRD,10.1186/s12882-020-01863-0,0.71,0.13,,,,,
,Myo-Ins,Myo,2020_wang_21,7,ESRD,10.1186/s12882-020-01863-0,0.73,0.13,,,,,
,Myo-Ins,Myo,2020_wang_21,8,ESRD,10.1186/s12882-020-01863-0,0.69,0.11,,,,,
,Myo-Ins,Myo,2020_wang_21,9,Control,10.1186/s12882-020-01863-0,0.64,0.14,,,,,
,Myo-Ins,Myo,2020_wang_21,10,Control,10.1186/s12882-020-01863-0,0.61,0.13,,,,,
,Myo,Myo,2019_monnig_54,1,Healthy - Baseline,10.1093/alcalc/agz062,0.794,0.116,,,,,
,Myo,Myo,2019_monnig_54,2,Healthy - Descending limb,10.1093/alcalc/agz062,0.832,0.08,,,,,
,Myo,Myo,2019_monnig_54,3,Healthy - Baseline,10.1093/alcalc/agz062,0.693,0.168,,,,,
,Myo,Myo,2019_monnig_54,4,Healthy - Descending limb,10.1093/alcalc/agz062,0.721,0.117,,,,,
,Myo,Myo,2019_parmar_73,1,Obsessive-compulsive disorder - Unmedicated - 10mg escitalopram - Baseline,10.1111/pcn.12850,,,3.71,0.67,,,
,Myo,Myo,2019_parmar_73,2,Obsessive-compulsive disorder - Unmedicated - 10mg escitalopram - 12wk,10.1111/pcn.12850,,,3.38,0.81,,,
,Myo,Myo,2019_parmar_73,3,Control,10.1111/pcn.12850,,,3.62,1.22,,,
,Myo,Myo,2019_parmar_73,4,Obsessive-compulsive disorder - Unmedicated - 10mg escitalopram - Baseline,10.1111/pcn.12850,,,4.65,1.22,,,
,Myo,Myo,2019_parmar_73,5,Obsessive-compulsive disorder - Unmedicated - 10mg escitalopram - 12wk,10.1111/pcn.12850,,,4.07,0.89,,,
,Myo,Myo,2019_parmar_73,6,Control,10.1111/pcn.12850,,,4.3,0.8,,,
,Myo,Myo,2019_parmar_73,7,Obsessive-compulsive disorder - Unmedicated - 10mg escitalopram - Baseline,10.1111/pcn.12850,,,4.66,1,,,
,Myo,Myo,2019_parmar_73,8,Obsessive-compulsive disorder - Unmedicated - 10mg escitalopram - 12wk,10.1111/pcn.12850,,,3.8,0.79,,,
,Myo,Myo,2019_parmar_73,9,Control,10.1111/pcn.12850,,,3.74,0.7,,,
,Myo,Myo,2019_pflugrad_14,1,Chronic liver disease - Before OLT,10.1371/journal.pone.0221626,,,1.61,0.73,,,
,Myo,Myo,2019_pflugrad_14,2,Chronic liver disease - Before OLT,10.1371/journal.pone.0221626,,,1.85,,,,"Median,IQR (1.85, 1.31)"
,Myo,Myo,2019_pflugrad_14,3,Chronic liver disease - Before OLT,10.1371/journal.pone.0221626,,,1.43,0.85,,,
,Myo,Myo,2019_pflugrad_14,4,Chronic liver disease - Before OLT_PTE,10.1371/journal.pone.0221626,,,1.44,0.54,,,
,Myo,Myo,2019_pflugrad_14,5,Chronic liver disease - Before OLT_PTE,10.1371/journal.pone.0221626,,,1.32,,,,"Median,IQR (1.32, 1.26)"
,Myo,Myo,2019_pflugrad_14,6,Chronic liver disease - Before OLT_PTE,10.1371/journal.pone.0221626,,,1.13,0.95,,,
,Myo,Myo,2019_pflugrad_14,7,Chronic liver disease - Before OLT_no PTE,10.1371/journal.pone.0221626,,,1.65,0.85,,,
,Myo,Myo,2019_pflugrad_14,8,Chronic liver disease - Before OLT_no PTE,10.1371/journal.pone.0221626,,,1.81,,,,"Median,IQR (1.81, 1.59)"
,Myo,Myo,2019_pflugrad_14,9,Chronic liver disease - Before OLT_no PTE,10.1371/journal.pone.0221626,,,1.54,0.85,,,
,Myo,Myo,2019_pflugrad_14,10,Control,10.1371/journal.pone.0221626,,,2.72,0.32,,,
,Myo,Myo,2019_pflugrad_14,11,Control,10.1371/journal.pone.0221626,,,2.72,,,,"Median,IQR (2.72, .39)"
,Myo,Myo,2019_pflugrad_14,12,Control,10.1371/journal.pone.0221626,,,3.08,0.63,,,
,Myo,Myo,2019_pflugrad_14,13,Chronic liver disease - After OLT,10.1371/journal.pone.0221626,,,2.71,0.5,,,
,Myo,Myo,2019_pflugrad_14,14,Chronic liver disease - After OLT,10.1371/journal.pone.0221626,,,2.82,,,,"Median,IQR (2.82, .86)"
,Myo,Myo,2019_pflugrad_14,15,Chronic liver disease - After OLT,10.1371/journal.pone.0221626,,,2.85,1.06,,,
,Myo,Myo,2019_pflugrad_14,16,Chronic liver disease - After OLT_PTE,10.1371/journal.pone.0221626,,,2.65,0.33,,,
,Myo,Myo,2019_pflugrad_14,17,Chronic liver disease - After OLT_PTE,10.1371/journal.pone.0221626,,,2.5,,,,"Median,IQR (2.5, 1.28)"
,Myo,Myo,2019_pflugrad_14,18,Chronic liver disease - After OLT_PTE,10.1371/journal.pone.0221626,,,2.52,0.54,,,
,Myo,Myo,2019_pflugrad_14,19,Chronic liver disease - After OLT_no PTE,10.1371/journal.pone.0221626,,,2.74,0.58,,,
,Myo,Myo,2019_pflugrad_14,20,Chronic liver disease - After OLT_no PTE,10.1371/journal.pone.0221626,,,2.83,,,,"Median,IQR (2.83, .89)"
,Myo,Myo,2019_pflugrad_14,21,Chronic liver disease - After OLT_no PTE,10.1371/journal.pone.0221626,,,3.03,1.23,,,
,ml,Myo,2021_rowe_133,1,LOGG,10.1016/j.ymgme.2021.06.008,,,,,7.4,1.67,
,ml,Myo,2021_rowe_133,4,LOTS,10.1016/j.ymgme.2021.06.008,,,,,8.1,1.48,
,ml,Myo,2021_rowe_133,7,LOSD,10.1016/j.ymgme.2021.06.008,,,,,5.77,0.58,
,ml,Myo,2021_rowe_133,10,Control,10.1016/j.ymgme.2021.06.008,,,,,5.84,0.81,
,Ins ,Myo,2021_shiga_30,1,Non-progression,10.1016/j.jstrokecerebrovasdis.2021.105747,0.87,0.17,,,,,
,Ins ,Myo,2021_shiga_30,2,Non-progression,10.1016/j.jstrokecerebrovasdis.2021.105747,1.03,0.2,,,,,
,Ins ,Myo,2021_shiga_30,3,Progression,10.1016/j.jstrokecerebrovasdis.2021.105747,0.85,0.14,,,,,
,Ins ,Myo,2021_shiga_30,4,Progression,10.1016/j.jstrokecerebrovasdis.2021.105747,1.03,0.19,,,,,
,mI,Myo,2021_siegel-ramsay_313,1,Control,10.1016/j.pscychresns.2021.111302,,,6.84,1.12,,,
,mI,Myo,2021_siegel-ramsay_313,2,Autism,10.1016/j.pscychresns.2021.111302,,,6.63,1.52,,,
,mI,Myo,2021_soeiro-de-souza_49,1,Bipolar,10.1016/j.euroneuro.2021.03.020,0.72,0.07,,,,,
,mI,Myo,2021_soeiro-de-souza_49,2,Control,10.1016/j.euroneuro.2021.03.020,0.67,0.08,,,,,
,mI,Myo,2020_colizzi_25,1,Healthy,10.1038/s41380-019-0374-8,,,9.67,4.67,,,
,mI,Myo,2020_colizzi_25,2,Healthy,10.1038/s41380-019-0374-8,,,5.12,1.89,,,
,mI,Myo,2020_colizzi_25,3,Healthy,10.1038/s41380-019-0374-8,,,6.06,1.65,,,
,mI,Myo,2020_colizzi_25,4,Psychosis ,10.1038/s41380-019-0374-8,,,8.07,3.47,,,
,mI,Myo,2020_colizzi_25,5,Psychosis ,10.1038/s41380-019-0374-8,,,4.69,0.6,,,
,mI,Myo,2020_colizzi_25,6,Psychosis ,10.1038/s41380-019-0374-8,,,5.37,1.09,,,
,Myo,Myo,2019_prisci_43,1,Alcohol use disorder ,10.1111/acer.13931,,,2.85,0.41,,,
,Myo,Myo,2019_prisci_43,2,Control,10.1111/acer.13931,,,2.8,0.6,,,
,Myo,Myo,2019_schmitz_49,1,Control,10.1111/apt.15256,,,3.181,0.425,,,
,Myo,Myo,2019_schmitz_49,2,Liver transplantation - Calcineurin inhibitor free,10.1111/apt.15256,,,2.719,0.549,,,
,Myo,Myo,2019_schmitz_49,3,Liver transplantation - Calcineurin inhibitor low-dose,10.1111/apt.15256,,,3.13,0.513,,,
,Myo,Myo,2019_schmitz_49,4,Liver transplantation - Calcineurin inhibitor standard-dose,10.1111/apt.15256,,,3.207,0.632,,,
,Myo,Myo,2019_sheth_248,1,PTSD,10.1016/j.jad.2019.01.037,0.76,0.1,1.54,3.20E-05,,,
,Myo,Myo,2019_sheth_248,2,Trauma-exposed ,10.1016/j.jad.2019.01.037,0.69,0.08,1.38,5.10E-05,,,
,Myo,Myo,2019_sheth_248,3,Control,10.1016/j.jad.2019.01.037,0.74,0.11,1.59,4.20E-05,,,
,ml,Myo,2020_lyros_87,1,Healthy Control,10.1016/j.neurobiolaging.2019.11.012,0.97,0.15,,,,,
,ml,Myo,2020_lyros_87,2,Healthy Control ,10.1016/j.neurobiolaging.2019.11.012,0.95,0.15,,,,,
,ml,Myo,2020_lyros_87,3,Alzheimer's disease,10.1016/j.neurobiolaging.2019.11.012,1.11,0.18,,,,,
,ml,Myo,2020_lyros_87,4,Vascular Dementia ,10.1016/j.neurobiolaging.2019.11.012,1.02,0.3,,,,,
,ml,Myo,2020_lyros_87,5,Mixed Type AD and VaD,10.1016/j.neurobiolaging.2019.11.012,1.05,0.24,,,,,
,ml,Myo,2020_lyros_87,6,FTLD,10.1016/j.neurobiolaging.2019.11.012,1.06,0.14,,,,,
,ml,Myo,2020_lyros_87,7,Mild cognitive impairment,10.1016/j.neurobiolaging.2019.11.012,1.04,0.2,,,,,
,ml,Myo,2020_lyros_87,8,Healthy Control,10.1016/j.neurobiolaging.2019.11.012,0.68,0.11,,,,,
,ml,Myo,2020_lyros_87,9,Healthy Control ,10.1016/j.neurobiolaging.2019.11.012,0.59,0.09,,,,,
,ml,Myo,2020_lyros_87,10,Alzheimer's disease,10.1016/j.neurobiolaging.2019.11.012,0.64,0.11,,,,,
,ml,Myo,2020_lyros_87,11,Vascular Dementia ,10.1016/j.neurobiolaging.2019.11.012,0.61,0.15,,,,,
,ml,Myo,2020_lyros_87,12,Mixed Type AD and VaD,10.1016/j.neurobiolaging.2019.11.012,0.58,0.1,,,,,
,ml,Myo,2020_lyros_87,13,FTLD,10.1016/j.neurobiolaging.2019.11.012,0.6,0.14,,,,,
,ml,Myo,2020_lyros_87,14,Mild cognitive impairment,10.1016/j.neurobiolaging.2019.11.012,0.62,,,,,,
,Ins,Myo,2019_smaragdi_93,1,ASPD,10.1016/j.pnpbp.2019.04.002,,,,,6.87,1.08,
,Ins,Myo,2019_smaragdi_93,2,ASPD,10.1016/j.pnpbp.2019.04.002,,,,,9.27,1.32,
,Ins,Myo,2019_smaragdi_93,3,BD,10.1016/j.pnpbp.2019.04.002,,,,,6.72,1.55,
,Ins,Myo,2019_smaragdi_93,4,BD,10.1016/j.pnpbp.2019.04.002,,,,,8.97,1.48,
,Ins,Myo,2019_smaragdi_93,5,HC,10.1016/j.pnpbp.2019.04.002,,,,,6.51,0.75,
,Ins,Myo,2019_smaragdi_93,6,HC,10.1016/j.pnpbp.2019.04.002,,,,,9.07,1.1,
,Myo,Myo,2019_simmonite_26,1,Healthy - Young adults,10.1016/j.acra.2018.07.024,0.6,0.06,,,,,
,Myo,Myo,2019_simmonite_26,2,Healthy - Older adults,10.1016/j.acra.2018.07.024,0.53,0.13,,,,,
,Ins,Myo,2019_starmose_20,1,Control,10.1186/s10194-019-1059-z,0.745,0.2,4.349,0.558,,,
,Ins,Myo,2019_starmose_20,2,Control,10.1186/s10194-019-1059-z,0.774,0.064,4.588,0.389,,,
,Ins,Myo,2019_starmose_20,3,Migraine with aura,10.1186/s10194-019-1059-z,0.685,0.071,4.113,0.459,,,
,Ins,Myo,2019_starmose_20,4,Migraine with aura,10.1186/s10194-019-1059-z,0.752,0.092,4.307,0.413,,,
,mIns,Myo,2019_wagoner_317,1,Non-OI,10.1152/ajpheart.00680.2018,,,5.4,2.91,,,
,mIns,Myo,2019_wagoner_317,2,OI,10.1152/ajpheart.00680.2018,,,7.8,1.327,,,
,mI,Myo,2019_wang_28,1,PTSD,10.1007/s00787-018-1241-x,,,,,8.57,1.36,
,mI,Myo,2019_wang_28,2,PTSD,10.1007/s00787-018-1241-x,,,,,7.65,1.04,
,mI,Myo,2019_wang_28,3,Non-PTSD,10.1007/s00787-018-1241-x,,,,,9.57,1.15,
,mI,Myo,2019_wang_28,4,Non-PTSD,10.1007/s00787-018-1241-x,,,,,8.09,1.25,
,Myo,Myo,2018_horowitz-kraus_12,1,Control,10.3389/fnhum.2018.00466,,,,,5.66,0.58,
,Myo,Myo,2018_horowitz-kraus_12,2,Dyslexia,10.3389/fnhum.2018.00466,,,,,5.76,0.43,
,Ins,Myo,2018_povazan_79,1,Healthy,10.1002/mrm.26778,,,7.5,0.55,,,
,Ins,Myo,2018_povazan_79,2,Healthy,10.1002/mrm.26778,,,7.56,0.55,,,
,Ins,Myo,2018_povazan_79,3,Healthy,10.1002/mrm.26778,,,7.78,0.55,,,
,Ins,Myo,2018_povazan_79,4,Healthy,10.1002/mrm.26778,,,8.38,0.57,,,
,Ins,Myo,2018_povazan_79,5,Healthy,10.1002/mrm.26778,,,7.78,0.6,,,
,Ins,Myo,2018_povazan_79,6,Healthy,10.1002/mrm.26778,,,7.56,1.33,,,
,Ins,Myo,2018_povazan_79,7,Healthy,10.1002/mrm.26778,,,7.22,0.83,,,
,mI,Myo,2020_mazibuko_10,1,Control,10.3390/diagnostics10070482,,,4.07,1.44,,,
,mI,Myo,2020_mazibuko_10,2,Control,10.3390/diagnostics10070482,,,3.97,1.06,,,
,mI,Myo,2020_mazibuko_10,3,Subacute Ischemic Stroke,10.3390/diagnostics10070482,,,4.29,2.06,,,
,mI,Myo,2020_mazibuko_10,4,Subacute Ischemic Stroke,10.3390/diagnostics10070482,,,4.38,2.25,,,
,mI,Myo,2020_mazibuko_10,5,Subacute Ischemic Stroke ,10.3390/diagnostics10070482,,,4.07,3.11,,,
,mI,Myo,2020_mazibuko_10,6,Subacute Ischemic Stroke ,10.3390/diagnostics10070482,,,4.29,1.54,,,
,mI,Myo,2020_mazibuko_10,7,Subacute Ischemic Stroke ,10.3390/diagnostics10070482,,,6.33,3.21,,,
,mI,Myo,2020_mazibuko_10,8,Subacute Ischemic Stroke ,10.3390/diagnostics10070482,,,4.32,1.43,,,
,mI,Myo,2020_menshchikov_84,1,Control,10.1002/mrm.28332,0.609,0.075,,,4.25,0.59,
,mI,Myo,2020_menshchikov_84,2,Mild Traumatic Brain Injury ,10.1002/mrm.28332,0.65,0.04,,,4.58,0.44,
,Myo,Myo,2019_wiegers_62,1,Control,10.1007/s00125-019-4862-9,,,,,5.51,0.79,
,Myo,Myo,2019_wiegers_62,2,Type 1 diabetes - Normal awareness of hypoglycaemia,10.1007/s00125-019-4862-9,,,,,5.45,1.09,
,Myo,Myo,2019_wiegers_62,3,Type 1 diabetes,10.1007/s00125-019-4862-9,,,,,5.86,0.93,
,Myo,Myo,2019_xu_98,1,Non-alcoholic fatty liver disease - No mild cognitive impairment,10.1097/MD.0000000000018189,1.06,0.64,,,,,
,Myo,Myo,2019_xu_98,2,Non-alcoholic fatty liver disease - No mild cognitive impairment,10.1097/MD.0000000000018189,0.9,0.53,,,,,
,Myo,Myo,2019_xu_98,3,Non-alcoholic fatty liver disease - No mild cognitive impairment,10.1097/MD.0000000000018189,0.78,0.36,,,,,
,Myo,Myo,2019_xu_98,4,Non-alcoholic fatty liver disease - No mild cognitive impairment,10.1097/MD.0000000000018189,0.78,0.25,,,,,
,Myo,Myo,2019_xu_98,5,Non-alcoholic fatty liver disease - No mild cognitive impairment,10.1097/MD.0000000000018189,0.86,0.43,,,,,
,Myo,Myo,2019_xu_98,6,Non-alcoholic fatty liver disease - No mild cognitive impairment,10.1097/MD.0000000000018189,1.03,0.89,,,,,
,Myo,Myo,2019_xu_98,7,Non-alcoholic fatty liver disease - Mild cognitive impairment,10.1097/MD.0000000000018189,0.81,0.32,,,,,
,Myo,Myo,2019_xu_98,8,Non-alcoholic fatty liver disease - Mild cognitive impairment,10.1097/MD.0000000000018189,0.8,0.44,,,,,
,Myo,Myo,2019_xu_98,9,Non-alcoholic fatty liver disease - Mild cognitive impairment,10.1097/MD.0000000000018189,0.76,0.37,,,,,
,Myo,Myo,2019_xu_98,10,Non-alcoholic fatty liver disease - Mild cognitive impairment,10.1097/MD.0000000000018189,0.68,0.44,,,,,
,Myo,Myo,2019_xu_98,11,Non-alcoholic fatty liver disease - Mild cognitive impairment,10.1097/MD.0000000000018189,0.88,0.54,,,,,
,Myo,Myo,2019_xu_98,12,Non-alcoholic fatty liver disease - Mild cognitive impairment,10.1097/MD.0000000000018189,0.78,0.3,,,,,
,Ins,Myo,2020_gonen_14,1,Healthy,10.3389/fnins.2020.566643,,,,,7.67,1.2,
,Ins,Myo,2020_gonen_14,2,Healthy,10.3389/fnins.2020.566643,,,,,7.14,0.76,
,Ins,Myo,2020_gonen_14,3,Healthy,10.3389/fnins.2020.566643,,,,,7.69,0.94,
,Ins,Myo,2020_gonen_14,4,Healthy,10.3389/fnins.2020.566643,,,,,7.59,0.9,
,mI,Myo,2018_shan_227,1,Control,10.1016/j.jad.2017.10.030,0.21,0.28,,,,,
,mI,Myo,2018_shan_227,2,Control,10.1016/j.jad.2017.10.030,0.16,0.12,,,,,
,mI,Myo,2018_shan_227,3,Control,10.1016/j.jad.2017.10.030,0.17,0.18,,,,,
,mI,Myo,2018_shan_227,4,Control,10.1016/j.jad.2017.10.030,0.13,0.12,,,,,
,mI,Myo,2018_shan_227,5,Depression,10.1016/j.jad.2017.10.030,0.2,0.2,,,,,
,mI,Myo,2018_shan_227,6,Depression,10.1016/j.jad.2017.10.030,0.14,0.06,,,,,
,mI,Myo,2018_shan_227,7,Depression,10.1016/j.jad.2017.10.030,0.14,0.68,,,,,
,mI,Myo,2018_shan_227,8,Depression,10.1016/j.jad.2017.10.030,0.17,0.2,,,,,
,Myo,Myo,2019_morgenroth_117,4,Trait Anxiety,10.1016/j.cortex.2019.02.021,,,5.67,0.47,,,
,Myo,Myo,2019_morgenroth_117,5,Trait Anxiety - Low trait anxiety,10.1016/j.cortex.2019.02.021,,,5.73,0.5,,,
,Myo,Myo,2019_morgenroth_117,6,Trait Anxiety - High trait anxiety,10.1016/j.cortex.2019.02.021,,,5.62,0.44,,,
,Myo,Myo,2018_soeiro-de-souza_241,1,Control,10.1016/j.jad.2018.08.039,,,,,8.183,1.09,
,Myo,Myo,2018_soeiro-de-souza_241,2,Bipolar,10.1016/j.jad.2018.08.039,,,,,8.156,0.921,
,Myo,Myo,2018_soeiro-de-souza_241,3,Bipolar,10.1016/j.jad.2018.08.039,,,,,8.038,0.898,
,Myo,Myo,2018_soeiro-de-souza_241,4,Bipolar,10.1016/j.jad.2018.08.039,,,,,8.726,1.463,
,mI,Myo,2018_su_241,1,Control,10.1016/j.jad.2018.08.018,,,,,7.05,1.17,
,mI,Myo,2018_su_241,2,Control,10.1016/j.jad.2018.08.018,,,,,9.41,1.14,
,mI,Myo,2018_su_241,3,Control,10.1016/j.jad.2018.08.018,,,,,8.6,1.81,
,mI,Myo,2018_su_241,4,PTSD,10.1016/j.jad.2018.08.018,,,,,8,1.51,
,mI,Myo,2018_su_241,5,PTSD,10.1016/j.jad.2018.08.018,,,,,10.07,1.83,
,mI,Myo,2018_su_241,6,PTSD,10.1016/j.jad.2018.08.018,,,,,10.38,2.1,
,Myo,Myo,2019_nery_21,1,At risk for bipolar disorder,10.1111/bdi.12770,,,,,4.76,0.88,
,Myo,Myo,2019_nery_21,2,At risk for bipolar disorder,10.1111/bdi.12770,,,,,5.41,0.98,
,Myo,Myo,2019_nery_21,3,At risk for bipolar disorder,10.1111/bdi.12770,,,,,5.47,0.94,
,Myo,Myo,2019_nery_21,4,Control,10.1111/bdi.12770,,,,,4.72,0.8,
,Myo,Myo,2019_nery_21,5,Control,10.1111/bdi.12770,,,,,5.26,0.89,
,Myo,Myo,2019_nery_21,6,Control,10.1111/bdi.12770,,,,,5.46,1.06,
,Myo,Myo,2019_nery_21,7,At risk for bipolar disorder - Before first mood episode,10.1111/bdi.12770,,,,,4.29,0.69,
,Myo,Myo,2019_nery_21,8,At risk for bipolar disorder - Before first mood episode,10.1111/bdi.12770,,,,,5.32,1.14,
,Myo,Myo,2019_nery_21,9,At risk for bipolar disorder - Before first mood episode,10.1111/bdi.12770,,,,,5.41,1.28,
,Myo,Myo,2019_nery_21,10,At risk for bipolar disorder - After first mood episode,10.1111/bdi.12770,,,,,4.54,0.65,
,Myo,Myo,2019_nery_21,11,At risk for bipolar disorder - After first mood episode,10.1111/bdi.12770,,,,,4.9,0.72,
,Myo,Myo,2019_nery_21,12,At risk for bipolar disorder - After first mood episode,10.1111/bdi.12770,,,,,5.45,1.15,
,Myo,Myo,2019_nery_21,13,Control,10.1111/bdi.12770,,,,,4.82,0.71,
,Myo,Myo,2019_nery_21,14,Control,10.1111/bdi.12770,,,,,5.16,0.72,
,Myo,Myo,2019_nery_21,15,Control,10.1111/bdi.12770,,,,,5.37,1.33,
,Myo,Myo,2019_nery_21,16,Control,10.1111/bdi.12770,,,,,4.68,0.82,
,Myo,Myo,2019_nery_21,17,Control,10.1111/bdi.12770,,,,,4.9,0.94,
,Myo,Myo,2019_nery_21,18,Control,10.1111/bdi.12770,,,,,5.29,0.63,
,mI,Myo,2019_oneill_111,1,Control,10.1002/bdr2.1460,,,3.4,1,,,
,mI,Myo,2019_oneill_111,2,ADHD,10.1002/bdr2.1460,,,3.6,0.9,,,
,mI,Myo,2019_oneill_111,3,ADHD,10.1002/bdr2.1460,,,3.7,0.7,,,
,mI,Myo,2019_oneill_111,4,ADHD,10.1002/bdr2.1460,,,3.8,0.4,,,
,mI,Myo,2019_oneill_111,5,ADHD,10.1002/bdr2.1460,,,3.3,0.4,,,
,mI,Myo,2019_oneill_111,6,ADHD,10.1002/bdr2.1460,,,3.4,0.8,,,
,Myo,Myo,2019_reid_45,1,Control,10.1093/schbul/sbx190,,,5.03,0.5,,,
,Myo,Myo,2019_reid_45,2,Schizophrenia,10.1093/schbul/sbx190,,,4.88,0.47,,,
,Myo,Myo,2019_tamrazi_40,1,Pediatric atypical teratoid/rhabdoid tumors - ASCL1 Pos.,10.3174/ajnr.A6024,,,9,1.5,,,
,Myo,Myo,2019_tamrazi_40,2,Pediatric atypical teratoid/rhabdoid tumors - ASCL1 Neg.,10.3174/ajnr.A6024,,,4.7,3.6,,,
,Myo-Ins,Myo,2020_demnitz_295,1,Addiction ,10.1016/j.pscychresns.2019.111019,,,,,10.95,2.79,
,Myo-Ins ,Myo,2020_dehghani_83,1,Protocol 1,10.1002/mrm.28066,,,,,2.75,0.47,
,Myo-Ins ,Myo,2020_dehghani_83,2,Protocol 2,10.1002/mrm.28066,,,,,1.2,0.22,
,Myo-Ins ,Myo,2020_dehghani_83,3,Protocol 3,10.1002/mrm.28066,,,,,1.47,0.34,
,mIns,Myo,2020_lind_40,1,Control,10.1523/JNEUROSCI.2883-19.2020,,,,,5.67,0.41,
,mIns,Myo,2020_lind_40,2,Aging,10.1523/JNEUROSCI.2883-19.2020,,,,,6.34,0.97,
,mIns,Myo,2020_lind_40,3,Aging,10.1523/JNEUROSCI.2883-19.2020,,,,,6.31,0.69,
,mIns,Myo,2020_lind_40,4,Control,10.1523/JNEUROSCI.2883-19.2020,,,,,5.16,0.56,
,mIns,Myo,2020_lind_40,5,Aging,10.1523/JNEUROSCI.2883-19.2020,,,,,6.25,0.78,
,mIns,Myo,2020_lind_40,6,Aging,10.1523/JNEUROSCI.2883-19.2020,,,,,5.67,0.74,
,mIns,Myo,2020_lind_40,7,Control,10.1523/JNEUROSCI.2883-19.2020,,,,,5.72,0.61,
,mIns,Myo,2020_lind_40,8,Aging,10.1523/JNEUROSCI.2883-19.2020,,,,,6.55,0.82,
,mIns,Myo,2020_lind_40,9,Aging,10.1523/JNEUROSCI.2883-19.2020,,,,,7.45,0.94,
,mIns,Myo,2020_lind_40,10,Control,10.1523/JNEUROSCI.2883-19.2020,,,,,4.39,0.7,
,mIns,Myo,2020_lind_40,11,Aging,10.1523/JNEUROSCI.2883-19.2020,,,,,4.73,0.47,
,mIns,Myo,2020_lind_40,12,Aging,10.1523/JNEUROSCI.2883-19.2020,,,,,5.25,1.1,
,Ins,Myo,2020_draganov_266,1,Control,10.1016/j.jad.2020.01.138,,,,,4.44,0.7,
,Ins,Myo,2020_draganov_266,2,Depression,10.1016/j.jad.2020.01.138,,,,,4.92,1.3,
,Ins,Myo,2020_draganov_266,3,Depression,10.1016/j.jad.2020.01.138,,,,,4.68,0.99,
,Ins,Myo,2020_draganov_266,4,Depression,10.1016/j.jad.2020.01.138,,,,,5.36,0.82,
,Ins,Myo,2020_macmaster_35,1,Orthopedic Injury,10.1097/HTR.0000000000000535,,,,,5.1,0.63,
,Ins,Myo,2020_macmaster_35,2,Concussion,10.1097/HTR.0000000000000535,,,,,4.88,0.51,
,Ins,Myo,2020_macmaster_35,3,Single Concussion,10.1097/HTR.0000000000000535,,,,,4.82,0.56,
,Ins,Myo,2020_macmaster_35,4,Multiple Concussion,10.1097/HTR.0000000000000535,,,,,4.93,0.48,
,Ins,Myo,2020_macmaster_35,5,Orthopedic Injury,10.1097/HTR.0000000000000535,,,,,5.28,0.6,
,Ins,Myo,2020_macmaster_35,6,Concussion,10.1097/HTR.0000000000000535,,,,,5.06,0.6,
,Ins,Myo,2020_macmaster_35,7,Single Concussion,10.1097/HTR.0000000000000535,,,,,5.22,0.72,
,Ins,Myo,2020_macmaster_35,8,Multiple Concussion,10.1097/HTR.0000000000000535,,,,,4.95,0.47,
,Myo-Ins,Myo,2020_simani_112,1,Healthy Controls,10.1016/j.yebeh.2020.107480,0.27,0.19,,,,,
,Myo-Ins,Myo,2020_simani_112,2,Idiopathic Generalized Epilepsy,10.1016/j.yebeh.2020.107480,0.254,0.12,,,,,
,Myo-Ins,Myo,2020_simani_112,3,Psychogenic Nonepileptic Seizure,10.1016/j.yebeh.2020.107480,0.26,0.09,,,,,
,Myo-Ins,Myo,2020_simani_112,4,Healthy Controls,10.1016/j.yebeh.2020.107480,0.21,0.12,,,,,
,Myo-Ins,Myo,2020_simani_112,5,Idiopathic Generalized Epilepsy,10.1016/j.yebeh.2020.107480,0.27,0.12,,,,,
,Myo-Ins,Myo,2020_simani_112,6,Psychogenic Nonepileptic Seizure,10.1016/j.yebeh.2020.107480,0.26,0.09,,,,,
,Myo-Ins,Myo,2020_simani_112,7,Healthy Controls,10.1016/j.yebeh.2020.107480,0.33,0.02,,,,,
,Myo-Ins,Myo,2020_simani_112,8,Idiopathic Generalized Epilepsy,10.1016/j.yebeh.2020.107480,0.32,0.02,,,,,
,Myo-Ins,Myo,2020_simani_112,9,Psychogenic Nonepileptic Seizure,10.1016/j.yebeh.2020.107480,0.31,0.02,,,,,
,Myo-Ins,Myo,2020_simani_112,10,Healthy Controls,10.1016/j.yebeh.2020.107480,0.33,0.07,,,,,
,Myo-Ins,Myo,2020_simani_112,11,Idiopathic Generalized Epilepsy,10.1016/j.yebeh.2020.107480,0.31,0.16,,,,,
,Myo-Ins,Myo,2020_simani_112,12,Psychogenic Nonepileptic Seizure,10.1016/j.yebeh.2020.107480,0.32,0.19,,,,,
,Myo-Ins,Myo,2020_simani_112,13,Healthy Controls,10.1016/j.yebeh.2020.107480,0.47,0.1,,,,,
,Myo-Ins,Myo,2020_simani_112,14,Idiopathic Generalized Epilepsy,10.1016/j.yebeh.2020.107480,0.55,0.08,,,,,
,Myo-Ins,Myo,2020_simani_112,15,Psychogenic Nonepileptic Seizure,10.1016/j.yebeh.2020.107480,0.49,0.08,,,,,
,Myo-Ins,Myo,2020_simani_112,16,Healthy Controls,10.1016/j.yebeh.2020.107480,0.38,0.4,,,,,
,Myo-Ins,Myo,2020_simani_112,17,Idiopathic Generalized Epilepsy,10.1016/j.yebeh.2020.107480,0.59,0.56,,,,,
,Myo-Ins,Myo,2020_simani_112,18,Psychogenic Nonepileptic Seizure,10.1016/j.yebeh.2020.107480,0.58,0.71,,,,,
,Myo-Ins,Myo,2020_simani_112,19,Healthy Controls,10.1016/j.yebeh.2020.107480,0.21,0.24,,,,,
,Myo-Ins,Myo,2020_simani_112,20,Idiopathic Generalized Epilepsy,10.1016/j.yebeh.2020.107480,0.16,0.09,,,,,
,Myo-Ins,Myo,2020_simani_112,21,Psychogenic Nonepileptic Seizure,10.1016/j.yebeh.2020.107480,0.22,0.3,,,,,
,Myo-Ins,Myo,2020_simani_112,22,Healthy Controls,10.1016/j.yebeh.2020.107480,0.26,0.26,,,,,
,Myo-Ins,Myo,2020_simani_112,23,Idiopathic Generalized Epilepsy,10.1016/j.yebeh.2020.107480,0.32,0.5,,,,,
,Myo-Ins,Myo,2020_simani_112,24,Psychogenic Nonepileptic Seizure,10.1016/j.yebeh.2020.107480,0.27,0.43,,,,,
,Myo-Ins,Myo,2020_ozcelik_31,1,Healthy Controls,10.5080/u25195,0.43,0.17,,,,,
,Myo-Ins,Myo,2020_ozcelik_31,2,Schizophrenia,10.5080/u25195,0.38,0.12,,,,,
,Myo-Ins,Myo,2020_ozcelik_31,3,Schizophrenia,10.5080/u25195,0.38,0.13,,,,,
,Myo-Ins,Myo,2020_ozcelik_31,4,Healthy Controls,10.5080/u25195,0.49,0.3,,,,,
,Myo-Ins,Myo,2020_ozcelik_31,5,Schizophrenia,10.5080/u25195,0.41,0.24,,,,,
,Myo-Ins,Myo,2020_ozcelik_31,6,Schizophrenia,10.5080/u25195,0.41,0.2,,,,,
,Myo-Ins,Myo,2020_ozcelik_31,7,Healthy Controls,10.5080/u25195,0.36,0.08,,,,,
,Myo-Ins,Myo,2020_ozcelik_31,8,Schizophrenia,10.5080/u25195,0.4,0.23,,,,,
,Myo-Ins,Myo,2020_ozcelik_31,9,Schizophrenia,10.5080/u25195,0.47,0.34,,,,,
,Myo,Myo,2020_jasek_54,1,Multiple scclerosis - Late onset,10.5603/PJNNS.a2020.0036,,,4.88,1.4,,,
,Myo,Myo,2020_jasek_54,2,Multiple scclerosis - Typical onset,10.5603/PJNNS.a2020.0036,,,4.49,1.13,,,
,mIns,Myo,2021_imrich_31,1,MS,10.1007/s10286-021-00790-w,1.26,0.09,,,,,
,mIns,Myo,2021_imrich_32,2,MS,10.1007/s10286-021-00790-w,0.99,0.08,,,,,
,mIns,Myo,2021_imrich_33,3,Control,10.1007/s10286-021-00790-w,0.75,0.06,,,,,
,ml,Myo,2020_sheth_123,1,Traumatic Brain Injury,10.1152/jn.00765.2019,,,1.61,0.06,,,
,ml,Myo,2020_sheth_123,2,Non Traumatic Brain Injury,10.1152/jn.00765.2019,,,1.31,0.08,,,
,mI,Myo,2018_giapitzakis_79,1,Healthy,10.1002/mrm.26873,,,,,7.15,0.96,Med/Quartile --> Mean/Std Wan 2014
,mI,Myo,2018_giapitzakis_79,2,Healthy,10.1002/mrm.26873,,,,,6.5,1.69,Med/Quartile --> Mean/Std Greco 2015
,Myo,Myo,2020_mohamadi_101,1,Tension-type headache - Positional release technique - Baseline,10.1016/j.apmr.2020.05.028,0.24,0.06,,,,,
,Myo,Myo,2020_mohamadi_101,2,Tension-type headache - Positional release technique - 5wks,10.1016/j.apmr.2020.05.028,0.22,0.09,,,,,
,Myo,Myo,2020_mohamadi_101,3,Tension-type headache - Positional release technique - Baseline,10.1016/j.apmr.2020.05.028,0.39,0.07,,,,,
,Myo,Myo,2020_mohamadi_101,4,Tension-type headache - Positional release technique - 5wks,10.1016/j.apmr.2020.05.028,0.35,0.09,,,,,
,Myo,Myo,2020_mohamadi_101,5,Tension-type headache - Positional release technique - Baseline,10.1016/j.apmr.2020.05.028,0.39,0.09,,,,,
,Myo,Myo,2020_mohamadi_101,6,Tension-type headache - Positional release technique - 5wks,10.1016/j.apmr.2020.05.028,0.39,0.09,,,,,
,Myo,Myo,2020_mohamadi_101,7,Tension-type headache - Control - Baseline,10.1016/j.apmr.2020.05.028,0.24,0.1,,,,,
,Myo,Myo,2020_mohamadi_101,8,Tension-type headache - Control - 5wks,10.1016/j.apmr.2020.05.028,0.26,0.09,,,,,
,Myo,Myo,2020_mohamadi_101,9,Tension-type headache - Control - Baseline,10.1016/j.apmr.2020.05.028,0.42,0.09,,,,,
,Myo,Myo,2020_mohamadi_101,10,Tension-type headache - Control - 5wks,10.1016/j.apmr.2020.05.028,0.38,0.05,,,,,
,Myo,Myo,2020_mohamadi_101,11,Tension-type headache - Control - Baseline,10.1016/j.apmr.2020.05.028,0.34,0.07,,,,,
,Myo,Myo,2020_mohamadi_101,12,Tension-type headache - Control - 5wks,10.1016/j.apmr.2020.05.028,0.41,0.09,,,,,
,Myo,Myo,2021_egerton_47,1,Psychosis - Antipsychotic responder,10.1093/schbul/sbaa128,,,10.17,2.15,,,
,Myo,Myo,2021_egerton_47,2,Psychosis - Antipsychotic responder,10.1093/schbul/sbaa128,,,6.91,0.79,,,
,Myo,Myo,2021_egerton_47,3,Psychosis - Antipsychotic responder,10.1093/schbul/sbaa128,,,7,1.15,,,
,Myo,Myo,2021_egerton_47,4,Psychosis - Antipsychotic responder,10.1093/schbul/sbaa128,,,7.08,1.41,,,
,Myo,Myo,2021_egerton_47,5,Psychosis - Antipsychotic responder,10.1093/schbul/sbaa128,,,10.25,1.15,,,
,Myo,Myo,2021_egerton_47,6,Psychosis - Antipsychotic responder,10.1093/schbul/sbaa128,,,7.64,0.89,,,
,Myo,Myo,2021_egerton_47,7,Psychosis - Antipsychotic responder,10.1093/schbul/sbaa128,,,7.78,0.56,,,
,Myo,Myo,2021_egerton_47,8,Psychosis - Antipsychotic responder,10.1093/schbul/sbaa128,,,7.41,1.35,,,
,Myo,Myo,2021_egerton_47,9,Psychosis - Antipsychotic non-responder,10.1093/schbul/sbaa128,,,4.19,0.71,,,
,Myo,Myo,2021_egerton_47,10,Psychosis - Antipsychotic non-responder,10.1093/schbul/sbaa128,,,3.46,0.78,,,
,Myo,Myo,2021_egerton_47,11,Psychosis - Antipsychotic non-responder,10.1093/schbul/sbaa128,,,3.86,1.1,,,n=3
,Myo,Myo,2021_egerton_47,12,Psychosis - Antipsychotic non-responder,10.1093/schbul/sbaa128,,,5.65,5.94,,,
,Myo,Myo,2021_egerton_47,13,Psychosis - Antipsychotic non-responder,10.1093/schbul/sbaa128,,,4.27,1.56,,,
,Myo,Myo,2021_egerton_47,14,Psychosis - Antipsychotic non-responder,10.1093/schbul/sbaa128,,,3.69,0.52,,,
,Myo,Myo,2021_egerton_47,15,Psychosis - Antipsychotic non-responder,10.1093/schbul/sbaa128,,,3.97,1.58,,,n=4
,Myo,Myo,2021_egerton_47,16,Psychosis - Antipsychotic non-responder,10.1093/schbul/sbaa128,,,3.88,1.21,,,n=4
,Myo,Myo,2015_guo_15,1,Alzheimer's disease - Depressed,10.1186/s12888-015-0691-7,0.66,0.13,,,,,
,Myo,Myo,2015_guo_15,2,Alzheimer's disease - Depressed,10.1186/s12888-015-0691-7,0.61,0.13,,,,,
,Myo,Myo,2015_guo_15,3,Alzheimer's disease - Non-depressed,10.1186/s12888-015-0691-7,0.58,0.09,,,,,
,Myo,Myo,2015_guo_15,4,Alzheimer's disease - Non-depressed,10.1186/s12888-015-0691-7,0.59,0.09,,,,,
,Ins,Myo,2018_raschke_39,1,Healthy,10.3174/ajnr.A5457,0.721,0.077,12.787,1.039,,,Med/Quartile --> Mean/Std Greco 2015; Greco 2015
,Ins,Myo,2018_raschke_39,2,Healthy,10.3174/ajnr.A5457,0.619,0.032,14.643,0.959,,,Med/Quartile --> Mean/Std Greco 2015; Wan 2014
,Ins,Myo,2016_lopezkolkovsky_75,1,Healthy_Rodent,10.1002/mrm.25602,,,,,5.9,0.6,
,mI,Myo,2021_mitolo_82,1,PPA,10.3233/JAD-210211,0.83,0.11,,,,,
,mI,Myo,2021_mitolo_82,2,AD,10.3233/JAD-210211,0.96,0.14,,,,,
,mI,Myo,2021_mitolo_82,3,Healthy controls,10.3233/JAD-210211,0.79,0.1,,,,,
,Myo,Myo,2021_oneill_35,1,PSY-PLB (placebo),10.1177/02698811211001107,,,,,6.27,1.064,
,Myo,Myo,2021_oneill_35,2,PSY-CBD,10.1177/02698811211001107,,,,,6.41,1.11,
,mI,Myo,2020_tarumi_45,1,Healthy Control,10.1038/s41386-019-0589-z,,,6.25,0.95,,,
,mI,Myo,2020_tarumi_45,2,Treatment Resistant Schizophrenia ,10.1038/s41386-019-0589-z,,,6.49,1.14,,,
,mI,Myo,2020_tarumi_45,3,Non-treatment Resistant Schizophrenia ,10.1038/s41386-019-0589-z,,,6.45,1.13,,,
,mI,Myo,2020_tarumi_45,4,Healthy Control,10.1038/s41386-019-0589-z,,,10.11,1.06,,,
,mI,Myo,2020_tarumi_45,5,Treatment Resistant Schizophrenia ,10.1038/s41386-019-0589-z,,,10.52,1.47,,,
,mI,Myo,2020_tarumi_45,6,Non-treatment Resistant Schizophrenia ,10.1038/s41386-019-0589-z,,,10.99,1.2,,,
,Myo,Myo,2018_burger_185,1,Addiction - Methamphetamine Acute Abstinence,10.1016/j.drugalcdep.2017.11.029,1.011,0.141,,,,,
,Myo,Myo,2018_burger_185,2,Addiction - Methamphetamine Acute Abstinence,10.1016/j.drugalcdep.2017.11.029,1.034,0.128,,,,,
,Myo,Myo,2018_burger_185,3,Addiction - Methamphetamine Acute Abstinence,10.1016/j.drugalcdep.2017.11.029,0.946,0.111,,,,,
,Myo,Myo,2018_burger_185,4,Addiction - Methamphetamine Acute Abstinence,10.1016/j.drugalcdep.2017.11.029,0.949,0.147,,,,,
,Myo,Myo,2018_burger_185,5,Addiction - Methamphetamine Acute Abstinence,10.1016/j.drugalcdep.2017.11.029,0.955,0.118,,,,,
,Myo,Myo,2018_burger_185,6,Addiction - Methamphetamine Acute Abstinence,10.1016/j.drugalcdep.2017.11.029,0.949,0.157,,,,,
,Myo,Myo,2018_burger_185,7,Addiction - Methamphetamine Short-term Abstinence,10.1016/j.drugalcdep.2017.11.029,1.085,0.132,,,,,
,Myo,Myo,2018_burger_185,8,Addiction - Methamphetamine Short-term Abstinence,10.1016/j.drugalcdep.2017.11.029,1.028,0.157,,,,,
,Myo,Myo,2018_burger_185,9,Addiction - Methamphetamine Short-term Abstinence,10.1016/j.drugalcdep.2017.11.029,0.95,0.189,,,,,
,Myo,Myo,2018_burger_185,10,Addiction - Methamphetamine Short-term Abstinence,10.1016/j.drugalcdep.2017.11.029,0.936,0.196,,,,,
,Myo,Myo,2018_burger_185,11,Addiction - Methamphetamine Short-term Abstinence,10.1016/j.drugalcdep.2017.11.029,0.957,0.15,,,,,
,Myo,Myo,2018_burger_185,12,Addiction - Methamphetamine Short-term Abstinence,10.1016/j.drugalcdep.2017.11.029,0.989,0.136,,,,,
,Myo,Myo,2018_burger_185,13,Control,10.1016/j.drugalcdep.2017.11.029,1.008,0.105,,,,,
,Myo,Myo,2018_burger_185,14,Control,10.1016/j.drugalcdep.2017.11.029,1.09,0.127,,,,,
,Myo,Myo,2018_burger_185,15,Control,10.1016/j.drugalcdep.2017.11.029,0.982,0.127,,,,,
,Myo,Myo,2018_burger_185,16,Control,10.1016/j.drugalcdep.2017.11.029,0.978,0.121,,,,,
,Myo,Myo,2018_burger_185,17,Control,10.1016/j.drugalcdep.2017.11.029,0.988,0.108,,,,,
,Myo,Myo,2018_burger_185,18,Control,10.1016/j.drugalcdep.2017.11.029,0.955,0.125,,,,,
,Ins,Myo,2018_deelchand_79,1,Healthy,10.1002/mrm.26788,,,,,8.187,1.138,
,Ins,Myo,2018_deelchand_79,2,Healthy,10.1002/mrm.26788,,,,,7.099,1.138,
,Myo,Myo,2018_guo_27,1,Open-angle glaucoma - Early,10.1097/IJG.0000000000001098,0.812,0.556,,,,,
,Myo,Myo,2018_guo_27,2,Control,10.1097/IJG.0000000000001098,1.385,0.449,,,,,
,Myo,Myo,2018_kameda_34,1,Chronic Low Back Pain,10.1097/AJP.0000000000000583,0.904,0.082,6.277,0.868,,,
,Myo,Myo,2018_kameda_34,2,Control,10.1097/AJP.0000000000000583,0.894,0.092,6.451,0.728,,,
,Myo,Myo,2018_karczewska-kupczewska_103,1,Drug - Intralipid/Heparin Baseline,10.1210/jc.2018-00107,0.534,0.158,0.137,0.056,,,
,Myo,Myo,2018_karczewska-kupczewska_103,2,Drug - Intralipid/Heparin Baseline,10.1210/jc.2018-00107,0.899,0.376,0.181,0.057,,,
,Myo,Myo,2018_karczewska-kupczewska_103,3,Drug - Intralipid/Heparin Baseline,10.1210/jc.2018-00107,0.868,0.292,0.17,0.061,,,
,Myo,Myo,2018_karczewska-kupczewska_103,4,Drug - Intralipid/Heparin 4 hour infusion,10.1210/jc.2018-00107,0.814,0.352,0.206,0.042,,,
,Myo,Myo,2018_karczewska-kupczewska_103,5,Drug - Intralipid/Heparin 4 hour infusion,10.1210/jc.2018-00107,0.929,0.456,0.194,0.084,,,
,Myo,Myo,2018_karczewska-kupczewska_103,6,Drug - Intralipid/Heparin 4 hour infusion,10.1210/jc.2018-00107,0.941,0.274,0.164,0.034,,,
,Myo,Myo,2018_karczewska-kupczewska_103,7,Control - Saline Baseline,10.1210/jc.2018-00107,0.632,0.255,0.164,0.049,,,
,Myo,Myo,2018_karczewska-kupczewska_103,8,Control - Saline Baseline,10.1210/jc.2018-00107,0.814,0.376,0.153,0.063,,,
,Myo,Myo,2018_karczewska-kupczewska_103,9,Control - Saline Baseline,10.1210/jc.2018-00107,0.953,0.614,0.217,0.134,,,
,Myo,Myo,2018_karczewska-kupczewska_103,10,Control - Saline 4 hour infusion,10.1210/jc.2018-00107,0.51,0.152,0.146,0.055,,,
,Myo,Myo,2018_karczewska-kupczewska_103,11,Control - Saline 4 hour infusion,10.1210/jc.2018-00107,0.741,0.631,0.125,0.086,,,
,Myo,Myo,2018_karczewska-kupczewska_103,12,Control - Saline 4 hour infusion,10.1210/jc.2018-00107,1.063,0.309,0.197,0.051,,,
,NAA,NAA,2017_sijens_42,3,control (normal development),10.1016/j.mri.2017.06.001,0.3,0.04,,,,,
,NAA,NAA,2017_sijens_42,7,mild disability,10.1016/j.mri.2017.06.001,0.28,0.03,,,,,
,NAA,NAA,2017_sijens_42,11,deceased,10.1016/j.mri.2017.06.001,0.26,0.02,,,,,
,NAA,NAA,2017_sijens_42,15,control (normal development),10.1016/j.mri.2017.06.001,0.26,0.03,,,,,
,NAA,NAA,2017_sijens_42,19,mild disability,10.1016/j.mri.2017.06.001,0.25,0.03,,,,,
,NAA,NAA,2017_sijens_42,23,deceased,10.1016/j.mri.2017.06.001,0.22,0.04,,,,,
,tNAA,tNAA,2019_andrade_13,1,Control,10.3389/fnhum.2019.00186,1.11,0.16,,,,,
,tNAA,tNAA,2019_andrade_13,2,OCD,10.3389/fnhum.2019.00186,1.18,0.16,,,,,
,NAA,NAA,2019_barbagallo_62,1,Control,10.1016/j.parkreldis.2018.12.008,1.385,0.025,6.8,0.35,,,
,NAA,NAA,2019_barbagallo_62,2,Progressive Supranuclear Palsy,10.1016/j.parkreldis.2018.12.008,1.35,0.07,5.45,0.675,,,
,NAA,NAA,2019_bell_39,1,Behavior,10.1523/JNEUROSCI.2110-18.2019,,,,,8.73,0.77,
,NAA,NAA,2019_bell_39,2,Behavior,10.1523/JNEUROSCI.2110-18.2019,,,,,5.39,1.97,
,NAA,NAA,2019_bell_39,3,Behavior,10.1523/JNEUROSCI.2110-18.2019,,,,,,,
,NAA,NAA,2019_bell_39,4,No-Behavior,10.1523/JNEUROSCI.2110-18.2019,,,,,8.83,2.37,
,NAA,NAA,2019_bell_39,5,No-Behavior,10.1523/JNEUROSCI.2110-18.2019,,,,,5.45,1.54,
,NAA,NAA,2019_bell_39,6,No-Behavior,10.1523/JNEUROSCI.2110-18.2019,,,,,,,
,NAA,tNAA,2019_boban_27,1,Control,10.3174/ajnr.A5160,2.041,0.269,,,,,Assumed Total (tNAA) Based on Analysis Methods
,NAA,tNAA,2019_boban_27,2,Control,10.3174/ajnr.A5160,1.749,0.197,,,,,Assumed Total (tNAA) Based on Analysis Methods
,NAA,tNAA,2019_boban_27,3,Control,10.3174/ajnr.A5160,1.604,0.178,,,,,Assumed Total (tNAA) Based on Analysis Methods
,NAA,tNAA,2019_boban_27,4,Control,10.3174/ajnr.A5160,2.42,0.32,,,,,Assumed Total (tNAA) Based on Analysis Methods
,NAA,tNAA,2019_boban_27,5,Control,10.3174/ajnr.A5160,2.726,0.324,,,,,Assumed Total (tNAA) Based on Analysis Methods
,NAA,tNAA,2019_boban_27,6,Control,10.3174/ajnr.A5160,1.582,0.218,,,,,Assumed Total (tNAA) Based on Analysis Methods
,NAA,tNAA,2019_boban_27,7,Control,10.3174/ajnr.A5160,2.082,0.247,,,,,Assumed Total (tNAA) Based on Analysis Methods
,NAA,tNAA,2019_boban_27,8,Control,10.3174/ajnr.A5160,1.995,0.347,,,,,Assumed Total (tNAA) Based on Analysis Methods
,NAA,tNAA,2019_boban_27,9,Control,10.3174/ajnr.A5160,2.26,0.367,,,,,Assumed Total (tNAA) Based on Analysis Methods
,NAA,tNAA,2019_boban_27,10,Control,10.3174/ajnr.A5160,1.998,0.308,,,,,Assumed Total (tNAA) Based on Analysis Methods
,NAA,tNAA,2019_boban_27,11,Control,10.3174/ajnr.A5160,1.742,0.25,,,,,Assumed Total (tNAA) Based on Analysis Methods
,NAA,tNAA,2019_boban_27,12,Control,10.3174/ajnr.A5160,2.507,0.414,,,,,Assumed Total (tNAA) Based on Analysis Methods
,NAA,tNAA,2019_boban_27,13,HIV,10.3174/ajnr.A5160,1.67,0.325,,,,,Assumed Total (tNAA) Based on Analysis Methods
,NAA,tNAA,2019_boban_27,14,HIV,10.3174/ajnr.A5160,1.53,0.181,,,,,Assumed Total (tNAA) Based on Analysis Methods
,NAA,tNAA,2019_boban_27,15,HIV,10.3174/ajnr.A5160,1.42,0.305,,,,,Assumed Total (tNAA) Based on Analysis Methods
,NAA,tNAA,2019_boban_27,16,HIV,10.3174/ajnr.A5160,2.127,0.335,,,,,Assumed Total (tNAA) Based on Analysis Methods
,NAA,tNAA,2019_boban_27,17,HIV,10.3174/ajnr.A5160,2.249,0.404,,,,,Assumed Total (tNAA) Based on Analysis Methods
,NAA,tNAA,2019_boban_27,18,HIV,10.3174/ajnr.A5160,1.387,0.284,,,,,Assumed Total (tNAA) Based on Analysis Methods
,NAA,tNAA,2019_boban_27,19,HIV,10.3174/ajnr.A5160,1.846,0.273,,,,,Assumed Total (tNAA) Based on Analysis Methods
,NAA,tNAA,2019_boban_27,20,HIV,10.3174/ajnr.A5160,1.592,0.543,,,,,Assumed Total (tNAA) Based on Analysis Methods
,NAA,tNAA,2019_boban_27,21,HIV,10.3174/ajnr.A5160,1.984,0.36,,,,,Assumed Total (tNAA) Based on Analysis Methods
,NAA,tNAA,2019_boban_27,22,HIV,10.3174/ajnr.A5160,1.705,0.219,,,,,Assumed Total (tNAA) Based on Analysis Methods
,NAA,tNAA,2019_boban_27,23,HIV,10.3174/ajnr.A5160,1.479,0.157,,,,,Assumed Total (tNAA) Based on Analysis Methods
,NAA,tNAA,2019_boban_27,24,HIV,10.3174/ajnr.A5160,2.052,0.427,,,,,Assumed Total (tNAA) Based on Analysis Methods
,NAA,tNAA,2019_boban_27,25,HIV - cART,10.3174/ajnr.A5160,1.683,0.362,,,,,Assumed Total (tNAA) Based on Analysis Methods
,NAA,tNAA,2019_boban_27,26,HIV - cART,10.3174/ajnr.A5160,1.597,0.183,,,,,Assumed Total (tNAA) Based on Analysis Methods
,NAA,tNAA,2019_boban_27,27,HIV - cART,10.3174/ajnr.A5160,1.347,0.221,,,,,Assumed Total (tNAA) Based on Analysis Methods
,NAA,tNAA,2019_boban_27,28,HIV - cART,10.3174/ajnr.A5160,2.163,0.35,,,,,Assumed Total (tNAA) Based on Analysis Methods
,NAA,tNAA,2019_boban_27,29,HIV - cART,10.3174/ajnr.A5160,2.441,0.462,,,,,Assumed Total (tNAA) Based on Analysis Methods
,NAA,tNAA,2019_boban_27,30,HIV - cART,10.3174/ajnr.A5160,1.338,0.217,,,,,Assumed Total (tNAA) Based on Analysis Methods
,NAA,tNAA,2019_boban_27,31,HIV - cART,10.3174/ajnr.A5160,1.956,0.283,,,,,Assumed Total (tNAA) Based on Analysis Methods
,NAA,tNAA,2019_boban_27,32,HIV - cART,10.3174/ajnr.A5160,1.551,0.3,,,,,Assumed Total (tNAA) Based on Analysis Methods
,NAA,tNAA,2019_boban_27,33,HIV - cART,10.3174/ajnr.A5160,1.975,0.349,,,,,Assumed Total (tNAA) Based on Analysis Methods
,NAA,tNAA,2019_boban_27,34,HIV - cART,10.3174/ajnr.A5160,1.942,0.226,,,,,Assumed Total (tNAA) Based on Analysis Methods
,NAA,tNAA,2019_boban_27,35,HIV - cART,10.3174/ajnr.A5160,1.54,0.158,,,,,Assumed Total (tNAA) Based on Analysis Methods
,NAA,tNAA,2019_boban_27,36,HIV - cART,10.3174/ajnr.A5160,2.089,0.394,,,,,Assumed Total (tNAA) Based on Analysis Methods
,NAA,tNAA,2019_boban_27,37,HIV - cART_Long,10.1038/s41598-019-56330-0,2.017,0.33,,,,,Assumed Total (tNAA) Based on Analysis Methods
,NAA,tNAA,2019_boban_27,38,HIV - cART_Long,10.1038/s41598-019-56330-0,1.955,0.351,,,,,Assumed Total (tNAA) Based on Analysis Methods
,NAA,tNAA,2019_boban_27,39,HIV - cART_Long,10.1038/s41598-019-56330-0,1.89,0.173,,,,,Assumed Total (tNAA) Based on Analysis Methods
,NAA,tNAA,2019_boban_27,40,HIV - cART_Long,10.1038/s41598-019-56330-0,2.141,0.294,,,,,Assumed Total (tNAA) Based on Analysis Methods
,NAA,tNAA,2019_boban_27,41,HIV - cART_Long,10.1038/s41598-019-56330-0,2.392,0.539,,,,,Assumed Total (tNAA) Based on Analysis Methods
,NAA,tNAA,2019_boban_27,42,HIV - cART_Long,10.1038/s41598-019-56330-0,2.176,0.407,,,,,Assumed Total (tNAA) Based on Analysis Methods
,NAA,tNAA,2019_boban_27,43,HIV - cART_Long,10.1038/s41598-019-56330-0,1.769,0.3,,,,,Assumed Total (tNAA) Based on Analysis Methods
,NAA,tNAA,2019_boban_27,44,HIV - cART_Long,10.1038/s41598-019-56330-0,1.781,0.38,,,,,Assumed Total (tNAA) Based on Analysis Methods
,NAA,tNAA,2019_boban_27,45,HIV - cART_Long,10.1038/s41598-019-56330-0,2.376,0.38,,,,,Assumed Total (tNAA) Based on Analysis Methods
,NAA,tNAA,2019_boban_27,46,HIV - cART_Long,10.1038/s41598-019-56330-0,2.163,0.329,,,,,Assumed Total (tNAA) Based on Analysis Methods
,NAA,tNAA,2019_boban_27,47,HIV - cART_Long,10.1038/s41598-019-56330-0,1.947,0.236,,,,,Assumed Total (tNAA) Based on Analysis Methods
,NAA,tNAA,2019_boban_27,48,HIV - cART_Long,10.1038/s41598-019-56330-0,1.908,0.212,,,,,Assumed Total (tNAA) Based on Analysis Methods
,NAA,NAA,2019_borgan_9,1,Control,10.1038/s41598-019-45018-0,,,,,12.33,1.18,
,NAA,NAA,2019_borgan_9,2,Psychosis,10.1038/s41598-019-45018-0,,,,,12.1,1.38,
,NAA,NAA,2019_borgelt_21,1,Bipolar - First,10.1111/bdi.12782,,,,,6.58,1.73,
,NAA,NAA,2019_borgelt_21,2,Bipolar - First,10.1111/bdi.12782,,,,,10.45,1.4,
,NAA,NAA,2019_borgelt_21,3,Bipolar - First,10.1111/bdi.12782,,,,,8.64,1.37,
,NAA,NAA,2019_borgelt_21,4,Bipolar - Multiple,10.1111/bdi.12782,,,,,6.09,1.59,
,NAA,NAA,2019_borgelt_21,5,Bipolar - Multiple,10.1111/bdi.12782,,,,,9.89,1.48,
,NAA,NAA,2019_borgelt_21,6,Bipolar - Multiple,10.1111/bdi.12782,,,,,8.35,1.37,
,NAA,NAA,2019_bossong_76,1,Control,10.1001/jamapsychiatry.2018.3252,,,,,9.34,1.43,
,NAA,NAA,2019_bossong_76,2,Psychosis - HighRisk,10.1001/jamapsychiatry.2018.3252,,,,,9.34,1.18,
,NAA,NAA,2019_bossong_76,3,Psychosis,10.1001/jamapsychiatry.2018.3252,,,,,9.49,0.8,
,NAA,NAA,2019_brown_29,1,Corticosteroid,10.1016/j.euroneuro.2018.12.012,1.36,0.12,,,,,
,NAA,NAA,2019_brown_29,2,Corticosteroid,10.1016/j.euroneuro.2018.12.012,1.38,0.2,,,,,
,NAA,NAA,2019_brown_29,3,Corticosteroid,10.1016/j.euroneuro.2018.12.012,1.3,0.16,,,,,
,NAA,NAA,2019_brown_29,4,Corticosteroid,10.1016/j.euroneuro.2018.12.012,1.35,0.17,,,,,
,NAA,NAA,2019_brown_29,5,Corticosteroid,10.1016/j.euroneuro.2018.12.012,1.31,0.18,,,,,
,NAA,NAA,2019_brown_29,6,Corticosteroid,10.1016/j.euroneuro.2018.12.012,1.38,0.23,,,,,
,NAA,NAA,2019_brown_29,7,Corticosteroid,10.1016/j.euroneuro.2018.12.012,1.28,0.17,,,,,
,NAA,NAA,2019_brown_29,8,Corticosteroid,10.1016/j.euroneuro.2018.12.012,1.35,0.18,,,,,
,NAA,tNAA,2019_bustillo_246,1,Control <40 GM,10.1016/j.jad.2018.12.064,,,,,19.1,1.4,
,NAA,tNAA,2019_bustillo_246,2,Control <40 WM,10.1016/j.jad.2018.12.064,,,,,17.4,1.2,
,NAA,tNAA,2019_bustillo_246,3,Control >40 GM,10.1016/j.jad.2018.12.064,,,,,19,1.7,
,NAA,tNAA,2019_bustillo_246,4,Control >40 WM,10.1016/j.jad.2018.12.064,,,,,17.4,1.4,
,NAA,tNAA,2019_bustillo_246,5,Bipolar <40 GM,10.1016/j.jad.2018.12.064,,,,,18.5,1.4,
,NAA,tNAA,2019_bustillo_246,6,Bipolar <40 WM,10.1016/j.jad.2018.12.064,,,,,16.9,1.3,
,NAA,tNAA,2019_bustillo_246,7,Bipolar >40 GM,10.1016/j.jad.2018.12.064,,,,,19.2,2.5,
,NAA,tNAA,2019_bustillo_246,8,Bipolar >40 WM,10.1016/j.jad.2018.12.064,,,,,16.8,1.5,
,NAA,tNAA,2019_bustillo_246,9,Schizophrenia <40 GM,10.1016/j.jad.2018.12.064,,,,,19.3,1.7,
,NAA,tNAA,2019_bustillo_246,10,Schizophrenia <40 WM,10.1016/j.jad.2018.12.064,,,,,17.5,1.4,
,NAA,tNAA,2019_bustillo_246,11,Schizophrenia >40 GM,10.1016/j.jad.2018.12.064,,,,,19.6,2.5,
,NAA,tNAA,2019_bustillo_246,12,Schizophrenia >40 WM,10.1016/j.jad.2018.12.064,,,,,16.7,1.8,
,NAA+NAAG,tNAA,2019_basu_9,2,Premature Infant,10.1038/s41598-018-37203-4,0.818,0.258,3.882,1.245,,,
,NAA+NAAG,tNAA,2019_basu_9,6,Premature Infant,10.1038/s41598-018-37203-4,0.793,0.125,2.349,0.67,,,
,NAA,tNAA,2019_cheng_43,1,Control,10.1097/RCT.0000000000000854,1.59,0.35,,,,,Assumed Total (tNAA) Based on Analysis Methods
,NAA,tNAA,2019_cheng_43,2,MMA-HC,10.1097/RCT.0000000000000854,1.28,0.26,,,,,Assumed Total (tNAA) Based on Analysis Methods
,NAA,NAA,2019_cheong_90,1,Control - Visit 1,10.1136/jnnp-2018-318795,,,,,11.193,0.556,
,NAA,NAA,2019_cheong_90,2,Control - Visit 2,10.1136/jnnp-2018-318795,,,,,11.276,0.724,
,NAA,NAA,2019_cheong_90,3,Control - Visit 3,10.1136/jnnp-2018-318795,,,,,11.555,0.222,
,NAA,NAA,2019_cheong_90,4,Control - Visit 1,10.1136/jnnp-2018-318795,,,,,12.387,0.936,
,NAA,NAA,2019_cheong_90,5,Control - Visit 2,10.1136/jnnp-2018-318795,,,,,12.581,1.484,
,NAA,NAA,2019_cheong_90,6,Control - Visit 3,10.1136/jnnp-2018-318795,,,,,12.806,0.775,
,NAA,NAA,2019_cheong_90,7,ALS - Visit 1,10.1136/jnnp-2018-318795,,,,,10.764,0.742,
,NAA,NAA,2019_cheong_90,8,ALS - Visit 2,10.1136/jnnp-2018-318795,,,,,10.462,0.961,
,NAA,NAA,2019_cheong_90,9,ALS - Visit 3,10.1136/jnnp-2018-318795,,,,,10.847,0.686,
,NAA,NAA,2019_cheong_90,10,ALS - Visit 1,10.1136/jnnp-2018-318795,,,,,10.921,1.07,
,NAA,NAA,2019_cheong_90,11,ALS - Visit 2,10.1136/jnnp-2018-318795,,,,,11.148,1.199,
,NAA,NAA,2019_cheong_90,12,ALS - Visit 3,10.1136/jnnp-2018-318795,,,,,11.643,1.385,
,tNAA,tNAA,2019_costigan_40,1,Healthy,10.1002/hbm.24566,,,,,16.39,0.9,
,tNAA,tNAA,2019_costigan_40,4,Healthy,10.1002/hbm.24566,,,,,13.42,1.4,
,NAA,NAA,2019_davies_29,1,High-Risk Psychosis,10.1016/j.euroneuro.2019.03.008,1.23,0.16,8.8,0.84,,,
,NAA,NAA,2019_davies_29,2,High-Risk Psychosis,10.1016/j.euroneuro.2019.03.008,1.24,0.08,14.15,1.23,,,
,NAA,NAA,2019_davies_29,3,High-Risk Psychosis,10.1016/j.euroneuro.2019.03.008,1.58,0.19,11.62,0.69,,,
,NAA,NAA,2019_davies_29,4,High-Risk Psychosis,10.1016/j.euroneuro.2019.03.008,1.24,0.19,9.05,0.9,,,
,NAA,NAA,2019_davies_29,5,High-Risk Psychosis,10.1016/j.euroneuro.2019.03.008,1.24,0.09,14.33,1.12,,,
,NAA,NAA,2019_davies_29,6,High-Risk Psychosis,10.1016/j.euroneuro.2019.03.008,1.59,0.15,11.75,0.87,,,
,tNAA,tNAA,2018_adanyeguh_31,2,Healthy,10.1002/nbm.3880,,,,,10.6,0.4,Estimated Bar Graph
,tNAA,tNAA,2018_adanyeguh_31,4,HD,10.1002/nbm.3880,,,,,10.5,0.5,Estimated Bar Graph
,tNAA,tNAA,2018_adanyeguh_31,1,Healthy,10.1002/nbm.3880,,,,,8.9,0.4,Estimated Bar Graph
,tNAA,tNAA,2018_adanyeguh_31,3,HD,10.1002/nbm.3880,,,,,8.5,0.5,Estimated Bar Graph
,NAA,NAA,2018_al-iedani_108,1,Healthy,10.1016/j.ejrad.2018.09.020,1.45,0.04,,,,,
,NAA,NAA,2018_al-iedani_108,2,Healthy,10.1016/j.ejrad.2018.09.020,1.38,0.02,,,,,
,tNAA,tNAA,2018_al-iedani_108,1,Healthy,10.1016/j.ejrad.2018.09.020,1.59,0.06,,,,,
,tNAA,tNAA,2018_al-iedani_108,2,Healthy,10.1016/j.ejrad.2018.09.020,1.53,0.03,,,,,
,NAA,NAA,2018_an_80,1,Healthy,10.1002/mrm.27172,1.26,0.1,,,,,
,NAA,NAA,2018_atagun_235,1,BD-I,10.1016/j.jad.2018.04.010,,,1.59,0.18,,,
,NAA,NAA,2018_atagun_235,2,BD-I,10.1016/j.jad.2018.04.010,,,1.02,0.13,,,
,NAA,NAA,2018_atagun_235,3,BD-II,10.1016/j.jad.2018.04.010,,,1.72,0.18,,,
,NAA,NAA,2018_atagun_235,4,BD-II,10.1016/j.jad.2018.04.010,,,1.23,0.29,,,
,NAA,NAA,2018_atagun_235,5,Control,10.1016/j.jad.2018.04.010,,,1.74,0.2,,,
,NAA,NAA,2018_atagun_235,6,Control,10.1016/j.jad.2018.04.010,,,1.17,0.13,,,
,tNAA,tNAA,2018_barbagallo_47,4,Control,10.1016/j.parkreldis.2017.11.345,1.68,0.19,11.3,1.81,,,
,tNAA,tNAA,2018_barbagallo_47,5,Control,10.1016/j.parkreldis.2017.11.345,1.71,0.37,11.4,1.39,,,
,tNAA,tNAA,2018_barbagallo_47,6,Control,10.1016/j.parkreldis.2017.11.345,1.65,0.23,12.2,1.76,,,
,tNAA,tNAA,2018_barbagallo_47,1,Essential Tremor,10.1016/j.parkreldis.2017.11.345,1.74,0.21,11.3,2.18,,,
,tNAA,tNAA,2018_barbagallo_47,2,Essential Tremor,10.1016/j.parkreldis.2017.11.345,1.77,0.28,11.9,1.91,,,
,tNAA,tNAA,2018_barbagallo_47,3,Essential Tremor,10.1016/j.parkreldis.2017.11.345,1.71,0.31,12.3,1.65,,,
,tNAA,tNAA,2018_bauer_19,1,Healthy,10.1080/15622975.2016.1262060,,,10.89,1.26,,,
,tNAA,tNAA,2018_bauer_19,2,Healthy,10.1080/15622975.2016.1262060,,,10.62,1.54,,,
,tNAA,tNAA,2018_bauer_19,3,ADHD,10.1080/15622975.2016.1262060,,,11.23,1.16,,,
,tNAA,tNAA,2018_bauer_19,4,ADHD,10.1080/15622975.2016.1262060,,,10.72,0.8,,,
,NAA ,NAA ,2020_mohamadi_10,1,TTH,10.31661/jbpe.v0i0.1039,1.74,31,,,,,
,NAA ,NAA ,2020_mohamadi_10,2,TTH,10.31661/jbpe.v0i0.1039,1.61,0.36,,,,,
,NAA ,NAA ,2020_mohamadi_10,3,TTH,10.31661/jbpe.v0i0.1039,1.43,0.29,,,,,
,NAA,NAA,2018_bednarik_38,1,Healthy,10.1177/0271678X17695291,,,,,12.1,0.7,
,NAA,NAA,2021_akiyama_61,1,Control,10.2176/nmc.oa.2020-0274,,,11.18,0.61,,,
,NAA,NAA,2021_akiyama_61,2,NPH,10.2176/nmc.oa.2020-0274,,,7.53,2.89,,,
,tNAA,tNAA,2021_akiyama_61,1,Control,10.2176/nmc.oa.2020-0274,,,14.34,0.64,,,
,tNAA,tNAA,2021_akiyama_61,2,NPH,10.2176/nmc.oa.2020-0274,,,10.7,3.31,,,
,NAA,NAA,2018_caravaggio_28,1,Healthy,10.1016/j.euroneuro.2017.12.002,,,8.89,1.26,,,
,NAA,NAA,2018_caravaggio_28,2,Healthy,10.1016/j.euroneuro.2017.12.002,,,8.22,1.47,,,
,NAA,NAA,2018_caravaggio_28,3,Healthy,10.1016/j.euroneuro.2017.12.002,,,11.31,1.33,,,
,NAA,NAA,2018_caravaggio_28,4,Healthy,10.1016/j.euroneuro.2017.12.002,,,11.23,0.91,,,
,NAA,NAA,2018_chiu_193,3,First-episode Schizophrenia,10.1016/j.schres.2017.07.021,,,,,10.56,1.88,
,NAA,NAA,2018_chiu_193,4,Healthy,10.1016/j.schres.2017.07.021,,,,,9.51,1.76,
,NAA,tNAA,2018_cichocka_83,1,Healthy,10.5114/pjr.2018.74536,1.8,0.258,,,,,Assumed Total (tNAA) based on Analysis
,NAA,tNAA,2018_cichocka_83,2,Healthy,10.5114/pjr.2018.74536,1.98,0.277,,,,,Assumed Total (tNAA) based on Analysis
,NAA,tNAA,2018_cichocka_83,3,Healthy,10.5114/pjr.2018.74536,1.69,0.261,,,,,Assumed Total (tNAA) based on Analysis
,NAA,tNAA,2018_cichocka_83,4,Healthy,10.5114/pjr.2018.74536,1.61,0.405,,,,,Assumed Total (tNAA) based on Analysis
,NAA,tNAA,2018_cichocka_83,5,Healthy,10.5114/pjr.2018.74536,1.62,0.207,,,,,Assumed Total (tNAA) based on Analysis
,NAA,tNAA,2018_cichocka_83,6,Healthy,10.5114/pjr.2018.74536,1.91,0.403,,,,,Assumed Total (tNAA) based on Analysis
,NAA,tNAA,2018_cichocka_83,7,Healthy,10.5114/pjr.2018.74536,1.31,0.236,,,,,Assumed Total (tNAA) based on Analysis
,NAA,tNAA,2018_cichocka_83,8,Healthy,10.5114/pjr.2018.74536,1.86,0.409,,,,,Assumed Total (tNAA) based on Analysis
,NAA,tNAA,2018_cichocka_83,9,Healthy,10.5114/pjr.2018.74536,1.93,0.319,,,,,Assumed Total (tNAA) based on Analysis
,NAA,tNAA,2018_cichocka_83,10,Healthy,10.5114/pjr.2018.74536,1.66,0.159,,,,,Assumed Total (tNAA) based on Analysis
,NAA,tNAA,2018_cichocka_83,11,Healthy,10.5114/pjr.2018.74536,1.69,0.336,,,,,Assumed Total (tNAA) based on Analysis
,NAA,tNAA,2018_cichocka_83,12,Healthy,10.5114/pjr.2018.74536,1.61,0.271,,,,,Assumed Total (tNAA) based on Analysis
,NAA,tNAA,2018_cichocka_83,13,Healthy,10.5114/pjr.2018.74536,1.65,0.431,,,,,Assumed Total (tNAA) based on Analysis
,NAA,tNAA,2018_cichocka_83,14,Healthy,10.5114/pjr.2018.74536,1.36,0.156,,,,,Assumed Total (tNAA) based on Analysis
,NAA,NAA,2018_cirstea_97,1,Healthy,10.1097/PHM.0000000000000791,,,,,11.2,1.7,
,NAA,NAA,2018_cirstea_97,2,Healthy,10.1097/PHM.0000000000000791,,,,,11.9,2.2,
,NAA,NAA,2018_cirstea_97,3,Healthy,10.1097/PHM.0000000000000791,,,,,12.5,2.1,
,NAA,NAA,2018_cirstea_97,4,Healthy,10.1097/PHM.0000000000000791,,,,,11.6,2,
,NAA,NAA,2018_cirstea_97,5,Healthy,10.1097/PHM.0000000000000791,,,,,12.2,2,
,NAA,NAA,2018_cirstea_97,6,Healthy,10.1097/PHM.0000000000000791,,,,,11.1,2.2,
,NAA,NAA,2018_cirstea_97,7,Stroke,10.1097/PHM.0000000000000791,,,,,9.7,0.9,
,NAA,NAA,2018_cirstea_97,8,Stroke,10.1097/PHM.0000000000000791,,,,,10.8,1.8,
,NAA,NAA,2018_cirstea_97,9,Stroke,10.1097/PHM.0000000000000791,,,,,10.6,1.5,
,NAA,NAA,2018_cirstea_97,10,Stroke,10.1097/PHM.0000000000000791,,,,,10.5,1.1,
,NAA,NAA,2018_cirstea_97,11,Stroke,10.1097/PHM.0000000000000791,,,,,11.7,1.8,
,NAA,NAA,2018_cirstea_97,12,Stroke,10.1097/PHM.0000000000000791,,,,,10.6,1.2,
,NAA,NAA,2018_de_239,1,Postpartum Depression,10.1016/j.jad.2018.07.028,1,0.09,,,,,
,NAA,NAA,2018_de_239,2,Postpartum Euthymic ,10.1016/j.jad.2018.07.028,1.1,0.2,,,,,
,tNAA,tNAA,2018_dejaeger_9,1,Painful Diabetic Polyneuropathy - Pregabalin Visit 1,10.1007/s13300-018-0460-y,,,,,6.32,1.73,
,tNAA,tNAA,2018_dejaeger_9,2,Painful Diabetic Polyneuropathy - Pregabalin Visit 1,10.1007/s13300-018-0460-y,,,,,9.33,1.01,
,tNAA,tNAA,2018_dejaeger_9,3,Painful Diabetic Polyneuropathy - Pregabalin Visit 1,10.1007/s13300-018-0460-y,,,,,10.65,0.91,
,tNAA,tNAA,2018_dejaeger_9,4,Painful Diabetic Polyneuropathy - Pregabalin Visit 1,10.1007/s13300-018-0460-y,,,,,10.62,1.02,
,tNAA,tNAA,2018_dejaeger_9,5,Painful Diabetic Polyneuropathy - Pregabalin Visit 3,10.1007/s13300-018-0460-y,,,,,6.77,1.14,
,tNAA,tNAA,2018_dejaeger_9,6,Painful Diabetic Polyneuropathy - Pregabalin Visit 3,10.1007/s13300-018-0460-y,,,,,9.03,1.27,
,tNAA,tNAA,2018_dejaeger_9,7,Painful Diabetic Polyneuropathy - Pregabalin Visit 3,10.1007/s13300-018-0460-y,,,,,10.83,1.05,
,tNAA,tNAA,2018_dejaeger_9,8,Painful Diabetic Polyneuropathy - Pregabalin Visit 3,10.1007/s13300-018-0460-y,,,,,10.6,0.71,
,tNAA,tNAA,2018_dejaeger_9,9,Painful Diabetic Polyneuropathy - Pregabalin Visit 5,10.1007/s13300-018-0460-y,,,,,5.98,1.59,
,tNAA,tNAA,2018_dejaeger_9,10,Painful Diabetic Polyneuropathy - Pregabalin Visit 5,10.1007/s13300-018-0460-y,,,,,8.36,1.74,
,tNAA,tNAA,2018_dejaeger_9,11,Painful Diabetic Polyneuropathy - Pregabalin Visit 5,10.1007/s13300-018-0460-y,,,,,9.92,1.09,
,tNAA,tNAA,2018_dejaeger_9,12,Painful Diabetic Polyneuropathy - Pregabalin Visit 5,10.1007/s13300-018-0460-y,,,,,9.25,1.66,
,tNAA,tNAA,2018_dejaeger_9,13,Painful Diabetic Polyneuropathy - Pregabalin Visit 7,10.1007/s13300-018-0460-y,,,,,6.17,2.14,
,tNAA,tNAA,2018_dejaeger_9,14,Painful Diabetic Polyneuropathy - Pregabalin Visit 7,10.1007/s13300-018-0460-y,,,,,8.98,1.32,
,tNAA,tNAA,2018_dejaeger_9,15,Painful Diabetic Polyneuropathy - Pregabalin Visit 7,10.1007/s13300-018-0460-y,,,,,10.06,1.49,
,tNAA,tNAA,2018_dejaeger_9,16,Painful Diabetic Polyneuropathy - Pregabalin Visit 7,10.1007/s13300-018-0460-y,,,,,10.88,0.96,
,tNAA,tNAA,2018_dejaeger_9,17,Painful Diabetic Polyneuropathy - Placebo Visit 1,10.1007/s13300-018-0460-y,,,,,7.69,1.35,
,tNAA,tNAA,2018_dejaeger_9,18,Painful Diabetic Polyneuropathy - Placebo Visit 1,10.1007/s13300-018-0460-y,,,,,8.7,1.04,
,tNAA,tNAA,2018_dejaeger_9,19,Painful Diabetic Polyneuropathy - Placebo Visit 1,10.1007/s13300-018-0460-y,,,,,11.11,1.26,
,tNAA,tNAA,2018_dejaeger_9,20,Painful Diabetic Polyneuropathy - Placebo Visit 1,10.1007/s13300-018-0460-y,,,,,10.62,0.89,
,tNAA,tNAA,2018_dejaeger_9,21,Painful Diabetic Polyneuropathy - Placebo Visit 3,10.1007/s13300-018-0460-y,,,,,7.85,1.33,
,tNAA,tNAA,2018_dejaeger_9,22,Painful Diabetic Polyneuropathy - Placebo Visit 3,10.1007/s13300-018-0460-y,,,,,8.76,1.26,
,tNAA,tNAA,2018_dejaeger_9,23,Painful Diabetic Polyneuropathy - Placebo Visit 3,10.1007/s13300-018-0460-y,,,,,10.46,0.98,
,tNAA,tNAA,2018_dejaeger_9,24,Painful Diabetic Polyneuropathy - Placebo Visit 3,10.1007/s13300-018-0460-y,,,,,10.66,1.09,
,tNAA,tNAA,2018_dejaeger_9,25,Painful Diabetic Polyneuropathy - Placebo Visit 5,10.1007/s13300-018-0460-y,,,,,6.76,1.47,
,tNAA,tNAA,2018_dejaeger_9,26,Painful Diabetic Polyneuropathy - Placebo Visit 5,10.1007/s13300-018-0460-y,,,,,8.94,1.14,
,tNAA,tNAA,2018_dejaeger_9,27,Painful Diabetic Polyneuropathy - Placebo Visit 5,10.1007/s13300-018-0460-y,,,,,9.61,2.36,
,tNAA,tNAA,2018_dejaeger_9,28,Painful Diabetic Polyneuropathy - Placebo Visit 5,10.1007/s13300-018-0460-y,,,,,10.09,1.04,
,tNAA,tNAA,2018_dejaeger_9,29,Painful Diabetic Polyneuropathy - Placebo Visit 7,10.1007/s13300-018-0460-y,,,,,7.58,0.95,
,tNAA,tNAA,2018_dejaeger_9,30,Painful Diabetic Polyneuropathy - Placebo Visit 7,10.1007/s13300-018-0460-y,,,,,8.64,1.11,
,tNAA,tNAA,2018_dejaeger_9,31,Painful Diabetic Polyneuropathy - Placebo Visit 7,10.1007/s13300-018-0460-y,,,,,10.46,1.34,
,tNAA,tNAA,2018_dejaeger_9,32,Painful Diabetic Polyneuropathy - Placebo Visit 7,10.1007/s13300-018-0460-y,,,,,10.75,1.81,
,tNAA,tNAA,2018_dejaeger_9,33,Painful Diabetic Polyneuropathy - Pregabalin 0 mg,10.1007/s13300-018-0460-y,,,,,7.17,1.49,
,tNAA,tNAA,2018_dejaeger_9,34,Painful Diabetic Polyneuropathy - Pregabalin 0 mg,10.1007/s13300-018-0460-y,,,,,8.81,1.16,
,tNAA,tNAA,2018_dejaeger_9,35,Painful Diabetic Polyneuropathy - Pregabalin 0 mg,10.1007/s13300-018-0460-y,,,,,10.39,1.55,
,tNAA,tNAA,2018_dejaeger_9,36,Painful Diabetic Polyneuropathy - Pregabalin 0 mg,10.1007/s13300-018-0460-y,,,,,10.33,1.5,
,tNAA,tNAA,2018_dejaeger_9,37,Painful Diabetic Polyneuropathy - Pregabalin 75 mg,10.1007/s13300-018-0460-y,,,,,6.98,1.09,
,tNAA,tNAA,2018_dejaeger_9,38,Painful Diabetic Polyneuropathy - Pregabalin 75 mg,10.1007/s13300-018-0460-y,,,,,8.48,1.33,
,tNAA,tNAA,2018_dejaeger_9,39,Painful Diabetic Polyneuropathy - Pregabalin 75 mg,10.1007/s13300-018-0460-y,,,,,10.79,1.48,
,tNAA,tNAA,2018_dejaeger_9,40,Painful Diabetic Polyneuropathy - Pregabalin 75 mg,10.1007/s13300-018-0460-y,,,,,9.71,2.04,
,tNAA,tNAA,2018_dejaeger_9,41,Painful Diabetic Polyneuropathy - Pregabalin 225 mg,10.1007/s13300-018-0460-y,,,,,6.34,1.81,
,tNAA,tNAA,2018_dejaeger_9,42,Painful Diabetic Polyneuropathy - Pregabalin 225 mg,10.1007/s13300-018-0460-y,,,,,8.51,1.46,
,tNAA,tNAA,2018_dejaeger_9,43,Painful Diabetic Polyneuropathy - Pregabalin 225 mg,10.1007/s13300-018-0460-y,,,,,9.86,1.28,
,tNAA,tNAA,2018_dejaeger_9,44,Painful Diabetic Polyneuropathy - Pregabalin 225 mg,10.1007/s13300-018-0460-y,,,,,9.67,1.51,
,tNAA,tNAA,2018_dejaeger_9,45,Painful Diabetic Polyneuropathy - Pregabalin 450 mg,10.1007/s13300-018-0460-y,,,,,6.78,1.89,
,tNAA,tNAA,2018_dejaeger_9,46,Painful Diabetic Polyneuropathy - Pregabalin 450 mg,10.1007/s13300-018-0460-y,,,,,8.66,1.25,
,tNAA,tNAA,2018_dejaeger_9,47,Painful Diabetic Polyneuropathy - Pregabalin 450 mg,10.1007/s13300-018-0460-y,,,,,9.74,1.77,
,tNAA,tNAA,2018_dejaeger_9,48,Painful Diabetic Polyneuropathy - Pregabalin 450 mg,10.1007/s13300-018-0460-y,,,,,10.13,1.53,
,NAA,NAA,2018_ding_38,1,Healthy - Pre-fasting,10.1177/0271678X17697721,,,10.68,0.64,,,
,NAA,NAA,2018_ding_38,2,Healthy - Pre-fasting,10.1177/0271678X17697721,,,10.87,0.59,,,
,NAA,NAA,2018_ding_38,3,Healthy - Pre-fasting,10.1177/0271678X17697721,,,9.1,0.6,,,
,NAA,NAA,2018_ding_38,4,Healthy - Pre-fasting,10.1177/0271678X17697721,,,9.55,0.68,,,
,NAA,NAA,2018_ding_38,5,Healthy - Pre-fasting,10.1177/0271678X17697721,,,11.3,0.59,,,
,NAA,NAA,2018_ding_38,6,Healthy - Pre-fasting,10.1177/0271678X17697721,,,11.23,0.6,,,
,NAA,NAA,2018_ding_38,7,Healthy - Pre-fasting,10.1177/0271678X17697721,,,10.99,0.61,,,
,NAA,NAA,2018_ding_38,8,Healthy - Pre-fasting,10.1177/0271678X17697721,,,11.27,0.66,,,
,NAA,NAA,2018_ding_38,9,Healthy - Pre-fasting,10.1177/0271678X17697721,,,8.95,0.47,,,
,NAA,NAA,2018_ding_38,10,Healthy - Post-fasting,10.1177/0271678X17697721,,,10.24,0.58,,,
,NAA,NAA,2018_ding_38,11,Healthy - Post-fasting,10.1177/0271678X17697721,,,10.32,0.65,,,
,NAA,NAA,2018_ding_38,12,Healthy - Post-fasting,10.1177/0271678X17697721,,,8.79,0.52,,,
,NAA,NAA,2018_ding_38,13,Healthy - Post-fasting,10.1177/0271678X17697721,,,9.11,0.72,,,
,NAA,NAA,2018_ding_38,14,Healthy - Post-fasting,10.1177/0271678X17697721,,,10.79,0.52,,,
,NAA,NAA,2018_ding_38,15,Healthy - Post-fasting,10.1177/0271678X17697721,,,10.92,0.46,,,
,NAA,NAA,2018_ding_38,16,Healthy - Post-fasting,10.1177/0271678X17697721,,,10.81,0.57,,,
,NAA,NAA,2018_ding_38,17,Healthy - Post-fasting,10.1177/0271678X17697721,,,10.89,0.71,,,
,NAA,NAA,2018_ding_38,18,Healthy - Post-fasting,10.1177/0271678X17697721,,,8.73,0.54,,,
,NAA,NAA,2018_ding_38,19,Healthy - Non-fasting,10.1177/0271678X17697721,,,10.6,0.73,,,
,NAA,NAA,2018_ding_38,20,Healthy - Non-fasting,10.1177/0271678X17697721,,,10.63,0.77,,,
,NAA,NAA,2018_ding_38,21,Healthy - Non-fasting,10.1177/0271678X17697721,,,8.87,0.65,,,
,NAA,NAA,2018_ding_38,22,Healthy - Non-fasting,10.1177/0271678X17697721,,,9.37,0.51,,,
,NAA,NAA,2018_ding_38,23,Healthy - Non-fasting,10.1177/0271678X17697721,,,10.93,0.75,,,
,NAA,NAA,2018_ding_38,24,Healthy - Non-fasting,10.1177/0271678X17697721,,,11.09,0.64,,,
,NAA,NAA,2018_ding_38,25,Healthy - Non-fasting,10.1177/0271678X17697721,,,10.8,0.69,,,
,NAA,NAA,2018_ding_38,26,Healthy - Non-fasting,10.1177/0271678X17697721,,,11.23,0.67,,,
,NAA,NAA,2018_ding_38,27,Healthy - Non-fasting,10.1177/0271678X17697721,,,8.89,0.75,,,
,NAA,NAA,2017_aleks_282,1,Control - Baseline,10.1148/radiol.2016152083,1.91,0.04,,,,,
,NAA,NAA,2017_aleks_282,2,Control - Follow-Up,10.1148/radiol.2016152083,1.9,0.07,,,,,
,NAA,NAA,2017_aleks_282,3,Cervical Spondylotic Myelopathy - Preoperative,10.1148/radiol.2016152083,1.72,0.09,,,,,
,NAA,NAA,2017_aleks_282,4,Cervical Spondylotic Myelopathy - Postoperative,10.1148/radiol.2016152083,1.48,0.08,,,,,
,tNAA,tNAA,2018_egerton_23,1,Healthy - Baseline,10.1038/s41380-018-0082-9,1.24,0.11,,,,,
,tNAA,tNAA,2018_egerton_23,2,Healthy - Baseline,10.1038/s41380-018-0082-9,1.23,0.09,,,,,
,tNAA,tNAA,2018_egerton_23,3,Healthy - Baseline,10.1038/s41380-018-0082-9,1.2,0.07,,,,,
,tNAA,tNAA,2018_egerton_23,4,Healthy - Baseline,10.1038/s41380-018-0082-9,1.61,0.18,,,,,
,tNAA,tNAA,2018_egerton_23,5,Healthy - Baseline,10.1038/s41380-018-0082-9,1.54,0.19,,,,,
,tNAA,tNAA,2018_egerton_23,6,Healthy - Baseline,10.1038/s41380-018-0082-9,1.55,0.19,,,,,
,tNAA,tNAA,2018_egerton_23,7,Healthy - After Amisulpride,10.1038/s41380-018-0082-9,1.26,0.15,,,,,
,tNAA,tNAA,2018_egerton_23,8,Healthy - After Amisulpride,10.1038/s41380-018-0082-9,1.24,0.07,,,,,
,tNAA,tNAA,2018_egerton_23,9,Healthy - After Amisulpride,10.1038/s41380-018-0082-9,1.17,0.04,,,,,
,tNAA,tNAA,2018_egerton_23,10,Healthy - After Amisulpride,10.1038/s41380-018-0082-9,1.65,0.18,,,,,
,tNAA,tNAA,2018_egerton_23,11,Healthy - After Amisulpride,10.1038/s41380-018-0082-9,1.54,0.16,,,,,
,tNAA,tNAA,2018_egerton_23,12,Healthy - After Amisulpride,10.1038/s41380-018-0082-9,1.53,0.1,,,,,
,tNAA,tNAA,2018_egerton_23,13,First Episode Psychosis - Baseline,10.1038/s41380-018-0082-9,1.26,0.12,,,,,
,tNAA,tNAA,2018_egerton_23,14,First Episode Psychosis - Baseline,10.1038/s41380-018-0082-9,1.19,0.09,,,,,
,tNAA,tNAA,2018_egerton_23,15,First Episode Psychosis - Baseline,10.1038/s41380-018-0082-9,1.17,0.06,,,,,
,tNAA,tNAA,2018_egerton_23,16,First Episode Psychosis - Baseline,10.1038/s41380-018-0082-9,1.63,0.18,,,,,
,tNAA,tNAA,2018_egerton_23,17,First Episode Psychosis - Baseline,10.1038/s41380-018-0082-9,1.47,0.18,,,,,
,tNAA,tNAA,2018_egerton_23,18,First Episode Psychosis - Baseline,10.1038/s41380-018-0082-9,1.5,0.18,,,,,
,tNAA,tNAA,2018_egerton_23,19,First Episode Psychosis - After Amisulpride,10.1038/s41380-018-0082-9,1.21,0.13,,,,,
,tNAA,tNAA,2018_egerton_23,20,First Episode Psychosis - After Amisulpride,10.1038/s41380-018-0082-9,1.17,0.09,,,,,
,tNAA,tNAA,2018_egerton_23,21,First Episode Psychosis - After Amisulpride,10.1038/s41380-018-0082-9,1.18,0.08,,,,,
,tNAA,tNAA,2018_egerton_23,22,First Episode Psychosis - After Amisulpride,10.1038/s41380-018-0082-9,1.64,0.17,,,,,
,tNAA,tNAA,2018_egerton_23,23,First Episode Psychosis - After Amisulpride,10.1038/s41380-018-0082-9,1.48,0.14,,,,,
,tNAA,tNAA,2018_egerton_23,24,First Episode Psychosis - After Amisulpride,10.1038/s41380-018-0082-9,1.47,0.12,,,,,
,tNAA,tNAA,2018_egerton_23,25,First Episode Psychosis - Remission (Baseline),10.1038/s41380-018-0082-9,1.24,0.11,,,,,
,tNAA,tNAA,2018_egerton_23,26,First Episode Psychosis - Remission (Baseline),10.1038/s41380-018-0082-9,1.18,0.08,,,,,
,tNAA,tNAA,2018_egerton_23,27,First Episode Psychosis - Remission (Baseline),10.1038/s41380-018-0082-9,1.17,0.07,,,,,
,tNAA,tNAA,2018_egerton_23,28,First Episode Psychosis - Remission (Baseline),10.1038/s41380-018-0082-9,1.62,0.19,,,,,
,tNAA,tNAA,2018_egerton_23,29,First Episode Psychosis - Remission (Baseline),10.1038/s41380-018-0082-9,1.49,0.13,,,,,
,tNAA,tNAA,2018_egerton_23,30,First Episode Psychosis - Remission (Baseline),10.1038/s41380-018-0082-9,1.57,0.17,,,,,
,tNAA,tNAA,2018_egerton_23,31,First Episode Psychosis - Remission (After Amisulpride),10.1038/s41380-018-0082-9,1.2,0.12,,,,,
,tNAA,tNAA,2018_egerton_23,32,First Episode Psychosis - Remission (After Amisulpride),10.1038/s41380-018-0082-9,1.17,0.09,,,,,
,tNAA,tNAA,2018_egerton_23,33,First Episode Psychosis - Remission (After Amisulpride),10.1038/s41380-018-0082-9,1.16,0.05,,,,,
,tNAA,tNAA,2018_egerton_23,34,First Episode Psychosis - Remission (After Amisulpride),10.1038/s41380-018-0082-9,1.63,0.19,,,,,
,tNAA,tNAA,2018_egerton_23,35,First Episode Psychosis - Remission (After Amisulpride),10.1038/s41380-018-0082-9,1.45,0.11,,,,,
,tNAA,tNAA,2018_egerton_23,36,First Episode Psychosis - Remission (After Amisulpride),10.1038/s41380-018-0082-9,1.5,0.11,,,,,
,tNAA,tNAA,2018_egerton_23,37,First Episode Psychosis - No Remission (Baseline),10.1038/s41380-018-0082-9,1.37,0.14,,,,,
,tNAA,tNAA,2018_egerton_23,38,First Episode Psychosis - No Remission (Baseline),10.1038/s41380-018-0082-9,1.2,0.1,,,,,
,tNAA,tNAA,2018_egerton_23,39,First Episode Psychosis - No Remission (Baseline),10.1038/s41380-018-0082-9,1.17,0.07,,,,,
,tNAA,tNAA,2018_egerton_23,40,First Episode Psychosis - No Remission (Baseline),10.1038/s41380-018-0082-9,1.7,0.18,,,,,
,tNAA,tNAA,2018_egerton_23,41,First Episode Psychosis - No Remission (Baseline),10.1038/s41380-018-0082-9,1.44,0.25,,,,,
,tNAA,tNAA,2018_egerton_23,42,First Episode Psychosis - No Remission (Baseline),10.1038/s41380-018-0082-9,1.35,0.12,,,,,
,tNAA,tNAA,2018_egerton_23,43,First Episode Psychosis - No Remission (After Amisulpride),10.1038/s41380-018-0082-9,1.26,0.2,,,,,
,tNAA,tNAA,2018_egerton_23,44,First Episode Psychosis - No Remission (After Amisulpride),10.1038/s41380-018-0082-9,1.17,0.09,,,,,
,tNAA,tNAA,2018_egerton_23,45,First Episode Psychosis - No Remission (After Amisulpride),10.1038/s41380-018-0082-9,1.22,0.14,,,,,
,tNAA,tNAA,2018_egerton_23,46,First Episode Psychosis - No Remission (After Amisulpride),10.1038/s41380-018-0082-9,1.7,0.15,,,,,
,tNAA,tNAA,2018_egerton_23,47,First Episode Psychosis - No Remission (After Amisulpride),10.1038/s41380-018-0082-9,1.54,0.18,,,,,
,tNAA,tNAA,2018_egerton_23,48,First Episode Psychosis - No Remission (After Amisulpride),10.1038/s41380-018-0082-9,1.38,0.11,,,,,
,NAA,NAA,2018_elmaki_36,1,Parkinson's Disease,10.1007/s11604-017-0714-z,,,7.63,0.77,,,
,NAA,NAA,2018_elmaki_36,2,Healthy,10.1007/s11604-017-0714-z,,,7.85,0.72,,,
,tNAA,tNAA,2018_evans_43,1,Control - Baseline,10.1038/s41386-018-0057-1,1.58,0.02,,,,,
,tNAA,tNAA,2018_evans_43,2,Control - Ketamine,10.1038/s41386-018-0057-1,1.57,0.03,,,,,
,tNAA,tNAA,2018_evans_43,3,Control - Placebo,10.1038/s41386-018-0057-1,1.66,0.03,,,,,
,tNAA,tNAA,2018_evans_43,4,Major Depressive Disorder - Baseline,10.1038/s41386-018-0057-1,1.59,0.02,,,,,
,tNAA,tNAA,2018_evans_43,5,Major Depressive Disorder - Ketamine,10.1038/s41386-018-0057-1,1.63,0.02,,,,,
,tNAA,tNAA,2018_evans_43,6,Major Depressive Disorder - Placebo,10.1038/s41386-018-0057-1,1.59,0.02,,,,,
,tNAA,tNAA,2018_ford_10,1,Healthy - Vitamin B (Baseline),10.3390/nu10121860,,,8.46,0.17,,,
,tNAA,tNAA,2018_ford_10,2,Healthy - Placebo (Baseline),10.3390/nu10121860,,,8.36,0.2,,,
,tNAA,tNAA,2018_ford_10,3,Healthy - Vitamin B (6 Months),10.3390/nu10121860,,,8.85,0.13,,,
,tNAA,tNAA,2018_ford_10,4,Healthy - Placebo (6 Months),10.3390/nu10121860,,,8.38,0.14,,,
,NAA,NAA,2018_galinska-skok_2018,1,Schizophrenia,10.1155/2018/3654894,1.75,0.22,0.47,0.08,,,
,NAA,NAA,2018_galinska-skok_2018,2,Schizophrenia,10.1155/2018/3654894,1.83,0.37,0.45,0.11,,,
,NAA,NAA,2018_galinska-skok_2018,3,Bipolar Disorder,10.1155/2018/3654894,1.75,0.32,0.47,0.08,,,
,NAA,NAA,2018_galinska-skok_2018,4,Bipolar Disorder,10.1155/2018/3654894,1.73,0.36,0.39,0.07,,,
,NAA,NAA,2018_galinska-skok_2018,5,Control,10.1155/2018/3654894,1.74,0.21,0.46,0.06,,,
,NAA,NAA,2018_galinska-skok_2018,6,Control,10.1155/2018/3654894,1.78,0.35,0.4,0.08,,,
,tNAA,tNAA,2018_gasparovic_48,1,Preterm Birth - Placebo (Scan 1),10.1007/s00247-017-4052-1,,,14.03,0.9,,,
,tNAA,tNAA,2018_gasparovic_48,2,Preterm Birth - Placebo (Scan 1),10.1007/s00247-017-4052-1,,,12.99,0.91,,,
,tNAA,tNAA,2018_gasparovic_48,3,Preterm Birth - Placebo (Scan 2),10.1007/s00247-017-4052-1,,,14.42,0.94,,,
,tNAA,tNAA,2018_gasparovic_48,4,Preterm Birth - Placebo (Scan 2),10.1007/s00247-017-4052-1,,,13.32,0.89,,,
,tNAA,tNAA,2018_gasparovic_48,5,Preterm Birth - Erythropoiesis Stimulating Agent (Scan 1),10.1007/s00247-017-4052-1,,,14.35,0.99,,,
,tNAA,tNAA,2018_gasparovic_48,6,Preterm Birth - Erythropoiesis Stimulating Agent (Scan 1),10.1007/s00247-017-4052-1,,,12.79,1.3,,,
,tNAA,tNAA,2018_gasparovic_48,7,Preterm Birth - Erythropoiesis Stimulating Agent (Scan 2),10.1007/s00247-017-4052-1,,,14.74,0.7,,,
,tNAA,tNAA,2018_gasparovic_48,8,Preterm Birth - Erythropoiesis Stimulating Agent (Scan 2),10.1007/s00247-017-4052-1,,,13.59,1,,,
,tNAA,tNAA,2018_gasparovic_48,9,Control - Scan 1,10.1007/s00247-017-4052-1,,,14.22,0.96,,,
,tNAA,tNAA,2018_gasparovic_48,10,Control - Scan 1,10.1007/s00247-017-4052-1,,,12.84,1.74,,,
,tNAA,tNAA,2018_gasparovic_48,11,Control - Scan 2,10.1007/s00247-017-4052-1,,,14.66,0.69,,,
,tNAA,tNAA,2018_gasparovic_48,12,Control - Scan 3,10.1007/s00247-017-4052-1,,,13.93,0.76,,,
,NAA,NAA,2018_gramegna_39,1,Mitochondrial Neurogastrointestinal Encephalopathy,10.3174/ajnr.A5507,1.85,0.18,,,6.98,0.79,
,NAA,NAA,2018_gramegna_39,2,Control,10.3174/ajnr.A5507,1.8,0.11,,,9.81,0.94,
,NAA,NAA,2018_harper_17,1,Urologic Chronic Pelvic Pain Syndrome,10.1016/j.nicl.2017.11.014,1.22,0.11,6.79,0.75,,,
,NAA,NAA,2018_harper_17,2,Urologic Chronic Pelvic Pain Syndrome,10.1016/j.nicl.2017.11.014,1.18,0.11,7.1,0.44,,,
,NAA,NAA,2018_harper_17,3,Urologic Chronic Pelvic Pain Syndrome,10.1016/j.nicl.2017.11.014,1.19,0.08,6.98,0.53,,,
,NAA,NAA,2018_harper_17,4,Urologic Chronic Pelvic Pain Syndrome,10.1016/j.nicl.2017.11.014,1.32,0.14,8.28,0.67,,,
,NAA,NAA,2018_harper_17,5,Control,10.1016/j.nicl.2017.11.014,1.24,0.11,6.97,0.55,,,
,NAA,NAA,2018_harper_17,6,Control,10.1016/j.nicl.2017.11.014,1.18,0.1,7.05,0.65,,,
,NAA,NAA,2018_harper_17,7,Control,10.1016/j.nicl.2017.11.014,1.21,0.09,7.12,0.46,,,
,NAA,NAA,2018_harper_17,8,Control,10.1016/j.nicl.2017.11.014,1.38,0.87,8.54,0.58,,,
,NAA,NAA,2018_hegarty_48,1,Autism Spectrum Disorder,10.1007/s10803-018-3613-y,,,13.04,1.66,,,
,NAA,NAA,2018_hegarty_48,2,Autism Spectrum Disorder,10.1007/s10803-018-3613-y,,,15.06,1.85,,,
,NAA,NAA,2018_hegarty_48,3,Control,10.1007/s10803-018-3613-y,,,13.61,2.41,,,
,NAA,NAA,2018_hegarty_48,4,Control,10.1007/s10803-018-3613-y,,,15.61,1.21,,,
,NAA,NAA,2018_hegarty_81,1,Autism Spectrum Disorder,10.1016/j.pnpbp.2017.09.016,1.39,0.17,,,,,
,NAA,NAA,2018_hegarty_81,2,Autism Spectrum Disorder,10.1016/j.pnpbp.2017.09.016,1.22,0.25,,,,,
,NAA,NAA,2018_hegarty_81,3,Control,10.1016/j.pnpbp.2017.09.016,1.47,0.12,,,,,
,NAA,NAA,2018_hegarty_81,4,Control,10.1016/j.pnpbp.2017.09.016,1.24,0.19,,,,,
,NAA,NAA,2018_hegarty_81,5,Autism Spectrum Disorder,10.1016/j.pnpbp.2017.09.016,1.43,0.18,,,,,
,NAA,NAA,2018_hegarty_81,6,Autism Spectrum Disorder,10.1016/j.pnpbp.2017.09.016,1.11,0.17,,,,,
,NAA,NAA,2018_hegarty_81,7,Control,10.1016/j.pnpbp.2017.09.016,1.51,0.18,,,,,
,NAA,NAA,2018_hegarty_81,8,Control,10.1016/j.pnpbp.2017.09.016,1.25,0.38,,,,,
,NAA,NAA,2018_hjelmervik_172,1,Healthy - Menstrual Phase,10.1016/j.neuroimage.2018.01.043,,,7.83,1.09,,,
,NAA,NAA,2018_hjelmervik_172,2,Healthy - Menstrual Phase,10.1016/j.neuroimage.2018.01.043,,,6.93,1.33,,,
,NAA,NAA,2018_hjelmervik_172,3,Healthy - Follicular Phase,10.1016/j.neuroimage.2018.01.043,,,8.12,0.87,,,
,NAA,NAA,2018_hjelmervik_172,4,Healthy - Follicular Phase,10.1016/j.neuroimage.2018.01.043,,,6.82,1.21,,,
,NAA,NAA,2018_hjelmervik_172,5,Healthy - Luteal Phase,10.1016/j.neuroimage.2018.01.043,,,7.55,1.01,,,
,NAA,NAA,2018_hjelmervik_172,6,Healthy - Luteal Phase,10.1016/j.neuroimage.2018.01.043,,,7.01,1.28,,,
,NAA,NAA,2018_hjelmervik_172,7,Healthy - Total,10.1016/j.neuroimage.2018.01.043,,,7.38,0.71,,,
,NAA,NAA,2018_hjelmervik_172,8,Healthy - Session 1,10.1016/j.neuroimage.2018.01.043,,,7.91,0.89,,,
,NAA,NAA,2018_hjelmervik_172,9,Healthy - Session 1,10.1016/j.neuroimage.2018.01.043,,,7.45,1.35,,,
,NAA,NAA,2018_hjelmervik_172,10,Healthy - Session 2,10.1016/j.neuroimage.2018.01.043,,,7.85,0.44,,,
,NAA,NAA,2018_hjelmervik_172,11,Healthy - Session 2,10.1016/j.neuroimage.2018.01.043,,,7.2,1.18,,,
,NAA,NAA,2018_hjelmervik_172,12,Healthy - Session 3,10.1016/j.neuroimage.2018.01.043,,,7.97,0.77,,,
,NAA,NAA,2018_hjelmervik_172,13,Healthy - Session 3,10.1016/j.neuroimage.2018.01.043,,,7.19,1.08,,,
,NAA,NAA,2018_hjelmervik_172,14,Healthy - Total,10.1016/j.neuroimage.2018.01.043,,,7.59,0.61,,,
,tNAA,tNAA,2018_horder_8,1,Control,10.1038/s41398-018-0155-1,,,10.88,1.08,,,StdDev calculated from SEM
,tNAA,tNAA,2018_horder_8,2,Control,10.1038/s41398-018-0155-1,,,9.7,1.26,,,StdDev calculated from SEM
,tNAA,tNAA,2018_horder_8,3,Autism Spectrum Disorder,10.1038/s41398-018-0155-1,,,10.61,1.05,,,StdDev calculated from SEM
,tNAA,tNAA,2018_horder_8,4,Autism Spectrum Disorder,10.1038/s41398-018-0155-1,,,9.99,0.95,,,StdDev calculated from SEM
,NAA,NAA,2018_huber_225,1,Bipolar Disorder,10.1016/j.jad.2017.07.052,,,9.31,0.79,,,
,NAA,NAA,2018_huber_225,2,Bipolar Disorder,10.1016/j.jad.2017.07.052,,,9.19,1.53,,,
,NAA,NAA,2018_huber_225,3,Control,10.1016/j.jad.2017.07.052,,,9.32,0.45,,,
,NAA,NAA,2018_huber_225,4,Control,10.1016/j.jad.2017.07.052,,,10.01,0.62,,,
,NAA,tNAA,2018_ikeguchi_26,1,Glioma,10.1016/j.msard.2018.08.025,1.39,0.45,,,,,Assumed Total (tNAA) based on Analysis
,NAA,tNAA,2018_ikeguchi_26,2,High-grade Glioma,10.1016/j.msard.2018.08.025,1.11,0,,,,,2 patients' data excluded (n_exclusions=1); Assumed Total (tNAA) based on Analysis
,NAA,tNAA,2018_ikeguchi_26,3,Low-grade Glioma,10.1016/j.msard.2018.08.025,1.53,0.54,,,,,Assumed Total (tNAA) based on Analysis
,NAA,tNAA,2018_ikeguchi_26,4,Tumefactive Demyelinating Lesion,10.1016/j.msard.2018.08.025,3.15,2.75,,,,,Assumed Total (tNAA) based on Analysis
,NAA,tNAA,2018_ikeguchi_26,5,Multiple Sclerosis,10.1016/j.msard.2018.08.025,1.96,0.3,,,,,Assumed Total (tNAA) based on Analysis
,NAA,tNAA,2018_ikeguchi_26,6,Glioma,10.1016/j.msard.2018.08.025,1.08,0.46,,,,,Assumed Total (tNAA) based on Analysis
,NAA,tNAA,2018_ikeguchi_26,7,High-grade Glioma,10.1016/j.msard.2018.08.025,0.8,0.29,,,,,Assumed Total (tNAA) based on Analysis
,NAA,tNAA,2018_ikeguchi_26,8,Low-grade Glioma,10.1016/j.msard.2018.08.025,1.32,0.46,,,,,Assumed Total (tNAA) based on Analysis
,NAA,tNAA,2018_ikeguchi_26,9,Tumefactive Demyelinating Lesion,10.1016/j.msard.2018.08.025,1.44,0.43,,,,,Assumed Total (tNAA) based on Analysis
,NAA,NAA,2018_kim_23,1,Methamphetamine Dependence ,10.1111/adb.12473,,,6.68,0.85,,,
,NAA,NAA,2018_kim_23,2,Control,10.1111/adb.12473,,,7.2,0.8,,,
,NAA,NAA,2018_kim_83,1,First-episode Psychosis,10.1016/j.biopsych.2017.08.022,1.61,0.36,14.4,3,,,IU estimated from bar graph
,NAA,NAA,2018_kim_83,2,First-episode Psychosis,10.1016/j.biopsych.2017.08.022,1.62,0.32,14.5,3,,,IU estimated from bar graph
,NAA,NAA,2018_kim_83,3,Control,10.1016/j.biopsych.2017.08.022,1.64,0.25,15,3.5,,,IU estimated from bar graph
,NAA,NAA,2018_kim_83,4,Control,10.1016/j.biopsych.2017.08.022,1.58,0.27,14.6,3.75,,,IU estimated from bar graph
,tNAA,tNAA,2018_kim_83,1,First-episode Psychosis,10.1016/j.biopsych.2017.08.022,1.85,0.37,16.5,3.5,,,IU estimated from bar graph
,tNAA,tNAA,2018_kim_83,2,First-episode Psychosis,10.1016/j.biopsych.2017.08.022,1.82,0.39,16.4,3.5,,,IU estimated from bar graph
,tNAA,tNAA,2018_kim_83,3,Control,10.1016/j.biopsych.2017.08.022,1.83,0.23,16.75,3.75,,,IU estimated from bar graph
,tNAA,tNAA,2018_kim_83,4,Control,10.1016/j.biopsych.2017.08.022,1.82,0.29,16.75,4.25,,,IU estimated from bar graph
,tNAA,tNAA,2020_bhogal_10,1,Healthy,10.1002/brb3.1852,1.26,0.22,,,,,
,tNAA,tNAA,2020_bhogal_10,2,Healthy,10.1002/brb3.1852,1,0.17,,,,,
,tNAA,tNAA,2020_bhogal_10,3,Healthy,10.1002/brb3.1852,0.54,0.07,,,,,
,tNAA,tNAA,2020_bhogal_10,4,Healthy,10.1002/brb3.1852,0.84,0.18,,,,,
,tNAA,tNAA,2020_bhogal_10,5,Healthy,10.1002/brb3.1852,0.85,0.19,,,,,
,tNAA,tNAA,2020_bhogal_10,6,Healthy,10.1002/brb3.1852,0.84,0.14,,,,,
,tNAA,tNAA,2020_bhogal_10,7,Healthy,10.1002/brb3.1852,1.07,0.12,,,,,
,tNAA,tNAA,2020_bhogal_10,8,Healthy,10.1002/brb3.1852,1.36,0.21,,,,,
,tNAA,tNAA,2020_bhogal_10,9,Healthy,10.1002/brb3.1852,1.12,0.15,,,,,
,tNAA,tNAA,2020_bhogal_10,10,Healthy,10.1002/brb3.1852,1.13,0.28,,,,,
,NAA,NAA,2018_kirov_139,1,Epilepsy,10.1016/j.eplepsyres.2017.11.017,,,,,11.5,1.5,
,NAA,NAA,2018_kirov_139,2,Control,10.1016/j.eplepsyres.2017.11.017,,,,,13,0.8,
,tNAA,tNAA,2018_kroll_19,1,Asthma,10.1016/j.nicl.2018.04.012,1.5,0.19,13.56,0.92,,,
,tNAA,tNAA,2018_kroll_19,2,Control,10.1016/j.nicl.2018.04.012,1.46,0.17,15.31,1.24,,,
,NAA,tNAA,2018_lai_225,1,Acute Depressive Episode Bipolar Disorder,10.1016/j.jad.2017.07.036,1.58,0.28,,,,,Assumed Total (tNAA) based on Analysis
,NAA,tNAA,2018_lai_225,2,Acute Depressive Episode Bipolar Disorder,10.1016/j.jad.2017.07.036,1.52,0.21,,,,,Assumed Total (tNAA) based on Analysis
,NAA,tNAA,2018_lai_225,3,Euthymic Bipolar Disorder,10.1016/j.jad.2017.07.036,1.5,0.17,,,,,Assumed Total (tNAA) based on Analysis
,NAA,tNAA,2018_lai_225,4,Euthymic Bipolar Disorder,10.1016/j.jad.2017.07.036,1.5,0.18,,,,,Assumed Total (tNAA) based on Analysis
,NAA,tNAA,2018_lai_225,5,Control,10.1016/j.jad.2017.07.036,1.71,0.3,,,,,Assumed Total (tNAA) based on Analysis
,NAA,tNAA,2018_lai_225,6,Control,10.1016/j.jad.2017.07.036,1.65,0.29,,,,,Assumed Total (tNAA) based on Analysis
,NAA,NAA,2020_boillat_40,1,Baseline,10.1177/0271678X19831022,,,10.71,0.23,,,
,NAA,NAA,2020_boillat_40,2,positive BOLD,10.1177/0271678X19831022,,,0,0.16,,,
,NAA,NAA,2020_boillat_40,3,Baseline,10.1177/0271678X19831022,,,10.46,0.22,,,
,NAA,NAA,2020_boillat_40,4,negative BOLD,10.1177/0271678X19831022,,,0.03,0.19,,,
,NAA,NAA,2020_zhang_33,1,Healthy,10.1002/nbm.4313,1.5,0.1,16.8,1.6,,,
,NAA,NAA,2020_zhang_33,2,Healthy,10.1002/nbm.4313,1.5,0.1,18.7,2,,,
,NAA,NAA,2020_zhang_33,3,Healthy,10.1002/nbm.4313,1.4,0.1,16.3,2,,,
,NAA,NAA,2020_zhang_33,4,Healthy,10.1002/nbm.4313,1.4,0.1,17,1.6,,,
,NAA,NAA,2020_zhang_33,5,Healthy,10.1002/nbm.4313,1.4,0.1,17.3,2.1,,,
,NAA,NAA,2020_zhang_33,6,Healthy,10.1002/nbm.4313,1.4,0.1,18.8,2.8,,,
,NAA,NAA,2020_zhang_33,7,Healthy,10.1002/nbm.4313,1.3,0.1,17.5,1.6,,,
,NAA,NAA,2020_zhang_33,8,Healthy,10.1002/nbm.4313,1.4,0.1,16.5,1.1,,,
,NAA,NAA,2020_zhang_33,9,Healthy,10.1002/nbm.4313,1.3,0.1,15.4,2,,,
,NAA,NAA,2020_zhang_33,10,Healthy,10.1002/nbm.4313,1.3,0.1,18.5,2.5,,,
,NAA,NAA,2020_zhang_33,11,Healthy,10.1002/nbm.4313,1.2,0.1,18.1,2.6,,,
,NAA,NAA,2020_zhang_33,12,Healthy,10.1002/nbm.4313,1.3,0.1,17.4,3,,,
,NAA,NAA,2020_zhang_33,13,Healthy,10.1002/nbm.4313,1.4,0.1,17.3,1.8,,,
,NAA,NAA,2020_zhang_33,14,Healthy,10.1002/nbm.4313,1.4,0.1,17.7,1.7,,,
,NAA,NAA,2020_zhang_33,15,Healthy,10.1002/nbm.4313,1.5,0.2,15.5,1.9,,,
,NAA,NAA,2020_zhang_33,16,Healthy,10.1002/nbm.4313,1.5,0.2,15.7,2.1,,,
,NAA,NAA,2020_zhang_33,17,Healthy,10.1002/nbm.4313,1.2,0.1,9.4,1.9,,,
,NAA,NAA,2020_zhang_33,18,Healthy,10.1002/nbm.4313,1.1,0.1,10.9,1.8,,,
,NAA,NAA,2020_zhang_33,19,Healthy,10.1002/nbm.4313,1.4,0.1,18.6,2.2,,,
,NAA,NAA,2020_zhang_33,20,Healthy,10.1002/nbm.4313,1.4,0.1,18.6,2.2,,,
,NAA,NAA,2020_zhang_33,21,Healthy,10.1002/nbm.4313,1.4,0.1,19.4,2.2,,,
,NAA,NAA,2020_zhang_33,22,Healthy,10.1002/nbm.4313,1.5,0.1,19.1,2.4,,,
,NAA,NAA,2020_zhang_33,23,Healthy,10.1002/nbm.4313,1.3,0.1,15.5,1.7,,,
,NAA,NAA,2020_zhang_33,24,Healthy,10.1002/nbm.4313,1.3,0.1,16.6,1.9,,,
,NAA,NAA,2020_zhang_33,25,Healthy,10.1002/nbm.4313,1.4,0.1,18,2,,,
,NAA,NAA,2020_zhang_33,26,Healthy,10.1002/nbm.4313,1.4,0.1,17.8,1.6,,,
,NAA,NAA,2020_zhang_33,27,Healthy,10.1002/nbm.4313,1.2,0.1,12.3,2.3,,,
,NAA,NAA,2020_zhang_33,28,Healthy,10.1002/nbm.4313,1.2,0.1,13.2,2.1,,,
,NAA,NAA,2020_zhang_33,29,Healthy,10.1002/nbm.4313,1.5,0.1,17.6,1.6,,,
,NAA,NAA,2020_zhang_33,30,Healthy,10.1002/nbm.4313,1.4,0.1,18.9,1.8,,,
,NAA,NAA,2020_zhang_33,31,Healthy,10.1002/nbm.4313,1.5,0.1,17.9,1.2,,,
,NAA,NAA,2020_zhang_33,32,Healthy,10.1002/nbm.4313,1.5,0.1,18.7,1.5,,,
,NAA,NAA,2020_zhang_33,33,Healthy,10.1002/nbm.4313,1.4,0.1,17.3,1.3,,,
,NAA,NAA,2020_zhang_33,34,Healthy,10.1002/nbm.4313,1.4,0.1,17.1,1.2,,,
,NAA,NAA,2020_zhang_33,35,Healthy,10.1002/nbm.4313,1.4,0.1,16,1.5,,,
,NAA,NAA,2020_zhang_33,36,Healthy,10.1002/nbm.4313,1.4,0.1,16.8,1.9,,,
,NAA,NAA,2020_zhang_33,37,Healthy,10.1002/nbm.4313,1.3,0.1,15.6,2.7,,,
,NAA,NAA,2020_zhang_33,38,Healthy,10.1002/nbm.4313,1.3,0.1,16.2,2.6,,,
,NAA,NAA,2020_zhang_33,39,Healthy,10.1002/nbm.4313,1.2,0.1,12.6,2.1,,,
,NAA,NAA,2020_zhang_33,40,Healthy,10.1002/nbm.4313,1.2,0.1,14.6,2.3,,,
,NAA,NAA,2020_zhang_33,41,Healthy,10.1002/nbm.4313,1.2,0.2,11.4,2.5,,,
,NAA,NAA,2020_zhang_33,42,Healthy,10.1002/nbm.4313,1.1,0.1,12.5,2,,,
,NAA,NAA,2020_zhang_33,43,Healthy,10.1002/nbm.4313,1.3,0.1,12.2,2.3,,,
,NAA,NAA,2020_zhang_33,44,Healthy,10.1002/nbm.4313,1.3,0.1,13.3,1.6,,,
,NAA,NAA,2020_zhang_33,45,Healthy,10.1002/nbm.4313,1.3,0.1,14.6,1.5,,,
,NAA,NAA,2020_zhang_33,46,Healthy,10.1002/nbm.4313,1.3,0.1,16,1.8,,,
,NAA,NAA,2020_zhang_33,47,Healthy,10.1002/nbm.4313,0.7,0.1,9.5,2.1,,,
,NAA,NAA,2017_barbagallo_43,1,Control,10.1016/j.parkreldis.2017.07.028,1.86,0.38,,,,,
,NAA,NAA,2017_barbagallo_43,2,Control,10.1016/j.parkreldis.2017.07.028,1.67,0.2,,,,,
,NAA,NAA,2017_barbagallo_43,3,Control,10.1016/j.parkreldis.2017.07.028,1.77,0.13,,,,,
,NAA,NAA,2017_barbagallo_43,4,Parkinson's Disease,10.1016/j.parkreldis.2017.07.028,1.44,0.25,,,,,
,NAA,NAA,2017_barbagallo_43,5,Parkinson's Disease,10.1016/j.parkreldis.2017.07.028,1.43,0.2,,,,,
,NAA,NAA,2017_barbagallo_43,6,Parkinson's Disease,10.1016/j.parkreldis.2017.07.028,1.44,0.13,,,,,
,NAA,NAA,2017_barbagallo_43,7,Essential Tremor,10.1016/j.parkreldis.2017.07.028,1.83,0.19,,,,,
,NAA,NAA,2017_barbagallo_43,8,Essential Tremor,10.1016/j.parkreldis.2017.07.028,1.84,0.22,,,,,
,NAA,NAA,2017_barbagallo_43,9,Essential Tremor,10.1016/j.parkreldis.2017.07.028,1.84,0.14,,,,,
,NAA,tNAA,2018_lu_29,1,Liver Cirrhosis,10.1097/WNR.0000000000001063,1.4,0.2,,,,,Assumed Total (tNAA) based on Analysis
,NAA,tNAA,2018_lu_29,2,Liver Cirrhosis with Hepatic Encephalopathy,10.1097/WNR.0000000000001063,1.4,0.3,,,,,Assumed Total (tNAA) based on Analysis
,NAA,tNAA,2018_lu_29,3,Liver Cirrhosis without Hepatic Encephalopathy,10.1097/WNR.0000000000001063,1.4,0.2,,,,,Assumed Total (tNAA) based on Analysis
,NAA,tNAA,2018_lu_29,4,Control,10.1097/WNR.0000000000001063,1.3,0.2,,,,,Assumed Total (tNAA) based on Analysis
,NAA,NAA,2018_marshall_265,1,Secondary Progressive Multiple Sclerosis,10.1007/s00415-018-8903-y,1.8,0.02,1449,23,,,
,NAA,NAA,2018_marshall_265,2,Secondary Progressive Multiple Sclerosis,10.1007/s00415-018-8903-y,1.55,0.05,1469,62,,,
,NAA,NAA,2018_marshall_265,3,Secondary Progressive Multiple Sclerosis,10.1007/s00415-018-8903-y,1.66,0.03,1447,27,,,
,NAA,NAA,2018_mcqueen_235,1,Schizophrenia - Placebo,10.1007/s00213-018-4997-2,1.31,0.11,14.96,2.16,,,
,NAA,NAA,2018_mcqueen_235,2,Schizophrenia - Placebo,10.1007/s00213-018-4997-2,1.28,0.16,11.95,1.75,,,
,NAA,NAA,2018_mcqueen_235,3,Schizophrenia - N-Acetylcysteine ,10.1007/s00213-018-4997-2,1.28,0.13,15.47,1.28,,,
,NAA,NAA,2018_mcqueen_235,4,Schizophrenia - N-Acetylcysteine ,10.1007/s00213-018-4997-2,1.22,0.11,12.82,5.26,,,
,NAA,NAA,2018_modinos_48,1,Healthy - Low Schizotypy,10.1017/S0033291717003403,,,14.88,1.34,,,
,NAA,NAA,2018_modinos_48,2,Healthy - High Schizotypy,10.1017/S0033291717003403,,,15.25,1.54,,,
,NAA,NAA,2018_moon_227,1,Obsessive-compulsive Disorder,10.1016/j.jad.2017.11.059,1.55,0.19,,,,,
,NAA,NAA,2018_moon_227,2,Control,10.1016/j.jad.2017.11.059,1.71,0.12,,,,,
,NAA,NAA,2018_mora-peris_32,1,HIV - Baseline,10.1097/QAD.0000000000001786,1.11,0.16,,,,,
,NAA,NAA,2018_mora-peris_32,2,HIV - Baseline,10.1097/QAD.0000000000001786,1.27,0.2,,,,,
,NAA,NAA,2018_mora-peris_32,3,HIV - Baseline,10.1097/QAD.0000000000001786,1.28,0.19,,,,,
,NAA,NAA,2018_mora-peris_32,4,HIV - ART Week 48,10.1097/QAD.0000000000001786,1.1,0.16,,,,,
,NAA,NAA,2018_mora-peris_32,5,HIV - ART Week 49,10.1097/QAD.0000000000001786,1.23,0.22,,,,,
,NAA,NAA,2018_mora-peris_32,6,HIV - ART Week 50,10.1097/QAD.0000000000001786,1.29,0.21,,,,,
,NAA,NAA,2018_morley_9,1,Alcohol Dependence - Placebo,10.3389/fpsyt.2018.00412,1.4,0.13,,,,,
,NAA,NAA,2018_morley_9,2,Alcohol Dependence - Baclofen,10.3389/fpsyt.2018.00412,1.47,0.11,,,,,
,NAA,NAA,2018_morley_9,3,"Alcohol Dependence - Recent alcohol consumption, placebo",10.3389/fpsyt.2018.00412,1.38,0.09,,,,,
,NAA,NAA,2018_morley_9,4,"Alcohol Dependence - Recent alcohol consumption, Baclofen",10.3389/fpsyt.2018.00412,1.54,0.05,,,,,
,tNAA,tNAA,2018_plitman_273,1,Schizophrenia,10.1016/j.pscychresns.2018.01.004,,,11.07,0.89,,,
,tNAA,tNAA,2018_plitman_273,2,Control,10.1016/j.pscychresns.2018.01.004,,,10.73,0.6,,,
,tNAA,tNAA,2018_plitman_273,3,Schizophrenia - Point 1,10.1016/j.pscychresns.2018.01.004,,,11.05,1.11,,,
,tNAA,tNAA,2018_plitman_273,4,Schizophrenia - Point 2,10.1016/j.pscychresns.2018.01.004,,,11.2,0.78,,,
,tNAA,tNAA,2018_plitman_273,5,Control - Point 1,10.1016/j.pscychresns.2018.01.004,,,11.03,0.96,,,
,tNAA,tNAA,2018_plitman_273,6,Control - Point 2,10.1016/j.pscychresns.2018.01.004,,,10.72,0.73,,,
,NAA,NAA,2018_psomiades_8,1,Schizophrenia - Auditory Verbal Hallucinations,10.1038/s41598-018-22597-y,,,6.63,0.91,,,
,NAA,NAA,2018_psomiades_8,2,Schizophrenia - Auditory Verbal Hallucinations,10.1038/s41598-018-22597-y,,,7.54,0.97,,,
,NAA,NAA,2018_psomiades_8,3,Schizophrenia - No Auditory Verbal Hallucinations,10.1038/s41598-018-22597-y,,,7.12,1.08,,,
,NAA,NAA,2018_psomiades_8,4,Schizophrenia - No Auditory Verbal Hallucinations,10.1038/s41598-018-22597-y,,,6.67,1.02,,,
,NAA,NAA,2018_rudler_48,1,"Cirrhosis - Before TIPSS, no MHE",10.1111/apt.14938,,,,,11.1,0.9,
,NAA,NAA,2018_rudler_48,2,"Cirrhosis - Before TIPSS, no MHE",10.1111/apt.14938,,,,,11.7,1.1,
,NAA,NAA,2018_rudler_48,3,"Cirrhosis - Before TIPSS, MHE",10.1111/apt.14938,,,,,10.1,3.2,
,NAA,NAA,2018_rudler_48,4,"Cirrhosis - Before TIPSS, MHE",10.1111/apt.14938,,,,,11.7,0.9,
,NAA,NAA,2018_rudler_48,5,"Cirrhosis - Before TIPSS, no development of HE after TIPSS",10.1111/apt.14938,,,,,11.1,0.8,
,NAA,NAA,2018_rudler_48,6,"Cirrhosis - Before TIPSS, no development of HE after TIPSS",10.1111/apt.14938,,,,,11.8,1,
,NAA,NAA,2018_rudler_48,7,"Cirrhosis - Before TIPSS, development of HE after TIPSS",10.1111/apt.14938,,,,,10,2.7,
,NAA,NAA,2018_rudler_48,8,"Cirrhosis - Before TIPSS, development of HE after TIPSS",10.1111/apt.14938,,,,,11.3,1,
,NAA,NAA,2018_rudler_48,9,"Cirrhosis - After TIPSS, no development of HE",10.1111/apt.14938,,,,,10.9,0.7,
,NAA,NAA,2018_rudler_48,10,"Cirrhosis - After TIPSS, no development of HE",10.1111/apt.14938,,,,,11,0.9,
,NAA,NAA,2018_rudler_48,11,"Cirrhosis - After TIPSS, development of HE",10.1111/apt.14938,,,,,10.6,0.9,
,NAA,NAA,2018_rudler_48,12,"Cirrhosis - After TIPSS, development of HE",10.1111/apt.14938,,,,,11.4,0.7,
,NAA,NAA,2021_borbath_85,1,Healthy,10.1002/mrm.28442,,,,,17.47,2.25,
,NAA,NAA,2021_borbath_85,1,Healthy,10.1002/mrm.28442,,,,,7.45,0.96,
,NAA,tNAA,2018_ryan_13,1,Healthy - Sham,10.1371/journal.pone.0198053,1.67,0.03,,,16.2,0.65,Assumed Total (tNAA) based on Analysis
,NAA,tNAA,2018_ryan_13,2,Healthy - Transcranial direct current stimulation,10.1371/journal.pone.0198053,1.73,0.03,,,15.6,0.46,Assumed Total (tNAA) based on Analysis
,NAA,NAA,2021_bednarik_15,1,Healthy,10.3389/fnins.2021.609485,,,,,11.8,0.3,
,NAA,NAA,2021_bednarik_15,2,Healthy,10.3389/fnins.2021.609485,,,,,11.6,0.3,
,NAA,NAA,2018_schmitz_28,1,Healthy - <30 yrs,10.1111/jon.12514,,,14.73,0.41,,,
,NAA,NAA,2018_schmitz_28,2,Healthy - 30-39 yrs,10.1111/jon.12514,,,14.23,0.46,,,
,NAA,NAA,2018_schmitz_28,3,Healthy - 40-49 yrs,10.1111/jon.12514,,,14.33,1.15,,,
,NAA,NAA,2018_schmitz_28,4,Healthy - 50-59 yrs,10.1111/jon.12514,,,13.65,0.39,,,
,NAA,NAA,2018_schmitz_28,5,Healthy - >60 yrs,10.1111/jon.12514,,,13.77,0.34,,,
,NAA,NAA,2018_schmitz_28,6,Healthy,10.1111/jon.12514,,,14.12,0.71,,,
,NAA,NAA,2021_chaudhary_42,1,PD-CN,10.1007/s10072-020-04626-9,,,14.44,3.34,,,
,NAA,NAA,2021_chaudhary_42,16,PD-CI,10.1007/s10072-020-04626-9,,,12.48,2.63,,,
,NAA,NAA,2021_chaudhary_42,31,HC,10.1007/s10072-020-04626-9,,,14.68,3.22,,,
,NAA,NAA,2021_chaudhary_42,6,PD-CN,10.1007/s10072-020-04626-9,,,14.71,4.33,,,
,NAA,NAA,2021_chaudhary_42,21,PD-CI,10.1007/s10072-020-04626-9,,,11.6,4.05,,,
,NAA,NAA,2021_chaudhary_42,36,HC,10.1007/s10072-020-04626-9,,,14.08,3.38,,,
,tNAA,tNAA,2021_chaudhary_42,8,PD-CN,10.1007/s10072-020-04626-9,,,16.79,4.54,,,
,tNAA,tNAA,2021_chaudhary_42,23,PD-CI,10.1007/s10072-020-04626-9,,,13.17,4,,,
,tNAA,tNAA,2021_chaudhary_42,38,HC,10.1007/s10072-020-04626-9,,,14.97,3.53,,,
,NAA,NAA,2021_chaudhary_42,9,PD-CN,10.1007/s10072-020-04626-9,,,12.64,3.22,,,
,NAA,NAA,2021_chaudhary_42,24,PD-CI,10.1007/s10072-020-04626-9,,,9.94,2.88,,,
,NAA,NAA,2021_chaudhary_42,39,HC,10.1007/s10072-020-04626-9,,,13.05,3.25,,,
,NAA,NAA,2021_chen_299,1,BD with anxiety,10.1016/j.psychres.2021.113859,,,,,1.87,0.37,
,NAA,NAA,2021_chen_299,2,BD with anxiety,10.1016/j.psychres.2021.113859,,,,,1.64,0.28,
,NAA,NAA,2021_chen_299,7,BD without anxiety,10.1016/j.psychres.2021.113859,,,,,1.91,0.37,
,NAA,NAA,2021_chen_299,8,BD without anxiety,10.1016/j.psychres.2021.113859,,,,,1.64,0.36,
,NAA,NAA,2021_chenji_282,1,Control,10.1016/j.jad.2020.12.176,,,8.14,0.93,,,
,NAA,NAA,2021_chenji_282,3,MDD-Normal BMI,10.1016/j.jad.2020.12.176,,,7.86,0.96,,,
,NAA,NAA,2021_chenji_282,5,MDD-High BMI,10.1016/j.jad.2020.12.176,,,8.23,0.98,,,
,NAA,NAA,2021_chenji_282,2,Control,10.1016/j.jad.2020.12.176,,,8.3,1.03,,,
,NAA,NAA,2021_chenji_282,4,MDD-Normal BMI,10.1016/j.jad.2020.12.176,,,8.47,1.05,,,
,NAA,NAA,2021_chenji_282,6,MDD-High BMI,10.1016/j.jad.2020.12.176,,,8.65,1.07,,,
,NAA,NAA,2020_cen_54,1,Healthy Controls,10.1177/0004867419898520,,,3.51,0.6,,,
,NAA,NAA,2020_cen_54,2,FEP,10.1177/0004867419898520,,,3.47,0.39,,,
,NAA,NAA,2020_chen_131,1,Healthy Controls,10.1016/j.ejrad.2020.109252,1.87,0.87,,,,,
,NAA,NAA,2020_chen_131,2,NHE,10.1016/j.ejrad.2020.109252,1.97,0.84,,,,,
,NAA,NAA,2020_chen_131,3,Minimal Hepatic Encephalopathy,10.1016/j.ejrad.2020.109252,1.55,0.68,,,,,
,NAA,NAA,2018_shakory_43,1,Control,10.1038/s41386-018-0163-0,,,8.72,0.78,,,
,NAA,NAA,2018_shakory_43,2,Clinical high risk of psychosis,10.1038/s41386-018-0163-0,,,8.26,0.7,,,
,NAA,NAA,2018_shakory_43,3,First Episode Psychosis,10.1038/s41386-018-0163-0,,,8.61,0.76,,,
,NAA,tNAA,2020_dehghan_33,1,Control,10.1177/1971400920932793,1.769,,,,,,Assumed Total (tNAA) based on Analysis
,NAA,tNAA,2020_dehghan_33,1,Control,10.1177/1971400920932793,1.769,,,,,,Assumed Total (tNAA) based on Analysis
,NAA,tNAA,2020_dehghan_33,2,Migraine without aura,10.1177/1971400920932793,1.379,,,,,,Assumed Total (tNAA) based on Analysis
,NAA,tNAA,2020_dehghan_33,2,Migraine without aura,10.1177/1971400920932793,1.379,,,,,,Assumed Total (tNAA) based on Analysis
,NAA,NAA,2020_poletti_11,1,Bipolar Disorder,10.3389/fpsyt.2020.590095,,,6.62,0.43,,,
,NAA,NAA,2020_poletti_11,2,Healthy Controls,10.3389/fpsyt.2020.590095,,,7.14,0.54,,,
,NAA,NAA,2021_faulkner_26,1,Nonsmokers,10.1111/adb.12986,,,,,9.31,0.24,
,NAA,NAA,2021_faulkner_26,2,Intermittent smokers,10.1111/adb.12986,,,,,7.869,0.15,
,NAA,NAA,2021_faulkner_26,3,Smokers,10.1111/adb.12986,,,,,7.779,0.21,
,NAA,NAA,2018_sheth_276,1,Veterans - Suicidal behavior,10.1016/j.pscychresns.2018.04.004,,,2.86,0.11,,,
,NAA,NAA,2018_sheth_276,2,Veterans - Suicidal behavior,10.1016/j.pscychresns.2018.04.004,,,2.93,0.06,,,
,NAA,NAA,2018_sheth_276,3,Veterans - No suicidal behavior,10.1016/j.pscychresns.2018.04.004,,,2.6,0.17,,,
,NAA,NAA,2018_sheth_276,4,Veterans - No suicidal behavior,10.1016/j.pscychresns.2018.04.004,,,2.83,0.06,,,
,NAA,NAA,2018_singh_60,1,Control,10.1007/s00234-017-1954-4,0.94,0.18,,,,,
,NAA,NAA,2018_singh_60,2,Schizophrenia,10.1007/s00234-017-1954-4,0.94,0.12,,,,,
,tNAA,tNAA,2018_singh_60,1,Control,10.1007/s00234-017-1954-4,1.09,0.12,,,,,
,tNAA,tNAA,2018_singh_60,2,Schizophrenia,10.1007/s00234-017-1954-4,1.04,0.13,,,,,
,NAA,NAA,2018_sivaraman_281,1,Control,10.1016/j.pscychresns.2018.06.003,,,0.44,0.05,,,
,NAA,NAA,2018_sivaraman_281,2,First episode psychosis,10.1016/j.pscychresns.2018.06.003,,,0.44,0.05,,,
,NAA,NAA,2018_smesny_227,1,Control - Voxel 1,10.1016/j.jad.2017.10.044,,,,,9.45,1.24,
,NAA,NAA,2018_smesny_227,2,Control - Voxel 2,10.1016/j.jad.2017.10.044,,,,,9.32,1.05,
,NAA,NAA,2018_smesny_227,3,Control - Voxel 3,10.1016/j.jad.2017.10.044,,,,,9.38,1.34,
,NAA,NAA,2018_smesny_227,4,Control - Voxel 4,10.1016/j.jad.2017.10.044,,,,,10.62,1.73,
,NAA,NAA,2018_smesny_227,5,Control - Voxel 5,10.1016/j.jad.2017.10.044,,,,,9.95,0.9,
,NAA,NAA,2018_smesny_227,6,Control - Voxel 6,10.1016/j.jad.2017.10.044,,,,,9.96,0.84,
,NAA,NAA,2018_smesny_227,7,Cluster B personality disorder - Voxel 1,10.1016/j.jad.2017.10.044,,,,,9.12,1.35,
,NAA,NAA,2018_smesny_227,8,Cluster B personality disorder - Voxel 2,10.1016/j.jad.2017.10.044,,,,,8.94,1.36,
,NAA,NAA,2018_smesny_227,9,Cluster B personality disorder - Voxel 3,10.1016/j.jad.2017.10.044,,,,,9.25,1.27,
,NAA,NAA,2018_smesny_227,10,Cluster B personality disorder - Voxel 4,10.1016/j.jad.2017.10.044,,,,,10.25,1.94,
,NAA,NAA,2018_smesny_227,11,Cluster B personality disorder - Voxel 5,10.1016/j.jad.2017.10.044,,,,,9.44,0.95,
,NAA,NAA,2018_smesny_227,12,Cluster B personality disorder - Voxel 6,10.1016/j.jad.2017.10.044,,,,,9.63,1.08,
,NAA,NAA,2018_smesny_227,13,Cluster C personality disorder - Voxel 1,10.1016/j.jad.2017.10.044,,,,,8.87,1.77,
,NAA,NAA,2018_smesny_227,14,Cluster C personality disorder - Voxel 2,10.1016/j.jad.2017.10.044,,,,,8.65,1.82,
,NAA,NAA,2018_smesny_227,15,Cluster C personality disorder - Voxel 3,10.1016/j.jad.2017.10.044,,,,,8.68,1.71,
,NAA,NAA,2018_smesny_227,16,Cluster C personality disorder - Voxel 4,10.1016/j.jad.2017.10.044,,,,,9.59,1.85,
,NAA,NAA,2018_smesny_227,17,Cluster C personality disorder - Voxel 5,10.1016/j.jad.2017.10.044,,,,,9.6,1.51,
,NAA,NAA,2018_smesny_227,18,Cluster C personality disorder - Voxel 6,10.1016/j.jad.2017.10.044,,,,,9.31,1.21,
,NAA,NAA,2018_tan_28,1,Control,10.1007/s00330-018-5443-x,,,,,7.7,0.5,
,NAA,NAA,2018_tan_28,2,Control,10.1007/s00330-018-5443-x,,,,,7.2,0.9,
,NAA,NAA,2018_tan_28,3,Control,10.1007/s00330-018-5443-x,,,,,7.5,0.6,
,NAA,NAA,2018_tan_28,4,Temporal lobe epilespsy,10.1007/s00330-018-5443-x,,,,,7.1,0.7,
,NAA,NAA,2018_tan_28,5,Temporal lobe epilespsy,10.1007/s00330-018-5443-x,,,,,7,0.6,
,NAA,NAA,2018_tan_28,6,Temporal lobe epilespsy - Left seizure foci,10.1007/s00330-018-5443-x,,,,,7.2,0.4,
,NAA,NAA,2018_tan_28,7,Temporal lobe epilespsy - Left seizure foci,10.1007/s00330-018-5443-x,,,,,7.3,0.5,
,NAA,NAA,2018_tan_28,8,Temporal lobe epilespsy - Right seizure foci,10.1007/s00330-018-5443-x,,,,,6.9,0.8,
,NAA,NAA,2018_tan_28,9,Temporal lobe epilespsy - Right seizure foci,10.1007/s00330-018-5443-x,,,,,6.8,0.6,
,NAA,NAA,2018_van_89,1,Control,10.1136/jnnp-2017-316364,,,,,6.99,0.65,
,NAA,NAA,2018_van_89,2,Metachromatic leukodystrophy - Good outcome,10.1136/jnnp-2017-316364,,,,,6.53,0.98,
,NAA,NAA,2018_van_89,3,Metachromatic leukodystrophy - Moderate outcome,10.1136/jnnp-2017-316364,,,,,5.56,0.2,
,NAA,NAA,2018_van_89,4,Metachromatic leukodystrophy - Poor outcome,10.1136/jnnp-2017-316364,,,,,1.99,0.73,
,NAA,NAA,2019_davitz_50,1,TBI (Post-Concussive),10.1002/jmri.26718,,,,,7.3,1.5,
,NAA,NAA,2019_davitz_50,2,TBI (Post-Concussive),10.1002/jmri.26718,,,,,8.4,1.7,
,NAA,NAA,2019_davitz_50,3,TBI (Post-Concussive),10.1002/jmri.26718,,,,,8.7,1.3,
,NAA,NAA,2019_davitz_50,4,TBI (Post-Concussive),10.1002/jmri.26718,,,,,7.7,0.9,
,NAA,NAA,2019_davitz_50,5,TBI (Post-Concussive),10.1002/jmri.26718,,,,,7.2,0.9,
,NAA,NAA,2019_davitz_50,6,Control,10.1002/jmri.26718,,,,,7.7,1.6,
,NAA,NAA,2019_davitz_50,7,Control,10.1002/jmri.26718,,,,,9.1,1.6,
,NAA,NAA,2019_davitz_50,8,Control,10.1002/jmri.26718,,,,,9.3,1.5,
,NAA,NAA,2019_davitz_50,9,Control,10.1002/jmri.26718,,,,,8.4,1.5,
,NAA,NAA,2019_davitz_50,10,Control,10.1002/jmri.26718,,,,,7.7,1.3,
,tNAA,tNAA,2019_fayed_32,1,Fibromyalgia - Baseline,10.1177/1971400919857544,,,,,,,
,tNAA,tNAA,2019_fayed_32,2,Fibromyalgia - Baseline,10.1177/1971400919857544,,,7.56,0.68,,,
,NAA,NAA,2019_fayed_32,4,Fibromyalgia - Baseline,10.1177/1971400919857544,,,4.47,1.53,,,
,tNAA,tNAA,2019_fayed_32,4,Fibromyalgia - Baseline,10.1177/1971400919857544,,,5.89,1.12,,,
,tNAA,tNAA,2019_fayed_32,5,Fibromyalgia - Baseline,10.1177/1971400919857544,,,5.31,1.12,,,
,tNAA,tNAA,2019_fayed_32,7,Fibromyalgia - Treatment,10.1177/1971400919857544,,,7.7,0.81,,,
,NAA,NAA,2019_fayed_32,9,Fibromyalgia - Treatment,10.1177/1971400919857544,,,4.71,0.98,,,
,tNAA,tNAA,2019_fayed_32,9,Fibromyalgia - Treatment,10.1177/1971400919857544,,,5.98,1.29,,,
,tNAA,tNAA,2019_fayed_32,10,Fibromyalgia - Treatment,10.1177/1971400919857544,,,5.79,0.96,,,
,NAA,tNAA,2019_ferland_237,1,Healthy TMS,10.1007/s00221-019-05691-z,,,,,22.268,0.47,
,NAA,tNAA,2019_ferland_237,2,Healthy TMS,10.1007/s00221-019-05691-z,,,,,22.17,0.758,
,tNAA,tNAA,2019_flamez_130,1,Parkinson's Dyskinesia - Sham Baseline,10.1016/j.clinph.2019.04.720,1.07,0.15,,,,,
,tNAA,tNAA,2019_flamez_130,2,Parkinson's Dyskinesia - Real Baseline,10.1016/j.clinph.2019.04.720,1.14,0.15,,,,,
,tNAA,tNAA,2019_flamez_130,3,Parkinson's Dyskinesia - Sham TMS,10.1016/j.clinph.2019.04.720,1.04,0.17,,,,,
,tNAA,tNAA,2019_flamez_130,4,Parkinson's Dyskinesia - Real TMS,10.1016/j.clinph.2019.04.720,1.21,0.14,,,,,
,tNAA,tNAA,2019_flamez_130,5,Parkinson's No Dyskinesia - Sham Baseline,10.1016/j.clinph.2019.04.720,1.17,0.21,,,,,
,tNAA,tNAA,2019_flamez_130,6,Parkinson's No Dyskinesia - Real Baseline,10.1016/j.clinph.2019.04.720,1.24,0.14,,,,,
,tNAA,tNAA,2019_flamez_130,7,Parkinson's No Dyskinesia - Sham TMS,10.1016/j.clinph.2019.04.720,1.23,0.22,,,,,
,tNAA,tNAA,2019_flamez_130,8,Parkinson's No Dyskinesia - Real TMS,10.1016/j.clinph.2019.04.720,1.27,0.12,,,,,
,NAA,NAA,2019_garkowski_266,1,Control,10.1007/s00415-019-09359-0,2.079,0.249,,,,,
,NAA,NAA,2019_garkowski_266,2,Control,10.1007/s00415-019-09359-0,2.096,0.3,,,,,
,NAA,NAA,2019_garkowski_266,3,Control,10.1007/s00415-019-09359-0,2.639,0.256,,,,,
,NAA,NAA,2019_garkowski_266,4,Control,10.1007/s00415-019-09359-0,2.449,0.268,,,,,
,NAA,NAA,2019_garkowski_266,5,Lyme Neuroborreliosis,10.1007/s00415-019-09359-0,1.777,0.319,,,,,
,NAA,NAA,2019_garkowski_266,6,Lyme Neuroborreliosis,10.1007/s00415-019-09359-0,1.832,0.27,,,,,
,NAA,NAA,2019_garkowski_266,7,Lyme Neuroborreliosis,10.1007/s00415-019-09359-0,2.254,0.286,,,,,
,NAA,NAA,2019_garkowski_266,8,Lyme Neuroborreliosis,10.1007/s00415-019-09359-0,2.259,0.346,,,,,
,NAA,NAA,2019_giapitzakis_81,1,Healthy,10.1002/mrm.27467,,,,,8.9,0.7,
,NAA,NAA,2019_giapitzakis_81,2,Healthy,10.1002/mrm.27467,,,,,7.9,0.7,
,NAA,NAA,2019_graf_32,1,Healthy,10.1002/nbm.4083,,,7.7,1.631,,,Med/Quartile --> Mean/Std Greco 2015
,NAA,NAA,2019_hansen_33,1,Control,10.1016/j.jdiacomp.2018.12.016,1.61,0.21,,,8.85,0.57,
,NAA,NAA,2019_hansen_33,2,Diabetes,10.1016/j.jdiacomp.2018.12.016,1.46,0.15,,,8.46,0.72,
,tNAA,tNAA,2019_hnilicova_407,1,Control,10.1016/j.jns.2019.116458,1.344,0.312,,,,,
,tNAA,tNAA,2019_hnilicova_407,2,Multiple Sclerosis,10.1016/j.jns.2019.116458,1.182,0.259,,,,,
,NAA,NAA,2019_holshouser_36,1,Control,10.1089/neu.2018.5919,2.03,0.22,,,,,
,NAA,NAA,2019_holshouser_36,2,Control,10.1089/neu.2018.5919,2.08,0.2,,,,,
,NAA,NAA,2019_holshouser_36,3,TBI Mild Acute,10.1089/neu.2018.5919,1.87,0.22,,,,,
,NAA,NAA,2019_holshouser_36,4,TBI Mild 12Month,10.1089/neu.2018.5919,2.03,0.25,,,,,
,NAA,NAA,2019_holshouser_36,5,TBI Severe Acute,10.1089/neu.2018.5919,1.52,0.33,,,,,
,NAA,NAA,2019_holshouser_36,6,TBI Severe 12Month,10.1089/neu.2018.5919,1.83,0.3,,,,,
,NAA,NAA,2019_holshouser_36,7,Control,10.1089/neu.2018.5919,1.91,0.23,,,,,
,NAA,NAA,2019_holshouser_36,8,Control,10.1089/neu.2018.5919,1.95,0.23,,,,,
,NAA,NAA,2019_holshouser_36,9,TBI Mild Acute,10.1089/neu.2018.5919,1.83,0.25,,,,,
,NAA,NAA,2019_holshouser_36,10,TBI Mild 12Month,10.1089/neu.2018.5919,2,0.25,,,,,
,NAA,NAA,2019_holshouser_36,11,TBI Severe Acute,10.1089/neu.2018.5919,1.5,0.26,,,,,
,NAA,NAA,2019_holshouser_36,12,TBI Severe 12Month,10.1089/neu.2018.5919,1.77,0.28,,,,,
,NAA,NAA,2019_holshouser_36,13,Control,10.1089/neu.2018.5919,1.58,0.33,,,,,
,NAA,NAA,2019_holshouser_36,14,Control,10.1089/neu.2018.5919,1.59,0.27,,,,,
,NAA,NAA,2019_holshouser_36,15,TBI Mild Acute,10.1089/neu.2018.5919,1.39,0.29,,,,,
,NAA,NAA,2019_holshouser_36,16,TBI Mild 12Month,10.1089/neu.2018.5919,1.6,0.64,,,,,
,NAA,NAA,2019_holshouser_36,17,TBI Severe Acute,10.1089/neu.2018.5919,1.38,0.26,,,,,
,NAA,NAA,2019_holshouser_36,18,TBI Severe 12Month,10.1089/neu.2018.5919,1.53,0.46,,,,,
,NAA,NAA,2019_holshouser_36,19,Control,10.1089/neu.2018.5919,2.76,0.26,,,,,
,NAA,NAA,2019_holshouser_36,20,Control,10.1089/neu.2018.5919,2.82,0.26,,,,,
,NAA,NAA,2019_holshouser_36,21,TBI Mild Acute,10.1089/neu.2018.5919,2.66,0.29,,,,,
,NAA,NAA,2019_holshouser_36,22,TBI Mild 12Month,10.1089/neu.2018.5919,2.77,0.29,,,,,
,NAA,NAA,2019_holshouser_36,23,TBI Severe Acute,10.1089/neu.2018.5919,2.27,0.43,,,,,
,NAA,NAA,2019_holshouser_36,24,TBI Severe 12Month,10.1089/neu.2018.5919,2.53,0.34,,,,,
,NAA,NAA,2019_holshouser_36,25,Control,10.1089/neu.2018.5919,2.37,0.3,,,,,
,NAA,NAA,2019_holshouser_36,26,Control,10.1089/neu.2018.5919,2.38,0.3,,,,,
,NAA,NAA,2019_holshouser_36,27,TBI Mild Acute,10.1089/neu.2018.5919,2.15,0.35,,,,,
,NAA,NAA,2019_holshouser_36,28,TBI Mild 12Month,10.1089/neu.2018.5919,2.31,0.32,,,,,
,NAA,NAA,2019_holshouser_36,29,TBI Severe Acute,10.1089/neu.2018.5919,1.97,0.45,,,,,
,NAA,NAA,2019_holshouser_36,30,TBI Severe 12Month,10.1089/neu.2018.5919,2.19,0.44,,,,,
,NAA,NAA,2019_holshouser_36,31,Control,10.1089/neu.2018.5919,2.61,0.32,,,,,
,NAA,NAA,2019_holshouser_36,32,Control,10.1089/neu.2018.5919,2.7,0.27,,,,,
,NAA,NAA,2019_holshouser_36,33,TBI Mild Acute,10.1089/neu.2018.5919,2.56,0.31,,,,,
,NAA,NAA,2019_holshouser_36,34,TBI Mild 12Month,10.1089/neu.2018.5919,2.64,0.32,,,,,
,NAA,NAA,2019_holshouser_36,35,TBI Severe Acute,10.1089/neu.2018.5919,2.22,0.43,,,,,
,NAA,NAA,2019_holshouser_36,36,TBI Severe 12Month,10.1089/neu.2018.5919,2.31,0.56,,,,,
,NAA,NAA,2019_holshouser_36,37,Control,10.1089/neu.2018.5919,2.51,0.39,,,,,
,NAA,NAA,2019_holshouser_36,38,Control,10.1089/neu.2018.5919,2.48,0.33,,,,,
,NAA,NAA,2019_holshouser_36,39,TBI Mild Acute,10.1089/neu.2018.5919,2.16,0.35,,,,,
,NAA,NAA,2019_holshouser_36,40,TBI Mild 12Month,10.1089/neu.2018.5919,2.57,0.56,,,,,
,NAA,NAA,2019_holshouser_36,41,TBI Severe Acute,10.1089/neu.2018.5919,1.89,0.36,,,,,
,NAA,NAA,2019_holshouser_36,42,TBI Severe 12Month,10.1089/neu.2018.5919,2.17,0.49,,,,,
,NAA,NAA,2019_holshouser_36,43,Control,10.1089/neu.2018.5919,2.65,0.37,,,,,
,NAA,NAA,2019_holshouser_36,44,Control,10.1089/neu.2018.5919,2.61,0.29,,,,,
,NAA,NAA,2019_holshouser_36,45,TBI Mild Acute,10.1089/neu.2018.5919,2.51,0.34,,,,,
,NAA,NAA,2019_holshouser_36,46,TBI Mild 12Month,10.1089/neu.2018.5919,2.57,0.39,,,,,
,NAA,NAA,2019_holshouser_36,47,TBI Severe Acute,10.1089/neu.2018.5919,2.21,0.38,,,,,
,NAA,NAA,2019_holshouser_36,48,TBI Severe 12Month,10.1089/neu.2018.5919,2.45,0.31,,,,,
,NAA,NAA,2019_holshouser_36,49,Control,10.1089/neu.2018.5919,3.16,0.29,,,,,
,NAA,NAA,2019_holshouser_36,50,Control,10.1089/neu.2018.5919,3.16,0.28,,,,,
,NAA,NAA,2019_holshouser_36,51,TBI Mild Acute,10.1089/neu.2018.5919,3,0.36,,,,,
,NAA,NAA,2019_holshouser_36,52,TBI Mild 12Month,10.1089/neu.2018.5919,3.13,0.28,,,,,
,NAA,NAA,2019_holshouser_36,53,TBI Severe Acute,10.1089/neu.2018.5919,2.75,0.41,,,,,
,NAA,NAA,2019_holshouser_36,54,TBI Severe 12Month,10.1089/neu.2018.5919,2.79,0.46,,,,,
,NAA,NAA,2019_holshouser_36,55,Control,10.1089/neu.2018.5919,2.02,0.2,,,,,
,NAA,NAA,2019_holshouser_36,56,Control,10.1089/neu.2018.5919,1.95,0.26,,,,,
,NAA,NAA,2019_holshouser_36,57,TBI Mild Acute,10.1089/neu.2018.5919,1.89,0.24,,,,,
,NAA,NAA,2019_holshouser_36,58,TBI Mild 12Month,10.1089/neu.2018.5919,2,0.31,,,,,
,NAA,NAA,2019_holshouser_36,59,TBI Severe Acute,10.1089/neu.2018.5919,1.61,0.3,,,,,
,NAA,NAA,2019_holshouser_36,60,TBI Severe 12Month,10.1089/neu.2018.5919,1.86,0.35,,,,,
,NAA,NAA,2019_holshouser_36,61,Control,10.1089/neu.2018.5919,2.42,0.27,,,,,
,NAA,NAA,2019_holshouser_36,62,Control,10.1089/neu.2018.5919,2.41,0.26,,,,,
,NAA,NAA,2019_holshouser_36,63,TBI Mild Acute,10.1089/neu.2018.5919,2.29,0.25,,,,,
,NAA,NAA,2019_holshouser_36,64,TBI Mild 12Month,10.1089/neu.2018.5919,2.3,0.29,,,,,
,NAA,NAA,2019_holshouser_36,65,TBI Severe Acute,10.1089/neu.2018.5919,2.04,0.31,,,,,
,NAA,NAA,2019_holshouser_36,66,TBI Severe 12Month,10.1089/neu.2018.5919,2.12,0.35,,,,,
,NAA,NAA,2019_holshouser_36,67,Control,10.1089/neu.2018.5919,2.13,0.22,,,,,
,NAA,NAA,2019_holshouser_36,68,Control,10.1089/neu.2018.5919,2.16,0.19,,,,,
,NAA,NAA,2019_holshouser_36,69,TBI Mild Acute,10.1089/neu.2018.5919,1.98,0.23,,,,,
,NAA,NAA,2019_holshouser_36,70,TBI Mild 12Month,10.1089/neu.2018.5919,2.13,0.31,,,,,
,NAA,NAA,2019_holshouser_36,71,TBI Severe Acute,10.1089/neu.2018.5919,1.65,0.31,,,,,
,NAA,NAA,2019_holshouser_36,72,TBI Severe 12Month,10.1089/neu.2018.5919,1.89,0.38,,,,,
,NAA,NAA,2019_iwata_85,1,Control,10.1016/j.biopsych.2018.09.009,,,10.62,0.63,,,
,NAA,NAA,2019_iwata_85,2,Control,10.1016/j.biopsych.2018.09.009,,,13.44,1.04,,,
,NAA,NAA,2019_iwata_85,3,Control,10.1016/j.biopsych.2018.09.009,,,13.48,1.12,,,
,NAA,NAA,2019_iwata_85,4,Schizophrenia Ultra-Resistant,10.1016/j.biopsych.2018.09.009,,,10.63,1.72,,,
,NAA,NAA,2019_iwata_85,5,Schizophrenia Ultra-Resistant,10.1016/j.biopsych.2018.09.009,,,14.38,1.31,,,
,NAA,NAA,2019_iwata_85,6,Schizophrenia Ultra-Resistant,10.1016/j.biopsych.2018.09.009,,,13.96,1.45,,,
,NAA,NAA,2019_iwata_85,7,Schizophrenia Non-Ultra Resistant,10.1016/j.biopsych.2018.09.009,,,10.86,1.16,,,
,NAA,NAA,2019_iwata_85,8,Schizophrenia Non-Ultra Resistant,10.1016/j.biopsych.2018.09.009,,,14.36,1.08,,,
,NAA,NAA,2019_iwata_85,9,Schizophrenia Non-Ultra Resistant,10.1016/j.biopsych.2018.09.009,,,14.22,1.62,,,
,NAA,NAA,2019_iwata_85,10,Schizophrenia Non-Treatment Resistant,10.1016/j.biopsych.2018.09.009,,,10.95,0.99,,,
,NAA,NAA,2019_iwata_85,11,Schizophrenia Non-Treatment Resistant,10.1016/j.biopsych.2018.09.009,,,13.97,0.7,,,
,NAA,NAA,2019_iwata_85,12,Schizophrenia Non-Treatment Resistant,10.1016/j.biopsych.2018.09.009,,,14.42,1.15,,,
,NAA,NAA,2019_joe_13,1,Predisposed Alzheimer's Mutation Carriers,10.1007/s11682-018-9913-1,1.51,0.13,7.62,0.42,,,
,NAA,NAA,2019_joe_13,2,Predisposed Alzheimer's Mutation Carriers,10.1007/s11682-018-9913-1,1.41,0.23,7.84,0.95,,,
,NAA,NAA,2019_joe_13,3,Predisposed Alzheimer's Mutation Carriers,10.1007/s11682-018-9913-1,1.44,0.2,9.48,0.77,,,
,NAA,NAA,2019_joe_13,4,Predisposed Alzheimer's Mutation Carriers,10.1007/s11682-018-9913-1,1.49,0.14,8.87,0.38,,,
,NAA,NAA,2019_joe_13,5,Predisposed Alzheimer's Non-Carriers,10.1007/s11682-018-9913-1,1.6,0.28,8.38,1.32,,,
,NAA,NAA,2019_joe_13,6,Predisposed Alzheimer's Non-Carriers,10.1007/s11682-018-9913-1,1.55,0.24,8.37,0.75,,,
,NAA,NAA,2019_joe_13,7,Predisposed Alzheimer's Non-Carriers,10.1007/s11682-018-9913-1,1.47,0.15,9.83,1.06,,,
,NAA,NAA,2019_joe_13,8,Predisposed Alzheimer's Non-Carriers,10.1007/s11682-018-9913-1,1.57,0.16,9.66,0.81,,,
,NAA,NAA,2019_kaur_113,1,Bipolar,10.1016/j.jpsychires.2019.03.018,1.3,0.2,,,,,
,NAA,NAA,2019_kaur_113,2,Bipolar,10.1016/j.jpsychires.2019.03.018,1.3,0.2,,,,,
,NAA,NAA,2019_kaur_113,3,Schizophrenia,10.1016/j.jpsychires.2019.03.018,1.3,0.1,,,,,
,NAA,NAA,2019_kaur_113,4,Schizophrenia,10.1016/j.jpsychires.2019.03.018,1.2,0.1,,,,,
,NAA,NAA,2019_khomenko_49,1,Aged,10.1007/s11055-019-00858-1,1.96,0.21,,,,,
,NAA,NAA,2019_khomenko_49,2,Aged,10.1007/s11055-019-00858-1,2.05,0.19,,,,,
,NAA,NAA,2019_khomenko_49,3,Aged,10.1007/s11055-019-00858-1,1.98,0.18,,,,,
,NAA,NAA,2019_khomenko_49,4,Aged,10.1007/s11055-019-00858-1,2.02,0.18,,,,,
,NAA,NAA,2019_khomenko_49,5,Aged,10.1007/s11055-019-00858-1,2.16,0.2,,,,,
,NAA,NAA,2019_khomenko_49,6,Aged,10.1007/s11055-019-00858-1,2.1,0.18,,,,,
,NAA,NAA,2019_khomenko_49,7,Aged,10.1007/s11055-019-00858-1,1.58,0.11,,,,,
,NAA,NAA,2019_khomenko_49,8,Aged,10.1007/s11055-019-00858-1,1.56,0.14,,,,,
,NAA,NAA,2019_khomenko_49,9,Aged,10.1007/s11055-019-00858-1,1.62,0.11,,,,,
,NAA,NAA,2019_khomenko_49,10,MCI,10.1007/s11055-019-00858-1,1.85,0.14,,,,,
,NAA,NAA,2019_khomenko_49,11,MCI,10.1007/s11055-019-00858-1,1.98,0.17,,,,,
,NAA,NAA,2019_khomenko_49,12,MCI,10.1007/s11055-019-00858-1,1.93,0.16,,,,,
,NAA,NAA,2019_khomenko_49,13,MCI,10.1007/s11055-019-00858-1,1.94,0.19,,,,,
,NAA,NAA,2019_khomenko_49,14,MCI,10.1007/s11055-019-00858-1,2.01,0.18,,,,,
,NAA,NAA,2019_khomenko_49,15,MCI,10.1007/s11055-019-00858-1,1.85,0.15,,,,,
,NAA,NAA,2019_khomenko_49,16,MCI,10.1007/s11055-019-00858-1,1.5,0.11,,,,,
,NAA,NAA,2019_khomenko_49,17,MCI,10.1007/s11055-019-00858-1,1.52,0.09,,,,,
,NAA,NAA,2019_khomenko_49,18,MCI,10.1007/s11055-019-00858-1,1.57,0.12,,,,,
,NAA,NAA,2019_khomenko_49,19,Alzheimer's Disease,10.1007/s11055-019-00858-1,1.7,0.18,,,,,
,NAA,NAA,2019_khomenko_49,20,Alzheimer's Disease,10.1007/s11055-019-00858-1,1.79,0.16,,,,,
,NAA,NAA,2019_khomenko_49,21,Alzheimer's Disease,10.1007/s11055-019-00858-1,1.75,0.15,,,,,
,NAA,NAA,2019_khomenko_49,22,Alzheimer's Disease,10.1007/s11055-019-00858-1,1.69,0.18,,,,,
,NAA,NAA,2019_khomenko_49,23,Alzheimer's Disease,10.1007/s11055-019-00858-1,1.86,0.24,,,,,
,NAA,NAA,2019_khomenko_49,24,Alzheimer's Disease,10.1007/s11055-019-00858-1,1.85,0.14,,,,,
,NAA,NAA,2019_khomenko_49,25,Alzheimer's Disease,10.1007/s11055-019-00858-1,1.46,0.17,,,,,
,NAA,NAA,2019_khomenko_49,26,Alzheimer's Disease,10.1007/s11055-019-00858-1,1.45,0.18,,,,,
,NAA,NAA,2019_khomenko_49,27,Alzheimer's Disease,10.1007/s11055-019-00858-1,1.45,0.14,,,,,
,NAA,NAA,2019_lally_18,1,Infant (Control),10.1016/S1474-4422(18)30325-9,1.56,0.23,,,7.1,0.8,
,NAA,NAA,2019_lally_18,2,Infant (Adverse),10.1016/S1474-4422(18)30325-9,1.25,0.31,,,4,1.3,
,tNAA,tNAA,2019_lawrence_33,1,Control,10.1080/02699052.2019.1584332,16.068,1.891,,,,,
,tNAA,tNAA,2019_lawrence_33,2,TBI,10.1080/02699052.2019.1584332,13.865,1.565,,,,,
,tNAA,tNAA,2019_lawrence_33,3,TBI,10.1080/02699052.2019.1584332,12.982,1.785,,,,,
,NAA,NAA,2019_levin_202,1,Control (Young),10.1016/j.neuroimage.2019.116050,,,7,0.99,,,
,NAA,NAA,2019_levin_202,2,Middle-Aged,10.1016/j.neuroimage.2019.116050,,,6.43,1.12,,,
,NAA,NAA,2019_levin_202,3,Old-Middle Aged,10.1016/j.neuroimage.2019.116050,,,6.27,1.15,,,
,NAA,NAA,2019_levin_202,4,Aged,10.1016/j.neuroimage.2019.116050,,,5.72,0.81,,,
,NAA,NAA,2019_levin_202,5,Control (Young),10.1016/j.neuroimage.2019.116050,,,7.53,1.76,,,
,NAA,NAA,2019_levin_202,6,Middle-Aged,10.1016/j.neuroimage.2019.116050,,,7.29,1.36,,,
,NAA,NAA,2019_levin_202,7,Old-Middle Aged,10.1016/j.neuroimage.2019.116050,,,6.01,1.25,,,
,NAA,NAA,2019_levin_202,8,Aged,10.1016/j.neuroimage.2019.116050,,,5.89,1.11,,,
,NAA,NAA,2018_veeramuthu_25,1,Complicated mTBI,10.1016/j.acra.2018.01.005,1.593,0.202,2.69,0.536,,,
,NAA,NAA,2018_veeramuthu_25,2,Uncomplicated mTBI,10.1016/j.acra.2018.01.005,1.68,0.163,2.862,0.541,,,
,NAA,NAA,2018_veeramuthu_25,3,Control,10.1016/j.acra.2018.01.005,1.72,0.125,3.019,0.284,,,
,tNAA,tNAA,2018_veeramuthu_25,1,Complicated mTBI,10.1016/j.acra.2018.01.005,1.82,0.282,3.097,0.775,,,
,tNAA,tNAA,2018_veeramuthu_25,2,Uncomplicated mTBI,10.1016/j.acra.2018.01.005,1.895,0.287,3.235,0.708,,,
,tNAA,tNAA,2018_veeramuthu_25,3,Control,10.1016/j.acra.2018.01.005,2.059,0.11,3.62,0.352,,,
,NAA,NAA,2018_volk_39,1,Healthy - Evening,10.1002/hbm.24225,1.54,0.12,11.59,0.52,,,
,NAA,NAA,2018_volk_39,2,Healthy - Morning,10.1002/hbm.24225,1.54,0.12,11.53,0.48,,,
,tNAA,tNAA,2018_volk_39,1,Healthy - Evening,10.1002/hbm.24225,1.68,0.16,12.64,0.6,,,
,tNAA,tNAA,2018_volk_39,2,Healthy - Morning,10.1002/hbm.24225,1.68,0.16,12.5,0.48,,,
,NAA,NAA,2018_wang_277,1,OCD,10.1016/j.pscychresns.2018.05.004,1.45,0.09,,,,,
,NAA,NAA,2018_wang_277,2,OCD,10.1016/j.pscychresns.2018.05.004,1.36,0.11,,,,,
,NAA,NAA,2018_wang_277,3,Control,10.1016/j.pscychresns.2018.05.004,1.47,0.11,,,,,
,NAA,NAA,2018_wang_277,4,Control,10.1016/j.pscychresns.2018.05.004,1.26,0.41,,,,,
,tNAA,tNAA,2018_white_43,1,Healthy_Placebo,10.1038/s41386-018-0027-7,,,8.18,0.83,,,
,tNAA,tNAA,2018_white_43,2,Healthy_d-amphetamine,10.1038/s41386-018-0027-7,,,8.32,0.71,,,
,tNAA,tNAA,2018_white_43,3,Healthy_methamphetamine,10.1038/s41386-018-0027-7,,,8.2,0.65,,,
,NAA,NAA,2018_wu_9,1,MA dependence (Abstinent),10.3389/fpsyt.2018.00478,1.12,0.08,,,,,
,NAA,NAA,2018_wu_9,2,Control,10.3389/fpsyt.2018.00478,1.17,0.07,,,,,
,NAA,NAA,2018_yeh_30,1,Alzheimer's Disease,10.1017/S1041610217002381,1.12,0.13,,,,,
,NAA,NAA,2018_yeh_30,2,Alzheimer's Disease,10.1017/S1041610217002381,1.06,0.21,,,,,
,NAA,NAA,2018_younis_19,1,Healthy - Sildenafil_Baseline,10.1186/s10194-018-0870-2,,,,,7.73,0.79,
,NAA,NAA,2018_younis_19,2,Healthy - Sildenafil_40min,10.1186/s10194-018-0870-2,,,,,7.93,0.79,
,NAA,NAA,2018_younis_19,3,Healthy - Sildenafil_140min,10.1186/s10194-018-0870-2,,,,,7.95,0.69,
,NAA,NAA,2018_younis_19,4,Healthy - Calcitonin gene-related peptide_Baseline,10.1186/s10194-018-0870-2,,,,,7.58,0.72,
,NAA,NAA,2018_younis_19,5,Healthy - Calcitonin gene-related peptide_40min,10.1186/s10194-018-0870-2,,,,,7.56,0.68,
,NAA,NAA,2018_younis_19,6,Healthy - Calcitonin gene-related peptide_140min,10.1186/s10194-018-0870-2,,,,,7.64,0.58,
,NAA,NAA,2018_younis_19,7,Healthy - Placebo_Baseline,10.1186/s10194-018-0870-2,,,,,7.95,0.69,
,NAA,NAA,2018_younis_19,8,Healthy - Placebo_40min,10.1186/s10194-018-0870-2,,,,,8.06,0.82,
,NAA,NAA,2018_younis_19,9,Healthy - Placebo_140min,10.1186/s10194-018-0870-2,,,,,7.73,0.72,
,tNAA,tNAA,2018_zarinabad_79,1,Medulloblastoma,10.1002/mrm.26837,,,,,1.03,0.44,
,tNAA,tNAA,2018_zarinabad_79,2,Pilocytic Astrocytoma,10.1002/mrm.26837,,,,,1.37,0.95,
,tNAA,tNAA,2018_zarinabad_79,3,Ependymoma,10.1002/mrm.26837,,,,,0.53,0.25,
,NAA,tNAA,2018_zhong_241,1,BD - with suicidal ideation,10.1016/j.jad.2018.08.031,2.1,0.42,,,,,Assumed Total (tNAA) based on use of Total Choline
,NAA,tNAA,2018_zhong_241,2,BD - with suicidal ideation,10.1016/j.jad.2018.08.031,2.17,0.45,,,,,Assumed Total (tNAA) based on use of Total Choline
,NAA,tNAA,2018_zhong_241,3,BD - with suicidal ideation,10.1016/j.jad.2018.08.031,1.72,0.24,,,,,Assumed Total (tNAA) based on use of Total Choline
,NAA,tNAA,2018_zhong_241,4,BD - with suicidal ideation,10.1016/j.jad.2018.08.031,1.64,0.21,,,,,Assumed Total (tNAA) based on use of Total Choline
,NAA,tNAA,2018_zhong_241,5,BD - with suicidal ideation,10.1016/j.jad.2018.08.031,1.48,0.4,,,,,Assumed Total (tNAA) based on use of Total Choline
,NAA,tNAA,2018_zhong_241,6,BD - with suicidal ideation,10.1016/j.jad.2018.08.031,1.61,0.3,,,,,Assumed Total (tNAA) based on use of Total Choline
,NAA,tNAA,2018_zhong_241,7,BD - with suicidal ideation,10.1016/j.jad.2018.08.031,1.85,0.25,,,,,Assumed Total (tNAA) based on use of Total Choline
,NAA,tNAA,2018_zhong_241,8,BD - with suicidal ideation,10.1016/j.jad.2018.08.031,1.78,0.32,,,,,Assumed Total (tNAA) based on use of Total Choline
,NAA,tNAA,2018_zhong_241,9,BD - without suicidal ideation,10.1016/j.jad.2018.08.031,2.03,0.36,,,,,Assumed Total (tNAA) based on use of Total Choline
,NAA,tNAA,2018_zhong_241,10,BD - without suicidal ideation,10.1016/j.jad.2018.08.031,2.29,0.45,,,,,Assumed Total (tNAA) based on use of Total Choline
,NAA,tNAA,2018_zhong_241,11,BD - without suicidal ideation,10.1016/j.jad.2018.08.031,1.78,0.33,,,,,Assumed Total (tNAA) based on use of Total Choline
,NAA,tNAA,2018_zhong_241,12,BD - without suicidal ideation,10.1016/j.jad.2018.08.031,1.78,0.71,,,,,Assumed Total (tNAA) based on use of Total Choline
,NAA,tNAA,2018_zhong_241,13,BD - without suicidal ideation,10.1016/j.jad.2018.08.031,1.59,0.32,,,,,Assumed Total (tNAA) based on use of Total Choline
,NAA,tNAA,2018_zhong_241,14,BD - without suicidal ideation,10.1016/j.jad.2018.08.031,1.75,0.41,,,,,Assumed Total (tNAA) based on use of Total Choline
,NAA,tNAA,2018_zhong_241,15,BD - without suicidal ideation,10.1016/j.jad.2018.08.031,1.86,0.28,,,,,Assumed Total (tNAA) based on use of Total Choline
,NAA,tNAA,2018_zhong_241,16,BD - without suicidal ideation,10.1016/j.jad.2018.08.031,1.77,0.34,,,,,Assumed Total (tNAA) based on use of Total Choline
,NAA,tNAA,2018_zhong_241,17,Control ,10.1016/j.jad.2018.08.031,2.28,0.31,,,,,Assumed Total (tNAA) based on use of Total Choline
,NAA,tNAA,2018_zhong_241,18,Control,10.1016/j.jad.2018.08.031,2.31,0.47,,,,,Assumed Total (tNAA) based on use of Total Choline
,NAA,tNAA,2018_zhong_241,19,Control,10.1016/j.jad.2018.08.031,1.72,0.22,,,,,Assumed Total (tNAA) based on use of Total Choline
,NAA,tNAA,2018_zhong_241,20,Control,10.1016/j.jad.2018.08.031,1.53,0.22,,,,,Assumed Total (tNAA) based on use of Total Choline
,NAA,tNAA,2018_zhong_241,21,Control,10.1016/j.jad.2018.08.031,1.56,0.24,,,,,Assumed Total (tNAA) based on use of Total Choline
,NAA,tNAA,2018_zhong_241,22,Control,10.1016/j.jad.2018.08.031,1.59,0.23,,,,,Assumed Total (tNAA) based on use of Total Choline
,NAA,tNAA,2018_zhong_241,23,Control,10.1016/j.jad.2018.08.031,1.73,0.25,,,,,Assumed Total (tNAA) based on use of Total Choline
,NAA,tNAA,2018_zhong_241,24,Control,10.1016/j.jad.2018.08.031,1.7,0.15,,,,,Assumed Total (tNAA) based on use of Total Choline
,NAA,NAA,2017_craciunas_26,1,Control,10.3171/2016.10.SPINE16479,1.6,0.14,,,,,
,NAA,NAA,2017_craciunas_26,2,Control,10.3171/2016.10.SPINE16479,1.62,0.14,,,,,
,NAA,NAA,2017_craciunas_26,3,Control,10.3171/2016.10.SPINE16479,,,,,,,
,NAA,NAA,2017_craciunas_26,4,Control,10.3171/2016.10.SPINE16479,,,,,,,
,NAA,NAA,2017_craciunas_26,5,Cervical spondylotic myelopathy,10.3171/2016.10.SPINE16479,,,,,,,
,NAA,NAA,2017_craciunas_26,6,Cervical spondylotic myelopathy,10.3171/2016.10.SPINE16479,,,,,,,
,NAA,NAA,2017_craciunas_26,7,Cervical spondylotic myelopathy,10.3171/2016.10.SPINE16479,,,,,,,
,NAA,NAA,2017_craciunas_26,8,Cervical spondylotic myelopathy,10.3171/2016.10.SPINE16479,,,,,,,
,NAA,NAA,2017_bustillo_43,1,Control,10.1093/schbul/sbw122,,,,,5.3,0.8,
,NAA,NAA,2017_bustillo_43,2,Schizophrenia,10.1093/schbul/sbw123,,,,,5.4,0.9,
,NAA,NAA,2017_cao_42,1,Control,10.1038/npp.2017.39,,,10.41,0.25,,,
,NAA,NAA,2017_cao_42,2,Control,10.1038/npp.2017.39,,,12.54,0.4,,,
,NAA,NAA,2017_cao_42,3,Control,10.1038/npp.2017.39,,,6.41,0.34,,,
,NAA,NAA,2017_cao_42,4,Control,10.1038/npp.2017.39,,,11.87,0.42,,,
,NAA,NAA,2017_cao_42,5,BD-1-Non Rapid Cycling,10.1038/npp.2017.39,,,10.38,0.26,,,
,NAA,NAA,2017_cao_42,6,BD-1-Non Rapid Cycling,10.1038/npp.2017.39,,,12.68,0.4,,,
,NAA,NAA,2017_cao_42,7,BD-1-Non Rapid Cycling,10.1038/npp.2017.39,,,7.19,0.38,,,
,NAA,NAA,2017_cao_42,8,BD-1-Non Rapid Cycling,10.1038/npp.2017.39,,,12.47,0.49,,,
,NAA,NAA,2017_cao_42,9,BD-1-Rapid Cycling,10.1038/npp.2017.39,,,11.56,0.38,,,
,NAA,NAA,2017_cao_42,10,BD-1-Rapid Cycling,10.1038/npp.2017.39,,,14.39,0.57,,,
,NAA,NAA,2017_cao_42,11,BD-1-Rapid Cycling,10.1038/npp.2017.39,,,7.16,0.45,,,
,NAA,NAA,2017_cao_42,12,BD-1-Rapid Cycling,10.1038/npp.2017.39,,,13.3,0.59,,,
,NAA,NAA,2017_holmes_12,1,Healthy - 5 year olds,10.1371/journal.pone.0180973,1.184,0.102,6.341,0.719,,,
,NAA,NAA,2017_holmes_12,2,Healthy - 5 year olds,10.1371/journal.pone.0180973,0.933,0.097,5.518,0.487,,,
,NAA,NAA,2017_holmes_12,3,Healthy - 5 year olds,10.1371/journal.pone.0180973,1.551,0.141,5.583,0.594,,,
,NAA,NAA,2017_holmes_12,4,Healthy - 7 year olds,10.1371/journal.pone.0180973,1.215,0.121,6.549,0.491,,,
,NAA,NAA,2017_holmes_12,5,Healthy - 7 year olds,10.1371/journal.pone.0180973,0.977,0.109,5.716,0.383,,,
,NAA,NAA,2017_holmes_12,6,Healthy - 7 year olds,10.1371/journal.pone.0180973,1.55,0.18,5.58,0.6,,,
,NAA,NAA,2017_holmes_12,7,Healthy - 9 year olds,10.1371/journal.pone.0180973,1.248,0.095,7.144,0.65,,,
,NAA,NAA,2017_holmes_12,8,Healthy - 9 year olds,10.1371/journal.pone.0180973,1.005,0.123,5.782,0.57,,,
,NAA,NAA,2017_holmes_12,9,Healthy - 9 year olds,10.1371/journal.pone.0180973,1.566,0.254,6.019,0.839,,,
,tNAA,tNAA,2017_holmes_12,1,Healthy - 5 year olds,10.1371/journal.pone.0180973,1.265,0.094,6.768,0.674,,,
,tNAA,tNAA,2017_holmes_12,2,Healthy - 5 year olds,10.1371/journal.pone.0180973,0.998,0.078,5.907,0.416,,,
,tNAA,tNAA,2017_holmes_12,3,Healthy - 5 year olds,10.1371/journal.pone.0180973,1.661,0.154,5.974,0.591,,,
,tNAA,tNAA,2017_holmes_12,4,Healthy - 7 year olds,10.1371/journal.pone.0180973,1.29,0.116,6.956,0.505,,,
,tNAA,tNAA,2017_holmes_12,5,Healthy - 7 year olds,10.1371/journal.pone.0180973,1.043,0.118,6.112,0.527,,,
,tNAA,tNAA,2017_holmes_12,6,Healthy - 7 year olds,10.1371/journal.pone.0180973,1.66,0.17,5.98,0.58,,,
,tNAA,tNAA,2017_holmes_12,7,Healthy - 9 year olds,10.1371/journal.pone.0180973,1.327,0.099,7.594,0.66,,,
,tNAA,tNAA,2017_holmes_12,8,Healthy - 9 year olds,10.1371/journal.pone.0180973,1.088,0.115,6.263,0.497,,,
,tNAA,tNAA,2017_holmes_12,9,Healthy - 9 year olds,10.1371/journal.pone.0180973,1.71,0.191,6.584,0.647,,,
,NAA,NAA,2017_carlson_38,1,Control-Typical Developing Volunteers,,,,,,,,
,NAA,NAA,2017_carlson_38,2,Periventricular venous infarctions,,,,,,,,
,NAA,NAA,2017_carlson_38,3,Atrial,,,,,,,,
,NAA,NAA,2017_simoes_216,1,Control,10.1016/j.ajog.2016.09.089,0.92,0.11,,,,,
,NAA,NAA,2017_simoes_216,2,Preterm,10.1016/j.ajog.2016.09.089,1.01,0.12,,,,,
,NAA,NAA,2017_simoes_216,3,Preterm - Intra-uterine growth restricted,10.1016/j.ajog.2016.09.089,0.88,0.12,,,,,
,tNAA,tNAA,2017_simoes_216,1,Control,10.1016/j.ajog.2016.09.089,1.02,0.13,,,,,
,tNAA,tNAA,2017_simoes_216,2,Preterm,10.1016/j.ajog.2016.09.089,1.13,0.12,,,,,
,tNAA,tNAA,2017_simoes_216,3,Preterm - Intra-uterine growth restricted,10.1016/j.ajog.2016.09.089,1.01,1.3,,,,,
,NAA,NAA,2017_carlson_38,2,Control- Non-dominant Hand ,10.1002/hbm.23472,1.56,0.105,11.7,1.08,,,Non-Dominant hand activity is analogous to Lesioned brain activity
,NAA,NAA,2017_carlson_38,1,Control- Dominant Hand,10.1002/hbm.23472,1.57,0.113,12.8,1.313,,,Dominant hand activity is analogous to Non-lesioned brain activity 
,NAA,NAA,2017_carlson_38,4,Bipolar with Periventricular Venous Infarctions- Lesioned Side,10.1002/hbm.23472,1.53,0.083,12.25,1.275,,,Non-Dominant hand activity is analogous to Lesioned brain activity
,NAA,NAA,2017_carlson_38,3,Bipolar with Periventricular Venous Infarctions- Non-lesioned Side,10.1002/hbm.23472,1.56,0.18,11.6,1.725,,,Dominant hand activity is analogous to Non-lesioned brain activity 
,NAA,NAA,2017_carlson_38,5,Bipolar with Arterial Ischemic Strokes- Lesioned Side ,10.1002/hbm.23472,1.35,0.094,10.9,1.65,,,Non-Dominant hand activity is analogous to Lesioned brain activity
,NAA,NAA,2017_carlson_38,6,Bipolar with Arterial Ischemic Strokes- Non-lesioned Side,10.1002/hbm.23472,1.54,0.09,12,1.725,,,Dominant hand activity is analogous to Non-lesioned brain activity 
,tNAA,tNAA,2020_zheng_265,1,Control,10.1016/j.jad.2020.01.059,,,8.18,1.01,,,
,tNAA,tNAA,2020_zheng_265,2,Control,10.1016/j.jad.2020.01.059,,,8.47,1.16,,,
,tNAA,tNAA,2020_zheng_265,3,Control,10.1016/j.jad.2020.01.059,,,7.92,0.71,,,
,tNAA,tNAA,2020_zheng_265,4,OCD,10.1016/j.jad.2020.01.059,,,8.14,1.52,,,
,tNAA,tNAA,2020_zheng_265,5,OCD,10.1016/j.jad.2020.01.059,,,8.69,1.7,,,
,tNAA,tNAA,2020_zheng_265,6,OCD,10.1016/j.jad.2020.01.059,,,7.35,0.81,,,
,tNAA,tNAA,2020_zheng_265,7,OCD + SPD,10.1016/j.jad.2020.01.059,,,6.58,2.66,,,
,tNAA,tNAA,2020_zheng_265,8,OCD + SPD,10.1016/j.jad.2020.01.059,,,7.49,1.94,,,
,tNAA,tNAA,2020_zheng_265,9,OCD + SPD,10.1016/j.jad.2020.01.059,,,6.17,2.94,,,
,NAA,NAA,2015_glodzik_43,1,Control,10.3233/JAD-140609,,,,,14.1,2.4,
,NAA,NAA,2015_glodzik_43,2,Mild cognitive impairment,10.3233/JAD-140609,,,,,10.5,3,
,NAA,NAA,2015_glodzik_43,3,Alzheimer's disease,10.3233/JAD-140609,,,,,10.1,2.9,
,NAA,NAA,2015_glodzik_43,4,Control,10.3233/JAD-140609,,,,,10.5,2,
,NAA,NAA,2015_glodzik_43,5,Mild cognitive impairment,10.3233/JAD-140609,,,,,7.6,2.2,
,NAA,NAA,2015_glodzik_43,6,Alzheimer's disease,10.3233/JAD-140609,,,,,7,2.1,
,NAA,NAA,2021_gramegna_8,2,Patients with MELAS,10.1002/acn3.51329,1.24,0.16,,,,,
,NAA,NAA,2021_gramegna_8,2,Patients with MELAS,10.1002/acn3.51329,,,,,,,Ratio:1.63/StdDev: 0.4 ; these values were referenced to ml (myo-inositol)
,NAA,NAA,2021_gramegna_8,3,Patients with MELAS,10.1002/acn3.51329,1.62,0.23,,,,,
,NAA,NAA,2021_gramegna_8,3,Patients with MELAS,10.1002/acn3.51329,,,,,,,Ratio: 1.56/StdDev: 0.53 ; these values were referenced to ml (myo-inositol)
,NAA,NAA,2021_gramegna_8,4,Patients with MELAS,10.1002/acn3.51329,0.96,0.15,,,,,
,NAA,NAA,2021_gramegna_8,4,Patients with MELAS,10.1002/acn3.51329,,,,,,,Ratio: 1.37/StdDev: 0.29 ; these values were referenced to ml (myo-inositol)
,NAA,NAA,2021_gramegna_8,6,Patients with MELAS,10.1002/acn3.51329,1.39,0.11,,,,,
,NAA,NAA,2021_gramegna_8,6,Patients with MELAS,10.1002/acn3.51329,,,,,,,Ratio: 1.91/StdDev: 0.23 ; these values were referenced to ml (myo-inositol)
,NAA,NAA,2021_gramegna_8,7,Patients with MELAS,10.1002/acn3.51329,1.8,0.14,,,,,
,NAA,NAA,2021_gramegna_8,7,Patients with MELAS,10.1002/acn3.51329,,,,,,,Ratio: 2.07/StdDev: 0.50 ; these values were referenced to ml (myo-inositol)
,NAA,NAA,2021_gramegna_8,8,Patients with MELAS,10.1002/acn3.51329,1.29,0.2,,,,,
,NAA,NAA,2021_gramegna_8,8,Patients with MELAS,10.1002/acn3.51329,,,,,,,Ratio: 1.90/StdDev: 0.37 ; these values were referenced to ml (myo-inositol)
,NAA,NAA,2021_malaspina_42,1,Schizophrenia,10.3174/ajnr.A6879,,,,,,,
,NAA,NAA,2020_korenic_120,1,Schizophrenia,10.1016/j.jpsychires.2019.10.006,,,10.8,0.9,,,
,NAA,NAA,2020_korenic_120,2,Schizophrenia,10.1016/j.jpsychires.2019.10.006,,,7.9,0.6,,,
,NAA,NAA,2020_korenic_120,3,Schizophrenia,10.1016/j.jpsychires.2019.10.006,,,10.8,0.8,,,
,NAA,NAA,2020_korenic_120,4,Control,10.1016/j.jpsychires.2019.10.006,,,11,0.6,,,
,NAA,NAA,2020_korenic_120,5,Control,10.1016/j.jpsychires.2019.10.006,,,8.1,0.8,,,
,NAA,NAA,2020_korenic_120,6,Control,10.1016/j.jpsychires.2019.10.006,,,11.1,1,,,
,NAA,NAA,2020_kahl_101,1,Control,10.1016/j.pnpbp.2020.109916,,,11.28,0.15,,,
,NAA,NAA,2020_kahl_101,2,Control,10.1016/j.pnpbp.2020.109916,,,11.16,0.19,,,
,NAA,NAA,2020_kahl_101,3,Control,10.1016/j.pnpbp.2020.109916,,,9.62,0.16,,,
,NAA,NAA,2020_kahl_101,4,Control,10.1016/j.pnpbp.2020.109916,,,10.08,0.17,,,
,NAA,NAA,2020_kahl_101,5,Control,10.1016/j.pnpbp.2020.109916,,,11.42,0.15,,,
,NAA,NAA,2020_kahl_101,6,Control,10.1016/j.pnpbp.2020.109916,,,11.63,0.16,,,
,NAA,NAA,2020_kahl_101,7,Control,10.1016/j.pnpbp.2020.109916,,,11.42,0.2,,,
,NAA,NAA,2020_kahl_101,8,Control,10.1016/j.pnpbp.2020.109916,,,11.79,0.17,,,
,NAA,NAA,2020_kahl_101,9,Control,10.1016/j.pnpbp.2020.109916,,,8.8,0.11,,,
,NAA,NAA,2020_kahl_101,10,MDD,10.1016/j.pnpbp.2020.109916,,,10.52,0.2,,,
,NAA,NAA,2020_kahl_101,11,MDD,10.1016/j.pnpbp.2020.109916,,,10.71,0.24,,,
,NAA,NAA,2020_kahl_101,12,MDD,10.1016/j.pnpbp.2020.109916,,,9.29,0.2,,,
,NAA,NAA,2020_kahl_101,13,MDD,10.1016/j.pnpbp.2020.109916,,,9.82,0.19,,,
,NAA,NAA,2020_kahl_101,14,MDD,10.1016/j.pnpbp.2020.109916,,,10.83,0.2,,,
,NAA,NAA,2020_kahl_101,15,MDD,10.1016/j.pnpbp.2020.109916,,,11.26,0.18,,,
,NAA,NAA,2020_kahl_101,16,MDD,10.1016/j.pnpbp.2020.109916,,,11.24,0.24,,,
,NAA,NAA,2020_kahl_101,17,MDD,10.1016/j.pnpbp.2020.109916,,,11.62,0.19,,,
,NAA,NAA,2020_kahl_101,18,MDD,10.1016/j.pnpbp.2020.109916,,,8.76,0.19,,,
,NAA,tNAA,2020_gules_79,1,MDD,10.1159/000505782,1.65,0.42,7.79,2.3,,,Assumed Total (tNAA) based on Analysis
,NAA,tNAA,2020_gules_79,2,Healthy Control,10.1159/000505782,2.28,0.18,6.11,2.57,,,Assumed Total (tNAA) based on Analysis
,NAA,NAA,2021_malaspina_42,2,Schizophrenia,10.3174/ajnr.A6879,,,,,9.49,2.35,
,NAA,NAA,2017_cao_660,1,Control ,10.1016/j.neulet.2017.08.050,2,0.25,,,,,Brain Region: Medulla Oblongata 
,NAA,NAA,2017_cao_660,1,Control ,10.1016/j.neulet.2017.08.050,2.1,0.15,,,,,Brain Region: Substantia Nigra  
,NAA,NAA,2017_cao_660,1,Control,10.1016/j.neulet.2017.08.050,1.25,0.15,,,,,Brain Region: Putamen 
,NAA,NAA,2017_cao_660,1,Control,10.1016/j.neulet.2017.08.050,1.75,0.15,,,,,Brain Region: Motor Cortex
,NAA,NAA,2017_cao_660,2,Parkinsons Disease ,10.1016/j.neulet.2017.08.050,1.75,0.15,,,,,Brain Region: Medulla Oblongata 
,NAA,NAA,2017_cao_660,2,Parkinsons Disease ,10.1016/j.neulet.2017.08.050,1.5,0.15,,,,,Brain Region: Substantia Nigra  
,NAA,NAA,2017_cao_660,2,Parkinsons Disease ,10.1016/j.neulet.2017.08.050,1.45,0.1,,,,,Brain Region: Putamen 
,NAA,NAA,2017_cao_660,2,Parkinsons Disease ,10.1016/j.neulet.2017.08.050,1.9,0.1,,,,,Brain Region: Motor Cortex
,NAA,NAA,2021_onwordi_11,1,Schizophrenia,10.1038/s41398-021-01515-3,1.14,0.085,,,,,
,NAA,NAA,2020_lewis_10,1,Healthy Control,10.1038/s41398-020-0792-z,,,85.74,2.4,,,
,NAA,NAA,2020_lewis_10,2,Depressed,10.1038/s41398-020-0792-z,,,80.39,2.12,,,
,NAA,NAA,2020_lewis_10,3,Depressed,10.1038/s41398-020-0792-z,,,81.07,2.25,,,
,tNAA,tNAA,2015_seraji-bozorgzad_30,1,Parkinson's Disease - Baseline,10.1002/mds.26323,1.9,0.192,,,,,
,tNAA,tNAA,2015_seraji-bozorgzad_30,2,Parkinson's Disease - 3 Months,10.1002/mds.26323,1.82,0.281,,,,,
,tNAA,tNAA,2015_seraji-bozorgzad_30,3,Contol - Baseline,10.1002/mds.26323,2.18,0.22,,,,,
,tNAA,tNAA,2015_seraji-bozorgzad_30,4,Control - 3 Months,10.1002/mds.26323,2.19,0.196,,,,,
,tNAA,tNAA,2015_simoes_213,1,Control,10.1016/j.ajog.2015.04.011,1,0.1,,,4.4,0.8,
,tNAA,tNAA,2015_simoes_213,2,Small-born infants,10.1016/j.ajog.2015.04.011,1.1,1.4,,,4.7,0.5,
,tNAA,tNAA,2015_simoes_213,3,Small-born infants - Small for gestational age,10.1016/j.ajog.2015.04.011,1,0.2,,,4.7,0.7,
,tNAA,tNAA,2015_simoes_213,4,Small-born infants - Late intrauterine growth restriction,10.1016/j.ajog.2015.04.011,1.1,0.1,,,4.7,0.5,
,NAA,tNAA,2016_guo_69,1,Control,10.1016/j.comppsych.2016.06.001,1.63,0.44,,,,,Assumed Total (tNAA) based on Analysis
,NAA,tNAA,2016_guo_69,2,Control,10.1016/j.comppsych.2016.06.001,1.61,0.44,,,,,Assumed Total (tNAA) based on Analysis
,NAA,tNAA,2016_guo_69,3,Control,10.1016/j.comppsych.2016.06.001,1.73,0.28,,,,,Assumed Total (tNAA) based on Analysis
,NAA,tNAA,2016_guo_69,4,Control,10.1016/j.comppsych.2016.06.001,1.89,0.46,,,,,Assumed Total (tNAA) based on Analysis
,NAA,tNAA,2016_guo_69,5,Amnestic mild cognitive impairment,10.1016/j.comppsych.2016.06.001,1.37,0.24,,,,,Assumed Total (tNAA) based on Analysis
,NAA,tNAA,2016_guo_69,6,Amnestic mild cognitive impairment,10.1016/j.comppsych.2016.06.001,1.29,0.17,,,,,Assumed Total (tNAA) based on Analysis
,NAA,tNAA,2016_guo_69,7,Amnestic mild cognitive impairment,10.1016/j.comppsych.2016.06.001,1.82,0.13,,,,,Assumed Total (tNAA) based on Analysis
,NAA,tNAA,2016_guo_69,8,Amnestic mild cognitive impairment,10.1016/j.comppsych.2016.06.001,1.88,0.32,,,,,Assumed Total (tNAA) based on Analysis
,NAA,tNAA,2016_guo_69,9,Alzheimer's disease,10.1016/j.comppsych.2016.06.001,1.52,0.34,,,,,Assumed Total (tNAA) based on Analysis
,NAA,tNAA,2016_guo_69,10,Alzheimer's disease,10.1016/j.comppsych.2016.06.001,1.4,0.3,,,,,Assumed Total (tNAA) based on Analysis
,NAA,tNAA,2016_guo_69,11,Alzheimer's disease,10.1016/j.comppsych.2016.06.001,1.64,0.47,,,,,Assumed Total (tNAA) based on Analysis
,NAA,tNAA,2016_guo_69,12,Alzheimer's disease,10.1016/j.comppsych.2016.06.001,1.61,0.58,,,,,Assumed Total (tNAA) based on Analysis
,NAA,NAA,2021_onwordi_11,2,Schizophrenia,10.1038/s41398-021-01515-3,1.07,0.17,,,,,
,NAA,NAA,2021_onwordi_11,3,Control,10.1038/s41398-021-01515-3,1.13,0.094,,,,,
,tNAA,tNAA,2016_howells_31,1,In utero alcohol exposure,10.1007/s11011-016-9850-x,1,0.17,,,2.76,1.1,
,tNAA,tNAA,2016_howells_31,2,In utero alcohol exposure,10.1007/s11011-016-9850-x,1.01,0.13,,,3.45,0.36,
,tNAA,tNAA,2016_howells_31,3,In utero alcohol exposure - Female,10.1007/s11011-016-9850-x,1,0.21,,,2.61,1.23,
,tNAA,tNAA,2016_howells_31,4,In utero alcohol exposure - Female,10.1007/s11011-016-9850-x,1.05,0.12,,,3.43,0.23,
,tNAA,tNAA,2016_howells_31,5,In utero alcohol exposure - Male,10.1007/s11011-016-9850-x,1.01,0.13,,,2.93,1,
,tNAA,tNAA,2016_howells_31,6,In utero alcohol exposure - Male,10.1007/s11011-016-9850-x,0.98,0.13,,,3.47,0.45,
,tNAA,tNAA,2016_howells_31,7,Infants - Control,10.1007/s11011-016-9850-x,1.01,0.14,,,3.09,0.76,
,tNAA,tNAA,2016_howells_31,8,Infants - Control,10.1007/s11011-016-9850-x,0.99,0.12,,,3.4,0.67,
,tNAA,tNAA,2016_howells_31,9,Infants - Control_Female,10.1007/s11011-016-9850-x,1,0.14,,,2.99,0.75,
,tNAA,tNAA,2016_howells_31,10,Infants - Control_Female,10.1007/s11011-016-9850-x,1.01,0.08,,,2.99,0.75,
,tNAA,tNAA,2016_howells_31,11,Infants - Control_Male,10.1007/s11011-016-9850-x,1.04,0.15,,,3.24,0.81,
,tNAA,tNAA,2016_howells_31,12,Infants - Control_Male,10.1007/s11011-016-9850-x,0.97,0.13,,,3.58,0.57,
,NAA,NAA,2016_howells_31,1,In utero alcohol exposure,10.1007/s11011-016-9850-x,0.8,0.25,,,2.15,1.06,
,NAA,NAA,2016_howells_31,2,In utero alcohol exposure,10.1007/s11011-016-9850-x,0.7,0.18,,,2.42,0.66,
,NAA,NAA,2016_howells_31,3,In utero alcohol exposure - Female,10.1007/s11011-016-9850-x,0.81,0.28,,,2.09,1.13,
,NAA,NAA,2016_howells_31,4,In utero alcohol exposure - Female,10.1007/s11011-016-9850-x,0.75,0.17,,,2.41,0.74,
,NAA,NAA,2016_howells_31,5,In utero alcohol exposure - Male,10.1007/s11011-016-9850-x,0.8,0.24,,,2.21,1.04,
,NAA,NAA,2016_howells_31,6,In utero alcohol exposure - Male,10.1007/s11011-016-9850-x,0.66,0.18,,,2.44,0.6,
,NAA,NAA,2016_howells_31,7,Infants - Control,10.1007/s11011-016-9850-x,0.79,0.16,,,2.37,0.7,
,NAA,NAA,2016_howells_31,8,Infants - Control,10.1007/s11011-016-9850-x,0.72,0.17,,,2.37,0.87,
,NAA,NAA,2016_howells_31,9,Infants - Control_Female,10.1007/s11011-016-9850-x,0.79,0.16,,,2.43,0.67,
,NAA,NAA,2016_howells_31,10,Infants - Control_Female,10.1007/s11011-016-9850-x,0.69,0.16,,,1.97,0.69,
,NAA,NAA,2016_howells_31,11,Infants - Control_Male,10.1007/s11011-016-9850-x,0.8,0.16,,,2.28,0.78,
,NAA,NAA,2016_howells_31,12,Infants - Control_Male,10.1007/s11011-016-9850-x,0.73,0.17,,,2.55,0.91,
,NAA,NAA,2020_savic_30,1,Control,10.1093/cercor/bhz340,,,,,11.25,1.75,
,NAA,NAA,2020_savic_30,2,Control,10.1093/cercor/bhz340,,,,,11.2,1.7,
,NAA,NAA,2020_savic_30,3,Control,10.1093/cercor/bhz340,,,,,8.3,1.2,
,NAA,NAA,2020_savic_30,4,Control,10.1093/cercor/bhz340,,,,,12.9,0.6,
,NAA,NAA,2020_savic_30,5,ES Patients,10.1093/cercor/bhz340,,,,,10.75,1.4,
,NAA,NAA,2020_savic_30,6,ES Patients,10.1093/cercor/bhz340,,,,,10.6,1.5,
,NAA,NAA,2020_savic_30,7,ES Patients,10.1093/cercor/bhz340,,,,,8.9,1.8,
,NAA,NAA,2020_savic_30,8,ES Patients,10.1093/cercor/bhz340,,,,,12.1,0.6,
,NAA,NAA,2020_su_71,1,Healthy Controls,10.1016/j.jocn.2019.11.021,,,13.28,2.29,,,
,NAA,NAA,2020_su_71,2,Methamphetamine Dependence,10.1016/j.jocn.2019.11.021,,,9.51,2.9,,,
,NAA + NAAG,tNAA,2020_su_71,1,Healthy Controls,10.1016/j.jocn.2019.11.021,,,15.23,2.84,,,
,NAA + NAAG,tNAA,2020_su_71,2,Methamphetamine Dependence,10.1016/j.jocn.2019.11.021,,,10.71,3.24,,,
,tNAA,tNAA,2016_koob_11,1,Premature Neonates,10.1371/journal.pone.0160990,,,0.062,0.02,,,
,tNAA,tNAA,2016_koob_11,2,Premature Neonates,10.1371/journal.pone.0160990,,,0.055,0.014,,,
,tNAA,tNAA,2016_koob_11,3,Infants - Control,10.1371/journal.pone.0160990,,,0.062,0.019,,,
,tNAA,tNAA,2016_koob_11,4,Infants - Control,10.1371/journal.pone.0160990,,,0.058,0.01,,,
,tNAA,tNAA,2016_mazuel_278,1,Parkinson's Disease - Drug-on,10.1148/radiol.2015142764,,,9.1,1.8,,,
,tNAA,tNAA,2016_mazuel_278,2,Parkinson's Disease - Drug-off,10.1148/radiol.2015142764,,,8.1,0.9,,,
,tNAA,tNAA,2016_mazuel_278,3,Control,10.1148/radiol.2015142764,,,9.4,1.8,,,
,NAA,NAA,2021_onwordi_11,4,Control,10.1038/s41398-021-01515-3,1.1,0.141,,,,,
,NAA,NAA,2016_wu_206,1,Parkinson's Disease,10.2214/AJR.14.14052,1.32,0.66,,,,,
,NAA,NAA,2016_wu_206,2,Parkinson's Disease,10.2214/AJR.14.14052,1.22,0.45,,,,,
,NAA,NAA,2016_wu_206,3,Parkinson's Disease - Hoehn-Yahr Stages 1-2,10.2214/AJR.14.14052,1.69,0.7,,,,,
,NAA,NAA,2016_wu_206,4,Parkinson's Disease - Hoehn-Yahr Stages 1-2,10.2214/AJR.14.14052,1.3,0.46,,,,,
,NAA,NAA,2016_wu_206,5,Parkinson's Disease - Hoehn-Yahr Stages 3-5,10.2214/AJR.14.14052,0.99,0.43,,,,,
,NAA,NAA,2016_wu_206,6,Parkinson's Disease - Hoehn-Yahr Stages 3-5,10.2214/AJR.14.14052,1.15,0.45,,,,,
,NAA,NAA,2019_marjanska_68,1,Alzheimer's disease,10.3233/JAD-180861,,,,,10.49,1.12,
,NAA,NAA,2019_marjanska_68,2,Alzheimer's disease,10.3233/JAD-180861,,,,,11.81,1.12,
,NAA,NAA,2019_marjanska_68,3,Control,10.3233/JAD-180861,,,,,10.84,1.091,
,NAA,NAA,2019_marjanska_68,4,Control,10.3233/JAD-180861,,,,,11.65,1.091,
,NAA,NAA,2020_basu_10,1,Preterm Infants,10.1038/s41598-020-67188-y,1.03,0.03,3.71,0.19,,,
,NAA,NAA,2020_basu_10,4,Preterm Infants,10.1038/s41598-020-67188-y,1.04,0.04,3.95,0.28,,,
,NAA,NAA,2020_basu_10,7,Preterm Infants,10.1038/s41598-020-67188-y,1.03,0.04,3.46,0.24,,,
,NAA,NAA,2020_basu_10,10,Preterm Infants,10.1038/s41598-020-67188-y,,,3.86,0.2,,,
,NAA,NAA,2020_basu_10,13,Preterm Infants,10.1038/s41598-020-67188-y,,,3.59,0.29,,,
,NAA,NAA,2020_archibald_10,1,Baseline,10.1038/s41598-020-76263-3,,,,,9.41,0.26,
,NAA,NAA,2020_archibald_10,2,Baseline 2,10.1038/s41598-020-76263-3,,,,,10.03,0.28,
,NAA,NAA,2020_archibald_10,3,Baseline 4,10.1038/s41598-020-76263-3,,,,,9.6,0.26,
,NAA,NAA,2020_archibald_10,4,Baseline 6,10.1038/s41598-020-76263-3,,,,,9.68,0.26,
,NAA,NAA,2020_archibald_10,5,Baseline 8,10.1038/s41598-020-76263-3,,,,,9.71,0.25,
,NAA,NAA,2020_archibald_10,6,Heat 10,10.1038/s41598-020-76263-3,,,,,9.48,0.26,
,NAA,NAA,2020_archibald_10,7,Heat 12,10.1038/s41598-020-76263-3,,,,,9.49,0.26,
,NAA,NAA,2020_archibald_10,8,Post Heat 14,10.1038/s41598-020-76263-3,,,,,9.05,0.25,
,NAA,NAA,2020_archibald_10,9,Post Heat 16,10.1038/s41598-020-76263-3,,,,,9.71,0.26,
,NAA,NAA,2020_archibald_10,10,Post Heat 18,10.1038/s41598-020-76263-3,,,,,9.52,0.24,
,NAA,NAA,2020_archibald_10,11,Post Heat 20,10.1038/s41598-020-76263-3,,,,,9.58,0.26,
,NAA,NAA,2019_mellen_27,1,Bipolar disorder - Older age bipolar depression,10.1016/j.jagp.2019.02.017,0.69,0.16,,,,,
,NAA,NAA,2019_mellen_27,2,Bipolar disorder - Older age bipolar depression,10.1016/j.jagp.2019.02.017,0.99,0.28,,,,,
,NAA,NAA,2019_mellen_27,3,Control,10.1016/j.jagp.2019.02.017,0.84,0.15,,,,,
,NAA,NAA,2019_mellen_27,4,Control,10.1016/j.jagp.2019.02.017,1.1,0.13,,,,,
,NAA,NAA,2019_meyer_10,1,Control,10.3389/fneur.2019.00556,,,,,104.26,16.22,
,NAA,NAA,2019_meyer_10,2,Control,10.3389/fneur.2019.00556,,,,,92.54,19.74,
,NAA,NAA,2019_meyer_10,3,Concussion,10.3389/fneur.2019.00556,,,,,101.12,9.22,
,NAA,NAA,2019_meyer_10,4,Concussion,10.3389/fneur.2019.00556,,,,,90.28,34.58,
,NAA,NAA,2019_meyer_10,5,Concussion,10.3389/fneur.2019.00556,,,,,109.33,8.11,
,NAA,NAA,2019_meyer_10,6,Concussion,10.3389/fneur.2019.00556,,,,,96.5,42.43,
,NAA,NAA,2019_meyer_10,7,Concussion,10.3389/fneur.2019.00556,,,,,102.96,4.02,
,NAA,NAA,2019_meyer_10,8,Concussion,10.3389/fneur.2019.00556,,,,,82.55,27.36,
,NAA,tNAA,2020_wang_21,1,ESRD,10.1186/s12882-020-01863-0,1.63,0.16,,,,,
,NAA,tNAA,2020_wang_21,2,ESRD,10.1186/s12882-020-01863-0,1.6,0.19,,,,,
,NAA,tNAA,2020_wang_21,3,ESRD,10.1186/s12882-020-01863-0,1.59,0.2,,,,,
,NAA,tNAA,2020_wang_21,4,ESRD,10.1186/s12882-020-01863-0,1.54,0.22,,,,,
,NAA,tNAA,2020_wang_21,5,ESRD,10.1186/s12882-020-01863-0,1.66,0.19,,,,,
,NAA,tNAA,2020_wang_21,6,ESRD,10.1186/s12882-020-01863-0,1.66,0.23,,,,,
,NAA,tNAA,2020_wang_21,7,ESRD,10.1186/s12882-020-01863-0,1.72,0.12,,,,,
,NAA,tNAA,2020_wang_21,8,ESRD,10.1186/s12882-020-01863-0,1.71,0.19,,,,,
,NAA,tNAA,2020_wang_21,9,Control,10.1186/s12882-020-01863-0,1.74,0.18,,,,,
,NAA,tNAA,2020_wang_21,10,Control,10.1186/s12882-020-01863-0,1.76,0.16,,,,,
,tNAA,tNAA,2019_monnig_54,1,Healthy - Baseline,10.1093/alcalc/agz062,1.61,0.113,,,,,
,tNAA,tNAA,2019_monnig_54,2,Healthy - Descending limb,10.1093/alcalc/agz062,1.573,0.097,,,,,
,tNAA,tNAA,2019_monnig_54,3,Healthy - Baseline,10.1093/alcalc/agz062,1.562,0.177,,,,,
,tNAA,tNAA,2019_monnig_54,4,Healthy - Descending limb,10.1093/alcalc/agz062,1.623,0.143,,,,,
,tNAA,tNAA,2019_parmar_73,1,Obsessive-compulsive disorder - Unmedicated - 10mg escitalopram - Baseline,10.1111/pcn.12850,,,6.89,0.69,,,
,tNAA,tNAA,2019_parmar_73,2,Obsessive-compulsive disorder - Unmedicated - 10mg escitalopram - 12wk,10.1111/pcn.12850,,,7.14,0.77,,,
,tNAA,tNAA,2019_parmar_73,3,Control,10.1111/pcn.12850,,,7.34,1.25,,,
,tNAA,tNAA,2019_parmar_73,4,Obsessive-compulsive disorder - Unmedicated - 10mg escitalopram - Baseline,10.1111/pcn.12850,,,7.17,0.89,,,
,tNAA,tNAA,2019_parmar_73,5,Obsessive-compulsive disorder - Unmedicated - 10mg escitalopram - 12wk,10.1111/pcn.12850,,,7.83,1.29,,,
,tNAA,tNAA,2019_parmar_73,6,Control,10.1111/pcn.12850,,,7.23,1.13,,,
,tNAA,tNAA,2019_parmar_73,7,Obsessive-compulsive disorder - Unmedicated - 10mg escitalopram - Baseline,10.1111/pcn.12850,,,8.72,1.15,,,
,tNAA,tNAA,2019_parmar_73,8,Obsessive-compulsive disorder - Unmedicated - 10mg escitalopram - 12wk,10.1111/pcn.12850,,,8.63,0.94,,,
,tNAA,tNAA,2019_parmar_73,9,Control,10.1111/pcn.12850,,,8.08,1.57,,,
,NAA,NAA,2019_pflugrad_14,1,Chronic liver disease - Before OLT,10.1371/journal.pone.0221626,,,4.92,0.86,,,
,NAA,NAA,2019_pflugrad_14,2,Chronic liver disease - Before OLT,10.1371/journal.pone.0221626,,,5.12,0.71,,,
,NAA,NAA,2019_pflugrad_14,3,Chronic liver disease - Before OLT,10.1371/journal.pone.0221626,,,5.72,,,,"Median,IQR (5.72, .72)"
,NAA,NAA,2019_pflugrad_14,4,Chronic liver disease - Before OLT_PTE,10.1371/journal.pone.0221626,,,4.79,1.08,,,
,NAA,NAA,2019_pflugrad_14,5,Chronic liver disease - Before OLT_PTE,10.1371/journal.pone.0221626,,,5.02,0.6,,,
,NAA,NAA,2019_pflugrad_14,6,Chronic liver disease - Before OLT_PTE,10.1371/journal.pone.0221626,,,5.98,,,,"Median,IQR (5.98, .73)"
,NAA,NAA,2019_pflugrad_14,7,Chronic liver disease - Before OLT_no PTE,10.1371/journal.pone.0221626,,,5.1,0.71,,,
,NAA,NAA,2019_pflugrad_14,8,Chronic liver disease - Before OLT_no PTE,10.1371/journal.pone.0221626,,,5.14,0.74,,,
,NAA,NAA,2019_pflugrad_14,9,Chronic liver disease - Before OLT_no PTE,10.1371/journal.pone.0221626,,,5.59,,,,"Median,IQR (5.59, .71)"
,NAA,NAA,2019_pflugrad_14,10,Control,10.1371/journal.pone.0221626,,,5.04,0.86,,,
,NAA,NAA,2019_pflugrad_14,11,Control,10.1371/journal.pone.0221626,,,4.96,0.47,,,
,NAA,NAA,2019_pflugrad_14,12,Control,10.1371/journal.pone.0221626,,,5.6,,,,"Median,IQR (5.6, .69)"
,NAA,NAA,2019_pflugrad_14,13,Chronic liver disease - After OLT,10.1371/journal.pone.0221626,,,4.9,0.84,,,
,NAA,NAA,2019_pflugrad_14,14,Chronic liver disease - After OLT,10.1371/journal.pone.0221626,,,5.02,0.81,,,
,NAA,NAA,2019_pflugrad_14,15,Chronic liver disease - After OLT,10.1371/journal.pone.0221626,,,5.37,,,,"Median,IQR (5.37, 1.01)"
,NAA,NAA,2019_pflugrad_14,16,Chronic liver disease - After OLT_PTE,10.1371/journal.pone.0221626,,,4.83,0.83,,,
,NAA,NAA,2019_pflugrad_14,17,Chronic liver disease - After OLT_PTE,10.1371/journal.pone.0221626,,,4.9,0.66,,,
,NAA,NAA,2019_pflugrad_14,18,Chronic liver disease - After OLT_PTE,10.1371/journal.pone.0221626,,,5.37,,,,"Median,IQR (5.37, 1.56)"
,NAA,NAA,2019_pflugrad_14,19,Chronic liver disease - After OLT_no PTE,10.1371/journal.pone.0221626,,,4.94,0.87,,,
,NAA,NAA,2019_pflugrad_14,20,Chronic liver disease - After OLT_no PTE,10.1371/journal.pone.0221626,,,5.08,0.89,,,
,NAA,NAA,2019_pflugrad_14,21,Chronic liver disease - After OLT_no PTE,10.1371/journal.pone.0221626,,,5.39,,,,"Median,IQR (5.39, .73)"
,NAA,NAA,2021_rowe_133,1,LOGG,10.1016/j.ymgme.2021.06.008,,,,,5.71,1.24,
,NAA,NAA,2021_rowe_133,2,LOGG,10.1016/j.ymgme.2021.06.008,,,,,8.87,1.14,
,NAA,NAA,2021_rowe_133,4,LOTS,10.1016/j.ymgme.2021.06.008,,,,,5.13,0.99,
,NAA,NAA,2021_rowe_133,5,LOTS,10.1016/j.ymgme.2021.06.008,,,,,8.78,1.43,
,NAA,NAA,2021_rowe_133,7,LOSD,10.1016/j.ymgme.2021.06.008,,,,,7.06,0.26,
,NAA,NAA,2021_rowe_133,10,Control,10.1016/j.ymgme.2021.06.008,,,,,7.14,0.5,
,NAA,NAA,2021_rowe_133,11,Control,10.1016/j.ymgme.2021.06.008,,,,,9.89,0.55,
,tNAA,tNAA,2021_shiga_30,1,Non-progression,10.1016/j.jstrokecerebrovasdis.2021.105747,1.58,0.2,,,,,
,tNAA,tNAA,2021_shiga_30,2,Non-progression,10.1016/j.jstrokecerebrovasdis.2021.105747,0.96,0.15,,,,,
,tNAA,tNAA,2021_shiga_30,3,Progression,10.1016/j.jstrokecerebrovasdis.2021.105747,1.56,0.23,,,,,
,tNAA,tNAA,2021_shiga_30,4,Progression,10.1016/j.jstrokecerebrovasdis.2021.105747,1.01,0.23,,,,,
,NAA+NAAG,tNAA,2021_siegel-ramsay_313,1,Control,10.1016/j.pscychresns.2021.111302,,,11.95,1.04,,,
,NAA+NAAG,tNAA,2021_siegel-ramsay_313,2,Autism,10.1016/j.pscychresns.2021.111302,,,11.07,1.89,,,
,NAA+NAAG,tNAA,2021_steinegger_26,1,Control,10.1111/adb.13027,,,,,9.13,0.77,
,NAA+NAAG,tNAA,2021_steinegger_26,4,Smokers,10.1111/adb.13027,,,,,8.63,0.85,
,NAA+NAAG,tNAA,2021_steinegger_26,6,Baseline,10.1111/adb.13027,,,,,8.71,0.88,
,NAA+NAAG,tNAA,2021_steinegger_26,7,Withdrawal,10.1111/adb.13027,,,,,8.78,1.48,
,NAA+NAAG,tNAA,2021_steinegger_26,8,Satiation,10.1111/adb.13027,,,,,9.12,1.2,
,NAA,NAA,2021_wang_59,1,Control,10.1016/j.mito.2021.06.012,1.66,0.21,,,10.89,1.49,
,NAA,NAA,2021_wang_59,2,Control,10.1016/j.mito.2021.06.013,1.66,0.21,,,10.89,1.49,
,NAA,NAA,2021_wang_59,3,MELAS,10.1016/j.mito.2021.06.014,0.75,0.29,,,5.01,2.17,
,NAA,tNAA,2021_yao_45,1,low-grade gliomas,10.1097/RCT.0000000000001130,1.084,0.504,,,,,Assumed Total (tNAA) based on Analysis
,NAA,tNAA,2021_yao_45,2,high-grade gliomas,10.1097/RCT.0000000000001130,0.626,0.351,,,,,Assumed Total (tNAA) based on Analysis
,NAA,NAA,2021_younis_41,1,Baseline,10.1177/0271678X20906902,,,,,10.3,0.12,
,NAA,NAA,2021_younis_41,2,Migraine attack ,10.1177/0271678X20906902,,,,,10.63,0.13,
,NAA,NAA,2021_henigsberg_238,1,AD discontinuation,10.1007/s00213-019-05303-2,1.18,0.12,,,,,
,NAA,NAA,2021_henigsberg_238,2,Episode recurrence,10.1007/s00213-019-05303-2,1.18,0.14,,,,,
,NAA,NAA,2021_mansur_281,1,Placebo,10.1016/j.jad.2020.11.128,,,,,5.8,0.42,
,NAA,NAA,2021_mansur_281,2,Infliximab,10.1016/j.jad.2020.11.128,,,,,5.72,0.39,
,NAA,NAA,2019_prisci_43,1,Alcohol use disorder ,10.1111/acer.13931,,,4.86,0.61,,,
,NAA,NAA,2019_prisci_43,2,Control,10.1111/acer.13931,,,4.94,0.94,,,
,NAA,NAA,2019_schmitz_49,1,Control,10.1111/apt.15256,,,6.415,0.493,,,
,NAA,NAA,2019_schmitz_49,2,Liver transplantation - Calcineurin inhibitor free,10.1111/apt.15256,,,6.486,0.574,,,
,NAA,NAA,2019_schmitz_49,3,Liver transplantation - Calcineurin inhibitor low-dose,10.1111/apt.15256,,,6.361,0.691,,,
,NAA,NAA,2019_schmitz_49,4,Liver transplantation - Calcineurin inhibitor standard-dose,10.1111/apt.15256,,,6.357,0.54,,,
,NAA,NAA,2019_sheth_248,1,PTSD,10.1016/j.jad.2019.01.037,1.38,0.1,,,,,IU = 2.81 (0.000052)
,NAA,NAA,2019_sheth_248,2,Trauma-exposed ,10.1016/j.jad.2019.01.037,1.33,0.21,,,,,IU = 2.77 (0.000068)
,NAA,NAA,2019_sheth_248,3,Control,10.1016/j.jad.2019.01.037,1.36,0.16,,,,,IU = 2.87 (0.000069)
,NAA,NAA,2020_lyros_87,1,Healthy Control,10.1016/j.neurobiolaging.2019.11.012,1.5,0.31,,,,,
,NAA,NAA,2020_lyros_87,2,Healthy Control ,10.1016/j.neurobiolaging.2019.11.012,1.16,0.18,,,,,
,NAA,NAA,2020_lyros_87,3,Alzheimer's disease,10.1016/j.neurobiolaging.2019.11.012,1.23,0.17,,,,,
,NAA,NAA,2020_lyros_87,4,Vascular Dementia ,10.1016/j.neurobiolaging.2019.11.012,1.23,0.12,,,,,
,NAA,NAA,2020_lyros_87,5,Mixed Type AD and VaD,10.1016/j.neurobiolaging.2019.11.012,1.27,0.17,,,,,
,NAA,NAA,2020_lyros_87,6,FTLD,10.1016/j.neurobiolaging.2019.11.012,1.1,0.19,,,,,
,NAA,NAA,2020_lyros_87,7,Mild cognitive impairment,10.1016/j.neurobiolaging.2019.11.012,1.18,0.31,,,,,
,NAA,NAA,2020_lyros_87,8,Healthy Control,10.1016/j.neurobiolaging.2019.11.012,1.05,0.11,,,,,
,NAA,NAA,2020_lyros_87,9,Healthy Control ,10.1016/j.neurobiolaging.2019.11.012,0.99,0.12,,,,,
,NAA,NAA,2020_lyros_87,10,Alzheimer's disease,10.1016/j.neurobiolaging.2019.11.012,0.99,0.17,,,,,
,NAA,NAA,2020_lyros_87,11,Vascular Dementia ,10.1016/j.neurobiolaging.2019.11.012,0.93,0.09,,,,,
,NAA,NAA,2020_lyros_87,12,Mixed Type AD and VaD,10.1016/j.neurobiolaging.2019.11.012,0.88,0.1,,,,,
,NAA,NAA,2020_lyros_87,13,FTLD,10.1016/j.neurobiolaging.2019.11.012,0.9,0.1,,,,,
,NAA,NAA,2020_lyros_87,14,Mild cognitive impairment,10.1016/j.neurobiolaging.2019.11.012,0.86,0.11,,,,,
,NAA+NAAG,tNAA,2019_smaragdi_93,1,ASPD - DLPFC,10.1016/j.pnpbp.2019.04.002,,,,,13.26,1.31,
,NAA+NAAG,tNAA,2019_smaragdi_93,2,ASPD - ACC,10.1016/j.pnpbp.2019.04.002,,,,,13.25,2.95,
,NAA+NAAG,tNAA,2019_smaragdi_93,3,BD - DLPFC,10.1016/j.pnpbp.2019.04.002,,,,,12.39,1.2,
,NAA+NAAG,tNAA,2019_smaragdi_93,4,BD - ACC,10.1016/j.pnpbp.2019.04.002,,,,,13.09,0.86,
,NAA+NAAG,tNAA,2019_smaragdi_93,5,HC - DLPFC,10.1016/j.pnpbp.2019.04.002,,,,,12.78,1.13,
,NAA+NAAG,tNAA,2019_smaragdi_93,6,HC - ACC,10.1016/j.pnpbp.2019.04.002,,,,,13.21,1.16,
,NAA,NAA,2019_simmonite_26,1,Healthy - Young adults,10.1016/j.acra.2018.07.024,1.49,0.11,,,,,
,NAA,NAA,2019_simmonite_26,2,Healthy - Older adults,10.1016/j.acra.2018.07.024,1.39,0.09,,,,,
,tNAA,tNAA,2019_starmose_20,1,Control,10.1186/s10194-019-1059-z,1.742,0.09,10.946,0.725,,,
,tNAA,tNAA,2019_starmose_20,2,Control,10.1186/s10194-019-1059-z,1.598,0.089,9.46,0.399,,,
,tNAA,tNAA,2019_starmose_20,3,Migraine with aura,10.1186/s10194-019-1059-z,1.834,0.098,10.888,0.738,,,
,tNAA,tNAA,2019_starmose_20,4,Migraine with aura,10.1186/s10194-019-1059-z,1.693,0.111,9.712,0.55,,,
,NAA,NAA,2020_mastaloudis_153,4,Female Control- Baseline ,10.1016/j.freeradbiomed.2020.04.017,,,0.028,0.001,,,
,NAA,NAA,2020_mastaloudis_153,5,Female Control- 6 weeks,10.1016/j.freeradbiomed.2020.04.017,,,0.027,0.001,,,
,NAA,NAA,2020_mastaloudis_153,6,Female Experimental- Baseline ,10.1016/j.freeradbiomed.2020.04.017,,,0.025,0.001,,,
,NAA,NAA,2020_mastaloudis_153,7,Female Experimental- 6 weeks,10.1016/j.freeradbiomed.2020.04.017,,,0.027,0.001,,,
,NAA,NAA,2020_mastaloudis_153,8,Male Control- Baseline ,10.1016/j.freeradbiomed.2020.04.017,,,0.024,0.001,,,
,NAA,NAA,2020_mastaloudis_153,9,Male Control- 6 weeks ,10.1016/j.freeradbiomed.2020.04.017,,,0.026,0.001,,,
,NAA,NAA,2020_mastaloudis_153,10,Male Experimental- Baseline ,10.1016/j.freeradbiomed.2020.04.017,,,0.028,0.001,,,
,NAA,NAA,2020_mastaloudis_153,11,Male Experimental- Baseline ,10.1016/j.freeradbiomed.2020.04.017,,,0.028,0.001,,,
,NAA,NAA,2019_wagoner_317,1,Non-OI,10.1152/ajpheart.00680.2018,,,3.9,1.323,,,
,NAA,NAA,2019_wagoner_317,2,OI,10.1152/ajpheart.00680.2018,,,3,0.663,,,
,NAA + NAAG,tNAA,2019_wagoner_317,1,Non-OI,10.1152/ajpheart.00680.2018,,,6.7,0.265,,,
,NAA + NAAG,tNAA,2019_wagoner_317,2,OI,10.1152/ajpheart.00680.2018,,,7.4,0.663,,,
,NAA,NAA,2019_wang_28,1,PTSD,10.1007/s00787-018-1241-x,,,,,9.31,1.16,
,NAA,NAA,2019_wang_28,2,PTSD,10.1007/s00787-018-1241-x,,,,,9.44,1.35,
,NAA,NAA,2019_wang_28,3,Non-PTSD,10.1007/s00787-018-1241-x,,,,,9.13,0.76,
,NAA,NAA,2019_wang_28,4,Non-PTSD,10.1007/s00787-018-1241-x,,,,,8.22,1.08,
,NAA,NAA,2019_wang_76,1,FEP,10.1001/jamapsychiatry.2018.3637,,,7.5,1,,,
,NAA,NAA,2019_wang_76,2,FEP,10.1001/jamapsychiatry.2018.3637,,,7.6,1,,,
,NAA,NAA,2019_wang_76,3,FEP,10.1001/jamapsychiatry.2018.3637,,,7.65,1.7,,,
,NAA,NAA,2019_wang_76,4,FEP,10.1001/jamapsychiatry.2018.3637,,,7.2,1.5,,,
,NAA,NAA,2019_wang_76,5,FEP,10.1001/jamapsychiatry.2018.3637,,,7.2,1.7,,,
,NAA,NAA,2019_wang_76,6,Control,10.1001/jamapsychiatry.2018.3637,,,7.8,1.2,,,
,NAA,NAA,2019_wang_76,7,Control,10.1001/jamapsychiatry.2018.3637,,,7.7,0.8,,,
,NAA,NAA,2019_wang_76,8,Control,10.1001/jamapsychiatry.2018.3637,,,8,1.5,,,
,NAA,NAA,2019_wang_76,9,Control,10.1001/jamapsychiatry.2018.3637,,,7.5,1,,,
,NAA,NAA,2019_wang_76,10,Control,10.1001/jamapsychiatry.2018.3637,,,7.5,1,,,
,NAA,NAA,2019_zawadzki_9,1,Control,10.1038/s41598-019-39352-6,2.17,0.27,,,,,
,NAA,NAA,2019_zawadzki_9,2,Control,10.1038/s41598-019-39352-6,2.284,0.234,,,,,
,NAA,NAA,2019_zawadzki_9,3,Control,10.1038/s41598-019-39352-6,1.631,0.644,,,,,
,NAA,NAA,2019_zawadzki_9,4,Control,10.1038/s41598-019-39352-6,1.442,0.207,,,,,
,NAA,NAA,2019_zawadzki_9,5,Control,10.1038/s41598-019-39352-6,1.545,0.196,,,,,
,NAA,NAA,2019_zawadzki_9,6,Control,10.1038/s41598-019-39352-6,1.489,0.22,,,,,
,NAA,NAA,2019_zawadzki_9,7,TBE,10.1038/s41598-019-39352-6,1.863,0.246,,,,,
,NAA,NAA,2019_zawadzki_9,8,TBE,10.1038/s41598-019-39352-6,1.988,0.365,,,,,
,NAA,NAA,2019_zawadzki_9,9,TBE,10.1038/s41598-019-39352-6,1.389,0.171,,,,,
,NAA,NAA,2019_zawadzki_9,10,TBE,10.1038/s41598-019-39352-6,1.441,0.173,,,,,
,NAA,NAA,2019_zawadzki_9,11,TBE,10.1038/s41598-019-39352-6,1.563,0.307,,,,,
,NAA,NAA,2019_zawadzki_9,12,TBE,10.1038/s41598-019-39352-6,1.577,0.223,,,,,
,NAA,tNAA,2018_gu_11,1,Control,10.2147/JPR.S162696,2.36,0.36,,,,,Assumed Total (tNAA) based on Analysis
,NAA,tNAA,2018_gu_11,2,Control,10.2147/JPR.S162696,2.35,0.41,,,,,Assumed Total (tNAA) based on Analysis
,NAA,tNAA,2018_gu_11,3,Control,10.2147/JPR.S162696,2.19,0.2,,,,,Assumed Total (tNAA) based on Analysis
,NAA,tNAA,2018_gu_11,4,Control,10.2147/JPR.S162696,2.12,0.31,,,,,Assumed Total (tNAA) based on Analysis
,NAA,tNAA,2018_gu_11,5,Control,10.2147/JPR.S162696,1.55,0.15,,,,,Assumed Total (tNAA) based on Analysis
,NAA,tNAA,2018_gu_11,6,Control,10.2147/JPR.S162696,1.66,0.09,,,,,Assumed Total (tNAA) based on Analysis
,NAA,tNAA,2018_gu_11,7,Control,10.2147/JPR.S162696,1.73,0.08,,,,,Assumed Total (tNAA) based on Analysis
,NAA,tNAA,2018_gu_11,8,Control,10.2147/JPR.S162696,1.71,0.15,,,,,Assumed Total (tNAA) based on Analysis
,NAA,tNAA,2018_gu_11,9,Migraine,10.2147/JPR.S162696,1.91,0.22,,,,,Assumed Total (tNAA) based on Analysis
,NAA,tNAA,2018_gu_11,10,Migraine,10.2147/JPR.S162696,2.11,0.35,,,,,Assumed Total (tNAA) based on Analysis
,NAA,tNAA,2018_gu_11,11,Migraine,10.2147/JPR.S162696,1.83,0.18,,,,,Assumed Total (tNAA) based on Analysis
,NAA,tNAA,2018_gu_11,12,Migraine,10.2147/JPR.S162696,1.96,0.14,,,,,Assumed Total (tNAA) based on Analysis
,NAA,tNAA,2018_gu_11,13,Migraine,10.2147/JPR.S162696,1.51,0.15,,,,,Assumed Total (tNAA) based on Analysis
,NAA,tNAA,2018_gu_11,14,Migraine,10.2147/JPR.S162696,1.51,0.13,,,,,Assumed Total (tNAA) based on Analysis
,NAA,tNAA,2018_gu_11,15,Migraine,10.2147/JPR.S162696,1.62,0.12,,,,,Assumed Total (tNAA) based on Analysis
,NAA,tNAA,2018_gu_11,16,Migraine,10.2147/JPR.S162696,1.67,0.14,,,,,Assumed Total (tNAA) based on Analysis
,NAA,tNAA,2018_gu_11,17,Cervicogenic Headache,10.2147/JPR.S162696,1.94,0.27,,,,,Assumed Total (tNAA) based on Analysis
,NAA,tNAA,2018_gu_11,18,Cervicogenic Headache,10.2147/JPR.S162696,1.86,0.2,,,,,Assumed Total (tNAA) based on Analysis
,NAA,tNAA,2018_gu_11,19,Cervicogenic Headache,10.2147/JPR.S162696,1.82,0.18,,,,,Assumed Total (tNAA) based on Analysis
,NAA,tNAA,2018_gu_11,20,Cervicogenic Headache,10.2147/JPR.S162696,1.78,0.15,,,,,Assumed Total (tNAA) based on Analysis
,NAA,tNAA,2018_gu_11,21,Cervicogenic Headache,10.2147/JPR.S162696,1.51,0.11,,,,,Assumed Total (tNAA) based on Analysis
,NAA,tNAA,2018_gu_11,22,Cervicogenic Headache,10.2147/JPR.S162696,1.41,0.13,,,,,Assumed Total (tNAA) based on Analysis
,NAA,tNAA,2018_gu_11,23,Cervicogenic Headache,10.2147/JPR.S162696,1.62,0.13,,,,,Assumed Total (tNAA) based on Analysis
,NAA,tNAA,2018_gu_11,24,Cervicogenic Headache,10.2147/JPR.S162696,1.54,0.19,,,,,Assumed Total (tNAA) based on Analysis
,NAA,NAA,2018_horowitz-kraus_12,1,Control,10.3389/fnhum.2018.00466,,,,,9.12,0.97,
,NAA,NAA,2018_horowitz-kraus_12,2,Dyslexia,10.3389/fnhum.2018.00466,,,,,9.43,0.68,
,NAA,NAA,2018_modinos_21,1,Control,10.1093/ijnp/pyx076,1.1,0.1,,,,,
,NAA,NAA,2018_modinos_21,2,Psychosis,10.1093/ijnp/pyx076,1.1,0.1,,,,,
,NAA,NAA,2018_posporelis_3,1,Control,10.1016/j.bpsc.2017.04.003,1.32,0.07,7.56,1.34,,,
,NAA,NAA,2018_posporelis_3,2,Schizophrenia,10.1016/j.bpsc.2017.04.003,1.29,0.07,8.33,2.45,,,
,NAA,NAA,2018_posporelis_3,3,Control,10.1016/j.bpsc.2017.04.003,,,8.38,1.42,,,
,NAA,NAA,2018_posporelis_3,4,Schizophrenia,10.1016/j.bpsc.2017.04.003,,,9.09,2.55,,,
,NAA,NAA,2018_povazan_79,1,Healthy,10.1002/mrm.26778,,,12.96,1.21,,,
,NAA,NAA,2018_povazan_79,2,Healthy,10.1002/mrm.26778,,,13.89,1.15,,,
,NAA,NAA,2018_povazan_79,3,Healthy,10.1002/mrm.26778,,,13.55,1.69,,,
,NAA,NAA,2018_povazan_79,4,Healthy,10.1002/mrm.26778,,,14.65,1.11,,,
,NAA,NAA,2018_povazan_79,5,Healthy,10.1002/mrm.26778,,,14.08,1.35,,,
,NAA,NAA,2018_povazan_79,6,Healthy,10.1002/mrm.26778,,,12.92,2.46,,,
,NAA,NAA,2018_povazan_79,7,Healthy,10.1002/mrm.26778,,,12.73,1.44,,,
,NAA,NAA,2020_mazibuko_10,1,Control,10.3390/diagnostics10070482,,,11.17,1.01,,,
,NAA,NAA,2020_mazibuko_10,2,Control,10.3390/diagnostics10070482,,,11.19,0.59,,,
,NAA,NAA,2020_mazibuko_10,3,Subacute Ischemic Stroke,10.3390/diagnostics10070482,,,10,2.03,,,
,NAA,NAA,2020_mazibuko_10,4,Subacute Ischemic Stroke,10.3390/diagnostics10070482,,,10.46,1.94,,,
,NAA,NAA,2020_mazibuko_10,5,Subacute Ischemic Stroke ,10.3390/diagnostics10070482,,,6.85,4.08,,,
,NAA,NAA,2020_mazibuko_10,6,Subacute Ischemic Stroke ,10.3390/diagnostics10070482,,,12.18,3.42,,,
,NAA,NAA,2020_mazibuko_10,7,Subacute Ischemic Stroke ,10.3390/diagnostics10070482,,,7.97,1.69,,,
,NAA,NAA,2020_mazibuko_10,8,Subacute Ischemic Stroke ,10.3390/diagnostics10070482,,,10.52,0.92,,,
,NAA,NAA,2020_menshchikov_84,1,Control,10.1002/mrm.28332,0.661,0.063,,,9.06,0.68,
,NAA,NAA,2020_menshchikov_84,2,Mild Traumatic Brain Injury ,10.1002/mrm.28332,0.665,0.049,,,8.99,0.47,
,tNAA,tNAA,2020_menshchikov_84,1,Control,10.1002/mrm.28332,1.65,0.099,,,11.48,0.71,
,tNAA,tNAA,2020_menshchikov_84,2,Mild Traumatic Brain Injury ,10.1002/mrm.28332,1.555,0.098,,,10.99,0.69,
,tNAA,tNAA,2019_wiegers_62,1,Control,10.1007/s00125-019-4862-9,,,,,11.12,0.55,
,tNAA,tNAA,2019_wiegers_62,2,Type 1 diabetes - Normal awareness of hypoglycaemia,10.1007/s00125-019-4862-9,,,,,10.74,0.58,
,tNAA,tNAA,2019_wiegers_62,3,Type 1 diabetes,10.1007/s00125-019-4862-9,,,,,10.98,0.46,
,NAA,tNAA,2019_xu_98,1,Non-alcoholic fatty liver disease - No mild cognitive impairment,10.1097/MD.0000000000018189,2.2,0.73,,,,,Assumed Total (tNAA) based on Analysis
,NAA,tNAA,2019_xu_98,2,Non-alcoholic fatty liver disease - No mild cognitive impairment,10.1097/MD.0000000000018189,2,0.42,,,,,Assumed Total (tNAA) based on Analysis
,NAA,tNAA,2019_xu_98,3,Non-alcoholic fatty liver disease - No mild cognitive impairment,10.1097/MD.0000000000018189,2.24,0.74,,,,,Assumed Total (tNAA) based on Analysis
,NAA,tNAA,2019_xu_98,4,Non-alcoholic fatty liver disease - No mild cognitive impairment,10.1097/MD.0000000000018189,2.18,0.57,,,,,Assumed Total (tNAA) based on Analysis
,NAA,tNAA,2019_xu_98,5,Non-alcoholic fatty liver disease - No mild cognitive impairment,10.1097/MD.0000000000018189,1.86,0.77,,,,,Assumed Total (tNAA) based on Analysis
,NAA,tNAA,2019_xu_98,6,Non-alcoholic fatty liver disease - No mild cognitive impairment,10.1097/MD.0000000000018189,1.68,0.4,,,,,Assumed Total (tNAA) based on Analysis
,NAA,tNAA,2019_xu_98,7,Non-alcoholic fatty liver disease - Mild cognitive impairment,10.1097/MD.0000000000018189,2.27,0.84,,,,,Assumed Total (tNAA) based on Analysis
,NAA,tNAA,2019_xu_98,8,Non-alcoholic fatty liver disease - Mild cognitive impairment,10.1097/MD.0000000000018189,2.2,1.3,,,,,Assumed Total (tNAA) based on Analysis
,NAA,tNAA,2019_xu_98,9,Non-alcoholic fatty liver disease - Mild cognitive impairment,10.1097/MD.0000000000018189,2.32,0.92,,,,,Assumed Total (tNAA) based on Analysis
,NAA,tNAA,2019_xu_98,10,Non-alcoholic fatty liver disease - Mild cognitive impairment,10.1097/MD.0000000000018189,2.28,0.67,,,,,Assumed Total (tNAA) based on Analysis
,NAA,tNAA,2019_xu_98,11,Non-alcoholic fatty liver disease - Mild cognitive impairment,10.1097/MD.0000000000018189,2.06,1.18,,,,,Assumed Total (tNAA) based on Analysis
,NAA,tNAA,2019_xu_98,12,Non-alcoholic fatty liver disease - Mild cognitive impairment,10.1097/MD.0000000000018189,2.05,0.58,,,,,Assumed Total (tNAA) based on Analysis
,NAA,NAA,2020_gonen_14,1,Healthy,10.3389/fnins.2020.566643,,,,,12.01,0.81,
,NAA,NAA,2020_gonen_14,2,Healthy,10.3389/fnins.2020.566643,,,,,11.46,0.93,
,NAA,NAA,2020_gonen_14,3,Healthy,10.3389/fnins.2020.566643,,,,,11.93,0.72,
,NAA,NAA,2020_gonen_14,4,Healthy,10.3389/fnins.2020.566643,,,,,12.29,1.64,
,NAA,tNAA,2018_shan_227,1,Control,10.1016/j.jad.2017.10.030,2.32,0.32,,,,,Assumed Total (tNAA) based on Analysis
,NAA,tNAA,2018_shan_227,2,Control,10.1016/j.jad.2017.10.030,2.39,0.38,,,,,Assumed Total (tNAA) based on Analysis
,NAA,tNAA,2018_shan_227,3,Control,10.1016/j.jad.2017.10.030,1.58,0.25,,,,,Assumed Total (tNAA) based on Analysis
,NAA,tNAA,2018_shan_227,4,Control,10.1016/j.jad.2017.10.030,1.55,0.19,,,,,Assumed Total (tNAA) based on Analysis
,NAA,tNAA,2018_shan_227,5,Depression,10.1016/j.jad.2017.10.030,1.91,0.41,,,,,Assumed Total (tNAA) based on Analysis
,NAA,tNAA,2018_shan_227,6,Depression,10.1016/j.jad.2017.10.030,1.9,0.47,,,,,Assumed Total (tNAA) based on Analysis
,NAA,tNAA,2018_shan_227,7,Depression,10.1016/j.jad.2017.10.030,1.6,0.22,,,,,Assumed Total (tNAA) based on Analysis
,NAA,tNAA,2018_shan_227,8,Depression,10.1016/j.jad.2017.10.030,1.61,0.47,,,,,Assumed Total (tNAA) based on Analysis
,NAA,NAA,2019_morgenroth_117,4,Trait Anxiety,10.1016/j.cortex.2019.02.021,,,8.39,0.66,,,
,NAA,NAA,2019_morgenroth_117,5,Trait Anxiety - Low trait anxiety,10.1016/j.cortex.2019.02.021,,,8.5,0.44,,,
,NAA,NAA,2019_morgenroth_117,6,Trait Anxiety - High trait anxiety,10.1016/j.cortex.2019.02.021,,,8.29,0.81,,,
,NAA,NAA,2018_soeiro-de-souza_241,1,Control,10.1016/j.jad.2018.08.039,,,,,15.183,1.462,
,NAA,NAA,2018_soeiro-de-souza_241,2,Bipolar,10.1016/j.jad.2018.08.039,,,,,15.444,3.035,
,NAA,NAA,2018_soeiro-de-souza_241,3,Bipolar,10.1016/j.jad.2018.08.039,,,,,15.161,1.438,
,NAA,NAA,2018_soeiro-de-souza_241,4,Bipolar,10.1016/j.jad.2018.08.039,,,,,15.048,3.012,
,NAA,NAA,2018_su_241,1,Control,10.1016/j.jad.2018.08.018,,,,,8.35,1.22,
,NAA,NAA,2018_su_241,2,Control,10.1016/j.jad.2018.08.018,,,,,9.19,1.4,
,NAA,NAA,2018_su_241,3,Control,10.1016/j.jad.2018.08.018,,,,,9.35,2.32,
,NAA,NAA,2018_su_241,4,PTSD,10.1016/j.jad.2018.08.018,,,,,9.12,1.29,
,NAA,NAA,2018_su_241,5,PTSD,10.1016/j.jad.2018.08.018,,,,,9.79,1.63,
,NAA,NAA,2018_su_241,6,PTSD,10.1016/j.jad.2018.08.018,,,,,9.15,1.55,
,NAA,NAA,2019_nery_21,1,At risk for bipolar disorder,10.1111/bdi.12770,,,,,8.52,1.22,
,NAA,NAA,2019_nery_21,2,At risk for bipolar disorder,10.1111/bdi.12770,,,,,9.74,1.35,
,NAA,NAA,2019_nery_21,3,At risk for bipolar disorder,10.1111/bdi.12770,,,,,6.45,1.35,
,NAA,NAA,2019_nery_21,4,Control,10.1111/bdi.12770,,,,,8.72,1.37,
,NAA,NAA,2019_nery_21,5,Control,10.1111/bdi.12770,,,,,9.99,1.26,
,NAA,NAA,2019_nery_21,6,Control,10.1111/bdi.12770,,,,,6.4,1.55,
,NAA,NAA,2019_nery_21,7,At risk for bipolar disorder - Before first mood episode,10.1111/bdi.12770,,,,,8.23,1.08,
,NAA,NAA,2019_nery_21,8,At risk for bipolar disorder - Before first mood episode,10.1111/bdi.12770,,,,,9.36,1.69,
,NAA,NAA,2019_nery_21,9,At risk for bipolar disorder - Before first mood episode,10.1111/bdi.12770,,,,,6.22,1.06,
,NAA,NAA,2019_nery_21,10,At risk for bipolar disorder - After first mood episode,10.1111/bdi.12770,,,,,8.52,1.17,
,NAA,NAA,2019_nery_21,11,At risk for bipolar disorder - After first mood episode,10.1111/bdi.12770,,,,,9.21,1.04,
,NAA,NAA,2019_nery_21,12,At risk for bipolar disorder - After first mood episode,10.1111/bdi.12770,,,,,6.5,1.25,
,NAA,NAA,2019_nery_21,13,Control,10.1111/bdi.12770,,,,,8.28,1.19,
,NAA,NAA,2019_nery_21,14,Control,10.1111/bdi.12770,,,,,9.75,1.32,
,NAA,NAA,2019_nery_21,15,Control,10.1111/bdi.12770,,,,,6.81,1.83,
,NAA,NAA,2019_nery_21,16,Control,10.1111/bdi.12770,,,,,8.22,1.17,
,NAA,NAA,2019_nery_21,17,Control,10.1111/bdi.12770,,,,,9.43,1.64,
,NAA,NAA,2019_nery_21,18,Control,10.1111/bdi.12770,,,,,6,1.57,
,tNAA,tNAA,2019_oneill_111,1,Control,10.1002/bdr2.1460,,,6.2,1.2,,,
,tNAA,tNAA,2019_oneill_111,2,ADHD,10.1002/bdr2.1460,,,5.8,1.4,,,
,tNAA,tNAA,2019_oneill_111,3,ADHD,10.1002/bdr2.1460,,,6.3,1.2,,,
,tNAA,tNAA,2019_oneill_111,4,ADHD,10.1002/bdr2.1460,,,6.5,0.6,,,
,tNAA,tNAA,2019_oneill_111,5,ADHD,10.1002/bdr2.1460,,,6.3,0.3,,,
,tNAA,tNAA,2019_oneill_111,6,ADHD,10.1002/bdr2.1460,,,6.3,0.8,,,
,NAA,NAA,2019_polacek_163,1,Control,10.5507/bp.2018.036,1.5,0.15,,,,,Assumed 10% StdDev
,NAA,NAA,2019_polacek_163,2,Multiple Sclerosis,10.5507/bp.2018.036,1.3,0.13,,,,,Assumed 10% StdDev
,NAA,NAA,2019_reid_45,1,Control,10.1093/schbul/sbx190,,,6.82,0.53,,,
,NAA,NAA,2019_reid_45,2,Schizophrenia,10.1093/schbul/sbx190,,,6.46,0.5,,,
,NAA,NAA,2020_bolo_69,1,Control ,10.2337/db19-0936,,,,,8.9,1.1,
,NAA,NAA,2020_bolo_69,2,Control ,10.2337/db19-0936,,,,,8.9,1.2,
,NAA,NAA,2020_bolo_69,3,T1D,10.2337/db19-0936,,,,,8.9,1.1,
,NAA,NAA,2020_bolo_69,4,T1D,10.2337/db19-0936,,,,,9.4,1.1,
,NAA,NAA,2020_bolo_69,5,Control ,10.2337/db19-0936,,,,,7.5,0.3,
,NAA,NAA,2020_bolo_69,6,Control ,10.2337/db19-0936,,,,,7.5,0.2,
,NAA,NAA,2020_bolo_69,7,T1D,10.2337/db19-0936,,,,,7.8,0.4,
,NAA,NAA,2020_bolo_69,8,T1D,10.2337/db19-0936,,,,,7.7,0.4,
,NAA,NAA,2020_demnitz_295,1,Addiction ,10.1016/j.pscychresns.2019.111019,,,,,11.36,1.25,
,NAA,NAA,2020_lind_40,4,Aging,10.1523/JNEUROSCI.2883-19.2020,,,,,10.16,0.69,
,NAA,NAA,2020_lind_40,5,Aging,10.1523/JNEUROSCI.2883-19.2020,,,,,9.82,0.79,
,NAA,NAA,2020_lind_40,6,Aging,10.1523/JNEUROSCI.2883-19.2020,,,,,9.41,0.81,
,NAA,tNAA,2020_liu_99,1,Healthy Controls,10.1016/j.pnpbp.2019.109828,2.19,0.3,,,,,Assumed Total (tNAA) based on Analysis
,NAA,tNAA,2020_liu_99,2,Healthy Controls,10.1016/j.pnpbp.2019.109828,2.2,0.34,,,,,Assumed Total (tNAA) based on Analysis
,NAA,tNAA,2020_liu_99,3,Healthy Controls,10.1016/j.pnpbp.2019.109828,1.5,0.39,,,,,Assumed Total (tNAA) based on Analysis
,NAA,tNAA,2020_liu_99,4,Healthy Controls,10.1016/j.pnpbp.2019.109828,1.54,0.32,,,,,Assumed Total (tNAA) based on Analysis
,NAA,tNAA,2020_liu_99,5,MDD,10.1016/j.pnpbp.2019.109828,1.83,0.26,,,,,Assumed Total (tNAA) based on Analysis
,NAA,tNAA,2020_liu_99,6,MDD,10.1016/j.pnpbp.2019.109828,1.87,0.36,,,,,Assumed Total (tNAA) based on Analysis
,NAA,tNAA,2020_liu_99,7,MDD,10.1016/j.pnpbp.2019.109828,1.48,0.28,,,,,Assumed Total (tNAA) based on Analysis
,NAA,tNAA,2020_liu_99,8,MDD,10.1016/j.pnpbp.2019.109828,1.53,0.22,,,,,Assumed Total (tNAA) based on Analysis
,NAA,NAA,2020_dehghani_83,1,Protocol 1,10.1002/mrm.28066,,,,,9.04,0.5,
,NAA (CH3),,2020_dehghani_83,2,Protocol 2,10.1002/mrm.28066,,,,,5.39,0.54,
,NAA (CH2),,2020_dehghani_83,2,Protocol 2,10.1002/mrm.28066,,,,,4.27,0.51,
,NAA (CH3),,2020_dehghani_83,3,Protocol 3,10.1002/mrm.28066,,,,,5.14,0.8,
,NAA (CH2) ,,2020_dehghani_83,3,Protocol 3,10.1002/mrm.28066,,,,,3.37,0.63,
,NAA,tNAA,2020_didehdar_189,1,Pain,10.1007/s11845-019-02140-2,1.365,0.147,,,,,Values from bar graph; Assumed Total (tNAA) based on Analysis
,NAA,tNAA,2020_didehdar_189,2,Pain,10.1007/s11845-019-02140-2,1.351,0.18,,,,,Values from bar graph; Assumed Total (tNAA) based on Analysis
,NAA,tNAA,2020_didehdar_189,3,Pain,10.1007/s11845-019-02140-2,1.526,0.289,,,,,Values from bar graph; Assumed Total (tNAA) based on Analysis
,NAA,tNAA,2020_didehdar_189,4,Pain,10.1007/s11845-019-02140-2,1.521,0.27,,,,,Values from bar graph; Assumed Total (tNAA) based on Analysis
,NAA,tNAA,2020_didehdar_189,5,Pain,10.1007/s11845-019-02140-2,1.294,0.151,,,,,Values from bar graph; Assumed Total (tNAA) based on Analysis
,NAA,tNAA,2020_didehdar_189,6,Pain,10.1007/s11845-019-02140-2,1.679,0.164,,,,,Values from bar graph; Assumed Total (tNAA) based on Analysis
,NAA,tNAA,2020_didehdar_189,7,Pain,10.1007/s11845-019-02140-2,1.537,0.209,,,,,Values from bar graph; Assumed Total (tNAA) based on Analysis
,NAA,tNAA,2020_didehdar_189,8,Pain,10.1007/s11845-019-02140-2,1.657,0.239,,,,,Values from bar graph; Assumed Total (tNAA) based on Analysis
,NAA,tNAA,2020_didehdar_189,9,Pain,10.1007/s11845-019-02140-2,1.858,0.224,,,,,Values from bar graph; Assumed Total (tNAA) based on Analysis
,NAA,tNAA,2020_didehdar_189,10,Pain,10.1007/s11845-019-02140-2,1.47,0.217,,,,,Values from bar graph; Assumed Total (tNAA) based on Analysis
,NAA,tNAA,2020_didehdar_189,11,Pain,10.1007/s11845-019-02140-2,1.569,0.185,,,,,Values from bar graph; Assumed Total (tNAA) based on Analysis
,NAA,tNAA,2020_didehdar_189,12,Pain,10.1007/s11845-019-02140-2,1.559,0.123,,,,,Values from bar graph; Assumed Total (tNAA) based on Analysis
,NAA,tNAA,2020_didehdar_189,13,Pain,10.1007/s11845-019-02140-2,1.36,0.19,,,,,Values from bar graph; Assumed Total (tNAA) based on Analysis
,NAA,tNAA,2020_didehdar_189,14,Pain,10.1007/s11845-019-02140-2,1.626,0.184,,,,,Values from bar graph; Assumed Total (tNAA) based on Analysis
,NAA,tNAA,2020_didehdar_189,15,Pain,10.1007/s11845-019-02140-2,1.483,0.228,,,,,Values from bar graph; Assumed Total (tNAA) based on Analysis
,NAA,tNAA,2020_didehdar_189,16,Pain,10.1007/s11845-019-02140-2,1.53,0.171,,,,,Values from bar graph; Assumed Total (tNAA) based on Analysis
,NAA,tNAA,2020_didehdar_189,17,Pain,10.1007/s11845-019-02140-2,1.56,0.104,,,,,Values from bar graph; Assumed Total (tNAA) based on Analysis
,NAA,tNAA,2020_didehdar_189,18,Pain,10.1007/s11845-019-02140-2,1.381,0.171,,,,,Values from bar graph; Assumed Total (tNAA) based on Analysis
,NAA,tNAA,2020_didehdar_189,19,Pain,10.1007/s11845-019-02140-2,1.493,0.201,,,,,Values from bar graph; Assumed Total (tNAA) based on Analysis
,NAA,tNAA,2020_didehdar_189,20,Pain,10.1007/s11845-019-02140-2,1.306,0.216,,,,,Values from bar graph; Assumed Total (tNAA) based on Analysis
,tNAA,tNAA,2020_lind_40,1,Control,10.1523/JNEUROSCI.2883-19.2020,,,,,9.71,0.57,
,tNAA,tNAA,2020_lind_40,2,Aging,10.1523/JNEUROSCI.2883-19.2020,,,,,9.98,0.8,
,tNAA,tNAA,2020_lind_40,3,Aging,10.1523/JNEUROSCI.2883-19.2020,,,,,9.82,0.75,
,tNAA,tNAA,2020_lind_40,4,Control,10.1523/JNEUROSCI.2883-19.2020,,,,,11.07,0.72,
,tNAA,tNAA,2020_lind_40,5,Aging,10.1523/JNEUROSCI.2883-19.2020,,,,,10.87,1.07,
,tNAA,tNAA,2020_lind_40,6,Aging,10.1523/JNEUROSCI.2883-19.2020,,,,,10.63,0.92,
,tNAA,tNAA,2020_lind_40,7,Control,10.1523/JNEUROSCI.2883-19.2020,,,,,9.71,0.84,
,tNAA,tNAA,2020_lind_40,8,Aging,10.1523/JNEUROSCI.2883-19.2020,,,,,9.49,1.11,
,tNAA,tNAA,2020_lind_40,9,Aging,10.1523/JNEUROSCI.2883-19.2020,,,,,10.24,0.94,
,tNAA,tNAA,2020_lind_40,10,Control,10.1523/JNEUROSCI.2883-19.2020,,,,,12.53,1.12,
,tNAA,tNAA,2020_lind_40,11,Aging,10.1523/JNEUROSCI.2883-19.2020,,,,,11.86,1.12,
,tNAA,tNAA,2020_lind_40,12,Aging,10.1523/JNEUROSCI.2883-19.2020,,,,,12.39,1.47,
,tNAA,tNAA,2020_draganov_266,1,Control,10.1016/j.jad.2020.01.138,,,,,4.41,1.1,
,tNAA,tNAA,2020_draganov_266,2,Depression,10.1016/j.jad.2020.01.138,,,,,4.55,1.3,
,tNAA,tNAA,2020_draganov_266,3,Depression,10.1016/j.jad.2020.01.138,,,,,4.6,1.5,
,tNAA,tNAA,2020_draganov_266,4,Depression,10.1016/j.jad.2020.01.138,,,,,4.37,0.98,
,NAA,NAA,2020_macmaster_35,1,Orthopedic Injury,10.1097/HTR.0000000000000535,,,,,11.05,0.45,
,NAA,NAA,2020_macmaster_35,2,Concussion,10.1097/HTR.0000000000000535,,,,,10.63,0.58,
,NAA,NAA,2020_macmaster_35,3,Single Concussion,10.1097/HTR.0000000000000535,,,,,10.46,0.67,
,NAA,NAA,2020_macmaster_35,4,Multiple Concussion,10.1097/HTR.0000000000000535,,,,,10.77,0.46,
,NAA,NAA,2020_macmaster_35,5,Orthopedic Injury,10.1097/HTR.0000000000000535,,,,,11.2,0.93,
,NAA,NAA,2020_macmaster_35,6,Concussion,10.1097/HTR.0000000000000535,,,,,10.9,0.66,
,NAA,NAA,2020_macmaster_35,7,Single Concussion,10.1097/HTR.0000000000000535,,,,,10.59,0.54,
,NAA,NAA,2020_macmaster_35,8,Multiple Concussion,10.1097/HTR.0000000000000535,,,,,11.16,0.65,
,NAA,tNAA,2020_simani_112,1,Healthy Controls,10.1016/j.yebeh.2020.107480,1.55,0.34,,,,,Assumed Total (tNAA) based on Analysis
,NAA,tNAA,2020_simani_112,2,Idiopathic Generalized Epilepsy,10.1016/j.yebeh.2020.107480,1.69,0.26,,,,,Assumed Total (tNAA) based on Analysis
,NAA,tNAA,2020_simani_112,3,Psychogenic Nonepileptic Seizure,10.1016/j.yebeh.2020.107480,1.73,0.24,,,,,Assumed Total (tNAA) based on Analysis
,NAA,tNAA,2020_simani_112,4,Healthy Controls,10.1016/j.yebeh.2020.107480,1.43,0.23,,,,,Assumed Total (tNAA) based on Analysis
,NAA,tNAA,2020_simani_112,5,Idiopathic Generalized Epilepsy,10.1016/j.yebeh.2020.107480,1.37,0.16,,,,,Assumed Total (tNAA) based on Analysis
,NAA,tNAA,2020_simani_112,6,Psychogenic Nonepileptic Seizure,10.1016/j.yebeh.2020.107480,1.45,0.16,,,,,Assumed Total (tNAA) based on Analysis
,NAA,tNAA,2020_simani_112,7,Healthy Controls,10.1016/j.yebeh.2020.107480,1.41,0.03,,,,,Assumed Total (tNAA) based on Analysis
,NAA,tNAA,2020_simani_112,8,Idiopathic Generalized Epilepsy,10.1016/j.yebeh.2020.107480,1.31,0.02,,,,,Assumed Total (tNAA) based on Analysis
,NAA,tNAA,2020_simani_112,9,Psychogenic Nonepileptic Seizure,10.1016/j.yebeh.2020.107480,1.28,0.02,,,,,Assumed Total (tNAA) based on Analysis
,NAA,tNAA,2020_simani_112,10,Healthy Controls,10.1016/j.yebeh.2020.107480,1.45,0.04,,,,,Assumed Total (tNAA) based on Analysis
,NAA,tNAA,2020_simani_112,11,Idiopathic Generalized Epilepsy,10.1016/j.yebeh.2020.107480,1.34,0.03,,,,,Assumed Total (tNAA) based on Analysis
,NAA,tNAA,2020_simani_112,12,Psychogenic Nonepileptic Seizure,10.1016/j.yebeh.2020.107480,1.31,0.03,,,,,Assumed Total (tNAA) based on Analysis
,NAA,tNAA,2020_simani_112,13,Healthy Controls,10.1016/j.yebeh.2020.107480,2.7,0.24,,,,,Assumed Total (tNAA) based on Analysis
,NAA,tNAA,2020_simani_112,14,Idiopathic Generalized Epilepsy,10.1016/j.yebeh.2020.107480,1.64,0.19,,,,,Assumed Total (tNAA) based on Analysis
,NAA,tNAA,2020_simani_112,15,Psychogenic Nonepileptic Seizure,10.1016/j.yebeh.2020.107480,1.68,0.18,,,,,Assumed Total (tNAA) based on Analysis
,NAA,tNAA,2020_simani_112,16,Healthy Controls,10.1016/j.yebeh.2020.107480,2.3,1.6,,,,,Assumed Total (tNAA) based on Analysis
,NAA,tNAA,2020_simani_112,17,Idiopathic Generalized Epilepsy,10.1016/j.yebeh.2020.107480,1.7,0.53,,,,,Assumed Total (tNAA) based on Analysis
,NAA,tNAA,2020_simani_112,18,Psychogenic Nonepileptic Seizure,10.1016/j.yebeh.2020.107480,1.74,0.69,,,,,Assumed Total (tNAA) based on Analysis
,NAA,tNAA,2020_simani_112,19,Healthy Controls,10.1016/j.yebeh.2020.107480,1.8,0.06,,,,,Assumed Total (tNAA) based on Analysis
,NAA,tNAA,2020_simani_112,20,Idiopathic Generalized Epilepsy,10.1016/j.yebeh.2020.107480,1.51,0.05,,,,,Assumed Total (tNAA) based on Analysis
,NAA,tNAA,2020_simani_112,21,Psychogenic Nonepileptic Seizure,10.1016/j.yebeh.2020.107480,1.61,0.04,,,,,Assumed Total (tNAA) based on Analysis
,NAA,tNAA,2020_simani_112,22,Healthy Controls,10.1016/j.yebeh.2020.107480,2.1,0.81,,,,,Assumed Total (tNAA) based on Analysis
,NAA,tNAA,2020_simani_112,23,Idiopathic Generalized Epilepsy,10.1016/j.yebeh.2020.107480,1.64,0.06,,,,,Assumed Total (tNAA) based on Analysis
,NAA,tNAA,2020_simani_112,24,Psychogenic Nonepileptic Seizure,10.1016/j.yebeh.2020.107480,1.56,0.06,,,,,Assumed Total (tNAA) based on Analysis
,NAA,NAA,2020_wong_73,4,Control,10.3233/JAD-190773,,,,,13.582,0.429,
,NAA,NAA,2020_wong_73,5,Mild cognitive impairment,10.3233/JAD-190773,,,,,11.991,0.602,
,NAA,NAA,2020_wong_73,6,Alzheimer's disease,10.3233/JAD-190773,,,,,11.003,0.645,
,NAA,tNAA,2020_ozcelik_31,1,Healthy Controls,10.5080/u25195,1.58,0.48,,,,,Assumed Total (tNAA) based on Analysis
,NAA,tNAA,2020_ozcelik_31,2,Schizophrenia,10.5080/u25195,1.47,0.44,,,,,Assumed Total (tNAA) based on Analysis
,NAA,tNAA,2020_ozcelik_31,3,Schizophrenia,10.5080/u25195,1.38,0.5,,,,,Assumed Total (tNAA) based on Analysis
,NAA,tNAA,2020_ozcelik_31,4,Healthy Controls,10.5080/u25195,1.6,0.51,,,,,Assumed Total (tNAA) based on Analysis
,NAA,tNAA,2020_ozcelik_31,5,Schizophrenia,10.5080/u25195,1.68,1,,,,,Assumed Total (tNAA) based on Analysis
,NAA,tNAA,2020_ozcelik_31,6,Schizophrenia,10.5080/u25195,1.34,0.64,,,,,Assumed Total (tNAA) based on Analysis
,NAA,tNAA,2020_ozcelik_31,7,Healthy Controls,10.5080/u25195,1.37,0.32,,,,,Assumed Total (tNAA) based on Analysis
,NAA,tNAA,2020_ozcelik_31,8,Schizophrenia,10.5080/u25195,1.78,1.12,,,,,Assumed Total (tNAA) based on Analysis
,NAA,tNAA,2020_ozcelik_31,9,Schizophrenia,10.5080/u25195,1.79,0.59,,,,,Assumed Total (tNAA) based on Analysis
,tNAA,tNAA,2020_jasek_54,1,Multiple scclerosis - Late onset,10.5603/PJNNS.a2020.0036,,,7.1,1.56,,,
,tNAA,tNAA,2020_jasek_54,2,Multiple scclerosis - Typical onset,10.5603/PJNNS.a2020.0036,,,8.81,1.42,,,
,tNAA,tNAA,2021_imrich_31,1,MS,10.1007/s10286-021-00790-w,0.96,0.1,,,,,
,tNAA,tNAA,2021_imrich_32,2,MS,10.1007/s10286-021-00790-w,1.22,0.06,,,,,
,tNAA,tNAA,2021_imrich_33,3,Control,10.1007/s10286-021-00790-w,1.47,0.07,,,,,
,NAA,NAA,2020_kaminski_87,1,Control,10.1016/j.biopsych.2019.07.011,,,12.09,0.99,,,
,NAA,NAA,2020_kaminski_87,2,Schizophrenia - Medicated,10.1016/j.biopsych.2019.07.011,,,12.06,1.36,,,
,NAA,NAA,2020_kaminski_87,3,Schizophrenia - Unmedicated,10.1016/j.biopsych.2019.07.011,,,11.91,1.07,,,
,NAA,NAA,2020_sheth_123,1,Traumatic Brain Injury,10.1152/jn.00765.2019,,,2.9,0.09,,,
,NAA,NAA,2020_sheth_123,2,Non Traumatic Brain Injury,10.1152/jn.00765.2019,,,2.72,0.13,,,
,NAA,NAA,2018_giapitzakis_79,1,Healthy,10.1002/mrm.26873,,,,,12.15,1.359,Med/Quartile --> Mean/Std Wan 2014
,NAA,NAA,2018_giapitzakis_79,2,Healthy,10.1002/mrm.26873,,,,,11.34,1.379,Med/Quartile --> Mean/Std Greco 2015
,tNAA,tNAA,2018_giapitzakis_79,1,Healthy,10.1002/mrm.26873,,,,,13.06,1.461,Med/Quartile --> Mean/Std Wan 2014
,tNAA,tNAA,2018_giapitzakis_79,2,Healthy,10.1002/mrm.26873,,,,,12.87,1.883,Med/Quartile --> Mean/Std Wan 2014
,NAA,tNAA,2020_mohamadi_101,1,Tension-type headache - Positional release technique - Baseline,10.1016/j.apmr.2020.05.028,1.69,0.58,,,,,Assumed Total (tNAA) based on Analysis
,NAA,tNAA,2020_mohamadi_101,2,Tension-type headache - Positional release technique - 5wks,10.1016/j.apmr.2020.05.028,1.58,0.34,,,,,Assumed Total (tNAA) based on Analysis
,NAA,tNAA,2020_mohamadi_101,3,Tension-type headache - Positional release technique - Baseline,10.1016/j.apmr.2020.05.028,1.65,0.38,,,,,Assumed Total (tNAA) based on Analysis
,NAA,tNAA,2020_mohamadi_101,4,Tension-type headache - Positional release technique - 5wks,10.1016/j.apmr.2020.05.028,1.66,0.22,,,,,Assumed Total (tNAA) based on Analysis
,NAA,tNAA,2020_mohamadi_101,5,Tension-type headache - Positional release technique - Baseline,10.1016/j.apmr.2020.05.028,1.42,0.3,,,,,Assumed Total (tNAA) based on Analysis
,NAA,tNAA,2020_mohamadi_101,6,Tension-type headache - Positional release technique - 5wks,10.1016/j.apmr.2020.05.028,1.4,0.33,,,,,Assumed Total (tNAA) based on Analysis
,NAA,tNAA,2020_mohamadi_101,7,Tension-type headache - Control - Baseline,10.1016/j.apmr.2020.05.028,1.77,0.55,,,,,Assumed Total (tNAA) based on Analysis
,NAA,tNAA,2020_mohamadi_101,8,Tension-type headache - Control - 5wks,10.1016/j.apmr.2020.05.028,1.88,0.55,,,,,Assumed Total (tNAA) based on Analysis
,NAA,tNAA,2020_mohamadi_101,9,Tension-type headache - Control - Baseline,10.1016/j.apmr.2020.05.028,1.87,0.18,,,,,Assumed Total (tNAA) based on Analysis
,NAA,tNAA,2020_mohamadi_101,10,Tension-type headache - Control - 5wks,10.1016/j.apmr.2020.05.028,1.72,0.34,,,,,Assumed Total (tNAA) based on Analysis
,NAA,tNAA,2020_mohamadi_101,11,Tension-type headache - Control - Baseline,10.1016/j.apmr.2020.05.028,1.49,0.28,,,,,Assumed Total (tNAA) based on Analysis
,NAA,tNAA,2020_mohamadi_101,12,Tension-type headache - Control - 5wks,10.1016/j.apmr.2020.05.028,1.66,0.26,,,,,Assumed Total (tNAA) based on Analysis
,NAA,NAA,2021_egerton_47,1,Psychosis - Antipsychotic responder,10.1093/schbul/sbaa128,,,16.94,3.1,,,
,NAA,NAA,2021_egerton_47,2,Psychosis - Antipsychotic responder,10.1093/schbul/sbaa128,,,11.32,1.37,,,
,NAA,NAA,2021_egerton_47,3,Psychosis - Antipsychotic responder,10.1093/schbul/sbaa128,,,10.96,2,,,
,NAA,NAA,2021_egerton_47,4,Psychosis - Antipsychotic responder,10.1093/schbul/sbaa128,,,11.11,2.11,,,
,NAA,NAA,2021_egerton_47,5,Psychosis - Antipsychotic responder,10.1093/schbul/sbaa128,,,17.25,2.22,,,
,NAA,NAA,2021_egerton_47,6,Psychosis - Antipsychotic responder,10.1093/schbul/sbaa128,,,11.71,0.98,,,
,NAA,NAA,2021_egerton_47,7,Psychosis - Antipsychotic responder,10.1093/schbul/sbaa128,,,12.56,0.86,,,
,NAA,NAA,2021_egerton_47,8,Psychosis - Antipsychotic responder,10.1093/schbul/sbaa128,,,10.53,2.56,,,
,NAA,NAA,2021_egerton_47,9,Psychosis - Antipsychotic non-responder,10.1093/schbul/sbaa128,,,11.26,1.41,,,
,NAA,NAA,2021_egerton_47,10,Psychosis - Antipsychotic non-responder,10.1093/schbul/sbaa128,,,8.02,0.64,,,
,NAA,NAA,2021_egerton_47,11,Psychosis - Antipsychotic non-responder,10.1093/schbul/sbaa128,,,8.56,0.73,,,n=6
,NAA,NAA,2021_egerton_47,12,Psychosis - Antipsychotic non-responder,10.1093/schbul/sbaa128,,,5.94,2.35,,,
,NAA,NAA,2021_egerton_47,13,Psychosis - Antipsychotic non-responder,10.1093/schbul/sbaa128,,,11.33,0.8,,,
,NAA,NAA,2021_egerton_47,14,Psychosis - Antipsychotic non-responder,10.1093/schbul/sbaa128,,,7.55,0.59,,,
,NAA,NAA,2021_egerton_47,15,Psychosis - Antipsychotic non-responder,10.1093/schbul/sbaa128,,,7.4,1.23,,,n=4
,NAA,NAA,2021_egerton_47,16,Psychosis - Antipsychotic non-responder,10.1093/schbul/sbaa128,,,8.83,0.58,,,n=4
,NAA,NAA,2021_manzhurtsev_34,1,Healthy - Visual stimulation,10.1007/s10334-021-00912-5,,,,,11.95,0.27,
,NAA,tNAA,2015_guo_15,1,Alzheimer's disease - Depressed,10.1186/s12888-015-0691-7,1.35,0.18,,,,,Assumed Total (tNAA) based on Analysis
,NAA,tNAA,2015_guo_15,2,Alzheimer's disease - Depressed,10.1186/s12888-015-0691-7,1.47,0.28,,,,,Assumed Total (tNAA) based on Analysis
,NAA,tNAA,2015_guo_15,3,Alzheimer's disease - Non-depressed,10.1186/s12888-015-0691-7,1.5,0.23,,,,,Assumed Total (tNAA) based on Analysis
,NAA,tNAA,2015_guo_15,4,Alzheimer's disease - Non-depressed,10.1186/s12888-015-0691-7,1.52,0.4,,,,,Assumed Total (tNAA) based on Analysis
,tNAA,tNAA,2018_raschke_39,1,Healthy,10.3174/ajnr.A5457,1.918,0.18,33.545,3.399,,,Med/Quartile --> Mean/Std Greco 2015; Wan 2014
,tNAA,tNAA,2018_raschke_39,2,Healthy,10.3174/ajnr.A5457,1.104,0.039,25.782,1.039,,,Med/Quartile --> Mean/Std Wan 2014; Greco 2015
,NAA,NAA,2016_lopezkolkovsky_75,1,Healthy_Rodent,10.1002/mrm.25602,,,,,9.2,0.7,
,tNAA,tNAA,2016_lopezkolkovsky_75,1,Healthy_Rodent,10.1002/mrm.25602,,,,,9.9,0.7,
,NAA,NAA,2018_an_79,1,Glioma - IDH1-mutated grade-II oligodendroglioma,10.1002/mrm.26884,,,8.974,0.726,,,
,NAA,NAA,2018_an_79,2,Glioma - IDH1-mutated grade-II oligodendroglioma,10.1002/mrm.26884,,,2.524,1.156,,,
,NAA,NAA,2018_an_79,3,Glioma - Radiographically suggested glioma,10.1002/mrm.26884,,,7.651,1.048,,,
,NAA,NAA,2018_an_79,4,Glioma - Radiographically suggested glioma,10.1002/mrm.26884,,,5.397,1.52,,,
,NAA,NAA,2018_an_79,5,Glioma - IDH wild-type glioblastoma,10.1002/mrm.26884,,,5.247,0.901,,,
,NAA,NAA,2018_an_79,6,Glioma - IDH wild-type glioblastoma,10.1002/mrm.26884,,,1.749,0.265,,,
,NAA,NAA,2021_mitolo_82,1,PPA,10.3233/JAD-210211,1.2,0.31,,,,,
,NAA,NAA,2021_mitolo_82,2,AD,10.3233/JAD-210211,1.19,0.28,,,,,
,NAA,NAA,2021_mitolo_82,3,Healthy controls,10.3233/JAD-210211,1.37,0.12,,,,,
,NAA,NAA,2021_oneill_35,1,PSY-PLB (placebo),10.1177/02698811211001107,,,,,9.17,1.18,
,NAA,NAA,2021_oneill_35,2,PSY-CBD,10.1177/02698811211001107,,,,,9.37,1.26,
,NAA,NAA,2020_tarumi_45,1,Healthy Control,10.1038/s41386-019-0589-z,,,,9.78,0.57,,
,NAA,NAA,2020_tarumi_45,2,Treatment Resistant Schizophrenia ,10.1038/s41386-019-0589-z,,,,9.74,1.11,,
,NAA,NAA,2020_tarumi_45,3,Non-treatment Resistant Schizophrenia ,10.1038/s41386-019-0589-z,,,,9.69,0.7,,
,NAA,NAA,2020_tarumi_45,4,Healthy Control,10.1038/s41386-019-0589-z,,,,13.1,0.62,,
,NAA,NAA,2020_tarumi_45,5,Treatment Resistant Schizophrenia ,10.1038/s41386-019-0589-z,,,,13.69,0.94,,
,NAA,NAA,2020_tarumi_45,6,Non-treatment Resistant Schizophrenia ,10.1038/s41386-019-0589-z,,,,13.44,1.1,,
,NAA,NAA,2018_burger_185,1,Addiction - Methamphetamine Acute Abstinence,10.1016/j.drugalcdep.2017.11.029,1.194,0.089,,,,,
,NAA,NAA,2018_burger_185,2,Addiction - Methamphetamine Acute Abstinence,10.1016/j.drugalcdep.2017.11.029,1.142,0.121,,,,,
,NAA,NAA,2018_burger_185,3,Addiction - Methamphetamine Acute Abstinence,10.1016/j.drugalcdep.2017.11.029,1.338,0.105,,,,,
,NAA,NAA,2018_burger_185,4,Addiction - Methamphetamine Acute Abstinence,10.1016/j.drugalcdep.2017.11.029,1.302,0.141,,,,,
,NAA,NAA,2018_burger_185,5,Addiction - Methamphetamine Acute Abstinence,10.1016/j.drugalcdep.2017.11.029,1.312,0.111,,,,,
,NAA,NAA,2018_burger_185,6,Addiction - Methamphetamine Acute Abstinence,10.1016/j.drugalcdep.2017.11.029,1.335,0.187,,,,,
,NAA,NAA,2018_burger_185,7,Addiction - Methamphetamine Short-term Abstinence,10.1016/j.drugalcdep.2017.11.029,1.114,0,,,,,
,NAA,NAA,2018_burger_185,8,Addiction - Methamphetamine Short-term Abstinence,10.1016/j.drugalcdep.2017.11.029,1.171,0.139,,,,,
,NAA,NAA,2018_burger_185,9,Addiction - Methamphetamine Short-term Abstinence,10.1016/j.drugalcdep.2017.11.029,1.349,0.142,,,,,
,NAA,NAA,2018_burger_185,10,Addiction - Methamphetamine Short-term Abstinence,10.1016/j.drugalcdep.2017.11.029,1.288,0.171,,,,,
,NAA,NAA,2018_burger_185,11,Addiction - Methamphetamine Short-term Abstinence,10.1016/j.drugalcdep.2017.11.029,1.349,0.089,,,,,
,NAA,NAA,2018_burger_185,12,Addiction - Methamphetamine Short-term Abstinence,10.1016/j.drugalcdep.2017.11.029,1.345,0.185,,,,,
,NAA,NAA,2018_burger_185,13,Control,10.1016/j.drugalcdep.2017.11.029,1.155,0.105,,,,,
,NAA,NAA,2018_burger_185,14,Control,10.1016/j.drugalcdep.2017.11.029,1.207,0.108,,,,,
,NAA,NAA,2018_burger_185,15,Control,10.1016/j.drugalcdep.2017.11.029,1.361,0.148,,,,,
,NAA,NAA,2018_burger_185,16,Control,10.1016/j.drugalcdep.2017.11.029,1.404,0.137,,,,,
,NAA,NAA,2018_burger_185,17,Control,10.1016/j.drugalcdep.2017.11.029,1.315,0.102,,,,,
,NAA,NAA,2018_burger_185,18,Control,10.1016/j.drugalcdep.2017.11.029,1.423,0.177,,,,,
,tNAA,tNAA,2018_burger_185,1,Addiction - Methamphetamine Acute Abstinence,10.1016/j.drugalcdep.2017.11.029,1.273,0.137,,,,,
,tNAA,tNAA,2018_burger_185,2,Addiction - Methamphetamine Acute Abstinence,10.1016/j.drugalcdep.2017.11.029,1.207,0.161,,,,,
,tNAA,tNAA,2018_burger_185,3,Addiction - Methamphetamine Acute Abstinence,10.1016/j.drugalcdep.2017.11.029,1.361,0.141,,,,,
,tNAA,tNAA,2018_burger_185,4,Addiction - Methamphetamine Acute Abstinence,10.1016/j.drugalcdep.2017.11.029,1.371,0.147,,,,,
,tNAA,tNAA,2018_burger_185,5,Addiction - Methamphetamine Acute Abstinence,10.1016/j.drugalcdep.2017.11.029,1.391,0.131,,,,,
,tNAA,tNAA,2018_burger_185,6,Addiction - Methamphetamine Acute Abstinence,10.1016/j.drugalcdep.2017.11.029,1.469,0.17,,,,,
,tNAA,tNAA,2018_burger_185,7,Addiction - Methamphetamine Short-term Abstinence,10.1016/j.drugalcdep.2017.11.029,1.173,0.108,,,,,
,tNAA,tNAA,2018_burger_185,8,Addiction - Methamphetamine Short-term Abstinence,10.1016/j.drugalcdep.2017.11.029,1.231,0.136,,,,,
,tNAA,tNAA,2018_burger_185,9,Addiction - Methamphetamine Short-term Abstinence,10.1016/j.drugalcdep.2017.11.029,1.399,0.138,,,,,
,tNAA,tNAA,2018_burger_185,10,Addiction - Methamphetamine Short-term Abstinence,10.1016/j.drugalcdep.2017.11.029,1.374,0.124,,,,,
,tNAA,tNAA,2018_burger_185,11,Addiction - Methamphetamine Short-term Abstinence,10.1016/j.drugalcdep.2017.11.029,1.42,0.142,,,,,
,tNAA,tNAA,2018_burger_185,12,Addiction - Methamphetamine Short-term Abstinence,10.1016/j.drugalcdep.2017.11.029,1.459,0.174,,,,,
,tNAA,tNAA,2018_burger_185,13,Control,10.1016/j.drugalcdep.2017.11.029,1.263,0.121,,,,,
,tNAA,tNAA,2018_burger_185,14,Control,10.1016/j.drugalcdep.2017.11.029,1.286,0.164,,,,,
,tNAA,tNAA,2018_burger_185,15,Control,10.1016/j.drugalcdep.2017.11.029,1.476,0.19,,,,,
,tNAA,tNAA,2018_burger_185,16,Control,10.1016/j.drugalcdep.2017.11.029,1.489,0.141,,,,,
,tNAA,tNAA,2018_burger_185,17,Control,10.1016/j.drugalcdep.2017.11.029,1.417,0.167,,,,,
,tNAA,tNAA,2018_burger_185,18,Control,10.1016/j.drugalcdep.2017.11.029,1.574,0.2,,,,,
,tNAA,tNAA,2018_deelchand_79,1,Healthy,10.1002/mrm.26788,,,,,10.512,1.138,
,tNAA,tNAA,2018_deelchand_79,2,Healthy,10.1002/mrm.26788,,,,,11.007,1.014,
,NAA,tNAA,2018_guo_27,1,Open-angle glaucoma - Early,10.1097/IJG.0000000000001098,1.716,0.817,,,,,Assumed Total (tNAA) based on Analysis
,NAA,tNAA,2018_guo_27,2,Control,10.1097/IJG.0000000000001098,1.544,0.481,,,,,Assumed Total (tNAA) based on Analysis
,NAA,NAA,2018_kameda_34,1,Chronic Low Back Pain,10.1097/AJP.0000000000000583,1.197,0.111,8.393,0.971,,,
,NAA,NAA,2018_kameda_34,2,Control,10.1097/AJP.0000000000000583,1.269,0.101,9.191,0.659,,,
,NAA,tNAA,2018_karczewska-kupczewska_103,1,Drug - Intralipid/Heparin Baseline,10.1210/jc.2018-00107,1.609,0.401,0.409,0.093,,,Assumed Total (tNAA) based on Analysis
,NAA,tNAA,2018_karczewska-kupczewska_103,2,Drug - Intralipid/Heparin Baseline,10.1210/jc.2018-00107,1.834,0.474,0.351,0.068,,,Assumed Total (tNAA) based on Analysis
,NAA,tNAA,2018_karczewska-kupczewska_103,3,Drug - Intralipid/Heparin Baseline,10.1210/jc.2018-00107,1.64,0.51,0.339,0.13,,,Assumed Total (tNAA) based on Analysis
,NAA,tNAA,2018_karczewska-kupczewska_103,4,Drug - Intralipid/Heparin 4 hour infusion,10.1210/jc.2018-00107,1.597,0.474,0.39,0.112,,,Assumed Total (tNAA) based on Analysis
,NAA,tNAA,2018_karczewska-kupczewska_103,5,Drug - Intralipid/Heparin 4 hour infusion,10.1210/jc.2018-00107,1.19,0.353,0.295,0.089,,,Assumed Total (tNAA) based on Analysis
,NAA,tNAA,2018_karczewska-kupczewska_103,6,Drug - Intralipid/Heparin 4 hour infusion,10.1210/jc.2018-00107,1.846,0.948,0.35,0.109,,,Assumed Total (tNAA) based on Analysis
,NAA,tNAA,2018_karczewska-kupczewska_103,7,Control - Saline Baseline,10.1210/jc.2018-00107,1.652,0.249,0.419,0.069,,,Assumed Total (tNAA) based on Analysis
,NAA,tNAA,2018_karczewska-kupczewska_103,8,Control - Saline Baseline,10.1210/jc.2018-00107,1.597,0.711,0.36,0.15,,,Assumed Total (tNAA) based on Analysis
,NAA,tNAA,2018_karczewska-kupczewska_103,9,Control - Saline Baseline,10.1210/jc.2018-00107,1.524,0.365,0.369,0.09,,,Assumed Total (tNAA) based on Analysis
,NAA,tNAA,2018_karczewska-kupczewska_103,10,Control - Saline 4 hour infusion,10.1210/jc.2018-00107,1.822,0.65,0.425,0.106,,,Assumed Total (tNAA) based on Analysis
,NAA,tNAA,2018_karczewska-kupczewska_103,11,Control - Saline 4 hour infusion,10.1210/jc.2018-00107,1.706,0.347,0.388,0.072,,,Assumed Total (tNAA) based on Analysis
,NAA,tNAA,2018_karczewska-kupczewska_103,12,Control - Saline 4 hour infusion,10.1210/jc.2018-00107,1.998,0.632,0.367,0.102,,,Assumed Total (tNAA) based on Analysis
,NAA,NAA,2018_menshchikov_67,2,Healthy,10.1007/s11172-018-2119-2,1.47,0.08,,,,,
,NAAG,NAAG,2019_cheong_90,1,Control - Visit 1,10.1136/jnnp-2018-318795,,,,,,,
,NAAG,NAAG,2019_cheong_90,2,Control - Visit 2,10.1136/jnnp-2018-318795,,,,,,,
,NAAG,NAAG,2019_cheong_90,3,Control - Visit 3,10.1136/jnnp-2018-318795,,,,,,,
,NAAG,NAAG,2019_cheong_90,4,Control - Visit 1,10.1136/jnnp-2018-318795,,,,,,,
,NAAG,NAAG,2019_cheong_90,5,Control - Visit 2,10.1136/jnnp-2018-318795,,,,,,,
,NAAG,NAAG,2019_cheong_90,6,Control - Visit 3,10.1136/jnnp-2018-318795,,,,,,,
,NAAG,NAAG,2019_cheong_90,7,ALS - Visit 1,10.1136/jnnp-2018-318795,,,,,,,
,NAAG,NAAG,2019_cheong_90,8,ALS - Visit 2,10.1136/jnnp-2018-318795,,,,,,,
,NAAG,NAAG,2019_cheong_90,9,ALS - Visit 3,10.1136/jnnp-2018-318795,,,,,,,
,NAAG,NAAG,2019_cheong_90,10,ALS - Visit 1,10.1136/jnnp-2018-318795,,,,,,,
,NAAG,NAAG,2019_cheong_90,11,ALS - Visit 2,10.1136/jnnp-2018-318795,,,,,,,
,NAAG,NAAG,2019_cheong_90,12,ALS - Visit 3,10.1136/jnnp-2018-318795,,,,,,,
,NAAG,NAAG,2018_an_80,1,Healthy,10.1002/mrm.27172,0.08,0.03,,,,,
,NAAG,NAAG,2018_bednarik_38,1,Healthy,10.1177/0271678X17695291,,,,,1.27,0.14,
,NAA+NAAG,tNAA,2020_blest-hopley_25,1,Current CU,10.1111/adb.12827,,,9.854,1.06,,,
,NAA+NAAG,tNAA,2020_blest-hopley_25,2,Healthy,10.1111/adb.12827,,,9.207,1.09,,,
,NAAG,NAAG,2020_boillat_40,1,Baseline,10.1177/0271678X19831022,,,0.95,0.08,,,
,NAAG,NAAG,2020_boillat_40,2,positive BOLD,10.1177/0271678X19831022,,,0.04,0.07,,,
,NAAG,NAAG,2020_boillat_40,3,Baseline,10.1177/0271678X19831022,,,0.88,0.06,,,
,NAAG,NAAG,2020_boillat_40,4,negative BOLD,10.1177/0271678X19831022,,,0.05,0.1,,,
,NAAG,NAAG,2018_morley_9,1,Alcohol Dependence - Placebo,10.3389/fpsyt.2018.00412,0.14,0.05,,,,,
,NAAG,NAAG,2018_morley_9,2,Alcohol Dependence - Baclofen,10.3389/fpsyt.2018.00412,0.13,0.07,,,,,
,NAAG,NAAG,2018_morley_9,3,"Alcohol Dependence - Recent alcohol consumption, placebo",10.3389/fpsyt.2018.00412,0.12,0.03,,,,,
,NAAG,NAAG,2018_morley_9,4,"Alcohol Dependence - Recent alcohol consumption, Baclofen",10.3389/fpsyt.2018.00412,0.09,0.05,,,,,
,NAAG,NAAG,2021_akiyama_61,1,Control,10.2176/nmc.oa.2020-0274,,,3.16,0.64,,,
,NAAG,NAAG,2021_akiyama_61,2,NPH,10.2176/nmc.oa.2020-0274,,,2.47,0.87,,,
,NAA+NAAG,tNAA,2021_chenji_282,1,Control,10.1016/j.jad.2020.12.176,,,8.24,1.07,,,
,NAA+NAAG,tNAA,2021_chenji_282,3,MDD-Normal BMI,10.1016/j.jad.2020.12.176,,,8.19,1.05,,,
,NAA+NAAG,tNAA,2021_chenji_282,5,MDD-High BMI,10.1016/j.jad.2020.12.176,,,8.6,1.02,,,
,NAA+NAAG,tNAA,2021_chenji_282,2,Control,10.1016/j.jad.2020.12.176,,,8.77,1.03,,,
,NAA+NAAG,tNAA,2021_chenji_282,4,MDD-Normal BMI,10.1016/j.jad.2020.12.176,,,8.72,1.05,,,
,NAA+NAAG,tNAA,2021_chenji_282,6,MDD-High BMI,10.1016/j.jad.2020.12.176,,,9.09,1.07,,,
,NAAG,NAAG,2019_giapitzakis_81,1,Healthy,10.1002/mrm.27467,,,,,1,0.2,
,NAAG,NAAG,2019_giapitzakis_81,2,Healthy,10.1002/mrm.27467,,,,,1.7,0.4,
,NAAG,NAAG,2019_marjanska_68,1,Alzheimer's disease,10.3233/JAD-180861,,,,,1.02,0.2,
,NAAG,NAAG,2019_marjanska_68,2,Alzheimer's disease,10.3233/JAD-180861,,,,,0.93,0.2,
,NAAG,NAAG,2019_marjanska_68,3,Control,10.3233/JAD-180861,,,,,0.99,0.172,
,NAAG,NAAG,2019_marjanska_68,4,Control,10.3233/JAD-180861,,,,,1.07,0.172,
,NAA+NAAG,tNAA,2020_colizzi_25,1,Healthy,10.1038/s41380-019-0374-8,,,3.19,0.54,,,
,NAA+NAAG,tNAA,2020_colizzi_25,2,Healthy,10.1038/s41380-019-0374-8,,,2.69,0.6,,,
,NAA+NAAG,tNAA,2020_colizzi_25,3,Healthy,10.1038/s41380-019-0374-8,,,4.75,1.13,,,
,NAA+NAAG,tNAA,2020_colizzi_25,4,Psychosis ,10.1038/s41380-019-0374-8,,,3.62,1.15,,,
,NAA+NAAG,tNAA,2020_colizzi_25,5,Psychosis ,10.1038/s41380-019-0374-8,,,2.69,0.48,,,
,NAA+NAAG,tNAA,2020_colizzi_25,6,Psychosis ,10.1038/s41380-019-0374-8,,,4,1.21,,,
,NAAG,NAAG,2019_wagoner_317,1,Non-OI,10.1152/ajpheart.00680.2018,,,4.9,2.117,,,
,NAAG,NAAG,2019_wagoner_317,2,OI,10.1152/ajpheart.00680.2018,,,5.4,0.995,,,
,NAAG,NAAG,2019_wang_76,1,FEP,10.1001/jamapsychiatry.2018.3637,,,0.7,0.3,,,
,NAAG,NAAG,2019_wang_76,2,FEP,10.1001/jamapsychiatry.2018.3637,,,2.1,0.6,,,
,NAAG,NAAG,2019_wang_76,3,FEP,10.1001/jamapsychiatry.2018.3637,,,0.8,0.4,,,
,NAAG,NAAG,2019_wang_76,4,FEP,10.1001/jamapsychiatry.2018.3637,,,0.9,0.5,,,
,NAAG,NAAG,2019_wang_76,5,FEP,10.1001/jamapsychiatry.2018.3637,,,1.4,0.9,,,
,NAAG,NAAG,2019_wang_76,6,Control,10.1001/jamapsychiatry.2018.3637,,,0.8,0.2,,,
,NAAG,NAAG,2019_wang_76,7,Control,10.1001/jamapsychiatry.2018.3637,,,2.2,0.5,,,
,NAAG,NAAG,2019_wang_76,8,Control,10.1001/jamapsychiatry.2018.3637,,,0.85,0.5,,,
,NAAG,NAAG,2019_wang_76,9,Control,10.1001/jamapsychiatry.2018.3637,,,0.95,0.5,,,
,NAAG,NAAG,2019_wang_76,10,Control,10.1001/jamapsychiatry.2018.3637,,,1.4,0.8,,,
,NAAG,NAAG,2018_povazan_79,1,Healthy,10.1002/mrm.26778,,,2.7,0.38,,,
,NAAG,NAAG,2018_povazan_79,2,Healthy,10.1002/mrm.26778,,,4.28,0.59,,,
,NAAG,NAAG,2018_povazan_79,3,Healthy,10.1002/mrm.26778,,,3.85,0.73,,,
,NAAG,NAAG,2018_povazan_79,4,Healthy,10.1002/mrm.26778,,,3.89,0.49,,,
,NAAG,NAAG,2018_povazan_79,5,Healthy,10.1002/mrm.26778,,,4.14,0.53,,,
,NAAG,NAAG,2018_povazan_79,6,Healthy,10.1002/mrm.26778,,,3.07,0.73,,,
,NAAG,NAAG,2018_povazan_79,7,Healthy,10.1002/mrm.26778,,,3.22,0.77,,,
,NAAG,NAAG,2020_menshchikov_84,1,Control,10.1002/mrm.28332,0.169,0.018,,,2.3,0.25,
,NAAG,NAAG,2020_menshchikov_84,2,Mild Traumatic Brain Injury ,10.1002/mrm.28332,0.136,0.02,,,1.84,0.27,
,NAAG,NAAG,2019_reid_45,1,Control,10.1093/schbul/sbx190,,,0.46,0.1,,,
,NAAG,NAAG,2019_reid_45,2,Schizophrenia,10.1093/schbul/sbx190,,,0.45,0.08,,,
,NAAG,NAAG,2020_lind_40,7,Aging,10.1523/JNEUROSCI.2883-19.2020,,,,,1.84,0.48,
,NAAG,NAAG,2020_lind_40,8,Aging,10.1523/JNEUROSCI.2883-19.2020,,,,,2.26,0.61,
,NAAG,NAAG,2020_lind_40,9,Aging,10.1523/JNEUROSCI.2883-19.2020,,,,,2.28,0.68,
,NAAG,NAAG,2020_dehghani_83,1,Protocol 1,10.1002/mrm.28066,,,,,0.89,0.24,
,NAAG,NAAG,2020_dehghani_83,1,Protocol 2,10.1002/mrm.28066,,,,,0.26,0.08,
,NAAG,NAAG,2020_dehghani_83,1,Protocol 3,10.1002/mrm.28066,,,,,0.4,0.09,
,NAAG,NAAG,2018_giapitzakis_79,1,Healthy,10.1002/mrm.26873,,,,,1.38,0.59,Med/Quartile --> Mean/Std Greco 2015
,NAAG,NAAG,2018_giapitzakis_79,2,Healthy,10.1002/mrm.26873,,,,,1.08,1,Med/Quartile --> Mean/Std Wan 2014
,NAAG,NAAG,2021_manzhurtsev_34,2,Healthy - Visual stimulation,10.1007/s10334-021-00912-5,,,,,1.55,0.05,
,NAAG,NAAG,2016_lopezkolkovsky_75,1,Healthy_Rodent,10.1002/mrm.25602,,,,,0.8,0.1,
,PE,PE,2018_bednarik_38,1,Healthy,10.1177/0271678X17695291,,,,,0.88,0.07,
,PE,PE,2019_betinaip_39,1,Behavior - ON - 3% Visual Contrast,10.1523/JNEUROSCI.3021-18.2019,,,2.146,0.361,,,
,PE,PE,2019_betinaip_39,2,Behavior - ON - 12.5% Visual Contrast,10.1523/JNEUROSCI.3021-18.2019,,,2.132,0.393,,,
,PE,PE,2019_betinaip_39,3,Behavior - ON - 50% Visual Contrast,10.1523/JNEUROSCI.3021-18.2019,,,1.956,0.534,,,
,PE,PE,2019_betinaip_39,4,Behavior - ON - 100% Visual Contrast,10.1523/JNEUROSCI.3021-18.2019,,,2.094,0.52,,,
,PE,PE,2019_betinaip_39,5,Resting,10.1523/JNEUROSCI.3021-18.2019,,,2.087,0.354,,,
,PE,PE,2019_betinaip_39,6,Behavior - OFF - 3% Visual Contrast,10.1523/JNEUROSCI.3021-18.2019,,,2.18,0.414,,,
,PE,PE,2019_betinaip_39,7,Behavior - OFF - 12.5% Visual Contrast,10.1523/JNEUROSCI.3021-18.2019,,,2.073,0.426,,,
,PE,PE,2019_betinaip_39,8,Behavior - OFF - 50% Visual Contrast,10.1523/JNEUROSCI.3021-18.2019,,,2.081,0.519,,,
,PE,PE,2019_betinaip_39,9,Behavior - OFF - 100% Visual Contrast,10.1523/JNEUROSCI.3021-18.2019,,,2.047,0.51,,,
,PE,PE,2019_betinaip_39,10,Resting,10.1523/JNEUROSCI.3021-18.2019,,,2.026,0.416,,,
,PE,PE,2019_giapitzakis_81,1,Healthy,10.1002/mrm.27467,,,,,1.5,0.5,
,PE,PE,2019_giapitzakis_81,2,Healthy,10.1002/mrm.27467,,,,,0.7,0.3,
,PE,PE,2019_marjanska_68,1,Alzheimer's disease,10.3233/JAD-180861,,,,,0.97,0.28,
,PE,PE,2019_marjanska_68,2,Alzheimer's disease,10.3233/JAD-180861,,,,,0.75,0.28,
,PE,PE,2019_marjanska_68,3,Control,10.3233/JAD-180861,,,,,1.16,0.23,
,PE,PE,2019_marjanska_68,4,Control,10.3233/JAD-180861,,,,,0.77,0.23,
,PE,PE,2020_dehghani_83,1,Control ,10.1002/mrm.28066,,,,,1.76,0.17,
,PE,PE,2020_dehghani_83,2,Control ,10.1002/mrm.28066,,,,,0.8,0.47,
,PE,PE,2020_dehghani_83,3,Control ,10.1002/mrm.28066,,,,,0.44,0.11,
,PE,PE,2018_giapitzakis_79,1,Healthy,10.1002/mrm.26873,,,,,1.77,0.83,Med/Quartile --> Mean/Std Greco 2015
,PE,PE,2018_giapitzakis_79,2,Healthy,10.1002/mrm.26873,,,,,1.15,1.068,Med/Quartile --> Mean/Std Greco 2015
,PE,PE,2016_lopezkolkovsky_75,1,Healthy_Rodent,10.1002/mrm.25602,,,,,1.7,0.2,
,PE,PE,2018_deelchand_79,2,Healthy,10.1002/mrm.26788,,,,,1.163,0.494,
,Scyllo,Scy,2019_barbagallo_62,1,Control,10.1016/j.parkreldis.2018.12.008,0.054,0.007,0.27,0.043,,,
,Scyllo,Scy,2019_barbagallo_62,2,Progressive Supranuclear Palsy,10.1016/j.parkreldis.2018.12.008,0.033,0.011,0.125,0.033,,,
,Scy,Scy,2018_adanyeguh_31,2,Healthy,10.1002/nbm.3880,,,,,0.3,0.1,Estimated Bar Graph
,Scy,Scy,2018_adanyeguh_31,4,HD,10.1002/nbm.3880,,,,,0.4,0.1,Estimated Bar Graph
,Scy,Scy,2018_bednarik_38,1,Healthy,10.1177/0271678X17695291,,,,,0.36,0.24,
,Scy,Scy,2020_boillat_40,1,Baseline,10.1177/0271678X19831022,,,0.19,0.01,,,
,Scy,Scy,2020_boillat_40,2,positive BOLD,10.1177/0271678X19831022,,,0.01,0.02,,,
,Scy,Scy,2020_boillat_40,3,Baseline,10.1177/0271678X19831022,,,0.19,0.02,,,
,Scy,Scy,2020_boillat_40,4,negative BOLD,10.1177/0271678X19831022,,,0,0.012,,,
,Scy,Scy,2019_betinaip_39,1,Behavior - ON - 3% Visual Contrast,10.1523/JNEUROSCI.3021-18.2019,,,0.252,0.086,,,
,Scy,Scy,2019_betinaip_39,2,Behavior - ON - 12.5% Visual Contrast,10.1523/JNEUROSCI.3021-18.2019,,,0.262,0.074,,,
,Scy,Scy,2019_betinaip_39,3,Behavior - ON - 50% Visual Contrast,10.1523/JNEUROSCI.3021-18.2019,,,0.26,0.085,,,
,Scy,Scy,2019_betinaip_39,4,Behavior - ON - 100% Visual Contrast,10.1523/JNEUROSCI.3021-18.2019,,,0.257,0.087,,,
,Scy,Scy,2019_betinaip_39,5,Resting,10.1523/JNEUROSCI.3021-18.2019,,,0.248,0.093,,,
,Scy,Scy,2019_betinaip_39,6,Behavior - OFF - 3% Visual Contrast,10.1523/JNEUROSCI.3021-18.2019,,,0.246,0.075,,,
,Scy,Scy,2019_betinaip_39,7,Behavior - OFF - 12.5% Visual Contrast,10.1523/JNEUROSCI.3021-18.2019,,,0.255,0.082,,,
,Scy,Scy,2019_betinaip_39,8,Behavior - OFF - 50% Visual Contrast,10.1523/JNEUROSCI.3021-18.2019,,,0.241,0.081,,,
,Scy,Scy,2019_betinaip_39,9,Behavior - OFF - 100% Visual Contrast,10.1523/JNEUROSCI.3021-18.2019,,,0.257,0.096,,,
,Scy,Scy,2019_betinaip_39,10,Resting,10.1523/JNEUROSCI.3021-18.2019,,,0.254,0.089,,,
,sI,Scy,2019_giapitzakis_81,1,Healthy,10.1002/mrm.27467,,,,,0.4,0.2,
,sI,Scy,2019_giapitzakis_81,2,Healthy,10.1002/mrm.27467,,,,,0.2,0.2,
,Scy,Scy,2018_zarinabad_79,1,Medulloblastoma,10.1002/mrm.26837,,,,,0.37,0.47,
,Scy,Scy,2018_zarinabad_79,2,Pilocytic Astrocytoma,10.1002/mrm.26837,,,,,0.05,0.08,
,Scy,Scy,2018_zarinabad_79,3,Ependymoma,10.1002/mrm.26837,,,,,0.008,0.01,
,Scy,Scy,2021_akiyama_61,1,Control,10.2176/nmc.oa.2020-0274,,,0.12,0.39,,,
,Scy,Scy,2021_akiyama_61,2,NPH,10.2176/nmc.oa.2020-0274,,,0.08,0.12,,,
,Scy,Scy,2016_koob_11,1,Premature Neonates,10.1371/journal.pone.0160990,,,0.007,0.006,,,
,Scy,Scy,2016_koob_11,2,Premature Neonates,10.1371/journal.pone.0160990,,,0.005,0.005,,,
,Scy,Scy,2016_koob_11,3,Infants - Control,10.1371/journal.pone.0160990,,,0.01,0.01,,,
,Scy,Scy,2016_koob_11,4,Infants - Control,10.1371/journal.pone.0160990,,,0.004,0.005,,,
,Scy,Scy,2019_marjanska_68,1,Alzheimer's disease,10.3233/JAD-180861,,,,,0.41,0.24,
,Scy,Scy,2019_marjanska_68,2,Alzheimer's disease,10.3233/JAD-180861,,,,,0.4,0.24,
,Scy,Scy,2019_marjanska_68,3,Control,10.3233/JAD-180861,,,,,0.45,0.23,
,Scy,Scy,2019_marjanska_68,4,Control,10.3233/JAD-180861,,,,,0.45,0.23,
,Scy,Scy,2019_wiegers_62,1,Control,10.1007/s00125-019-4862-9,,,,,0.57,0.17,
,Scy,Scy,2019_wiegers_62,2,Type 1 diabetes - Normal awareness of hypoglycaemia,10.1007/s00125-019-4862-9,,,,,0.41,0.13,
,Scy,Scy,2019_wiegers_62,3,Type 1 diabetes,10.1007/s00125-019-4862-9,,,,,0.45,0.18,
,Scy-Ins,Scy,2020_lind_40,7,Aging,10.1523/JNEUROSCI.2883-19.2020,,,,,0.23,0.09,
,Scy-Ins,Scy,2020_lind_40,8,Aging,10.1523/JNEUROSCI.2883-19.2020,,,,,0.25,0.11,
,Scy-Ins,Scy,2020_lind_40,9,Aging,10.1523/JNEUROSCI.2883-19.2020,,,,,0.34,0.16,
,Scy-Ins ,Scy,2020_dehghani_83,1,Protocol 1,10.1002/mrm.28066,,,,,0.12,0.05,
,Scy-Ins ,Scy,2020_dehghani_83,2,Protocol 2,10.1002/mrm.28066,,,,,0.05,0.03,
,Scy-Ins ,Scy,2020_dehghani_83,3,Protocol 3,10.1002/mrm.28066,,,,,0.08,0.04,
,sI,Scy,2018_giapitzakis_79,1,Healthy,10.1002/mrm.26873,,,,,0.17,0.27,Med/Quartile --> Mean/Std Greco 2015
,sI,Scy,2018_giapitzakis_79,2,Healthy,10.1002/mrm.26873,,,,,0.01,0.16,Med/Quartile --> Mean/Std Greco 2015
,Scy,Scy,2018_deelchand_79,1,Healthy,10.1002/mrm.26788,,,,,0.668,0.519,
,Scy,Scy,2018_deelchand_79,2,Healthy,10.1002/mrm.26788,,,,,0.519,0.223,
,Ser ,Ser ,2020_lind_40,7,Aging,10.1523/JNEUROSCI.2883-19.2020,,,,,0.99,0.4,
,Ser ,Ser ,2020_lind_40,8,Aging,10.1523/JNEUROSCI.2883-19.2020,,,,,1.58,0.58,
,Ser ,Ser ,2020_lind_40,9,Aging,10.1523/JNEUROSCI.2883-19.2020,,,,,1.65,1.03,
,Ser ,Ser ,2020_dehghani_83,3,Protocol 3,10.1002/mrm.28066,,,,,0.28,0.11,
,Ser ,Ser ,2016_lopezkolkovsky_75,1,Healthy_Rodent,10.1002/mrm.25602,,,,,1,0.2,
,Tau,Tau,2018_adanyeguh_31,2,Healthy,10.1002/nbm.3880,,,,,1.5,0.2,Estimated Bar Graph
,Tau,Tau,2018_adanyeguh_31,4,HD,10.1002/nbm.3880,,,,,1.4,0.2,Estimated Bar Graph
,Tau,Tau,2018_bednarik_38,1,Healthy,10.1177/0271678X17695291,,,,,1.24,0.17,
,Tau,Tau,2020_boillat_40,1,Baseline,10.1177/0271678X19831022,,,0.96,0.06,,,
,Tau,Tau,2020_boillat_40,2,positive BOLD,10.1177/0271678X19831022,,,0,0.11,,,
,Tau,Tau,2020_boillat_40,3,Baseline,10.1177/0271678X19831022,,,0.93,0.06,,,
,Tau,Tau,2020_boillat_40,4,negative BOLD,10.1177/0271678X19831022,,,0.01,0.14,,,
,Tau,Tau,2021_akiyama_61,1,Control,10.2176/nmc.oa.2020-0274,,,0.55,0.7,,,
,Tau,Tau,2021_akiyama_61,2,NPH,10.2176/nmc.oa.2020-0274,,,0.08,0.18,,,
,Tau,Tau,2021_bednarik_15,1,Healthy,10.3389/fnins.2021.609485,,,,,2.1,0.04,
,Tau,Tau,2021_bednarik_15,2,Healthy,10.3389/fnins.2021.609485,,,,,1.98,0.1,
,Tau,Tau,2019_betinaip_39,1,Behavior - ON - 3% Visual Contrast,10.1523/JNEUROSCI.3021-18.2019,,,1.227,0.226,,,
,Tau,Tau,2019_betinaip_39,2,Behavior - ON - 12.5% Visual Contrast,10.1523/JNEUROSCI.3021-18.2019,,,1.338,0.275,,,
,Tau,Tau,2019_betinaip_39,3,Behavior - ON - 50% Visual Contrast,10.1523/JNEUROSCI.3021-18.2019,,,1.292,0.289,,,
,Tau,Tau,2019_betinaip_39,4,Behavior - ON - 100% Visual Contrast,10.1523/JNEUROSCI.3021-18.2019,,,1.281,0.266,,,
,Tau,Tau,2019_betinaip_39,5,Resting,10.1523/JNEUROSCI.3021-18.2019,,,1.319,0.322,,,
,Tau,Tau,2019_betinaip_39,6,Behavior - OFF - 3% Visual Contrast,10.1523/JNEUROSCI.3021-18.2019,,,1.193,0.259,,,
,Tau,Tau,2019_betinaip_39,7,Behavior - OFF - 12.5% Visual Contrast,10.1523/JNEUROSCI.3021-18.2019,,,1.3,0.303,,,
,Tau,Tau,2019_betinaip_39,8,Behavior - OFF - 50% Visual Contrast,10.1523/JNEUROSCI.3021-18.2019,,,1.238,0.246,,,
,Tau,Tau,2019_betinaip_39,9,Behavior - OFF - 100% Visual Contrast,10.1523/JNEUROSCI.3021-18.2019,,,1.285,0.296,,,
,Tau,Tau,2019_betinaip_39,10,Resting,10.1523/JNEUROSCI.3021-18.2019,,,1.358,0.301,,,
,Tau,Tau,2019_giapitzakis_81,1,Healthy,10.1002/mrm.27467,,,,,0.8,0.5,
,Tau,Tau,2019_giapitzakis_81,2,Healthy,10.1002/mrm.27467,,,,,1.1,0.7,
,Tau,Tau,2019_levin_202,1,Control (Young),10.1016/j.neuroimage.2019.116050,,,1.05,0.28,,,
,Tau,Tau,2019_levin_202,2,Middle-Aged,10.1016/j.neuroimage.2019.116050,,,1.01,0.38,,,
,Tau,Tau,2019_levin_202,3,Old-Middle Aged,10.1016/j.neuroimage.2019.116050,,,1.18,0.43,,,
,Tau,Tau,2019_levin_202,4,Aged,10.1016/j.neuroimage.2019.116050,,,0.9,0.36,,,
,Tau,Tau,2019_levin_202,5,Control (Young),10.1016/j.neuroimage.2019.116050,,,1.43,0.72,,,
,Tau,Tau,2019_levin_202,6,Middle-Aged,10.1016/j.neuroimage.2019.116050,,,1.4,0.5,,,
,Tau,Tau,2019_levin_202,7,Old-Middle Aged,10.1016/j.neuroimage.2019.116050,,,1.11,0.55,,,
,Tau,Tau,2019_levin_202,8,Aged,10.1016/j.neuroimage.2019.116050,,,1.04,0.5,,,
,Tau,Tau,2018_zarinabad_79,1,Medulloblastoma,10.1002/mrm.26837,,,,,6.3,4.1,
,Tau,Tau,2018_zarinabad_79,2,Pilocytic Astrocytoma,10.1002/mrm.26837,,,,,1.07,1.03,
,Tau,Tau,2018_zarinabad_79,3,Ependymoma,10.1002/mrm.26837,,,,,0.6,0.75,
,Tau,Tau,2016_koob_11,1,Premature Neonates,10.1371/journal.pone.0160990,,,0.068,0.027,,,
,Tau,Tau,2016_koob_11,2,Premature Neonates,10.1371/journal.pone.0160990,,,0.044,0.017,,,
,Tau,Tau,2016_koob_11,3,Infants - Control,10.1371/journal.pone.0160990,,,0.098,0.026,,,
,Tau,Tau,2016_koob_11,4,Infants - Control,10.1371/journal.pone.0160990,,,0.043,0.018,,,
,Tau,Tau,2019_marjanska_68,1,Alzheimer's disease,10.3233/JAD-180861,,,,,1.71,0.28,
,Tau,Tau,2019_marjanska_68,2,Alzheimer's disease,10.3233/JAD-180861,,,,,1.73,0.28,
,Tau,Tau,2019_marjanska_68,3,Control,10.3233/JAD-180861,,,,,1.83,0.287,
,Tau,Tau,2019_marjanska_68,4,Control,10.3233/JAD-180861,,,,,1.8,0.287,
,Tau,Tau,2019_strasser_29,1,Healthy,10.1016/j.euroneuro.2018.12.015,,,,,1.14,0.33,
,Tau,Tau,2019_strasser_29,2,Healthy,10.1016/j.euroneuro.2018.12.015,,,,,1.57,0.31,
,Tau,Tau,2018_povazan_79,1,Healthy,10.1002/mrm.26778,,,1.82,0.56,,,
,Tau,Tau,2018_povazan_79,2,Healthy,10.1002/mrm.26778,,,1.65,0.56,,,
,Tau,Tau,2018_povazan_79,3,Healthy,10.1002/mrm.26778,,,1.05,0.28,,,
,Tau,Tau,2018_povazan_79,4,Healthy,10.1002/mrm.26778,,,1.71,0.84,,,
,Tau,Tau,2018_povazan_79,5,Healthy,10.1002/mrm.26778,,,1.6,0.84,,,
,Tau,Tau,2018_povazan_79,6,Healthy,10.1002/mrm.26778,,,1.48,0.57,,,
,Tau,Tau,2018_povazan_79,7,Healthy,10.1002/mrm.26778,,,1.43,0.55,,,
,Tau,Tau,2019_wiegers_62,1,Control,10.1007/s00125-019-4862-9,,,,,1.74,0.5,
,Tau,Tau,2019_wiegers_62,2,Type 1 diabetes - Normal awareness of hypoglycaemia,10.1007/s00125-019-4862-9,,,,,1.98,0.54,
,Tau,Tau,2019_wiegers_62,3,Type 1 diabetes,10.1007/s00125-019-4862-9,,,,,1.63,0.39,
,Tau,Tau,2019_reid_45,1,Control,10.1093/schbul/sbx190,,,1.48,0.12,,,
,Tau,Tau,2019_reid_45,2,Schizophrenia,10.1093/schbul/sbx190,,,1.59,0.27,,,
,Tau,Tau,2020_lind_40,7,Aging,10.1523/JNEUROSCI.2883-19.2020,,,,,1.57,0.32,
,Tau,Tau,2020_lind_40,8,Aging,10.1523/JNEUROSCI.2883-19.2020,,,,,1.67,0.59,
,Tau,Tau,2020_lind_40,9,Aging,10.1523/JNEUROSCI.2883-19.2020,,,,,2.09,0.65,
,Tau,Tau,2020_dehghani_83,1,Protocol 1,10.1002/mrm.28066,,,,,0.66,0.12,
,Tau,Tau,2020_dehghani_83,2,Protocol 2,10.1002/mrm.28066,,,,,0.25,0.07,
,Tau,Tau,2020_dehghani_83,3,Protocol 3,10.1002/mrm.28066,,,,,0.6,0.15,
,Tau,Tau,2018_giapitzakis_79,1,Healthy,10.1002/mrm.26873,,,,,0.58,0.974,Med/Quartile --> Mean/Std Wan 2014
,Tau,Tau,2018_giapitzakis_79,2,Healthy,10.1002/mrm.26873,,,,,0.38,0.638,Med/Quartile --> Mean/Std Greco 2015
,Tau,Tau,2018_raschke_39,1,Healthy,10.3174/ajnr.A5457,0.2309,0.0347,4.104,0.62,,,Med/Quartile --> Mean/Std Wan 2014; Greco 2015
,Tau,Tau,2018_raschke_39,2,Healthy,10.3174/ajnr.A5457,0.2716,0.0429,6.779,1.561,,,Med/Quartile --> Mean/Std Wan 2014; Greco 2015
,Tau,Tau,2016_lopezkolkovsky_75,1,Healthy_Rodent,10.1002/mrm.25602,,,,,5.5,0.5,
,Glx,Glx,2021_bustillo_12,1,Control,10.3389/fpsyt.2021.660850,,,16.274,3.128,,,Cluster 01; Greco 2015
,Glx,Glx,2021_bustillo_12,2,Schizophrenia,10.3389/fpsyt.2021.660850,,,16.73,3.973,,,Cluster 01; Greco 2015
,Glx,Glx,2021_bustillo_12,3,Bipolar,10.3389/fpsyt.2021.660850,,,13.821,2.621,,,Cluster 01; Greco 2015
,NAA,NAA,2021_bustillo_12,4,Control,10.3389/fpsyt.2021.660850,,,27.121,2.381,,,Cluster 02; Wan 2014
,NAA,NAA,2021_bustillo_12,5,Schizophrenia,10.3389/fpsyt.2021.660850,,,28.161,2.482,,,Cluster 02; Greco 2015
,NAA,NAA,2021_bustillo_12,6,Bipolar,10.3389/fpsyt.2021.660850,,,26.035,1.187,,,Cluster 02; Wan 2014
,NAA,NAA,2021_bustillo_12,7,Control,10.3389/fpsyt.2021.660850,,,29.481,3.076,,,Cluster 03; Greco 2015
,NAA,NAA,2021_bustillo_12,8,Schizophrenia,10.3389/fpsyt.2021.660850,,,30.835,2.474,,,Cluster 03; Greco 2015
,NAA,NAA,2021_bustillo_12,9,Bipolar,10.3389/fpsyt.2021.660850,,,28.714,2.259,,,Cluster 03; Wan 2014
,NAA,NAA,2021_bustillo_12,10,Control,10.3389/fpsyt.2021.660850,,,31.105,2.306,,,Cluster 04; Wan 2014
,NAA,NAA,2021_bustillo_12,11,Schizophrenia,10.3389/fpsyt.2021.660850,,,31.511,1.759,,,Cluster 04; Wan 2014
,NAA,NAA,2021_bustillo_12,12,Bipolar,10.3389/fpsyt.2021.660850,,,30.023,1.672,,,Cluster 04; Greco 2015
,NAA,NAA,2021_bustillo_12,26,Schizophrenia,10.3389/fpsyt.2021.660850,,,29.974,1.794,,,Cluster 10; Wan 2014
,NAA,NAA,2021_bustillo_12,27,Schizophrenia,10.3389/fpsyt.2021.660850,,,32.562,2.741,,,Cluster 10; Wan 2014
,tCho,tCho,2021_bustillo_12,13,Control,10.3389/fpsyt.2021.660850,,,5.128,0.835,,,Cluster 05; Greco 2015
,tCho,tCho,2021_bustillo_12,14,Schizophrenia,10.3389/fpsyt.2021.660850,,,5.423,0.698,,,Cluster 05; Wan 2014
,tCho,tCho,2021_bustillo_12,15,Bipolar,10.3389/fpsyt.2021.660850,,,4.993,0.619,,,Cluster 05; Wan 2014
,tCho,tCho,2021_bustillo_12,16,Control,10.3389/fpsyt.2021.660850,,,4.778,0.542,,,Cluster 06; Wan 2014
,tCho,tCho,2021_bustillo_12,17,Schizophrenia,10.3389/fpsyt.2021.660850,,,5.167,0.433,,,Cluster 06; Wan 2014
,tCho,tCho,2021_bustillo_12,18,Bipolar,10.3389/fpsyt.2021.660850,,,4.789,0.424,,,Cluster 06; Wan 2014
,tCho,tCho,2021_bustillo_12,28,Schizophrenia,10.3389/fpsyt.2021.660850,,,5.286,0.569,,,Cluster 11; Greco 2015
,tCho,tCho,2021_bustillo_12,29,Schizophrenia,10.3389/fpsyt.2021.660850,,,5.67,0.917,,,Cluster 11; Wan 2014
,tCho,tCho,2021_bustillo_12,30,Schizophrenia,10.3389/fpsyt.2021.660850,,,4.086,0.664,,,Cluster 12; Greco 2015
,tCho,tCho,2021_bustillo_12,31,Schizophrenia,10.3389/fpsyt.2021.660850,,,4.651,1.235,,,Cluster 12; Greco 2015
,tCho,tCho,2021_bustillo_12,32,Schizophrenia,10.3389/fpsyt.2021.660850,,,5.484,0.961,,,Cluster 13; Greco 2015
,tCho,tCho,2021_bustillo_12,33,Schizophrenia,10.3389/fpsyt.2021.660850,,,6.147,0.8,,,Cluster 13; Wan 2014
,tCho,tCho,2021_bustillo_12,34,Schizophrenia,10.3389/fpsyt.2021.660850,,,5.207,0.546,,,Cluster 14; Wan 2014
,tCho,tCho,2021_bustillo_12,35,Schizophrenia,10.3389/fpsyt.2021.660850,,,5.453,0.444,,,Cluster 14; Wan 2014
,Inositol,Myo,2021_bustillo_12,19,Control,10.3389/fpsyt.2021.660850,,,16.823,3.03,,,Cluster 07; Wan 2014
,Inositol,Myo,2021_bustillo_12,20,Schizophrenia,10.3389/fpsyt.2021.660850,,,18.702,3.195,,,Cluster 07; Greco 2015
,Inositol,Myo,2021_bustillo_12,21,Bipolar,10.3389/fpsyt.2021.660850,,,16.216,1.713,,,Cluster 07; Wan 2014
,t-Cr,tCr,2021_bustillo_12,22,Schizophrenia,10.3389/fpsyt.2021.660850,,,23.412,2.3,,,Cluster 08; Wan 2014
,t-Cr,tCr,2021_bustillo_12,23,Schizophrenia,10.3389/fpsyt.2021.660850,,,24.408,1.175,,,Cluster 08; Wan 2014
,t-Cr,tCr,2021_bustillo_12,24,Schizophrenia,10.3389/fpsyt.2021.660850,,,27.721,2.98,,,Cluster 09; Wan 2014
,t-Cr,tCr,2021_bustillo_12,25,Schizophrenia,10.3389/fpsyt.2021.660850,,,28,3.046,,,Cluster 09; Wan 2014
,mI,Myo,2019_oeltzschner_73,1,Control,10.1016/j.neurobiolaging.2018.09.027,0.662,0.065,,,,,
,mI,Myo,2019_oeltzschner_73,2,MCI,10.1016/j.neurobiolaging.2018.09.027,0.75,0.065,,,,,
,mI,Myo,2019_oeltzschner_73,3,Control,10.1016/j.neurobiolaging.2018.09.027,0.685,0.065,,,,,
,mI,Myo,2019_oeltzschner_73,4,MCI,10.1016/j.neurobiolaging.2018.09.027,0.732,0.065,,,,,
,NAA,NAA,2019_oeltzschner_73,1,Control,10.1016/j.neurobiolaging.2018.09.027,1.44,0.101,,,,,
,NAA,NAA,2019_oeltzschner_73,2,MCI,10.1016/j.neurobiolaging.2018.09.027,1.374,0.097,,,,,
,NAA,NAA,2019_oeltzschner_73,3,Control,10.1016/j.neurobiolaging.2018.09.027,1.542,0.101,,,,,
,NAA,NAA,2019_oeltzschner_73,4,MCI,10.1016/j.neurobiolaging.2018.09.027,1.435,0.097,,,,,
,NAAG,NAAG,2019_oeltzschner_73,1,Control,10.1016/j.neurobiolaging.2018.09.027,0.209,0.054,,,,,
,NAAG,NAAG,2019_oeltzschner_73,2,MCI,10.1016/j.neurobiolaging.2018.09.027,0.197,0.047,,,,,
,NAAG,NAAG,2019_oeltzschner_73,3,Control,10.1016/j.neurobiolaging.2018.09.027,0.23,0.043,,,,,
,NAAG,NAAG,2019_oeltzschner_73,4,MCI,10.1016/j.neurobiolaging.2018.09.027,0.206,0.036,,,,,
,GSH,GSH,2019_oeltzschner_73,1,Control,10.1016/j.neurobiolaging.2018.09.027,0.215,0.04,,,,,
,GSH,GSH,2019_oeltzschner_73,2,MCI,10.1016/j.neurobiolaging.2018.09.027,0.208,0.036,,,,,
,GSH,GSH,2019_oeltzschner_73,3,Control,10.1016/j.neurobiolaging.2018.09.027,0.233,0.04,,,,,
,GSH,GSH,2019_oeltzschner_73,4,MCI,10.1016/j.neurobiolaging.2018.09.027,0.23,0.036,,,,,
,Glu,Glu,2019_oeltzschner_73,1,Control,10.1016/j.neurobiolaging.2018.09.027,1.418,0.09,,,,,
,Glu,Glu,2019_oeltzschner_73,2,MCI,10.1016/j.neurobiolaging.2018.09.027,1.34,0.083,,,,,
,Glu,Glu,2019_oeltzschner_73,3,Control,10.1016/j.neurobiolaging.2018.09.027,1.292,0.083,,,,,
,Glu,Glu,2019_oeltzschner_73,4,MCI,10.1016/j.neurobiolaging.2018.09.027,1.215,0.083,,,,,
,GABA,GABA,2019_oeltzschner_73,1,Control,10.1016/j.neurobiolaging.2018.09.027,0.418,0.065,,,,,
,GABA,GABA,2019_oeltzschner_73,2,MCI,10.1016/j.neurobiolaging.2018.09.027,0.343,0.061,,,,,
,GABA,GABA,2019_oeltzschner_73,3,Control,10.1016/j.neurobiolaging.2018.09.027,0.361,0.061,,,,,
,GABA,GABA,2019_oeltzschner_73,4,MCI,10.1016/j.neurobiolaging.2018.09.027,0.295,0.058,,,,,
,Cho,GPC,2019_shukla_41,13,Control,10.1002/hbm.24799,,,,,,,Taylor Series Ratio Approximation; No Partial Volume
,Cho,GPC,2019_shukla_41,14,Control,10.1002/hbm.24799,,,,,,,Taylor Series Ratio Approximation; No Partial Volume
,Cho,GPC,2019_shukla_41,15,MCI,10.1002/hbm.24799,,,,,,,Taylor Series Ratio Approximation; No Partial Volume
,Cho,GPC,2019_shukla_41,16,MCI,10.1002/hbm.24799,,,,,,,Taylor Series Ratio Approximation; No Partial Volume
,Cho,GPC,2019_shukla_41,17,Dementia,10.1002/hbm.24799,,,,,,,Taylor Series Ratio Approximation; No Partial Volume
,Cho,GPC,2019_shukla_41,18,Dementia,10.1002/hbm.24799,,,,,,,Taylor Series Ratio Approximation; No Partial Volume
,NAA,NAA,2019_shukla_41,13,Control,10.1002/hbm.24799,,,,,,,Taylor Series Ratio Approximation; No Partial Volume
,NAA,NAA,2019_shukla_41,14,Control,10.1002/hbm.24799,,,,,,,Taylor Series Ratio Approximation; No Partial Volume
,NAA,NAA,2019_shukla_41,15,MCI,10.1002/hbm.24799,,,,,,,Taylor Series Ratio Approximation; No Partial Volume
,NAA,NAA,2019_shukla_41,16,MCI,10.1002/hbm.24799,,,,,,,Taylor Series Ratio Approximation; No Partial Volume
,NAA,NAA,2019_shukla_41,17,Dementia,10.1002/hbm.24799,,,,,,,Taylor Series Ratio Approximation; No Partial Volume
,NAA,NAA,2019_shukla_41,18,Dementia,10.1002/hbm.24799,,,,,,,Taylor Series Ratio Approximation; No Partial Volume
,GSH,GSH,2019_shukla_41,1,Control,10.1002/hbm.24799,,,,,1.44,0.27,Partial Volume Corrected
,GSH,GSH,2019_shukla_41,2,Control,10.1002/hbm.24799,,,,,1.6,0.25,Partial Volume Corrected
,GSH,GSH,2019_shukla_41,3,MCI,10.1002/hbm.24799,,,,,1.27,0.3,Partial Volume Corrected
,GSH,GSH,2019_shukla_41,4,MCI,10.1002/hbm.24799,,,,,1.28,0.25,Partial Volume Corrected
,GSH,GSH,2019_shukla_41,5,Dementia,10.1002/hbm.24799,,,,,1.17,0.41,Partial Volume Corrected
,GSH,GSH,2019_shukla_41,6,Dementia,10.1002/hbm.24799,,,,,1.37,0.29,Partial Volume Corrected
,GSH,GSH,2019_shukla_41,7,Control,10.1002/hbm.24799,,,,,1.95,0.422,No Partial Volume
,GSH,GSH,2019_shukla_41,8,Control,10.1002/hbm.24799,,,,,2.367,0.405,No Partial Volume
,GSH,GSH,2019_shukla_41,9,MCI,10.1002/hbm.24799,,,,,1.622,0.387,No Partial Volume
,GSH,GSH,2019_shukla_41,10,MCI,10.1002/hbm.24799,,,,,1.771,0.344,No Partial Volume
,GSH,GSH,2019_shukla_41,11,Dementia,10.1002/hbm.24799,,,,,1.562,0.341,No Partial Volume
,GSH,GSH,2019_shukla_41,12,Dementia,10.1002/hbm.24799,,,,,1.779,0.436,No Partial Volume
,GSH,GSH,2019_shukla_41,13,Control,10.1002/hbm.24799,,,,,,,Taylor Series Ratio Approximation; No Partial Volume
,GSH,GSH,2019_shukla_41,14,Control,10.1002/hbm.24799,,,,,,,Taylor Series Ratio Approximation; No Partial Volume
,GSH,GSH,2019_shukla_41,15,MCI,10.1002/hbm.24799,,,,,,,Taylor Series Ratio Approximation; No Partial Volume
,GSH,GSH,2019_shukla_41,16,MCI,10.1002/hbm.24799,,,,,,,Taylor Series Ratio Approximation; No Partial Volume
,GSH,GSH,2019_shukla_41,17,Dementia,10.1002/hbm.24799,,,,,,,Taylor Series Ratio Approximation; No Partial Volume
,GSH,GSH,2019_shukla_41,18,Dementia,10.1002/hbm.24799,,,,,,,Taylor Series Ratio Approximation; No Partial Volume
,Asc,Asc,2018_mullins_5,1,Control,10.1002/acn3.530,0.79,0.03,,,,,
,Asc,Asc,2018_mullins_5,2,Aged,10.1002/acn3.530,0.8,0.06,,,,,
,Asc,Asc,2018_mullins_5,3,Dementia,10.1002/acn3.530,0.92,0.08,,,,,
,Lac,Lac,2018_mullins_5,1,Control,10.1002/acn3.530,0.17,0.01,,,,,
,Lac,Lac,2018_mullins_5,2,Aged,10.1002/acn3.530,0.17,0.01,,,,,
,Lac,Lac,2018_mullins_5,3,Dementia,10.1002/acn3.530,0.2,0.01,,,,,
,NAA,NAA,2018_mullins_5,1,Control,10.1002/acn3.530,1.56,0.12,,,,,
,NAA,NAA,2018_mullins_5,2,Aged,10.1002/acn3.530,1.5,0.11,,,,,
,NAA,NAA,2018_mullins_5,3,Dementia,10.1002/acn3.530,1.43,0.1,,,,,
,Glu,Glu,2018_mullins_5,1,Control,10.1002/acn3.530,1.57,0.07,,,,,
,Glu,Glu,2018_mullins_5,2,Aged,10.1002/acn3.530,1.48,0.05,,,,,
,Glu,Glu,2018_mullins_5,3,Dementia,10.1002/acn3.530,1.43,0.08,,,,,
,Gln,Gln,2018_mullins_5,1,Control,10.1002/acn3.530,0.34,0.01,,,,,
,Gln,Gln,2018_mullins_5,2,Aged,10.1002/acn3.530,0.37,0.02,,,,,
,Gln,Gln,2018_mullins_5,3,Dementia,10.1002/acn3.530,0.39,0.03,,,,,
,PCh,GPC,2018_mullins_5,1,Control,10.1002/acn3.530,0.21,0.01,,,,,
,PCh,GPC,2018_mullins_5,2,Aged,10.1002/acn3.530,0.2,0.01,,,,,
,PCh,GPC,2018_mullins_5,3,Dementia,10.1002/acn3.530,0.2,0.01,,,,,
,Myo,Myo,2018_mullins_5,1,Control,10.1002/acn3.530,1.03,0.04,,,,,
,Myo,Myo,2018_mullins_5,2,Aged,10.1002/acn3.530,0.99,0.04,,,,,
,Myo,Myo,2018_mullins_5,3,Dementia,10.1002/acn3.530,0.98,0.08,,,,,
,Scy,Scy,2018_mullins_5,5,Control,10.1002/acn3.530,0.05,0.01,,,,,
,Scy,Scy,2018_mullins_5,6,Aged,10.1002/acn3.530,0.07,0.01,,,,,
,Scy,Scy,2018_mullins_5,7,Dementia,10.1002/acn3.530,0.07,0.01,,,,,
,Glc,Glc,2018_mullins_5,1,Control,10.1002/acn3.530,0.31,0.02,,,,,
,Glc,Glc,2018_mullins_5,2,Aged,10.1002/acn3.530,0.36,0.03,,,,,
,Glc,Glc,2018_mullins_5,4,Dementia,10.1002/acn3.530,0.51,0.06,,,,,
,GSH,GSH,2018_mullins_5,1,Control,10.1002/acn3.530,0.26,0.01,,,,,
,GSH,GSH,2018_mullins_5,2,Aged,10.1002/acn3.530,0.26,0.02,,,,,
,GSH,GSH,2018_mullins_5,3,Dementia,10.1002/acn3.530,0.27,0.02,,,,,
,Ala,Ala,2018_mullins_5,8,Control,10.1002/acn3.530,0.14,0.01,,,,,
,Ala,Ala,2018_mullins_5,9,Aged,10.1002/acn3.530,0.15,0.01,,,,,
,Ala,Ala,2018_mullins_5,10,Dementia,10.1002/acn3.530,0.15,0.01,,,,,
,NAAG,NAAG,2018_mullins_5,11,Control,10.1002/acn3.530,0.16,0.03,,,,,
,NAAG,NAAG,2018_mullins_5,12,Aged,10.1002/acn3.530,0.17,0.02,,,,,
,NAAG,NAAG,2018_mullins_5,13,Dementia,10.1002/acn3.530,0.21,0.04,,,,,
,GABA,GABA,2018_mullins_5,14,Control,10.1002/acn3.530,0.19,0.01,,,,,
,GABA,GABA,2018_mullins_5,15,Aged,10.1002/acn3.530,0.2,0.01,,,,,
,GABA,GABA,2018_mullins_5,16,Dementia,10.1002/acn3.530,0.19,0.01,,,,,
,Glx,Glx,2021_schulte_762,1,Addiction - Cocaine use disorder,10.1016/j.neulet.2021.136146,1.48,0.27,,,,,
,Glx,Glx,2021_schulte_762,2,Addiction - Cocaine use disorder,10.1016/j.neulet.2021.136146,1.74,0.16,,,,,
,Glx,Glx,2021_schulte_762,3,Addiction - Cocaine use disorder,10.1016/j.neulet.2021.136146,1.67,0.17,,,,,
,Glx,Glx,2021_schulte_762,4,Addiction - Cocaine use disorder,10.1016/j.neulet.2021.136146,1.82,0.27,,,,,
,Glx,Glx,2021_smesny_228,1,First acute psychosis,10.1016/j.schres.2020.11.063,,,,,13.851,1.889,
,Glx,Glx,2021_smesny_228,2,Control,10.1016/j.schres.2020.11.063,,,,,13.822,1.338,
,Glx,Glx,2021_smesny_228,3,First acute psychosis,10.1016/j.schres.2020.11.063,,,,,14.903,1.522,
,Glx,Glx,2021_smesny_228,4,Control,10.1016/j.schres.2020.11.063,,,,,15.248,1.561,
,Glx,Glx,2021_smesny_228,5,First acute psychosis,10.1016/j.schres.2020.11.063,,,,,11.76,1.655,
,Glx,Glx,2021_smesny_228,6,Control,10.1016/j.schres.2020.11.063,,,,,12.407,1.509,
,Glx,Glx,2021_smesny_228,7,First acute psychosis,10.1016/j.schres.2020.11.063,,,,,12.12,2.614,
,Glx,Glx,2021_smesny_228,8,Control,10.1016/j.schres.2020.11.063,,,,,12.074,1.616,
,Glx,Glx,2021_smesny_228,9,First acute psychosis,10.1016/j.schres.2020.11.063,,,,,9.93,1.482,
,Glx,Glx,2021_smesny_228,10,Control,10.1016/j.schres.2020.11.063,,,,,10.599,0.906,
,Glx,Glx,2021_smesny_228,11,First acute psychosis,10.1016/j.schres.2020.11.063,,,,,9.958,1.591,
,Glx,Glx,2021_smesny_228,12,Control,10.1016/j.schres.2020.11.063,,,,,10.539,1.062,
,GSH,GSH,2021_smith_279,1,Control,10.1016/j.jad.2020.10.011,0.225,0.049,,,,,
,GSH,GSH,2021_smith_279,2,Depression,10.1016/j.jad.2020.10.011,0.226,0.043,,,,,
,GSH,GSH,2021_smith_279,3,Control,10.1016/j.jad.2020.10.011,0.217,0.052,,,,,
,GSH,GSH,2021_smith_279,4,Depression,10.1016/j.jad.2020.10.011,0.22,0.045,,,,,
,GSH,GSH,2021_smith_279,5,Depression,10.1016/j.jad.2020.10.011,0.224,0.036,,,,,
,GSH,GSH,2021_smith_279,6,Depression,10.1016/j.jad.2020.10.011,0.221,0.038,,,,,
,GABA,GABA,2021_smith_279,1,Control,10.1016/j.jad.2020.10.011,0.353,0.08,,,,,
,GABA,GABA,2021_smith_279,2,Depression,10.1016/j.jad.2020.10.011,0.334,0.087,,,,,
,GABA,GABA,2021_smith_279,3,Control,10.1016/j.jad.2020.10.011,0.337,0.081,,,,,
,GABA,GABA,2021_smith_279,4,Depression,10.1016/j.jad.2020.10.011,0.338,0.061,,,,,
,GABA,GABA,2021_smith_279,5,Depression,10.1016/j.jad.2020.10.011,0.319,0.079,,,,,
,GABA,GABA,2021_smith_279,6,Depression,10.1016/j.jad.2020.10.011,0.337,0.062,,,,,
,Glu,Glu,2021_smesny_228,1,First acute psychosis,10.1016/j.schres.2020.11.063,,,,,9.408,1.551,
,Glu,Glu,2021_smesny_228,2,Control,10.1016/j.schres.2020.11.063,,,,,9.68,0.841,
,Glu,Glu,2021_smesny_228,3,First acute psychosis,10.1016/j.schres.2020.11.063,,,,,9.757,1.44,
,Glu,Glu,2021_smesny_228,4,Control,10.1016/j.schres.2020.11.063,,,,,10.918,1.588,
,Glu,Glu,2021_smesny_228,5,First acute psychosis,10.1016/j.schres.2020.11.063,,,,,8.363,1.049,
,Glu,Glu,2021_smesny_228,6,Control,10.1016/j.schres.2020.11.063,,,,,8.915,0.744,
,Glu,Glu,2021_smesny_228,7,First acute psychosis,10.1016/j.schres.2020.11.063,,,,,8.658,1.107,
,Glu,Glu,2021_smesny_228,8,Control,10.1016/j.schres.2020.11.063,,,,,8.499,1.042,
,Glu,Glu,2021_smesny_228,9,First acute psychosis,10.1016/j.schres.2020.11.063,,,,,6.938,0.64,
,Glu,Glu,2021_smesny_228,10,Control,10.1016/j.schres.2020.11.063,,,,,7.121,0.717,
,Glu,Glu,2021_smesny_228,11,First acute psychosis,10.1016/j.schres.2020.11.063,,,,,6.777,0.904,
,Glu,Glu,2021_smesny_228,12,Control,10.1016/j.schres.2020.11.063,,,,,7.41,0.591,
,Glu,Glu,2021_smith_279,1,Control,10.1016/j.jad.2020.10.011,1.422,0.163,,,,,
,Glu,Glu,2021_smith_279,2,Depression,10.1016/j.jad.2020.10.011,1.405,0.154,,,,,
,Glu,Glu,2021_smith_279,3,Control,10.1016/j.jad.2020.10.011,1.323,0.09,,,,,
,Glu,Glu,2021_smith_279,4,Depression,10.1016/j.jad.2020.10.011,1.29,0.14,,,,,
,Glu,Glu,2021_smith_279,5,Depression,10.1016/j.jad.2020.10.011,1.318,0.148,,,,,
,Glu,Glu,2021_smith_279,6,Depression,10.1016/j.jad.2020.10.011,1.244,0.105,,,,,
,Myo,Myo,2021_smith_279,1,Control,10.1016/j.jad.2020.10.011,0.703,0.142,,,,,
,Myo,Myo,2021_smith_279,2,Depression,10.1016/j.jad.2020.10.011,0.785,0.126,,,,,
,Myo,Myo,2021_smith_279,3,Control,10.1016/j.jad.2020.10.011,0.67,0.043,,,,,
,Myo,Myo,2021_smith_279,4,Depression,10.1016/j.jad.2020.10.011,0.733,0.088,,,,,
,Myo,Myo,2021_smith_279,5,Depression,10.1016/j.jad.2020.10.011,0.702,0.065,,,,,
,Myo,Myo,2021_smith_279,6,Depression,10.1016/j.jad.2020.10.011,0.703,0.099,,,,,
,NAA,NAA,2021_smesny_228,1,First acute psychosis,10.1016/j.schres.2020.11.063,,,,,8.917,1.378,
,NAA,NAA,2021_smesny_228,2,Control,10.1016/j.schres.2020.11.063,,,,,9.854,0.974,
,NAA,NAA,2021_smesny_228,3,First acute psychosis,10.1016/j.schres.2020.11.063,,,,,9.48,1.756,
,NAA,NAA,2021_smesny_228,4,Control,10.1016/j.schres.2020.11.063,,,,,10.742,1.214,
,NAA,NAA,2021_smesny_228,5,First acute psychosis,10.1016/j.schres.2020.11.063,,,,,9.431,0.937,
,NAA,NAA,2021_smesny_228,6,Control,10.1016/j.schres.2020.11.063,,,,,10.025,0.492,
,NAA,NAA,2021_smesny_228,7,First acute psychosis,10.1016/j.schres.2020.11.063,,,,,9.395,1.121,
,NAA,NAA,2021_smesny_228,8,Control,10.1016/j.schres.2020.11.063,,,,,9.947,0.623,
,NAA,NAA,2021_smesny_228,9,First acute psychosis,10.1016/j.schres.2020.11.063,,,,,8.567,0.98,
,NAA,NAA,2021_smesny_228,10,Control,10.1016/j.schres.2020.11.063,,,,,9.117,0.544,
,NAA,NAA,2021_smesny_228,11,First acute psychosis,10.1016/j.schres.2020.11.063,,,,,8.462,1.053,
,NAA,NAA,2021_smesny_228,12,Control,10.1016/j.schres.2020.11.063,,,,,9.263,0.474,
,NAA,NAA,2021_smith_279,1,Control,10.1016/j.jad.2020.10.011,1.465,0.128,,,,,
,NAA,NAA,2021_smith_279,2,Depression,10.1016/j.jad.2020.10.011,1.411,0.218,,,,,
,NAA,NAA,2021_smith_279,3,Control,10.1016/j.jad.2020.10.011,1.51,0.159,,,,,
,NAA,NAA,2021_smith_279,4,Depression,10.1016/j.jad.2020.10.011,1.37,0.102,,,,,
,NAA,NAA,2021_smith_279,5,Depression,10.1016/j.jad.2020.10.011,1.369,0.112,,,,,
,NAA,NAA,2021_smith_279,6,Depression,10.1016/j.jad.2020.10.011,1.388,0.109,,,,,
,NAAG,NAAG,2021_smith_279,1,Control,10.1016/j.jad.2020.10.011,0.166,0.052,,,,,
,NAAG,NAAG,2021_smith_279,2,Depression,10.1016/j.jad.2020.10.011,0.15,0.097,,,,,
,NAAG,NAAG,2021_smith_279,3,Control,10.1016/j.jad.2020.10.011,0.225,0.098,,,,,
,NAAG,NAAG,2021_smith_279,4,Depression,10.1016/j.jad.2020.10.011,0.209,0.091,,,,,
,NAAG,NAAG,2021_smith_279,5,Depression,10.1016/j.jad.2020.10.011,0.118,0.097,,,,,
,NAAG,NAAG,2021_smith_279,6,Depression,10.1016/j.jad.2020.10.011,0.252,0.039,,,,,
,Cho,GPC,2021_song_422,1,Parkinson's disease - Pre-L-dopa,10.1016/j.jns.2021.117309,,,4.171,0.937,,,
,Cho,GPC,2021_song_422,2,Parkinson's disease - Post-L-dopa,10.1016/j.jns.2021.117309,,,4.247,0.831,,,
,Cho,GPC,2021_song_422,3,Control,10.1016/j.jns.2021.117309,,,3.793,0.484,,,
,tCho,GPC,2021_swanberg_34,1,Control,10.1002/nbm.4590,,,,,1.57,0.24,
,tCho,GPC,2021_swanberg_34,2,Multiple Sclerosis,10.1002/nbm.4590,,,,,1.57,0.19,
,tCho,GPC,2021_swanberg_34,3,Multiple Sclerosis - Relapsing-remitting,10.1002/nbm.4590,,,,,1.57,0.17,
,tCho,GPC,2021_swanberg_34,4,Multiple Sclerosis - Progressive,10.1002/nbm.4590,,,,,1.58,0.22,
,Cre,Cre,2021_song_422,1,Parkinson's disease - Pre-L-dopa,10.1016/j.jns.2021.117309,,,10.58,2.282,,,
,Cre,Cre,2021_song_422,2,Parkinson's disease - Post-L-dopa,10.1016/j.jns.2021.117309,,,10.58,1.92,,,
,Cre,Cre,2021_song_422,3,Control,10.1016/j.jns.2021.117309,,,8.986,0.905,,,
,GABA+,GABA,2021_song_422,1,Parkinson's disease - Pre-L-dopa,10.1016/j.jns.2021.117309,,,2.4,0.77,,,
,GABA+,GABA,2021_song_422,2,Parkinson's disease - Post-L-dopa,10.1016/j.jns.2021.117309,,,3.29,0.61,,,
,GABA+,GABA,2021_song_422,3,Control,10.1016/j.jns.2021.117309,,,3.5,0.79,,,
,GABA,GABA,2021_swanberg_34,5,Control,10.1002/nbm.4590,,,,,1.47,0.25,
,GABA,GABA,2021_swanberg_34,6,Multiple Sclerosis,10.1002/nbm.4590,,,,,1.39,0.26,
,GABA,GABA,2021_swanberg_34,7,Multiple Sclerosis - Relapsing-remitting,10.1002/nbm.4590,,,,,1.48,0.26,
,GABA,GABA,2021_swanberg_34,8,Multiple Sclerosis - Progressive,10.1002/nbm.4590,,,,,1.29,0.23,
,Gln,Gln,2021_swanberg_34,1,Control,10.1002/nbm.4590,,,,,4.84,0.42,
,Gln,Gln,2021_swanberg_34,2,Multiple Sclerosis,10.1002/nbm.4590,,,,,4.75,0.51,
,Gln,Gln,2021_swanberg_34,3,Multiple Sclerosis - Relapsing-remitting,10.1002/nbm.4590,,,,,4.77,0.62,
,Gln,Gln,2021_swanberg_34,4,Multiple Sclerosis - Progressive,10.1002/nbm.4590,,,,,4.71,0.35,
,Glu,Glu,2021_swanberg_34,1,Control,10.1002/nbm.4590,,,,,13.17,0.95,
,Glu,Glu,2021_swanberg_34,2,Multiple Sclerosis,10.1002/nbm.4590,,,,,12.7,0.99,
,Glu,Glu,2021_swanberg_34,3,Multiple Sclerosis - Relapsing-remitting,10.1002/nbm.4590,,,,,12.92,1.15,
,Glu,Glu,2021_swanberg_34,4,Multiple Sclerosis - Progressive,10.1002/nbm.4590,,,,,12.4,0.62,
,Glx,Glx,2021_swanberg_34,1,Control,10.1002/nbm.4590,,,,,16.89,1.09,
,Glx,Glx,2021_swanberg_34,2,Multiple Sclerosis,10.1002/nbm.4590,,,,,16.17,1.42,
,Glx,Glx,2021_swanberg_34,3,Multiple Sclerosis - Relapsing-remitting,10.1002/nbm.4590,,,,,16.53,1.69,
,Glx,Glx,2021_swanberg_34,4,Multiple Sclerosis - Progressive,10.1002/nbm.4590,,,,,15.69,0.77,
,GSH,GSH,2021_swanberg_34,9,Control,10.1002/nbm.4590,,,,,2.51,0.48,
,GSH,GSH,2021_swanberg_34,10,Multiple Sclerosis,10.1002/nbm.4590,,,,,2.4,0.46,
,GSH,GSH,2021_swanberg_34,11,Multiple Sclerosis - Relapsing-remitting,10.1002/nbm.4590,,,,,2.53,0.42,
,GSH,GSH,2021_swanberg_34,12,Multiple Sclerosis - Progressive,10.1002/nbm.4590,,,,,2.23,0.46,
,Myo,Myo,2021_swanberg_34,1,Control,10.1002/nbm.4590,,,,,6.2,0.78,
,Myo,Myo,2021_swanberg_34,2,Multiple Sclerosis,10.1002/nbm.4590,,,,,6.08,1.05,
,Myo,Myo,2021_swanberg_34,3,Multiple Sclerosis - Relapsing-remitting,10.1002/nbm.4590,,,,,6.22,1.04,
,Myo,Myo,2021_swanberg_34,4,Multiple Sclerosis - Progressive,10.1002/nbm.4590,,,,,5.9,1.07,
,NAA,NAA,2021_song_422,1,Parkinson's disease - Pre-L-dopa,10.1016/j.jns.2021.117309,,,15.373,1.079,,,
,NAA,NAA,2021_song_422,2,Parkinson's disease - Post-L-dopa,10.1016/j.jns.2021.117309,,,15.63,0.617,,,
,NAA,NAA,2021_song_422,3,Control,10.1016/j.jns.2021.117309,,,15.733,0.822,,,
,tNAA,tNAA,2021_swanberg_34,1,Control,10.1002/nbm.4590,,,,,14.25,1.06,
,tNAA,tNAA,2021_swanberg_34,2,Multiple Sclerosis,10.1002/nbm.4590,,,,,14.15,1,
,tNAA,tNAA,2021_swanberg_34,3,Multiple Sclerosis - Relapsing-remitting,10.1002/nbm.4590,,,,,14.33,1.13,
,tNAA,tNAA,2021_swanberg_34,4,Multiple Sclerosis - Progressive,10.1002/nbm.4590,,,,,13.9,0.75,
,Ala,Ala,2021_tackley_238,1,Multiple Sclerosis,10.1016/j.neuroimage.2021.118225,,,,,0.05,0.1,
,Ala,Ala,2021_tackley_238,2,Multiple Sclerosis,10.1016/j.neuroimage.2021.118225,,,,,0.18,0.4,
,Ala,Ala,2021_tackley_238,3,AQP4Ab-NMOSD,10.1016/j.neuroimage.2021.118225,,,,,0.16,0.1,
,Ala,Ala,2021_tackley_238,4,AQP4Ab-NMOSD,10.1016/j.neuroimage.2021.118225,,,,,0.1,0.1,
,Asc,Asc,2021_tackley_238,1,Multiple Sclerosis,10.1016/j.neuroimage.2021.118225,,,,,1.09,0.4,
,Asc,Asc,2021_tackley_238,2,Multiple Sclerosis,10.1016/j.neuroimage.2021.118225,,,,,0.92,0.5,
,Asc,Asc,2021_tackley_238,3,AQP4Ab-NMOSD,10.1016/j.neuroimage.2021.118225,,,,,1.18,0.7,
,Asc,Asc,2021_tackley_238,4,AQP4Ab-NMOSD,10.1016/j.neuroimage.2021.118225,,,,,1.39,0.3,
,Asp,Asp,2021_tackley_238,1,Multiple Sclerosis,10.1016/j.neuroimage.2021.118225,,,,,1.03,0.7,
,Asp,Asp,2021_tackley_238,2,Multiple Sclerosis,10.1016/j.neuroimage.2021.118225,,,,,0.7,0.5,
,Asp,Asp,2021_tackley_238,3,AQP4Ab-NMOSD,10.1016/j.neuroimage.2021.118225,,,,,0.68,0.3,
,Asp,Asp,2021_tackley_238,4,AQP4Ab-NMOSD,10.1016/j.neuroimage.2021.118225,,,,,0.97,0.4,
,GPC,GPC,2021_tackley_238,1,Multiple Sclerosis,10.1016/j.neuroimage.2021.118225,,,,,1.68,0.3,
,GPC,GPC,2021_tackley_238,2,Multiple Sclerosis,10.1016/j.neuroimage.2021.118225,,,,,1.63,0.4,
,GPC,GPC,2021_tackley_238,3,AQP4Ab-NMOSD,10.1016/j.neuroimage.2021.118225,,,,,1.47,0.3,
,GPC,GPC,2021_tackley_238,4,AQP4Ab-NMOSD,10.1016/j.neuroimage.2021.118225,,,,,1.63,0.2,
,PCho,PCho,2021_tackley_238,1,Multiple Sclerosis,10.1016/j.neuroimage.2021.118225,,,,,0.23,0.2,
,PCho,PCho,2021_tackley_238,2,Multiple Sclerosis,10.1016/j.neuroimage.2021.118225,,,,,0.16,0.2,
,PCho,PCho,2021_tackley_238,3,AQP4Ab-NMOSD,10.1016/j.neuroimage.2021.118225,,,,,0.06,0.1,
,PCho,PCho,2021_tackley_238,4,AQP4Ab-NMOSD,10.1016/j.neuroimage.2021.118225,,,,,0.04,0.1,
,tCho,tCho,2021_tackley_238,1,Multiple Sclerosis,10.1016/j.neuroimage.2021.118225,,,,,1.91,0.4,
,tCho,tCho,2021_tackley_238,2,Multiple Sclerosis,10.1016/j.neuroimage.2021.118225,,,,,1.78,0.3,
,tCho,tCho,2021_tackley_238,3,AQP4Ab-NMOSD,10.1016/j.neuroimage.2021.118225,,,,,1.54,0.3,
,tCho,tCho,2021_tackley_238,4,AQP4Ab-NMOSD,10.1016/j.neuroimage.2021.118225,,,,,1.67,0.2,
,Cre,Cre,2021_tackley_238,1,Multiple Sclerosis,10.1016/j.neuroimage.2021.118225,,,,,3.67,0.3,
,Cre,Cre,2021_tackley_238,2,Multiple Sclerosis,10.1016/j.neuroimage.2021.118225,,,,,3.69,0.3,
,Cre,Cre,2021_tackley_238,3,AQP4Ab-NMOSD,10.1016/j.neuroimage.2021.118225,,,,,4,0.4,
,Cre,Cre,2021_tackley_238,4,AQP4Ab-NMOSD,10.1016/j.neuroimage.2021.118225,,,,,3.63,0.1,
,PCr,PCr,2021_tackley_238,1,Multiple Sclerosis,10.1016/j.neuroimage.2021.118225,,,,,4.19,0.5,
,PCr,PCr,2021_tackley_238,2,Multiple Sclerosis,10.1016/j.neuroimage.2021.118225,,,,,4.11,0.5,
,PCr,PCr,2021_tackley_238,3,AQP4Ab-NMOSD,10.1016/j.neuroimage.2021.118225,,,,,3.5,0.7,
,PCr,PCr,2021_tackley_238,4,AQP4Ab-NMOSD,10.1016/j.neuroimage.2021.118225,,,,,3.98,0.3,
,tCr,tCr,2021_tackley_238,1,Multiple Sclerosis,10.1016/j.neuroimage.2021.118225,,,,,7.85,0.7,
,tCr,tCr,2021_tackley_238,2,Multiple Sclerosis,10.1016/j.neuroimage.2021.118225,,,,,7.79,0.7,
,tCr,tCr,2021_tackley_238,3,AQP4Ab-NMOSD,10.1016/j.neuroimage.2021.118225,,,,,7.5,0.7,
,tCr,tCr,2021_tackley_238,4,AQP4Ab-NMOSD,10.1016/j.neuroimage.2021.118225,,,,,7.61,0.3,
,GABA,GABA,2021_tackley_238,1,Multiple Sclerosis,10.1016/j.neuroimage.2021.118225,,,,,1.1,0.3,
,GABA,GABA,2021_tackley_238,2,Multiple Sclerosis,10.1016/j.neuroimage.2021.118225,,,,,1.13,0.2,
,GABA,GABA,2021_tackley_238,3,AQP4Ab-NMOSD,10.1016/j.neuroimage.2021.118225,,,,,1.17,0.3,
,GABA,GABA,2021_tackley_238,4,AQP4Ab-NMOSD,10.1016/j.neuroimage.2021.118225,,,,,1.28,0.3,
,Glc + Tau,Glc + Tau,2021_tackley_238,1,Multiple Sclerosis,10.1016/j.neuroimage.2021.118225,,,,,1.75,0.5,
,Glc + Tau,Glc + Tau,2021_tackley_238,2,Multiple Sclerosis,10.1016/j.neuroimage.2021.118225,,,,,1.55,0.4,
,Glc + Tau,Glc + Tau,2021_tackley_238,3,AQP4Ab-NMOSD,10.1016/j.neuroimage.2021.118225,,,,,2.15,0.4,
,Glc + Tau,Glc + Tau,2021_tackley_238,4,AQP4Ab-NMOSD,10.1016/j.neuroimage.2021.118225,,,,,1.72,0.1,
,Gln,Gln,2021_tackley_238,1,Multiple Sclerosis,10.1016/j.neuroimage.2021.118225,,,,,2.03,0.5,
,Gln,Gln,2021_tackley_238,2,Multiple Sclerosis,10.1016/j.neuroimage.2021.118225,,,,,1.73,0.6,
,Gln,Gln,2021_tackley_238,3,AQP4Ab-NMOSD,10.1016/j.neuroimage.2021.118225,,,,,2.04,0.3,
,Gln,Gln,2021_tackley_238,4,AQP4Ab-NMOSD,10.1016/j.neuroimage.2021.118225,,,,,1.76,0.2,
,Glu,Glu,2021_tackley_238,1,Multiple Sclerosis,10.1016/j.neuroimage.2021.118225,,,,,6,0.8,
,Glu,Glu,2021_tackley_238,2,Multiple Sclerosis,10.1016/j.neuroimage.2021.118225,,,,,6.61,1.1,
,Glu,Glu,2021_tackley_238,3,AQP4Ab-NMOSD,10.1016/j.neuroimage.2021.118225,,,,,5.56,1.2,
,Glu,Glu,2021_tackley_238,4,AQP4Ab-NMOSD,10.1016/j.neuroimage.2021.118225,,,,,5.69,0.7,
,Glx,Glx,2021_tackley_238,1,Multiple Sclerosis,10.1016/j.neuroimage.2021.118225,,,,,8.04,1.1,
,Glx,Glx,2021_tackley_238,2,Multiple Sclerosis,10.1016/j.neuroimage.2021.118225,,,,,8.34,1.5,
,Glx,Glx,2021_tackley_238,3,AQP4Ab-NMOSD,10.1016/j.neuroimage.2021.118225,,,,,7.6,1.5,
,Glx,Glx,2021_tackley_238,4,AQP4Ab-NMOSD,10.1016/j.neuroimage.2021.118225,,,,,7.45,0.8,
,GSH,GSH,2021_tackley_238,1,Multiple Sclerosis,10.1016/j.neuroimage.2021.118225,,,,,1.22,0.2,
,GSH,GSH,2021_tackley_238,2,Multiple Sclerosis,10.1016/j.neuroimage.2021.118225,,,,,1.18,0.2,
,GSH,GSH,2021_tackley_238,3,AQP4Ab-NMOSD,10.1016/j.neuroimage.2021.118225,,,,,1.14,0.1,
,GSH,GSH,2021_tackley_238,4,AQP4Ab-NMOSD,10.1016/j.neuroimage.2021.118225,,,,,1.23,0.2,
,Lac,Lac,2021_tackley_238,1,Multiple Sclerosis,10.1016/j.neuroimage.2021.118225,,,,,1.74,1.1,
,Lac,Lac,2021_tackley_238,2,Multiple Sclerosis,10.1016/j.neuroimage.2021.118225,,,,,1.02,0.5,
,Lac,Lac,2021_tackley_238,3,AQP4Ab-NMOSD,10.1016/j.neuroimage.2021.118225,,,,,1.53,0.6,
,Lac,Lac,2021_tackley_238,4,AQP4Ab-NMOSD,10.1016/j.neuroimage.2021.118225,,,,,1.44,0.3,
,Ins,Myo,2021_tackley_238,1,Multiple Sclerosis,10.1016/j.neuroimage.2021.118225,,,,,8.1,1.4,
,Ins,Myo,2021_tackley_238,2,Multiple Sclerosis,10.1016/j.neuroimage.2021.118225,,,,,7.28,1.2,
,Ins,Myo,2021_tackley_238,3,AQP4Ab-NMOSD,10.1016/j.neuroimage.2021.118225,,,,,7.86,1.3,
,Ins,Myo,2021_tackley_238,4,AQP4Ab-NMOSD,10.1016/j.neuroimage.2021.118225,,,,,7.23,0.8,
,NAA,NAA,2021_tackley_238,1,Multiple Sclerosis,10.1016/j.neuroimage.2021.118225,,,,,8.94,1.1,
,NAA,NAA,2021_tackley_238,2,Multiple Sclerosis,10.1016/j.neuroimage.2021.118225,,,,,9.69,0.9,
,NAA,NAA,2021_tackley_238,3,AQP4Ab-NMOSD,10.1016/j.neuroimage.2021.118225,,,,,7.9,2.2,
,NAA,NAA,2021_tackley_238,4,AQP4Ab-NMOSD,10.1016/j.neuroimage.2021.118225,,,,,8.69,0.7,
,tNAA,tNAA,2021_tackley_238,1,Multiple Sclerosis,10.1016/j.neuroimage.2021.118225,,,,,11.03,1.1,
,tNAA,tNAA,2021_tackley_238,2,Multiple Sclerosis,10.1016/j.neuroimage.2021.118225,,,,,12.24,0.9,
,tNAA,tNAA,2021_tackley_238,3,AQP4Ab-NMOSD,10.1016/j.neuroimage.2021.118225,,,,,9.4,2.3,
,tNAA,tNAA,2021_tackley_238,4,AQP4Ab-NMOSD,10.1016/j.neuroimage.2021.118225,,,,,10.89,0.4,
,NAAG,NAAG,2021_tackley_238,1,Multiple Sclerosis,10.1016/j.neuroimage.2021.118225,,,,,2.09,0.6,
,NAAG,NAAG,2021_tackley_238,2,Multiple Sclerosis,10.1016/j.neuroimage.2021.118225,,,,,2.55,0.9,
,NAAG,NAAG,2021_tackley_238,3,AQP4Ab-NMOSD,10.1016/j.neuroimage.2021.118225,,,,,1.5,0.2,
,NAAG,NAAG,2021_tackley_238,4,AQP4Ab-NMOSD,10.1016/j.neuroimage.2021.118225,,,,,2.19,0.3,
,PE,PE,2021_tackley_238,1,Multiple Sclerosis,10.1016/j.neuroimage.2021.118225,,,,,1.7,0.6,
,PE,PE,2021_tackley_238,2,Multiple Sclerosis,10.1016/j.neuroimage.2021.118225,,,,,2.09,0.5,
,PE,PE,2021_tackley_238,3,AQP4Ab-NMOSD,10.1016/j.neuroimage.2021.118225,,,,,1.95,0.4,
,PE,PE,2021_tackley_238,4,AQP4Ab-NMOSD,10.1016/j.neuroimage.2021.118225,,,,,2.11,0.1,
,Scy,Scy,2021_tackley_238,1,Multiple Sclerosis,10.1016/j.neuroimage.2021.118225,,,,,0.26,0.2,
,Scy,Scy,2021_tackley_238,2,Multiple Sclerosis,10.1016/j.neuroimage.2021.118225,,,,,0.28,0.2,
,Scy,Scy,2021_tackley_238,3,AQP4Ab-NMOSD,10.1016/j.neuroimage.2021.118225,,,,,0.18,0.09,
,Scy,Scy,2021_tackley_238,4,AQP4Ab-NMOSD,10.1016/j.neuroimage.2021.118225,,,,,0.19,0.095,
,Tau,Tau,2021_tackley_238,1,Multiple Sclerosis,10.1016/j.neuroimage.2021.118225,,,,,1.66,0.4,
,Tau,Tau,2021_tackley_238,2,Multiple Sclerosis,10.1016/j.neuroimage.2021.118225,,,,,1.54,0.4,
,Tau,Tau,2021_tackley_238,3,AQP4Ab-NMOSD,10.1016/j.neuroimage.2021.118225,,,,,1.84,0.2,
,Tau,Tau,2021_tackley_238,4,AQP4Ab-NMOSD,10.1016/j.neuroimage.2021.118225,,,,,1.72,0.1,
,Cho,GPC,2020_sendur_31,1,Depression - Before Treatment,10.5080/u22978,1.338,0.181,,,,,
,Cho,GPC,2020_sendur_31,2,Depression - Before Treatment,10.5080/u22978,1.355,0.179,,,,,
,Cho,GPC,2020_sendur_31,3,Depression - After Treatment,10.5080/u22978,1.313,0.147,,,,,
,Cho,GPC,2020_sendur_31,4,Depression - After Treatment,10.5080/u22978,1.304,0.173,,,,,
,Cho,GPC,2020_sendur_31,5,Control,10.5080/u22978,1.351,0.248,,,,,
,Cho,GPC,2020_sendur_31,6,Control,10.5080/u22978,1.316,0.144,,,,,
,NAA,NAA,2020_sendur_31,1,Depression - Before Treatment,10.5080/u22978,2.027,0.181,,,,,
,NAA,NAA,2020_sendur_31,2,Depression - Before Treatment,10.5080/u22978,2.063,0.216,,,,,
,NAA,NAA,2020_sendur_31,3,Depression - After Treatment,10.5080/u22978,2.047,0.267,,,,,
,NAA,NAA,2020_sendur_31,4,Depression - After Treatment,10.5080/u22978,2.061,0.196,,,,,
,NAA,NAA,2020_sendur_31,5,Control,10.5080/u22978,1.983,0.337,,,,,
,NAA,NAA,2020_sendur_31,6,Control,10.5080/u22978,2.059,0.208,,,,,
,Glu,Glu,2021_legarreta_163,1,Chronic Pain,10.1016/j.neures.2020.03.002,1.12,0.02,,,,,
,Glu,Glu,2021_legarreta_163,2,No Chronic Pain,10.1016/j.neures.2020.03.002,1.14,0.04,,,,,
,Gln,Gln,2021_legarreta_163,1,Chronic Pain,10.1016/j.neures.2020.03.002,0.26,0.01,,,,,
,Gln,Gln,2021_legarreta_163,2,No Chronic Pain,10.1016/j.neures.2020.03.002,0.24,0.02,,,,,
,GABA,GABA,2021_legarreta_163,1,Chronic Pain,10.1016/j.neures.2020.03.002,0.17,0.001,,,,,
,GABA,GABA,2021_legarreta_163,2,No Chronic Pain,10.1016/j.neures.2020.03.002,0.18,0.02,,,,,
,tCr,tCr,2021_lind_159,1,Control,10.1111/jnc.15456,,,6.97,0.33,,,
,tCr,tCr,2021_lind_159,2,Aged,10.1111/jnc.15456,,,7.17,0.7,,,
,tCr,tCr,2021_lind_159,3,Aged,10.1111/jnc.15456,,,7.6,0.5,,,
,tCho,tCho,2021_lind_159,1,Aging,10.1111/jnc.15456,,,1.44,0.16,,,
,tCho,tCho,2021_lind_159,2,Aging,10.1111/jnc.15456,,,1.63,0.23,,,
,tCho,tCho,2021_lind_159,3,Aging,10.1111/jnc.15456,,,1.71,0.19,,,
,ml,Myo,2021_lind_159,4,Aging,10.1111/jnc.15456,,,5.68,0.6,,,
,ml,Myo,2021_lind_159,5,Aging,10.1111/jnc.15456,,,6.69,1.02,,,
,ml,Myo,2021_lind_159,6,Aging,10.1111/jnc.15456,,,7.45,0.94,,,
,ml,Myo,2021_lind_159,7,Aging,10.1111/jnc.15456,,,4.43,0.69,,,
,ml,Myo,2021_lind_159,8,Aging,10.1111/jnc.15456,,,4.74,0.48,,,
,ml,Myo,2021_lind_159,9,Aging,10.1111/jnc.15456,,,5.25,1.1,,,
,Glu,Glu,2021_wang_12,1,Alcohol dependency - Withdrawal,10.3389/fpsyt.2021.656468,,,10.2,1.14,,,
,Glu,Glu,2021_wang_12,2,Alcohol dependency - Withdrawal,10.3389/fpsyt.2021.656468,,,9.8,0.63,,,
,Glu,Glu,2021_wang_12,3,Control,10.3389/fpsyt.2021.656468,,,9.56,0.67,,,
,GABA,GABA,2021_wang_12,1,Alcohol dependency - Withdrawal,10.3389/fpsyt.2021.656468,,,2.71,0.77,,,
,GABA,GABA,2021_wang_12,2,Alcohol dependency - Withdrawal,10.3389/fpsyt.2021.656468,,,2.55,0.49,,,
,GABA,GABA,2021_wang_12,3,Control,10.3389/fpsyt.2021.656468,,,2.7,0.58,,,
,tCr,tCr,2021_wang_12,1,Alcohol dependency - Withdrawal,10.3389/fpsyt.2021.656468,,,12.23,1.21,,,
,tCr,tCr,2021_wang_12,2,Alcohol dependency - Withdrawal,10.3389/fpsyt.2021.656468,,,12.2,0.82,,,
,tCr,tCr,2021_wang_12,3,Control,10.3389/fpsyt.2021.656468,,,11.91,1.14,,,
,Glx,Glx,2021_wang_12,1,Alcohol dependency - Withdrawal,10.3389/fpsyt.2021.656468,,,12.53,1.19,,,
,Glx,Glx,2021_wang_12,2,Alcohol dependency - Withdrawal,10.3389/fpsyt.2021.656468,,,12.31,0.84,,,
,Glx,Glx,2021_wang_12,3,Control,10.3389/fpsyt.2021.656468,,,11.86,0.94,,,
,tNAA,tNAA,2021_wang_12,1,Alcohol dependency - Withdrawal,10.3389/fpsyt.2021.656468,,,13.41,0.75,,,
,tNAA,tNAA,2021_wang_12,2,Alcohol dependency - Withdrawal,10.3389/fpsyt.2021.656468,,,17.09,0.91,,,
,tNAA,tNAA,2021_wang_12,3,Control,10.3389/fpsyt.2021.656468,,,14.07,0.64,,,
,Cho,GPC,2021_wang_99,1,Sleep-related hypermotor epilepsy,10.1002/jnr.24866,,,,,1.34,0.15,
,Cho,GPC,2021_wang_99,4,Control,10.1002/jnr.24866,,,,,1.39,0.16,
,Cho,GPC,2021_wang_99,8,Sleep-related hypermotor epilepsy,10.1002/jnr.24866,,,,,1.35,0.16,
,Cho,GPC,2021_wang_99,11,Control,10.1002/jnr.24866,,,,,1.36,0.14,
,Cre,Cre,2021_wang_99,1,Sleep-related hypermotor epilepsy,10.1002/jnr.24866,,,,,5.69,0.51,
,Cre,Cre,2021_wang_99,4,Control,10.1002/jnr.24866,,,,,5.74,0.48,
,Cre,Cre,2021_wang_99,8,Sleep-related hypermotor epilepsy,10.1002/jnr.24866,,,,,5.82,0.45,
,Cre,Cre,2021_wang_99,11,Control,10.1002/jnr.24866,,,,,5.75,0.49,
,GABA,GABA,2021_wang_99,3,Sleep-related hypermotor epilepsy,10.1002/jnr.24866,,,,,1.4,0.26,
,GABA,GABA,2021_wang_99,7,Control,10.1002/jnr.24866,,,,,1.32,0.22,
,GABA,GABA,2021_wang_99,10,Sleep-related hypermotor epilepsy,10.1002/jnr.24866,,,,,1.39,0.3,
,GABA,GABA,2021_wang_99,13,Control,10.1002/jnr.24866,,,,,1.35,0.22,
,Glx,Glx,2021_wang_99,2,Sleep-related hypermotor epilepsy,10.1002/jnr.24866,,,,,9.87,1.43,
,Glx,Glx,2021_wang_99,6,Control,10.1002/jnr.24866,,,,,10.24,1.62,
,Glx,Glx,2021_wang_99,8,Sleep-related hypermotor epilepsy,10.1002/jnr.24866,,,,,10.57,1.6,
,Glx,Glx,2021_wang_99,12,Control,10.1002/jnr.24866,,,,,10.05,1.31,
,GSH,GSH,2021_wang_99,2,Sleep-related hypermotor epilepsy,10.1002/jnr.24866,,,,,2.43,0.43,
,GSH,GSH,2021_wang_99,5,Control,10.1002/jnr.24866,,,,,2.42,0.45,
,GSH,GSH,2021_wang_99,9,Sleep-related hypermotor epilepsy,10.1002/jnr.24866,,,,,2.52,0.5,
,GSH,GSH,2021_wang_99,12,Control,10.1002/jnr.24866,,,,,2.23,0.37,
,Myo,Myo,2021_wang_99,2,Sleep-related hypermotor epilepsy,10.1002/jnr.24866,,,,,4.6,0.65,
,Myo,Myo,2021_wang_99,5,Control,10.1002/jnr.24866,,,,,4.92,0.68,
,Myo,Myo,2021_wang_99,8,Sleep-related hypermotor epilepsy,10.1002/jnr.24866,,,,,4.66,0.82,
,Myo,Myo,2021_wang_99,11,Control,10.1002/jnr.24866,,,,,4.93,0.71,
,NAA,NAA,2021_wang_99,1,Sleep-related hypermotor epilepsy,10.1002/jnr.24866,,,,,7.2,0.64,
,NAA,NAA,2021_wang_99,4,Control,10.1002/jnr.24866,,,,,7.63,0.67,
,NAA,NAA,2021_wang_99,8,Sleep-related hypermotor epilepsy,10.1002/jnr.24866,,,,,7.18,0.72,
,NAA,NAA,2021_wang_99,11,Control,10.1002/jnr.24866,,,,,7.28,0.9,
,NAA,NAA,2021_kirov_98,1,Healthy,10.1016/j.neurobiolaging.2020.10.024,,,,,11.874,1.326,
,NAA,NAA,2021_kirov_98,2,Healthy,10.1016/j.neurobiolaging.2020.10.024,,,,,12.111,1.351,
,NAA,NAA,2021_kirov_98,3,Healthy,10.1016/j.neurobiolaging.2020.10.024,,,,,11.734,2.154,
,NAA,NAA,2021_kirov_98,4,Healthy,10.1016/j.neurobiolaging.2020.10.024,,,,,9.433,2.138,
,NAA,NAA,2021_kirov_98,5,Healthy,10.1016/j.neurobiolaging.2020.10.024,,,,,9.455,1.647,
,NAA,NAA,2021_kirov_98,6,Healthy,10.1016/j.neurobiolaging.2020.10.024,,,,,8.252,1.889,
,NAA,NAA,2021_kirov_98,7,Healthy,10.1016/j.neurobiolaging.2020.10.024,,,,,9.293,2.043,
,NAA,NAA,2021_kirov_98,8,Healthy,10.1016/j.neurobiolaging.2020.10.024,,,,,12.822,2.047,
,NAA,NAA,2021_kirov_98,9,Healthy,10.1016/j.neurobiolaging.2020.10.024,,,,,11.897,1.501,
,NAA,NAA,2021_kirov_98,10,Healthy,10.1016/j.neurobiolaging.2020.10.024,,,,,10.979,2.421,
,NAA,NAA,2021_kirov_98,11,Healthy,10.1016/j.neurobiolaging.2020.10.024,,,,,10.004,1.023,
,NAA,NAA,2021_kirov_98,12,Healthy,10.1016/j.neurobiolaging.2020.10.024,,,,,10.177,2.5,
,NAA,NAA,2021_kirov_98,13,Healthy,10.1016/j.neurobiolaging.2020.10.024,,,,,9.383,2.249,
,NAA,NAA,2021_kirov_98,14,Healthy,10.1016/j.neurobiolaging.2020.10.024,,,,,10.717,1.39,
,NAA,NAA,2021_xia_18,1,Lifelong premature ejuaculation,10.1016/j.jsxm.2020.11.014,1.63,0.18,12.52,2.12,,,
,NAA,NAA,2021_xia_18,2,Lifelong premature ejuaculation,10.1016/j.jsxm.2020.11.014,1.54,0.26,12.12,1.92,,,
,NAA,NAA,2021_xia_18,3,Lifelong premature ejuaculation,10.1016/j.jsxm.2020.11.014,1.69,0.13,12.83,2.32,,,
,NAA,NAA,2021_xia_18,4,Control,10.1016/j.jsxm.2020.11.014,1.62,0.25,12.71,1.93,,,
,NAA,NAA,2021_xia_18,5,Control,10.1016/j.jsxm.2020.11.014,1.64,0.18,12.31,2.23,,,
,NAA,NAA,2021_xia_18,6,Control,10.1016/j.jsxm.2020.11.014,1.61,0.35,13.05,2.45,,,
,Cho,GPC,2021_xia_18,1,Lifelong premature ejuaculation,10.1016/j.jsxm.2020.11.014,0.35,0.06,2.65,0.77,,,
,Cho,GPC,2021_xia_18,2,Lifelong premature ejuaculation,10.1016/j.jsxm.2020.11.014,0.32,0.05,2.25,0.92,,,
,Cho,GPC,2021_xia_18,3,Lifelong premature ejuaculation,10.1016/j.jsxm.2020.11.014,0.36,0.07,2.87,0.65,,,
,Cho,GPC,2021_xia_18,4,Control,10.1016/j.jsxm.2020.11.014,0.32,0.04,2.54,0.92,,,
,Cho,GPC,2021_xia_18,5,Control,10.1016/j.jsxm.2020.11.014,0.35,0.06,2.61,0.74,,,
,Cho,GPC,2021_xia_18,6,Control,10.1016/j.jsxm.2020.11.014,0.33,0.08,2.43,0.95,,,
,Cre,Cre,2021_xia_18,1,Lifelong premature ejuaculation,10.1016/j.jsxm.2020.11.014,,,7.64,0.67,,,
,Cre,Cre,2021_xia_18,2,Lifelong premature ejuaculation,10.1016/j.jsxm.2020.11.014,,,7.84,0.73,,,
,Cre,Cre,2021_xia_18,3,Lifelong premature ejuaculation,10.1016/j.jsxm.2020.11.014,,,7.56,0.54,,,
,Cre,Cre,2021_xia_18,4,Control,10.1016/j.jsxm.2020.11.014,,,7.86,0.78,,,
,Cre,Cre,2021_xia_18,5,Control,10.1016/j.jsxm.2020.11.014,,,7.56,0.63,,,
,Cre,Cre,2021_xia_18,6,Control,10.1016/j.jsxm.2020.11.014,,,7.92,0.82,,,
,Glu,Glu,2021_xia_18,1,Lifelong premature ejuaculation,10.1016/j.jsxm.2020.11.014,2.51,0.42,19.21,3.56,,,
,Glu,Glu,2021_xia_18,2,Lifelong premature ejuaculation,10.1016/j.jsxm.2020.11.014,2.57,0.51,20.13,4.03,,,
,Glu,Glu,2021_xia_18,3,Lifelong premature ejuaculation,10.1016/j.jsxm.2020.11.014,2.49,0.38,19.01,3.78,,,
,Glu,Glu,2021_xia_18,4,Control,10.1016/j.jsxm.2020.11.014,1.93,0.31,15.15,2.21,,,
,Glu,Glu,2021_xia_18,5,Control,10.1016/j.jsxm.2020.11.014,2.01,0.24,16.32,3.05,,,
,Glu,Glu,2021_xia_18,6,Control,10.1016/j.jsxm.2020.11.014,1.91,0.29,15.02,3.49,,,
,Cho,GPC,2021_yang_82,1,Control,10.1016/j.neuro.2020.11.002,0.92,0.12,,,,,
,Cho,GPC,2021_yang_82,2,CO poisoning,10.1016/j.neuro.2020.11.002,1.04,0.16,,,,,
,Cho,GPC,2021_yang_82,3,Control,10.1016/j.neuro.2020.11.002,0.53,0.06,,,,,
,Cho,GPC,2021_yang_82,4,CO poisoning,10.1016/j.neuro.2020.11.002,0.59,0.07,,,,,
,Myo,Myo,2021_yang_82,1,Control,10.1016/j.neuro.2020.11.002,0.65,0.07,,,,,
,Myo,Myo,2021_yang_82,2,CO poisoning,10.1016/j.neuro.2020.11.002,0.66,0.07,,,,,
,Myo,Myo,2021_yang_82,3,Control,10.1016/j.neuro.2020.11.002,0.57,0.03,,,,,
,Myo,Myo,2021_yang_82,4,CO poisoning,10.1016/j.neuro.2020.11.002,0.57,0.04,,,,,
,NAA,NAA,2021_yang_82,1,Control,10.1016/j.neuro.2020.11.002,1.75,0.16,,,,,
,NAA,NAA,2021_yang_82,2,CO poisoning,10.1016/j.neuro.2020.11.002,1.48,0.22,,,,,
,NAA,NAA,2021_yang_82,3,Control,10.1016/j.neuro.2020.11.002,1.6,0.11,,,,,
,NAA,NAA,2021_yang_82,4,CO poisoning,10.1016/j.neuro.2020.11.002,1.45,0.15,,,,,
,Cho,GPC,2021_zhang_30,1,Mood disorder - Bipolar offspring,10.1007/s00787-020-01483-x,,,,,1.574,0.119,
,Cho,GPC,2021_zhang_30,2,Control - Bipolar offspring,10.1007/s00787-020-01483-x,,,,,1.842,0.297,
,Cho,GPC,2021_zhang_30,3,Mood disorder - Bipolar offspring,10.1007/s00787-020-01483-x,,,,,1.757,0.208,
,Cho,GPC,2021_zhang_30,4,Control - Bipolar offspring,10.1007/s00787-020-01483-x,,,,,1.906,0.178,
,Cho,GPC,2021_zhang_30,5,Mood disorder - Bipolar offspring,10.1007/s00787-020-01483-x,,,,,1.915,0.374,
,Cho,GPC,2021_zhang_30,6,Control - Bipolar offspring,10.1007/s00787-020-01483-x,,,,,1.94,0.224,
,PCr + Cr,tCr,2021_zhang_30,1,Mood disorder - Bipolar offspring,10.1007/s00787-020-01483-x,,,,,6.149,0.712,
,PCr + Cr,tCr,2021_zhang_30,2,Control - Bipolar offspring,10.1007/s00787-020-01483-x,,,,,7.04,0.802,
,PCr + Cr,tCr,2021_zhang_30,3,Mood disorder - Bipolar offspring,10.1007/s00787-020-01483-x,,,,,6.789,0.864,
,PCr + Cr,tCr,2021_zhang_30,4,Control - Bipolar offspring,10.1007/s00787-020-01483-x,,,,,7.444,1.013,
,PCr + Cr,tCr,2021_zhang_30,5,Mood disorder - Bipolar offspring,10.1007/s00787-020-01483-x,,,,,6.766,1.095,
,PCr + Cr,tCr,2021_zhang_30,6,Control - Bipolar offspring,10.1007/s00787-020-01483-x,,,,,7.09,0.87,
,Glu,Glu,2021_zhang_30,1,Mood disorder - Bipolar offspring,10.1007/s00787-020-01483-x,,,,,5.436,0.683,
,Glu,Glu,2021_zhang_30,2,Control - Bipolar offspring,10.1007/s00787-020-01483-x,,,,,5.911,0.445,
,Glu,Glu,2021_zhang_30,3,Mood disorder - Bipolar offspring,10.1007/s00787-020-01483-x,,,,,5.985,1.072,
,Glu,Glu,2021_zhang_30,4,Control - Bipolar offspring,10.1007/s00787-020-01483-x,,,,,5.955,0.804,
,Glu,Glu,2021_zhang_30,5,Mood disorder - Bipolar offspring,10.1007/s00787-020-01483-x,,,,,5.498,0.845,
,Glu,Glu,2021_zhang_30,6,Control - Bipolar offspring,10.1007/s00787-020-01483-x,,,,,5.97,1.02,
,Myo,Myo,2021_zhang_30,1,Mood disorder - Bipolar offspring,10.1007/s00787-020-01483-x,,,,,4.307,0.594,
,Myo,Myo,2021_zhang_30,2,Control - Bipolar offspring,10.1007/s00787-020-01483-x,,,,,5.079,0.802,
,Myo,Myo,2021_zhang_30,3,Mood disorder - Bipolar offspring,10.1007/s00787-020-01483-x,,,,,5.27,0.924,
,Myo,Myo,2021_zhang_30,4,Control - Bipolar offspring,10.1007/s00787-020-01483-x,,,,,5.241,0.774,
,Myo,Myo,2021_zhang_30,5,Mood disorder - Bipolar offspring,10.1007/s00787-020-01483-x,,,,,5.498,1.069,
,Myo,Myo,2021_zhang_30,6,Control - Bipolar offspring,10.1007/s00787-020-01483-x,,,,,5.896,0.721,
,NAA,NAA,2021_zhang_30,1,Mood disorder - Bipolar offspring,10.1007/s00787-020-01483-x,,,,,8.139,0.95,
,NAA,NAA,2021_zhang_30,2,Control - Bipolar offspring,10.1007/s00787-020-01483-x,,,,,8.97,0.862,
,NAA,NAA,2021_zhang_30,3,Mood disorder - Bipolar offspring,10.1007/s00787-020-01483-x,,,,,9.35,1.37,
,NAA,NAA,2021_zhang_30,4,Control - Bipolar offspring,10.1007/s00787-020-01483-x,,,,,9.797,1.042,
,NAA,NAA,2021_zhang_30,5,Mood disorder - Bipolar offspring,10.1007/s00787-020-01483-x,,,,,6.318,0.946,
,NAA,NAA,2021_zhang_30,6,Control - Bipolar offspring,10.1007/s00787-020-01483-x,,,,,7.04,1.268,
,GPC+PC,tCho,2021_jabbari-zadeh_289,1,Healthy Control,10.1016/j.jad.2021.04.011,,,,,2.28,0.35,
,GPC+PC,tCho,2021_jabbari-zadeh_289,2,Healthy Control,10.1016/j.jad.2021.04.011,,,,,2.48,0.4,
,GPC+PC,tCho,2021_jabbari-zadeh_289,3,Healthy Control,10.1016/j.jad.2021.04.011,,,,,1.57,0.37,
,GPC+PC,tCho,2021_jabbari-zadeh_289,4,Healthy Control,10.1016/j.jad.2021.04.011,,,,,2.43,0.41,
,GPC+PC,tCho,2021_jabbari-zadeh_289,5,Bipolar Disorder,10.1016/j.jad.2021.04.011,,,,,2.44,0.47,
,GPC+PC,tCho,2021_jabbari-zadeh_289,6,Bipolar Disorder,10.1016/j.jad.2021.04.011,,,,,2.51,0.43,
,GPC+PC,tCho,2021_jabbari-zadeh_289,7,Bipolar Disorder,10.1016/j.jad.2021.04.011,,,,,2.24,0.6,
,GPC+PC,tCho,2021_jabbari-zadeh_289,8,Bipolar Disorder,10.1016/j.jad.2021.04.011,,,,,3.16,0.39,
,GPC+PC,tCho,2021_jabbari-zadeh_289,9,Bipolar Disorder,10.1016/j.jad.2021.04.011,,,,,2.43,0.42,
,GPC+PC,tCho,2021_jabbari-zadeh_289,10,Bipolar Disorder,10.1016/j.jad.2021.04.011,,,,,2.74,0.49,
,GPC+PC,tCho,2021_jabbari-zadeh_289,11,Bipolar Disorder,10.1016/j.jad.2021.04.011,,,,,1.91,0.47,
,GPC+PC,tCho,2021_jabbari-zadeh_289,12,Bipolar Disorder,10.1016/j.jad.2021.04.011,,,,,2.64,0.36,
,NAA,NAA,2021_jabbari-zadeh_289,1,Healthy Control,10.1016/j.jad.2021.04.011,,,,,10.44,1.25,
,NAA,NAA,2021_jabbari-zadeh_289,2,Healthy Control,10.1016/j.jad.2021.04.011,,,,,12.5,1.72,
,NAA,NAA,2021_jabbari-zadeh_289,3,Healthy Control,10.1016/j.jad.2021.04.011,,,,,6.38,1.24,
,NAA,NAA,2021_jabbari-zadeh_289,4,Healthy Control,10.1016/j.jad.2021.04.011,,,,,11.86,1.99,
,NAA,NAA,2021_jabbari-zadeh_289,5,Bipolar Disorder,10.1016/j.jad.2021.04.011,,,,,10.75,1.78,
,NAA,NAA,2021_jabbari-zadeh_289,6,Bipolar Disorder,10.1016/j.jad.2021.04.011,,,,,12.4,2.5,
,NAA,NAA,2021_jabbari-zadeh_289,7,Bipolar Disorder,10.1016/j.jad.2021.04.011,,,,,7.76,1.71,
,NAA,NAA,2021_jabbari-zadeh_289,8,Bipolar Disorder,10.1016/j.jad.2021.04.011,,,,,12.63,2.62,
,NAA,NAA,2021_jabbari-zadeh_289,9,Bipolar Disorder,10.1016/j.jad.2021.04.011,,,,,10.77,1.66,
,NAA,NAA,2021_jabbari-zadeh_289,10,Bipolar Disorder,10.1016/j.jad.2021.04.011,,,,,13.63,2.91,
,NAA,NAA,2021_jabbari-zadeh_289,11,Bipolar Disorder,10.1016/j.jad.2021.04.011,,,,,6.98,1.67,
,NAA,NAA,2021_jabbari-zadeh_289,12,Bipolar Disorder,10.1016/j.jad.2021.04.011,,,,,12.88,1.89,
,PCr+Cr,tCr,2021_jabbari-zadeh_289,1,Healthy Control,10.1016/j.jad.2021.04.011,,,,,9.37,1.11,
,PCr+Cr,tCr,2021_jabbari-zadeh_289,2,Healthy Control,10.1016/j.jad.2021.04.011,,,,,9.98,1.31,
,PCr+Cr,tCr,2021_jabbari-zadeh_289,3,Healthy Control,10.1016/j.jad.2021.04.011,,,,,5.77,1.09,
,PCr+Cr,tCr,2021_jabbari-zadeh_289,4,Healthy Control,10.1016/j.jad.2021.04.011,,,,,11.15,1.56,
,PCr+Cr,tCr,2021_jabbari-zadeh_289,5,Bipolar Disorder,10.1016/j.jad.2021.04.011,,,,,9.8,1.42,
,PCr+Cr,tCr,2021_jabbari-zadeh_289,6,Bipolar Disorder,10.1016/j.jad.2021.04.011,,,,,9.9,1.51,
,PCr+Cr,tCr,2021_jabbari-zadeh_289,7,Bipolar Disorder,10.1016/j.jad.2021.04.011,,,,,7.13,1.04,
,PCr+Cr,tCr,2021_jabbari-zadeh_289,8,Bipolar Disorder,10.1016/j.jad.2021.04.011,,,,,12.45,2.38,
,PCr+Cr,tCr,2021_jabbari-zadeh_289,9,Bipolar Disorder,10.1016/j.jad.2021.04.011,,,,,9.63,1.24,
,PCr+Cr,tCr,2021_jabbari-zadeh_289,10,Bipolar Disorder,10.1016/j.jad.2021.04.011,,,,,10.53,1.43,
,PCr+Cr,tCr,2021_jabbari-zadeh_289,11,Bipolar Disorder,10.1016/j.jad.2021.04.011,,,,,6.5,1.35,
,PCr+Cr,tCr,2021_jabbari-zadeh_289,12,Bipolar Disorder,10.1016/j.jad.2021.04.011,,,,,11.67,1.49,
,Myo-Ins,Myo,2021_jabbari-zadeh_289,1,Healthy Control,10.1016/j.jad.2021.04.011,,,,,8.76,1.39,
,Myo-Ins,Myo,2021_jabbari-zadeh_289,2,Healthy Control,10.1016/j.jad.2021.04.011,,,,,8.86,1.53,
,Myo-Ins,Myo,2021_jabbari-zadeh_289,3,Healthy Control,10.1016/j.jad.2021.04.011,,,,,5.32,1.14,
,Myo-Ins,Myo,2021_jabbari-zadeh_289,4,Healthy Control,10.1016/j.jad.2021.04.011,,,,,8,2.14,
,Myo-Ins,Myo,2021_jabbari-zadeh_289,5,Bipolar Disorder,10.1016/j.jad.2021.04.011,,,,,8.31,1.65,
,Myo-Ins,Myo,2021_jabbari-zadeh_289,6,Bipolar Disorder,10.1016/j.jad.2021.04.011,,,,,8.41,1.79,
,Myo-Ins,Myo,2021_jabbari-zadeh_289,7,Bipolar Disorder,10.1016/j.jad.2021.04.011,,,,,7.03,1.13,
,Myo-Ins,Myo,2021_jabbari-zadeh_289,8,Bipolar Disorder,10.1016/j.jad.2021.04.011,,,,,9.08,2.52,
,Myo-Ins,Myo,2021_jabbari-zadeh_289,9,Bipolar Disorder,10.1016/j.jad.2021.04.011,,,,,8.41,1.79,
,Myo-Ins,Myo,2021_jabbari-zadeh_289,10,Bipolar Disorder,10.1016/j.jad.2021.04.011,,,,,9.14,3.19,
,Myo-Ins,Myo,2021_jabbari-zadeh_289,11,Bipolar Disorder,10.1016/j.jad.2021.04.011,,,,,5.92,1.39,
,Myo-Ins,Myo,2021_jabbari-zadeh_289,12,Bipolar Disorder,10.1016/j.jad.2021.04.011,,,,,7.41,1.76,
,ml,Myo,2021_jimenez-espinoza_26,1,Autism spectrum disorders,10.3390/molecules26030675,,,,,5.4,3.659,Adjusted from SEM
,ml,Myo,2021_jimenez-espinoza_26,2,Autism spectrum disorders,10.3390/molecules26030675,,,,,4.98,3.189,Adjusted from SEM
,ml,Myo,2021_jimenez-espinoza_26,3,Typical development,10.3390/molecules26030675,,,,,5.25,1.771,Adjusted from SEM
,ml,Myo,2021_jimenez-espinoza_26,4,Typical development,10.3390/molecules26030675,,,,,5.13,1.771,Adjusted from SEM
,ml,Myo,2021_jimenez-espinoza_26,5,Autism spectrum disorders,10.3390/molecules26030675,,,,,6.12,3.34,Adjusted from SEM
,ml,Myo,2021_jimenez-espinoza_26,6,Autism spectrum disorders,10.3390/molecules26030675,,,,,5.47,7.241,Adjusted from SEM
,ml,Myo,2021_jimenez-espinoza_26,7,Autism spectrum disorders,10.3390/molecules26030675,,,,,7.29,10.83,Adjusted from SEM
,ml,Myo,2021_jimenez-espinoza_26,8,Autism spectrum disorders,10.3390/molecules26030675,,,,,4.83,6.959,Adjusted from SEM
,ml,Myo,2021_jimenez-espinoza_26,9,Autism spectrum disorders,10.3390/molecules26030675,,,,,5.99,7.38,Adjusted from SEM
,ml,Myo,2021_jimenez-espinoza_26,10,Autism spectrum disorders,10.3390/molecules26030675,,,,,4.8,3.62,Adjusted from SEM
,ml,Myo,2021_jimenez-espinoza_26,11,Autism spectrum disorders,10.3390/molecules26030675,,,,,5.51,2.97,Adjusted from SEM
,ml,Myo,2021_jimenez-espinoza_26,12,Autism spectrum disorders,10.3390/molecules26030675,,,,,4.91,2.993,Adjusted from SEM
,Cre,Cre,2021_jimenez-espinoza_26,1,Autism spectrum disorders,10.3390/molecules26030675,,,,,6.98,7.317,Adjusted from SEM
,Cre,Cre,2021_jimenez-espinoza_26,2,Autism spectrum disorders,10.3390/molecules26030675,,,,,6.72,4.221,Adjusted from SEM
,Cre,Cre,2021_jimenez-espinoza_26,3,Typical development,10.3390/molecules26030675,,,,,7.4,12.262,Adjusted from SEM
,Cre,Cre,2021_jimenez-espinoza_26,4,Typical development,10.3390/molecules26030675,,,,,6.99,2.754,Adjusted from SEM
,Cr+PCr,tCr,2021_jimenez-espinoza_26,5,Autism spectrum disorders,10.3390/molecules26030675,,,,,7.48,3.34,Adjusted from SEM
,Cr+PCr,tCr,2021_jimenez-espinoza_26,6,Autism spectrum disorders,10.3390/molecules26030675,,,,,7.42,9.484,Adjusted from SEM
,Cr+PCr,tCr,2021_jimenez-espinoza_26,7,Autism spectrum disorders,10.3390/molecules26030675,,,,,6.53,2.94,Adjusted from SEM
,Cr+PCr,tCr,2021_jimenez-espinoza_26,8,Autism spectrum disorders,10.3390/molecules26030675,,,,,7.72,6.382,Adjusted from SEM
,Cr+PCr,tCr,2021_jimenez-espinoza_26,9,Autism spectrum disorders,10.3390/molecules26030675,,,,,7.05,1.855,Adjusted from SEM
,Cr+PCr,tCr,2021_jimenez-espinoza_26,10,Autism spectrum disorders,10.3390/molecules26030675,,,,,6.69,7.037,Adjusted from SEM
,Cr+PCr,tCr,2021_jimenez-espinoza_26,11,Autism spectrum disorders,10.3390/molecules26030675,,,,,6.21,2.07,Adjusted from SEM
,Cr+PCr,tCr,2021_jimenez-espinoza_26,12,Autism spectrum disorders,10.3390/molecules26030675,,,,,6.68,1.839,Adjusted from SEM
,Cho,tCho,2021_jimenez-espinoza_26,1,Autism spectrum disorders,10.3390/molecules26030675,,,,,2.08,0.657,Adjusted from SEM
,Cho,tCho,2021_jimenez-espinoza_26,2,Autism spectrum disorders,10.3390/molecules26030675,,,,,1.55,2.064,Adjusted from SEM
,Cho,tCho,2021_jimenez-espinoza_26,3,Typical development,10.3390/molecules26030675,,,,,2.08,0.852,Adjusted from SEM
,Cho,tCho,2021_jimenez-espinoza_26,4,Typical development,10.3390/molecules26030675,,,,,1.61,2.492,Adjusted from SEM
,GPC+PCho,tCho,2021_jimenez-espinoza_26,5,Autism spectrum disorders,10.3390/molecules26030675,,,,,1.83,2.02,Adjusted from SEM
,GPC+PCho,tCho,2021_jimenez-espinoza_26,6,Autism spectrum disorders,10.3390/molecules26030675,,,,,2.26,3.008,Adjusted from SEM
,GPC+PCho,tCho,2021_jimenez-espinoza_26,7,Autism spectrum disorders,10.3390/molecules26030675,,,,,1.63,2.1,Adjusted from SEM
,GPC+PCho,tCho,2021_jimenez-espinoza_26,8,Autism spectrum disorders,10.3390/molecules26030675,,,,,2.18,2.271,Adjusted from SEM
,GPC+PCho,tCho,2021_jimenez-espinoza_26,9,Autism spectrum disorders,10.3390/molecules26030675,,,,,1.63,1.608,Adjusted from SEM
,GPC+PCho,tCho,2021_jimenez-espinoza_26,10,Autism spectrum disorders,10.3390/molecules26030675,,,,,1.66,2.091,Adjusted from SEM
,GPC+PCho,tCho,2021_jimenez-espinoza_26,11,Autism spectrum disorders,10.3390/molecules26030675,,,,,1.29,1.08,Adjusted from SEM
,GPC+PCho,tCho,2021_jimenez-espinoza_26,12,Autism spectrum disorders,10.3390/molecules26030675,,,,,1.48,1.154,Adjusted from SEM
,Glu,Glu,2021_jimenez-espinoza_26,1,Autism spectrum disorders,10.3390/molecules26030675,,,,,12.1,18.386,Adjusted from SEM
,Glu,Glu,2021_jimenez-espinoza_26,2,Autism spectrum disorders,10.3390/molecules26030675,,,,,10.22,14.962,Adjusted from SEM
,Glu,Glu,2021_jimenez-espinoza_26,3,Typical development,10.3390/molecules26030675,,,,,10.54,36.984,Adjusted from SEM
,Glu,Glu,2021_jimenez-espinoza_26,4,Typical development,10.3390/molecules26030675,,,,,10.71,13.508,Adjusted from SEM
,Glu+Gln,Glx,2021_jimenez-espinoza_26,5,Autism spectrum disorders,10.3390/molecules26030675,,,,,13.74,16.74,Adjusted from SEM
,Glu+Gln,Glx,2021_jimenez-espinoza_26,6,Autism spectrum disorders,10.3390/molecules26030675,,,,,15.67,21.059,Adjusted from SEM
,Glu+Gln,Glx,2021_jimenez-espinoza_26,7,Autism spectrum disorders,10.3390/molecules26030675,,,,,17.34,4.29,Adjusted from SEM
,Glu+Gln,Glx,2021_jimenez-espinoza_26,8,Autism spectrum disorders,10.3390/molecules26030675,,,,,16.65,26.104,Adjusted from SEM
,Glu+Gln,Glx,2021_jimenez-espinoza_26,9,Autism spectrum disorders,10.3390/molecules26030675,,,,,13.37,8.7,Adjusted from SEM
,Glu+Gln,Glx,2021_jimenez-espinoza_26,10,Autism spectrum disorders,10.3390/molecules26030675,,,,,13.76,4.232,Adjusted from SEM
,Glu+Gln,Glx,2021_jimenez-espinoza_26,11,Autism spectrum disorders,10.3390/molecules26030675,,,,,10.39,1.11,Adjusted from SEM
,Glu+Gln,Glx,2021_jimenez-espinoza_26,12,Autism spectrum disorders,10.3390/molecules26030675,,,,,14.14,19.65,Adjusted from SEM
,Glu,Glu,2021_jimenez-espinoza_26,5,Autism spectrum disorders,10.3390/molecules26030675,,,,,8.04,6.679,Adjusted from SEM
,Glu,Glu,2021_jimenez-espinoza_26,6,Autism spectrum disorders,10.3390/molecules26030675,,,,,10.25,13.767,Adjusted from SEM
,Glu,Glu,2021_jimenez-espinoza_26,7,Autism spectrum disorders,10.3390/molecules26030675,,,,,13.87,6.39,Adjusted from SEM
,Glu,Glu,2021_jimenez-espinoza_26,8,Autism spectrum disorders,10.3390/molecules26030675,,,,,13.14,14.927,Adjusted from SEM
,Glu,Glu,2021_jimenez-espinoza_26,9,Autism spectrum disorders,10.3390/molecules26030675,,,,,10.51,10.225,Adjusted from SEM
,Glu,Glu,2021_jimenez-espinoza_26,10,Autism spectrum disorders,10.3390/molecules26030675,,,,,9.74,10.963,Adjusted from SEM
,Glu,Glu,2021_jimenez-espinoza_26,11,Autism spectrum disorders,10.3390/molecules26030675,,,,,8.94,7.98,Adjusted from SEM
,Glu,Glu,2021_jimenez-espinoza_26,12,Autism spectrum disorders,10.3390/molecules26030675,,,,,10.1,7.932,Adjusted from SEM
,NAA,NAA,2021_jimenez-espinoza_26,1,Autism spectrum disorders,10.3390/molecules26030675,,,,,9.37,6.379,Adjusted from SEM
,NAA,NAA,2021_jimenez-espinoza_26,2,Autism spectrum disorders,10.3390/molecules26030675,,,,,10.47,6.52,Adjusted from SEM
,NAA,NAA,2021_jimenez-espinoza_26,3,Typical development,10.3390/molecules26030675,,,,,9.91,4.459,Adjusted from SEM
,NAA,NAA,2021_jimenez-espinoza_26,4,Typical development,10.3390/molecules26030675,,,,,10.68,1.312,Adjusted from SEM
,NAA,NAA,2021_jimenez-espinoza_26,5,Autism spectrum disorders,10.3390/molecules26030675,,,,,9.96,5.236,Adjusted from SEM
,NAA,NAA,2021_jimenez-espinoza_26,6,Autism spectrum disorders,10.3390/molecules26030675,,,,,9.95,12.136,Adjusted from SEM
,NAA,NAA,2021_jimenez-espinoza_26,7,Autism spectrum disorders,10.3390/molecules26030675,,,,,8.41,1.14,Adjusted from SEM
,NAA,NAA,2021_jimenez-espinoza_26,8,Autism spectrum disorders,10.3390/molecules26030675,,,,,9.71,6.418,Adjusted from SEM
,NAA,NAA,2021_jimenez-espinoza_26,9,Autism spectrum disorders,10.3390/molecules26030675,,,,,9.89,8.906,Adjusted from SEM
,NAA,NAA,2021_jimenez-espinoza_26,10,Autism spectrum disorders,10.3390/molecules26030675,,,,,10.47,10.402,Adjusted from SEM
,NAA,NAA,2021_jimenez-espinoza_26,11,Autism spectrum disorders,10.3390/molecules26030675,,,,,8.98,3.63,Adjusted from SEM
,NAA,NAA,2021_jimenez-espinoza_26,12,Autism spectrum disorders,10.3390/molecules26030675,,,,,10.57,5.625,Adjusted from SEM
,NAA+NAAG,tNAA,2021_jimenez-espinoza_26,1,Autism spectrum disorders,10.3390/molecules26030675,,,,,9.78,2.298,Adjusted from SEM
,NAA+NAAG,tNAA,2021_jimenez-espinoza_26,2,Autism spectrum disorders,10.3390/molecules26030675,,,,,10.8,4.034,Adjusted from SEM
,NAA+NAAG,tNAA,2021_jimenez-espinoza_26,3,Typical development,10.3390/molecules26030675,,,,,10.44,1.902,Adjusted from SEM
,NAA+NAAG,tNAA,2021_jimenez-espinoza_26,4,Typical development,10.3390/molecules26030675,,,,,11.02,4.459,Adjusted from SEM
,NAAG,NAAG,2021_jimenez-espinoza_26,1,Autism spectrum disorders,10.3390/molecules26030675,,,,,0.41,1.113,Adjusted from SEM
,NAAG,NAAG,2021_jimenez-espinoza_26,2,Autism spectrum disorders,10.3390/molecules26030675,,,,,0.34,2.185,Adjusted from SEM
,NAAG,NAAG,2021_jimenez-espinoza_26,3,Typical development,10.3390/molecules26030675,,,,,0.55,0.852,Adjusted from SEM
,NAAG,NAAG,2021_jimenez-espinoza_26,4,Typical development,10.3390/molecules26030675,,,,,0.32,9.049,Adjusted from SEM
,NAA+NAAG,tNAA,2021_jimenez-espinoza_26,5,Autism spectrum disorders,10.3390/molecules26030675,,,,,10.41,3.257,Adjusted from SEM
,NAA+NAAG,tNAA,2021_jimenez-espinoza_26,6,Autism spectrum disorders,10.3390/molecules26030675,,,,,10.66,13.92,Adjusted from SEM
,NAA+NAAG,tNAA,2021_jimenez-espinoza_26,7,Autism spectrum disorders,10.3390/molecules26030675,,,,,8.46,1.47,Adjusted from SEM
,NAA+NAAG,tNAA,2021_jimenez-espinoza_26,8,Autism spectrum disorders,10.3390/molecules26030675,,,,,10.56,9.266,Adjusted from SEM
,NAA+NAAG,tNAA,2021_jimenez-espinoza_26,9,Autism spectrum disorders,10.3390/molecules26030675,,,,,10.28,10.72,Adjusted from SEM
,NAA+NAAG,tNAA,2021_jimenez-espinoza_26,10,Autism spectrum disorders,10.3390/molecules26030675,,,,,10.79,14.277,Adjusted from SEM
,NAA+NAAG,tNAA,2021_jimenez-espinoza_26,11,Autism spectrum disorders,10.3390/molecules26030675,,,,,9.6,2.85,Adjusted from SEM
,NAA+NAAG,tNAA,2021_jimenez-espinoza_26,12,Autism spectrum disorders,10.3390/molecules26030675,,,,,10.98,4.471,Adjusted from SEM
,NAAG,NAAG,2021_jimenez-espinoza_26,5,Autism spectrum disorders,10.3390/molecules26030675,,,,,0.43,4.37,Adjusted from SEM
,NAAG,NAAG,2021_jimenez-espinoza_26,6,Autism spectrum disorders,10.3390/molecules26030675,,,,,0.56,4.946,Adjusted from SEM
,NAAG,NAAG,2021_jimenez-espinoza_26,7,Autism spectrum disorders,10.3390/molecules26030675,,,,,0.21,1.38,Adjusted from SEM
,NAAG,NAAG,2021_jimenez-espinoza_26,8,Autism spectrum disorders,10.3390/molecules26030675,,,,,0.81,5.012,Adjusted from SEM
,NAAG,NAAG,2021_jimenez-espinoza_26,9,Autism spectrum disorders,10.3390/molecules26030675,,,,,0.35,5.69,Adjusted from SEM
,NAAG,NAAG,2021_jimenez-espinoza_26,10,Autism spectrum disorders,10.3390/molecules26030675,,,,,0.35,2.6,Adjusted from SEM
,NAAG,NAAG,2021_jimenez-espinoza_26,11,Autism spectrum disorders,10.3390/molecules26030675,,,,,0.41,1.35,Adjusted from SEM
,NAAG,NAAG,2021_jimenez-espinoza_26,12,Autism spectrum disorders,10.3390/molecules26030675,,,,,0.3,1.37,Adjusted from SEM
,Glx,Glx,2021_jimenez-espinoza_26,1,Autism spectrum disorders,10.3390/molecules26030675,,,,,16.1,32.223,Adjusted from SEM
,Glx,Glx,2021_jimenez-espinoza_26,2,Autism spectrum disorders,10.3390/molecules26030675,,,,,13.87,19.184,Adjusted from SEM
,Glx,Glx,2021_jimenez-espinoza_26,3,Typical development,10.3390/molecules26030675,,,,,15.19,59.148,Adjusted from SEM
,Glx,Glx,2021_jimenez-espinoza_26,4,Typical development,10.3390/molecules26030675,,,,,14.08,14.098,Adjusted from SEM
,GPC,GPC,2021_jung_17a,1,Control,10.1177/1744806921990946,0.22,0.03,,,,,
,GPC,GPC,2021_jung_17a,2,Fibromyalgia,10.1177/1744806921990946,0.233,0.046,,,,,
,GPC,GPC,2021_jung_17a,3,Control,10.1177/1744806921990946,0.236,0.037,,,,,
,GPC,GPC,2021_jung_17a,4,Fibromyalgia,10.1177/1744806921990946,0.258,0.054,,,,,
,GPC,GPC,2021_jung_17a,5,Control,10.1177/1744806921990946,0.257,0.022,,,,,
,GPC,GPC,2021_jung_17a,6,Fibromyalgia,10.1177/1744806921990946,0.274,0.028,,,,,
,GPC,GPC,2021_jung_17a,7,Control,10.1177/1744806921990946,0.244,0.037,,,,,
,GPC,GPC,2021_jung_17a,8,Fibromyalgia,10.1177/1744806921990946,0.256,0.024,,,,,
,GPC,GPC,2021_jung_17a,9,Control,10.1177/1744806921990946,0.268,0.049,,,,,
,GPC,GPC,2021_jung_17a,10,Fibromyalgia,10.1177/1744806921990946,0.243,0.021,,,,,
,tCho,tCho,2021_jung_17a,1,Control,10.1177/1744806921990946,0.219,0.029,,,,,
,tCho,tCho,2021_jung_17a,2,Fibromyalgia,10.1177/1744806921990946,0.244,0.03,,,,,
,tCho,tCho,2021_jung_17a,3,Control,10.1177/1744806921990946,0.236,0.037,,,,,
,tCho,tCho,2021_jung_17a,4,Fibromyalgia,10.1177/1744806921990946,0.258,0.054,,,,,
,tCho,tCho,2021_jung_17a,5,Control,10.1177/1744806921990946,0.262,0.031,,,,,
,tCho,tCho,2021_jung_17a,6,Fibromyalgia,10.1177/1744806921990946,0.274,0.028,,,,,
,tCho,tCho,2021_jung_17a,7,Control,10.1177/1744806921990946,0.265,0.54,,,,,
,tCho,tCho,2021_jung_17a,8,Fibromyalgia,10.1177/1744806921990946,0.256,0.024,,,,,
,tCho,tCho,2021_jung_17a,9,Control,10.1177/1744806921990946,0.276,0.063,,,,,
,tCho,tCho,2021_jung_17a,10,Fibromyalgia,10.1177/1744806921990946,0.243,0.021,,,,,
,Gln,Gln,2021_jung_17a,1,Control,10.1177/1744806921990946,0.503,0.227,,,,,
,Gln,Gln,2021_jung_17a,2,Fibromyalgia,10.1177/1744806921990946,0.508,0.15,,,,,
,Gln,Gln,2021_jung_17a,3,Control,10.1177/1744806921990946,0.709,0.39,,,,,
,Gln,Gln,2021_jung_17a,4,Fibromyalgia,10.1177/1744806921990946,0.554,0.227,,,,,
,Gln,Gln,2021_jung_17a,5,Control,10.1177/1744806921990946,0.604,0.12,,,,,
,Gln,Gln,2021_jung_17a,6,Fibromyalgia,10.1177/1744806921990946,0.567,0.12,,,,,
,Gln,Gln,2021_jung_17a,7,Control,10.1177/1744806921990946,0.354,0.06,,,,,
,Gln,Gln,2021_jung_17a,8,Fibromyalgia,10.1177/1744806921990946,0.344,0.093,,,,,
,Gln,Gln,2021_jung_17a,9,Control,10.1177/1744806921990946,0.496,0.183,,,,,
,Gln,Gln,2021_jung_17a,10,Fibromyalgia,10.1177/1744806921990946,0.376,0.03,,,,,
,Glu,Glu,2021_jung_17a,1,Control,10.1177/1744806921990946,1.379,0.099,,,,,
,Glu,Glu,2021_jung_17a,2,Fibromyalgia,10.1177/1744806921990946,1.431,0.17,,,,,
,Glu,Glu,2021_jung_17a,3,Control,10.1177/1744806921990946,1.122,0.259,,,,,
,Glu,Glu,2021_jung_17a,4,Fibromyalgia,10.1177/1744806921990946,1.125,0.081,,,,,
,Glu,Glu,2021_jung_17a,5,Control,10.1177/1744806921990946,1.153,0.138,,,,,
,Glu,Glu,2021_jung_17a,6,Fibromyalgia,10.1177/1744806921990946,1.25,0.112,,,,,
,Glu,Glu,2021_jung_17a,7,Control,10.1177/1744806921990946,1.205,0.181,,,,,
,Glu,Glu,2021_jung_17a,8,Fibromyalgia,10.1177/1744806921990946,1.296,0.075,,,,,
,Glu,Glu,2021_jung_17a,9,Control,10.1177/1744806921990946,1.109,0.204,,,,,
,Glu,Glu,2021_jung_17a,10,Fibromyalgia,10.1177/1744806921990946,1.129,0.152,,,,,
,Glx,Glx,2021_jung_17a,1,Control,10.1177/1744806921990946,1.835,0.239,,,,,
,Glx,Glx,2021_jung_17a,2,Fibromyalgia,10.1177/1744806921990946,1.939,0.117,,,,,
,Glx,Glx,2021_jung_17a,3,Control,10.1177/1744806921990946,1.642,0.557,,,,,
,Glx,Glx,2021_jung_17a,4,Fibromyalgia,10.1177/1744806921990946,1.586,0.203,,,,,
,Glx,Glx,2021_jung_17a,5,Control,10.1177/1744806921990946,1.685,0.213,,,,,
,Glx,Glx,2021_jung_17a,6,Fibromyalgia,10.1177/1744806921990946,1.667,0.164,,,,,
,Glx,Glx,2021_jung_17a,7,Control,10.1177/1744806921990946,1.473,0.257,,,,,
,Glx,Glx,2021_jung_17a,8,Fibromyalgia,10.1177/1744806921990946,1.611,0.111,,,,,
,Glx,Glx,2021_jung_17a,9,Control,10.1177/1744806921990946,1.436,0.307,,,,,
,Glx,Glx,2021_jung_17a,10,Fibromyalgia,10.1177/1744806921990946,1.403,0.271,,,,,
,GSH,GSH,2021_jung_17a,1,Control,10.1177/1744806921990946,0.299,0.078,,,,,
,GSH,GSH,2021_jung_17a,2,Fibromyalgia,10.1177/1744806921990946,0.3,0.058,,,,,
,GSH,GSH,2021_jung_17a,3,Control,10.1177/1744806921990946,0.357,0.176,,,,,
,GSH,GSH,2021_jung_17a,4,Fibromyalgia,10.1177/1744806921990946,0.316,0.079,,,,,
,GSH,GSH,2021_jung_17a,5,Control,10.1177/1744806921990946,0.343,0.111,,,,,
,GSH,GSH,2021_jung_17a,6,Fibromyalgia,10.1177/1744806921990946,0.371,0.076,,,,,
,GSH,GSH,2021_jung_17a,7,Control,10.1177/1744806921990946,0.269,0.053,,,,,
,GSH,GSH,2021_jung_17a,8,Fibromyalgia,10.1177/1744806921990946,0.298,0.041,,,,,
,GSH,GSH,2021_jung_17a,9,Control,10.1177/1744806921990946,0.301,0.069,,,,,
,GSH,GSH,2021_jung_17a,10,Fibromyalgia,10.1177/1744806921990946,0.278,0.062,,,,,
,ml,Myo,2021_jung_17a,1,Control,10.1177/1744806921990946,0.781,0.08,,,,,
,ml,Myo,2021_jung_17a,2,Fibromyalgia,10.1177/1744806921990946,0.824,0.74,,,,,
,ml,Myo,2021_jung_17a,3,Control,10.1177/1744806921990946,0.357,0.176,,,,,
,ml,Myo,2021_jung_17a,4,Fibromyalgia,10.1177/1744806921990946,0.316,0.079,,,,,
,ml,Myo,2021_jung_17a,5,Control,10.1177/1744806921990946,0.343,0.111,,,,,
,ml,Myo,2021_jung_17a,6,Fibromyalgia,10.1177/1744806921990946,0.371,0.076,,,,,
,ml,Myo,2021_jung_17a,7,Control,10.1177/1744806921990946,0.269,0.053,,,,,
,ml,Myo,2021_jung_17a,8,Fibromyalgia,10.1177/1744806921990946,0.298,0.041,,,,,
,ml,Myo,2021_jung_17a,9,Control,10.1177/1744806921990946,0.301,0.069,,,,,
,ml,Myo,2021_jung_17a,10,Fibromyalgia,10.1177/1744806921990946,0.278,0.062,,,,,
,NAA,NAA,2021_jung_17a,1,Control,10.1177/1744806921990946,0.822,0.225,,,,,
,NAA,NAA,2021_jung_17a,2,Fibromyalgia,10.1177/1744806921990946,1.029,0.216,,,,,
,NAA,NAA,2021_jung_17a,3,Control,10.1177/1744806921990946,0.731,0.187,,,,,
,NAA,NAA,2021_jung_17a,4,Fibromyalgia,10.1177/1744806921990946,0.836,0.275,,,,,
,NAA,NAA,2021_jung_17a,5,Control,10.1177/1744806921990946,0.797,0.208,,,,,
,NAA,NAA,2021_jung_17a,6,Fibromyalgia,10.1177/1744806921990946,0.898,0.26,,,,,
,NAA,NAA,2021_jung_17a,7,Control,10.1177/1744806921990946,0.993,0.192,,,,,
,NAA,NAA,2021_jung_17a,8,Fibromyalgia,10.1177/1744806921990946,0.992,0.19,,,,,
,NAA,NAA,2021_jung_17a,9,Control,10.1177/1744806921990946,0.808,0.317,,,,,
,NAA,NAA,2021_jung_17a,10,Fibromyalgia,10.1177/1744806921990946,0.871,0.264,,,,,
,tNAA,tNAA,2021_jung_17a,1,Control,10.1177/1744806921990946,1.201,0.13,,,,,
,tNAA,tNAA,2021_jung_17a,2,Fibromyalgia,10.1177/1744806921990946,1.171,0.132,,,,,
,tNAA,tNAA,2021_jung_17a,3,Control,10.1177/1744806921990946,1.335,0.216,,,,,
,tNAA,tNAA,2021_jung_17a,4,Fibromyalgia,10.1177/1744806921990946,1.362,0.159,,,,,
,tNAA,tNAA,2021_jung_17a,5,Control,10.1177/1744806921990946,1.442,0.15,,,,,
,tNAA,tNAA,2021_jung_17a,6,Fibromyalgia,10.1177/1744806921990946,1.436,0.124,,,,,
,tNAA,tNAA,2021_jung_17a,7,Control,10.1177/1744806921990946,1.275,0.105,,,,,
,tNAA,tNAA,2021_jung_17a,8,Fibromyalgia,10.1177/1744806921990946,1.159,0.111,,,,,
,tNAA,tNAA,2021_jung_17a,9,Control,10.1177/1744806921990946,1.199,0.137,,,,,
,tNAA,tNAA,2021_jung_17a,10,Fibromyalgia,10.1177/1744806921990946,1.044,0.115,,,,,
,NAAG,NAAG,2021_jung_17a,3,Control,10.1177/1744806921990946,0.84,0.162,,,,,
,NAAG,NAAG,2021_jung_17a,4,Fibromyalgia,10.1177/1744806921990946,0.663,0.257,,,,,
,NAAG,NAAG,2021_jung_17a,5,Control,10.1177/1744806921990946,0.692,0.186,,,,,
,NAAG,NAAG,2021_jung_17a,6,Fibromyalgia,10.1177/1744806921990946,0.597,0.236,,,,,
,NAAG,NAAG,2021_jung_17a,7,Control,10.1177/1744806921990946,0.355,0.153,,,,,
,NAAG,NAAG,2021_jung_17a,8,Fibromyalgia,10.1177/1744806921990946,0.388,0.121,,,,,
,NAAG,NAAG,2021_jung_17a,9,Control,10.1177/1744806921990946,0.662,0.242,,,,,
,NAAG,NAAG,2021_jung_17a,10,Fibromyalgia,10.1177/1744806921990946,0.571,0.118,,,,,
,Cho,GPC,2021_white_225,1,Healthy,10.1016/j.neuroimage.2020.117509,,,1.83,0.18,,,
,tCr,tCr,2021_white_225,1,Healthy,10.1016/j.neuroimage.2020.117509,,,6.42,0.43,,,
,Glx,Glx,2021_white_225,1,Healthy,10.1016/j.neuroimage.2020.117509,,,13.13,1.42,,,
,Myo,Myo,2021_white_225,1,Healthy,10.1016/j.neuroimage.2020.117509,,,4.84,0.52,,,
,tNAA,tNAA,2021_white_225,1,Healthy,10.1016/j.neuroimage.2020.117509,,,8.32,0.78,,,
,tCho,tCho,2021_zollner_34,1,Healthy,10.1002/nbm.4482,0.19,0.02,,,,,
,tCho,tCho,2021_zollner_34,2,Healthy,10.1002/nbm.4482,0.18,0.02,,,,,
,tCho,tCho,2021_zollner_34,3,Healthy,10.1002/nbm.4482,0.22,0.03,,,,,
,tCho,tCho,2021_zollner_34,4,Healthy,10.1002/nbm.4482,0.17,0.02,,,,,
,tCho,tCho,2021_zollner_34,5,Healthy,10.1002/nbm.4482,0.18,0.02,,,,,
,tCho,tCho,2021_zollner_34,6,Healthy,10.1002/nbm.4482,0.16,0.03,,,,,
,tCho,tCho,2021_zollner_34,7,Healthy,10.1002/nbm.4482,0.19,0.02,,,,,
,tCho,tCho,2021_zollner_34,8,Healthy,10.1002/nbm.4482,0.19,0.02,,,,,
,tCho,tCho,2021_zollner_34,9,Healthy,10.1002/nbm.4482,0.18,0.03,,,,,
,tCho,tCho,2021_zollner_34,10,Healthy,10.1002/nbm.4482,0.18,0.02,,,,,
,tCho,tCho,2021_zollner_34,11,Healthy,10.1002/nbm.4482,0.18,0.02,,,,,
,tCho,tCho,2021_zollner_34,12,Healthy,10.1002/nbm.4482,0.18,0.04,,,,,
,Glx,Glx,2021_zollner_34,1,Healthy,10.1002/nbm.4482,1.75,0.25,,,,,
,Glx,Glx,2021_zollner_34,2,Healthy,10.1002/nbm.4482,1.42,0.17,,,,,
,Glx,Glx,2021_zollner_34,3,Healthy,10.1002/nbm.4482,2.05,0.22,,,,,
,Glx,Glx,2021_zollner_34,4,Healthy,10.1002/nbm.4482,1.46,0.14,,,,,
,Glx,Glx,2021_zollner_34,5,Healthy,10.1002/nbm.4482,1.34,0.16,,,,,
,Glx,Glx,2021_zollner_34,6,Healthy,10.1002/nbm.4482,1.78,0.19,,,,,
,Glx,Glx,2021_zollner_34,7,Healthy,10.1002/nbm.4482,1.65,0.31,,,,,
,Glx,Glx,2021_zollner_34,8,Healthy,10.1002/nbm.4482,1.45,0.14,,,,,
,Glx,Glx,2021_zollner_34,9,Healthy,10.1002/nbm.4482,2.04,0.19,,,,,
,Glx,Glx,2021_zollner_34,10,Healthy,10.1002/nbm.4482,1.45,0.15,,,,,
,Glx,Glx,2021_zollner_34,11,Healthy,10.1002/nbm.4482,1.5,0.12,,,,,
,Glx,Glx,2021_zollner_34,12,Healthy,10.1002/nbm.4482,1.93,0.24,,,,,
,Myo,Myo,2021_zollner_34,1,Healthy,10.1002/nbm.4482,0.85,0.1,,,,,
,Myo,Myo,2021_zollner_34,2,Healthy,10.1002/nbm.4482,0.78,0.09,,,,,
,Myo,Myo,2021_zollner_34,3,Healthy,10.1002/nbm.4482,0.57,0.07,,,,,
,Myo,Myo,2021_zollner_34,4,Healthy,10.1002/nbm.4482,0.81,0.08,,,,,
,Myo,Myo,2021_zollner_34,5,Healthy,10.1002/nbm.4482,0.86,0.1,,,,,
,Myo,Myo,2021_zollner_34,6,Healthy,10.1002/nbm.4482,0.6,0.09,,,,,
,Myo,Myo,2021_zollner_34,7,Healthy,10.1002/nbm.4482,0.83,0.09,,,,,
,Myo,Myo,2021_zollner_34,8,Healthy,10.1002/nbm.4482,0.89,0.06,,,,,
,Myo,Myo,2021_zollner_34,9,Healthy,10.1002/nbm.4482,0.65,0.07,,,,,
,Myo,Myo,2021_zollner_34,10,Healthy,10.1002/nbm.4482,0.83,0.09,,,,,
,Myo,Myo,2021_zollner_34,11,Healthy,10.1002/nbm.4482,0.84,0.09,,,,,
,Myo,Myo,2021_zollner_34,12,Healthy,10.1002/nbm.4482,0.6,0.08,,,,,
,tNAA,tNAA,2021_zollner_34,1,Healthy,10.1002/nbm.4482,1.48,0.12,,,,,
,tNAA,tNAA,2021_zollner_34,2,Healthy,10.1002/nbm.4482,1.47,0.1,,,,,
,tNAA,tNAA,2021_zollner_34,3,Healthy,10.1002/nbm.4482,1.48,0.11,,,,,
,tNAA,tNAA,2021_zollner_34,4,Healthy,10.1002/nbm.4482,1.38,0.1,,,,,
,tNAA,tNAA,2021_zollner_34,5,Healthy,10.1002/nbm.4482,1.5,0.12,,,,,
,tNAA,tNAA,2021_zollner_34,6,Healthy,10.1002/nbm.4482,1.4,0.12,,,,,
,tNAA,tNAA,2021_zollner_34,7,Healthy,10.1002/nbm.4482,1.52,0.19,,,,,
,tNAA,tNAA,2021_zollner_34,8,Healthy,10.1002/nbm.4482,1.54,0.12,,,,,
,tNAA,tNAA,2021_zollner_34,9,Healthy,10.1002/nbm.4482,1.5,0.15,,,,,
,tNAA,tNAA,2021_zollner_34,10,Healthy,10.1002/nbm.4482,1.45,0.15,,,,,
,tNAA,tNAA,2021_zollner_34,11,Healthy,10.1002/nbm.4482,1.5,0.12,,,,,
,tNAA,tNAA,2021_zollner_34,12,Healthy,10.1002/nbm.4482,1.46,0.14,,,,,
,Myo,Myo,2019_voevodskaya_92,1,Control,10.1212/WNL.0000000000006852,0.815,0.102,,,,,Med/Quartile --> Mean/Std Wan 2014
,Myo,Myo,2019_voevodskaya_92,2,Control,10.1212/WNL.0000000000006852,0.816,0.093,,,,,Med/Quartile --> Mean/Std Wan 2014
,Myo,Myo,2019_voevodskaya_92,3,Control,10.1212/WNL.0000000000006852,0.831,0.062,,,,,Med/Quartile --> Mean/Std Greco 2015
,Myo,Myo,2019_voevodskaya_92,4,MCI,10.1212/WNL.0000000000006852,0.82,0.104,,,,,Med/Quartile --> Mean/Std Wan 2014
,Myo,Myo,2019_voevodskaya_92,5,MCI,10.1212/WNL.0000000000006852,0.838,0.102,,,,,Med/Quartile --> Mean/Std Wan 2014
,Myo,Myo,2019_voevodskaya_92,6,MCI,10.1212/WNL.0000000000006852,0.849,0.093,,,,,Med/Quartile --> Mean/Std Wan 2014
,Myo,Myo,2019_voevodskaya_92,7,MCI,10.1212/WNL.0000000000006852,0.856,0.115,,,,,Med/Quartile --> Mean/Std Wan 2014
,Myo,Myo,2019_voevodskaya_92,8,MCI,10.1212/WNL.0000000000006852,0.896,0.112,,,,,Med/Quartile --> Mean/Std Wan 2014
,Myo,Myo,2019_voevodskaya_92,9,MCI,10.1212/WNL.0000000000006852,0.946,0.162,,,,,Med/Quartile --> Mean/Std Greco 2015
,Cho,GPC,2019_voevodskaya_92,1,Control,10.1212/WNL.0000000000006852,0.176,0.016,,,,,Med/Quartile --> Mean/Std Wan 2014
,Cho,GPC,2019_voevodskaya_92,2,Control,10.1212/WNL.0000000000006852,0.174,0.018,,,,,Med/Quartile --> Mean/Std Wan 2014
,Cho,GPC,2019_voevodskaya_92,3,Control,10.1212/WNL.0000000000006852,0.181,0.024,,,,,Med/Quartile --> Mean/Std Greco 2015
,Cho,GPC,2019_voevodskaya_92,4,MCI,10.1212/WNL.0000000000006852,0.179,0.017,,,,,Med/Quartile --> Mean/Std Wan 2014
,Cho,GPC,2019_voevodskaya_92,5,MCI,10.1212/WNL.0000000000006852,0.175,0.027,,,,,Med/Quartile --> Mean/Std Greco 2015
,Cho,GPC,2019_voevodskaya_92,6,MCI,10.1212/WNL.0000000000006852,0.182,0.021,,,,,Med/Quartile --> Mean/Std Wan 2014
,Cho,GPC,2019_voevodskaya_92,7,MCI,10.1212/WNL.0000000000006852,0.178,0.026,,,,,Med/Quartile --> Mean/Std Greco 2015
,Cho,GPC,2019_voevodskaya_92,8,MCI,10.1212/WNL.0000000000006852,0.187,0.019,,,,,Med/Quartile --> Mean/Std Wan 2014
,Cho,GPC,2019_voevodskaya_92,9,MCI,10.1212/WNL.0000000000006852,0.189,0.018,,,,,Med/Quartile --> Mean/Std Wan 2014
,NAA,NAA,2019_voevodskaya_92,1,Control,10.1212/WNL.0000000000006852,1.355,0.083,,,,,Med/Quartile --> Mean/Std Wan 2014
,NAA,NAA,2019_voevodskaya_92,2,Control,10.1212/WNL.0000000000006852,1.368,0.118,,,,,Med/Quartile --> Mean/Std Wan 2014
,NAA,NAA,2019_voevodskaya_92,3,Control,10.1212/WNL.0000000000006852,1.398,0.092,,,,,Med/Quartile --> Mean/Std Wan 2014
,NAA,NAA,2019_voevodskaya_92,4,MCI,10.1212/WNL.0000000000006852,1.347,0.094,,,,,Med/Quartile --> Mean/Std Wan 2014
,NAA,NAA,2019_voevodskaya_92,5,MCI,10.1212/WNL.0000000000006852,1.368,0.107,,,,,Med/Quartile --> Mean/Std Wan 2014
,NAA,NAA,2019_voevodskaya_92,6,MCI,10.1212/WNL.0000000000006852,1.421,0.108,,,,,Med/Quartile --> Mean/Std Wan 2014
,NAA,NAA,2019_voevodskaya_92,7,MCI,10.1212/WNL.0000000000006852,1.322,0.123,,,,,Med/Quartile --> Mean/Std Wan 2014
,NAA,NAA,2019_voevodskaya_92,8,MCI,10.1212/WNL.0000000000006852,1.312,0.127,,,,,Med/Quartile --> Mean/Std Wan 2014
,NAA,NAA,2019_voevodskaya_92,9,MCI,10.1212/WNL.0000000000006852,1.335,0.162,,,,,Med/Quartile --> Mean/Std Wan 2014
,NAA,NAA,2017_cheong_42,1,Control,10.1007/s11064-017-2248-2,,,,,9.27,0.5,
,tNAA,tNAA,2017_cheong_42,1,Control,10.1007/s11064-017-2248-2,1.9,0.21,,,11.08,0.57,
,NAA,NAA,2017_cheong_42,2,Control,10.1007/s11064-017-2248-2,,,,,9.83,0.87,
,tNAA,tNAA,2017_cheong_42,2,Control,10.1007/s11064-017-2248-2,2.01,0.17,,,12.03,1,
,NAA,NAA,2017_cheong_42,3,ALS,10.1007/s11064-017-2248-2,,,,,8.9,0.69,
,tNAA,tNAA,2017_cheong_42,3,ALS,10.1007/s11064-017-2248-2,1.82,0.18,,,10.72,0.79,
,NAA,NAA,2017_cheong_42,4,ALS,10.1007/s11064-017-2248-2,,,,,9.51,0.95,
,tNAA,tNAA,2017_cheong_42,4,ALS,10.1007/s11064-017-2248-2,1.87,0.26,,,11.35,1.05,
,Gln,Gln,2017_cheong_42,1,Control,10.1007/s11064-017-2248-2,,,,,2.38,0.35,
,Gln,Gln,2017_cheong_42,3,ALS,10.1007/s11064-017-2248-2,,,,,2.36,0.29,
,Glu,Glu,2017_cheong_42,1,Control,10.1007/s11064-017-2248-2,,,,,5.99,0.41,
,Glu,Glu,2017_cheong_42,3,ALS,10.1007/s11064-017-2248-2,,,,,5.99,0.42,
,GSH,GSH,2017_cheong_42,1,Control,10.1007/s11064-017-2248-2,0.15,0.02,,,0.91,0.2,
,GSH,GSH,2017_cheong_42,3,ALS,10.1007/s11064-017-2248-2,0.17,0.03,,,1.01,0.19,
,Lac,Lac,2017_cheong_42,1,Control,10.1007/s11064-017-2248-2,,,,,0.79,0.33,
,Lac,Lac,2017_cheong_42,3,ALS,10.1007/s11064-017-2248-2,,,,,0.71,0.36,
,mIns,Myo,2017_cheong_42,1,Control,10.1007/s11064-017-2248-2,0.85,0.08,,,5,0.67,
,mIns,Myo,2017_cheong_42,2,Control,10.1007/s11064-017-2248-2,1.26,0.12,,,7.59,0.96,
,mIns,Myo,2017_cheong_42,3,ALS,10.1007/s11064-017-2248-2,0.93,0.09,,,5.51,0.6,
,mIns,Myo,2017_cheong_42,4,ALS,10.1007/s11064-017-2248-2,1.29,0.06,,,8.07,1.25,
,NAAG,NAAG,2017_cheong_42,1,Control,10.1007/s11064-017-2248-2,,,,,1.81,0.29,
,NAAG,NAAG,2017_cheong_42,2,Control,10.1007/s11064-017-2248-2,,,,,2.2,0.31,
,NAAG,NAAG,2017_cheong_42,3,ALS,10.1007/s11064-017-2248-2,,,,,1.82,0.32,
,NAAG,NAAG,2017_cheong_42,4,ALS,10.1007/s11064-017-2248-2,,,,,1.84,0.32,
,tCho,tCho,2017_cheong_42,1,Control,10.1007/s11064-017-2248-2,,,,,1.35,0.16,
,tCho,tCho,2017_cheong_42,2,Control,10.1007/s11064-017-2248-2,,,,,2.99,0.31,
,tCho,tCho,2017_cheong_42,3,ALS,10.1007/s11064-017-2248-2,,,,,1.39,0.13,
,tCho,tCho,2017_cheong_42,4,ALS,10.1007/s11064-017-2248-2,,,,,3.07,0.36,
,tCr,tCr,2017_cheong_42,1,Control,10.1007/s11064-017-2248-2,,,,,5.88,0.6,
,tCr,tCr,2017_cheong_42,2,Control,10.1007/s11064-017-2248-2,,,,,6.01,0.5,
,tCr,tCr,2017_cheong_42,3,ALS,10.1007/s11064-017-2248-2,,,,,5.93,0.51,
,tCr,tCr,2017_cheong_42,4,ALS,10.1007/s11064-017-2248-2,,,,,6.15,0.78,
,Glx,Glx,2017_cheong_42,2,Control,10.1007/s11064-017-2248-2,,,,,4.56,0.84,
,Glx,Glx,2017_cheong_42,4,ALS,10.1007/s11064-017-2248-2,,,,,4.24,0.76,
,Glc + Tau,GlcTau,2017_cheong_42,1,Control,10.1007/s11064-017-2248-2,,,,,1.57,0.46,
,Glc + Tau,GlcTau,2017_cheong_42,2,Control,10.1007/s11064-017-2248-2,,,,,2.37,0.39,
,Glc + Tau,GlcTau,2017_cheong_42,3,ALS,10.1007/s11064-017-2248-2,,,,,1.8,0.44,
,Glc + Tau,GlcTau,2017_cheong_42,4,ALS,10.1007/s11064-017-2248-2,,,,,2.61,0.54,
,GPC,GPC,2020_dehghani_83,1,Protocol 1,10.1002/mrm.28066,,,,,0.46,0.15,
,GPC,GPC,2020_dehghani_83,2,Protocol 2,10.1002/mrm.28066,,,,,0.13,0.08,
,GPC,GPC,2020_dehghani_83,3,Protocol 3,10.1002/mrm.28066,,,,,0.34,0.07,
,Gln,Gln,2020_dehghani_83,1,Protocol 1,10.1002/mrm.28066,,,,,1.04,0.43,
,Gln,Gln,2020_dehghani_83,2,Protocol 2,10.1002/mrm.28066,,,,,0.49,0.14,
,Gln,Gln,2020_dehghani_83,3,Protocol 3,10.1002/mrm.28066,,,,,0.95,0.26,
,GSH,GSH,2020_dehghani_83,1,Protocol 1,10.1002/mrm.28066,,,,,0.55,0.13,
,GSH,GSH,2020_dehghani_83,2,Protocol 2,10.1002/mrm.28066,,,,,0.17,0.04,
,GSH,GSH,2020_dehghani_83,3,Protocol 3,10.1002/mrm.28066,,,,,0.3,0.08,
,GABA,GABA,2020_dehghani_83,1,Protocol 1,10.1002/mrm.28066,,,,,0.8,0.18,
,GABA,GABA,2020_dehghani_83,2,Protocol 2,10.1002/mrm.28066,,,,,0.22,0.04,
,GABA,GABA,2020_dehghani_83,3,Protocol 3,10.1002/mrm.28066,,,,,0.55,0.23,
,Glx,Glx,2020_younis_14,1,Healthy,10.3389/fnins.2020.559314,,,11.92,1.899,,,
,Glx,Glx,2020_younis_14,2,Healthy,10.3389/fnins.2020.559314,,,18.186,1.982,,,
,Glx,Glx,2020_younis_14,3,Healthy,10.3389/fnins.2020.559314,,,8.186,2.215,,,
,Glx,Glx,2020_younis_14,4,Healthy,10.3389/fnins.2020.559314,,,12.868,1.46,,,
,tCr,tCr,2020_younis_14,1,Healthy,10.3389/fnins.2020.559314,,,6.435,0.844,,,
,tCr,tCr,2020_younis_14,2,Healthy,10.3389/fnins.2020.559314,,,9.573,0.521,,,
,tCr,tCr,2020_younis_14,3,Healthy,10.3389/fnins.2020.559314,,,7.848,0.844,,,
,tCr,tCr,2020_younis_14,4,Healthy,10.3389/fnins.2020.559314,,,9.114,0.834,,,
,tNAA,tNAA,2020_younis_14,1,Healthy,10.3389/fnins.2020.559314,,,14.114,1.161,,,
,tNAA,tNAA,2020_younis_14,2,Healthy,10.3389/fnins.2020.559314,,,12.93,0.835,,,
,tNAA,tNAA,2020_younis_14,3,Healthy,10.3389/fnins.2020.559314,,,17.342,1.688,,,
,tNAA,tNAA,2020_younis_14,4,Healthy,10.3389/fnins.2020.559314,,,16.642,1.147,,,
,Glu,Glu,2020_younis_14,3,Healthy,10.3389/fnins.2020.559314,,,7.004,1.372,,,
,Glu,Glu,2020_younis_14,4,Healthy,10.3389/fnins.2020.559314,,,10.136,1.147,,,
,Gln,Gln,2020_younis_14,4,Healthy,10.3389/fnins.2020.559314,,,2.669,1.148,,,
,GABA,GABA,2020_younis_14,3,Healthy,10.3389/fnins.2020.559314,,,2.363,0.844,,,
,GABA,GABA,2020_younis_14,4,Healthy,10.3389/fnins.2020.559314,,,2.941,1.147,,,
,tCho,tCho,2020_younis_14,1,Healthy,10.3389/fnins.2020.559314,,,3.144,0.633,,,
,tCho,tCho,2020_younis_14,2,Healthy,10.3389/fnins.2020.559314,,,2.607,0.313,,,
,tCho,tCho,2020_younis_14,3,Healthy,10.3389/fnins.2020.559314,,,3.101,0.528,,,
,tCho,tCho,2020_younis_14,4,Healthy,10.3389/fnins.2020.559314,,,2.086,0.624,,,
,Myo,Myo,2020_younis_14,1,Healthy,10.3389/fnins.2020.559314,,,8.017,1.688,,,
,Myo,Myo,2020_younis_14,2,Healthy,10.3389/fnins.2020.559314,,,6.486,1.669,,,
,Myo,Myo,2020_younis_14,3,Healthy,10.3389/fnins.2020.559314,,,9.768,2.216,,,
,Myo,Myo,2020_younis_14,4,Healthy,10.3389/fnins.2020.559314,,,6.423,1.147,,,
,ml,Myo,2021_foret_13,1,Metabolic Syndrome,10.3389/fnagi.2021.691691,0.77,0.09,,,,,
,ml,Myo,2021_foret_13,2,Metabolic Syndrome,10.3389/fnagi.2021.691691,0.73,0.08,,,,,
,NAA,NAA,2021_foret_13,1,Metabolic Syndrome,10.3389/fnagi.2021.691691,1.34,0.24,,,,,
,NAA,NAA,2021_foret_13,2,Metabolic Syndrome,10.3389/fnagi.2021.691691,1.35,0.22,,,,,
,NAA,NAA,2020_kumar_25,1,Healthy,10.1038/s41380-018-0104-7,,,,,5.15,0.62,
,NAA,NAA,2020_kumar_25,2,Healthy,10.1038/s41380-018-0104-7,,,,,6.13,0.46,
,NAA,NAA,2020_kumar_25,3,Healthy,10.1038/s41380-018-0104-7,,,,,5.16,0.51,
,NAA,NAA,2020_kumar_25,4,Schizophrenia,10.1038/s41380-018-0104-7,,,,,5.11,0.52,
,NAA,NAA,2020_kumar_25,5,Schizophrenia,10.1038/s41380-018-0104-7,,,,,6.03,0.55,
,NAA,NAA,2020_kumar_25,6,Schizophrenia,10.1038/s41380-018-0104-7,,,,,5.15,0.65,
,NAA,NAA,2020_kumar_25,7,Residual SZ,10.1038/s41380-018-0104-7,,,,,4.91,0.54,
,NAA,NAA,2020_kumar_25,8,Residual SZ,10.1038/s41380-018-0104-7,,,,,6.15,0.62,
,NAA,NAA,2020_kumar_25,9,Residual SZ,10.1038/s41380-018-0104-7,,,,,5.36,0.49,
,Cre,Cre,2020_kumar_25,1,Healthy,10.1038/s41380-018-0104-7,,,,,2.98,0.69,
,Cre,Cre,2020_kumar_25,2,Healthy,10.1038/s41380-018-0104-7,,,,,2.6,0.39,
,Cre,Cre,2020_kumar_25,3,Healthy,10.1038/s41380-018-0104-7,,,,,3.28,0.57,
,Cre,Cre,2020_kumar_25,4,Schizophrenia,10.1038/s41380-018-0104-7,,,,,2.9,0.54,
,Cre,Cre,2020_kumar_25,5,Schizophrenia,10.1038/s41380-018-0104-7,,,,,2.61,0.52,
,Cre,Cre,2020_kumar_25,6,Schizophrenia,10.1038/s41380-018-0104-7,,,,,3.27,0.5,
,Cre,Cre,2020_kumar_25,7,Residual SZ,10.1038/s41380-018-0104-7,,,,,2.74,0.49,
,Cre,Cre,2020_kumar_25,8,Residual SZ,10.1038/s41380-018-0104-7,,,,,2.54,0.57,
,Cre,Cre,2020_kumar_25,9,Residual SZ,10.1038/s41380-018-0104-7,,,,,3.28,0.68,
,Myo,Myo,2020_kumar_25,1,Healthy,10.1038/s41380-018-0104-7,,,,,3.68,0.46,
,Myo,Myo,2020_kumar_25,2,Healthy,10.1038/s41380-018-0104-7,,,,,3.33,0.39,
,Myo,Myo,2020_kumar_25,3,Healthy,10.1038/s41380-018-0104-7,,,,,3.87,0.53,
,Myo,Myo,2020_kumar_25,4,Schizophrenia,10.1038/s41380-018-0104-7,,,,,3.47,0.49,
,Myo,Myo,2020_kumar_25,5,Schizophrenia,10.1038/s41380-018-0104-7,,,,,3.27,0.5,
,Myo,Myo,2020_kumar_25,6,Schizophrenia,10.1038/s41380-018-0104-7,,,,,3.68,0.49,
,Myo,Myo,2020_kumar_25,7,Residual SZ,10.1038/s41380-018-0104-7,,,,,3.36,0.52,
,Myo,Myo,2020_kumar_25,8,Residual SZ,10.1038/s41380-018-0104-7,,,,,3.06,0.57,
,Myo,Myo,2020_kumar_25,9,Residual SZ,10.1038/s41380-018-0104-7,,,,,3.56,0.53,
,GSH,GSH,2016_deelchand_29,1,Healthy,10.1002/nbm.3507,,,,,1.35,0.09,
,GSH,GSH,2016_deelchand_29,2,Healthy,10.1002/nbm.3507,,,,,1.33,0.09,
,GSH,GSH,2016_deelchand_29,3,Healthy,10.1002/nbm.3507,,,,,1.35,0.08,
,Asc,Asc,2010_terpstra_24,1,Healthy,10.1002/nbm.1619,,,0.547,0.016,,,
,Asc,Asc,2010_terpstra_24,2,Healthy,10.1002/nbm.1619,,,0.565,0.067,,,
,Asc,Asc,2010_terpstra_24,3,Healthy,10.1002/nbm.1619,,,0.607,0.092,,,
,Asc,Asc,2010_terpstra_24,4,Healthy,10.1002/nbm.1619,,,0.645,0.087,,,
,Asc,Asc,2010_terpstra_24,5,Healthy,10.1002/nbm.1619,,,0.557,0.01,,,
,Asc,Asc,2010_terpstra_24,6,Healthy,10.1002/nbm.1619,,,0.617,0.072,,,
,Asc,Asc,2010_terpstra_24,7,Healthy,10.1002/nbm.1619,,,0.596,0.084,,,
,Asc,Asc,2010_terpstra_24,8,Healthy,10.1002/nbm.1619,,,0.63,0.113,,,
,Asc,Asc,2010_terpstra_24,9,Healthy,10.1002/nbm.1619,,,0.625,0.095,,,
,Asc,Asc,2010_terpstra_24,10,Healthy,10.1002/nbm.1619,,,0.635,0.054,,,
,GSH,GSH,2010_terpstra_24,1,Healthy,10.1002/nbm.1619,,,0.781,0.122,,,
,GSH,GSH,2010_terpstra_24,2,Healthy,10.1002/nbm.1619,,,0.746,0.128,,,
,GSH,GSH,2010_terpstra_24,3,Healthy,10.1002/nbm.1619,,,0.793,0.071,,,
,GSH,GSH,2010_terpstra_24,4,Healthy,10.1002/nbm.1619,,,0.803,0.117,,,
,GSH,GSH,2010_terpstra_24,5,Healthy,10.1002/nbm.1619,,,0.741,0.07,,,
,GSH,GSH,2010_terpstra_24,6,Healthy,10.1002/nbm.1619,,,0.815,0.111,,,
,GSH,GSH,2010_terpstra_24,7,Healthy,10.1002/nbm.1619,,,0.774,0.094,,,
,GSH,GSH,2010_terpstra_24,8,Healthy,10.1002/nbm.1619,,,0.797,0.085,,,
,GSH,GSH,2010_terpstra_24,9,Healthy,10.1002/nbm.1619,,,0.828,0.108,,,
,GSH,GSH,2010_terpstra_24,10,Healthy,10.1002/nbm.1619,,,0.802,0.184,,,
,Glu+Gln,Glx,2008_shih_28,1,Healthy,10.1002/jmri.21466,0.945,0.15,,,,,
,Glu+Gln,Glx,2008_shih_28,2,Healthy,10.1002/jmri.21466,1.342,0.298,,,,,
,Glu+Gln,Glx,2008_shih_28,3,Healthy,10.1002/jmri.21466,1.192,0.309,,,,,
,Glu+Gln,Glx,2008_shih_28,4,Healthy,10.1002/jmri.21466,1.547,0.226,,,,,
,Glu+Gln,Glx,2008_shih_28,5,Healthy,10.1002/jmri.21466,1.378,0.178,,,,,
,Asc,Asc,2008_shih_28,1,Healthy,10.1002/jmri.21466,0.44,0.118,,,,,
,Asc,Asc,2008_shih_28,2,Healthy,10.1002/jmri.21466,0.535,0.127,,,,,
,Asc,Asc,2008_shih_28,3,Healthy,10.1002/jmri.21466,0.507,0.042,,,,,
,Asc,Asc,2008_shih_28,4,Healthy,10.1002/jmri.21466,0.507,0.068,,,,,
,Asc,Asc,2008_shih_28,5,Healthy,10.1002/jmri.21466,0.493,0.042,,,,,
,Myo,Myo,2008_shih_28,1,Healthy,10.1002/jmri.21466,0.632,0.089,,,,,
,Myo,Myo,2008_shih_28,2,Healthy,10.1002/jmri.21466,0.702,0.093,,,,,
,Myo,Myo,2008_shih_28,3,Healthy,10.1002/jmri.21466,0.672,0.042,,,,,
,Myo,Myo,2008_shih_28,4,Healthy,10.1002/jmri.21466,0.609,0.044,,,,,
,Myo,Myo,2008_shih_28,5,Healthy,10.1002/jmri.21466,0.619,0.101,,,,,
,NAA+NAAG,tNAA,2008_shih_28,1,Healthy,10.1002/jmri.21466,1.118,0.159,,,,,
,NAA+NAAG,tNAA,2008_shih_28,2,Healthy,10.1002/jmri.21466,1.298,0.127,,,,,
,NAA+NAAG,tNAA,2008_shih_28,3,Healthy,10.1002/jmri.21466,1.469,0.118,,,,,
,NAA+NAAG,tNAA,2008_shih_28,4,Healthy,10.1002/jmri.21466,1.291,0.066,,,,,
,NAA+NAAG,tNAA,2008_shih_28,5,Healthy,10.1002/jmri.21466,1.209,0.142,,,,,
,GPC+PCh,tCho,2008_shih_28,1,Healthy,10.1002/jmri.21466,0.292,0.023,,,,,
,GPC+PCh,tCho,2008_shih_28,2,Healthy,10.1002/jmri.21466,0.302,0.021,,,,,
,GPC+PCh,tCho,2008_shih_28,3,Healthy,10.1002/jmri.21466,0.262,0.044,,,,,
,GPC+PCh,tCho,2008_shih_28,4,Healthy,10.1002/jmri.21466,0.167,0.011,,,,,
,GPC+PCh,tCho,2008_shih_28,5,Healthy,10.1002/jmri.21466,0.273,0.04,,,,,
,Asp,Asp,2021_okada_11,1,Healthy,10.21037/qims-20-517,,,2.98,0.63,,,
,Asp,Asp,2021_okada_11,2,Healthy,10.21037/qims-20-517,,,2.95,0.63,,,
,Asp,Asp,2021_okada_11,3,Healthy,10.21037/qims-20-517,,,1.45,0.23,,,
,Asp,Asp,2021_okada_11,4,Healthy,10.21037/qims-20-517,,,1.43,0.25,,,
,Asp,Asp,2021_okada_11,5,Healthy,10.21037/qims-20-517,,,1.3,0.29,,,
,Asp,Asp,2021_okada_11,6,Healthy,10.21037/qims-20-517,,,1.4,0.26,,,
,GABA,GABA,2021_okada_11,1,Healthy,10.21037/qims-20-517,,,1.84,0.53,,,
,GABA,GABA,2021_okada_11,2,Healthy,10.21037/qims-20-517,,,1.76,0.61,,,
,GABA,GABA,2021_okada_11,3,Healthy,10.21037/qims-20-517,,,1.05,0.12,,,
,GABA,GABA,2021_okada_11,4,Healthy,10.21037/qims-20-517,,,1.03,0.13,,,
,GABA,GABA,2021_okada_11,5,Healthy,10.21037/qims-20-517,,,0.99,0.13,,,
,GABA,GABA,2021_okada_11,6,Healthy,10.21037/qims-20-517,,,0.99,0.13,,,
,Gln,Gln,2021_okada_11,1,Healthy,10.21037/qims-20-517,,,2.71,0.45,,,
,Gln,Gln,2021_okada_11,2,Healthy,10.21037/qims-20-517,,,2.61,0.44,,,
,Gln,Gln,2021_okada_11,3,Healthy,10.21037/qims-20-517,,,1.69,0.29,,,
,Gln,Gln,2021_okada_11,4,Healthy,10.21037/qims-20-517,,,1.71,0.3,,,
,Gln,Gln,2021_okada_11,5,Healthy,10.21037/qims-20-517,,,1.74,0.3,,,
,Gln,Gln,2021_okada_11,6,Healthy,10.21037/qims-20-517,,,1.65,0.25,,,
,Glu,Glu,2021_okada_11,1,Healthy,10.21037/qims-20-517,,,8.11,0.7,,,
,Glu,Glu,2021_okada_11,2,Healthy,10.21037/qims-20-517,,,7.99,0.71,,,
,Glu,Glu,2021_okada_11,3,Healthy,10.21037/qims-20-517,,,6.52,0.771,,,"Med/Quartile --> Mean/Std Greco, 2015"
,Glu,Glu,2021_okada_11,4,Healthy,10.21037/qims-20-517,,,6.56,0.771,,,"Med/Quartile --> Mean/Std Greco, 2015"
,Glu,Glu,2021_okada_11,5,Healthy,10.21037/qims-20-517,,,6.43,0.756,,,"Med/Quartile --> Mean/Std Greco, 2015"
,Glu,Glu,2021_okada_11,6,Healthy,10.21037/qims-20-517,,,6.31,0.48,,,
,GSH,GSH,2021_okada_11,1,Healthy,10.21037/qims-20-517,,,1.5,0.34,,,
,GSH,GSH,2021_okada_11,2,Healthy,10.21037/qims-20-517,,,1.46,0.39,,,
,GSH,GSH,2021_okada_11,3,Healthy,10.21037/qims-20-517,,,1.3,0.236,,,"Med/Quartile --> Mean/Std Wan, 2014"
,GSH,GSH,2021_okada_11,4,Healthy,10.21037/qims-20-517,,,1.28,0.228,,,"Med/Quartile --> Mean/Std Wan, 2014"
,GSH,GSH,2021_okada_11,5,Healthy,10.21037/qims-20-517,,,1.27,0.219,,,"Med/Quartile --> Mean/Std Wan, 2014"
,GSH,GSH,2021_okada_11,6,Healthy,10.21037/qims-20-517,,,1.17,0.187,,,"Med/Quartile --> Mean/Std Wan, 2014"
,Myo,Myo,2021_okada_11,1,Healthy,10.21037/qims-20-517,,,5.81,0.52,,,
,Myo,Myo,2021_okada_11,2,Healthy,10.21037/qims-20-517,,,5.8,0.51,,,
,Myo,Myo,2021_okada_11,3,Healthy,10.21037/qims-20-517,,,5.03,0.57,,,
,Myo,Myo,2021_okada_11,4,Healthy,10.21037/qims-20-517,,,5.16,0.47,,,
,Myo,Myo,2021_okada_11,5,Healthy,10.21037/qims-20-517,,,5.24,0.41,,,
,Myo,Myo,2021_okada_11,6,Healthy,10.21037/qims-20-517,,,4.58,0.51,,,
,Tau,Tau,2021_okada_11,1,Healthy,10.21037/qims-20-517,,,1.31,0.27,,,
,Tau,Tau,2021_okada_11,2,Healthy,10.21037/qims-20-517,,,1.29,0.25,,,
,Tau,Tau,2021_okada_11,3,Healthy,10.21037/qims-20-517,,,1.07,0.22,,,
,Tau,Tau,2021_okada_11,4,Healthy,10.21037/qims-20-517,,,1.06,0.18,,,
,Tau,Tau,2021_okada_11,5,Healthy,10.21037/qims-20-517,,,1.05,0.18,,,
,Tau,Tau,2021_okada_11,6,Healthy,10.21037/qims-20-517,,,1.1,0.17,,,
,tCho,tCho,2021_okada_11,1,Healthy,10.21037/qims-20-517,,,1.34,0.14,,,
,tCho,tCho,2021_okada_11,2,Healthy,10.21037/qims-20-517,,,1.33,0.14,,,
,tCho,tCho,2021_okada_11,3,Healthy,10.21037/qims-20-517,,,1.22,0.133,,,"Med/Quartile --> Mean/Std Greco, 2015"
,tCho,tCho,2021_okada_11,4,Healthy,10.21037/qims-20-517,,,1.22,0.148,,,"Med/Quartile --> Mean/Std Greco, 2015"
,tCho,tCho,2021_okada_11,5,Healthy,10.21037/qims-20-517,,,1.2,0.122,,,"Med/Quartile --> Mean/Std Wan, 2014"
,tCho,tCho,2021_okada_11,6,Healthy,10.21037/qims-20-517,,,1.1,0.119,,,"Med/Quartile --> Mean/Std Greco, 2015"
,tNAA,tNAA,2021_okada_11,1,Healthy,10.21037/qims-20-517,,,10.77,0.74,,,
,tNAA,tNAA,2021_okada_11,2,Healthy,10.21037/qims-20-517,,,10.77,0.73,,,
,tNAA,tNAA,2021_okada_11,3,Healthy,10.21037/qims-20-517,,,7.67,0.712,,,"Med/Quartile --> Mean/Std Greco, 2015"
,tNAA,tNAA,2021_okada_11,4,Healthy,10.21037/qims-20-517,,,7.64,0.771,,,"Med/Quartile --> Mean/Std Greco, 2015"
,tNAA,tNAA,2021_okada_11,5,Healthy,10.21037/qims-20-517,,,7.59,0.682,,,"Med/Quartile --> Mean/Std Greco, 2015"
,tNAA,tNAA,2021_okada_11,6,Healthy,10.21037/qims-20-517,,,7.23,0.845,,,"Med/Quartile --> Mean/Std Greco, 2015"
,tCr,tCr,2021_okada_11,1,Healthy,10.21037/qims-20-517,,,7.33,0.43,,,
,tCr,tCr,2021_okada_11,2,Healthy,10.21037/qims-20-517,,,7.23,0.44,,,
,tCr,tCr,2021_okada_11,3,Healthy,10.21037/qims-20-517,,,5.39,0.326,,,"Med/Quartile --> Mean/Std Greco, 2015"
,tCr,tCr,2021_okada_11,4,Healthy,10.21037/qims-20-517,,,5.42,0.385,,,"Med/Quartile --> Mean/Std Greco, 2015"
,tCr,tCr,2021_okada_11,5,Healthy,10.21037/qims-20-517,,,5.51,0.309,,,"Med/Quartile --> Mean/Std Wan, 2014"
,tCr,tCr,2021_okada_11,6,Healthy,10.21037/qims-20-517,,,5.26,0.37,,,
,Asc,Asc,2017_marjanska_354,1,Control,10.1016/j.neuroscience.2017.04.035,,,,,1.41,0.165,
,Asc,Asc,2017_marjanska_354,2,Control,10.1016/j.neuroscience.2017.04.035,,,,,1.26,0.165,
,Asc,Asc,2017_marjanska_354,3,Aged,10.1016/j.neuroscience.2017.04.035,,,,,1.66,0.165,
,Asc,Asc,2017_marjanska_354,4,Aged,10.1016/j.neuroscience.2017.04.035,,,,,1.42,0.165,
,Asp,Asp,2017_marjanska_354,1,Control,10.1016/j.neuroscience.2017.04.035,,,,,1.86,0.289,
,Asp,Asp,2017_marjanska_354,2,Control,10.1016/j.neuroscience.2017.04.035,,,,,1.74,0.28,
,Asp,Asp,2017_marjanska_354,3,Aged,10.1016/j.neuroscience.2017.04.035,,,,,1.92,0.289,
,Asp,Asp,2017_marjanska_354,4,Aged,10.1016/j.neuroscience.2017.04.035,,,,,1.74,0.28,
,GABA,GABA,2017_marjanska_354,1,Control,10.1016/j.neuroscience.2017.04.035,,,,,0.78,0.247,
,GABA,GABA,2017_marjanska_354,2,Control,10.1016/j.neuroscience.2017.04.035,,,,,0.89,0.24,
,GABA,GABA,2017_marjanska_354,3,Aged,10.1016/j.neuroscience.2017.04.035,,,,,0.85,0.247,
,GABA,GABA,2017_marjanska_354,4,Aged,10.1016/j.neuroscience.2017.04.035,,,,,1.03,0.24,
,Gln,Gln,2017_marjanska_354,1,Control,10.1016/j.neuroscience.2017.04.035,,,,,3.18,0.3298,
,Gln,Gln,2017_marjanska_354,2,Control,10.1016/j.neuroscience.2017.04.035,,,,,2.9,0.32,
,Gln,Gln,2017_marjanska_354,3,Aged,10.1016/j.neuroscience.2017.04.035,,,,,3.36,0.33,
,Gln,Gln,2017_marjanska_354,4,Aged,10.1016/j.neuroscience.2017.04.035,,,,,2.99,0.32,
,Glu,Glu,2017_marjanska_354,1,Control,10.1016/j.neuroscience.2017.04.035,,,,,10.74,0.6185,
,Glu,Glu,2017_marjanska_354,2,Control,10.1016/j.neuroscience.2017.04.035,,,,,9.99,0.6,
,Glu,Glu,2017_marjanska_354,3,Aged,10.1016/j.neuroscience.2017.04.035,,,,,10.09,0.6185,
,Glu,Glu,2017_marjanska_354,4,Aged,10.1016/j.neuroscience.2017.04.035,,,,,8.94,0.6,
,GSH,GSH,2017_marjanska_354,1,Control,10.1016/j.neuroscience.2017.04.035,,,,,1.07,0.0825,
,GSH,GSH,2017_marjanska_354,2,Control,10.1016/j.neuroscience.2017.04.035,,,,,1,0.08,
,GSH,GSH,2017_marjanska_354,3,Aged,10.1016/j.neuroscience.2017.04.035,,,,,1.12,0.0825,
,GSH,GSH,2017_marjanska_354,4,Aged,10.1016/j.neuroscience.2017.04.035,,,,,1,0.08,
,mIns,Myo,2017_marjanska_354,1,Control,10.1016/j.neuroscience.2017.04.035,,,,,7.12,0.5772,
,mIns,Myo,2017_marjanska_354,2,Control,10.1016/j.neuroscience.2017.04.035,,,,,7.8,0.6,
,mIns,Myo,2017_marjanska_354,3,Aged,10.1016/j.neuroscience.2017.04.035,,,,,7.33,0.5772,
,mIns,Myo,2017_marjanska_354,4,Aged,10.1016/j.neuroscience.2017.04.035,,,,,7.8,0.6,
,NAA,NAA,2017_marjanska_354,1,Control,10.1016/j.neuroscience.2017.04.035,,,,,10.82,0.6185,
,NAA,NAA,2017_marjanska_354,2,Control,10.1016/j.neuroscience.2017.04.035,,,,,12.9,0.6,
,NAA,NAA,2017_marjanska_354,3,Aged,10.1016/j.neuroscience.2017.04.035,,,,,10.72,0.6185,
,NAA,NAA,2017_marjanska_354,4,Aged,10.1016/j.neuroscience.2017.04.035,,,,,11.57,0.6,
,NAAG,NAAG,2017_marjanska_354,1,Control,10.1016/j.neuroscience.2017.04.035,,,,,1.17,0.3711,
,NAAG,NAAG,2017_marjanska_354,2,Control,10.1016/j.neuroscience.2017.04.035,,,,,1.38,0.12,
,NAAG,NAAG,2017_marjanska_354,3,Aged,10.1016/j.neuroscience.2017.04.035,,,,,0.96,0.1237,
,NAAG,NAAG,2017_marjanska_354,4,Aged,10.1016/j.neuroscience.2017.04.035,,,,,1.1,0.12,
,PE,PE,2017_marjanska_354,1,Control,10.1016/j.neuroscience.2017.04.035,,,,,2.12,0.2062,
,PE,PE,2017_marjanska_354,2,Control,10.1016/j.neuroscience.2017.04.035,,,,,1.66,0.2,
,PE,PE,2017_marjanska_354,3,Aged,10.1016/j.neuroscience.2017.04.035,,,,,1.21,0.2062,
,PE,PE,2017_marjanska_354,4,Aged,10.1016/j.neuroscience.2017.04.035,,,,,0.82,0.2,
,sIns,Scy,2017_marjanska_354,1,Control,10.1016/j.neuroscience.2017.04.035,,,,,0.26,0.2062,
,sIns,Scy,2017_marjanska_354,2,Control,10.1016/j.neuroscience.2017.04.035,,,,,0.28,0.2,
,sIns,Scy,2017_marjanska_354,3,Aged,10.1016/j.neuroscience.2017.04.035,,,,,0.47,0.2062,
,sIns,Scy,2017_marjanska_354,4,Aged,10.1016/j.neuroscience.2017.04.035,,,,,0.47,0.2,
,Tau,Tau,2017_marjanska_354,1,Control,10.1016/j.neuroscience.2017.04.035,,,,,1.86,0.2474,
,Tau,Tau,2017_marjanska_354,2,Control,10.1016/j.neuroscience.2017.04.035,,,,,1.75,0.24,
,Tau,Tau,2017_marjanska_354,3,Aged,10.1016/j.neuroscience.2017.04.035,,,,,1.85,0.2474,
,Tau,Tau,2017_marjanska_354,4,Aged,10.1016/j.neuroscience.2017.04.035,,,,,1.85,0.24,
,tCho,tCho,2017_marjanska_354,1,Control,10.1016/j.neuroscience.2017.04.035,,,,,1.21,0.1237,
,tCho,tCho,2017_marjanska_354,2,Control,10.1016/j.neuroscience.2017.04.035,,,,,0.96,0.12,
,tCho,tCho,2017_marjanska_354,3,Aged,10.1016/j.neuroscience.2017.04.035,,,,,1.47,0.1237,
,tCho,tCho,2017_marjanska_354,4,Aged,10.1016/j.neuroscience.2017.04.035,,,,,1.14,0.12,
,tCr,tCr,2017_marjanska_354,1,Control,10.1016/j.neuroscience.2017.04.035,,,,,8.89,0.5772,
,tCr,tCr,2017_marjanska_354,2,Control,10.1016/j.neuroscience.2017.04.035,,,,,9.26,0.56,
,tCr,tCr,2017_marjanska_354,3,Aged,10.1016/j.neuroscience.2017.04.035,,,,,9.63,0.5772,
,tCr,tCr,2017_marjanska_354,4,Aged,10.1016/j.neuroscience.2017.04.035,,,,,9.39,0.56,
,Cre,Cre,2017_zeydan_27,1,Control,10.1111/jon.12454,,,,,8.7,1.038,"Med/Quartile --> Mean/Std Greco, 2015"
,Cre,Cre,2017_zeydan_27,2,MCI,10.1111/jon.12454,,,,,8,1.038,"Med/Quartile --> Mean/Std Greco, 2015"
,Myo,Myo,2017_zeydan_27,1,Control,10.1111/jon.12454,,,,,6.9,1.086,"Med/Quartile --> Mean/Std Wan, 2014"
,Myo,Myo,2017_zeydan_27,2,MCI,10.1111/jon.12454,,,,,7.1,1.631,"Med/Quartile --> Mean/Std Greco, 2015"
,Cho,GPC,2017_zeydan_27,1,Control,10.1111/jon.12454,,,,,1.8,0.445,"Med/Quartile --> Mean/Std Greco, 2015"
,Cho,GPC,2017_zeydan_27,2,MCI,10.1111/jon.12454,,,,,1.8,0.445,"Med/Quartile --> Mean/Std Greco, 2015"
,Glu,Glu,2017_zeydan_27,1,Control,10.1111/jon.12454,,,,,8.9,0.621,"Med/Quartile --> Mean/Std Wan, 2015"
,Glu,Glu,2017_zeydan_27,2,MCI,10.1111/jon.12454,,,,,8.1,0.89,"Med/Quartile --> Mean/Std Greco, 2015"
,NAA,NAA,2017_zeydan_27,1,Control,10.1111/jon.12454,,,,,10.8,1.186,"Med/Quartile --> Mean/Std Greco, 2015"
,NAA,NAA,2017_zeydan_27,2,MCI,10.1111/jon.12454,,,,,10.4,1.631,"Med/Quartile --> Mean/Std Greco, 2015"
,Glx,Glx,2019_pesch_8,1,Control,10.3390/cells8020096,,,,,10.5,1.701,Med/Quartile --> Mean/Std Wan 2014
,Glx,Glx,2019_pesch_8,2,Parkinson's,10.3390/cells8020096,,,,,10.5,2.164,Med/Quartile --> Mean/Std Wan 2014
,Glx,Glx,2019_pesch_8,3,Parkinson's,10.3390/cells8020096,,,,,9.6,2.076,Med/Quartile --> Mean/Std Greco 2015
,Glx,Glx,2019_pesch_8,4,Parkinson's,10.3390/cells8020096,,,,,11.4,1.788,Med/Quartile --> Mean/Std Wan 2014
,Glx,Glx,2019_pesch_8,5,Control,10.3390/cells8020096,,,,,7.2,1.631,Med/Quartile --> Mean/Std Greco 2015
,Glx,Glx,2019_pesch_8,6,Parkinson's,10.3390/cells8020096,,,,,7.7,1.314,Med/Quartile --> Mean/Std Wan 2014
,Glx,Glx,2019_pesch_8,7,Parkinson's,10.3390/cells8020096,,,,,7.5,1.201,Med/Quartile --> Mean/Std Wan 2014
,Glx,Glx,2019_pesch_8,8,Parkinson's,10.3390/cells8020096,,,,,7.8,1.631,Med/Quartile --> Mean/Std Greco 2015
,GABA,GABA,2019_pesch_8,1,Control,10.3390/cells8020096,,,,,1.9,0.297,Med/Quartile --> Mean/Std Greco 2015
,GABA,GABA,2019_pesch_8,2,Parkinson's,10.3390/cells8020096,,,,,2,0.309,Med/Quartile --> Mean/Std Wan 2014
,GABA,GABA,2019_pesch_8,3,Parkinson's,10.3390/cells8020096,,,,,2,0.481,Med/Quartile --> Mean/Std Wan 2014
,GABA,GABA,2019_pesch_8,4,Parkinson's,10.3390/cells8020096,,,,,2.1,0.406,Med/Quartile --> Mean/Std Wan 2014
,GABA,GABA,2019_pesch_8,5,Control,10.3390/cells8020096,,,,,1.9,0.741,Med/Quartile --> Mean/Std Greco 2015
,GABA,GABA,2019_pesch_8,6,Parkinson's,10.3390/cells8020096,,,,,2.1,0.386,Med/Quartile --> Mean/Std Wan 2014
,GABA,GABA,2019_pesch_8,7,Parkinson's,10.3390/cells8020096,,,,,2.2,0.4,Med/Quartile --> Mean/Std Wan 2014
,GABA,GABA,2019_pesch_8,8,Parkinson's,10.3390/cells8020096,,,,,2,0.163,Med/Quartile --> Mean/Std Wan 2014
,Myo,Myo,2019_pesch_8,1,Control,10.3390/cells8020096,,,,,4.3,0.618,Med/Quartile --> Mean/Std Wan 2014
,Myo,Myo,2019_pesch_8,2,Parkinson's,10.3390/cells8020096,,,,,4.4,0.928,Med/Quartile --> Mean/Std Wan 2014
,Myo,Myo,2019_pesch_8,3,Parkinson's,10.3390/cells8020096,,,,,4.3,0.721,Med/Quartile --> Mean/Std Wan 2014
,Myo,Myo,2019_pesch_8,4,Parkinson's,10.3390/cells8020096,,,,,4.6,0.975,Med/Quartile --> Mean/Std Wan 2014
,Myo,Myo,2019_pesch_8,5,Control,10.3390/cells8020096,,,,,4.6,0.464,Med/Quartile --> Mean/Std Wan 2014
,Myo,Myo,2019_pesch_8,6,Parkinson's,10.3390/cells8020096,,,,,4.9,0.85,Med/Quartile --> Mean/Std Wan 2014
,Myo,Myo,2019_pesch_8,7,Parkinson's,10.3390/cells8020096,,,,,4.7,1.121,Med/Quartile --> Mean/Std Wan 2014
,Myo,Myo,2019_pesch_8,8,Parkinson's,10.3390/cells8020096,,,,,5,0.813,Med/Quartile --> Mean/Std Wan 2014
,tCr,tCr,2019_pesch_8,1,Control,10.3390/cells8020096,,,,,7.5,0.541,Med/Quartile --> Mean/Std Wan 2014
,tCr,tCr,2019_pesch_8,2,Parkinson's,10.3390/cells8020096,,,,,7.2,0.85,Med/Quartile --> Mean/Std Wan 2014
,tCr,tCr,2019_pesch_8,3,Parkinson's,10.3390/cells8020096,,,,,6.7,1.038,Med/Quartile --> Mean/Std Greco 2015
,tCr,tCr,2019_pesch_8,4,Parkinson's,10.3390/cells8020096,,,,,7.4,0.732,Med/Quartile --> Mean/Std Wan 2014
,tCr,tCr,2019_pesch_8,5,Control,10.3390/cells8020096,,,,,6.3,0.741,Med/Quartile --> Mean/Std Greco 2015
,tCr,tCr,2019_pesch_8,6,Parkinson's,10.3390/cells8020096,,,,,6.3,0.741,Med/Quartile --> Mean/Std Greco 2015
,tCr,tCr,2019_pesch_8,7,Parkinson's,10.3390/cells8020096,,,,,6.2,0.4,Med/Quartile --> Mean/Std Wan 2014
,tCr,tCr,2019_pesch_8,8,Parkinson's,10.3390/cells8020096,,,,,6.5,0.488,Med/Quartile --> Mean/Std Wan 2014
,Glu,Glu,2021_tannous_26,1,Control,10.1038/s41380-020-00927-9,,,9.29,1.65,,,
,Glu,Glu,2021_tannous_26,2,Bipolar,10.1038/s41380-020-00927-9,,,9.28,2.3,,,
,Glu,Glu,2021_tannous_26,3,Control,10.1038/s41380-020-00927-9,,,10.54,1.56,,,
,Glu,Glu,2021_tannous_26,4,Bipolar,10.1038/s41380-020-00927-9,,,10.2,1.84,,,
,Glu,Glu,2021_tannous_26,5,Control,10.1038/s41380-020-00927-9,,,12.12,1.7,,,
,Glu,Glu,2021_tannous_26,6,Bipolar,10.1038/s41380-020-00927-9,,,11.51,2.25,,,
,Glu,Glu,2021_tannous_26,7,Control,10.1038/s41380-020-00927-9,,,11.8,2.24,,,
,Glu,Glu,2021_tannous_26,8,Bipolar,10.1038/s41380-020-00927-9,,,10.54,1.74,,,
,GPC+PC,tCho,2021_tannous_26,1,Control,10.1038/s41380-020-00927-9,,,2.69,0.53,,,
,GPC+PC,tCho,2021_tannous_26,2,Bipolar,10.1038/s41380-020-00927-9,,,2.37,0.46,,,
,GPC+PC,tCho,2021_tannous_26,3,Control,10.1038/s41380-020-00927-9,,,2.87,0.57,,,
,GPC+PC,tCho,2021_tannous_26,4,Bipolar,10.1038/s41380-020-00927-9,,,2.57,0.49,,,
,GPC+PC,tCho,2021_tannous_26,5,Control,10.1038/s41380-020-00927-9,,,3.05,0.64,,,
,GPC+PC,tCho,2021_tannous_26,6,Bipolar,10.1038/s41380-020-00927-9,,,2.83,0.57,,,
,GPC+PC,tCho,2021_tannous_26,7,Control,10.1038/s41380-020-00927-9,,,2.87,0.72,,,
,GPC+PC,tCho,2021_tannous_26,8,Bipolar,10.1038/s41380-020-00927-9,,,2.57,0.56,,,
,MI,Myo,2021_tannous_26,1,Control,10.1038/s41380-020-00927-9,,,7.4,1.9,,,
,MI,Myo,2021_tannous_26,2,Bipolar,10.1038/s41380-020-00927-9,,,7.27,1.82,,,
,MI,Myo,2021_tannous_26,3,Control,10.1038/s41380-020-00927-9,,,7.67,1.98,,,
,MI,Myo,2021_tannous_26,4,Bipolar,10.1038/s41380-020-00927-9,,,8.02,2.11,,,
,MI,Myo,2021_tannous_26,5,Control,10.1038/s41380-020-00927-9,,,8.77,2.27,,,
,MI,Myo,2021_tannous_26,6,Bipolar,10.1038/s41380-020-00927-9,,,8.96,2.14,,,
,MI,Myo,2021_tannous_26,7,Control,10.1038/s41380-020-00927-9,,,8.54,2.41,,,
,MI,Myo,2021_tannous_26,8,Bipolar,10.1038/s41380-020-00927-9,,,8.32,2.03,,,
,NAA+NAAG,tNAA,2021_tannous_26,1,Control,10.1038/s41380-020-00927-9,,,14.73,3.77,,,
,NAA+NAAG,tNAA,2021_tannous_26,2,Bipolar,10.1038/s41380-020-00927-9,,,13.12,2.97,,,
,NAA+NAAG,tNAA,2021_tannous_26,3,Control,10.1038/s41380-020-00927-9,,,18.21,3.75,,,
,NAA+NAAG,tNAA,2021_tannous_26,4,Bipolar,10.1038/s41380-020-00927-9,,,16.55,3.19,,,
,NAA+NAAG,tNAA,2021_tannous_26,5,Control,10.1038/s41380-020-00927-9,,,21.24,4.42,,,
,NAA+NAAG,tNAA,2021_tannous_26,6,Bipolar,10.1038/s41380-020-00927-9,,,19.58,3.58,,,
,NAA+NAAG,tNAA,2021_tannous_26,7,Control,10.1038/s41380-020-00927-9,,,20.17,4.34,,,
,NAA+NAAG,tNAA,2021_tannous_26,8,Bipolar,10.1038/s41380-020-00927-9,,,18.97,3.35,,,
,NAA,NAA,2021_tannous_26,1,Control,10.1038/s41380-020-00927-9,,,13.05,3.49,,,
,NAA,NAA,2021_tannous_26,2,Bipolar,10.1038/s41380-020-00927-9,,,11.56,2.8,,,
,NAA,NAA,2021_tannous_26,3,Control,10.1038/s41380-020-00927-9,,,15.41,3.61,,,
,NAA,NAA,2021_tannous_26,4,Bipolar,10.1038/s41380-020-00927-9,,,13.89,3.38,,,
,NAA,NAA,2021_tannous_26,5,Control,10.1038/s41380-020-00927-9,,,17.65,4.01,,,
,NAA,NAA,2021_tannous_26,6,Bipolar,10.1038/s41380-020-00927-9,,,16.16,3.22,,,
,NAA,NAA,2021_tannous_26,7,Control,10.1038/s41380-020-00927-9,,,17,4.21,,,
,NAA,NAA,2021_tannous_26,8,Bipolar,10.1038/s41380-020-00927-9,,,16.19,3.53,,,
,PCr+Cr,tCr,2021_tannous_26,1,Control,10.1038/s41380-020-00927-9,,,9.19,1.81,,,
,PCr+Cr,tCr,2021_tannous_26,2,Bipolar,10.1038/s41380-020-00927-9,,,8.26,1.74,,,
,PCr+Cr,tCr,2021_tannous_26,3,Control,10.1038/s41380-020-00927-9,,,9.86,1.56,,,
,PCr+Cr,tCr,2021_tannous_26,4,Bipolar,10.1038/s41380-020-00927-9,,,9.5,1.79,,,
,PCr+Cr,tCr,2021_tannous_26,5,Control,10.1038/s41380-020-00927-9,,,11,1.64,,,
,PCr+Cr,tCr,2021_tannous_26,6,Bipolar,10.1038/s41380-020-00927-9,,,10.74,1.93,,,
,PCr+Cr,tCr,2021_tannous_26,7,Control,10.1038/s41380-020-00927-9,,,10.24,2.42,,,
,PCr+Cr,tCr,2021_tannous_26,8,Bipolar,10.1038/s41380-020-00927-9,,,9.63,1.75,,,
,tNAA,tNAA,2021_shibasaki_239,1,Development,10.1016/j.jpeds.2021.08.011,,,,,5.4,1.201,"Med/Quartile --> Mean/Std Greco, 2015"
,tNAA,tNAA,2021_shibasaki_239,2,Development,10.1016/j.jpeds.2021.08.011,,,,,4.02,0.769,"Med/Quartile --> Mean/Std Wan, 2014"
,tNAA,tNAA,2021_shibasaki_239,3,Development,10.1016/j.jpeds.2021.08.011,,,,,5.77,0.99,"Med/Quartile --> Mean/Std Wan, 2014"
,tNAA,tNAA,2021_shibasaki_239,4,Development,10.1016/j.jpeds.2021.08.011,,,,,2.88,1.039,"Med/Quartile --> Mean/Std Wan, 2014"
,Lac,Lac,2021_shibasaki_239,1,Development,10.1016/j.jpeds.2021.08.011,,,,,0.62,0.608,"Med/Quartile --> Mean/Std Greco, 2015"
,Lac,Lac,2021_shibasaki_239,2,Development,10.1016/j.jpeds.2021.08.011,,,,,2.74,1.693,"Med/Quartile --> Mean/Std Wan, 2014"
,Lac,Lac,2021_shibasaki_239,3,Development,10.1016/j.jpeds.2021.08.011,,,,,0.92,0.484,"Med/Quartile --> Mean/Std Wan, 2014"
,Lac,Lac,2021_shibasaki_239,4,Development,10.1016/j.jpeds.2021.08.011,,,,,1.57,1.489,"Med/Quartile --> Mean/Std Wan, 2014"
,tCho,tCho,2021_shibasaki_239,1,Development,10.1016/j.jpeds.2021.08.011,,,,,2.25,0.2,"Med/Quartile --> Mean/Std Wan, 2014"
,tCho,tCho,2021_shibasaki_239,2,Development,10.1016/j.jpeds.2021.08.011,,,,,1.76,0.286,"Med/Quartile --> Mean/Std Wan, 2014"
,tCho,tCho,2021_shibasaki_239,3,Development,10.1016/j.jpeds.2021.08.011,,,,,2.71,0.348,"Med/Quartile --> Mean/Std Wan, 2014"
,tCho,tCho,2021_shibasaki_239,4,Development,10.1016/j.jpeds.2021.08.011,,,,,2.05,0.589,"Med/Quartile --> Mean/Std Wan, 2014"
,m-Ins,Myo,2021_gajdosik_34,1,Healthy,10.1002/nbm.4538,,,,,5,2,
,m-Ins,Myo,2021_gajdosik_34,2,Healthy,10.1002/nbm.4538,,,,,5.8,0.5,
,s-Ins,Scy,2021_gajdosik_34,1,Healthy,10.1002/nbm.4538,,,,,0.6,0.2,
,s-Ins,Scy,2021_gajdosik_34,2,Healthy,10.1002/nbm.4538,,,,,0.4,0.4,
,Cho,GPC,2021_gajdosik_34,1,Healthy,10.1002/nbm.4538,,,,,1.6,0.2,
,Cho,GPC,2021_gajdosik_34,2,Healthy,10.1002/nbm.4538,,,,,1.8,0.3,
,Cre,Cre,2021_gajdosik_34,1,Healthy,10.1002/nbm.4538,,,,,5.7,0.4,
,Cre,Cre,2021_gajdosik_34,2,Healthy,10.1002/nbm.4538,,,,,5.9,0.3,
,Gln,Gln,2021_gajdosik_34,1,Healthy,10.1002/nbm.4538,,,,,2,1.3,
,Gln,Gln,2021_gajdosik_34,2,Healthy,10.1002/nbm.4538,,,,,2.7,0.8,
,Glu,Glu,2021_gajdosik_34,1,Healthy,10.1002/nbm.4538,,,,,9.2,2.4,
,Glu,Glu,2021_gajdosik_34,2,Healthy,10.1002/nbm.4538,,,,,9.2,1.1,
,Glx,Glx,2021_gajdosik_34,1,Healthy,10.1002/nbm.4538,,,,,11.2,1.8,
,Glx,Glx,2021_gajdosik_34,2,Healthy,10.1002/nbm.4538,,,,,11.9,0.4,
,NAA,NAA,2021_gajdosik_34,1,Healthy,10.1002/nbm.4538,,,,,5.9,0.5,
,NAA,NAA,2021_gajdosik_34,2,Healthy,10.1002/nbm.4538,,,,,5.9,0.3,
,Lac+,Lac,2021_gajdosik_34,1,Healthy,10.1002/nbm.4538,,,,,2.6,0.6,
,Lac+,Lac,2021_gajdosik_34,2,Healthy,10.1002/nbm.4538,,,,,2.4,0.9,
,Myo,Myo,2017_suri_152,1,Control,10.1016/j.neuroimage.2017.03.031,0.749,0.049,,,,,
,Myo,Myo,2017_suri_152,2,Aged,10.1016/j.neuroimage.2017.03.031,0.761,0.061,,,,,
,Myo,Myo,2017_suri_152,3,Aged,10.1016/j.neuroimage.2017.03.031,0.786,0.062,,,,,
,Myo,Myo,2017_suri_152,4,Aged,10.1016/j.neuroimage.2017.03.031,0.749,0.061,,,,,
,Myo,Myo,2017_suri_152,5,APOE4,10.1016/j.neuroimage.2017.03.031,0.76,0.054,,,,,
,NAA,NAA,2017_suri_152,1,Control,10.1016/j.neuroimage.2017.03.031,1.44,0.078,,,,,
,NAA,NAA,2017_suri_152,2,Aged,10.1016/j.neuroimage.2017.03.031,1.331,0.093,,,,,
,NAA,NAA,2017_suri_152,3,Aged,10.1016/j.neuroimage.2017.03.031,1.399,0.123,,,,,
,NAA,NAA,2017_suri_152,4,Aged,10.1016/j.neuroimage.2017.03.031,1.356,0.093,,,,,
,NAA,NAA,2017_suri_152,5,APOE4,10.1016/j.neuroimage.2017.03.031,1.339,0.113,,,,,
,Asp,Asp,2017_suri_152,1,Control,10.1016/j.neuroimage.2017.03.031,0.364,0.022,,,,,Values were estimated using Freidrich 2011 method (10.1016/j.jclinepi.2010.09.016).
,Asp,Asp,2017_suri_152,2,Aged,10.1016/j.neuroimage.2017.03.031,0.351,0.021,,,,,Values were estimated using Freidrich 2011 method (10.1016/j.jclinepi.2010.09.016).
,Asp,Asp,2017_suri_152,3,Aged,10.1016/j.neuroimage.2017.03.031,0.365,0.022,,,,,Values were estimated using Freidrich 2011 method (10.1016/j.jclinepi.2010.09.016).
,Asp,Asp,2017_suri_152,4,Aged,10.1016/j.neuroimage.2017.03.031,0.353,0.021,,,,,Values were estimated using Freidrich 2011 method (10.1016/j.jclinepi.2010.09.016).
,Asp,Asp,2017_suri_152,5,APOE4,10.1016/j.neuroimage.2017.03.031,0.353,0.021,,,,,Values were estimated using Freidrich 2011 method (10.1016/j.jclinepi.2010.09.016).
,Glu,Glu,2017_suri_152,1,Control,10.1016/j.neuroimage.2017.03.031,1.243,0.0745,,,,,Values were estimated using Freidrich 2011 method (10.1016/j.jclinepi.2010.09.016).
,Glu,Glu,2017_suri_152,2,Aged,10.1016/j.neuroimage.2017.03.031,1.084,0.065,,,,,Values were estimated using Freidrich 2011 method (10.1016/j.jclinepi.2010.09.016).
,Glu,Glu,2017_suri_152,3,Aged,10.1016/j.neuroimage.2017.03.031,1.146,0.0687,,,,,Values were estimated using Freidrich 2011 method (10.1016/j.jclinepi.2010.09.016).
,Glu,Glu,2017_suri_152,4,Aged,10.1016/j.neuroimage.2017.03.031,1.113,0.0668,,,,,Values were estimated using Freidrich 2011 method (10.1016/j.jclinepi.2010.09.016).
,Glu,Glu,2017_suri_152,5,APOE4,10.1016/j.neuroimage.2017.03.031,1.109,0.0665,,,,,Values were estimated using Freidrich 2011 method (10.1016/j.jclinepi.2010.09.016).
,Gln,Gln,2017_suri_152,1,Control,10.1016/j.neuroimage.2017.03.031,0.258,0.016,,,,,Values were estimated using Freidrich 2011 method (10.1016/j.jclinepi.2010.09.016).
,Gln,Gln,2017_suri_152,2,Aged,10.1016/j.neuroimage.2017.03.031,0.297,0.018,,,,,Values were estimated using Freidrich 2011 method (10.1016/j.jclinepi.2010.09.016).
,Gln,Gln,2017_suri_152,3,Aged,10.1016/j.neuroimage.2017.03.031,0.28,0.017,,,,,Values were estimated using Freidrich 2011 method (10.1016/j.jclinepi.2010.09.016).
,Gln,Gln,2017_suri_152,4,Aged,10.1016/j.neuroimage.2017.03.031,0.287,0.017,,,,,Values were estimated using Freidrich 2011 method (10.1016/j.jclinepi.2010.09.016).
,Gln,Gln,2017_suri_152,5,APOE4,10.1016/j.neuroimage.2017.03.031,0.291,0.018,,,,,Values were estimated using Freidrich 2011 method (10.1016/j.jclinepi.2010.09.016).
,GSH,GSH,2017_suri_152,1,Control,10.1016/j.neuroimage.2017.03.031,0.139,0.008,,,,,Values were estimated using Freidrich 2011 method (10.1016/j.jclinepi.2010.09.016).
,GSH,GSH,2017_suri_152,2,Aged,10.1016/j.neuroimage.2017.03.031,0.123,0.007,,,,,Values were estimated using Freidrich 2011 method (10.1016/j.jclinepi.2010.09.016).
,GSH,GSH,2017_suri_152,3,Aged,10.1016/j.neuroimage.2017.03.031,0.129,0.008,,,,,Values were estimated using Freidrich 2011 method (10.1016/j.jclinepi.2010.09.016).
,GSH,GSH,2017_suri_152,4,Aged,10.1016/j.neuroimage.2017.03.031,0.126,0.008,,,,,Values were estimated using Freidrich 2011 method (10.1016/j.jclinepi.2010.09.016).
,GSH,GSH,2017_suri_152,5,APOE4,10.1016/j.neuroimage.2017.03.031,0.128,0.008,,,,,Values were estimated using Freidrich 2011 method (10.1016/j.jclinepi.2010.09.016).
,tCho,tCho,2017_suri_152,1,Control,10.1016/j.neuroimage.2017.03.031,0.154,0.009,,,,,Values were estimated using Freidrich 2011 method (10.1016/j.jclinepi.2010.09.016).
,tCho,tCho,2017_suri_152,2,Aged,10.1016/j.neuroimage.2017.03.031,0.151,0.009,,,,,Values were estimated using Freidrich 2011 method (10.1016/j.jclinepi.2010.09.016).
,tCho,tCho,2017_suri_152,3,Aged,10.1016/j.neuroimage.2017.03.031,0.155,0.009,,,,,Values were estimated using Freidrich 2011 method (10.1016/j.jclinepi.2010.09.016).
,tCho,tCho,2017_suri_152,4,Aged,10.1016/j.neuroimage.2017.03.031,0.151,0.009,,,,,Values were estimated using Freidrich 2011 method (10.1016/j.jclinepi.2010.09.016).
,tCho,tCho,2017_suri_152,5,APOE4,10.1016/j.neuroimage.2017.03.031,0.151,0.009,,,,,Values were estimated using Freidrich 2011 method (10.1016/j.jclinepi.2010.09.016).
,Total Glucose,Glc,2017_suri_152,1,Control,10.1016/j.neuroimage.2017.03.031,0.431,0.026,,,,,Values were estimated using Freidrich 2011 method (10.1016/j.jclinepi.2010.09.016).
,Total Glucose,Glc,2017_suri_152,2,Aged,10.1016/j.neuroimage.2017.03.031,0.43,0.026,,,,,Values were estimated using Freidrich 2011 method (10.1016/j.jclinepi.2010.09.016).
,Total Glucose,Glc,2017_suri_152,3,Aged,10.1016/j.neuroimage.2017.03.031,0.436,0.026,,,,,Values were estimated using Freidrich 2011 method (10.1016/j.jclinepi.2010.09.016).
,Total Glucose,Glc,2017_suri_152,4,Aged,10.1016/j.neuroimage.2017.03.031,0.428,0.026,,,,,Values were estimated using Freidrich 2011 method (10.1016/j.jclinepi.2010.09.016).
,Total Glucose,Glc,2017_suri_152,5,APOE4,10.1016/j.neuroimage.2017.03.031,0.429,0.026,,,,,Values were estimated using Freidrich 2011 method (10.1016/j.jclinepi.2010.09.016).
,Cho,GPC,2014_gomar_75,1,Control,10.1016/j.biopsych.2013.05.022,0.61,0.038,,,,,"All values were estimated from Scatter Plot; Age was broken down under 60 and over 60 to even out the group Ns. However, total subjects and Male/Female breakdown reflects the information provided within the article."
,Cho,GPC,2014_gomar_75,2,APOE4,10.1016/j.biopsych.2013.05.022,0.612,0.024,,,,,"All values were estimated from Scatter Plot; Age was broken down under 60 and over 60 to even out the group Ns. However, total subjects and Male/Female breakdown reflects the information provided within the article."
,Cho,GPC,2014_gomar_75,3,Control,10.1016/j.biopsych.2013.05.022,0.597,0.05,,,,,"All values were estimated from Scatter Plot; Age was broken down under 60 and over 60 to even out the group Ns. However, total subjects and Male/Female breakdown reflects the information provided within the article."
,Cho,GPC,2014_gomar_75,4,APOE4,10.1016/j.biopsych.2013.05.022,0.626,0.065,,,,,"All values were estimated from Scatter Plot; Age was broken down under 60 and over 60 to even out the group Ns. However, total subjects and Male/Female breakdown reflects the information provided within the article."
,NAA,NAA,2014_gomar_75,5,Control,10.1016/j.biopsych.2013.05.022,1.524,0.079,,,,,"All values were estimated from Scatter Plot; Age was broken down under 60 and over 60 to even out the group Ns. However, total subjects and Male/Female breakdown reflects the information provided within the article."
,NAA,NAA,2014_gomar_75,6,APOE4,10.1016/j.biopsych.2013.05.022,1.524,0.065,,,,,"All values were estimated from Scatter Plot; Age was broken down under 60 and over 60 to even out the group Ns. However, total subjects and Male/Female breakdown reflects the information provided within the article."
,NAA,NAA,2014_gomar_75,7,Control,10.1016/j.biopsych.2013.05.022,1.527,0.086,,,,,"All values were estimated from Scatter Plot; Age was broken down under 60 and over 60 to even out the group Ns. However, total subjects and Male/Female breakdown reflects the information provided within the article."
,NAA,NAA,2014_gomar_75,8,APOE4,10.1016/j.biopsych.2013.05.022,1.533,0.059,,,,,"All values were estimated from Scatter Plot; Age was broken down under 60 and over 60 to even out the group Ns. However, total subjects and Male/Female breakdown reflects the information provided within the article."
,Myo,Myo,2014_gomar_75,9,Control,10.1016/j.biopsych.2013.05.022,0.546,0.034,,,,,"All values were estimated from Scatter Plot; Age was broken down under 60 and over 60 to even out the group Ns. However, total subjects and Male/Female breakdown reflects the information provided within the article."
,Myo,Myo,2014_gomar_75,10,APOE4,10.1016/j.biopsych.2013.05.022,0.563,0.036,,,,,"All values were estimated from Scatter Plot; Age was broken down under 60 and over 60 to even out the group Ns. However, total subjects and Male/Female breakdown reflects the information provided within the article."
,Myo,Myo,2014_gomar_75,11,Control,10.1016/j.biopsych.2013.05.022,0.55,0.054,,,,,"All values were estimated from Scatter Plot; Age was broken down under 60 and over 60 to even out the group Ns. However, total subjects and Male/Female breakdown reflects the information provided within the article."
,Myo,Myo,2014_gomar_75,12,APOE4,10.1016/j.biopsych.2013.05.022,0.583,0.083,,,,,"All values were estimated from Scatter Plot; Age was broken down under 60 and over 60 to even out the group Ns. However, total subjects and Male/Female breakdown reflects the information provided within the article."
,NAA,NAA,2015_calderon-garciduenas_48,1,Control - Parents,10.3233/JAD-150415,1.7,0.22,,,,,
,NAA,NAA,2015_calderon-garciduenas_48,2,APOE3 - Parents,10.3233/JAD-150415,1.55,0.17,,,,,
,NAA,NAA,2015_calderon-garciduenas_48,3,APOE4 - Parents,10.3233/JAD-150415,1.546,0.123,,,,,
,NAA,NAA,2015_calderon-garciduenas_48,4,Control - Parents,10.3233/JAD-150415,1.673,0.241,,,,,
,NAA,NAA,2015_calderon-garciduenas_48,5,APOE3 - Parents,10.3233/JAD-150415,1.578,0.308,,,,,
,NAA,NAA,2015_calderon-garciduenas_48,6,APOE4 - Parents,10.3233/JAD-150415,1.483,0.214,,,,,
,NAA,NAA,2015_calderon-garciduenas_48,7,Control - Children,10.3233/JAD-150415,1.54,0.152,,,,,
,NAA,NAA,2015_calderon-garciduenas_48,8,APOE3 - Children,10.3233/JAD-150415,1.457,0.181,,,,,
,NAA,NAA,2015_calderon-garciduenas_48,9,APOE4 - Children,10.3233/JAD-150415,1.43,0.176,,,,,
,NAA,NAA,2015_calderon-garciduenas_48,10,Control - Children,10.3233/JAD-150415,1.517,0.158,,,,,
,NAA,NAA,2015_calderon-garciduenas_48,11,APOE3 - Children,10.3233/JAD-150415,1.569,0.26,,,,,
,NAA,NAA,2015_calderon-garciduenas_48,12,APOE4 - Children,10.3233/JAD-150415,1.638,0.315,,,,,
,mI,Myo,2015_calderon-garciduenas_48,1,Control - Parents,10.3233/JAD-150415,0.868,0.141,,,,,
,mI,Myo,2015_calderon-garciduenas_48,2,APOE3 - Parents,10.3233/JAD-150415,0.873,0.309,,,,,
,mI,Myo,2015_calderon-garciduenas_48,3,APOE4 - Parents,10.3233/JAD-150415,0.946,0.28,,,,,
,mI,Myo,2015_calderon-garciduenas_48,4,Control - Parents,10.3233/JAD-150415,0.76,0.125,,,,,
,mI,Myo,2015_calderon-garciduenas_48,5,APOE3 - Parents,10.3233/JAD-150415,0.833,0.25,,,,,
,mI,Myo,2015_calderon-garciduenas_48,6,APOE4 - Parents,10.3233/JAD-150415,0.895,0.27,,,,,
,mI,Myo,2015_calderon-garciduenas_48,7,Control - Children,10.3233/JAD-150415,0.769,0.125,,,,,
,mI,Myo,2015_calderon-garciduenas_48,8,APOE3 - Children,10.3233/JAD-150415,0.709,0.225,,,,,
,mI,Myo,2015_calderon-garciduenas_48,9,APOE4 - Children,10.3233/JAD-150415,0.76,0.249,,,,,
,mI,Myo,2015_calderon-garciduenas_48,10,Control - Children,10.3233/JAD-150415,0.75,0.107,,,,,
,mI,Myo,2015_calderon-garciduenas_48,11,APOE3 - Children,10.3233/JAD-150415,0.828,0.192,,,,,
,mI,Myo,2015_calderon-garciduenas_48,12,APOE4 - Children,10.3233/JAD-150415,0.951,0.449,,,,,
,Cho,GPC,2015_calderon-garciduenas_48,1,Control - Parents,10.3233/JAD-150415,1.044,0.133,,,,,
,Cho,GPC,2015_calderon-garciduenas_48,2,APOE3 - Parents,10.3233/JAD-150415,1.034,0.269,,,,,
,Cho,GPC,2015_calderon-garciduenas_48,3,APOE4 - Parents,10.3233/JAD-150415,0.994,0.195,,,,,
,Cho,GPC,2015_calderon-garciduenas_48,4,Control - Parents,10.3233/JAD-150415,1.007,0.116,,,,,
,Cho,GPC,2015_calderon-garciduenas_48,5,APOE3 - Parents,10.3233/JAD-150415,1.035,0.215,,,,,
,Cho,GPC,2015_calderon-garciduenas_48,6,APOE4 - Parents,10.3233/JAD-150415,0.983,0.229,,,,,
,Cho,GPC,2015_calderon-garciduenas_48,7,Control - Children,10.3233/JAD-150415,0.921,0.106,,,,,
,Cho,GPC,2015_calderon-garciduenas_48,8,APOE3 - Children,10.3233/JAD-150415,0.914,0.115,,,,,
,Cho,GPC,2015_calderon-garciduenas_48,9,APOE4 - Children,10.3233/JAD-150415,0.829,0.288,,,,,
,Cho,GPC,2015_calderon-garciduenas_48,10,Control - Children,10.3233/JAD-150415,0.949,0.192,,,,,
,Cho,GPC,2015_calderon-garciduenas_48,11,APOE3 - Children,10.3233/JAD-150415,1.023,0.169,,,,,
,Cho,GPC,2015_calderon-garciduenas_48,12,APOE4 - Children,10.3233/JAD-150415,0.977,0.184,,,,,
,NAA,NAA,2018_li_9,1,Cancer - Low-grade - 3Long,10.1021/acschemneuro.7b00286,0.96,0.235,,,,,Mean/Std calculated from Confidence Interval (Two-Tailed w/Alpha=.05)
,NAA,NAA,2018_li_9,4,Cancer - High-grade - 3Long,10.1021/acschemneuro.7b00286,1.32,0.174,,,,,Mean/Std calculated from Confidence Interval (Two-Tailed w/Alpha=.05)
,NAA,NAA,2018_li_9,7,Control - 3Long,10.1021/acschemneuro.7b00286,1.53,0.234,,,,,Mean/Std calculated from Confidence Interval (Two-Tailed w/Alpha=.05)
,NAA,NAA,2018_li_9,2,Cancer - Low-grade - 3Short,10.1021/acschemneuro.7b00286,1.035,0.158,,,,,Mean/Std calculated from Confidence Interval (Two-Tailed w/Alpha=.05)
,NAA,NAA,2018_li_9,5,Cancer - High-grade - 3Short,10.1021/acschemneuro.7b00286,1.175,0.059,,,,,Mean/Std calculated from Confidence Interval (Two-Tailed w/Alpha=.05)
,NAA,NAA,2018_li_9,8,Control - 3Short,10.1021/acschemneuro.7b00286,1.495,0.084,,,,,Mean/Std calculated from Confidence Interval (Two-Tailed w/Alpha=.05)
,NAA,NAA,2018_li_9,3,Cancer - Low-grade - 7Short,10.1021/acschemneuro.7b00286,0.915,0.385,,,,,Mean/Std calculated from Confidence Interval (Two-Tailed w/Alpha=.05)
,NAA,NAA,2018_li_9,6,Cancer - High-grade - 7Short,10.1021/acschemneuro.7b00286,1.17,0.214,,,,,Mean/Std calculated from Confidence Interval (Two-Tailed w/Alpha=.05)
,NAA,NAA,2018_li_9,9,Control - 7Short,10.1021/acschemneuro.7b00286,1.47,0.234,,,,,Mean/Std calculated from Confidence Interval (Two-Tailed w/Alpha=.05)
,Cho,GPC,2018_li_9,1,Cancer - Low-grade - 3Long,10.1021/acschemneuro.7b00286,0.44,0.109,,,,,Mean/Std calculated from Confidence Interval (Two-Tailed w/Alpha=.05)
,Cho,GPC,2018_li_9,4,Cancer - High-grade - 3Long,10.1021/acschemneuro.7b00286,0.505,0.067,,,,,Mean/Std calculated from Confidence Interval (Two-Tailed w/Alpha=.05)
,Cho,GPC,2018_li_9,7,Control - 3Long,10.1021/acschemneuro.7b00286,0.39,0.065,,,,,Mean/Std calculated from Confidence Interval (Two-Tailed w/Alpha=.05)
,Cho,GPC,2018_li_9,2,Cancer - Low-grade - 3Short,10.1021/acschemneuro.7b00286,0.485,0.086,,,,,Mean/Std calculated from Confidence Interval (Two-Tailed w/Alpha=.05)
,Cho,GPC,2018_li_9,5,Cancer - High-grade - 3Short,10.1021/acschemneuro.7b00286,0.43,0.079,,,,,Mean/Std calculated from Confidence Interval (Two-Tailed w/Alpha=.05)
,Cho,GPC,2018_li_9,8,Control - 3Short,10.1021/acschemneuro.7b00286,0.365,0.02,,,,,Mean/Std calculated from Confidence Interval (Two-Tailed w/Alpha=.05)
,Cho,GPC,2018_li_9,3,Cancer - Low-grade - 7Short,10.1021/acschemneuro.7b00286,0.355,0.086,,,,,Mean/Std calculated from Confidence Interval (Two-Tailed w/Alpha=.05)
,Cho,GPC,2018_li_9,6,Cancer - High-grade - 7Short,10.1021/acschemneuro.7b00286,0.355,0.075,,,,,Mean/Std calculated from Confidence Interval (Two-Tailed w/Alpha=.05)
,Cho,GPC,2018_li_9,9,Control - 7Short,10.1021/acschemneuro.7b00286,0.29,0.026,,,,,Mean/Std calculated from Confidence Interval (Two-Tailed w/Alpha=.05)
,Glu,Glu,2018_li_9,2,Cancer - Low-grade - 3Short,10.1021/acschemneuro.7b00286,1.37,0.217,,,,,Mean/Std calculated from Confidence Interval (Two-Tailed w/Alpha=.05)
,Glu,Glu,2018_li_9,5,Cancer - High-grade - 3Short,10.1021/acschemneuro.7b00286,1.255,0.099,,,,,Mean/Std calculated from Confidence Interval (Two-Tailed w/Alpha=.05)
,Glu,Glu,2018_li_9,8,Control - 3Short,10.1021/acschemneuro.7b00286,1.25,0.052,,,,,Mean/Std calculated from Confidence Interval (Two-Tailed w/Alpha=.05)
,Glu,Glu,2018_li_9,3,Cancer - Low-grade - 7Short,10.1021/acschemneuro.7b00286,1.35,0.226,,,,,Mean/Std calculated from Confidence Interval (Two-Tailed w/Alpha=.05)
,Glu,Glu,2018_li_9,6,Cancer - High-grade - 7Short,10.1021/acschemneuro.7b00286,1.06,0.095,,,,,Mean/Std calculated from Confidence Interval (Two-Tailed w/Alpha=.05)
,Glu,Glu,2018_li_9,9,Control - 7Short,10.1021/acschemneuro.7b00286,1.135,0.149,,,,,Mean/Std calculated from Confidence Interval (Two-Tailed w/Alpha=.05)
,mI,Myo,2018_li_9,2,Cancer - Low-grade - 3Short,10.1021/acschemneuro.7b00286,1.165,0.095,,,,,Mean/Std calculated from Confidence Interval (Two-Tailed w/Alpha=.05)
,mI,Myo,2018_li_9,5,Cancer - High-grade - 3Short,10.1021/acschemneuro.7b00286,0.9,0.119,,,,,Mean/Std calculated from Confidence Interval (Two-Tailed w/Alpha=.05)
,mI,Myo,2018_li_9,8,Control - 3Short,10.1021/acschemneuro.7b00286,0.88,0.065,,,,,Mean/Std calculated from Confidence Interval (Two-Tailed w/Alpha=.05)
,mI,Myo,2018_li_9,3,Cancer - Low-grade - 7Short,10.1021/acschemneuro.7b00286,0.735,0.177,,,,,Mean/Std calculated from Confidence Interval (Two-Tailed w/Alpha=.05)
,mI,Myo,2018_li_9,6,Cancer - High-grade - 7Short,10.1021/acschemneuro.7b00286,0.74,0.166,,,,,Mean/Std calculated from Confidence Interval (Two-Tailed w/Alpha=.05)
,mI,Myo,2018_li_9,9,Control - 7Short,10.1021/acschemneuro.7b00286,0.63,0.104,,,,,Mean/Std calculated from Confidence Interval (Two-Tailed w/Alpha=.05)
,mIG,Myo+Gly,2018_li_9,2,Cancer - Low-grade - 3Short,10.1021/acschemneuro.7b00286,1.17,0.154,,,,,Mean/Std calculated from Confidence Interval (Two-Tailed w/Alpha=.05)
,mIG,Myo+Gly,2018_li_9,5,Cancer - High-grade - 3Short,10.1021/acschemneuro.7b00286,0.86,0.063,,,,,Mean/Std calculated from Confidence Interval (Two-Tailed w/Alpha=.05)
,mIG,Myo+Gly,2018_li_9,8,Control - 3Short,10.1021/acschemneuro.7b00286,0.82,0.065,,,,,Mean/Std calculated from Confidence Interval (Two-Tailed w/Alpha=.05)
,mIG,Myo+Gly,2018_li_9,3,Cancer - Low-grade - 7Short,10.1021/acschemneuro.7b00286,0.84,0.226,,,,,Mean/Std calculated from Confidence Interval (Two-Tailed w/Alpha=.05)
,mIG,Myo+Gly,2018_li_9,6,Cancer - High-grade - 7Short,10.1021/acschemneuro.7b00286,0.715,0.138,,,,,Mean/Std calculated from Confidence Interval (Two-Tailed w/Alpha=.05)
,mIG,Myo+Gly,2018_li_9,9,Control - 7Short,10.1021/acschemneuro.7b00286,0.795,0.162,,,,,Mean/Std calculated from Confidence Interval (Two-Tailed w/Alpha=.05)
,Glx,Glx,2018_li_9,2,Cancer - Low-grade - 3Short,10.1021/acschemneuro.7b00286,1.66,0.127,,,,,Mean/Std calculated from Confidence Interval (Two-Tailed w/Alpha=.05)
,Glx,Glx,2018_li_9,5,Cancer - High-grade - 3Short,10.1021/acschemneuro.7b00286,1.495,0.115,,,,,Mean/Std calculated from Confidence Interval (Two-Tailed w/Alpha=.05)
,Glx,Glx,2018_li_9,8,Control - 3Short,10.1021/acschemneuro.7b00286,1.525,0.046,,,,,Mean/Std calculated from Confidence Interval (Two-Tailed w/Alpha=.05)
,Glx,Glx,2018_li_9,3,Cancer - Low-grade - 7Short,10.1021/acschemneuro.7b00286,0.965,0.557,,,,,Mean/Std calculated from Confidence Interval (Two-Tailed w/Alpha=.05)
,Glx,Glx,2018_li_9,6,Cancer - High-grade - 7Short,10.1021/acschemneuro.7b00286,1.32,0.119,,,,,Mean/Std calculated from Confidence Interval (Two-Tailed w/Alpha=.05)
,Glx,Glx,2018_li_9,9,Control - 7Short,10.1021/acschemneuro.7b00286,1.13,0.065,,,,,Mean/Std calculated from Confidence Interval (Two-Tailed w/Alpha=.05)
,NAA,NAA,2017_barbagallo_43,10,Control,10.1016/j.parkreldis.2017.07.028,,,12,1.41,,,Right
,NAA,NAA,2017_barbagallo_43,11,Control,10.1016/j.parkreldis.2017.07.028,,,12.01,1.73,,,Left
,NAA,NAA,2017_barbagallo_43,12,Control,10.1016/j.parkreldis.2017.07.028,,,11.57,1.91,,,Both
,NAA,NAA,2017_barbagallo_43,13,Parkinson's Disease,10.1016/j.parkreldis.2017.07.028,,,11.52,2.04,,,Contralateral
,NAA,NAA,2017_barbagallo_43,14,Parkinson's Disease,10.1016/j.parkreldis.2017.07.028,,,10.38,1.82,,,Ipsilateral
,NAA,NAA,2017_barbagallo_43,15,Parkinson's Disease,10.1016/j.parkreldis.2017.07.028,,,10.95,1.24,,,Both
,NAA,NAA,2017_barbagallo_43,16,Essential Tremor,10.1016/j.parkreldis.2017.07.028,,,14.34,5.1,,,Contralateral
,NAA,NAA,2017_barbagallo_43,17,Essential Tremor,10.1016/j.parkreldis.2017.07.028,,,15.02,5.08,,,Ipsilateral
,NAA,NAA,2017_barbagallo_43,18,Essential Tremor,10.1016/j.parkreldis.2017.07.028,,,14.68,4.86,,,Both
,Glu,Glu,2017_barbagallo_43,10,Control,10.1016/j.parkreldis.2017.07.028,,,15.79,6.13,,,Right
,Glu,Glu,2017_barbagallo_43,11,Control,10.1016/j.parkreldis.2017.07.028,,,13.81,3.57,,,Left
,Glu,Glu,2017_barbagallo_43,12,Control,10.1016/j.parkreldis.2017.07.028,,,14.8,3.99,,,Both
,Glu,Glu,2017_barbagallo_43,13,Parkinson's Disease,10.1016/j.parkreldis.2017.07.028,,,17.51,4.26,,,Contralateral
,Glu,Glu,2017_barbagallo_43,14,Parkinson's Disease,10.1016/j.parkreldis.2017.07.028,,,17.12,2.59,,,Ipsilateral
,Glu,Glu,2017_barbagallo_43,15,Parkinson's Disease,10.1016/j.parkreldis.2017.07.028,,,17.32,3.01,,,Both
,Glu,Glu,2017_barbagallo_43,16,Essential Tremor,10.1016/j.parkreldis.2017.07.028,,,16.68,7.73,,,Contralateral
,Glu,Glu,2017_barbagallo_43,17,Essential Tremor,10.1016/j.parkreldis.2017.07.028,,,16.37,8.44,,,Ipsilateral
,Glu,Glu,2017_barbagallo_43,18,Essential Tremor,10.1016/j.parkreldis.2017.07.028,,,16.52,7.47,,,Both
,Cho,GPC,2017_barbagallo_43,10,Control,10.1016/j.parkreldis.2017.07.028,,,2.11,0.34,,,Right
,Cho,GPC,2017_barbagallo_43,11,Control,10.1016/j.parkreldis.2017.07.028,,,2.73,1.13,,,Left
,Cho,GPC,2017_barbagallo_43,12,Control,10.1016/j.parkreldis.2017.07.028,,,2.42,0.55,,,Both
,Cho,GPC,2017_barbagallo_43,13,Parkinson's Disease,10.1016/j.parkreldis.2017.07.028,,,2.06,0.35,,,Contralateral
,Cho,GPC,2017_barbagallo_43,14,Parkinson's Disease,10.1016/j.parkreldis.2017.07.028,,,2.01,0.28,,,Ipsilateral
,Cho,GPC,2017_barbagallo_43,15,Parkinson's Disease,10.1016/j.parkreldis.2017.07.028,,,2.03,0.29,,,Both
,Cho,GPC,2017_barbagallo_43,16,Essential Tremor,10.1016/j.parkreldis.2017.07.028,,,2.46,0.52,,,Contralateral
,Cho,GPC,2017_barbagallo_43,17,Essential Tremor,10.1016/j.parkreldis.2017.07.028,,,2.45,0.56,,,Ipsilateral
,Cho,GPC,2017_barbagallo_43,18,Essential Tremor,10.1016/j.parkreldis.2017.07.028,,,2.46,0.48,,,Both
,Cre,Cre,2017_barbagallo_43,10,Control,10.1016/j.parkreldis.2017.07.028,,,6.62,1.14,,,Right
,Cre,Cre,2017_barbagallo_43,11,Control,10.1016/j.parkreldis.2017.07.028,,,7.22,0.93,,,Left
,Cre,Cre,2017_barbagallo_43,12,Control,10.1016/j.parkreldis.2017.07.028,,,6.92,0.66,,,Both
,Cre,Cre,2017_barbagallo_43,13,Parkinson's Disease,10.1016/j.parkreldis.2017.07.028,,,7.74,0.97,,,Contralateral
,Cre,Cre,2017_barbagallo_43,14,Parkinson's Disease,10.1016/j.parkreldis.2017.07.028,,,7.55,0.85,,,Ipsilateral
,Cre,Cre,2017_barbagallo_43,15,Parkinson's Disease,10.1016/j.parkreldis.2017.07.028,,,7.64,0.76,,,Both
,Cre,Cre,2017_barbagallo_43,16,Essential Tremor,10.1016/j.parkreldis.2017.07.028,,,7.78,2.34,,,Contralateral
,Cre,Cre,2017_barbagallo_43,17,Essential Tremor,10.1016/j.parkreldis.2017.07.028,,,8.11,2.36,,,Ipsilateral
,Cre,Cre,2017_barbagallo_43,18,Essential Tremor,10.1016/j.parkreldis.2017.07.028,,,7.95,2.29,,,Both
,Glu,Glu,2021_foret_13,1,Metabolic Syndrome,10.3389/fnagi.2021.691691,1.25,0.15,,,,,n=88
,Glu,Glu,2021_foret_13,2,Metabolic Syndrome,10.3389/fnagi.2021.691691,1.23,0.11,,,,,n=115
,GABA,GABA,2017_brennan_269,1,Control,10.1016/j.pscychresns.2017.08.009,0.036,0.01,,,,,
,GABA,GABA,2017_brennan_269,2,MDD,10.1016/j.pscychresns.2017.08.009,0.049,0.022,,,,,
,GABA,GABA,2017_brennan_269,3,MDD,10.1016/j.pscychresns.2017.08.009,0.034,0.013,,,,,
,GABA,GABA,2017_brennan_269,4,MDD,10.1016/j.pscychresns.2017.08.009,0.047,0.02,,,,,
,GABA,GABA,2017_brennan_269,5,MDD,10.1016/j.pscychresns.2017.08.009,0.039,0.014,,,,,
,Glu,Glu,2017_shimizu_82,1,Child,10.1038/pr.2017.101,1.216,0.041,,,,,
,Glu,Glu,2017_shimizu_82,2,Child,10.1038/pr.2017.101,1.01,0.073,,,,,
,Glu,Glu,2017_shimizu_82,3,Control,10.1038/pr.2017.101,1.049,0.039,,,,,
,Glu,Glu,2017_shimizu_82,4,Control,10.1038/pr.2017.101,0.939,0.033,,,,,
,NAA,NAA,2017_shimizu_82,1,Child,10.1038/pr.2017.101,1.391,0.061,,,,,
,NAA,NAA,2017_shimizu_82,2,Child,10.1038/pr.2017.101,1.568,0.065,,,,,
,NAA,NAA,2017_shimizu_82,3,Control,10.1038/pr.2017.101,1.322,0.067,,,,,
,NAA,NAA,2017_shimizu_82,4,Control,10.1038/pr.2017.101,1.57,0.066,,,,,
,tNAA,tNAA,2020_tran_30,1,Control,10.1111/jon.12728,1.51,0.1,,,,,
,tNAA,tNAA,2020_tran_30,2,Control,10.1111/jon.12728,1.82,0.23,,,,,
,tNAA,tNAA,2020_tran_30,3,NAFLD,10.1111/jon.12728,1.48,0.13,,,,,
,tNAA,tNAA,2020_tran_30,4,NAFLD,10.1111/jon.12728,1.88,0.19,,,,,
,tNAA,tNAA,2020_tran_30,5,NAFLD,10.1111/jon.12728,1.44,0.15,,,,,
,tNAA,tNAA,2020_tran_30,6,NAFLD,10.1111/jon.12728,1.98,0.2,,,,,
,tCho,tCho,2020_tran_30,1,Control,10.1111/jon.12728,0.2,0.02,,,,,
,tCho,tCho,2020_tran_30,2,Control,10.1111/jon.12728,0.34,0.4,,,,,
,tCho,tCho,2020_tran_30,3,NAFLD,10.1111/jon.12728,0.18,0.2,,,,,
,tCho,tCho,2020_tran_30,4,NAFLD,10.1111/jon.12728,0.29,0.04,,,,,
,tCho,tCho,2020_tran_30,5,NAFLD,10.1111/jon.12728,0.17,0.01,,,,,
,tCho,tCho,2020_tran_30,6,NAFLD,10.1111/jon.12728,0.28,0.03,,,,,
,mI,Myo,2020_tran_30,1,Control,10.1111/jon.12728,0.75,0.1,,,,,
,mI,Myo,2020_tran_30,2,Control,10.1111/jon.12728,0.81,0.1,,,,,
,mI,Myo,2020_tran_30,3,NAFLD,10.1111/jon.12728,0.63,0.2,,,,,
,mI,Myo,2020_tran_30,4,NAFLD,10.1111/jon.12728,0.66,0.26,,,,,
,mI,Myo,2020_tran_30,5,NAFLD,10.1111/jon.12728,0.33,0.12,,,,,
,mI,Myo,2020_tran_30,6,NAFLD,10.1111/jon.12728,0.23,0.11,,,,,
,Glu,Glu,2020_tran_30,1,Control,10.1111/jon.12728,1.5,0.09,,,,,
,Glu,Glu,2020_tran_30,2,Control,10.1111/jon.12728,1.23,0.15,,,,,
,Glu,Glu,2020_tran_30,3,NAFLD,10.1111/jon.12728,0.63,0.2,,,,,
,Glu,Glu,2020_tran_30,4,NAFLD,10.1111/jon.12728,0.66,0.26,,,,,
,Glu,Glu,2020_tran_30,5,NAFLD,10.1111/jon.12728,0.33,0.12,,,,,
,Glu,Glu,2020_tran_30,6,NAFLD,10.1111/jon.12728,0.23,0.11,,,,,
,Gln,Gln,2020_tran_30,1,Control,10.1111/jon.12728,0.6,0.13,,,,,
,Gln,Gln,2020_tran_30,2,Control,10.1111/jon.12728,0.41,0.98,,,,,
,Gln,Gln,2020_tran_30,3,NAFLD,10.1111/jon.12728,0.81,0.32,,,,,
,Gln,Gln,2020_tran_30,4,NAFLD,10.1111/jon.12728,0.7,0.35,,,,,
,Gln,Gln,2020_tran_30,5,NAFLD,10.1111/jon.12728,1.75,0.71,,,,,
,Gln,Gln,2020_tran_30,6,NAFLD,10.1111/jon.12728,1.49,0.6,,,,,
